We	O
employed	O
a	O
cohort	O
study	O
design	O
in	O
a	O
retrospective	O
analysis	O
of	O
the	O
Clinformatics	O
Data	O
Mart	O
Database	O
(	O
OptumInsight	O
)	O
,	O
which	O
is	O
comprised	O
of	O
administrative	O
claims	O
of	O
13	O
million	O
privately	O
insured	O
enrollees	O
throughout	O
the	O
U	O
.	O
S	O
.	O
14	O
–	O
16	O
This	O
population	O
is	O
similar	O
to	O
the	O
US	O
population	O
of	O
commercially	O
insured	O
people	O
in	O
age	O
,	O
race	O
or	O
ethnicity	O
,	O
and	O
sex	O
and	O
has	O
a	O
median	O
continuous	O
enrollment	O
period	O
of	O
24	O
months	O
.	O

16	O

We	O
identified	O
all	O
index	O
ED	O
encounters	O
for	O
ankle	O
sprains	O
in	O
patients	O
aged	O
≥	O
18	O
years	O
old	O
that	O
occurred	O
from	O
January	O
1	O
,	O
2011	O
to	O
December	O
31	O
,	O
2015	O
.	O

The	O
index	O
visit	O
was	O
defined	O
as	O
the	O
earliest	O
visit	O
in	O
which	O
the	O
enrollee	O
had	O
a	O
provider	O
claim	O
by	O
an	O
emergency	O
physician	O
with	O
a	O
place	O
of	O
service	O
designation	O
in	O
the	O
emergency	O
department	O
and	O
a	O
diagnosis	O
code	O
of	O
ankle	B-phenotype
sprain	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
code	O
845	B-code
.	I-code
00–09	I-code
and	O
ICD10	B-coding_system
S93	B-code
.	I-code
4	I-code
)	O
.	O

We	O
excluded	O
patients	O
who	O
had	O
any	O
other	O
injury	O
diagnoses	O
as	O
defined	O
by	O
State	O
and	O
Territorial	O
Injury	O
Prevention	O
Directors	O
Association	O
consensus	O
definitions	O
,	O
17	O
–	O
19	O
and	O
those	O
who	O
had	O
recurrent	O
visits	O
for	O
ankle	O
sprain	O
during	O
the	O
study	O
period	O
to	O
decrease	O
the	O
likelihood	O
that	O
future	O
prescriptions	O
were	O
associated	O
with	O
a	O
more	O
severe	O
initial	O
presentation	O
.	O

To	O
restrict	O
the	O
study	O
population	O
to	O
those	O
who	O
are	O
likely	O
to	O
be	O
prescription	O
opioid	O
-	O
naïve	O
,	O
we	O
excluded	O
all	O
patients	O
who	O
were	O
not	O
continuously	O
enrolled	O
for	O
6	O
months	O
prior	O
to	O
the	O
index	O
ED	O
visit	O
and	O
those	O
who	O
had	O
filled	O
an	O
opioid	O
prescription	O
in	O
these	O
prior	O
6	O
months	O
.	O

6	O
,	O
12	O

We	O
identified	O
prescription	O
claims	O
corresponding	O
to	O
an	O
opioid	B-phenotype
according	O
to	O
National	B-coding_system
Drug	I-coding_system
Codes	I-coding_system
(	O
excluding	O
methadone	O
and	O
non	O
-	O
tablet	O
formulations	O
)	O
filled	O
within	O
3	O
days	O
of	O
the	O
index	O
ED	O
visit	O
.	O

We	O
excluded	O
any	O
encounters	O
for	O
patients	O
who	O
had	O
intervening	O
medical	O
claims	O
for	O
ankle	O
sprains	O
within	O
3	O
days	O
of	O
the	O
ED	O
visit	O
.	O

The	O
primary	O
outcome	O
was	O
opioid	O
prescription	O
rate	O
defined	O
as	O
the	O
proportion	O
of	O
adult	O
opioid	O
-	O
naïve	O
patients	O
treated	O
for	O
ankle	O
sprains	O
that	O
filled	O
an	O
opioid	O
prescription	O
with	O
3	O
days	O
of	O
the	O
ED	O
visit	O
.	O

Secondary	O
outcomes	O
included	O
characteristics	O
of	O
the	O
initial	O
prescription	O
and	O
continued	O
opioid	O
use	O
beyond	O
the	O
initial	O
prescription	O
.	O

Characteristics	O
of	O
the	O
initial	O
prescription	O
included	O
number	O
of	O
tablets	O
,	O
days	O
supplied	O
,	O
and	O
morphine	O
milligram	O
equivalents	O
(	O
MME	O
)	O
per	O
prescription	O
.	O

20	O
The	O
days	O
supplied	O
on	O
the	O
pharmacy	O
prescription	O
claims	O
are	O
entered	O
at	O
the	O
point	O
of	O
sale	O
by	O
the	O
pharmacist	O
based	O
on	O
dosing	O
instructions	O
and	O
number	O
of	O
tablets	O
dispensed	O
.	O

21	O

We	O
measured	O
prolonged	O
opioid	O
use	O
in	O
the	O
30–180	O
days	O
following	O
the	O
index	O
ED	O
visit	O
given	O
pain	O
from	O
ankle	O
sprains	O
rapidly	O
improves	O
within	O
2	O
weeks	O
.	O

9	O
We	O
defined	O
prolonged	O
use	O
as	O
filling	O
4	O
or	O
more	O
subsequent	O
opioid	O
prescriptions	O
during	O
this	O
time	O
period	O
,	O
22	O
,	O
23	O
and	O
used	O
alternative	O
specifications	O
in	O
our	O
sensitivity	O
analyses	O
.	O

Limiting	O
the	O
follow	O
-	O
up	O
period	O
to	O
six	O
months	O
captures	O
high	O
-	O
risk	O
individuals	O
who	O
drop	O
out	O
of	O
the	O
dataset	O
by	O
virtue	O
of	O
losing	O
employment	O
,	O
and	O
thus	O
insurance	O
coverage	O
,	O
due	O
to	O
an	O
opioid	O
use	O
disorder	O
if	O
longer	O
follow	O
up	O
periods	O
were	O
used	O
.	O

24	O
,	O
25	O
Indeed	O
,	O
in	O
our	O
final	O
study	O
sample	O
the	O
insurance	O
enrollment	O
attrition	O
rate	O
between	O
6	O
and	O
12	O
months	O
of	O
follow	O
-	O
up	O
was	O
1	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
4	O
%	O
,	O
2	O
.	O
5	O
%	O
)	O
higher	O
among	O
those	O
who	O
were	O
prescribed	O
opioids	O
(	O
16	O
.	O
7	O
%	O
)	O
compared	O
with	O
those	O
who	O
did	O
not	O
fill	O
opioids	O
(	O
15	O
.	O
2	O
%	O
)	O
.	O

To	O
further	O
validate	O
our	O
outcome	O
,	O
we	O
tabulated	O
the	O
most	O
common	O
first	O
listed	O
medical	O
diagnosis	O
codes	O
within	O
the	O
7	O
days	O
prior	O
to	O
new	O
opioid	O
prescription	O
fills	O
30–180	O
days	O
after	O
the	O
index	O
encounter	O
.	O

This	O
analysis	O
allowed	O
us	O
to	O
explore	O
the	O
extent	O
to	O
which	O
new	O
prescriptions	O
could	O
be	O
attributed	O
to	O
persistent	O
ankle	O
pain	O
rather	O
than	O
another	O
condition	O
completely	O
unrelated	O
to	O
the	O
index	O
ankle	O
sprain	O
.	O

We	O
extracted	O
information	O
on	O
patients’	O
age	O
,	O
sex	O
,	O
highest	O
level	O
of	O
education	O
,	O
and	O
race	O
.	O

We	O
also	O
identified	O
the	O
patients’	O
Elixhauaser	O
comorbidities	O
,	O
as	O
well	O
as	O
diagnosis	O
codes	O
for	O
drug	O
abuse	O
,	O
alcohol	O
abuse	O
,	O
depression	O
,	O
and	O
psychoses	O
as	O
gathered	O
from	O
diagnosis	O
codes	O
on	O
the	O
index	O
ED	O
visit	O
and	O
any	O
medical	O
claims	O
filed	O
in	O
the	O
previous	O
6	O
months	O
.	O

26	O

First	O
,	O
we	O
tabulated	O
patient	O
characteristics	O
according	O
to	O
whether	O
an	O
opioid	O
prescription	O
was	O
filled	O
or	O
not	O
.	O

Among	O
those	O
who	O
filled	O
opioids	O
,	O
we	O
stratified	O
patient	O
characteristics	O
according	O
to	O
whether	O
a	O
prescription	O
was	O
above	O
or	O
below	O
the	O
median	O
total	O
MME	O
prescribed	O
in	O
the	O
sample	O
.	O

We	O
compared	O
the	O
magnitude	O
of	O
differences	O
in	O
patient	O
and	O
prescription	O
characteristics	O
between	O
groups	O
using	O
95	O
%	O
confidence	O
intervals	O
for	O
the	O
differences	O
.	O

Second	O
,	O
we	O
described	O
the	O
variation	O
in	O
the	O
opioid	O
prescription	O
rate	O
and	O
characteristics	O
at	O
the	O
patient	O
-	O
and	O
state	O
-	O
level	O
and	O
over	O
time	O
.	O

Prescriptions	O
were	O
aggregated	O
by	O
state	O
according	O
the	O
state	O
associated	O
with	O
the	O
prescribers’	O
de	O
-	O
identified	O
National	O
Provider	O
Identifier	O
(	O
NPI	O
)	O
number	O
.	O

Next	O
,	O
we	O
calculated	O
the	O
patients’	O
expected	O
probability	O
of	O
receiving	O
an	O
opioid	O
prescription	O
using	O
a	O
logistic	O
regression	O
model	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
highest	O
level	O
of	O
education	O
,	O
race	O
,	O
the	O
total	O
number	O
of	O
Elixhauser	O
comorbidities	O
,	O
a	O
history	O
of	O
drug	O
abuse	O
,	O
alcohol	O
abuse	O
,	O
depression	O
,	O
or	O
psychosis	O
,	O
and	O
year	O
.	O

We	O
then	O
estimated	O
observed	O
-	O
to	O
-	O
expected	O
state	O
-	O
level	O
prescribing	O
ratios	O
with	O
95	O
%	O
confidence	O
intervals	O
,	O
with	O
values	O
over	O
1	O
indicating	O
patients	O
in	O
that	O
state	O
were	O
more	O
likely	O
than	O
expected	O
to	O
fill	O
opioid	O
prescriptions	O
and	O
less	O
than	O
1	O
indicating	O
patients	O
in	O
states	O
that	O
were	O
less	O
likely	O
than	O
expected	O
to	O
fill	O
opioid	O
prescriptions	O
.	O

27	O
For	O
these	O
state	O
-	O
level	O
analyses	O
we	O
excluded	O
states	O
with	O
less	O
than	O
25	O
patients	O
in	O
the	O
study	O
sample	O
.	O

We	O
then	O
quantified	O
the	O
number	O
of	O
tablets	O
that	O
would	O
be	O
prevented	O
from	O
entering	O
the	O
community	O
from	O
reducing	O
excessive	O
variation	O
by	O
:	O
1	O
)	O
reducing	O
all	O
states	O
with	O
above	O
-	O
median	O
opioid	O
prescribing	O
rates	O
to	O
the	O
median	O
rate	O
for	O
ankle	O
sprains	O
;	O
and	O
2	O
)	O
leveling	O
all	O
above	O
-	O
median	O
opioid	O
prescriptions	O
supplies	O
for	O
ankle	O
sprains	O
to	O
the	O
median	O
.	O

Finally	O
,	O
we	O
quantified	O
the	O
association	O
between	O
the	O
initial	O
MME	O
prescribed	O
among	O
those	O
who	O
filled	O
a	O
prescription	O
and	O
prolonged	O
use	O
.	O

MME	O
cutoffs	O
were	O
selected	O
based	O
on	O
common	O
tablet	O
quantities	O
dispensed	O
for	O
the	O
most	O
potent	O
opioid	O
prescribed	O
,	O
oxycodone	O
5	O
mg	O
:	O
1–75	O
MME	O
(	O
<	O
10	O
tabs	O
)	O
,	O
76–150	O
(	O
11–20	O
tabs	O
)	O
,	O
151–225	O
MME	O
(	O
21–30	O
tabs	O
)	O
,	O
and	O
>	O
225	O
MME	O
(	O
>	O
30	O
tabs	O
)	O
.	O

We	O
quantified	O
the	O
association	O
using	O
a	O
logistic	O
regression	O
model	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
highest	O
level	O
of	O
education	O
,	O
race	O
,	O
the	O
total	O
number	O
of	O
Elixhauser	O
comorbidities	O
,	O
a	O
history	O
of	O
drug	O
abuse	O
,	O
alcohol	O
abuse	O
,	O
depression	O
,	O
or	O
psychosis	O
,	O
year	O
,	O
and	O
state	O
.	O

We	O
then	O
performed	O
sensitivity	O
analyses	O
to	O
assess	O
the	O
robustness	O
of	O
our	O
findings	O
,	O
including	O
:	O
1	O
)	O
using	O
tablets	O
dispensed	O
(	O
adjusted	O
for	O
MME	O
/	O
tablet	O
)	O
,	O
and	O
days	O
supplied	O
as	O
the	O
independent	O
measure	O
of	O
interest	O
;	O
and	O
2	O
)	O
limiting	O
the	O
exposure	O
to	O
just	O
prescriptions	O
for	O
hydrocodone	O
and	O
oxycodone	O
;	O
and	O
3	O
)	O
considering	O
alternative	O
measures	O
of	O
prolonged	O
use	O
based	O
on	O
the	O
number	O
of	O
prescriptions	O
filled	O
in	O
the	O
follow	O
-	O
up	O
window	O
.	O

The	O
University	O
of	O
Pennsylvania	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
determined	O
that	O
this	O
study	O
was	O
eligible	O
for	O
IRB	O
exemption	O
.	O

Stata	O
14	O
.	O
1	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
TX	O
)	O
and	O
SAS	O
9	O
.	O
4	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
were	O
used	O
to	O
conduct	O
the	O
statistical	O
analyses	O
.	O

Our	O
study	O
was	O
based	O
on	O
the	O
patient	O
data	O
from	O
NHIRD	O
in	O
Taiwan	O
.	O

The	O
Taiwan	O
NHIRD	O
is	O
a	O
claims	O
database	O
maintained	O
by	O
the	O
Department	O
of	O
Health	O
and	O
the	O
National	O
Health	O
Research	O
Institutes	O
of	O
Taiwan	O
.	O

The	O
NHI	O
program	O
was	O
launched	O
in	O
Taiwan	O
on	O
March	O
1	O
st	O
1995	O
.	O

By	O
the	O
end	O
of	O
2010	O
,	O
more	O
than	O
23	O
.	O
07	O
million	O
of	O
Taiwan’s	O
23	O
.	O
16	O
million	O
people	O
were	O
enrolled	O
in	O
the	O
program	O
[	O
28	O
]	O
.	O

Starting	O
in	O
1999	O
,	O
the	O
Bureau	O
of	O
NHI	O
(	O
NHIB	O
)	O
began	O
to	O
release	O
all	O
claims	O
data	O
in	O
electronic	O
format	O
to	O
the	O
public	O
under	O
the	O
NHIRD	O
project	O
.	O

The	O
database	O
provides	O
scrambled	O
patient	O
identification	O
numbers	O
,	O
dates	O
of	O
birth	O
,	O
gender	O
,	O
and	O
diagnosis	O
in	O
the	O
format	O
of	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
Ninth	I-coding_system
Revision	I-coding_system
,	I-coding_system
Clinical	I-coding_system
Modification	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
)	I-coding_system
,	O
medication	O
prescribed	O
,	O
medical	O
costs	O
,	O
medical	O
care	O
facilities	O
,	O
and	O
their	O
specialties	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
medical	O
data	O
for	O
a	O
total	O
of	O
1	O
,	O
000	O
,	O
000	O
persons	O
(	O
approximately	O
4	O
%	O
of	O
Taiwan’s	O
population	O
)	O
,	O
were	O
randomly	O
selected	O
from	O
the	O
Taiwan	O
NHIRD	O
for	O
the	O
analysis	O
.	O

The	O
NHIB	O
uses	O
a	O
systematic	O
sampling	O
method	O
to	O
randomly	O
extract	O
a	O
representative	O
database	O
from	O
the	O
entire	O
database	O
.	O

There	O
are	O
no	O
statistically	O
significant	O
differences	O
in	O
age	O
,	O
sex	O
,	O
and	O
medical	O
costs	O
between	O
the	O
sample	O
group	O
and	O
all	O
other	O
enrollees	O
.	O

We	O
included	O
medical	O
data	O
from	O
individuals	O
who	O
were	O
enrolled	O
between	O
January	O
1	O
st	O
,	O
2000	O
,	O
and	O
December	O
31	O
st	O
,	O
2009	O
,	O
except	O
those	O
with	O
questionable	O
or	O
inadequate	O
basic	O
data	O
.	O

The	O
Institutional	O
Review	O
Board	O
of	O
Taichung	O
Veterans	O
General	O
Hospital	O
approved	O
this	O
study	O
(	O
IRB	O
No	O
.	O

CE13151	O
)	O
.	O

NHIB	O
released	O
the	O
dataset	O
which	O
consists	O
of	O
de	O
-	O
identified	O
secondary	O
data	O
for	O
research	O
purposes	O
,	O
and	O
therefore	O
written	O
consent	O
from	O
the	O
study	O
subjects	O
was	O
not	O
obtained	O
.	O

The	O
Institutional	O
Review	O
Board	O
of	O
Taichung	O
Veterans	O
General	O
Hospital	O
issued	O
a	O
formal	O
written	O
waiver	O
for	O
consent	O
for	O
this	O
study	O
.	O

We	O
conducted	O
a	O
retrospective	O
observational	O
study	O
on	O
the	O
impact	O
of	O
SSRIs	O
use	O
on	O
the	O
incidence	O
of	O
stroke	O
in	O
patients	O
diagnosed	O
with	O
OCD	O
in	O
Taiwan	O
from	O
2001	O
to	O
2009	O
.	O

Patients	O
were	O
excluded	O
if	O
before	O
2001	O
:	O
1	O
.	O

Ages	O
are	O
younger	O
than	O
twenty	O
years	O
;	O
2	O
.	O

Ever	O
diagnosed	O
with	O
a	O
stroke	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
430	B-code
.	I-code
XX	I-code
to	O
438	B-code
.	I-code
XX	I-code
)	O
;	O
3	O
.	O

Hospitalized	O
or	O
received	O
ambulatory	O
treatment	O
for	O
any	B-phenotype
mental	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
:	O
290	B-code
.	I-code
XX	I-code
-	I-code
319	I-code
.	I-code
XX	I-code
)	O
.	O

This	O
ensured	O
that	O
subsequent	O
diagnoses	O
of	O
stroke	O
and	O
OCD	O
were	O
of	O
newly	O
onset	O
.	O

Study	O
subjects	O
were	O
identified	O
from	O
2001	O
to	O
2007	O
and	O
the	O
observation	O
period	O
to	O
identify	O
first	O
stroke	O
events	O
or	O
death	O
extended	O
until	O
December	O
31	O
,	O
2009	O
to	O
ensure	O
that	O
study	O
subjects	O
could	O
be	O
followed	O
for	O
at	O
least	O
3	O
years	O
.	O

New	O
cases	O
of	O
OCD	B-phenotype
were	O
ascertained	O
by	O
the	O
diagnosis	O
of	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
300	B-code
.	I-code
3	I-code
.	O

To	O
ensure	O
the	O
validity	O
of	O
diagnosis	O
,	O
at	O
least	O
2	O
consensus	O
OCD	O
diagnoses	O
after	O
the	O
index	O
medical	O
visit	O
was	O
required	O
.	O

To	O
exclude	O
the	O
possible	O
confounding	O
effects	O
of	O
other	O
psychiatric	O
disorders	O
,	O
patients	O
with	O
any	B-phenotype
mental	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
:	O
290	B-code
.	I-code
XX	I-code
-	I-code
319	I-code
.	I-code
XX	I-code
)	O
one	O
year	O
prior	O
to	O
the	O
index	O
medical	O
visit	O
for	O
OCD	O
diagnosis	O
were	O
excluded	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
focused	O
on	O
the	O
long	O
-	O
term	O
SSRI	O
use	O
and	O
the	O
incidence	O
of	O
stroke	O
.	O

Medication	O
use	O
was	O
defined	O
by	O
receiving	O
a	O
prescription	O
for	O
a	O
SSRI	O
(	O
paroxetine	O
,	O
fluoxetine	O
,	O
sertraline	O
,	O
citalopram	O
,	O
escitalopram	O
,	O
or	O
fluvoxamine	O
)	O
for	O
at	O
least	O
two	O
consecutive	O
months	O
during	O
January	O
1	O
,	O
2001	O
,	O
to	O
December	O
31	O
,	O
2007	O
.	O

This	O
criteria	O
was	O
the	O
same	O
us	O
those	O
adopted	O
in	O
our	O
previous	O
studies	O
[	O
13	O
]	O
.	O

Patients	O
who	O
used	O
only	O
1	O
-	O
month	O
SSRI	O
were	O
excluded	O
from	O
the	O
analysis	O
because	O
high	O
possibilities	O
of	O
irregular	O
SSRI	O
use	O
;	O
the	O
others	O
were	O
defined	O
as	O
non	O
SSRI	O
exposure	O
group	O
.	O

The	O
final	O
sample	O
in	O
the	O
study	O
included	O
527	O
OCD	O
patients	O
,	O
412	O
subjects	O
in	O
the	O
SSRI	O
use	O
group	O
and	O
115	O
in	O
the	O
non	O
SSRI	O
use	O
group	O
.	O

Participants	O
were	O
met	O
criteria	O
for	O
incident	B-phenotype
stroke	I-phenotype
if	O
they	O
received	O
at	O
least	O
two	O
consecutive	O
diagnoses	O
of	O
codes	O
(	O
430	B-code
.	I-code
XX	I-code
to	O
438	B-code
.	I-code
XX	I-code
)	O
according	O
to	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
during	O
the	O
observation	O
period	O
after	O
the	O
index	O
medical	O
care	O
visit	O
for	O
OCD	O
.	O

Distributions	O
in	O
age	O
,	O
gender	O
,	O
concomitant	O
prescribed	O
medications	O
related	O
to	O
strokes	O
(	O
aspirin	O
and	O
Non	O
-	O
steroidal	O
Anti	O
-	O
inflammatory	O
Drugs	O
[	O
NSAIDs	O
]	O
)	O
and	O
comorbid	O
medical	O
conditions	O
(	O
(	O
angina	O
pectoris	O
,	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
,	O
hyperlipidemia	O
,	O
hypertension	O
,	O
atrial	O
fibrillation	O
,	O
and	O
myocardial	O
infarction	O
)	O
)	O
were	O
examined	O
by	O
using	O
χ	O
2	O
-	O
tests	O
.	O

Multivariable	O
Cox	O
proportional	O
-	O
hazards	O
models	O
were	O
used	O
to	O
explore	O
the	O
associations	O
between	O
SSRI	O
use	O
and	O
risk	O
of	O
stroke	O
,	O
controlling	O
for	O
age	O
,	O
gender	O
,	O
concomitant	O
medications	O
,	O
and	O
medical	O
comorbidities	O
.	O

All	O
statistical	O
tests	O
were	O
two	O
sided	O
,	O
conducted	O
at	O
significance	O
level	O
of	O
0	O
.	O
05	O
,	O
and	O
reported	O
using	O
P	O
value	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
the	O
SAS	O
software	O
,	O
version	O
9	O
.	O
2	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
.	O

The	O
data	O
,	O
analytic	O
methods	O
,	O
and	O
study	O
materials	O
will	O
not	O
be	O
automatically	O
made	O
available	O
to	O
other	O
researchers	O
for	O
purposes	O
of	O
reproducing	O
the	O
results	O
or	O
replicating	O
the	O
procedure	O
.	O

The	O
cohort	O
is	O
nested	O
within	O
the	O
WTC	O
Health	O
Program	O
(	O
WTCHP	O
)	O
and	O
authorization	O
will	O
have	O
to	O
be	O
obtained	O
from	O
the	O
WTCHP	O
too	O
.	O

WTC	O
-	O
Heart	O
is	O
a	O
prospective	O
,	O
fixed	O
cohort	O
of	O
6481	O
WTC	O
first	O
responders	O
involved	O
in	O
cleaning	O
up	O
the	O
debris	O
of	O
the	O
WTC	O
complex	O
in	O
New	O
York	O
(	O
NY	O
)	O
City	O
in	O
2001	O
and	O
2002	O
and	O
recruited	O
within	O
the	O
WTCHP	O
.	O

Active	O
follow	O
-	O
up	O
for	O
incident	O
and	O
recurrent	O
CVD	O
was	O
conducted	O
from	O
January	O
2012	O
until	O
June	O
2016	O
,	O
remotely	O
via	O
email	O
,	O
mail	O
,	O
and	O
phone	O
interviews	O
in	O
English	O
,	O
Spanish	O
,	O
and	O
Polish	O
.	O

The	O
cohort	O
was	O
also	O
linked	O
with	O
the	O
NY	O
State	O
hospitalization	O
database	O
,	O
SPARCS	O
.	O

The	O
cohort	O
was	O
recruited	O
from	O
two	O
WTCHP	O
sites	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
Icahn	O
School	O
of	O
Medicine	O
at	O
Mount	O
Sinai	O
or	O
North	O
Shore	O
Long	O
Island	O
Jewish	O
Hospital	O
)	O
in	O
NY	O
City	O
.	O

The	O
WTCHP	O
,	O
established	O
in	O
2002	O
,	O
comprises	O
non	O
-	O
firefighter	O
workers	O
and	O
volunteers	O
engaged	O
in	O
rescue	O
,	O
recovery	O
,	O
restoration	O
of	O
services	O
,	O
cleanup	O
,	O
or	O
other	O
support	O
work	O
on	O
or	O
after	O
9	O
/	O
11	O
.	O

These	O
first	O
responders	O
were	O
eligible	O
in	O
the	O
WTCHP	O
if	O
they	O
had	O
worked	O
for	O
≥4	O
hours	O
on	O
September	O
11	O
to	O
14	O
,	O
2001	O
,	O
≥24	O
hours	O
during	O
the	O
month	O
of	O
September	O
2001	O
,	O
or	O
≥80	O
hours	O
total	O
during	O
the	O
period	O
of	O
October	O
through	O
December	O
2001	O
.	O

13	O
Also	O
eligible	O
were	O
employees	O
of	O
the	O
Office	O
of	O
the	O
Chief	O
Medical	O
Examiner	O
who	O
processed	O
human	O
remains	O
,	O
of	O
the	O
Port	O
Authority	O
Trans	O
-	O
Hudson	O
Corporation	O
who	O
participated	O
in	O
the	O
cleanup	O
efforts	O
for	O
≥24	O
hours	O
from	O
February	O
to	O
July	O
2002	O
,	O
and	O
workers	O
who	O
drove	O
,	O
repaired	O
,	O
cleaned	O
,	O
or	O
maintained	O
vehicles	O
that	O
handled	O
WTC	O
debris	O
for	O
at	O
least	O
one	O
day	O
between	O
September	O
11	O
th	O
,	O
2001	O
and	O
July	O
31	O
st	O
,	O
2002	O
.	O

14	O

The	O
cohort	O
is	O
a	O
consecutive	O
sample	O
of	O
6481	O
women	O
and	O
men	O
attending	O
one	O
of	O
their	O
up	O
to	O
10	O
th	O
annual	O
clinical	O
visits	O
at	O
the	O
WTCHP	O
between	O
January	O
2012	O
and	O
June	O
2013	O
(	O
baseline	O
)	O
.	O

Annual	O
visits	O
are	O
not	O
necessarily	O
associated	O
with	O
medical	O
problems	O
requiring	O
care	O
.	O

Informed	O
consent	O
was	O
provided	O
on	O
the	O
day	O
of	O
recruitment	O
,	O
in	O
English	O
,	O
Spanish	O
and	O
Polish	O
.	O

The	O
Queens	O
College	O
IRB	O
and	O
those	O
of	O
the	O
two	O
recruitment	O
sites	O
approved	O
the	O
WTC	O
-	O
Heart	O
protocol	O
.	O

Recognized	O
cardiovascular	O
risk	O
factors	O
comprised	O
:	O
a	O
)	O
standardized	O
2	O
measurements	O
of	O
blood	O
pressure	O
to	O
the	O
3	O
rd	O
digit	O
(	O
e	O
.	O
g	O
.	O
,	O
12	O
.	O
2	O
)	O
after	O
sitting	O
down	O
;	O
b	O
)	O
a	O
comprehensive	O
smoking	O
history	O
;	O
c	O
)	O
body	O
weight	O
and	O
height	O
measured	O
in	O
lightly	O
dressed	O
subjects	O
;	O
d	O
)	O
blood	O
lipids	O
:	O
total	O
cholesterol	O
,	O
low	O
-	O
density	O
lipoprotein	O
,	O
and	O
triglycerides	O
.	O

Clinical	O
personnel	O
were	O
trained	O
specifically	O
for	O
this	O
study	O
and	O
provided	O
identical	O
,	O
new	O
instruments	O
(	O
scales	O
,	O
sphygmomanometers	O
)	O
.	O

Baseline	O
mental	O
health	O
symptoms	O
included	O
the	O
PTSD	O
checklist	O
PCL	O
-	O
C	O
(	O
civilian	O
)	O
for	O
DSM	O
-	O
IV	O
,	O
15	O
with	O
a	O
specific	O
preamble	O
relating	O
the	O
answers	O
to	O
the	O
participation	O
in	O
the	O
WTC	O
cleanup	O
.	O

The	O
cut	O
off	O
for	O
probable	O
PTSD	O
was	O
>	O
=	O
44	O
points	O
as	O
recommended	O
given	O
the	O
prevalence	O
of	O
PTSD	O
in	O
the	O
cohort	O
.	O

16	O
Possible	O
depression	O
was	O
defined	O
as	O
a	O
score	O
of	O
10	O
or	O
more	O
(	O
in	O
a	O
range	O
of	O
0	O
to	O
27	O
)	O
on	O
the	O
9	O
questions	O
of	O
the	O
Patient	O
Health	O
Questionnaire	O
-	O
9	O
(	O
PHQ	O
-	O
9	O
)	O
17	O

In	O
a	O
detailed	O
questionnaire	O
each	O
participant	O
indicated	O
:	O
1	O
)	O
which	O
day	O
on	O
or	O
after	O
September	O
11	O
they	O
began	O
working	O
on	O
the	O
WTC	O
complex	O
;	O
2	O
)	O
whether	O
they	O
were	O
“directly	O
in	O
the	O
cloud	O
of	O
dust	O
(	O
or	O
blackout	O
)	O
from	O
the	O
collapse	O
of	O
the	O
WTC	O
buildings”	O
or	O
not	O
;	O
3	O
)	O
whether	O
their	O
work	O
was	O
“adjacent”	O
or	O
“on”	O
the	O
pile	O
or	O
pit	O
,	O
terms	O
that	O
referred	O
to	O
the	O
former	O
location	O
of	O
the	O
twin	O
towers	O
of	O
the	O
WTC	O
complex	O
;	O
and	O
4	O
)	O
whether	O
they	O
wore	O
a	O
protective	O
mask	O
.	O

18	O

Attempts	O
were	O
made	O
to	O
contact	O
every	O
participant	O
once	O
a	O
year	O
from	O
the	O
2012	O
baseline	O
to	O
June	O
2016	O
.	O

At	O
each	O
annual	O
contact	O
,	O
incident	O
cardiac	O
and	O
incident	O
neurologic	O
events	O
were	O
reported	O
in	O
a	O
standardized	O
,	O
self	O
-	O
administered	O
survey	O
in	O
English	O
,	O
Spanish	O
,	O
and	O
Polish	O
either	O
online	O
,	O
by	O
mail	O
,	O
or	O
by	O
telephone	O
.	O

In	O
case	O
of	O
death	O
reported	O
by	O
a	O
relative	O
or	O
by	O
the	O
WTCHP	O
a	O
questionnaire	O
and	O
request	O
of	O
death	O
certificate	O
was	O
mailed	O
to	O
either	O
relatives	O
or	O
health	O
care	O
provider	O
.	O

All	O
self	O
-	O
reported	O
CV	O
events	O
on	O
the	O
follow	O
-	O
up	O
forms	O
,	O
including	O
positive	O
report	O
of	O
cardiac	O
symptoms	O
,	O
myocardial	O
infarction	O
(	O
MI	O
)	O
,	O
neurological	O
symptoms	O
,	O
and	O
/	O
or	O
stroke	O
,	O
were	O
tentatively	O
confirmed	O
by	O
specific	O
additional	O
personal	O
interviews	O
conducted	O
by	O
phone	O
by	O
trained	O
interviewers	O
in	O
English	O
,	O
Spanish	O
,	O
or	O
Polish	O
.	O

Determination	O
of	O
incident	O
and	O
recurrent	O
cardiovascular	O
outcomes	O
in	O
medical	O
charts	O
was	O
performed	O
by	O
a	O
blinded	O
adjudicating	O
panel	O
comprising	O
the	O
principal	O
investigator	O
(	O
AM	O
)	O
and	O
a	O
senior	O
research	O
worker	O
(	O
CMM	O
)	O
with	O
24	O
years	O
of	O
experience	O
adjudicating	O
acute	O
MI	O
and	O
stroke	O
in	O
several	O
large	O
population	O
-	O
based	O
studies	O
.	O

An	O
MI	O
was	O
confirmed	O
in	O
the	O
presence	O
of	O
typical	O
symptoms	O
,	O
EKG	O
signs	O
,	O
Troponin	O
,	O
and	O
/	O
or	O
enzymatic	O
movement	O
.	O

A	O
stroke	O
or	O
a	O
transient	O
ischemic	O
attack	O
was	O
confirmed	O
in	O
the	O
presence	O
of	O
typical	O
symptoms	O
and	O
medical	O
imaging	O
or	O
sonographic	O
signs	O
.	O

From	O
January	O
1	O
st	O
,	O
2012	O
through	O
December	O
31	O
st	O
,	O
2016	O
(	O
latest	O
year	O
available	O
)	O
all	O
WTC	O
-	O
Heart	O
participants	O
were	O
electronically	O
linked	O
to	O
NY	O
State	O
Department	O
of	O
Health’s	O
SPARCS	O
program	O
,	O
which	O
includes	O
diagnoses	O
and	O
dates	O
for	O
all	O
patients	O
discharged	O
from	O
acute	O
care	O
hospitals	O
,	O
excluding	O
psychiatric	O
and	O
federal	O
hospitals	O
.	O

The	O
coding	O
of	O
discharge	O
diagnoses	O
may	O
not	O
be	O
accurate	O
but	O
the	O
degree	O
of	O
inaccuracy	O
is	O
likely	O
to	O
be	O
homogeneous	O
across	O
the	O
cohort	O
.	O

Matched	O
records	O
had	O
identical	O
key	O
identifying	O
information	O
,	O
such	O
as	O
name	O
,	O
date	O
of	O
birth	O
,	O
4	O
last	O
digits	O
of	O
the	O
Social	O
Security	O
number	O
,	O
or	O
address	O
.	O

Analyses	O
were	O
restricted	O
to	O
the	O
5484	O
NY	O
City	O
or	O
State	O
residents	O
.	O

We	O
used	O
,	O
for	O
MI	B-phenotype
,	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
410–411	B-code
,	O
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
I21–I22	B-code
,	O
and	O
for	O
stroke	B-phenotype
,	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
430–432	B-code
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
I60–I63	B-code
.	O

For	O
the	O
follow	O
-	O
up	O
years	O
2012	O
through	O
2016	O
,	O
180	O
WTC	O
-	O
Heart	O
study	O
participants	O
were	O
identified	O
in	O
the	O
SPARCS	O
database	O
as	O
having	O
been	O
hospitalized	O
with	O
a	O
discharge	O
diagnosis	O
of	O
MI	O
or	O
stroke	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
analysis	O
was	O
used	O
to	O
plot	O
the	O
cumulative	O
incidence	O
of	O
MIs	O
and	O
/	O
or	O
stroke	O
.	O

Cox	O
proportional	O
hazards	O
models	O
were	O
used	O
to	O
estimate	O
adjusted	O
hazard	O
ratios	O
(	O
aHR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
of	O
MI	O
or	O
stroke	O
,	O
adjusted	O
for	O
use	O
of	O
a	O
respirator	O
and	O
for	O
recognized	O
cardiovascular	O
risk	O
factors	O
:	O
age	O
,	O
blood	O
pressure	O
,	O
total	O
cholesterol	O
,	O
body	O
mass	O
index	O
,	O
tobacco	O
use	O
,	O
and	O
,	O
when	O
relevant	O
,	O
gender	O
.	O

Firth’s	O
procedure	O
was	O
applied	O
to	O
improve	O
aHR	O
and	O
CI	O
estimates	O
from	O
Cox	O
proportional	O
hazard	O
models	O
with	O
small	O
sample	O
sizes	O
and	O
few	O
measured	O
outcome	O
events	O
.	O

19	O

Since	O
PTSD	O
may	O
have	O
increased	O
weight	O
gain	O
,	O
tobacco	O
use	O
,	O
blood	O
pressure	O
,	O
and	O
possibly	O
cholesterol	O
after	O
the	O
2001–2002	O
trauma	O
,	O
resulting	O
in	O
these	O
factors	O
being	O
on	O
the	O
pathway	O
to	O
MI	O
and	O
stroke	O
and	O
biasing	O
the	O
HRs	O
towards	O
the	O
null	O
,	O
we	O
present	O
primary	O
analyses	O
both	O
age	O
-	O
adjusted	O
and	O
,	O
when	O
sample	O
size	O
allows	O
,	O
adjusted	O
for	O
all	O
these	O
factors	O
.	O

Time	O
of	O
event	O
was	O
retrieved	O
from	O
the	O
participant’s	O
interview	O
or	O
SPARCS	O
records	O
.	O

For	O
event	O
-	O
free	O
participants	O
censoring	O
for	O
interview	O
-	O
based	O
incident	O
events	O
occurred	O
at	O
the	O
date	O
of	O
completion	O
of	O
the	O
most	O
recent	O
annual	O
survey	O
,	O
or	O
,	O
for	O
SPARCS	O
-	O
derived	O
events	O
,	O
on	O
December	O
31	O
st	O
,	O
2016	O
,	O
the	O
last	O
date	O
of	O
available	O
SPARCS	O
data	O
.	O

Analyses	O
of	O
post	O
-	O
baseline	O
,	O
incident	O
outcomes	O
were	O
therefore	O
repeated	O
including	O
and	O
excluding	O
MIs	O
and	O
strokes	O
recurring	O
during	O
follow	O
-	O
up	O
among	O
subjects	O
who	O
already	O
had	O
an	O
MI	O
or	O
stroke	O
before	O
2012	O
.	O

We	O
report	O
the	O
analysis	O
including	O
all	O
cases	O
in	O
the	O
article	O
for	O
four	O
reasons	O
:	O
1	O
)	O
because	O
this	O
cohort	O
had	O
a	O
mean	O
age	O
of	O
51y	O
in	O
2012	O
,	O
all	O
cardiovascular	O
events	O
occurred	O
after	O
2001	O
;	O
2	O
)	O
PTSD	O
is	O
a	O
chronic	O
disease	O
,	O
most	O
likely	O
secondary	O
to	O
2001	O
,	O
for	O
which	O
it	O
is	O
difficult	O
to	O
set	O
an	O
exact	O
date	O
of	O
onset	O
;	O
3	O
)	O
these	O
middle	O
aged	O
subjects	O
who	O
had	O
cardiovascular	O
events	O
before	O
baseline	O
were	O
subjects	O
at	O
highest	O
risk	O
in	O
the	O
cohort	O
and	O
excluding	O
them	O
would	O
also	O
introduce	O
selection	O
bias	O
;	O
4	O
)	O
removing	O
35	O
recurrent	O
cases	O

did	O
not	O
alter	O
the	O
statistical	O
power	O
for	O
the	O
full	O
analysis	O
(	O
as	O
shown	O
in	O
the	O
paper	O
)	O
but	O
left	O
thin	O
data	O
for	O
the	O
gender	O
-	O
and	O
disease	O
-	O
specific	O
analyses	O
.	O

Thus	O
,	O
subjects	O
who	O
had	O
had	O
pre	O
-	O
baseline	O
cardiovascular	O
events	O
were	O
excluded	O
for	O
some	O
of	O
the	O
exploratory	O
full	O
sample	O
analyses	O
but	O
kept	O
in	O
all	O
other	O
analyses	O
,	O
with	O
only	O
the	O
post	O
baseline	O
events	O
going	O
into	O
the	O
numerator	O
of	O
the	O
hazard	O
rates	O
and	O
risks	O
.	O

MI	O
and	O
stroke	O
were	O
analyzed	O
both	O
separately	O
and	O
pooled	O
as	O
a	O
single	O
outcome	O
(	O
MI	O
/	O
stroke	O
)	O
because	O
separate	O
analyses	O
of	O
self	O
-	O
reported	O
MI	O
and	O
stroke	O
,	O
provided	O
in	O
an	O
appendix	O
,	O
yielded	O
associations	O
of	O
consistent	O
magnitudes	O
.	O

Similarly	O
,	O
men	O
and	O
women	O
were	O
analyzed	O
estimating	O
both	O
separate	O
and	O
pooled	O
,	O
gender	O
-	O
adjusted	O
HRs	O
.	O

The	O
number	O
of	O
female	O
cases	O
(	O
9	O
MIs	O
,	O
7	O
strokes	O
and	O
22	O
hospitalizations	O
for	O
MI	O
or	O
stroke	O
)	O
precluded	O
statistical	O
power	O
for	O
most	O
analyses	O
,	O
but	O
,	O
as	O
shown	O
in	O
the	O
appendix	O
,	O
the	O
magnitude	O
of	O
the	O
associations	O
was	O
remarkably	O
consistent	O
across	O
gender	O
allowing	O
for	O
meaningful	O
gender	O
-	O
adjusted	O
HRs	O
.	O

The	O
participants	O
who	O
had	O
both	O
MI	O
and	O
stroke	O
were	O
analyzed	O
as	O
per	O
the	O
first	O
of	O
the	O
two	O
outcomes	O
in	O
the	O
analyses	O
pooling	O
MI	O
and	O
stroke	O
.	O

Because	O
PTSD	O
and	O
depression	O
are	O
highly	O
correlated	O
the	O
analyses	O
for	O
pooled	O
MI	O
and	O
stroke	O
adjusted	O
for	O
recognized	O
cardiovascular	O
risk	O
factors	O
were	O
repeated	O
among	O
n=4120	O
non	O
-	O
depressed	O
men	O
(	O
the	O
number	O
of	O
female	O
cases	O
was	O
too	O
small	O
to	O
perform	O
gender	O
adjusted	O
analyses	O
)	O
,	O
after	O
exclusion	O
of	O
men	O
having	O
either	O
depression	O
only	O
(	O
n=97	O
)	O
,	O
depression	O
and	O
PTSD	O
(	O
n=477	O
)	O
or	O
missing	O
depression	O
data	O
(	O
n=248	O
)	O
.	O

HUSH	O
is	O
a	O
pragmatic	O
,	O
patient	O
-	O
centered	O
,	O
parallel	O
-	O
group	O
,	O
randomized	O
,	O
controlled	O
trial	O
comparing	O
two	O
CBT	O
-	O
I	O
-	O
based	O
interventions	O
for	O
insomnia	O
to	O
EUC	O
.	O

The	O
study	O
has	O
been	O
approved	O
by	O
the	O
University	O
of	O
Pittsburgh	O
Institutional	O
Review	O
Board	O
(	O
last	O
renewed	O
on	O
May	O
2	O
,	O
2016	O
,	O
REN16040175	O
/	O
PRO14070337	O
)	O
and	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
Identifier	O
:	O
NCT02508129	O
;	O
last	O
updated	O
January	O
2016	O
)	O
.	O

Study	O
reporting	O
adheres	O
to	O
Standard	O
Protocol	O
Items	O
:	O
Recommendations	O
for	O
Interventional	O
Trials	O
Reporting	O
(	O
Additional	O
file	O
1	O
)	O
[	O
54	O
,	O
55	O
]	O
.	O

Participants	O
meeting	O
study	O
eligibility	O
criteria	O
are	O
enrolled	O
after	O
completing	O
initial	O
screening	O
and	O
signing	O
informed	O
consent	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Following	O
baseline	O
assessments	O
,	O
they	O
are	O
randomly	O
assigned	O
to	O
the	O
BBTI	O
,	O
SHUTi	O
,	O
or	O
EUC	O
condition	O
.	O

Participants	O
complete	O
follow	O
-	O
up	O
assessments	O
at	O
three	O
time	O
points	O
(	O
9	O
weeks	O
,	O
6	O
months	O
,	O
12	O
months	O
)	O
,	O
after	O
completing	O
the	O
intervention	O
phase	O
.	O

Trial	O
conduct	O
is	O
overseen	O
by	O
three	O
committees	O
,	O
namely	O
a	O
study	O
investigators’	O
team	O
,	O
which	O
provides	O
guidance	O
and	O
makes	O
key	O
decisions	O
about	O
the	O
conduct	O
and	O
implementation	O
of	O
the	O
study	O
as	O
a	O
whole	O
;	O
a	O
study	O
protocol	O
management	O
team	O
,	O
which	O
addresses	O
specific	O
challenges	O
in	O
protocol	O
procedures	O
and	O
data	O
management	O
;	O
and	O
an	O
external	O
data	O
and	O
safety	O
monitoring	O
board	O
(	O
DSMB	O
;	O
described	O
below	O
)	O
.	O

Fig	O
.	O

1	O
Study	O
flow	O
diagram	O

Study	O
flow	O
diagram	O

The	O
study	O
will	O
enroll	O
a	O
total	O
of	O
625	O
men	O
and	O
women	O
ages	O
18	O
and	O
over	O
with	O
a	O
diagnosis	O
of	O
HTN	O
,	O
and	O
either	O
hypnotic	O
use	O
or	O
insomnia	O
diagnosis	O
(	O
INS	O
)	O
.	O

Because	O
this	O
study	O
is	O
designed	O
to	O
recruit	O
a	O
sample	O
of	O
primary	O
care	O
patients	O
with	O
INS	O
plus	O
HTN	O
and	O
other	O
typical	O
co	O
-	O
morbidities	O
,	O
our	O
eligibility	O
criteria	O
are	O
intentionally	O
broad	O
.	O

Participants	O
from	O
all	O
racial	O
and	O
ethnic	O
groups	O
who	O
plan	O
to	O
remain	O
under	O
the	O
care	O
of	O
their	O
current	O
University	O
of	O
Pittsburgh	O
Medical	O
Center	O
(	O
UPMC	O
)	O
provider	O
for	O
at	O
least	O
1	O
year	O
are	O
enrolled	O
.	O

Inclusion	O
and	O
exclusion	O
criteria	O
and	O
their	O
method	O
of	O
ascertainment	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Because	O
all	O
participant	O
contact	O
,	O
measures	O
,	O
and	O
interventions	O
occur	O
via	O
telephone	O
or	O
Internet	O
,	O
participants	O
are	O
required	O
to	O
have	O
reliable	O
Internet	O
access	O
.	O

Participants	O
are	O
excluded	O
if	O
they	O
have	O
current	O
,	O
severe	O
,	O
untreated	O
sleep	O
disorders	O
other	O
than	O
insomnia	O
.	O

We	O
do	O
not	O
exclude	O
participants	O
for	O
using	O
medications	O
known	O
to	O
affect	O
sleep	O
or	O
wake	O
function	O
(	O
e	O
.	O
g	O
.	O
,	O
caffeine	O
,	O
alcohol	O
,	O
hypnotics	O
,	O
benzodiazepines	O
,	O
antidepressants	O
,	O
anxiolytics	O
,	O
antipsychotics	O
,	O
decongestants	O
and	O
sedating	O
antihistamines	O
,	O
beta	O
blockers	O
,	O
corticosteroids	O
)	O
,	O
since	O
they	O
are	O
common	O
among	O
“real	O
-	O
life”	O
insomnia	O
patients	O
.	O

Educational	O
components	O
of	O
the	O
interventions	O
are	O
,	O
in	O
part	O
,	O
targeted	O
at	O
the	O
use	O
of	O
these	O
substances	O
and	O
medications	O
.	O

Participants’	O
use	O
of	O
these	O
medications	O
is	O
monitored	O
via	O
sleep	O
-	O
wake	O
diaries	O
and	O
medication	O
lists	O
in	O
the	O
EHR	O
.	O

Table	O
1	O
Eligibility	O
criteria	O
Criterion	O
Method	O
Inclusion	O
criteria	O
Age	O
18–75	O
years	O
Interview	O
Hypertension	O
diagnosis	O
RRA	O
;	O
Diagnosis	O
code	O
401	B-code
.	I-code
9	I-code
Prescription	O
within	O
a	O
12	O
-	O
month	O
period	O
of	O
the	O
following	O
:	O
zolpidem	O
,	O
zaleplon	O
,	O
eszopiclone	O
,	O
triazolam	O
,	O
or	O
temazepam	O
a	O
RRA	O
;	O
Name	O
-	O
brand	O
or	O
generic	O
Prescription	O
within	O
a	O
12	O
-	O
month	O
period	O
,	O
with	O
instructions	O
to	O
take	O
at	O
bedtime	O
,	O
of	O
the	O
following	O
:	O
trazodone	O
,	O
doxepin	O
,	O
amitriptyline	O
,	O
lorazepam	O
,	O
clonazepam	O
a	O
RRA	O
;	O
Name	O
-	O
brand	O
or	O
generic	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
insomnia	B-phenotype
diagnosis	O
a	O
Diagnosis	O

codes	O
307	B-code
.	I-code
42	I-code
,	O
307	B-code
.	I-code
47	I-code
,	O
or	O
780	B-code
.	I-code
52	I-code
,	O
or	O
listed	O
in	O
chart’s	O
‘problem	O
list’	O
;	O
verified	O
with	O
structured	O
interview	O
At	O
least	O
moderate	O
insomnia	O
severity	O
:	O
Score	O
≥	O
8	O
on	O
Insomnia	O
Severity	O
Index	O
[	O
59	O
]	O
Telephone	O
questionnaire	O
Telephone	O
,	O
email	O
address	O
,	O
reliable	O
Internet	O
access	O
Interview	O
Stable	O
medical	O
,	O
psychiatric	O
condition	O
;	O
no	O
hospitalizations	O
in	O
3	O
months	O
Interview	O
Exclusion	O
criteria	O
Untreated	O
current	O
major	O
depression	O
(	O
PHQ	O
-	O
9	O
score	O
≥	O
10	O
;	O
GAD	O
-	O
7	O
score	O
≥	O
10	O
)	O
;	O
patients	O
using	O
stable	O
(	O
3	O
months	O
)	O
medication	O
or	O
psychological	O

treatment	O
are	O
eligible	O
Telephone	O
PHQ	O
-	O
9	O
[	O
61	O
]	O
,	O
GAD	O
-	O
7	O
[	O
62	O
]	O
;	O
Interview	O
Bipolar	B-phenotype
disorder	I-phenotype
RRA	I-phenotype
with	O
diagnosis	O
code	O
296	B-code
.	I-code
8	I-code
,	O
or	O
Interview	O
Dementia	B-phenotype
,	I-phenotype
probable	I-phenotype
dementia	I-phenotype
,	I-phenotype
or	I-phenotype
mild	I-phenotype
cognitive	I-phenotype
impairment	I-phenotype
RRA	I-phenotype
with	O
diagnosis	O
codes	O
290	B-code
.	I-code
XX	I-code
-	I-code
294	I-code
.	I-code
xx	I-code
or	O
331	B-code
.	I-code
83	I-code
,	O
and	O
Telephone	O
Montreal	O
Cognitive	O
Assessment	O
[	O
93	O
]	O
Substance	B-phenotype
use	I-phenotype
disorders	I-phenotype
within	O
the	O
past	O
3	O
months	O
Diagnosis	O
codes	O
291	B-code
.	I-code
XX	I-code
,	O
292	B-code
.	I-code
XX	I-code
,	O
303	B-code
.	I-code
XX	I-code
-	I-code
305	I-code
.	I-code
XX	I-code
,	O
and	O
NIDA	O
Quick	O
Screen	O
[	O
63	O
]	O
Schizophrenia	O
or	O
psychotic	O
disorder	O
RRA	O
with	O
diagnosis	O
codes	O
293	O
.	O
XX	O
-	O
298	O
.	O
XX	O
and	O
Interview	O

Treatment	O
with	O
lithium	O
or	O
antipsychotic	O
medication	O
RRA	O
and	O
electronic	O
health	O
record	O
review	O
;	O
Indicates	O
likely	O
diagnosis	O
of	O
bipolar	B-phenotype
disorder	I-phenotype
or	I-phenotype
psychotic	I-phenotype
disorder	I-phenotype
Active	I-phenotype
suicidal	I-phenotype
ideation	I-phenotype
or	I-phenotype
psychosis	I-phenotype
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
Dimensional	O
Symptom	O
Assessment	O
[	O
94	O
]	O
Severe	O
obstructive	O
sleep	O
apnea	O
(	O
Apnea	O
Hypopnea	O
Index	O
>	O
50	O
or	O
oxyhemoglobin	O
saturation	O
<	O
85	O
%	O
for	O
>	O
5	O
%	O
of	O
the	O
night	O
)	O
Screening	O
assessment	O
for	O
sleep	O
disorders	O
;	O
ApneaLink	O
Plus	O
Untreated	O
and	O
severe	O
insufficient	O
sleep	O
syndrome	O
,	O
delayed	O
sleep	O
phase	O
syndrome	O
(	O
habitual	O

bedtimes	O
later	O
than	O
2	O
:	O
00	O
a	O
.	O
m	O
.	O
,	O
habitual	O
waketimes	O
later	O
than	O
9	O
:	O
00	O
a	O
.	O
m	O
.	O
)	O
,	O
narcolepsy	O
,	O
severe	O
restless	O
legs	O
syndrome	O
,	O
and	O
current	O
night	O
shift	O
work	O
(	O
i	O
.	O
e	O
.	O
,	O
any	O
work	O
occurring	O
between	O
the	O
hours	O
of	O
midnight	O
and	O
6	O
:	O
00	O
a	O
.	O
m	O
.	O

)	O
Screening	O
assessment	O
for	O
sleep	O
disorders	O
Plans	O
to	O
move	O
or	O
leave	O
present	O
source	O
of	O
care	O
during	O
the	O
following	O
year	O
Interview	O
Non	O
-	O
English	O
speaking	O
,	O
illiterate	O
,	O
or	O
sensory	O
deficits	O
Interview	O
a	O
Participants	O
must	O
meet	O
one	O
of	O
these	O
criteria	O
to	O
be	O
eligible	O
for	O
inclusion	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
Diagnostic	I-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
(	I-coding_system
5th	I-coding_system
edition	I-coding_system
)	I-coding_system
,	O
GAD	O
-	O
7	O
Generalized	O
Anxiety	O
Disorder	O
7	O
-	O
item	O
scale	O
,	O
PHQ	O
-	O
9	O
Patient	O
Health	O
Questionnaire	O
(	O
9	O
item	O
)	O
,	O
RRA	O
Research	O
Recruitment	O
Alert	O

Eligibility	O
criteria	O

a	O
Participants	O
must	O
meet	O
one	O
of	O
these	O
criteria	O
to	O
be	O
eligible	O
for	O
inclusion	O

DSM	B-coding_system
-	I-coding_system
5	I-coding_system
Diagnostic	I-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
(	I-coding_system
5th	I-coding_system
edition	I-coding_system
)	I-coding_system
,	O
GAD	O
-	O
7	O
Generalized	O
Anxiety	O
Disorder	O
7	O
-	O
item	O
scale	O
,	O
PHQ	O
-	O
9	O
Patient	O
Health	O
Questionnaire	O
(	O
9	O
item	O
)	O
,	O
RRA	O
Research	O
Recruitment	O
Alert	O

Participants	O
are	O
recruited	O
via	O
alerts	O
triggered	O
in	O
the	O
EpicCare	O
EHR	O
from	O
approximately	O
20	O
of	O
the	O
120	O
primary	O
care	O
practices	O
affiliated	O
with	O
the	O
UPMC	O
,	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
.	O

We	O
maintain	O
engagement	O
with	O
practices	O
through	O
yearly	O
practice	O
visits	O
,	O
quarterly	O
physician	O
newsletters	O
,	O
and	O
reporting	O
patient	O
progress	O
through	O
the	O
protocol	O
to	O
referring	O
physicians	O
.	O

To	O
serve	O
as	O
additional	O
reminders	O
,	O
at	O
regular	O
intervals	O
we	O
offer	O
study	O
-	O
branded	O
materials	O
,	O
posters	O
,	O
brochures	O
,	O
and	O
pens	O
to	O
participating	O
practices	O
.	O

Recruitment	O
is	O
conducted	O
using	O
physician	O
alerts	O
in	O
the	O
EpicCare	O
EHR	O
.	O

At	O
the	O
time	O
of	O
the	O
patient	O
encounter	O
,	O
physicians	O
in	O
the	O
participating	O
primary	O
care	O
practices	O
receive	O
a	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
-	O
compliant	O
Research	O
Recruitment	O
Alert	O
(	O
RRA	O
;	O
Fig	O
.	O

2	O
)	O
in	O
the	O
EHR	O
,	O
triggered	O
by	O
relevant	O
patient	O
characteristics	O
.	O

A	O
list	O
of	O
specific	O
ICD	B-coding_system
codes	O
that	O
trigger	O
the	O
RRA	O
(	O
and	O
exclusion	O
criteria	O
codes	O
that	O
cause	O
an	O
alert	O
not	O
to	O
be	O
fired	O
)	O
are	O
available	O
in	O
Table	O
1	O
.	O

The	O
physician	O
then	O
asks	O
the	O
patient	O
if	O
they	O
would	O
like	O
to	O
consider	O
participating	O
in	O
our	O
study	O
.	O

Upon	O
obtaining	O
the	O
patients’	O
initial	O
assent	O
,	O
physicians	O
refer	O
eligible	O
patients	O
to	O
the	O
study	O
by	O
clicking	O
a	O
“yes”	O
or	O
“no”	O
button	O
in	O
the	O
EHR	O
.	O

A	O
“yes”	O
response	O
triggers	O
an	O
RRA	O
with	O
the	O
patient’s	O
basic	O
information	O
to	O
be	O
transmitted	O
to	O
the	O
study	O
team	O
,	O
including	O
name	O
,	O
contact	O
information	O
,	O
date	O
of	O
birth	O
,	O
primary	O
care	O
physician	O
name	O
,	O
and	O
allergies	O
,	O
among	O
other	O
basic	O
patient	O
information	O
.	O

Upon	O
receiving	O
the	O
RRA	O
,	O
an	O
automatically	O
-	O
generated	O
email	O
is	O
sent	O
from	O
the	O
study	O
team	O
to	O
the	O
patient	O
,	O
inviting	O
them	O
to	O
complete	O
an	O
online	O
screening	O
,	O
or	O
to	O
arrange	O
a	O
telephone	O
screening	O
with	O
a	O
study	O
staff	O
member	O
.	O

If	O
the	O
patient	O
does	O
not	O
have	O
an	O
email	O
address	O
or	O
does	O
not	O
respond	O
to	O
email	O
,	O
the	O
patient	O
is	O
contacted	O
via	O
telephone	O
.	O

Physicians	O
may	O
also	O
initiate	O
a	O
patient	O
referral	O
directly	O
to	O
the	O
trial	O
via	O
the	O
EHR	O
,	O
permitting	O
referrals	O
outside	O
of	O
office	O
visits	O
and	O
for	O
patients	O
who	O
may	O
qualify	O
,	O
but	O
whose	O
EHR	O
did	O
not	O
trigger	O
a	O
RRA	O
.	O

Fig	O
.	O

2	O
Example	O
of	O
research	O
recruitment	O
alert	O
Fig	O
.	O

3	O
Study	O
procedures	O
and	O
assessment	O
grid	O

Example	O
of	O
research	O
recruitment	O
alert	O

Study	O
procedures	O
and	O
assessment	O
grid	O

Potential	O
participants	O
complete	O
initial	O
study	O
screening	O
online	O
,	O
or	O
via	O
an	O
identical	O
telephone	O
interview	O
.	O

The	O
screening	O
provides	O
a	O
brief	O
description	O
of	O
the	O
research	O
study	O
,	O
interventions	O
,	O
and	O
assessment	O
procedures	O
.	O

If	O
the	O
patient	O
is	O
interested	O
and	O
elects	O
to	O
complete	O
the	O
online	O
screening	O
,	O
they	O
answer	O
several	O
questions	O
related	O
to	O
demographic	O
information	O
,	O
sleep	O
characteristics	O
,	O
symptoms	O
of	O
insomnia	O
,	O
medical	O
history	O
,	O
and	O
computer	O
and	O
Internet	O
access	O
,	O
using	O
the	O
instruments	O
described	O
above	O
.	O

If	O
the	O
patient	O
is	O
initially	O
eligible	O
to	O
proceed	O
based	O
on	O
this	O
information	O
and	O
expresses	O
interest	O
,	O
a	O
phone	O
appointment	O
is	O
scheduled	O
to	O
review	O
the	O
study	O
consent	O
form	O
and	O
to	O
conduct	O
additional	O
eligibility	O
assessments	O
.	O

The	O
participant	O
is	O
emailed	O
the	O
consent	O
form	O
and	O
the	O
URL	O
to	O
the	O
study	O
website	O
.	O

During	O
the	O
phone	O
appointment	O
,	O
the	O
patient	O
logs	O
in	O
and	O
reviews	O
the	O
online	O
consent	O
form	O
with	O
a	O
staff	O
member	O
.	O

The	O
patient	O
has	O
the	O
opportunity	O
to	O
ask	O
questions	O
and	O
clarifications	O
before	O
electronically	O
signing	O
the	O
consent	O
.	O

Study	O
staff	O
then	O
review	O
additional	O
study	O
criteria	O
(	O
Fig	O
.	O

3	O
)	O
with	O
the	O
participant	O
to	O
ensure	O
eligibility	O
,	O
entering	O
these	O
data	O
directly	O
via	O
the	O
web	O
interface	O
.	O

The	O
absence	O
of	O
exclusionary	O
diagnoses	O
(	O
e	O
.	O
g	O
.	O
,	O
bipolar	O
disorder	O
)	O
is	O
verified	O
by	O
study	O
staff	O
after	O
the	O
interview	O
,	O
by	O
reviewing	O
the	O
patient’s	O
problem	O
list	O
in	O
the	O
EHR	O
.	O

Additional	O
medical	O
information	O
is	O
also	O
extracted	O
from	O
the	O
patient’s	O
EHR	O
.	O

We	O
reduce	O
the	O
risk	O
of	O
receiving	O
unnecessary	O
information	O
from	O
the	O
patient’s	O
chart	O
through	O
the	O
use	O
of	O
an	O
intermediary	O
,	O
the	O
Center	O
for	O
Assistance	O
in	O
Research	O
using	O
e	O
-	O
Record	O
,	O
a	O
joint	O
program	O
of	O
the	O
University	O
of	O
Pittsburgh	O
,	O
and	O
UPMC	O
.	O

Medical	O
information	O
is	O
identified	O
only	O
by	O
participants’	O
UPMC	O
medical	O
record	O
number	O
,	O
not	O
by	O
any	O
other	O
identifying	O
information	O
.	O

If	O
all	O
eligibility	O
criteria	O
are	O
met	O
,	O
the	O
patient	O
is	O
enrolled	O
in	O
the	O
study	O
.	O

Those	O
who	O
do	O
not	O
meet	O
study	O
eligibility	O
criteria	O
will	O
be	O
given	O
local	O
resources	O
for	O
the	O
evaluation	O
and	O
treatment	O
of	O
sleep	O
problems	O
.	O

Fig	O
.	O

4	O
Pragmatic	O
explanatory	O
continuum	O
indicator	O
summary	O
(	O
PRECIS	O
)	O
for	O
HUSH	O
trial	O

Pragmatic	O
explanatory	O
continuum	O
indicator	O
summary	O
(	O
PRECIS	O
)	O
for	O
HUSH	O
trial	O

Enrolled	O
participants	O
are	O
provided	O
with	O
instructions	O
for	O
completing	O
baseline	O
study	O
instruments	O
described	O
below	O
.	O

These	O
assessments	O
are	O
accessed	O
via	O
a	O
secure	O
Internet	O
interface	O
.	O

The	O
estimated	O
total	O
time	O
for	O
completion	O
of	O
self	O
-	O
report	O
assessments	O
,	O
exclusive	O
of	O
the	O
sleep	O
wake	O
diary	O
,	O
is	O
45–60	O
minutes	O
.	O

Except	O
as	O
otherwise	O
indicated	O
,	O
the	O
same	O
assessments	O
are	O
used	O
at	O
the	O
9	O
-	O
week	O
and	O
6	O
-	O
and	O
12	O
-	O
month	O
evaluations	O
.	O

Objective	O
baseline	O
data	O
are	O
also	O
collected	O
from	O
the	O
EHR	O
,	O
as	O
noted	O
above	O
.	O

Following	O
completion	O
of	O
the	O
baseline	O
assessment	O
,	O
study	O
staff	O
send	O
the	O
BP	O
monitor	O
and	O
the	O
Apnea	O
Link	O
Plus	O
unit	O
with	O
written	O
instructions	O
and	O
web	O
links	O
to	O
demonstrate	O
their	O
use	O
.	O

Participants	O
then	O
complete	O
a	O
one	O
-	O
week	O
sleep	O
diary	O
and	O
HBPM	O
and	O
a	O
one	O
-	O
night	O
ApneaLink	O
Plus	O
home	O
sleep	O
apnea	O
test	O
(	O
Fig	O
.	O

3	O
)	O
.	O

Participants	O
keep	O
the	O
BP	O
monitor	O
for	O
reporting	O
at	O
the	O
9	O
-	O
week	O
and	O
6	O
-	O
and	O
12	O
-	O
month	O
evaluations	O
.	O

Eligible	O
patients	O
are	O
randomized	O
to	O
one	O
of	O
three	O
interventions	O
,	O
namely	O
BBTI	O
,	O
SHUTi	O
,	O
or	O
EUC	O
,	O
in	O
a	O
2:2:1	O
ratio	O
.	O

We	O
are	O
randomly	O
assigning	O
625	O
patients	O
to	O
intervention	O
arms	O
using	O
stratified	O
permuted	O
/	O
block	O
design	O
,	O
with	O
random	O
block	O
sizes	O
of	O
5	O
and	O
10	O
.	O

Stratification	O
by	O
sex	O
and	O
age	O
(	O
18–40	O
,	O
41–60	O
,	O
>	O
60	O
)	O
is	O
employed	O
because	O
insomnia	O
and	O
HTN	O
prevalence	O
vary	O
by	O
these	O
variables	O
.	O

Internet	O
literacy	O
may	O
also	O
vary	O
by	O
age	O
.	O

The	O
randomization	O
list	O
is	O
derived	O
from	O
computer	O
-	O
generated	O
random	O
numbers	O
programmed	O
by	O
a	O
study	O
statistician	O
using	O
R	O
version	O
3	O
.	O
2	O
.	O

2	O
statistical	O
software	O
.	O

The	O
randomization	O
table	O
is	O
stored	O
in	O
an	O
SQL	O
server	O
.	O

After	O
study	O
staff	O
determine	O
that	O
a	O
participant	O
is	O
eligible	O
,	O
the	O
data	O
manager	O
enters	O
them	O
into	O
the	O
randomization	O
allocation	O
sequence	O
.	O

A	O
query	O
is	O
run	O
to	O
determine	O
the	O
next	O
cell	O
,	O
stratified	O
on	O
age	O
and	O
sex	O
,	O
and	O
the	O
randomization	O
sequence	O
within	O
that	O
stratum	O
;	O
the	O
query	O
then	O
assigns	O
the	O
participant	O
to	O
the	O
appropriate	O
cell	O
.	O

The	O
allocation	O
concealment	O
is	O
preserved	O
by	O
showing	O
only	O
the	O
assignment	O
for	O
the	O
participant	O
being	O
randomized	O
.	O

Subsequent	O
allocations	O
are	O
not	O
known	O
to	O
research	O
staff	O
responsible	O
for	O
recruiting	O
.	O

Study	O
therapists	O
provide	O
care	O
only	O
in	O
the	O
BBTI	O
arm	O
,	O
so	O
they	O
are	O
not	O
blinded	O
to	O
randomization	O
.	O

All	O
outcome	O
assessments	O
are	O
completed	O
via	O
self	O
-	O
report	O
direct	O
data	O
entry	O
through	O
the	O
internet	O
to	O
the	O
secure	O
research	O
database	O
in	O
the	O
Department	O
of	O
Psychiatry	O
;	O
thus	O
,	O
study	O
staff	O
with	O
knowledge	O
of	O
randomization	O
will	O
not	O
bias	O
measurement	O
of	O
outcome	O
data	O
.	O

The	O
investigators	O
have	O
developed	O
novel	O
treatment	O
strategies	O
for	O
insomnia	O
with	O
the	O
goal	O
of	O
dissemination	O
into	O
routine	O
care	O
settings	O
.	O

Table	O
2	O
summarizes	O
their	O
key	O
components	O
.	O

The	O
two	O
active	O
interventions	O
share	O
several	O
features	O
,	O
but	O
also	O
differ	O
in	O
important	O
ways	O
.	O

BBTI	O
involves	O
a	O
human	O
interventionist	O
,	O
but	O
the	O
treatment	O
is	O
very	O
brief	O
.	O

SHUTi	O
is	O
a	O
self	O
-	O
guided	O
,	O
fully	O
-	O
automated	O
web	O
-	O
based	O
program	O
without	O
human	O
interaction	O
,	O
but	O
includes	O
a	O
larger	O
number	O
of	O
modules	O
.	O

Adherence	O
to	O
each	O
intervention	O
is	O
monitored	O
by	O
logging	O
the	O
dates	O
of	O
interventionist	O
contact	O
(	O
for	O
BBTI	O
)	O
,	O
core	O
module	O
completion	O
(	O
for	O
SHUTi	O
)	O
,	O
or	O
viewing	O
of	O
Emmi	O
Solutions	O
video	O
(	O
for	O
EUC	O
)	O
.	O

Study	O
participants	O
are	O
not	O
prohibited	O
from	O
receiving	O
any	O
other	O
care	O
or	O
treatment	O
while	O
participating	O
in	O
this	O
study	O
,	O
and	O
they	O
are	O
encouraged	O
to	O
follow	O
-	O
up	O
with	O
their	O
primary	O
care	O
physician	O
after	O
the	O
end	O
of	O
the	O
study	O
.	O

At	O
the	O
start	O
of	O
the	O
intervention	O
,	O
participants	O
in	O
BBTI	O
and	O
SHUTi	O
receive	O
a	O
brief	O
report	O
that	O
shows	O
their	O
baseline	O
BP	O
and	O
sleep	O
data	O
.	O

Participants	O
in	O
EUC	O
receive	O
this	O
report	O
,	O
with	O
additional	O
information	O
related	O
to	O
measures	O
of	O
functioning	O
in	O
other	O
areas	O
(	O
e	O
.	O
g	O
.	O
,	O
anxiety	O
,	O
fatigue	O
,	O
pain	O
,	O
etc	O
.	O
)	O
.	O

Each	O
patient’s	O
physician	O
also	O
receives	O
a	O
copy	O
of	O
this	O
individualized	O
report	O
,	O
which	O
includes	O
the	O
baseline	O
BP	O
and	O
sleep	O
data	O
.	O

Table	O
2	O
Intervention	O
components	O
Intervention	O
component	O
Intervention	O
BBTI	O
SHUTi	O
Usual	O
care	O
Practices	O
EpicCare	O
RRA	O
system	O
to	O
enroll	O
study	O
patients	O
•	O
•	O
•	O
Education	O
on	O
recognition	O
/	O
treatment	O
of	O
insomnia	O
•	O
•	O
•	O
Health	O
data	O
collected	O
via	O
electronic	O
health	O
record	O
(	O
blood	O
pressure	O
,	O
weight	O
,	O
medications	O
)	O
•	O
•	O
•	O
Physicians	O
Education	O
on	O
insomnia	O
;	O
how	O
to	O
refer	O
participants	O
via	O
RRA	O
;	O
interventions	O
•	O
•	O
•	O
Informed	O
about	O
patient	O
diagnoses	O
and	O
treatment	O
assignment	O
•	O
•	O
•	O
Receive	O
report	O
on	O
patient	O
sleep	O
•	O
•	O
Participants	O
Informed	O

of	O
insomnia	O
diagnosis	O
and	O
randomization	O
•	O
•	O
•	O
Receive	O
instructions	O
on	O
how	O
to	O
access	O
intervention	O
•	O
•	O
•	O
Interventionist	O
contact	O
via	O
telephone	O
,	O
web	O
•	O
Web	O
-	O
based	O
education	O
and	O
therapy	O
modules	O
•	O
Complete	O
outcomes	O
assessments	O
at	O
9	O
weeks	O
,	O
6	O
months	O
,	O
12	O
months	O
•	O
•	O
•	O
Screening	O
and	O
assessments	O
Telephone	O
screening	O
and	O
on	O
-	O
line	O
informed	O
consent	O
•	O
•	O
•	O
Baseline	O
and	O
follow	O
-	O
up	O
assessments	O
of	O
patient	O
-	O
reported	O
outcomes	O
completed	O
on	O
-	O
line	O
•	O
•	O
•	O
Home	O
blood	O
pressure	O
monitoring	O
•	O
•	O
•	O
Interventions	O
Emmi	O
educational	O
video	O
viewed	O

on	O
-	O
line	O
•	O
Interventionist	O
contact	O
via	O
telephone	O
,	O
web	O
(	O
4	O
total	O
)	O
for	O
individualized	O
behavioral	O
sleep	O
prescription	O
•	O
Self	O
-	O
guided	O
,	O
web	O
-	O
based	O
educational	O
and	O
therapy	O
modules	O
(	O
6	O
total	O
)	O
with	O
individualized	O
instruction	O
•	O
Feedback	O
on	O
initial	O
assessment	O
,	O
UPMC	O
treatment	O
resources	O
,	O
and	O
educational	O
materials	O
•	O
BBTI	O
brief	O
behavioral	O
treatment	O
of	O
insomnia	O
,	O
RRA	O
research	O
recruitment	O
alert	O
,	O
SHUTi	O
sleep	O
healthy	O
using	O
the	O
internet	O
,	O
UPMC	O
University	O
of	O
Pittsburgh	O
Medical	O
Center	O

Intervention	O
components	O

BBTI	O
brief	O
behavioral	O
treatment	O
of	O
insomnia	O
,	O
RRA	O
research	O
recruitment	O
alert	O
,	O
SHUTi	O
sleep	O
healthy	O
using	O
the	O
internet	O
,	O
UPMC	O
University	O
of	O
Pittsburgh	O
Medical	O
Center	O

BBTI	O
is	O
an	O
abbreviated	O
form	O
of	O
insomnia	O
treatment	O
appropriate	O
for	O
primary	O
care	O
settings	O
.	O

In	O
contrast	O
to	O
traditional	O
CBT	O
-	O
I	O
,	O
BBTI	O
is	O
administered	O
in	O
a	O
single	O
session	O
and	O
three	O
brief	O
follow	O
-	O
up	O
sessions	O
.	O

Sessions	O
are	O
generally	O
held	O
weekly	O
.	O

Live	O
interventionist	O
contact	O
is	O
provided	O
by	O
telephone	O
and	O
/	O
or	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
-	O
compliant	O
web	O
conferencing	O
rather	O
than	O
in	O
person	O
.	O

BBTI	O
is	O
delivered	O
in	O
individual	O
sessions	O
using	O
a	O
PowerPoint	O
workbook	O
.	O

BBTI	O
distills	O
efficacious	O
behavioral	O
strategies	O
for	O
treating	O
insomnia	O
,	O
including	O
stimulus	O
control	O
[	O
56	O
]	O
and	O
sleep	O
restriction	O
[	O
57	O
,	O
58	O
]	O
.	O

The	O
treatment	O
emphasizes	O
sleep	O
education	O
and	O
four	O
behavioral	O
recommendations	O
,	O
which	O
are	O
(	O
1	O
)	O
reduce	O
your	O
time	O
in	O
bed	O
;	O
(	O
2	O
)	O
get	O
up	O
at	O
the	O
same	O
time	O
every	O
day	O
of	O
the	O
week	O
,	O
regardless	O
of	O
how	O
long	O
you	O
slept	O
;	O
(	O
3	O
)	O
do	O
not	O
go	O
to	O
bed	O
unless	O
you	O
are	O
sleepy	O
;	O
and	O
(	O
4	O
)	O
do	O
not	O
stay	O
in	O
bed	O
unless	O
you	O
are	O
asleep	O
.	O

An	O
initial	O
trial	O
of	O
BBTI	O
demonstrated	O
significant	O
improvement	O
in	O
self	O
-	O
reported	O
and	O
actigraphic	O
sleep	O
measures	O
[	O
33	O
]	O
.	O

Patients	O
are	O
given	O
a	O
specific	O
“prescription”	O
of	O
recommended	O
sleep	O
times	O
and	O
record	O
their	O
times	O
in	O
an	O
online	O
sleep	O
diary	O
via	O
a	O
secure	O
web	O
interface	O
.	O

Diary	O
information	O
gauges	O
progress	O
and	O
tailors	O
treatment	O
.	O

SHUTi	O
is	O
a	O
self	O
-	O
guided	O
,	O
automated	O
,	O
interactive	O
,	O
and	O
tailored	O
web	O
-	O
based	O
program	O
modeled	O
on	O
the	O
primary	O
tenets	O
of	O
CBT	O
-	O
I	O
,	O
namely	O
sleep	O
restriction	O
,	O
stimulus	O
control	O
,	O
cognitive	O
restructuring	O
,	O
sleep	O
hygiene	O
,	O
and	O
relapse	O
prevention	O
.	O

Intervention	O
content	O
is	O
metered	O
out	O
over	O
time	O
through	O
six	O
“Cores	O
,	O
”	O
which	O
are	O
generally	O
completed	O
weekly	O
.	O

Users	O
obtain	O
access	O
to	O
a	O
new	O
Core	O
based	O
on	O
a	O
time	O
and	O
event	O
-	O
based	O
schedule	O
(	O
e	O
.	O
g	O
.	O
,	O
7	O
days	O
after	O
completion	O
of	O
previous	O
Core	O
)	O
.	O

This	O
schedule	O
is	O
consistent	O
with	O
recommendations	O
from	O
the	O
American	O
Academy	O
of	O
Sleep	O
Medicine	O
deeming	O
6–8	O
sessions	O
an	O
‘	O
adequate	O
treatment	O
exposure	O
’	O
[	O
13	O
]	O
.	O

SHUTi	O
uses	O
online	O
sleep	O
diaries	O
to	O
track	O
progress	O
and	O
to	O
tailor	O
treatment	O
(	O
e	O
.	O
g	O
.	O
,	O
assign	O
a	O
“sleep	O
restriction”	O
window	O
)	O
.	O

Each	O
Core	O
acts	O
as	O
an	O
online	O
analog	O
for	O
the	O
weekly	O
sessions	O
of	O
traditional	O
CBT	O
-	O
I	O
,	O
and	O
follows	O
the	O
same	O
structure	O
,	O
including	O
(	O
1	O
)	O
Core	O
objectives	O
(	O
what	O
will	O
be	O
learned	O
and	O
why	O
it	O
is	O
important	O
)	O
;	O
(	O
2	O
)	O
review	O
of	O
previous	O
week’s	O
homework	O
and	O
sleep	O
diary	O
data	O
;	O
(	O
3	O
)	O
new	O
intervention	O
material	O
;	O
(	O
4	O
)	O
assignment	O
of	O
homework	O
(	O
treatment	O
strategies	O
for	O
the	O
coming	O
week	O
)	O
;	O
and	O
(	O
5	O
)	O
summary	O
of	O
the	O
Core’s	O
main	O
points	O
.	O

Intervention	O
content	O
is	O
enhanced	O
through	O
interactive	O
features	O
including	O
personalized	O
goal	O
-	O
setting	O
,	O
graphical	O
feedback	O
based	O
on	O
participant	O
-	O
specific	O
symptoms	O
,	O
animations	O
/	O
illustrations	O
,	O
quizzes	O
to	O
test	O
user	O
knowledge	O
,	O
patient	O
vignettes	O
,	O
and	O
video	O
-	O
based	O
expert	O
explanation	O
.	O

Automated	O
emails	O
encourage	O
program	O
adherence	O
.	O

After	O
completing	O
the	O
post	O
-	O
assessment	O
end	O
of	O
study	O
battery	O
and	O
sleep	O
diaries	O
,	O
individuals	O
have	O
continued	O
access	O
to	O
the	O
online	O
program	O
for	O
1	O
year	O
.	O

In	O
an	O
initial	O
efficacy	O
trial	O
,	O
SHUTi	O
users	O
showed	O
significant	O
improvements	O
in	O
sleep	O
outcomes	O
and	O
insomnia	O
severity	O
compared	O
to	O
a	O
control	O
group	O
.	O

After	O
treatment	O
,	O
73	O
%	O
of	O
SHUTi	O
users	O
had	O
“no	O
insomnia”	O
vs	O
.	O
none	O
of	O
the	O
controls	O
,	O
and	O
significant	O
improvements	O
were	O
also	O
found	O
in	O
mood	O
,	O
fatigue	O
,	O
and	O
quality	O
of	O
life	O
[	O
30	O
,	O
59	O
]	O
.	O

In	O
addition	O
to	O
the	O
report	O
of	O
baseline	O
and	O
screening	O
data	O
described	O
above	O
,	O
participants	O
in	O
EUC	O
also	O
receive	O
a	O
listing	O
of	O
publically	O
-	O
available	O
educational	O
resources	O
(	O
websites	O
,	O
books	O
)	O
and	O
contact	O
information	O
for	O
treatment	O
resources	O
,	O
as	O
well	O
as	O
a	O
link	O
to	O
a	O
25	O
minute	O
animated	O
online	O
video	O
developed	O
by	O
Emmi	O
Solutions	O
in	O
consultation	O
with	O
two	O
of	O
the	O
investigators	O
(	O
DJB	O
,	O
PJS	O
)	O
.	O

The	O
video	O
includes	O
information	O
about	O
sleep	O
,	O
factors	O
that	O
help	O
to	O
regulate	O
sleep	O
,	O
and	O
habits	O
that	O
help	O
and	O
hurt	O
sleep	O
,	O
with	O
some	O
interactive	O
features	O
,	O
such	O
as	O
selecting	O
a	O
problem	O
area	O
,	O
goal	O
-	O
setting	O
,	O
and	O
self	O
-	O
efficacy	O
assessment	O
.	O

After	O
completing	O
the	O
post	O
-	O
assessment	O
battery	O
and	O
sleep	O
diaries	O
at	O
the	O
12	O
-	O
month	O
follow	O
-	O
up	O
,	O
individuals	O
randomized	O
to	O
EUC	O
will	O
subsequently	O
have	O
free	O
access	O
to	O
SHUTi	O
if	O
requested	O
.	O

Participants	O
in	O
each	O
of	O
the	O
three	O
intervention	O
conditions	O
complete	O
follow	O
-	O
up	O
assessments	O
at	O
9	O
weeks	O
and	O
6	O
and	O
12	O
months	O
following	O
the	O
start	O
of	O
the	O
intervention	O
.	O

The	O
9	O
-	O
week	O
follow	O
-	O
up	O
serves	O
as	O
the	O
primary	O
outcome	O
point	O
for	O
the	O
primary	O
study	O
outcome	O
measure	O
of	O
self	O
-	O
reported	O
sleep	O
.	O

The	O
6	O
-	O
month	O
follow	O
-	O
up	O
serves	O
as	O
the	O
primary	O
outcome	O
point	O
for	O
secondary	O
outcomes	O
.	O

We	O
promote	O
participant	O
retention	O
and	O
completion	O
of	O
follow	O
-	O
up	O
assessments	O
via	O
periodic	O
email	O
reminders	O
sent	O
to	O
participants	O
and	O
a	O
quarterly	O
participant	O
newsletter	O
.	O

We	O
have	O
included	O
validated	O
measures	O
intended	O
to	O
assess	O
inclusion	O
/	O
exclusion	O
criteria	O
,	O
and	O
outcomes	O
of	O
interest	O
.	O

Information	O
on	O
each	O
measure	O
can	O
be	O
found	O
below	O
,	O
and	O
in	O
the	O
references	O
cited	O
.	O

Screening	O
instruments	O
are	O
listed	O
in	O
Fig	O
.	O

3	O
.	O

Insomnia	O
diagnosis	O
is	O
verified	O
during	O
the	O
web	O
-	O
based	O
or	O
telephone	O
screening	O
,	O
using	O
structured	O
questions	O
based	O
on	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
diagnosis	O
for	O
insomnia	B-phenotype
disorder	I-phenotype
.	O

Insomnia	O
of	O
at	O
least	O
mild	O
severity	O
(	O
Insomnia	O
Severity	O
Index	O
>	O
7	O
)	O
is	O
required	O
at	O
baseline	O
to	O
observe	O
treatment	O
-	O
related	O
changes	O
in	O
insomnia	O
[	O
60	O
]	O
.	O

Other	O
sleep	O
disorders	O
are	O
also	O
evaluated	O
using	O
a	O
locally	O
-	O
developed	O
screening	O
questionnaire	O
for	O
sleep	O
disorders	O
.	O

Likelihood	O
of	O
having	O
sleep	O
apnea	O
is	O
evaluated	O
with	O
the	O
self	O
-	O
report	O
Multivariable	O
Apnea	O
Prediction	O
Questionnaire	O
[	O
61	O
]	O
,	O
and	O
home	O
sleep	O
apnea	O
testing	O
is	O
completed	O
using	O
the	O
Apnea	O
Link	O
Plus	O
or	O
Apnea	O
Link	O
Air	O
device	O
.	O

Participants	O
complete	O
a	O
locally	O
-	O
developed	O
questionnaire	O
regarding	O
sleep	O
quality	O
immediately	O
after	O
the	O
home	O
sleep	O
apnea	O
test	O
night	O
.	O

All	O
participants	O
are	O
given	O
a	O
report	O
of	O
the	O
findings	O
of	O
their	O
apnea	O
study	O
,	O
with	O
a	O
key	O
for	O
how	O
to	O
interpret	O
the	O
report	O
.	O

Those	O
with	O
an	O
Apnea	O
Hypopnea	O
Index	O
score	O
of	O
between	O
15	O
and	O
50	O
are	O
given	O
a	O
recommendation	O
and	O
resources	O
for	O
further	O
evaluation	O
and	O
treatment	O
;	O
this	O
information	O
is	O
also	O
provided	O
to	O
the	O
primary	O
care	O
physician	O
.	O

Participants	O
are	O
only	O
excluded	O
if	O
their	O
Apnea	O
Hypopnea	O
Index	O
score	O
is	O
50	O
or	O
above	O
.	O

Locally	O
-	O
developed	O
questions	O
assess	O
participant	O
demographics	O
,	O
availability	O
of	O
Internet	O
access	O
,	O
literacy	O
,	O
plans	O
for	O
receiving	O
medical	O
care	O
over	O
the	O
next	O
year	O
,	O
medical	O
history	O
,	O
and	O
history	O
of	O
bipolar	O
disorder	O
or	O
psychosis	O
.	O

Depressive	O
symptoms	O
,	O
anxiety	O
,	O
substance	O
use	O
,	O
and	O
suicidal	O
ideation	O
are	O
assessed	O
with	O
measures	O
listed	O
in	O
Table	O
1	O
[	O
62	O
–	O
64	O
]	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
the	O
Sleep	O
Disturbance	O
scale	O
from	O
the	O
Patient	O
Reported	O
Outcome	O
Measurement	O
Information	O
System	O
(	O
PROMIS	O
)	O
[	O
65	O
,	O
66	O
]	O
.	O

PROMIS	O
measures	O
are	O
well	O
validated	O
,	O
follow	O
a	O
common	O
format	O
,	O
and	O
are	O
administered	O
in	O
an	O
adaptive	O
testing	O
format	O
to	O
minimize	O
participant	O
burden	O
.	O

We	O
also	O
collect	O
the	O
PROMIS	O
Sleep	O
-	O
Related	O
Impairment	O
scale	O
and	O
the	O
Insomnia	O
Severity	O
Index	O
[	O
60	O
]	O
.	O

Finally	O
,	O
we	O
evaluate	O
sleep	O
parameters	O
daily	O
using	O
an	O
on	O
-	O
line	O
version	O
of	O
the	O
Consensus	O
Sleep	O
Diary	O
[	O
67	O
]	O
.	O

Daily	O
sleep	O
diaries	O
,	O
which	O
take	O
less	O
than	O
5	O
minutes	O
per	O
day	O
,	O
are	O
a	O
“gold	O
standard”	O
outcome	O
measure	O
in	O
insomnia	O
treatment	O
studies	O
[	O
67	O
,	O
68	O
]	O
.	O

HBPM	O
is	O
the	O
primary	O
measure	O
of	O
BP	O
control	O
.	O

All	O
participants	O
are	O
given	O
an	O
Omron	O
BP7	O
[	O
34	O
]	O
BP	O
Monitor	O
.	O

HBPM	O
is	O
accurate	O
when	O
compared	O
to	O
ambulatory	O
BP	O
monitoring	O
[	O
69	O
,	O
70	O
]	O
,	O
is	O
more	O
strongly	O
associated	O
with	O
cardiovascular	O
and	O
cerebrovascular	O
risk	O
,	O
target	O
organ	O
damage	O
,	O
and	O
mortality	O
than	O
office	O
BP	O
readings	O
[	O
71	O
–	O
74	O
]	O
,	O
and	O
is	O
recommended	O
as	O
a	O
routine	O
component	O
of	O
BP	O
measurement	O
in	O
patients	O
with	O
known	O
or	O
suspected	O
HTN	O
[	O
70	O
,	O
71	O
,	O
75	O
–	O
78	O
]	O
.	O

Participants	O
obtain	O
three	O
BP	O
readings	O
in	O
the	O
seated	O
position	O
,	O
with	O
the	O
arm	O
supported	O
at	O
heart	O
level	O
[	O
71	O
,	O
77	O
]	O
.	O

Readings	O
are	O
obtained	O
twice	O
per	O
day	O
,	O
in	O
the	O
morning	O
soon	O
after	O
awakening	O
,	O
and	O
at	O
night	O
before	O
going	O
to	O
bed	O
,	O
for	O
7	O
days	O
.	O

BP	O
values	O
observed	O
on	O
the	O
HBPM	O
are	O
entered	O
by	O
the	O
participant	O
into	O
the	O
online	O
sleep	O
diary	O
,	O
and	O
are	O
collected	O
electronically	O
.	O

Outcome	O
measures	O
include	O
weekly	O
average	O
values	O
for	O
morning	O
(	O
primary	O
outcome	O
)	O
and	O
evening	O
(	O
secondary	O
)	O
BP	O
(	O
Fig	O
.	O

3	O
)	O
.	O

If	O
participants	O
do	O
not	O
enter	O
these	O
values	O
at	O
each	O
follow	O
-	O
up	O
assessment	O
,	O
gentle	O
prompts	O
are	O
sent	O
to	O
the	O
participant	O
to	O
serve	O
as	O
reminders	O
to	O
complete	O
this	O
assessment	O
.	O

We	O
also	O
utilize	O
the	O
BP	O
assessed	O
during	O
the	O
patient’s	O
office	O
visit	O
at	O
which	O
the	O
research	O
referral	O
was	O
made	O
.	O

BMI	O
is	O
a	O
second	O
objective	O
measure	O
of	O
health	O
in	O
this	O
study	O
,	O
collected	O
via	O
self	O
-	O
report	O
during	O
the	O
consent	O
assessment	O
.	O

Self	O
-	O
reported	O
health	O
-	O
related	O
functioning	O
and	O
quality	O
of	O
life	O
are	O
assessed	O
with	O
the	O
RAND	O
12	O
-	O
item	O
Health	O
Status	O
Survey	O
[	O
79	O
]	O
.	O

Healthcare	O
utilization	O
and	O
medical	O
costs	O
over	O
the	O
past	O
3	O
months	O
are	O
measured	O
with	O
a	O
modification	O
of	O
a	O
previously	O
developed	O
healthcare	O
cost	O
questionnaire	O
[	O
80	O
]	O
.	O

The	O
Cumulative	O
Illness	O
Rating	O
Scale	O
[	O
81	O
]	O
is	O
used	O
to	O
measure	O
medical	O
burden	O
.	O

Patients	O
complete	O
a	O
modified	O
version	O
of	O
the	O
Frequency	O
,	O
Intensity	O
,	O
and	O
Burden	O
of	O
Side	O
Effects	O
Rating	O
[	O
82	O
]	O
to	O
determine	O
symptoms	O
that	O
may	O
be	O
related	O
to	O
insomnia	O
treatment	O
.	O

Patients	O
also	O
complete	O
a	O
locally	O
-	O
developed	O
rating	O
form	O
that	O
assesses	O
the	O
frequency	O
of	O
falls	O
and	O
their	O
potential	O
relation	O
to	O
insomnia	O
treatment	O
.	O

To	O
assess	O
patients’	O
expectations	O
for	O
improvement	O
as	O
a	O
result	O
of	O
treatment	O
,	O
and	O
their	O
confidence	O
in	O
the	O
treatment’s	O
ability	O
to	O
have	O
an	O
impact	O
,	O
they	O
complete	O
a	O
modified	O
version	O
of	O
the	O
Treatment	O
Expectations	O
Questionnaire	O
[	O
83	O
]	O
.	O

Patients	O
complete	O
the	O
locally	O
-	O
developed	O
Client	O
Satisfaction	O
Questionnaire	O
to	O
evaluate	O
their	O
experience	O
participating	O
in	O
this	O
study	O
,	O
and	O
satisfaction	O
with	O
the	O
services	O
offered	O
.	O

Providers	O
also	O
complete	O
a	O
locally	O
-	O
developed	O
Provider	O
Satisfaction	O
Questionnaire	O
that	O
assesses	O
the	O
ease	O
of	O
referral	O
to	O
the	O
study	O
,	O
whether	O
their	O
patients	O
entered	O
into	O
the	O
study	O
,	O
perceived	O
improvement	O
of	O
their	O
patients	O
as	O
a	O
result	O
of	O
participating	O
,	O
and	O
satisfaction	O
with	O
the	O
information	O
we	O
sent	O
to	O
the	O
providers	O
about	O
their	O
patients’	O
progress	O
.	O

A	O
subset	O
of	O
items	O
from	O
the	O
Tailored	O
Educational	O
Approaches	O
for	O
Consumer	O
Health	O
:	O
Market	O
Segmentation	O
Survey	O
[	O
84	O
]	O
is	O
completed	O
at	O
baseline	O
to	O
assess	O
participants’	O
computer	O
and	O
Internet	O
use	O
,	O
and	O
their	O
health	O
literacy	O
.	O

Additional	O
measures	O
are	O
collected	O
,	O
as	O
explanatory	O
variables	O
,	O
at	O
various	O
time	O
points	O
(	O
Fig	O
.	O

3	O
)	O
.	O

Sleep	O
measures	O
include	O
the	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
[	O
85	O
]	O
,	O
which	O
is	O
a	O
global	O
measure	O
of	O
subjective	O
sleep	O
quality	O
,	O
and	O
the	O
Epworth	O
Sleepiness	O
Scale	O
[	O
86	O
]	O
,	O
which	O
is	O
a	O
measure	O
of	O
daytime	O
sleepiness	O
.	O

Additional	O
health	O
indicators	O
are	O
collected	O
from	O
the	O
EHR	O
,	O
including	O
vital	O
signs	O
,	O
medical	O
problems	O
and	O
diagnoses	O
,	O
and	O
medication	O
names	O
,	O
dosages	O
and	O
timing	O
.	O

We	O
use	O
additional	O
PROMIS	O
scales	O
to	O
assess	O
psychosocial	O
health	O
and	O
functioning	O
,	O
including	O
measures	O
of	O
anxiety	O
,	O
depression	O
and	O
anger	O
,	O
fatigue	O
,	O
pain	O
behavior	O
,	O
pain	O
interference	O
,	O
physical	O
function	O
,	O
ability	O
to	O
participate	O
in	O
social	O
roles	O
and	O
activities	O
,	O
and	O
satisfaction	O
with	O
social	O
roles	O
and	O
activities	O
[	O
65	O
,	O
66	O
]	O
.	O

Finally	O
,	O
patients	O
complete	O
the	O
Patient	O
Global	O
Impressions	O
severity	O
and	O
improvement	O
scales	O
(	O
adapted	O
from	O
the	O
Clinical	O
Global	O
Impression	O
scale	O
[	O
87	O
]	O
)	O
to	O
evaluate	O
perceived	O
improvement	O
as	O
a	O
result	O
of	O
treatment	O
.	O

BBTI	O
and	O
SHUTi	O
have	O
medium	O
to	O
large	O
effect	O
sizes	O
(	O
0	O
.	O
40–1	O
.	O

00	O
)	O
for	O
typical	O
sleep	O
and	O
other	O
symptom	O
-	O
related	O
outcomes	O
in	O
published	O
studies	O
with	O
sample	O
sizes	O
of	O
up	O
to	O
40	O
per	O
group	O
[	O
33	O
,	O
59	O
,	O
88	O
]	O
.	O

The	O
observed	O
effect	O
sizes	O
for	O
this	O
study	O
are	O
likely	O
to	O
be	O
smaller	O
for	O
several	O
reasons	O
.	O

Firstly	O
,	O
we	O
are	O
recruiting	O
a	O
more	O
complex	O
“real	O
-	O
world”	O
sample	O
of	O
patients	O
from	O
primary	O
care	O
settings	O
.	O

Second	O
,	O
our	O
recruitment	O
method	O
does	O
not	O
rely	O
on	O
motivated	O
prospective	O
participants	O
contacting	O
the	O
researchers	O
.	O

Finally	O
,	O
the	O
study	O
design	O
does	O
not	O
include	O
any	O
in	O
-	O
person	O
contact	O
.	O

Thus	O
,	O
we	O
relied	O
on	O
conservative	O
analysis	O
methods	O
for	O
conducting	O
our	O
power	O
analyses	O
.	O

For	O
a	O
t	O
test	O
on	O
post	O
-	O
intervention	O
sleep	O
outcomes	O
comparing	O
each	O
treatment	O
group	O
to	O
EUC	O
,	O
and	O
using	O
a	O
Bonferroni	O
-	O
adjusted	O
alpha	O
level	O
of	O
2	O
.	O
5	O
%	O
due	O
to	O
pairwise	O
testing	O
(	O
i	O
.	O
e	O
.	O

,	O
BBTI	O
vs	O
.	O

EUC	O
and	O
SHUTi	O
vs	O
.	O

EUC	O
)	O
,	O
sample	O
sizes	O
of	O
180/180/90	O
for	O
BBTI	O
/	O
SHUTi	O
/	O
EUC	O
provide	O
at	O
least	O
80	O
%	O
power	O
to	O
detect	O
an	O
effect	O
size	O
of	O
0	O
.	O
4	O
.	O

As	O
above	O
,	O
our	O
primary	O
outcome	O
measures	O
include	O
the	O
PROMIS	O
Sleep	O
Disturbance	O
and	O
Sleep	O
-	O
Related	O
Impairment	O
scales	O
,	O
the	O
Insomnia	O
Severity	O
Index	O
,	O
and	O
sleep	O
parameters	O
gathered	O
from	O
the	O
Consensus	O
Sleep	O
Diary	O
.	O

Since	O
data	O
will	O
be	O
analyzed	O
using	O
linear	O
mixed	O
models	O
,	O
we	O
expect	O
to	O
have	O
higher	O
power	O
or	O
detect	O
smaller	O
effect	O
sizes	O
.	O

These	O
sample	O
sizes	O
also	O
provide	O
at	O
least	O
80	O
%	O
power	O
to	O
detect	O
effect	O
sizes	O
that	O
have	O
been	O
reported	O
for	O
depression	O
and	O
anxiety	O
outcomes	O
(	O
0	O
.	O
4–0	O
.	O

8	O
)	O
and	O
quality	O
of	O
life	O
(	O
0	O
.	O
91–1	O
.	O

16	O
)	O
[	O
33	O
,	O
59	O
,	O
88	O
]	O
.	O

For	O
the	O
exploratory	O
aims	O
,	O
we	O
will	O
have	O
adequate	O
power	O
to	O
detect	O
effect	O
sizes	O
as	O
small	O
as	O
0	O
.	O
3	O
in	O
comparing	O
BBTI	O
and	O
SHUTi	O
given	O
n	O
=	O
200	O
per	O
group	O
.	O

To	O
account	O
for	O
up	O
to	O
20	O
%	O
dropout	O
rate	O
,	O
we	O
propose	O
to	O
enroll	O
625	O
participants	O
(	O
BBTI	O
=	O
250	O
,	O
SHUTi	O
=	O
250	O
,	O
EUC	O
=	O
125	O
)	O
.	O

We	O
utilize	O
an	O
Internet	O
-	O
based	O
,	O
paperless	O
data	O
management	O
system	O
developed	O
by	O
the	O
Department	O
of	O
Psychiatry	O
at	O
the	O
University	O
of	O
Pittsburgh	O
and	O
UPMC	O
.	O

Study	O
staff	O
who	O
conduct	O
initial	O
screenings	O
record	O
subject	O
responses	O
directly	O
into	O
a	O
Microsoft	O
SQL	O
Server	O
database	O
using	O
extensive	O
data	O
integrity	O
checks	O
.	O

Subjects	O
also	O
complete	O
measures	O
online	O
for	O
direct	O
data	O
entry	O
via	O
a	O
password	O
-	O
protected	O
site	O
.	O

Data	O
collection	O
is	O
conducted	O
via	O
secure	O
,	O
encrypted	O
connections	O
with	O
data	O
stored	O
on	O
a	O
secure	O
server	O
at	O
UPMC	O
.	O

Web	O
sites	O
are	O
“insert	O
-	O
only	O
,	O
”	O
eliminating	O
any	O
possibility	O
that	O
existing	O
data	O
can	O
be	O
retrieved	O
from	O
the	O
databases	O
.	O

We	O
protect	O
confidentiality	O
by	O
using	O
computer	O
systems	O
that	O
are	O
protected	O
by	O
the	O
University	O
of	O
Pittsburgh	O
and	O
UPMC	O
,	O
which	O
require	O
passwords	O
.	O

The	O
database	O
servers	O
are	O
securely	O
behind	O
the	O
UPMC	O
firewall	O
with	O
permissions	O
granted	O
on	O
a	O
strict	O
as	O
-	O
needed	O
basis	O
to	O
members	O
of	O
the	O
research	O
team	O
.	O

All	O
connections	O
to	O
systems	O
inside	O
the	O
firewall	O
are	O
encrypted	O
using	O
a	O
128	O
-	O
bit	O
SSL	O
protocol	O
.	O

The	O
web	O
site	O
for	O
participant	O
data	O
entry	O
is	O
fully	O
encrypted	O
,	O
does	O
not	O
utilize	O
caching	O
or	O
cookies	O
,	O
and	O
is	O
strictly	O
a	O
one	O
-	O
way	O
connection	O
.	O

Participant	O
responses	O
are	O
inserted	O
into	O
the	O
database	O
without	O
any	O
permissions	O
to	O
select	O
or	O
update	O
existing	O
information	O
.	O

Participants	O
are	O
sent	O
emails	O
via	O
UPMC’s	O
secure	O
server	O
.	O

Participants	O
access	O
their	O
questionnaires	O
via	O
a	O
secure	O
link	O
,	O
and	O
login	O
with	O
a	O
study	O
ID	O
and	O
password	O
.	O

Any	O
paper	O
records	O
that	O
could	O
identify	O
a	O
participant	O
are	O
stored	O
in	O
locked	O
file	O
cabinets	O
,	O
and	O
all	O
electronic	O
records	O
are	O
stored	O
in	O
password	O
-	O
protected	O
files	O
.	O

Participants	O
in	O
the	O
SHUTi	O
condition	O
complete	O
online	O
sleep	O
diaries	O
during	O
the	O
course	O
of	O
the	O
intervention	O
.	O

These	O
diaries	O
are	O
maintained	O
in	O
the	O
Research	O
Infrastructure	O
Containing	O
E	O
-	O
interventions	O
system	O
that	O
also	O
hosts	O
SHUTi	O
at	O
the	O
University	O
of	O
Virginia	O
.	O

No	O
identifying	O
information	O
is	O
maintained	O
in	O
the	O
servers	O
.	O

Electronic	O
communications	O
with	O
participants	O
are	O
routed	O
through	O
UPMC’s	O
email	O
messaging	O
system	O
to	O
maintain	O
participant	O
confidentiality	O
.	O

We	O
hypothesize	O
that	O
BBTI	O
and	O
SHUTi	O
will	O
be	O
superior	O
to	O
EUC	O
on	O
patient	O
-	O
reported	O
symptoms	O
(	O
sleep	O
,	O
depression	O
,	O
anxiety	O
,	O
and	O
fatigue	O
)	O
at	O
9	O
weeks	O
,	O
6	O
months	O
,	O
and	O
12	O
months	O
,	O
and	O
on	O
health	O
indicators	O
(	O
HBPM	O
,	O
hypnotic	O
use	O
,	O
quality	O
of	O
life	O
,	O
and	O
healthcare	O
utilization	O
and	O
costs	O
)	O
at	O
6	O
and	O
12	O
months	O
.	O

The	O
primary	O
measure	O
of	O
sleep	O
is	O
the	O
PROMIS	O
sleep	O
disturbance	O
scale	O
.	O

We	O
also	O
hypothesize	O
that	O
BBTI	O
and	O
SHUTi	O
will	O
have	O
superior	O
measures	O
of	O
patient	O
and	O
provider	O
level	O
satisfaction	O
as	O
compared	O
to	O
EUC	O
.	O

All	O
analyses	O
for	O
intervention	O
group	O
comparisons	O
will	O
use	O
an	O
intention	O
-	O
to	O
-	O
treat	O
approach	O
,	O
in	O
which	O
all	O
participants	O
are	O
analyzed	O
based	O
on	O
the	O
intervention	O
to	O
which	O
they	O
were	O
randomized	O
,	O
regardless	O
of	O
intervention	O
receipt	O
.	O

Ignorable	O
missing	O
data	O
,	O
which	O
includes	O
missing	O
-	O
completely	O
-	O
at	O
-	O
random	O
and	O
missing	O
-	O
at	O
-	O
random	O
data	O
,	O
can	O
validly	O
be	O
analyzed	O
using	O
our	O
primary	O
analytical	O
methods	O
,	O
namely	O
linear	O
mixed	O
or	O
generalized	O
linear	O
mixed	O
models	O
for	O
longitudinal	O
data	O
.	O

Patient	O
characteristics	O
will	O
be	O
compared	O
between	O
completers	O
and	O
non	O
-	O
completers	O
.	O

Variables	O
found	O
to	O
be	O
different	O
between	O
these	O
two	O
groups	O
will	O
be	O
added	O
to	O
the	O
mixed	O
models	O
in	O
adjusted	O
analyses	O
.	O

Effects	O
will	O
be	O
examined	O
unadjusted	O
and	O
adjusted	O
for	O
stratification	O
variables	O
.	O

Analyses	O
will	O
use	O
linear	O
mixed	O
models	O
with	O
fixed	O
treatment	O
group	O
,	O
time	O
,	O
and	O
group	O
*	O
time	O
interaction	O
effects	O
,	O
and	O
random	O
participant	O
intercepts	O
.	O

We	O
will	O
include	O
random	O
intercepts	O
to	O
account	O
for	O
within	O
-	O
participant	O
correlations	O
due	O
to	O
repeated	O
measures	O
over	O
time	O
.	O

We	O
will	O
first	O
assess	O
short	O
-	O
term	O
effects	O
in	O
each	O
treatment	O
group	O
compared	O
to	O
EUC	O
,	O
using	O
data	O
from	O
the	O
9	O
-	O
week	O
follow	O
-	O
up	O
.	O

To	O
test	O
whether	O
improvements	O
in	O
outcomes	O
are	O
sustained	O
,	O
we	O
will	O
expand	O
the	O
model	O
to	O
include	O
6	O
and	O
12	O
month	O
time	O
points	O
.	O

We	O
will	O
use	O
similar	O
linear	O
mixed	O
models	O
in	O
analyses	O
of	O
secondary	O
outcomes	O
(	O
e	O
.	O
g	O
.	O
,	O
depression	O
)	O
.	O

For	O
categorical	O
outcomes	O
,	O
generalized	O
linear	O
mixed	O
models	O
with	O
logit	O
link	O
will	O
be	O
used	O
,	O
following	O
analysis	O
steps	O
described	O
for	O
continuous	O
outcomes	O
.	O

A	O
four	O
-	O
member	O
DSMB	O
has	O
been	O
established	O
.	O

DSMB	O
members	O
have	O
expertise	O
in	O
sleep	O
medicine	O
,	O
insomnia	O
intervention	O
research	O
,	O
clinical	O
trials	O
,	O
and	O
biostatistics	O
.	O

The	O
board	O
meets	O
at	O
least	O
annually	O
by	O
teleconference	O
,	O
and	O
receives	O
recruitment	O
and	O
adverse	O
event	O
updates	O
at	O
least	O
quarterly	O
.	O

The	O
DSMB	O
is	O
responsible	O
for	O
monitoring	O
the	O
overall	O
progress	O
and	O
conduct	O
of	O
the	O
study	O
,	O
the	O
safety	O
of	O
the	O
participants	O
,	O
and	O
reviewing	O
adverse	O
events	O
.	O

The	O
board	O
will	O
also	O
serve	O
as	O
a	O
reporting	O
body	O
to	O
both	O
the	O
study	O
sponsor	O
(	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
)	O
and	O
the	O
University	O
of	O
Pittsburgh	O
institutional	O
review	O
board	O
(	O
IRB	O
)	O
.	O

This	O
board	O
has	O
been	O
approved	O
by	O
the	O
study	O
sponsor	O
,	O
which	O
also	O
receives	O
reports	O
of	O
each	O
DSMB	O
meeting	O
.	O

Adverse	O
events	O
are	O
monitored	O
by	O
spontaneous	O
reporting	O
by	O
participants	O
and	O
questionnaire	O
-	O
based	O
inquiry	O
using	O
side	O
effects	O
questionnaires	O
,	O
administered	O
at	O
the	O
9	O
-	O
week	O
,	O
6	O
-	O
month	O
,	O
and	O
12	O
-	O
month	O
assessments	O
.	O

The	O
study	O
coordinator	O
reviews	O
reported	O
events	O
with	O
participants	O
.	O

Qualifying	O
events	O
are	O
reported	O
to	O
the	O
University	O
of	O
Pittsburgh	O
IRB	O
,	O
and	O
severe	O
adverse	O
events	O
are	O
reported	O
to	O
members	O
of	O
the	O
DSMB	O
immediately	O
via	O
email	O
.	O

All	O
adverse	O
events	O
are	O
reviewed	O
at	O
regularly	O
scheduled	O
DSMB	O
meetings	O
.	O

Changes	O
to	O
the	O
protocol	O
require	O
approval	O
by	O
the	O
University	O
of	O
Pittsburgh	O
IRB	O
and	O
are	O
reported	O
to	O
the	O
DSMB	O
.	O

After	O
study	O
completion	O
,	O
results	O
will	O
be	O
made	O
available	O
through	O
publication	O
in	O
peer	O
-	O
reviewed	O
journals	O
and	O
conference	O
presentations	O
.	O

Results	O
will	O
be	O
communicated	O
to	O
participants	O
and	O
referring	O
providers	O
via	O
newsletters	O
.	O

The	O
final	O
dataset	O
will	O
be	O
made	O
available	O
per	O
our	O
data	O
sharing	O
plan	O
(	O
additional	O
information	O
available	O
upon	O
request	O
)	O
,	O
which	O
adheres	O
to	O
the	O
NIH	O
Statement	O
on	O
Sharing	O
Research	O
Data	O
and	O
the	O
NIH	O
Grants	O
Policy	O
on	O
Availability	O
of	O
Research	O
Results	O
:	O
Publications	O
,	O
Intellectual	O
Property	O
Rights	O
,	O
Sharing	O
Biomedical	O
Research	O
Resources	O
and	O
Sharing	O
Model	O
Organisms	O
for	O
Biomedical	O
Research	O
.	O

All	O
investigators	O
of	O
the	O
current	O
study	O
will	O
have	O
access	O
to	O
the	O
final	O
dataset	O
.	O

The	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
program	O
supporting	O
this	O
study	O
is	O
specifically	O
intended	O
to	O
support	O
low	O
-	O
cost	O
,	O
pragmatic	O
[	O
89	O
]	O
,	O
randomized	O
controlled	O
trials	O
of	O
interventions	O
in	O
existing	O
clinical	O
practice	O
settings	O
.	O

To	O
measure	O
the	O
pragmatic	O
nature	O
of	O
this	O
and	O
other	O
similar	O
trials	O
,	O
the	O
PRagmatic	O
Explanatory	O
Continuum	O
Indicator	O
Summary	O
(	O
PRECIS	O
-	O
2	O
)	O
toolkit	O
was	O
applied	O
to	O
the	O
trial	O
design	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
precis	O
-	O
2	O
.	O
org	O
[	O
90	O
,	O
91	O
]	O
)	O
.	O

While	O
the	O
toolkit	O
was	O
originally	O
created	O
to	O
support	O
the	O
design	O
of	O
pragmatic	O
trials	O
across	O
various	O
domains	O
,	O
it	O
is	O
also	O
a	O
useful	O
framework	O
for	O
analyzing	O
the	O
pragmatic	O
nature	O
of	O
these	O
trials	O
post	O
-	O
hoc	O
.	O

The	O
PRECIS	O
-	O
2	O
includes	O
nine	O
domains	O
:	O
(	O
1	O
)	O
eligibility	O
of	O
participants	O
;	O
(	O
2	O
)	O
recruitment	O
of	O
participants	O
;	O
(	O
3	O
)	O
trial	O
setting	O
;	O
(	O
4	O
)	O
organizational	O
expertise	O
and	O
resources	O
needed	O
to	O
deliver	O
the	O
intervention	O
;	O
(	O
5	O
)	O
flexibility	O
in	O
intervention	O
delivery	O
;	O
(	O
6	O
)	O
flexibility	O
in	O
adherence	O
to	O
the	O
intervention	O
;	O
(	O
7	O
)	O
follow	O
-	O
up	O
of	O
participants	O
;	O
(	O
8	O
)	O
primary	O
outcome	O
relevant	O
to	O
participants	O
;	O
and	O
(	O
9	O
)	O
inclusion	O
of	O
all	O
data	O
in	O
the	O
primary	O
analysis	O
.	O

A	O
score	O
is	O
given	O
to	O
each	O
domain	O
using	O
a	O
five	O
-	O
point	O
Likert	O
scale	O
(	O
1	O
–	O
very	O
explanatory	O
(	O
basic	O
and	O
mechanism	O
focused	O
)	O
to	O
5	O
–	O
very	O
pragmatic	O
(	O
applied	O
and	O
widely	O
applicable	O
)	O
,	O
with	O
3	O
indicating	O
that	O
a	O
trial	O
is	O
equally	O
pragmatic	O
and	O
explanatory	O
)	O
[	O
91	O
]	O
.	O

These	O
domains	O
may	O
be	O
depicted	O
visually	O
on	O
a	O
radial	O
graph	O
for	O
easy	O
interpretation	O
of	O
the	O
overall	O
and	O
domain	O
-	O
specific	O
level	O
of	O
trial	O
pragmatism	O
.	O

While	O
there	O
are	O
absolute	O
scores	O
for	O
each	O
domain	O
,	O
the	O
scoring	O
may	O
also	O
be	O
used	O
for	O
comparison	O
to	O
another	O
trial	O
to	O
determine	O
the	O
level	O
of	O
similarity	O
across	O
trials	O
on	O
various	O
measures	O
of	O
pragmatism	O
.	O

Consensus	O
ratings	O
for	O
this	O
trial	O
,	O
and	O
other	O
similar	O
trials	O
funded	O
by	O
the	O
same	O
mechanism	O
(	O
RFA	O
-	O
HL	O
-	O
14	O
-	O
019	O
)	O
,	O
were	O
completed	O
last	O
year	O
by	O
investigators	O
of	O
the	O
six	O
funded	O
trials	O
.	O

Figure	O
4	O
indicates	O
that	O
this	O
trial	O
was	O
rated	O
as	O
very	O
pragmatic	O
(	O
score	O
of	O
5	O
)	O
with	O
regard	O
to	O
recruitment	O
,	O
setting	O
,	O
primary	O
outcome	O
,	O
and	O
primary	O
analysis	O
,	O
and	O
pragmatic	O
(	O
score	O
of	O
4	O
)	O
on	O
eligibility	O
and	O
adherence	O
flexibility	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
trial	O
was	O
rated	O
as	O
very	O
explanatory	O
(	O
score	O
of	O
1	O
)	O
on	O
follow	O
-	O
up	O
of	O
participants	O
,	O
explanatory	O
(	O
score	O
of	O
2	O
)	O
on	O
organizational	O
resources	O
needed	O
to	O
deliver	O
the	O
intervention	O
,	O
and	O
equally	O
pragmatic	O
and	O
explanatory	O
(	O
score	O
of	O
3	O
)	O
on	O
flexibility	O
in	O
intervention	O
delivery	O
.	O

As	O
the	O
rating	O
of	O
‘very	O
explanatory’	O
suggests	O
,	O
follow	O
-	O
up	O
of	O
participants	O
in	O
this	O
study	O
involves	O
repeated	O
measurement	O
using	O
multiple	O
scales	O
.	O

As	O
such	O
,	O
we	O
have	O
taken	O
steps	O
to	O
increase	O
interest	O
and	O
adherence	O
,	O
including	O
(	O
1	O
)	O
educating	O
patients	O
at	O
study	O
enrollment	O
about	O
the	O
rationale	O
behind	O
the	O
assessments	O
;	O
(	O
2	O
)	O
sending	O
quarterly	O
newsletters	O
to	O
reinforce	O
the	O
importance	O
of	O
the	O
study	O
and	O
our	O
interest	O
in	O
study	O
participants	O
;	O
and	O
(	O
3	O
)	O
sending	O
reminder	O
emails	O
and	O
text	O
messages	O
to	O
encourage	O
adherence	O
at	O
follow	O
-	O
up	O
time	O
points	O
.	O

The	O
Singapore	O
Chinese	O
Health	O
Study	O
was	O
established	O
between	O
1993	O
and	O
1998	O
with	O
63	O
,	O
257	O
Chinese	O
(	O
27	O
,	O
954	O
men	O
and	O
35	O
,	O
303	O
women	O
)	O
in	O
Singapore	O
,	O
aged	O
45	O
-	O
74	O
years	O
.	O

12	O
The	O
study	O
subjects	O
were	O
recruited	O
from	O
two	O
major	O
dialect	O
groups	O
in	O
Singapore	O
,	O
Hokkiens	O
and	O
Cantonese	O
,	O
who	O
originated	O
from	O
Fujian	O
and	O
Guangdong	O
provinces	O
in	O
Southern	O
China	O
,	O
respectively	O
.	O

During	O
the	O
enrolment	O
period	O
,	O
all	O
study	O
participants	O
were	O
residents	O
of	O
government	O
housing	O
estates	O
,	O
where	O
86	O
%	O
of	O
the	O
Singapore	O
population	O
resided	O
at	O
the	O
time	O
of	O
recruitment	O
.	O

The	O
Institutional	O
Review	O
Board	O
of	O
the	O
National	O
University	O
of	O
Singapore	O
approved	O
this	O
study	O
,	O
and	O
all	O
enrolled	O
subjects	O
gave	O
informed	O
consent	O
.	O

At	O
recruitment	O
,	O
the	O
trained	O
interviewers	O
conducted	O
the	O
face	O
-	O
to	O
-	O
face	O
interviews	O
using	O
a	O
structured	O
questionnaire	O
,	O
and	O
obtained	O
information	O
on	O
height	O
,	O
weight	O
,	O
cigarette	O
smoking	O
,	O
habitual	O
physical	O
activity	O
,	O
alcohol	O
drinking	O
and	O
habitual	O
dietary	O
intake	O
(	O
by	O
a	O
validated	O
165	O
-	O
item	O
food	O
-	O
frequency	O
questionnaire	O
)	O
.	O

Body	O
mass	O
index	O
(	O
BMI	O
,	O
in	O
kg	O
/	O
m	O
2	O
)	O
was	O
calculated	O
by	O
body	O
weight	O
in	O
kilogram	O
divided	O
by	O
square	O
of	O
height	O
in	O
meter	O
.	O

Participants	O
were	O
asked	O
about	O
their	O
history	O
of	O
medical	O
conditions	O
diagnosed	O
by	O
physicians	O
,	O
including	O
diabetes	O
,	O
hypertension	O
,	O
CHD	O
and	O
stroke	O
,	O
and	O
unknown	O
status	O
of	O
these	O
conditions	O
was	O
coded	O
as	O
“no”	O
on	O
the	O
questionnaires	O
.	O

History	O
of	O
cancer	O
was	O
ascertained	O
by	O
self	O
-	O
reports	O
and	O
record	O
linkage	O
with	O
the	O
Singapore	O
Cancer	O
Registry	O
database	O
.	O

Sleep	O
duration	O
was	O
assessed	O
by	O
the	O
following	O
question	O
:	O
“On	O
the	O
average	O
,	O
during	O
the	O
last	O
year	O
,	O
how	O
many	O
hours	O
in	O
a	O
day	O
did	O
you	O
sleep	O
?	O
”	O
with	O
the	O
following	O
responses	O
:	O
“5	O
hours	O
or	O
less”	O
,	O
“6	O
hours”	O
,	O
“7	O
hours”	O
,	O
“8	O
hours”	O
,	O
“9	O
hours”	O
,	O
“10	O
hours	O
or	O
more”	O
.	O

Deaths	O
were	O
identified	O
through	O
record	O
linkage	O
with	O
the	O
Singapore	O
Registry	O
of	O
Births	O
and	O
Deaths	O
up	O
to	O
December	O
31	O
,	O
2011	O
.	O

Underlying	B-Phenotype
death	I-Phenotype
causes	I-Phenotype
were	O
coded	O
according	O
to	O
the	O
International	B-Coding_system
Classification	I-Coding_system
of	I-Coding_system
Diseases	I-Coding_system
,	I-Coding_system
Ninth	I-Coding_system
Revision	I-Coding_system
(	I-Coding_system
ICD	I-Coding_system
-	I-Coding_system
9	I-Coding_system
)	I-Coding_system
:	O
codes	O
430	B-Code
-	I-Code
438	I-Code
for	O
all	B-Phenotype
stroke	I-Phenotype
deaths	I-Phenotype
,	O
430	B-Code
-	I-Code
432	I-Code
for	O
hemorrhagic	B-Phenotype
stroke	I-Phenotype
,	O
and	O
433	B-Code
-	I-Code
438	I-Code
for	O
ischemic	B-Phenotype
or	I-Phenotype
otherwise	I-Phenotype
unspecified	I-Phenotype
stroke	I-Phenotype
.	O

We	O
have	O
tried	O
to	O
verify	O
unspecified	O
stroke	O
cases	O
through	O
sources	O
of	O
medical	O
records	O
in	O
a	O
previous	O
pilot	O
study	O
:	O
among	O
308	O
cases	O
with	O
available	O
medical	O
records	O
,	O
86	O
%	O
were	O
ischemic	O
strokes	O
and	O
14	O
%	O
were	O
hemorrhagic	O
strokes	O
.	O

This	O
suggested	O
that	O
majority	O
of	O
the	O
strokes	O
classified	O
as	O
unspecified	O
were	O
actually	O
ischemic	O
strokes	O
(	O
unpublished	O
data	O
)	O
.	O

As	O
of	O
December	O
31	O
,	O
2011	O
,	O
only	O
47	O
subjects	O
from	O
this	O
cohort	O
were	O
known	O
to	O
be	O
lost	O
to	O
follow	O
-	O
up	O
due	O
to	O
migration	O
out	O
of	O
Singapore	O
or	O
for	O
other	O
reasons	O
.	O

Therefore	O
,	O
emigration	O
among	O
participants	O
seems	O
to	O
be	O
negligible	O
in	O
this	O
cohort	O
and	O
vital	O
statistics	O
during	O
follow	O
-	O
up	O
was	O
virtually	O
complete	O
.	O

We	O
chose	O
a	O
reference	O
category	O
of	O
7	O
hours	O
/	O
day	O
because	O
there	O
were	O
most	O
subjects	O
in	O
this	O
category	O
as	O
well	O
as	O
to	O
be	O
consistent	O
with	O
previous	O
studies	O
in	O
the	O
field	O
.	O

2	O
Person	O
-	O
years	O
for	O
each	O
participant	O
were	O
calculated	O
from	O
the	O
date	O
of	O
recruitment	O
until	O
date	O
of	O
death	O
,	O
lost	O
-	O
to	O
-	O
follow	O
-	O
up	O
or	O
December	O
31	O
,	O
2011	O
,	O
whichever	O
occurred	O
first	O
.	O

Cox	O
proportional	O
hazards	O
regressions	O
were	O
used	O
to	O
calculate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
and	O
their	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
for	O
stroke	O
mortality	O
associated	O
with	O
different	O
categories	O
of	O
sleep	O
duration	O
(	O
≤5	O
,	O
6	O
,	O
8	O
,	O
≥9	O
relative	O
to	O
7	O
hours	O
/	O
day	O
)	O
.	O

We	O
adjusted	O
for	O
age	O
,	O
year	O
of	O
recruitment	O
,	O
gender	O
,	O
dialect	O
group	O
,	O
level	O
of	O
education	O
,	O
BMI	O
,	O
alcohol	O
drinking	O
,	O
smoking	O
intensity	O
(	O
number	O
of	O
cigarettes	O
/	O
day	O
)	O
and	O
duration	O
(	O
number	O
of	O
years	O
of	O
smoking	O
)	O
,	O
level	O
of	O
moderate	O
physical	O
activity	O
,	O
and	O
daily	O
intakes	O
of	O
total	O
calorie	O
,	O
vegetables	O
,	O
fruits	O
,	O
dietary	O
fiber	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

In	O
a	O
separate	O
model	O
,	O
we	O
further	O
adjusted	O
for	O
history	O
of	O
hypertension	O
,	O
diabetes	O
,	O
CHD	O
,	O
stroke	O
,	O
and	O
cancer	O
,	O
since	O
these	O
comorbidities	O
could	O
be	O
potential	O
mediators	O
in	O
the	O
pathway	O
between	O
sleep	O
duration	O
and	O
stroke	O
death	O
.	O

Additionally	O
,	O
we	O
tested	O
the	O
interactions	O
between	O
sleep	O
duration	O
(	O
five	O
categories	O
)	O
and	O
these	O
comorbidities	O
or	O
overweight	O
/	O
obesity	O
status	O
on	O
the	O
risk	O
of	O
stroke	O
mortality	O
,	O
and	O
performed	O
stratified	O
analysis	O
by	O
these	O
variables	O
.	O

We	O
also	O
tested	O
the	O
curvilinear	O
relation	O
by	O
including	O
linear	O
and	O
quadratic	O
terms	O
of	O
sleep	O
duration	O
in	O
the	O
regression	O
model	O
.	O

Statistical	O
computing	O
was	O
conducted	O
using	O
SAS	O
version	O
9	O
.	O
1	O
(	O
SAS	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
)	O
,	O
and	O
two	O
sided	O
P	O
values	O
<	O
0	O
.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

This	O
is	O
a	O
multicentre	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
,	O
two	O
-	O
arm	O
,	O
controlled	O
,	O
feasibility	O
study	O
,	O
with	O
balanced	O
randomization	O
in	O
two	O
parallel	O
groups	O
(	O
wet	O
TBW	O
versus	O
dry	O
TBW	O
)	O
.	O

In	O
its	O
initial	O
version	O
,	O
the	O
study	O
was	O
planned	O
to	O
assess	O
the	O
efficacy	O
of	O
wet	O
TBW	O
versus	O
dry	O
TBW	O
and	O
versus	O
risperidone	O
.	O

Given	O
the	O
French	O
authorities’	O
expectation	O
to	O
collect	O
safety	O
data	O
and	O
the	O
reluctance	O
of	O
some	O
parents	O
toward	O
risperidone	O
use	O
,	O
the	O
protocol	O
was	O
amended	O
in	O
accordance	O
with	O
French	O
authorities’	O
decision	O
to	O
provide	O
data	O
about	O
the	O
effect	O
size	O
and	O
safety	O
of	O
wet	O
TBW	O
versus	O
dry	O
TBW	O
.	O

This	O
change	O
subsequently	O
allowed	O
a	O
sharp	O
decrease	O
in	O
the	O
number	O
of	O
participants	O
.	O

The	O
risperidone	O
arm	O
was	O
abandoned	O
and	O
it	O
was	O
not	O
possible	O
to	O
add	O
another	O
arm	O
with	O
patients	O
exposed	O
to	O
another	O
non	O
-	O
pharmacological	O
intervention	O
(	O
e	O
.	O
g	O
.	O
applied	O
behavioural	O
analysis	O
,	O
ABA	O
)	O
because	O
randomization	O
would	O
have	O
been	O
changed	O
dramatically	O
and	O
the	O
duration	O
of	O
the	O
study	O
to	O
reach	O
enough	O
statistical	O
power	O
would	O
have	O
been	O
even	O
longer	O
.	O

As	O
a	O
consequence	O
,	O
the	O
study	O
became	O
a	O
feasibility	O
study	O
after	O
this	O
amendment	O
[	O
27	O
]	O
.	O

The	O
ethics	O
committee	O
validated	O
all	O
these	O
amendments	O
to	O
the	O
protocol	O
before	O
breaking	O
the	O
blindness	O
,	O
including	O
the	O
validation	O
of	O
the	O
final	O
statistical	O
analysis	O
plan	O
.	O

The	O
randomization	O
procedure	O
was	O
centralized	O
according	O
to	O
a	O
randomization	O
table	O
provided	O
by	O
the	O
sponsor	O
.	O

The	O
computer	O
-	O
generated	O
randomization	O
table	O
allowed	O
a	O
1	O
:	O
1	O
allocation	O
using	O
a	O
block	O
size	O
of	O
six	O
.	O

The	O
block	O
size	O
had	O
been	O
blinded	O
for	O
investigators	O
.	O

The	O
randomization	O
list	O
was	O
not	O
disclosed	O
to	O
the	O
study	O
centres	O
,	O
monitors	O
,	O
project	O
statisticians	O
or	O
project	O
team	O
.	O

Allocation	O
was	O
concealed	O
using	O
a	O
sealed	O
opaque	O
envelope	O
system	O
and	O
occurred	O
as	O
soon	O
as	O
the	O
inclusion	O
was	O
decided	O
.	O

Since	O
maintaining	O
blindness	O
to	O
treatment	O
was	O
not	O
possible	O
with	O
therapists	O
in	O
charge	O
of	O
the	O
TBW	O
because	O
of	O
wet	O
/	O
dry	O
sheets	O
,	O
we	O
used	O
independent	O
raters	O
to	O
assess	O
primary	O
and	O
secondary	O
variables	O
(	O
see	O
list	O
below	O
)	O
following	O
the	O
PROBE	O
(	O
Prospective	O
Randomized	O
Open	O
Blinded	O
End	O
-	O
point	O
)	O
design	O
.	O

From	O
January	O
2008	O
to	O
January	O
2015	O
,	O
children	O
were	O
recruited	O
from	O
13	O
French	O
specialized	O
clinics	O
(	O
Centre	O
Hospitalier	O
Universitaire	O
in	O
Lille	O
,	O
Institut	O
Départemental	O
Albert	O
Calmette	O
in	O
Camiers	O
,	O
Centre	O
Hospitalier	O
Robert	O
Ballanger	O
in	O
Aulnay	O
-	O
sous	O
-	O
Bois	O
,	O
Groupe	O
Hospitalier	O
Pitié	O
-	O
Salpêtrière	O
in	O
Paris	O
,	O
Centre	O
Hospitalier	O
de	O
Douai	O
in	O
Douai	O
,	O
Etablissement	O
Public	O
de	O
Santé	O
Mentale	O
Val	O
de	O
Lys	O
-	O
Artois	O
in	O
Saint	O
-	O
Venant	O
,	O
Centre	O
de	O
Santé	O
Mentale	O
Angevin	O
in	O
Angers	O
,	O
Institut	O
Médico	O
-	O
éducatif	O
in	O
Montigny	O
in	O
Ostrevent	O
,	O
Centre	O

Hospitalier	O
de	O
Lens	O
in	O
Lens	O
,	O
Etablissement	O
de	O
Santé	O
Maison	O
Blanche	O
in	O
Paris	O
,	O
Etablissement	O
Public	O
de	O
Santé	O
Roger	O
Prévot	O
in	O
Gennevilliers	O
,	O
Centre	O
Hospitalier	O
Montfavet	O
in	O
Avignon	O
,	O
and	O
Centre	O
Hospitalier	O
d’Arras	O
in	O
Arras	O
)	O
under	O
the	O
supervision	O
of	O
the	O
Department	O
of	O
Child	O
and	O
Adolescent	O
Psychiatry	O
,	O
Lille	O
University	O
Hospital	O
,	O
Lille	O
,	O
France	O
.	O

The	O
study	O
was	O
registered	O
at	O
the	O
French	O
Drug	O
Agency	O
(	O
AFSSAPS	O
)	O
under	O
the	O
number	O
2007	O
-	O
A01376	O
-	O
47	O
.	O

The	O
study	O
was	O
then	O
approved	O
by	O
both	O
the	O
Lille	O
University	O
Hospital	O
ethics	O
committee	O
(	O
Comité	O
de	O
Protection	O
des	O
Personnes	O
CPP	O
Nord	O
Ouest	O
IV	O
under	O
agreement	O
number	O
CCP	O
08	O
/	O
08	O
)	O
and	O
the	O
French	O
Ministry	O
of	O
Health	O
(	O
number	O
DGS	O
2008–0070	O
)	O
.	O

All	O
these	O
regulatory	O
requirements	O
were	O
made	O
before	O
first	O
patient’s	O
enrolment	O
.	O

As	O
non	O
-	O
medication	O
trials	O
are	O
not	O
publicly	O
available	O
in	O
AFSSAPS	O
registry	O
and	O
are	O
registered	O
in	O
French	O
,	O
the	O
clinical	O
trial	O
was	O
also	O
registered	O
in	O
ClinicalTrials	O
.	O
gov	O
registry	O
under	O
the	O
number	O
NCT03164746	O
.	O

The	O
authors	O
confirm	O
that	O
all	O
ongoing	O
and	O
related	O
trials	O
for	O
this	O
drug	O
/	O
intervention	O
are	O
registered	O
.	O

Each	O
parent	O
(	O
and	O
child	O
,	O
when	O
possible	O
)	O
gave	O
informed	O
written	O
consent	O
before	O
inclusion	O
.	O

Inclusion	O
criteria	O
were	O
:	O
a	O
current	O
diagnosis	O
of	O
autism	B-phenotype
,	I-phenotype
Asperger	I-phenotype
syndrome	I-phenotype
,	I-phenotype
atypical	I-phenotype
autism	I-phenotype
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
criteria	O
[	O
31	O
]	O
confirmed	O
by	O
specialized	O
clinical	O
assessment	O
,	O
being	O
aged	O
5	O
to	O
18	O
years	O
,	O
and	O
presenting	O
severe	O
behavioural	O
disturbances	O
such	O
as	O
hetero	O
and	O
self	O
-	O
injurious	O
behaviours	O
,	O
automutilations	O
,	O
severe	O
motor	O
hyperactivity	O
,	O
and	O
severe	O
stereotypies	O
.	O

We	O
excluded	O
children	O
with	O
known	O
organic	O
syndrome	O
and	O
/	O
or	O
non	O
-	O
stabilized	O
neuropaediatric	O
(	O
e	O
.	O
g	O
.	O
,	O
seizures	O
)	O
or	O
medical	O
(	O
e	O
.	O
g	O
.	O
,	O
diabetes	O
mellitus	O
)	O
comorbidities	O
.	O

This	O
was	O
systematically	O
checked	O
after	O
a	O
neuropaediatric	O
assessment	O
.	O

For	O
patients	O
with	O
a	O
stabilized	O
seizure	O
condition	O
,	O
antiepileptic	O
medication	O
had	O
to	O
be	O
stable	O
for	O
at	O
least	O
4	O
weeks	O
.	O

Also	O
,	O
for	O
patients	O
already	O
given	O
psychotropic	O
medications	O
,	O
the	O
prescription	O
had	O
to	O
be	O
stable	O
for	O
at	O
least	O
4	O
weeks	O
.	O

In	O
total	O
,	O
56	O
patients	O
were	O
eligible	O
and	O
assessed	O
at	O
baseline	O
.	O

They	O
all	O
were	O
randomized	O
to	O
a	O
study	O
arm	O
,	O
including	O
8	O
patients	O
randomized	O
in	O
the	O
risperidone	O
arm	O
.	O

Finally	O
,	O
48	O
entered	O
the	O
trial	O
to	O
receive	O
TBW	O
and	O
were	O
allocated	O
to	O
the	O
WET	O
group	O
(	O
N	O
=	O
24	O
)	O
or	O
the	O
DRY	O
group	O
(	O
N	O
=	O
24	O
)	O
(	O
see	O
Fig	O
1	O
:	O
CONSORT	O
flow	O
diagram	O
)	O
.	O

TBW	O
is	O
aimed	O
at	O
restoring	O
sensory	O
integration	O
and	O
body	O
representations	O
and	O
reducing	O
anxiety	O
.	O

The	O
overall	O
treatment	O
encompassed	O
a	O
series	O
of	O
twice	O
-	O
a	O
-	O
week	O
sessions	O
over	O
3	O
months	O
.	O

The	O
sessions	O
took	O
place	O
in	O
the	O
same	O
quiet	O
room	O
,	O
and	O
they	O
usually	O
lasted	O
45	O
minutes	O
each	O
,	O
though	O
they	O
could	O
be	O
extended	O
up	O
to	O
1	O
hour	O
depending	O
on	O
the	O
patient’s	O
response	O
.	O

A	O
minimum	O
of	O
30	O
minutes	O
of	O
TBW	O
inside	O
the	O
sheets	O
is	O
recommended	O
.	O

During	O
the	O
sessions	O
,	O
the	O
patient	O
wore	O
a	O
bathing	O
suit	O
.	O

The	O
sessions	O
were	O
conducted	O
by	O
an	O
occupational	O
therapist	O
(	O
psychomotricien	O
in	O
the	O
French	O
medical	O
system	O
)	O
and	O
involved	O
at	O
least	O
two	O
members	O
of	O
the	O
patient’s	O
care	O
team	O
that	O
were	O
asked	O
to	O
keep	O
on	O
participating	O
to	O
all	O
patient’s	O
sessions	O
.	O

All	O
occupational	O
therapists	O
that	O
offered	O
TBW	O
were	O
trained	O
previously	O
by	O
the	O
Lille	O
team	O
,	O
the	O
principal	O
investigator	O
of	O
the	O
study	O
.	O

At	O
the	O
beginning	O
of	O
the	O
session	O
,	O
the	O
patient’s	O
consent	O
to	O
proceed	O
was	O
orally	O
obtained	O
,	O
as	O
no	O
session	O
was	O
compulsory	O
.	O

In	O
case	O
of	O
non	O
-	O
language	O
,	O
therapists	O
checked	O
behavioural	O
manifestations	O
of	O
refusal	O
.	O

Then	O
,	O
the	O
patient	O
was	O
first	O
wrapped	O
in	O
wet	O
damp	O
sheets	O
(	O
cold	O
phase	O
)	O
and	O
covered	O
up	O
with	O
a	O
rescue	O
and	O
a	O
dry	O
blanket	O
.	O

Afterward	O
,	O
the	O
body	O
spontaneously	O
warmed	O
up	O
(	O
warm	O
phase	O
)	O
.	O

The	O
patient	O
was	O
then	O
invited	O
to	O
freely	O
express	O
his	O
feelings	O
,	O
bodily	O
/	O
cutaneous	O
sensations	O
and	O
somatic	O
fantasies	O
.	O

A	O
brief	O
moment	O
(	O
usually	O
less	O
than	O
15	O
minutes	O
)	O
of	O
drawing	O
or	O
modelling	O
with	O
clay	O
was	O
proposed	O
at	O
the	O
end	O
of	O
each	O
session	O
to	O
provide	O
non	O
-	O
verbal	O
avenues	O
through	O
which	O
the	O
patient	O
could	O
express	O
feelings	O
and	O
explore	O
body	O
representations	O
.	O

Throughout	O
the	O
session	O
,	O
the	O
patient’s	O
comments	O
and	O
relevant	O
observations	O
from	O
the	O
clinicians	O
(	O
e	O
.	O
g	O
.	O
,	O
clinical	O
signs	O
,	O
body	O
image	O
,	O
cenesthesis	O
sensations	O
,	O
and	O
adverse	O
events	O
)	O
were	O
carefully	O
recorded	O
by	O
one	O
of	O
the	O
observers	O
[	O
7	O
,	O
20	O
]	O
.	O

A	O
10	O
-	O
minute	O
-	O
video	O
presents	O
video	O
clips	O
of	O
the	O
same	O
child	O
during	O
several	O
sessions	O
both	O
at	O
session	O
beginnings	O
and	O
session	O
endings	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
doi	O
.	O
org	O
/	O
10	O
.	O
5281	O
/	O
zenodo	O
.	O
1157306	O
)	O
.	O

The	O
clinical	O
history	O
of	O
this	O
child	O
has	O
been	O
reported	O
in	O
[	O
32	O
]	O
.	O

The	O
intervention	O
was	O
similar	O
in	O
the	O
dry	O
sheet	O
pack	O
control	O
group	O
,	O
with	O
the	O
notable	O
exception	O
that	O
the	O
sheets	O
were	O
dry	O
during	O
all	O
sessions	O
.	O

Apart	O
common	O
training	O
with	O
the	O
coordination	O
team	O
,	O
to	O
ensure	O
comparability	O
between	O
the	O
13	O
clinical	O
centers	O
,	O
occupational	O
therapists	O
in	O
charge	O
of	O
TBW	O
sessions	O
received	O
regular	O
supervision	O
on	O
sites	O
(	O
4	O
times	O
a	O
year	O
)	O
by	O
the	O
coordination	O
team	O
.	O

Autism	O
symptom	O
dimensions	O
were	O
assessed	O
at	O
baseline	O
using	O
the	O
current	O
Autism	O
Diagnostic	O
Interview	O
-	O
revised	O
(	O
ADI	O
-	O
R	O
)	O
,	O
addressed	O
to	O
parents	O
[	O
33	O
]	O
.	O

To	O
assess	O
clinical	O
change	O
during	O
the	O
3	O
-	O
month	O
exploratory	O
study	O
,	O
we	O
used	O
a	O
double	O
-	O
blind	O
procedure	O
,	O
and	O
we	O
measured	O
the	O
primary	O
variable	O
at	O
enrolment	O
,	O
1	O
month	O
,	O
2	O
months	O
and	O
3	O
months	O
.	O

The	O
primary	O
outcome	O
variable	O
was	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
irritability	O
score	O
[	O
34	O
]	O
.	O

Secondary	O
variables	O
included	O
:	O
(	O
1	O
)	O
the	O
other	O
ABC	O
scores	O
:	O
hyperactivity	O
,	O
lethargy	O
,	O
inappropriate	O
speech	O
,	O
stereotypic	O
behaviour	O
and	O
total	O
;	O
(	O
2	O
)	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Severity	O
(	O
CGI	O
-	O
S	O
)	O
scale	O
at	O
enrolment	O
and	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Improvement	O
(	O
CGI	O
-	O
I	O
)	O
scale	O
at	O
3	O
months	O
[	O
35	O
]	O
;	O
and	O
(	O
3	O
)	O
the	O
Child	O
Autism	O
Rating	O
Scale	O
(	O
CARS	O
)	O
[	O
36	O
]	O
at	O
enrolment	O
and	O
at	O
3	O
months	O
.	O

For	O
each	O
instrument	O
,	O
French	O
translation	O
sources	O
are	O
given	O
in	O
supporting	O
information	O
.	O

After	O
the	O
protocol	O
was	O
amended	O
,	O
the	O
study	O
was	O
designed	O
as	O
a	O
feasibility	O
study	O
.	O

The	O
primary	O
objective	O
was	O
the	O
comparison	O
of	O
change	O
in	O
ABC	O
-	O
irritability	O
scores	O
from	O
baseline	O
to	O
3	O
months	O
between	O
the	O
two	O
groups	O
(	O
wet	O
TBW	O
vs	O
.	O

dry	O
TBW	O
)	O
.	O

According	O
to	O
the	O
recruitment	O
potential	O
,	O
we	O
planned	O
to	O
recruit	O
30	O
subjects	O
in	O
each	O
group	O
.	O

This	O
sample	O
size	O
would	O
allow	O
us	O
to	O
detect	O
a	O
minimum	O
effect	O
size	O
(	O
Cohen’s	O
d	O
:	O
difference	O
in	O
means	O
divided	O
by	O
the	O
root	O
mean	O
square	O
standard	O
deviations	O
)	O
of	O
0	O
.	O
74	O
between	O
the	O
2	O
groups	O
for	O
the	O
comparison	O
of	O
mean	O
changes	O
in	O
irritability	O
score	O
from	O
baseline	O
to	O
3	O
months	O
with	O
a	O
power	O
of	O
80	O
%	O
(	O
two	O
-	O
sided	O
test	O
and	O
type	O
I	O
error	O
of	O
5	O
%	O
)	O
;	O
this	O
effect	O
size	O
was	O
considered	O
as	O
large	O
in	O
the	O
literature	O
[	O
37	O
]	O
.	O

Categorical	O
variables	O
were	O
expressed	O
as	O
frequencies	O
and	O
percentages	O
.	O

Continuous	O
variables	O
were	O
expressed	O
as	O
the	O
means	O
(	O
standard	O
deviation	O
)	O
in	O
the	O
case	O
of	O
a	O
normal	O
distribution	O
and	O
as	O
medians	O
(	O
inter	O
quartiles	O
)	O
otherwise	O
.	O

The	O
normality	O
of	O
distributions	O
was	O
checked	O
graphically	O
and	O
using	O
the	O
Shapiro	O
-	O
Wilk	O
test	O
.	O

For	O
categorical	O
variables	O
,	O
the	O
baseline	O
characteristics	O
were	O
described	O
for	O
each	O
group	O
and	O
compared	O
using	O
a	O
chi	O
-	O
square	O
test	O
or	O
Fisher’s	O
exact	O
test	O
.	O

For	O
continuous	O
variables	O
,	O
we	O
used	O
Student’s	O
t	O
test	O
or	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
when	O
appropriate	O
.	O

The	O
magnitude	O
of	O
the	O
between	O
-	O
group	O
differences	O
was	O
assessed	O
by	O
calculating	O
the	O
absolute	O
standardized	O
differences	O
(	O
Cohen’s	O
d	O
:	O
difference	O
in	O
means	O
or	O
rates	O
divided	O
by	O
the	O
root	O
mean	O
square	O
standard	O
deviations	O
)	O
;	O
an	O
absolute	O
standardized	O
difference	O
>	O
0	O
.	O
20	O
was	O
interpreted	O
as	O
a	O
meaningful	O
difference	O
.	O

A	O
comparison	O
of	O
primary	O
outcomes	O
between	O
the	O
2	O
groups	O
was	O
performed	O
with	O
an	O
analysis	O
of	O
covariance	O
(	O
ANCOVA	O
)	O
,	O
adjusted	O
for	O
the	O
baseline	O
value	O
.	O

The	O
effect	O
size	O
(	O
namely	O
,	O
the	O
baseline	O
-	O
adjusted	O
mean	O
differences	O
in	O
3	O
-	O
month	O
change	O
from	O
baseline	O
divided	O
by	O
the	O
root	O
mean	O
square	O
error	O
of	O
ANCOVA	O
model	O
)	O
was	O
computed	O
taking	O
into	O
account	O
the	O
adjustment	O
for	O
baseline	O
,	O
and	O
its	O
95	O
%	O
confidence	O
interval	O
was	O
estimated	O
using	O
a	O
bootstrap	O
resampling	O
.	O

The	O
validity	O
of	O
the	O
ANCOVA	O
model	O
was	O
checked	O
by	O
examining	O
the	O
model	O
residuals	O
.	O

The	O
same	O
methodology	O
was	O
employed	O
for	O
the	O
secondary	O
outcomes	O
.	O

When	O
the	O
normality	O
of	O
model	O
residuals	O
was	O
not	O
satisfied	O
,	O
nonparametric	O
analysis	O
was	O
used	O
.	O

The	O
relative	O
change	O
between	O
baseline	O
and	O
the	O
3	O
-	O
month	O
visit	O
was	O
calculated	O
and	O
compared	O
between	O
the	O
2	O
groups	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

Analysis	O
of	O
repeated	O
measurements	O
(	O
months	O
1	O
,	O
2	O
and	O
3	O
)	O
for	O
the	O
primary	O
and	O
secondary	O
outcomes	O
was	O
performed	O
using	O
the	O
linear	O
mixed	O
model	O
(	O
LMM	O
)	O
.	O

LMM	O
allows	O
handling	O
the	O
correlations	O
between	O
the	O
repeated	O
measurements	O
.	O

These	O
correlations	O
were	O
modelled	O
using	O
a	O
covariance	O
pattern	O
model	O
.	O

In	O
this	O
study	O
,	O
we	O
chose	O
a	O
first	O
-	O
order	O
,	O
autoregressive	O
covariance	O
pattern	O
(	O
because	O
the	O
measurements	O
were	O
taken	O
at	O
predetermined	O
and	O
evenly	O
spaced	O
intervals	O
)	O
.	O

In	O
this	O
model	O
,	O
the	O
effects	O
were	O
baseline	O
,	O
time	O
,	O
group	O
and	O
group	O
-	O
by	O
-	O
time	O
interaction	O
.	O

The	O
correlations	O
between	O
continuous	O
variables	O
were	O
analysed	O
using	O
Spearman’s	O
rank	O
correlation	O
coefficient	O
.	O

A	O
post	O
-	O
hoc	O
exploratory	O
analysis	O
was	O
performed	O
on	O
the	O
primary	O
and	O
secondary	O
outcomes	O
by	O
pooling	O
the	O
two	O
groups	O
together	O
.	O

The	O
change	O
between	O
baseline	O
and	O
3	O
months	O
was	O
analysed	O
using	O
the	O
paired	O
Student’s	O
t	O
test	O
in	O
the	O
case	O
of	O
a	O
normal	O
distribution	O
and	O
the	O
Wilcoxon	O
signed	O
-	O
rank	O
test	O
otherwise	O
.	O

The	O
effect	O
sizes	O
were	O
computed	O
as	O
the	O
mean	O
differences	O
(	O
3	O
-	O
months—baseline	O
)	O
divided	O
by	O
standard	O
deviations	O
at	O
baseline	O
.	O

All	O
statistical	O
tests	O
were	O
performed	O
at	O
the	O
2	O
-	O
tailed	O
α	O
level	O
of	O
0	O
.	O
05	O
.	O

The	O
data	O
were	O
analysed	O
using	O
SAS	O
version	O
9	O
.	O
4	O
[	O
SAS	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
27513	O
,	O
USA	O
]	O
.	O

The	O
study	O
was	O
a	O
single	O
-	O
blind	O
,	O
randomised	O
controlled	O
trial	O
done	O
in	O
the	O
South	O
London	O
and	O
Maudsley	O
NHS	O
Trust	O
.	O

Potential	O
participants	O
were	O
referred	O
to	O
the	O
study	O
by	O
their	O
treating	O
clinician	O
in	O
routine	O
clinical	O
service	O
.	O

All	O
referrals	O
were	O
screened	O
for	O
eligibility	O
against	O
the	O
following	O
inclusion	O
criteria	O
:	O
having	O
had	O
distressing	O
auditory	O
verbal	O
hallucinations	O
for	O
at	O
least	O
12	O
months	O
in	O
the	O
context	O
of	O
a	O
diagnosis	O
of	O
a	O
schizophrenia	B-phenotype
spectrum	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
F20–29	B-code
)	O
or	O
affective	B-phenotype
disorder	I-phenotype
with	I-phenotype
psychotic	I-phenotype
symptoms	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
F30–39	B-code
subcategories	O
with	O
psychotic	O
symptoms	O
)	O
,	O
currently	O
a	O
patient	O
of	O
NHS	O
psychiatric	O
services	O
,	O
older	O
than	O
18	O
years	O
,	O
and	O
able	O
to	O
speak	O
and	O
read	O
English	O
.	O

All	O
participants	O
had	O
been	O
taking	O
antipsychotic	O
medication	O
before	O
the	O
trial	O
but	O
their	O
auditory	O
verbal	O
hallucinations	O
had	O
been	O
unresponsive	O
or	O
only	O
partially	O
responsive	O
to	O
previous	O
treatment	O
.	O

Participants	O
were	O
excluded	O
if	O
they	O
were	O
unable	O
to	O
give	O
informed	O
written	O
consent	O
;	O
were	O
currently	O
receiving	O
psychological	O
therapy	O
for	O
psychosis	O
,	O
including	O
attending	O
so	O
-	O
called	O
hearing	O
voices	O
groups	O
;	O
were	O
refusing	O
medication	O
;	O
had	O
a	O
diagnosis	O
of	O
organic	O
brain	O
disease	O
,	O
learning	O
disability	O
,	O
or	O
primary	O
substance	O
dependency	O
;	O
and	O
heard	O
voices	O
in	O
a	O
language	O
not	O
spoken	O
by	O
the	O
therapists	O
.	O

All	O
participants	O
gave	O
written	O
informed	O
consent	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
London	O
-	O
Hampstead	O
Research	O
Ethics	O
Committee	O
(	O
reference	O
13	O
/	O
Lo	O
/	O
0482	O
)	O
.	O

The	O
trial	O
protocol	O
has	O
been	O
published	O
elswhere	O
.	O

11	O
The	O
study	O
was	O
overseen	O
by	O
an	O
independent	O
trial	O
steering	O
committee	O
and	O
a	O
separate	O
Data	O
Monitoring	O
and	O
Ethics	O
Committee	O
.	O

All	O
participants	O
continued	O
to	O
receive	O
standard	O
psychiatric	O
care	O
,	O
with	O
the	O
agreement	O
that	O
existing	O
medication	O
was	O
to	O
remain	O
unchanged	O
over	O
the	O
duration	O
of	O
the	O
trial	O
unless	O
otherwise	O
determined	O
by	O
clinical	O
need	O
.	O

Participants	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
AVATAR	O
therapy	O
or	O
supportive	O
counselling	O
with	O
randomised	O
permuted	O
blocks	O
(	O
block	O
size	O
randomly	O
varying	O
between	O
two	O
and	O
six	O
)	O
.	O

Randomisation	O
was	O
done	O
on	O
completion	O
of	O
baseline	O
assessments	O
through	O
an	O
independent	O
web	O
-	O
based	O
service	O
provided	O
by	O
the	O
UKCRC	O
Registered	O
Clinical	O
Trials	O
Unit	O
at	O
King	O
'	O
s	O
College	O
London	O
(	O
registration	O
number	O
053	O
)	O
to	O
maintain	O
allocation	O
concealment	O
.	O

Participants	O
were	O
informed	O
of	O
their	O
allocation	O
by	O
a	O
therapist	O
.	O

All	O
assessments	O
were	O
done	O
by	O
research	O
assessors	O
who	O
were	O
masked	O
to	O
therapy	O
allocation	O
.	O

To	O
avoid	O
unmasking	O
,	O
we	O
ensured	O
that	O
assessors	O
did	O
not	O
have	O
access	O
to	O
clinical	O
records	O
after	O
the	O
baseline	O
(	O
pre	O
-	O
randomisation	O
)	O
assessment	O
or	O
access	O
to	O
the	O
therapy	O
database	O
at	O
any	O
stage	O
,	O
that	O
all	O
assessments	O
were	O
done	O
at	O
sites	O
remote	O
from	O
the	O
clinic	O
,	O
and	O
that	O
participants	O
were	O
reminded	O
before	O
each	O
assessment	O
not	O
to	O
disclose	O
their	O
allocation	O
.	O

Therapy	O
in	O
both	O
groups	O
was	O
provided	O
at	O
a	O
single	O
clinical	O
location	O
.	O

AVATAR	O
therapy	O
was	O
delivered	O
by	O
experienced	O
clinicians	O
skilled	O
in	O
psychological	O
therapies	O
.	O

Participants	O
first	O
created	O
a	O
computerised	O
representation	O
of	O
the	O
entity	O
that	O
they	O
believed	O
was	O
the	O
source	O
of	O
their	O
main	O
voice	O
.	O

After	O
completing	O
the	O
set	O
-	O
up	O
of	O
the	O
avatar	O
in	O
an	O
introductory	O
session	O
,	O
which	O
included	O
a	O
comprehensive	O
assessment	O
of	O
the	O
voice	O
(	O
s	O
)	O
and	O
included	O
verbatim	O
content	O
,	O
the	O
therapy	O
was	O
delivered	O
over	O
six	O
weekly	O
50	O
-	O
min	O
sessions	O
.	O

10–15	O
min	O
of	O
each	O
session	O
involved	O
face	O
-	O
to	O
-	O
face	O
work	O
with	O
the	O
avatar	O
,	O
wherein	O
the	O
therapist	O
facilitated	O
a	O
direct	O
dialogue	O
between	O
the	O
participant	O
and	O
the	O
avatar	O
.	O

Participants	O
sat	O
in	O
one	O
room	O
facing	O
their	O
avatar	O
on	O
a	O
computer	O
monitor	O
.	O

The	O
therapist	O
sat	O
in	O
a	O
second	O
room	O
with	O
a	O
control	O
panel	O
that	O
allowed	O
them	O
to	O
speak	O
in	O
his	O
or	O
her	O
own	O
voice	O
,	O
or	O
as	O
the	O
avatar	O
.	O

A	O
video	O
link	O
allowed	O
the	O
therapist	O
to	O
see	O
and	O
hear	O
the	O
participant	O
'	O
s	O
responses	O
,	O
enabling	O
them	O
to	O
adjust	O
therapeutic	O
interventions	O
and	O
modify	O
the	O
avatar	O
interaction	O
according	O
to	O
the	O
unfolding	O
dialogue	O
.	O

The	O
progress	O
of	O
sessions	O
was	O
determined	O
by	O
a	O
discussion	O
in	O
each	O
session	O
concerning	O
any	O
change	O
in	O
severity	O
,	O
malevolence	O
,	O
or	O
frequency	O
of	O
the	O
voices	O
.	O

All	O
sessions	O
were	O
audio	O
recorded	O
and	O
a	O
copy	O
of	O
the	O
avatar	O
dialogue	O
was	O
provided	O
on	O
an	O
MP3	O
player	O
to	O
the	O
participant	O
with	O
instructions	O
to	O
listen	O
to	O
the	O
recording	O
at	O
home	O
,	O
especially	O
when	O
they	O
heard	O
the	O
voice	O
(	O
s	O
)	O
.	O

The	O
content	O
of	O
the	O
sessions	O
has	O
been	O
described	O
elsewhere	O
.	O

12	O
Briefly	O
,	O
therapy	O
proceeds	O
through	O
two	O
phases	O
.	O

Phase	O
one	O
(	O
typically	O
sessions	O
one	O
to	O
three	O
)	O
involved	O
exposure	O
to	O
the	O
avatar	O
speaking	O
the	O
typical	O
verbatim	O
content	O
of	O
the	O
participant	O
'	O
s	O
voices	O
while	O
the	O
therapist	O
encouraged	O
assertive	O
responding—eg	O
,	O
that	O
the	O
person	O
tell	O
the	O
avatar	O
that	O
they	O
are	O
no	O
longer	O
prepared	O
to	O
accept	O
these	O
threats	O
and	O
insults	O
and	O
to	O
challenge	O
any	O
apparent	O
misconceptions	O
the	O
avatar	O
seems	O
to	O
have	O
.	O

In	O
phase	O
two	O
(	O
typically	O
sessions	O
four	O
to	O
six	O
)	O
,	O
the	O
dialogue	O
gradually	O
evolved	O
as	O
the	O
avatar	O
conceded	O
ground	O
and	O
acknowledged	O
the	O
strengths	O
and	O
good	O
qualities	O
of	O
the	O
participant	O
.	O

There	O
is	O
an	O
explicit	O
focus	O
on	O
self	O
-	O
esteem	O
and	O
acknowledgments	O
of	O
the	O
participant	O
'	O
s	O
strengths	O
and	O
capabilities	O
.	O

Therapists	O
used	O
a	O
detailed	O
therapy	O
manual	O
written	O
for	O
the	O
trial	O
by	O
the	O
team	O
,	O
developed	O
from	O
an	O
earlier	O
brief	O
guide	O
provided	O
by	O
JPL	O
,	O
who	O
also	O
provided	O
initial	O
training	O
and	O
consultation	O
through	O
periodic	O
attendance	O
at	O
weekly	O
group	O
supervision	O
meetings	O
.	O

The	O
complete	O
audiotaped	O
clinical	O
record	O
of	O
64	O
sessions	O
across	O
a	O
random	O
selection	O
of	O
12	O
participants	O
(	O
including	O
discussions	O
before	O
and	O
after	O
active	O
dialogue	O
)	O
was	O
rated	O
by	O
JPL	O
against	O
a	O
25	O
-	O
item	O
scale	O
developed	O
to	O
assess	O
adherence	O
to	O
the	O
manualised	O
approach	O
and	O
skill	O
in	O
delivery	O
.	O

The	O
control	O
condition	O
,	O
supportive	O
counselling	O
,	O
was	O
delivered	O
by	O
graduate	O
assistant	O
psychologists	O
who	O
were	O
recruited	O
on	O
the	O
basis	O
of	O
extensive	O
experience	O
of	O
working	O
therapeutically	O
in	O
a	O
psychosis	O
context	O
.	O

They	O
were	O
trained	O
and	O
closely	O
supervised	O
throughout	O
by	O
the	O
therapy	O
co	O
-	O
ordinator	O
(	O
TW	O
)	O
.	O

The	O
intervention	O
comprised	O
a	O
manual	O
-	O
based	O
,	O
face	O
-	O
to	O
-	O
face	O
supportive	O
counselling	O
approach	O
adapted	O
with	O
permission	O
from	O
that	O
employed	O
by	O
the	O
SoCRATES	O
Trial	O
Group	O
.	O

13	O
Whereas	O
the	O
inherited	O
manual	O
proposed	O
activities	O
such	O
as	O
board	O
games	O
and	O
listening	O
to	O
music	O
together	O
,	O
we	O
wanted	O
to	O
provide	O
more	O
than	O
a	O
simple	O
attention	O
or	O
time	O
control	O
and	O
augmented	O
the	O
manual	O
to	O
deliver	O
an	O
emotion	O
-	O
focused	O
psychological	O
intervention	O
that	O
facilitated	O
exploration	O
of	O
issues	O
of	O
fundamental	O
importance	O
in	O
the	O
person	O
'	O
s	O
life	O
,	O
in	O
the	O
context	O
of	O
an	O
empathic	O
,	O
non	O
-	O
directive	O
therapeutic	O
relationship	O
.	O

14	O
At	O
the	O
same	O
time	O
,	O
we	O
wanted	O
to	O
avoid	O
the	O
interpersonal	O
treatment	O
targets	O
of	O
AVATAR	O
therapy	O
(	O
ie	O
,	O
shift	O
in	O
power	O
or	O
control	O
in	O
the	O
relationship	O
with	O
the	O
voice	O
[	O
s	O
]	O
)	O

Typical	O
themes	O
of	O
counselling	O
included	O
improving	O
quality	O
of	O
life	O
,	O
issues	O
of	O
identity	O
or	O
belonging	O
,	O
coming	O
to	O
terms	O
with	O
past	O
trauma	O
,	O
and	O
identifying	O
personal	O
resources	O
and	O
qualities	O
.	O

Counselling	O
was	O
delivered	O
over	O
the	O
same	O
number	O
and	O
duration	O
of	O
sessions	O
as	O
AVATAR	O
therapy	O
.	O

At	O
the	O
end	O
of	O
each	O
session	O
,	O
participants	O
recorded	O
a	O
weekly	O
positive	O
message	O
onto	O
an	O
MP3	O
player	O
to	O
listen	O
back	O
to	O
during	O
the	O
week	O
(	O
matching	O
the	O
use	O
of	O
MP3	O
recordings	O
in	O
the	O
AVATAR	O
therapy	O
group	O
)	O
.	O

An	O
independent	O
counselling	O
psychologist	O
rated	O
67	O
sessions	O
across	O
14	O
participants	O
for	O
fidelity	O
to	O
the	O
manual	O
and	O
evidence	O
of	O
key	O
therapeutic	O
processes	O
,	O
using	O
core	O
items	O
of	O
the	O
counselling	O
adherence	O
scale	O
.	O

15	O
For	O
the	O
counselling	O
adherence	O
scale	O
,	O
there	O
are	O
seven	O
items	O
,	O
scored	O
0	O
(	O
no	O
evidence	O
)	O
to	O
4	O
(	O
very	O
good	O
evidence	O
)	O
.	O

At	O
the	O
end	O
of	O
therapy	O
,	O
participants	O
in	O
both	O
groups	O
were	O
given	O
a	O
therapy	O
summary	O
letter	O
and	O
a	O
copy	O
of	O
this	O
was	O
sent	O
to	O
their	O
responsible	O
clinician	O
in	O
routine	O
care	O
.	O

No	O
attempt	O
was	O
made	O
to	O
intervene	O
or	O
monitor	O
participants	O
between	O
the	O
end	O
of	O
therapy	O
and	O
the	O
assessment	O
points	O
.	O

Discontinuation	O
of	O
therapy	O
from	O
either	O
group	O
was	O
defined	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
criteria	O
:	O
non	O
-	O
attendance	O
at	O
three	O
consecutive	O
sessions	O
,	O
the	O
participant	O
decided	O
to	O
discontinue	O
,	O
or	O
discontinuation	O
recommended	O
by	O
the	O
therapist	O
or	O
peer	O
supervision	O
group	O
.	O

Following	O
the	O
protocol	O
,	O
therapy	O
could	O
also	O
be	O
terminated	O
if	O
the	O
participant	O
reported	O
complete	O
absence	O
of	O
any	O
voices	O
for	O
at	O
least	O
three	O
consecutive	O
sessions	O
.	O

The	O
total	O
number	O
of	O
sessions	O
could	O
also	O
be	O
extended	O
by	O
up	O
to	O
three	O
sessions	O
when	O
there	O
was	O
a	O
rationale	O
for	O
probable	O
benefit	O
,	O
agreed	O
by	O
therapy	O
team	O
consensus	O
.	O

Audiotaped	O
assessments	O
were	O
carried	O
out	O
by	O
trained	O
research	O
staff	O
at	O
baseline	O
,	O
12	O
weeks	O
,	O
and	O
24	O
weeks	O
after	O
randomisation	O
.	O

We	O
assessed	O
inter	O
-	O
rater	O
reliability	O
using	O
intra	O
-	O
class	O
correlations	O
,	O
two	O
-	O
way	O
mixed	O
-	O
effects	O
model	O
,	O
and	O
absolute	O
agreement	O
type	O
for	O
the	O
main	O
outcome	O
measure	O
in	O
25	O
(	O
20	O
%	O
)	O
of	O
125	O
interviews	O
.	O

We	O
calculated	O
indices	O
for	O
each	O
of	O
the	O
items	O
and	O
total	O
score	O
of	O
this	O
scale	O
.	O

The	O
prespecified	O
primary	O
outcome	O
was	O
the	O
total	O
score	O
(	O
0–44	O
)	O
on	O
the	O
Psychotic	O
Symptom	O
Rating	O
Scales	O
,	O
auditory	O
hallucinations	O
subscale	O
(	O
PSYRATS–AH	O
16	O
)	O
at	O
12	O
weeks	O
.	O

The	O
secondary	O
outcome	O
measures	O
of	O
voices	O
were	O
dimensional	O
subscales	O
of	O
the	O
PSYRATS	O
-	O
AH	O
:	O
17	O
voice	O
frequency	O
(	O
frequency	O
,	O
duration	O
,	O
and	O
disruption	O
items	O
)	O
and	O
voice	O
distress	O
(	O
negative	O
content	O
,	O
distress	O
,	O
and	O
control	O
items	O
)	O
,	O
Revised	O
Beliefs	O
about	O
Voices	O
Questionnaire	O
18	O
(	O
BAVQ	O
-	O
R	O
;	O
perceived	O
malevolence	O
,	O
omnipotence	O
,	O
and	O
benevolence	O
subscales	O
)	O
,	O
the	O
Voice	O
Acceptance	O
and	O
Action	O
Scale	O
19	O
(	O
VAAS	O
;	O
acceptance	O
and	O
action	O
subscales	O
)	O
,	O
Voice	O
Power	O
Differential	O
Scale	O
20	O
(	O
VPDS	O
;	O
power	O
and	O
assertiveness	O
subscales	O
)	O
.	O

The	O
other	O
secondary	O
outcomes	O
measures	O
were	O
scores	O
for	O
the	O
Scale	O
for	O
Assessment	O
of	O
Positive	O
and	O
Negative	O
Symptoms	O
21	O
(	O
SAPS	O
and	O
SANS	O
)	O
,	O
Psychotic	O
Symptoms	O
Rating	O
Scale–Delusions	O
16	O
(	O
PSYRATS	O
-	O
DEL	O
)	O
,	O
Depression	O
Anxiety	O
and	O
Stress	O
Scale	O
22	O
(	O
DASS	O
-	O
21	O
)	O
,	O
Calgary	O
Depression	O
Scale	O
,	O
23	O
Rosenberg	O
self	O
-	O
esteem	O
,	O
24	O
Manchester	O
Short	O
Assessment	O
of	O
Quality	O
of	O
Life	O
(	O
MANSA	O
)	O
,	O
25	O
and	O
the	O
Maudsley	O
Addiction	O
Profile	O
(	O
MAP	O
)	O
.	O

26	O

Information	O
about	O
possible	O
adverse	O
events	O
was	O
monitored	O
for	O
the	O
duration	O
of	O
the	O
study	O
,	O
up	O
to	O
week	O
24	O
of	O
follow	O
-	O
up	O
.	O

Possible	O
adverse	O
events	O
included	O
hospital	O
admissions	O
(	O
due	O
to	O
physical	O
or	O
mental	O
health	O
deterioration	O
)	O
,	O
crisis	O
team	O
involvement	O
,	O
self	O
-	O
harming	O
behaviour	O
and	O
suicide	O
attempts	O
,	O
and	O
violent	O
incidents	O
necessitating	O
police	O
involvement	O
(	O
whether	O
the	O
participant	O
was	O
victim	O
or	O
perpetrator	O
)	O
.	O

All	O
adverse	O
events	O
were	O
reported	O
to	O
the	O
trial	O
steering	O
,	O
data	O
monitoring	O
and	O
ethics	O
,	O
and	O
research	O
ethics	O
committees	O
.	O

We	O
paid	O
close	O
attention	O
to	O
the	O
occurrence	O
of	O
any	O
adverse	O
events	O
that	O
might	O
be	O
attributed	O
to	O
either	O
therapy	O
,	O
including	O
whether	O
the	O
AVATAR	O
therapy	O
sessions	O
were	O
followed	O
by	O
any	O
therapy	O
-	O
specific	O
issues	O
such	O
as	O
seeing	O
the	O
avatar	O
outside	O
of	O
the	O
sessions	O
.	O

Therapy	O
was	O
to	O
be	O
terminated	O
in	O
the	O
event	O
of	O
any	O
evidence	O
of	O
therapy	O
being	O
associated	O
with	O
significant	O
increased	O
distress	O
,	O
risk	O
of	O
harm	O
to	O
self	O
or	O
others	O
,	O
or	O
both	O
.	O

We	O
planned	O
to	O
enrol	O
142	O
participants	O
.	O

In	O
the	O
pilot	O
study	O
10	O
there	O
was	O
a	O
clinically	O
meaningful	O
five	O
-	O
point	O
greater	O
change	O
in	O
the	O
total	O
PSYRATS–AH	O
score	O
,	O
favouring	O
the	O
AVATAR	O
condition	O
with	O
an	O
effect	O
size	O
(	O
Cohen	O
'	O
s	O
d	O
)	O
of	O
approximately	O
0·8	O
.	O

Supportive	O
therapy	O
typically	O
achieves	O
a	O
modest	O
effect	O
of	O
d	O
=0·2	O
.	O

On	O
the	O
assumption	O
that	O
a	O
replication	O
study	O
might	O
be	O
expected	O
to	O
achieve	O
broadly	O
similar	O
results	O
,	O
we	O
calculated	O
that	O
a	O
sample	O
size	O
of	O
71	O
in	O
each	O
group	O
would	O
have	O
90	O
%	O
power	O
to	O
detect	O
a	O
net	O
effect	O
size	O
of	O
0·6	O
,	O
using	O
a	O
two	O
-	O
group	O
t	O
-	O
test	O
with	O
a	O
0·05	O
two	O
-	O
sided	O
significance	O
level	O
,	O
while	O
also	O
allowing	O
for	O
a	O
20	O
%	O
loss	O
to	O
follow	O
-	O
up	O
.	O

We	O
did	O
the	O
statistical	O
analysis	O
with	O
Stata	O
(	O
version	O
14	O
.	O
1	O
)	O
.	O

We	O
report	O
on	O
all	O
outcomes	O
related	O
to	O
our	O
primary	O
(	O
efficacy	O
)	O
objective	O
,	O
as	O
specified	O
in	O
our	O
published	O
protocol	O
and	O
statistical	O
analysis	O
plan	O
,	O
and	O
as	O
agreed	O
with	O
the	O
data	O
monitoring	O
and	O
ethics	O
committee	O
before	O
any	O
analysis	O
was	O
done	O
.	O

All	O
analyses	O
used	O
the	O
original	O
randomised	O
groups	O
,	O
including	O
participants	O
with	O
observed	O
outcome	O
data	O
.	O

Descriptive	O
statistics	O
within	O
each	O
randomised	O
group	O
are	O
presented	O
for	O
baseline	O
values	O
,	O
including	O
counts	O
and	O
percentages	O
for	O
binary	O
and	O
categorical	O
variables	O
and	O
means	O
and	O
SDs	O
for	O
continuous	O
variables	O
and	O
counts	O
of	O
missing	O
values	O
.	O

No	O
statistical	O
tests	O
were	O
done	O
on	O
baseline	O
measures	O
.	O

We	O
analysed	O
the	O
primary	O
outcome	O
(	O
PSYRATS–AH	O
total	O
score	O
at	O
12	O
weeks	O
)	O
using	O
a	O
linear	O
mixed	O
-	O
effects	O
model	O
allowing	O
for	O
the	O
baseline	O
measurement	O
of	O
PSYRATS–AH	O
and	O
randomisation	O
as	O
fixed	O
effects	O
.	O

Because	O
of	O
the	O
nested	O
trial	O
design	O
,	O
we	O
used	O
mixed	O
models	O
to	O
include	O
a	O
random	O
intercept	O
for	O
each	O
therapist	O
in	O
the	O
two	O
randomised	O
groups	O
,	O
allowing	O
for	O
differential	O
clustering	O
by	O
group	O
.	O

We	O
analysed	O
secondary	O
outcome	O
measures	O
using	O
the	O
same	O
modelling	O
approach	O
.	O

We	O
also	O
analysed	O
the	O
primary	O
and	O
secondary	O
outcomes	O
at	O
24	O
weeks	O
using	O
mixed	O
models	O
.	O

We	O
examined	O
if	O
baseline	O
factors	O
were	O
associated	O
with	O
missing	O
outcomes	O
using	O
logistic	O
regression	O
,	O
and	O
no	O
significant	O
predictors	O
were	O
present	O
once	O
baseline	O
scores	O
and	O
randomised	O
group	O
were	O
accounted	O
for	O
.	O

In	O
the	O
event	O
that	O
a	O
participant	O
reported	O
a	O
complete	O
absence	O
of	O
auditory	O
verbal	O
hallucinations	O
for	O
the	O
entire	O
week	O
at	O
either	O
12	O
or	O
24	O
weeks	O
,	O
the	O
best	O
possible	O
score	O
was	O
imputed	O
for	O
BAVQ	O
-	O
R	O
,	O
VAAS	O
,	O
and	O
VPDS	O
scales	O
,	O
which	O
cannot	O
be	O
used	O
in	O
the	O
absence	O
of	O
auditory	O
verbal	O
hallucinations	O
.	O

Missing	O
data	O
on	O
other	O
measures	O
were	O
pro	O
-	O
rated	O
if	O
more	O
than	O
90	O
%	O
of	O
the	O
total	O
items	O
were	O
completed	O
,	O
otherwise	O
the	O
measure	O
was	O
considered	O
as	O
missing	O
.	O

We	O
used	O
logistic	O
regression	O
to	O
examine	O
if	O
baseline	O
factors	O
were	O
associated	O
with	O
missing	O
outcomes	O
,	O
and	O
no	O
significant	O
predictors	O
were	O
present	O
once	O
baseline	O
scores	O
and	O
randomised	O
group	O
were	O
accounted	O
for	O
.	O

The	O
trial	O
was	O
prospectively	O
registered	O
with	O
the	O
ISRCTN	O
registry	O
,	O
number	O
65314790	O
.	O

The	O
funder	O
of	O
the	O
study	O
had	O
no	O
role	O
in	O
study	O
design	O
,	O
data	O
,	O
collection	O
,	O
data	O
analysis	O
,	O
data	O
interpretation	O
,	O
or	O
writing	O
of	O
the	O
report	O
.	O

The	O
funder	O
reviewed	O
and	O
approved	O
the	O
application	O
for	O
the	O
trial	O
.	O

RE	O
had	O
full	O
access	O
to	O
all	O
the	O
data	O
in	O
the	O
study	O
and	O
the	O
corresponding	O
author	O
had	O
final	O
responsibility	O
for	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

Chinese	O
psychogeriatric	O
patients	O
with	O
a	O
diagnosis	O
of	O
Alzheimer’s	B-phenotype
disease	I-phenotype
(	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
10th	I-coding_system
Revision	I-coding_system
or	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
,	I-coding_system
4th	I-coding_system
Edition	I-coding_system
)	O
were	O
screened	O
for	O
in	O
psychogeriatric	O
day	O
hospitals	O
,	O
psychogeriatric	O
outpatients	O
at	O
Kwai	O
Chung	O
Hospital	O
,	O
and	O
an	O
elderly	O
daycare	O
center	O
in	O
Kwai	O
Chung	O
District	O
.	O

Selection	O
criteria	O
included	O
:	O
age	O
≥60	O
years	O
,	O
either	O
gender	O
,	O
early	O
dementia	O
(	O
score	O
of	O
1	O
on	O
screening	O
with	O
the	O
Chinese	O
Dementia	O
Rating	O
Scale	O
)	O
,	O
36	O
otherwise	O
mentally	O
stable	O
,	O
capable	O
of	O
following	O
instructions	O
,	O
and	O
an	O
attention	O
span	O
of	O
30–45	O
minutes	O
.	O

Subjects	O
with	O
severe	O
visual	O
or	O
hearing	O
impairment	O
,	O
computer	O
phobia	O
,	O
or	O
impaired	O
physical	O
functioning	O
that	O
precluded	O
the	O
use	O
of	O
a	O
touch	O
-	O
screen	O
computer	O
were	O
excluded	O
.	O

Ethical	O
approval	O
was	O
secured	O
from	O
the	O
ethics	O
committee	O
of	O
the	O
Hong	O
Kong	O
Polytechnic	O
University	O
and	O
clinical	O
research	O
ethics	O
committee	O
of	O
the	O
Kowloon	O
West	O
Cluster	O
in	O
the	O
Hong	O
Kong	O
Hospital	O
Authority	O
.	O

Written	O
consent	O
was	O
obtained	O
from	O
subjects	O
and	O
their	O
caregivers	O
before	O
assessment	O
and	O
training	O
.	O

Subjects	O
were	O
then	O
allocated	O
randomly	O
to	O
training	O
with	O
a	O
computer	O
-	O
assisted	O
errorless	O
learning	O
program	O
(	O
CELP	O
)	O
,	O
training	O
with	O
a	O
therapist	O
-	O
led	O
training	O
program	O
(	O
TELP	O
)	O
,	O
or	O
a	O
waiting	O
-	O
list	O
control	O
group	O
.	O

Outcome	O
evaluation	O
of	O
subjects	O
before	O
and	O
after	O
testing	O
and	O
at	O
three	O
-	O
month	O
follow	O
-	O
up	O
was	O
performed	O
by	O
independent	O
blinded	O
assessors	O
.	O

Most	O
of	O
the	O
subjects	O
completed	O
all	O
the	O
outcome	O
evaluations	O
,	O
including	O
follow	O
-	O
up	O
testing	O
.	O

The	O
intervention	O
was	O
led	O
by	O
occupational	O
therapists	O
with	O
prior	O
specialist	O
training	O
in	O
using	O
errorless	O
memory	O
programs	O
.	O

The	O
training	O
programs	O
were	O
implemented	O
on	O
an	O
individual	O
basis	O
,	O
approximately	O
twice	O
a	O
week	O
,	O
with	O
a	O
total	O
of	O
12	O
30	O
-	O
minute	O
training	O
sessions	O
,	O
which	O
were	O
completed	O
in	O
around	O
six	O
weeks	O
.	O

The	O
CELP	O
was	O
run	O
using	O
a	O
touch	O
-	O
screen	O
notebook	O
computer	O
with	O
a	O
touch	O
-	O
pen	O
input	O
device	O
.	O

Therapists	O
provided	O
guidance	O
if	O
the	O
subjects	O
had	O
difficulty	O
using	O
the	O
computer	O
input	O
device	O
or	O
had	O
literacy	O
problems	O
.	O

Similarly	O
,	O
the	O
TELP	O
was	O
run	O
on	O
an	O
individual	O
basis	O
.	O

A	O
training	O
manual	O
containing	O
colored	O
print	O
images	O
was	O
used	O
.	O

Therapists	O
implementing	O
training	O
were	O
provided	O
with	O
the	O
same	O
set	O
of	O
instructions	O
and	O
gave	O
similar	O
immediate	O
positive	O
feedback	O
to	O
subject	O
participants	O
,	O
as	O
did	O
the	O
CELP	O
.	O

The	O
waiting	O
-	O
list	O
control	O
group	O
received	O
general	O
cognitively	O
challenging	O
activities	O
to	O
perform	O
,	O
such	O
as	O
card	O
sorting	O
and	O
perceptual	O
games	O
,	O
or	O
an	O
errorful	O
memory	O
training	O
program	O
of	O
equal	O
duration	O
.	O

Two	O
memory	O
training	O
programs	O
were	O
developed	O
based	O
on	O
cognitive	O
reserve	O
and	O
neuroplasticity	O
theories	O
in	O
dementia	O
,	O
suggesting	O
that	O
the	O
brain’s	O
neuroplasticity	O
reserve	O
can	O
be	O
enriched	O
through	O
cognitive	O
experience	O
provided	O
by	O
training	O
.	O

37	O
,	O
38	O
The	O
programs	O
also	O
incorporated	O
the	O
technique	O
of	O
errorless	O
learning	O
,	O
used	O
together	O
with	O
spaced	O
retrieval	O
and	O
vanishing	O
cues	O
12	O
,	O
13	O
,	O
18	O
,	O
22	O
,	O
39	O
–	O
42	O
in	O
the	O
CELP	O
or	O
TELP	O
.	O

The	O
content	O
and	O
structure	O
of	O
both	O
programs	O
were	O
similar	O
,	O
except	O
for	O
the	O
mode	O
of	O
delivery	O
.	O

An	O
experienced	O
occupational	O
therapist	O
with	O
indepth	O
clinical	O
experience	O
in	O
psychogeriatrics	O
and	O
an	O
academic	O
expert	O
in	O
neurocognitive	O
training	O
were	O
responsible	O
for	O
the	O
design	O
of	O
the	O
errorless	O
learning	O
memory	O
training	O
program	O
.	O

The	O
programs	O
were	O
designed	O
using	O
a	O
culturally	O
relevant	O
training	O
program	O
with	O
familiar	O
daily	O
life	O
training	O
content	O
,	O
and	O
gradation	O
of	O
training	O
was	O
based	O
on	O
the	O
level	O
of	O
functioning	O
,	O
habits	O
,	O
and	O
interests	O
of	O
older	O
Chinese	O
adults	O
with	O
early	O
Alzheimer’s	O
disease	O
.	O

The	O
basic	O
training	O
principles	O
were	O
:	O
the	O
learned	O
task	O
was	O
broken	O
into	O
components	O
;	O
overlearning	O
of	O
components	O
through	O
repetition	O
and	O
practice	O
to	O
enhance	O
mastery	O
;	O
training	O
from	O
simple	O
to	O
complex	O
gradation	O
(	O
two	O
answers	O
upgraded	O
to	O
three	O
answers	O
)	O
;	O
provision	O
of	O
immediate	O
positive	O
feedback	O
to	O
reinforce	O
learning	O
;	O
provision	O
of	O
a	O
nonthreatening	O
training	O
atmosphere	O
with	O
hints	O
provided	O
;	O
and	O
incorporation	O
of	O
vanishing	O
cues	O
and	O
spaced	O
retrieval	O
strategies	O
.	O

The	O
rationale	O
for	O
adopting	O
a	O
specific	O
errorless	O
learning	O
program	O
is	O
to	O
bypass	O
errors	O
and	O
strengthen	O
accurate	O
association	O
,	O
given	O
that	O
patients	O
with	O
Alzheimer’s	O
disease	O
have	O
difficulty	O
self	O
-	O
correcting	O
errors	O
.	O

One	O
or	O
two	O
demonstration	O
questions	O
and	O
answers	O
were	O
done	O
so	O
that	O
subjects	O
would	O
feel	O
able	O
to	O
follow	O
the	O
programs	O
.	O

The	O
level	O
of	O
difficulty	O
of	O
questions	O
was	O
set	O
appropriate	O
to	O
the	O
level	O
of	O
cognitive	O
function	O
of	O
the	O
subjects	O
.	O

When	O
compared	O
with	O
the	O
training	O
program	O
not	O
using	O
errorless	O
learning	O
principles	O
,	O
answers	O
to	O
training	O
questions	O
might	O
be	O
too	O
difficult	O
,	O
and	O
without	O
hinting	O
cues	O
subjects	O
might	O
get	O
a	O
wrong	O
answer	O
easily	O
and	O
become	O
frustrated	O
during	O
training	O
.	O

For	O
example	O
,	O
in	O
simple	O
attention	O
training	O
,	O
subjects	O
were	O
asked	O
to	O
look	O
at	O
two	O
pictures	O
and	O
confirm	O
if	O
they	O
were	O
similar	O
or	O
not	O
.	O

The	O
participants	O
could	O
answer	O
this	O
question	O
easily	O
and	O
were	O
also	O
trained	O
to	O
use	O
the	O
computer	O
in	O
a	O
competent	O
way	O
during	O
training	O
.	O

Because	O
older	O
Chinese	O
adults	O
like	O
Chinese	O
foods	O
such	O
as	O
the	O
Dim	O
Sum	O
,	O
when	O
responding	O
to	O
some	O
questions	O
in	O
categorization	O
,	O
subjects	O
had	O
to	O
answer	O
if	O
a	O
photograph	O
of	O
a	O
Dim	O
Sum	O
was	O
in	O
the	O
same	O
category	O
or	O
not	O
.	O

Scenarios	O
presented	O
during	O
the	O
12	O
training	O
sessions	O
were	O
similar	O
to	O
tasks	O
in	O
everyday	O
life	O
(	O
Figure	O
1	O
)	O
.	O

The	O
program	O
was	O
structured	O
with	O
training	O
components	O
including	O
:	O
basic	O
training	O
on	O
various	O
memory	O
types	O
,	O
including	O
sensory	O
memory	O
(	O
visual	O
and	O
auditory	O
)	O
,	O
working	O
memory	O
,	O
prospective	O
memory	O
;	O
memory	O
strategies	O
for	O
using	O
mnemonics	O
(	O
like	O
chunking	O
,	O
organization	O
,	O
and	O
categorization	O
)	O
and	O
learning	O
principles	O
,	O
and	O
also	O
on	O
name	O
/	O
face	O
association	O
;	O
advanced	O
memory	O
training	O
on	O
application	O
of	O
strategies	O
to	O
ADL	O
,	O
including	O
home	O
-	O
making	O
,	O
habit	O
training	O
,	O
money	O
management	O
,	O
shopping	O
,	O
and	O
community	O
-	O
living	O
skills	O
.	O

Immediate	O
positive	O
feedback	O
was	O
integrated	O
into	O
the	O
training	O
to	O
encourage	O
active	O
subject	O
participation	O
(	O
see	O
Table	O
1	O
)	O
.	O

An	O
example	O
of	O
a	O
typical	O
training	O
session	O
had	O
three	O
parts	O
:	O
attention	O
,	O
working	O
memory	O
,	O
and	O
focus	O
of	O
one	O
training	O
theme	O
on	O
memory	O
(	O
dual	O
task	O
,	O
prospective	O
memory	O
,	O
name	O
/	O
face	O
recognition	O
/	O
memory	O
strategies	O
,	O
habit	O
training	O
,	O
shopping	O
,	O
or	O
community	O
-	O
living	O
tasks	O
,	O
with	O
gradation	O
of	O
complexity	O
)	O
.	O

The	O
Clinical	O
Dementia	O
Rating	O
Scale	O
(	O
CDR	O
)	O
was	O
used	O
to	O
screen	O
subjects	O
suitable	O
for	O
inclusion	O
in	O
the	O
present	O
study	O
.	O

The	O
CDR	O
is	O
a	O
widely	O
used	O
global	O
assessment	O
instrument	O
for	O
staging	O
the	O
severity	O
of	O
dementia	O
,	O
36	O
and	O
takes	O
the	O
form	O
of	O
a	O
semistructured	O
interview	O
with	O
the	O
patient	O
and	O
caregiver	O
.	O

43	O
A	O
CDR	O
score	O
of	O
1	O
indicates	O
that	O
a	O
person	O
has	O
mild	O
dementia	O
.	O

Participants	O
with	O
a	O
CDR	O
score	O
of	O
1	O
after	O
assessment	O
using	O
the	O
Chinese	O
version	O
of	O
the	O
CDR	O
were	O
recruited	O
for	O
this	O
study	O
.	O

Primary	O
outcomes	O
measures	O
used	O
pre	O
-	O
test	O
,	O
post	O
-	O
test	O
,	O
and	O
at	O
the	O
three	O
-	O
month	O
follow	O
-	O
up	O
evaluation	O
were	O
as	O
follows	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
validated	O
Chinese	O
version	O
of	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
which	O
assesses	O
orientation	O
,	O
memory	O
,	O
visual	O
-	O
spatial	O
copying	O
,	O
and	O
language	O
.	O

The	O
MMSE	O
was	O
developed	O
by	O
Folstein	O
et	O
al	O
44	O
and	O
is	O
a	O
well	O
known	O
cognitive	O
screening	O
tool	O
in	O
the	O
elderly	O
.	O

45	O
Scores	O
range	O
from	O
0	O
to	O
30	O
,	O
with	O
a	O
higher	O
score	O
indicating	O
better	O
cognitive	O
function	O
.	O

With	O
reference	O
to	O
the	O
educational	O
background	O
of	O
older	O
adults	O
,	O
different	O
cutoff	O
scores	O
are	O
used	O
for	O
dementia	O
:	O
a	O
score	O
≤22	O
for	O
those	O
with	O
more	O
than	O
two	O
years	O
of	O
education	O
;	O
a	O
score	O
≤20	O
for	O
those	O
with	O
1–2	O
years	O
of	O
education	O
;	O
and	O
a	O
score	O
≤18	O
for	O
those	O
with	O
no	O
education	O
.	O

The	O
reported	O
sensitivity	O
of	O
the	O
test	O
was	O
97	O
.	O
5	O
%	O
and	O
the	O
specificity	O
was	O
97	O
.	O
3	O
%	O
.	O

The	O
reported	O
test	O
-	O
retest	O
reliability	O
was	O
0	O
.	O
78	O
and	O
the	O
inter	O
-	O
rater	O
reliability	O
was	O
0	O
.	O
99	O
.	O

The	O
Chinese	O
version	O
of	O
the	O
Mattis	O
Dementia	O
Rating	O
Scale	O
(	O
CDRS	O
)	O
46	O
was	O
used	O
in	O
this	O
study	O
.	O

The	O
CDRS	O
consists	O
of	O
five	O
subscales	O
,	O
ie	O
,	O
attention	O
,	O
initiation	O
/	O
preservation	O
,	O
construction	O
,	O
conceptualization	O
,	O
and	O
memory	O
.	O

A	O
total	O
score	O
of	O
144	O
with	O
a	O
cutoff	O
score	O
of	O
112	O
was	O
used	O
to	O
differentiate	O
persons	O
with	O
dementia	O
.	O

The	O
cutoff	O
score	O
versus	O
full	O
score	O
for	O
the	O
subscales	O
were	O
:	O
29	O
/	O
37	O
for	O
attention	O
,	O
26	O
/	O
37	O
for	O
initiation	O
/	O
perseverance	O
,	O
3	O
/	O
6	O
for	O
construction	O
,	O
28	O
/	O
39	O
for	O
conceptualization	O
,	O
and	O
18	O
/	O
25	O
for	O
memory	O
.	O

More	O
detailed	O
outcome	O
measures	O
could	O
be	O
evaluated	O
pretest	O
and	O
post	O
-	O
test	O
depending	O
on	O
the	O
intervention	O
used	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
score	O
was	O
80	O
.	O
0	O
%	O
and	O
91	O
.	O
6	O
%	O
,	O
respectively	O
.	O

The	O
Cronbach’s	O
α	O
for	O
reliability	O
was	O
0	O
.	O
89	O
.	O

The	O
Hong	O
Kong	O
List	O
Learning	O
Test	O
(	O
HKLLT	O
)	O
47	O
is	O
a	O
Chinese	O
verbal	O
learning	O
test	O
,	O
which	O
was	O
developed	O
in	O
Hong	O
Kong	O
and	O
consists	O
of	O
two	O
16	O
-	O
word	O
lists	O
in	O
which	O
all	O
of	O
the	O
words	O
are	O
two	O
-	O
character	O
nouns	O
.	O

The	O
words	O
are	O
from	O
four	O
categories	O
and	O
are	O
randomly	O
organized	O
.	O

The	O
test	O
consists	O
of	O
three	O
immediate	O
recall	O
trials	O
,	O
and	O
two	O
delayed	O
recall	O
trials	O
(	O
10	O
and	O
30	O
minutes	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
HKLLT	O
-	O
Form	O
A	O
with	O
random	O
conditions	O
was	O
used	O
.	O

The	O
short	O
form	O
of	O
a	O
Chinese	O
assessment	O
of	O
prospective	O
memory	O
was	O
used	O
,	O
ie	O
,	O
the	O
Brief	O
Assessment	O
of	O
Prospective	O
Memory	O
-	O
Short	O
Form	O
(	O
BAPM	O
)	O
29	O
,	O
48	O
with	O
16	O
questions	O
covering	O
aspects	O
on	O
basic	O
self	O
-	O
care	O
and	O
instrumental	O
ADL	O
.	O

Each	O
question	O
was	O
scored	O
1	O
to	O
5	O
,	O
where	O
a	O
lower	O
score	O
indicates	O
better	O
functioning	O
for	O
elderly	O
subjects	O
.	O

The	O
validated	O
Cantonese	O
version	O
of	O
the	O
Geriatric	O
Depression	O
Scale	O
-	O
Short	O
Form	O
(	O
GDS	O
)	O
49	O
was	O
used	O
in	O
this	O
study	O
.	O

50	O
A	O
lower	O
score	O
indicates	O
better	O
subject	O
mood	O
.	O

A	O
score	O
≥8	O
(	O
of	O
15	O
)	O
indicates	O
the	O
possibility	O
of	O
depression	O
.	O

The	O
total	O
score	O
on	O
the	O
Chinese	O
version	O
of	O
the	O
Modified	O
Barthel	O
Index	O
(	O
MBI	O
)	O
51	O
is	O
100	O
points	O
.	O

This	O
is	O
a	O
self	O
-	O
care	O
assessment	O
instrument	O
covers	O
aspects	O
such	O
as	O
grooming	O
,	O
feeding	O
,	O
dressing	O
,	O
functional	O
mobility	O
,	O
toileting	O
,	O
bathing	O
,	O
and	O
continence	O
.	O

The	O
Hong	O
Kong	O
Lawton	O
Instrumental	O
Activities	O
of	O
Daily	O
Living	O
Scale	O
(	O
HKLIADL	O
)	O
52	O
evaluates	O
aspects	O
of	O
community	O
-	O
living	O
skills	O
,	O
such	O
as	O
cooking	O
,	O
use	O
of	O
a	O
telephone	O
,	O
use	O
of	O
transport	O
,	O
household	O
management	O
,	O
and	O
shopping	O
.	O

There	O
is	O
a	O
total	O
score	O
of	O
27	O
points	O
for	O
nine	O
items	O
of	O
community	O
-	O
living	O
skills	O
.	O

The	O
descriptions	O
below	O
follow	O
the	O
CONSORT	O
2010	O
statement	O
and	O
extension	O
for	O
cluster	O
-	O
randomised	O
trials	O
(	O
Campbell	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

A	O
cluster	O
-	O
randomised	O
crossover	O
(	O
CRXO	O
)	O
trial	O
was	O
undertaken	O
,	O
with	O
schools	O
defining	O
clusters	O
.	O

CRXO	O
is	O
a	O
refinement	O
of	O
the	O
matched	O
-	O
pair	O
cluster	O
design	O
;	O
in	O
CRXO	O
trials	O
,	O
all	O
clusters	O
receive	O
all	O
interventions	O
with	O
the	O
sequence	O
of	O
administration	O
being	O
randomly	O
assigned	O
.	O

It	O
is	O
particularly	O
suitable	O
when	O
only	O
a	O
small	O
number	O
of	O
clusters	O
are	O
available	O
as	O
it	O
allows	O
the	O
effects	O
of	O
the	O
intervention	O
to	O
be	O
estimated	O
within	O
clusters	O
,	O
controlling	O
for	O
within	O
-	O
cluster	O
variance	O
(	O
i	O
.	O
e	O
.	O
factors	O
in	O
specific	O
school	O
environments	O
)	O
that	O
may	O
influence	O
the	O
outcome	O
of	O
the	O
study	O
(	O
Parienti	O
and	O
Kuss	O
,	O
2007	O
)	O
.	O

With	O
two	O
interventions	O
,	O
two	O
distinct	O
waves	O
of	O
participants	O
(	O
periods	O
;	O
i	O
.	O
e	O
.	O
student	O
year	O
level	O
cohort	O
)	O
undertake	O
the	O
separate	O
trial	O
conditions	O
(	O
Figure	O
1	O
;	O
Giraudeau	O
et	O
al	O
.	O
,	O
2008	O
;	O
Turner	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Design	O
of	O
the	O
CRXO	O
study	O
.	O

In	O
CRXO	O
,	O
all	O
clusters	O
receive	O
all	O
interventions	O
,	O
with	O
the	O
sequence	O
of	O
administration	O
being	O
randomly	O
assigned	O
.	O

In	O
this	O
study	O
,	O
four	O
schools	O
enrolled	O
in	O
the	O
study	O
,	O
and	O
each	O
of	O
these	O
were	O
matched	O
in	O
a	O
pair	O
,	O
based	O
on	O
Index	O
of	O
Socio	O
-	O
educational	O
Advantage	O
(	O
ICSEA	O
)	O
and	O
size	O
of	O
Year	O
10	O
cohort	O
.	O

Pairs	O
of	O
schools	O
were	O
randomised	O
to	O
receive	O
either	O
tMHFA	O
or	O
PFA	O
in	O
the	O
first	O
wave	O
for	O
their	O
entire	O
Year	O
10	O
cohort	O
.	O

In	O
the	O
subsequent	O
year	O
,	O
the	O
new	O
Year	O
10	O
cohort	O
received	O
the	O
opposite	O
intervention	O
.	O

This	O
design	O
allows	O
counterbalancing	O
across	O
schools	O
,	O
while	O
also	O
controlling	O
for	O
within	O
-	O
school	O
variance	O
,	O
by	O
using	O
intervention	O
crossover	O
in	O
subsequent	O
waves	O
.	O

Individual	O
school	O
characteristics	O
are	O
shown	O
in	O
Table	O
3	O
.	O

This	O
research	O
was	O
registered	O
with	O
the	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
(	O
ACTRN12614000061639	O
)	O
and	O
had	O
ethics	O
approval	O
from	O
a	O
university	O
ethics	O
committee	O
(	O
HREC1341238	O
)	O
and	O
the	O
State	O
Government	O
Education	O
Department	O
for	O
Victoria	O
(	O
2014	O
_	O
002268	O
)	O
.	O

To	O
be	O
eligible	O
,	O
schools	O
needed	O
to	O
be	O
Government	O
funded	O
(	O
rather	O
than	O
independent	O
/	O
private	O
)	O
,	O
agree	O
to	O
two	O
consecutive	O
cohorts	O
of	O
Year	O
10	O
students	O
undertaking	O
three	O
survey	O
sessions	O
and	O
three	O
training	O
sessions	O
in	O
regular	O
class	O
time	O
,	O
and	O
agree	O
to	O
withhold	O
any	O
overlapping	O
mental	O
health	O
classroom	O
programmes	O
until	O
the	O
completion	O
of	O
the	O
research	O
.	O

The	O
only	O
exclusion	O
criterion	O
was	O
having	O
provided	O
a	O
mental	O
health	O
intervention	O
designed	O
to	O
increase	O
mental	O
health	O
literacy	O
or	O
help	O
seeking	O
to	O
the	O
current	O
Year	O
9	O
or	O
10	O
cohorts	O
over	O
the	O
previous	O
2	O
years	O
.	O

Students	O
were	O
eligible	O
to	O
participate	O
in	O
the	O
evaluation	O
surveys	O
if	O
they	O
had	O
parental	O
consent	O
and	O
provided	O
assent	O
at	O
the	O
beginning	O
of	O
each	O
survey	O
.	O

Students	O
with	O
a	O
known	O
mental	O
health	O
problem	O
,	O
previous	O
experience	O
of	O
mental	O
illness	O
or	O
suicide	O
bereavement	O
were	O
encouraged	O
to	O
speak	O
to	O
their	O
mental	O
health	O
professional	O
,	O
school	O
counsellor	O
and	O
/	O
or	O
parents	O
before	O
deciding	O
whether	O
to	O
participate	O
.	O

Passive	O
parental	O
consent	O
was	O
used	O
.	O

The	O
research	O
team	O
provided	O
parent	O
,	O
teacher	O
and	O
student	O
information	O
sessions	O
and	O
electronic	O
and	O
hardcopy	O
information	O
statements	O
,	O
3	O
weeks	O
prior	O
to	O
baseline	O
measures	O
.	O

Parents	O
could	O
opt	O
their	O
child	O
out	O
of	O
the	O
training	O
or	O
the	O
evaluation	O
by	O
returning	O
a	O
signed	O
form	O
to	O
the	O
participating	O
school	O
.	O

To	O
protect	O
the	O
identity	O
of	O
these	O
families	O
,	O
no	O
data	O
were	O
gathered	O
on	O
non	O
-	O
consenters	O
.	O

Both	O
interventions	O
consisted	O
of	O
three	O
75	O
-	O
minute	O
classroom	O
sessions	O
,	O
presented	O
by	O
trained	O
instructors	O
external	O
to	O
the	O
host	O
school	O
,	O
according	O
to	O
a	O
manualised	O
curriculum	O
.	O

In	O
each	O
intervention	O
,	O
students	O
were	O
provided	O
with	O
a	O
specific	O
programme	O
booklet	O
and	O
completion	O
certificate	O
.	O

Session	O
content	O
is	O
provided	O
in	O
Table	O
1	O
.	O

Training	O
was	O
normally	O
completed	O
within	O
3	O
weeks	O
(	O
one	O
session	O
per	O
week	O
)	O
.	O

Structure	O
and	O
content	O
of	O
training	O
interventions	O
.	O

MHFA	O
:	O
Mental	O
Health	O
First	O
Aid	O
training	O
;	O
PFA	O
:	O
Physical	O
First	O
Aid	O
.	O

The	O
central	O
teaching	O
of	O
both	O
MHFA	O
and	O
PFA	O
is	O
an	O
action	O
plan	O
.	O

Modelled	O
on	O
MHFA	O
for	O
adults	O
(	O
Kitchener	O
et	O
al	O
.	O
,	O
2010	O
;	O
Kelly	O
et	O
al	O
.	O
,	O
2010	O
)	O
and	O
based	O
on	O
the	O
key	O
messages	O
for	O
adolescents	O
from	O
a	O
Delphi	O
expert	O
consensus	O
study	O
(	O
Ross	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
the	O
tMHFA	O
action	O
plan	O
provides	O
five	O
strategies	O
taught	O
in	O
a	O
mnemonic	O
.	O

The	O
PFA	O
action	O
plan	O
is	O
based	O
on	O
the	O
CPR	O
recommendations	O
(	O
Eisenburger	O
and	O
Safar	O
,	O
1999	O
;	O
Hazinski	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

A	O
detailed	O
explanation	O
of	O
the	O
tMHFA	O
programme	O
has	O
been	O
provided	O
elsewhere	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
but	O
relevant	O
details	O
are	O
noted	O
here	O
.	O

Training	O
involved	O
a	O
PowerPoint	O
presentation	O
,	O
videos	O
,	O
role	O
-	O
plays	O
,	O
group	O
discussion	O
,	O
small	O
group	O
and	O
workbook	O
activities	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

tMHFA	O
instructors	O
completed	O
at	O
least	O
5	O
.	O
5	O
days	O
of	O
training	O
.	O

Because	O
a	O
core	O
message	O
of	O
the	O
tMHFA	O
training	O
is	O
to	O
seek	O
assistance	O
from	O
a	O
trusted	O
and	O
reliable	O
adult	O
when	O
a	O
peer	O
is	O
experiencing	O
a	O
mental	O
health	O
problem	O
,	O
the	O
Youth	O
MHFA	O
course	O
(	O
Kelly	O
et	O
al	O
.	O
,	O
2017	O
)	O
was	O
also	O
offered	O
to	O
staff	O
and	O
parents	O
at	O
participating	O
schools	O
.	O

One	O
course	O
was	O
provided	O
for	O
teachers	O
and	O
another	O
for	O
parents	O
.	O

The	O
course	O
is	O
a	O
14	O
-	O
hour	O
programme	O
for	O
adults	O
living	O
or	O
working	O
with	O
young	O
people	O
,	O
analogous	O
to	O
basic	O
PFA	O
training	O
for	O
adults	O
.	O

It	O
ensured	O
that	O
adults	O
who	O
were	O
likely	O
to	O
be	O
called	O
upon	O
to	O
assist	O
adolescents	O
as	O
a	O
result	O
of	O
tMHFA	O
were	O
confident	O
in	O
providing	O
support	O
and	O
could	O
facilitate	O
appropriate	O
referral	O
pathways	O
to	O
effective	O
treatment	O
interventions	O
.	O

A	O
previous	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
has	O
evaluated	O
the	O
effect	O
of	O
teacher	O
training	O
on	O
students	O
(	O
Jorm	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

A	O
parallel	O
PFA	O
course	O
for	O
parents	O
and	O
teachers	O
was	O
not	O
provided	O
for	O
control	O
condition	O
cohorts	O
,	O
as	O
the	O
level	O
of	O
attendance	O
at	O
prior	O
training	O
was	O
already	O
high	O
.	O

PFA	O
training	O
involved	O
instructor	O
introductions	O
of	O
topic	O
content	O
,	O
role	O
-	O
plays	O
using	O
mannequins	O
,	O
bandages	O
and	O
splints	O
and	O
group	O
discussions	O
.	O

PFA	O
instructors	O
underwent	O
a	O
minimum	O
of	O
3	O
days	O
training	O
in	O
first	O
aid	O
,	O
plus	O
an	O
additional	O
certificate	O
-	O
level	O
course	O
in	O
Workplace	O
Training	O
and	O
Assessment	O
(	O
8	O
-	O
week	O
full	O
-	O
time	O
equivalent	O
;	O
NRVET	O
,	O
2017	O
)	O
.	O

The	O
survey	O
,	O
which	O
was	O
modified	O
from	O
previous	O
national	O
mental	O
health	O
literacy	O
surveys	O
with	O
youth	O
(	O
Yap	O
et	O
al	O
.	O
,	O
2012b	O
)	O
and	O
evaluations	O
of	O
tMHFA	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2016	O
)	O
,	O
measured	O
quality	O
of	O
MHFA	O
intentions	O
(	O
helpful	O
and	O
harmful	O
intentions	O
,	O
confidence	O
in	O
providing	O
help	O
)	O
,	O
mental	O
health	O
literacy	O
(	O
problem	O
recognition	O
,	O
beliefs	O
about	O
helpfulness	O
of	O
adult	O
sources	O
of	O
help	O
)	O
and	O
stigmatising	O
beliefs	O
(	O
social	O
distance	O
,	O
weak	O
-	O
not	O
-	O
sick	O
,	O
dangerous	O
/	O
unpredictable	O
and	O
would	O
not	O
tell	O
anyone	O
)	O
.	O

It	O
presented	O
two	O
vignettes	O
:	O
one	O
(	O
John	O
)	O
depicting	O
an	O
adolescent	O
with	O
suicidal	B-Phenotype
ideation	I-Phenotype
and	I-Phenotype
symptoms	I-Phenotype
matching	O
Diagnostic	B-Coding_system
and	I-Coding_system
Statistical	I-Coding_system
Manual	I-Coding_system
of	I-Coding_system
Mental	I-Coding_system
Disorders	I-Coding_system
,	I-Coding_system
Fifth	I-Coding_system
Edition	I-Coding_system
(	I-Coding_system
DSM	I-Coding_system
-	I-Coding_system
5	I-Coding_system
)	I-Coding_system
and	O
International	B-Coding_system
Statistical	I-Coding_system
Classification	I-Coding_system
of	I-Coding_system
Diseases	I-Coding_system
and	I-Coding_system
Related	I-Coding_system
Health	I-Coding_system
Problems–10th	I-Coding_system
Revision	I-Coding_system
(	I-Coding_system
ICD	I-Coding_system
-	I-Coding_system
10	I-Coding_system
)	I-Coding_system
criteria	O
for	O
a	O
depressive	B-Phenotype
disorder	I-Phenotype
(	O
American	O
Psychiatric	O
Association	O
,	O
2013	O
;	O
World	O
Health	O
Organization	O
,	O
1994	O
)	O
and	O
another	O
(	O
Jeanie	O
)	O
with	O
symptoms	O
matching	O
criteria	O
for	O
social	B-Phenotype
anxiety	I-Phenotype
/	I-Phenotype
phobia	I-Phenotype
.	O

The	O
vignettes	O
are	O
provided	O
in	O
Additional	O
File	O
1	O
.	O

A	O
description	O
of	O
all	O
measures	O
,	O
including	O
reliability	O
coefficient	O
omega	O
(	O
ω	O
)	O
,	O
is	O
provided	O
in	O
Table	O
2	O
.	O

Omega	O
is	O
considered	O
a	O
better	O
indication	O
of	O
reliability	O
than	O
Cronbach’s	O
alpha	O
(	O
Dunn	O
et	O
al	O
.	O
,	O
2014	O
)	O
,	O
especially	O
where	O
response	O
options	O
to	O
individual	O
items	O
involve	O
binary	O
responses	O
or	O
scales	O
are	O
brief	O
(	O
McNeish	O
,	O
2017	O
)	O
.	O

Measures	O
used	O
at	O
baseline	O
and	O
post	O
-	O
training	O
to	O
assess	O
student	O
outcomes	O
.	O

tMHFA	O
:	O
teen	O
Mental	O
Health	O
First	O
Aid	O
;	O
PFA	O
:	O
Physical	O
First	O
Aid	O
.	O

ω	O
:	O
Revelle’s	O
omega	O
total	O
for	O
total	O
scores	O
and	O
subscales	O
.	O

Omega	O
is	O
considered	O
acceptable	O
when	O
above	O
0	O
.	O
70	O
.	O

r	O
:	O
calculated	O
based	O
on	O
the	O
control	O
condition	O
measures	O
taken	O
at	O
baseline	O
and	O
post	O
-	O
training	O
which	O
occurred	O
approximately	O
4	O
weeks	O
apart	O
.	O

Given	O
that	O
an	O
intervention	O
was	O
provided	O
in	O
between	O
the	O
measurement	O
occasions	O
,	O
this	O
may	O
have	O
led	O
to	O
lower	O
reliability	O
estimates	O
than	O
would	O
be	O
reported	O
by	O
a	O
training	O
-	O
naive	O
sample	O
.	O

Other	O
test–retest	O
reliability	O
data	O
on	O
these	O
instruments	O
have	O
not	O
been	O
previously	O
developed	O
,	O
as	O
this	O
was	O
the	O
first	O
implementation	O
of	O
the	O
John	O
and	O
Jeanie	O
vignettes	O
in	O
a	O
tMHFA	O
-	O
naive	O
sample	O
.	O

The	O
primary	O
outcome	O
was	O
quality	O
of	O
MHFA	O
intentions	O
.	O

Participants	O
were	O
asked	O
to	O
endorse	O
any	O
of	O
12	O
possible	O
actions	O
towards	O
John	O
/	O
Jeanie	O
.	O

The	O
possible	O
actions	O
were	O
designed	O
to	O
be	O
consistent	O
with	O
the	O
tMHFA	O
action	O
plan	O
(	O
helpful	O
intentions	O
)	O
or	O
contrary	O
to	O
the	O
plan	O
as	O
distractors	O
(	O
harmful	O
intentions	O
;	O
see	O
Table	O
2	O
for	O
examples	O
)	O
.	O

This	O
measure	O
was	O
chosen	O
because	O
research	O
based	O
on	O
the	O
Theory	O
of	O
Planned	O
Behaviour	O
shows	O
that	O
intention	O
ratings	O
correlate	O
strongly	O
with	O
future	O
behaviours	O
(	O
Armitage	O
and	O
Conner	O
,	O
2001	O
)	O
and	O
because	O
the	O
quality	O
of	O
young	O
people’s	O
MHFA	O
intentions	O
has	O
been	O
shown	O
to	O
predict	O
subsequent	O
helping	O
actions	O
2	O
years	O
later	O
(	O
Yap	O
and	O
Jorm	O
,	O
2012	O
)	O
.	O

Problem	O
recognition	O
was	O
assessed	O
by	O
asking	O
students	O
to	O
identify	O
what	O
,	O
if	O
anything	O
,	O
was	O
wrong	O
with	O
the	O
person	O
in	O
the	O
vignette	O
.	O

Responses	O
were	O
open	O
-	O
ended	O
,	O
and	O
resulting	O
data	O
were	O
coded	O
by	O
a	O
researcher	O
blind	O
to	O
period	O
,	O
cluster	O
and	O
cluster–period	O
and	O
in	O
accordance	O
with	O
a	O
structured	O
protocol	O
(	O
Mason	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O

Previous	O
evaluations	O
of	O
MHFA	O
training	O
have	O
found	O
statistically	O
significant	O
increases	O
in	O
correct	O
problem	O
recognition	O
(	O
Hadlaczky	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

However	O
,	O
because	O
of	O
its	O
brevity	O
and	O
specificity	O
to	O
adolescents	O
,	O
the	O
tMHFA	O
training	O
does	O
not	O
focus	O
on	O
teaching	O
correct	O
labelling	O
across	O
different	O
diagnoses	O
of	O
mental	O
disorder	O
.	O

Only	O
about	O
10	O
minutes	O
of	O
the	O
entire	O
225	O
-	O
minute	O
content	O
is	O
spent	O
on	O
explaining	O
differences	O
between	O
broad	O
psychiatric	O
groups	O
,	O
such	O
as	O
mood	O
versus	O
psychotic	O
illnesses	O
(	O
see	O
Table	O
1	O
;	O
Hart	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Instead	O
,	O
students	O
are	O
taught	O
to	O
assess	O
for	O
general	O
signs	O
that	O
a	O
person	O
might	O
be	O
developing	O
a	O
mental	O
health	O
problem	O
which	O
is	O
interfering	O
with	O
the	O
usual	O
activities	O
.	O

As	O
such	O
,	O
no	O
hypotheses	O
about	O
changes	O
in	O
students’	O
rates	O
of	O
correct	O
problem	O
recognition	O
were	O
made	O
.	O

Beliefs	O
about	O
the	O
helpfulness	O
of	O
adult	O
help	O
were	O
assessed	O
by	O
asking	O
participants	O
to	O
rate	O
a	O
range	O
of	O
individuals	O
who	O
have	O
a	O
clear	O
role	O
in	O
protecting	O
and	O
promoting	O
student	O
well	O
-	O
being	O
.	O

Although	O
examining	O
beliefs	O
about	O
the	O
helpfulness	O
of	O
a	O
broad	O
range	O
of	O
self	O
-	O
help	O
and	O
social	O
support	O
sources	O
,	O
has	O
been	O
a	O
feature	O
of	O
other	O
evaluations	O
of	O
mental	O
health	O
literacy	O
(	O
Reavley	O
et	O
al	O
.	O
,	O
2011	O
;	O
Yap	O
et	O
al	O
.	O
,	O
2010	O
,	O
2012b	O
,	O
2015	O
)	O
,	O
this	O
study	O
only	O
analysed	O
data	O
on	O
adult	O
sources	O
of	O
help	O
,	O
because	O
the	O
necessity	O
of	O
engaging	O
adult	O
help	O
is	O
a	O
key	O
message	O
of	O
the	O
tMHFA	O
training	O
.	O

Measures	O
of	O
stigmatising	O
beliefs	O
included	O
the	O
Social	O
Distance	O
Scale	O
(	O
SDS	O
;	O
Link	O
et	O
al	O
.	O
,	O
1999	O
)	O
and	O
the	O
Depression	O
Stigma	O
Scale	O
(	O
DSS	O
;	O
Griffiths	O
et	O
al	O
.	O
,	O
2004	O
)	O
,	O
modified	O
for	O
use	O
with	O
the	O
John	O
/	O
Jeanie	O
vignettes	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
evaluated	O
as	O
four	O
distinct	O
stigma	O
scales	O
:	O
‘social	O
distance’	O
,	O
‘weak	O
-	O
not	O
-	O
sick’	O
,	O
‘dangerous	O
/	O
unpredictable’	O
and	O
‘would	O
not	O
tell	O
anyone’	O
(	O
Yap	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

Additional	O
measures	O
of	O
self	O
-	O
reported	O
mental	O
health	O
status	O
,	O
help	O
-	O
seeking	O
,	O
psychological	O
distress	O
(	O
K6	O
)	O
and	O
experiences	O
with	O
provision	O
or	O
receipt	O
of	O
first	O
aid	O
were	O
administered	O
at	O
12	O
-	O
month	O
follow	O
-	O
up	O
,	O
but	O
are	O
not	O
reported	O
here	O
as	O
they	O
were	O
not	O
administered	O
at	O
post	O
-	O
training	O
.	O

These	O
measures	O
assessed	O
a	O
time	O
period	O
of	O
1–12	O
months	O
and	O
thus	O
may	O
have	O
overlapped	O
with	O
baseline	O
measures	O
if	O
given	O
earlier	O
.	O

Mixed	O
-	O
effects	O
models	O
were	O
used	O
for	O
analysing	O
continuous	O
and	O
binary	O
outcome	O
variables	O
,	O
including	O
group	O
-	O
by	O
-	O
measurement	O
-	O
occasion	O
interactions	O
,	O
taking	O
into	O
account	O
the	O
hierarchical	O
structure	O
(	O
i	O
.	O
e	O
.	O
the	O
correlation	O
of	O
measurement	O
occasions	O
within	O
clusters	O
,	O
periods	O
and	O
period–clusters	O
;	O
MAR	O
;	O
Rabe	O
-	O
Hesketh	O
and	O
Skrondal	O
,	O
2012	O
)	O
.	O

All	O
models	O
included	O
a	O
random	O
effect	O
for	O
student	O
cohort	O
(	O
period–clusters	O
)	O
and	O
fixed	O
effects	O
for	O
school	O
(	O
cluster	O
)	O
,	O
year	O
(	O
period	O
)	O
and	O
student	O
age	O
and	O
gender	O
to	O
accommodate	O
possible	O
non	O
-	O
independence	O
of	O
student	O
responses	O
in	O
cohorts	O
.	O

Gender	O
and	O
age	O
were	O
found	O
to	O
be	O
associated	O
with	O
missingness	O
,	O
with	O
older	O
boys	O
being	O
less	O
likely	O
to	O
provide	O
post	O
-	O
training	O
data	O
,	O
and	O
were	O
thus	O
included	O
as	O
fixed	O
effects	O
in	O
order	O
to	O
help	O
meet	O
the	O
missing	O
at	O
random	O
assumption	O
.	O

For	O
outcome	O
measures	O
with	O
no	O
substantial	O
baseline	O
imbalance	O
,	O
effect	O
sizes	O
(	O
Cohen’s	O
d	O
)	O
were	O
calculated	O
by	O
dividing	O
the	O
difference	O
between	O
the	O
two	O
group	O
means	O
at	O
post	O
-	O
intervention	O
by	O
their	O
pooled	O
standard	O
deviation	O
(	O
SD	O
)	O
.	O

With	O
baseline	O
imbalances	O
,	O
Cohen’s	O
d	O
was	O
calculated	O
by	O
dividing	O
the	O
mean	O
change	O
in	O
each	O
condition	O
by	O
the	O
pooled	O
SD	O
at	O
post	O
-	O
intervention	O
.	O

Analyses	O
were	O
performed	O
in	O
Stata	O
13	O
(	O
StataCorp	O
,	O
2013	O
)	O
.	O

It	O
was	O
conservatively	O
estimated	O
that	O
there	O
would	O
be	O
100	O
Year	O
10	O
students	O
per	O
school	O
,	O
with	O
a	O
50	O
%	O
consent	O
+	O
assent	O
rate	O
.	O

Across	O
four	O
schools	O
and	O
eight	O
clusters	O
,	O
this	O
would	O
give	O
400	O
adolescents	O
(	O
200	O
per	O
intervention	O
)	O
.	O

The	O
estimated	O
intra	O
-	O
class	O
correlation	O
(	O
ICC	O
)	O
for	O
students	O
(	O
ICC	O
=	O
0	O
.	O
003	O
)	O
at	O
the	O
school	O
cluster	O
level	O
was	O
based	O
on	O
findings	O
from	O
previous	O
research	O
(	O
Hart	O
et	O
al	O
.	O
,	O
2016	O
)	O
and	O
not	O
included	O
in	O
the	O
power	O
calculations	O
due	O
to	O
the	O
likely	O
small	O
design	O
effect	O
and	O
the	O
counterbalancing	O
of	O
schools	O
.	O

With	O
an	O
assumed	O
0	O
.	O
70	O
correlation	O
between	O
pre	O
-	O
post	O
measurements	O
,	O
the	O
study	O
would	O
have	O
a	O
0	O
.	O
80	O
power	O
to	O
detect	O
small	O
(	O
d	O
=	O
0	O
.	O
17	O
)	O
group	O
-	O
by	O
-	O
measurement	O
occasion	O
differences	O
at	O
α	O
=	O
0	O
.	O
05	O
.	O

The	O
research	O
team	O
emailed	O
a	O
request	O
to	O
all	O
accredited	O
Youth	O
MHFA	O
instructors	O
in	O
the	O
Melbourne	O
area	O
asking	O
for	O
an	O
introduction	O
to	O
any	O
secondary	O
schools	O
with	O
an	O
expressed	O
interest	O
in	O
receiving	O
training	O
for	O
staff	O
and	O
students	O
.	O

Two	O
schools	O
agreed	O
to	O
participate	O
through	O
this	O
mechanism	O
,	O
with	O
a	O
further	O
two	O
schools	O
selected	O
for	O
matched	O
demographic	O
variables	O
:	O
Index	O
of	O
Socio	O
-	O
Educational	O
Advantage	O
(	O
ICSEA	O
;	O
M	O
=	O
1000	O
,	O
SD	O
=	O
100	O
,	O
Barnes	O
,	O
2011	O
)	O
and	O
Year	O
10	O
cohort	O
size	O
in	O
the	O
first	O
year	O
.	O

Schools	O
were	O
required	O
to	O
be	O
within	O
1	O
SD	O
on	O
ICSEA	O
and	O
within	O
100	O
students	O
in	O
size	O
.	O

The	O
four	O
schools	O
were	O
enrolled	O
in	O
the	O
trial	O
upon	O
completion	O
of	O
a	O
research	O
agreement	O
signed	O
by	O
the	O
principal	O
.	O

A	O
random	O
sequence	O
generator	O
(	O
SPSS	O
)	O
was	O
used	O
by	O
the	O
trial	O
manager	O
to	O
generate	O
the	O
treatment	O
sequence	O
for	O
the	O
two	O
pairs	O
of	O
schools	O
,	O
with	O
the	O
research	O
assistant	O
assigning	O
the	O
first	O
school	O
enrolled	O
to	O
sequence	O
one	O
,	O
the	O
second	O
school	O
enrolled	O
to	O
sequence	O
two	O
and	O
the	O
remaining	O
schools	O
assigned	O
based	O
on	O
their	O
matching	O
demographic	O
variables	O
.	O
Although	O
randomisation	O
was	O
at	O
the	O
cluster	O
level	O
,	O
the	O
primary	O
outcome	O
was	O
analysed	O
at	O
the	O
individual	O
level	O
,	O
as	O
the	O
aim	O
of	O
this	O
research	O
was	O
to	O
understand	O
the	O
impact	O
of	O

first	O
aid	O
training	O
on	O
students’	O
supportive	O
intentions	O
towards	O
their	O
peers	O
,	O
rather	O
than	O
impact	O
on	O
the	O
school	O
community	O
.	O

Research	O
assistants	O
,	O
instructors	O
providing	O
training	O
and	O
students	O
could	O
not	O
be	O
blinded	O
to	O
intervention	O
.	O

However	O
,	O
research	O
staff	O
coding	O
and	O
analysing	O
data	O
were	O
blinded	O
to	O
measurement	O
occasion	O
,	O
school	O
identity	O
and	O
condition	O
.	O

Research	O
staff	O
completed	O
a	O
recruitment	O
meeting	O
with	O
Principals	O
and	O
Assistant	O
Principals	O
from	O
schools	O
indicating	O
interest	O
in	O
participating	O
in	O
the	O
current	O
research	O
.	O

Once	O
schools	O
had	O
signed	O
the	O
Research	O
Agreement	O
,	O
they	O
were	O
randomised	O
to	O
a	O
sequence	O
of	O
treatment	O
allocation	O
.	O

A	O
planning	O
meeting	O
was	O
then	O
conducted	O
,	O
where	O
the	O
number	O
of	O
students	O
enrolled	O
in	O
Year	O
10	O
and	O
the	O
number	O
of	O
classes	O
requiring	O
training	O
were	O
disclosed	O
to	O
the	O
research	O
team	O
.	O

Research	O
staff	O
relied	O
on	O
these	O
verbal	O
estimates	O
from	O
school	O
staff	O
to	O
schedule	O
training	O
and	O
survey	O
sessions	O
.	O

Parent	O
,	O
teacher	O
and	O
student	O
information	O
sessions	O
were	O
provided	O
3	O
weeks	O
before	O
the	O
baseline	O
survey	O
and	O
parental	O
opt	O
-	O
out	O
forms	O
could	O
be	O
returned	O
at	O
any	O
time	O
during	O
the	O
trial	O
.	O

The	O
baseline	O
survey	O
was	O
administered	O
1	O
week	O
before	O
the	O
first	O
training	O
session	O
.	O

All	O
surveys	O
were	O
completed	O
by	O
students	O
during	O
regular	O
class	O
times	O
via	O
the	O
online	O
hosting	O
software	O
SurveyMonkey	O
.	O

Each	O
school	O
was	O
emailed	O
a	O
generic	O
link	O
to	O
the	O
survey	O
,	O
and	O
school	O
staff	O
distributed	O
this	O
link	O
to	O
students	O
via	O
an	O
intranet	O
webpage	O
or	O
student	O
email	O
address	O
.	O

Upon	O
accessing	O
the	O
survey	O
,	O
students	O
were	O
required	O
to	O
enter	O
their	O
unique	O
identification	O
number	O
,	O
which	O
could	O
only	O
be	O
matched	O
to	O
personally	O
identifying	O
information	O
by	O
the	O
school	O
and	O
not	O
research	O
staff	O
.	O

The	O
first	O
session	O
of	O
tMHFA	O
or	O
PFA	O
training	O
usually	O
occurred	O
in	O
the	O
week	O
following	O
baseline	O
completion	O
and	O
all	O
three	O
sessions	O
were	O
usually	O
completed	O
within	O
3	O
weeks	O
.	O

The	O
post	O
-	O
training	O
measure	O
was	O
scheduled	O
in	O
regular	O
class	O
time	O
up	O
to	O
1	O
week	O
after	O
the	O
conclusion	O
of	O
the	O
final	O
training	O
session	O
.	O

Students	O
who	O
were	O
absent	O
during	O
scheduled	O
survey	O
sessions	O
were	O
tracked	O
by	O
school	O
staff	O
and	O
provided	O
with	O
alternative	O
opportunities	O
to	O
complete	O
the	O
survey	O
during	O
school	O
time	O
.	O

Research	O
staff	O
were	O
usually	O
present	O
to	O
support	O
the	O
process	O
of	O
implementation	O
for	O
the	O
baseline	O
survey	O
and	O
initial	O
training	O
session	O
across	O
a	O
whole	O
school	O
,	O
though	O
were	O
not	O
typically	O
present	O
in	O
individual	O
classrooms	O
.	O

All	O
survey	O
and	O
intervention	O
sessions	O
were	O
conducted	O
between	O
April	O
2014	O
and	O
October	O
2016	O
.	O

Although	O
the	O
paid	O
provider	O
of	O
the	O
PFA	O
sessions	O
changed	O
after	O
year	O
1	O
,	O
no	O
changes	O
to	O
the	O
content	O
presented	O
or	O
research	O
methods	O
occurred	O
after	O
trial	O
commencement	O
.	O

We	O
report	O
this	O
clinical	O
trial	O
according	O
to	O
CONSORT	O
guidelines	O
.	O

This	O
trial	O
was	O
registered	O
under	O
Clinical	O
Trials	O
.	O
gov	O
number	O
NCT02091167	O
.	O

This	O
clinical	O
trial	O
was	O
a	O
parallel	O
randomized	O
sham	O
controlled	O
and	O
single	O
center	O
trial	O
.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
receive	O
real	O
brain	O
stimulation	O
(	O
tDCS	O
group	O
)	O
or	O
a	O
simulation	O
of	O
this	O
procedure	O
(	O
sham	O
-	O
tDCS	O
group	O
)	O
in	O
a	O
1	O
:	O
1	O
ratio	O
(	O
Figure	O
1	O
)	O
using	O
a	O
computer	O
-	O
generated	O
randomization	O
sequence	O
that	O
was	O
kept	O
with	O
the	O
unblinded	O
study	O
coordinator	O
(	O
not	O
involved	O
in	O
the	O
recruitment	O
)	O
and	O
only	O
revealed	O
to	O
the	O
co	O
-	O
investigator	O
conducting	O
treatments	O
immediately	O
before	O
the	O
first	O
session	O
.	O

Diagram	O
of	O
the	O
general	O
procedure	O
:	O
eligible	O
crack	O
-	O
cocaine	O
users	O
were	O
recruited	O
from	O
the	O
clinics	O
for	O
treatment	O
of	O
drug	O
dependence	O
,	O
signed	O
the	O
term	O
of	O
consent	O
,	O
and	O
were	O
randomized	O
to	O
receive	O
repetitive	O
bilateral	O
(	O
cathode	O
left	O
/	O
anode	O
right	O
over	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
)	O
transcranial	O
direct	O
current	O
stimulation	O
(	O
tDCS	O
;	O
2	O
mA	O
,	O
35cm	O
2	O
,	O
stimulation	O
for	O
20min	O
)	O
every	O
other	O
day	O
for	O
a	O
total	O
of	O
5	O
sessions	O
.	O

Craving	O
to	O
the	O
use	O
of	O
crack	O
-	O
cocaine	O
was	O
examined	O
once	O
per	O
week	O
for	O
4	O
weeks	O
(	O
the	O
week	O
before	O
treatment	O
,	O
during	O
the	O
second	O
and	O
third	O
treatment	O
weeks	O
,	O
and	O
the	O
week	O
after	O
treatment	O
)	O
.	O

a	O
,	O
anode	O
;	O
A	O
,	O
anterior	O
;	O
BS	O
,	O
brain	O
stimulation	O
;	O
c	O
,	O
cathode	O
;	O
HAM	O
-	O
D	O
,	O
Hamilton	O
Scale	O
for	O
Depression	O
;	O
HAM	O
-	O
A	O
,	O
Hamilton	O
Scale	O
for	O
Anxiety	O
;	O
L	O
,	O
left	O
;	O
P	O
,	O
posterior	O
;	O
R	O
,	O
right	O
;	O
WHOQOL	O
,	O
Quality	O
of	O
Life	O
.	O

A	O
total	O
of	O
135	O
crack	B-phenotype
-	I-phenotype
cocaine	I-phenotype
addicted	I-phenotype
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
Classification	I-coding_system
of	I-coding_system
Mental	I-coding_system
and	I-coding_system
Behavioural	I-coding_system
Disorders	I-coding_system
and	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
,	I-coding_system
fourth	I-coding_system
edition	I-coding_system
subjects	I-coding_system
,	I-coding_system
as	I-coding_system
defined	I-coding_system
by	I-coding_system
the	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
,	O
were	O
interviewed	O
for	O
this	O
trial	O
,	O
and	O
38	O
subjects	O
meeting	O
our	O
inclusion	O
criteria	O
(	O
see	O
below	O
)	O
agreed	O
to	O
participate	O
in	O
this	O
study	O
.	O

They	O
were	O
recruited	O
from	O
the	O
Clinic	O
for	O
Drug	O
Dependence	O
Treatment	O
from	O
Espírito	O
Santo	O
state	O
,	O
Brazil	O
.	O

One	O
subject	O
declined	O
to	O
participate	O
after	O
the	O
beginning	O
of	O
the	O
study	O
and	O
one	O
subject	O
showed	O
claustrophobia	O
and	O
was	O
excluded	O
.	O

So	O
,	O
36	O
subjects	O
successfully	O
completed	O
the	O
study	O
(	O
see	O
diagram	O
flow	O
in	O
the	O
Figure	O
1	O
)	O
.	O

The	O
inclusion	O
criteria	O
for	O
this	O
study	O
were	O
:	O
(	O
1	O
)	O
male	O
patients	O
over	O
the	O
age	O
of	O
18	O
years	O
;	O
(	O
2	O
)	O
met	O
criteria	O
for	O
crack	B-phenotype
-	I-phenotype
cocaine	I-phenotype
dependence	I-phenotype
according	O
to	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
Classification	I-coding_system
of	I-coding_system
Mental	I-coding_system
and	I-coding_system
Behavioural	I-coding_system
Disorders	I-coding_system
and	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
,	I-coding_system
fourth	I-coding_system
edition	I-coding_system
,	O
as	O
determined	O
by	O
clinical	O
evaluation	O
;	O
(	O
3	O
)	O
in	O
stable	O
clinical	O
condition	O
with	O
no	O
need	O
for	O
inpatient	O
care	O
;	O
(	O
4	O
)	O
able	O
to	O
read	O
,	O
write	O
,	O
and	O
speak	O
Portuguese	O
;	O
and	O
(	O
5	O
)	O
no	O
severe	O
withdrawal	O
signs	O
or	O
symptoms	O
at	O
baseline	O
.	O

Conversely	O
,	O
exclusion	O
criteria	O
included	O
:	O
(	O
1	O
)	O
a	O
condition	O
of	O
intoxication	O
or	O
withdrawal	O
due	O
to	O
a	O
substance	O
other	O
than	O
crack	O
-	O
cocaine	O
,	O
(	O
2	O
)	O
unstable	O
mental	O
or	O
medical	O
disorder	O
or	O
substance	O
abuse	O
or	O
addiction	O
other	O
than	O
crack	O
-	O
cocaine	O
dependence	O
,	O
except	O
nicotine	O
and	O
/	O
or	O
caffeine	O
;	O
(	O
3	O
)	O
a	O
diagnosis	O
of	O
epilepsy	O
,	O
convulsions	O
,	O
or	O
delirium	O
tremens	O
during	O
abstinence	O
from	O
crack	O
-	O
cocaine	O
;	O
(	O
4	O
)	O
a	O
previous	O
history	O
of	O
drug	O
hypersensitivity	O
or	O
adverse	O
reactions	O
to	O
diazepam	O
or	O
other	O
benzodiazepines	O
and	O
haloperidol	O
;	O
(	O
5	O
)	O
any	O

contraindication	O
for	O
electrical	O
brain	O
stimulation	O
procedures	O
such	O
as	O
electronic	O
implants	O
or	O
metal	O
implants	O
.	O

Ethical	O
approval	O
was	O
provided	O
by	O
the	O
Brazilian	O
Institutional	O
Review	O
Board	O
of	O
the	O
Federal	O
University	O
of	O
Espírito	O
Santo	O
(	O
registration	O
384	O
.	O
281	O
)	O
,	O
Brazil	O
.	O

The	O
study	O
was	O
conducted	O
in	O
strict	O
adherence	O
to	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
is	O
in	O
accordance	O
with	O
the	O
ethical	O
standards	O
of	O
the	O
Committee	O
on	O
Human	O
Experimentation	O
of	O
the	O
Federal	O
University	O
of	O
Espírito	O
Santo	O
,	O
ES	O
,	O
Brazil	O
,	O
where	O
this	O
study	O
was	O
conducted	O
.	O

Subjects	O
were	O
fully	O
informed	O
about	O
the	O
experimental	O
protocol	O
and	O
voluntarily	O
signed	O
an	O
informed	O
consent	O
form	O
before	O
the	O
start	O
of	O
the	O
experiment	O
.	O

The	O
intervention	O
in	O
this	O
clinical	O
trial	O
was	O
noninvasive	O
brain	O
stimulation	O
by	O
transcranial	O
direct	O
current	O
stimulation	O
(	O
tDCS	O
)	O
.	O

Direct	O
currents	O
were	O
transferred	O
via	O
a	O
pair	O
of	O
carbonated	O
silicone	O
electrodes	O
(	O
35cm	O
2	O
)	O
with	O
a	O
thick	O
layer	O
of	O
high	O
-	O
conductive	O
EEG	O
gel	O
underneath	O
them	O
according	O
to	O
our	O
previous	O
study	O
(	O
Nakamura	O
-	O
Palacios	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

The	O
electric	O
current	O
was	O
delivered	O
by	O
an	O
electric	O
stimulator	O
(	O
Striat	O
,	O
Ibramed	O
Indústria	O
Brasileira	O
de	O
Equipamentos	O
Médicos	O
Ltd	O
,	O
São	O
Paulo	O
,	O
Brazil	O
)	O
.	O

For	O
tDCS	O
,	O
the	O
cathode	O
was	O
placed	O
over	O
the	O
left	O
dlPFC	O
(	O
F3	O
)	O
while	O
the	O
anode	O
was	O
placed	O
over	O
the	O
right	O
dlPFC	O
(	O
F4	O
)	O
according	O
to	O
the	O
10–20	O
international	O
system	O
(	O
Figure	O
1	O
)	O
.	O

In	O
each	O
session	O
,	O
the	O
currents	O
flowed	O
continuously	O
for	O
20	O
minutes	O
(	O
2	O
.	O
0	O
mA	O
)	O
.	O

For	O
sham	O
tDCS	O
,	O
the	O
electrodes	O
were	O
placed	O
at	O
the	O
same	O
positions	O
,	O
but	O
the	O
stimulator	O
was	O
gradually	O
turned	O
off	O
after	O
20	O
seconds	O
.	O

In	O
this	O
way	O
,	O
subjects	O
remain	O
blinded	O
to	O
the	O
respective	O
stimulation	O
condition	O
,	O
as	O
the	O
itching	O
sensation	O
typical	O
for	O
tDCS	O
is	O
often	O
only	O
experienced	O
initially	O
during	O
stimulation	O
(	O
Brunoni	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

A	O
previous	O
study	O
validated	O
the	O
sham	O
procedure	O
of	O
2	O
mA	O
tDCS	O
,	O
showing	O
similar	O
blinding	O
efficacy	O
as	O
a	O
placebo	O
pill	O
(	O
Brunoni	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

Both	O
groups	O
(	O
sham	O
-	O
and	O
real	O
tDCS	O
)	O
received	O
one	O
session	O
per	O
day	O
,	O
every	O
other	O
day	O
,	O
with	O
a	O
total	O
of	O
5	O
sessions	O
(	O
Figure	O
1	O
)	O
.	O

Patients	O
were	O
clinically	O
evaluated	O
(	O
HAM	O
-	O
D	O
,	O
HAM	O
-	O
A	O
,	O
and	O
WHOQOL	O
)	O
before	O
intervention	O
and	O
after	O
completion	O
of	O
the	O
protocol	O
.	O

Furthermore	O
,	O
craving	O
evaluation	O
was	O
performed	O
once	O
per	O
week	O
during	O
the	O
4	O
weeks	O
of	O
treatment	O
(	O
Figure	O
1	O
)	O
.	O

Craving	O
was	O
scored	O
with	O
a	O
brief	O
scale	O
composed	O
of	O
5	O
items	O
(	O
1	O
,	O
2	O
,	O
4	O
,	O
5	O
,	O
and	O
13	O
)	O
from	O
the	O
Obsessive	O
Compulsive	O
Drinking	O
Scale	O
(	O
Anton	O
et	O
al	O
.	O
,	O
1995	O
;	O
Anton	O
et	O
al	O
.	O
,	O
1996	O
;	O
Anton	O
,	O
2000	O
)	O
,	O
which	O
assesses	O
craving	O
in	O
a	O
narrow	O
sense	O
according	O
to	O
De	O
Wildt	O
et	O
al	O
.	O
(	O
2005	O
)	O
.	O

These	O
items	O
are	O
identical	O
with	O
those	O
from	O
the	O
Obsessive	O
Compulsive	O
Cocaine	O
Use	O
Scale	O
and	O
Obsessive	O
-	O
Compulsive	O
Cocaine	O
Scale	O
,	O
on	O
which	O
the	O
Obsessive	O
Compulsive	O
Drinking	O
Scale	O
was	O
based	O
,	O
as	O
proposed	O
recently	O
by	O
Hormes	O
et	O
al	O
.	O
(	O
2012	O
)	O
and	O
Vorspan	O
et	O
al	O
.	O
(	O
2012	O
)	O
.	O

They	O
allow	O
the	O
quantification	O
of	O
thoughts	O
and	O
feelings	O
(	O
obsessions	O
)	O
and	O
behavioral	O
intention	O
(	O
de	O
Wildt	O
et	O
al	O
.	O
,	O
2005	O
)	O
about	O
cocaine	O
/	O
crack	O
use	O
and	O
are	O
detailed	O
in	O
the	O
appendix	O
(	O
Appendix	O
1	O
,	O
supplementary	O
Data	O
)	O
.	O

Secondary	O
outcomes	O
consisted	O
of	O
global	O
physical	O
and	O
clinical	O
examination	O
,	O
including	O
the	O
assessment	O
of	O
depressive	O
and	O
anxiety	O
symptoms	O
,	O
and	O
quality	O
of	O
life	O
as	O
listed	O
below	O
and	O
detailed	O
in	O
the	O
appendix	O
(	O
Appendix	O
1	O
,	O
supplementary	O
Data	O
)	O
.	O

For	O
these	O
parameters	O
,	O
the	O
patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
the	O
5	O
-	O
session	O
treatment	O
period	O
(	O
2	O
weeks	O
)	O
:	O
(	O
1	O
)	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAM	O
-	O
D	O
)	O
;	O
(	O
2	O
)	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
(	O
HAM	O
-	O
A	O
)	O
;	O
and	O
(	O
3	O
)	O
quality	O
of	O
life	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHOQOL	O
-	O
BREF	O
)	O
.	O

All	O
clinical	O
measurements	O
were	O
conducted	O
by	O
one	O
of	O
the	O
experimenters	O
blinded	O
for	O
the	O
brain	O
stimulation	O
procedures	O
;	O
conversely	O
,	O
the	O
experimenter	O
responsible	O
for	O
tDCS	O
application	O
was	O
blinded	O
to	O
all	O
clinical	O
outcomes	O
for	O
the	O
entire	O
period	O
of	O
the	O
study	O
.	O

We	O
powered	O
the	O
study	O
for	O
a	O
moderate	O
effect	O
size	O
given	O
our	O
hypothesis	O
that	O
tDCS	O
would	O
be	O
associated	O
with	O
a	O
relevant	O
reduction	O
in	O
craving	O
scores	O
.	O

Thus	O
,	O
assuming	O
an	O
effect	O
size	O
of	O
0	O
.	O
35	O
considering	O
a	O
repeated	O
-	O
measure	O
ANOVA	O
as	O
principal	O
statistical	O
test	O
with	O
a	O
power	O
of	O
80	O
%	O
2	O
-	O
sided	O
probability	O
of	O
a	O
type	O
I	O
error	O
of	O
5	O
%	O
,	O
a	O
minimum	O
of	O
32	O
subjects	O
would	O
be	O
necessary	O
.	O

However	O
,	O
to	O
account	O
for	O
waiving	O
or	O
dropouts	O
expected	O
to	O
be	O
very	O
common	O
in	O
this	O
condition	O
,	O
we	O
increased	O
the	O
estimated	O
sample	O
to	O
10	O
%	O
,	O
resulting	O
in	O
36	O
subjects	O
.	O

Comparisons	O
of	O
craving	O
,	O
HAM	O
-	O
D	O
,	O
HAM	O
-	O
A	O
,	O
and	O
quality	O
of	O
life	O
scores	O
before	O
and	O
after	O
treatment	O
were	O
analyzed	O
by	O
a	O
repeated	O
-	O
measure	O
ANOVA	O
,	O
including	O
the	O
respective	O
baseline	O
values	O
as	O
moderator	O
variables	O
,	O
the	O
independent	O
group	O
factor	O
(	O
sham	O
-	O
tDCS	O
vs	O
tDCS	O
)	O
,	O
and	O
repeated	O
measure	O
factor	O
treatment	O
(	O
before	O
and	O
after	O
tDCS	O
)	O
,	O
followed	O
by	O
Bonferroni	O
-	O
corrected	O
posthoc	O
t	O
tests	O
.	O

Regarding	O
the	O
predictability	O
of	O
tDCS	O
intervention	O
on	O
craving	O
scores	O
,	O
a	O
linear	O
regression	O
was	O
employed	O
considering	O
the	O
4	O
weeks	O
of	O
treatment	O
.	O

When	O
the	O
interaction	O
was	O
not	O
statistically	O
significant	O
in	O
the	O
ANOVA	O
,	O
we	O
used	O
exploratory	O
paired	O
t	O
tests	O
to	O
compare	O
results	O
before	O
and	O
after	O
treatment	O
within	O
sham	O
and	O
real	O
tDCS	O
groups	O
.	O

Student	O
t	O
tests	O
for	O
independent	O
measures	O
were	O
used	O
for	O
between	O
-	O
group	O
comparisons	O
considering	O
the	O
extension	O
of	O
changes	O
(	O
final	O
–	O
initial	O
)	O
.	O

For	O
Likert	O
-	O
scale	O
data	O
of	O
subjective	O
confidence	O
regarding	O
the	O
treatment	O
they	O
were	O
receiving	O
,	O
the	O
Mann	O
-	O
Whitney	O
test	O
was	O
used	O
for	O
between	O
-	O
group	O
comparison	O
,	O
because	O
these	O
data	O
were	O
not	O
normally	O
distributed	O
(	O
Shapiro	O
-	O
Wilk	O
normality	O
test	O
)	O
.	O

For	O
nonparametric	O
nominal	O
data	O
,	O
chi	O
-	O
square	O
tests	O
were	O
used	O
to	O
compare	O
results	O
between	O
and	O
within	O
sham	O
and	O
real	O
tDCS	O
groups	O
.	O

The	O
amount	O
of	O
crack	O
-	O
rocks	O
consumed	O
per	O
day	O
was	O
missing	O
for	O
5	O
patients	O
,	O
and	O
the	O
days	O
of	O
abstinence	O
data	O
were	O
missing	O
for	O
1	O
patient	O
.	O

These	O
missing	O
data	O
were	O
imputed	O
by	O
linear	O
regression	O
.	O

A	O
2	O
-	O
tailed	O
P	O
≤	O
.	O
05	O
or	O
less	O
was	O
considered	O
to	O
indicate	O
statistical	O
significance	O
.	O

SPSS	O
Statistics	O
Base	O
17	O
.	O
0	O
(	O
SPSS	O
Inc	O
)	O
and	O
GraphPad	O
Prism	O
5	O
.	O
0	O
(	O
GraphPad	O
Software	O
Inc	O
)	O
were	O
employed	O
for	O
statistical	O
analysis	O
and	O
graphic	O
presentations	O
.	O

This	O
cross	O
-	O
sectional	O
,	O
observational	O
,	O
case	O
control	O
study	O
was	O
approved	O
by	O
the	O
Independent	O
Review	O
Boards	O
at	O
the	O
Penn	O
State	O
College	O
of	O
Medicine	O
and	O
the	O
State	O
University	O
of	O
New	O
York	O
Upstate	O
Medical	O
University	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
of	O
all	O
children	O
who	O
participated	O
in	O
the	O
study	O
.	O

Children	O
ages	O
2–6	O
years	O
(	O
n	O
=	O
346	O
)	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Participants	O
were	O
divided	O
into	O
three	O
groups	O
(	O
ASD	O
,	O
n	O
=	O
180	O
;	O
TD	O
,	O
n	O
=	O
106	O
;	O
DD	O
,	O
n	O
=	O
60	O
)	O
based	O
on	O
developmental	O
status	O
.	O

ASD	O
was	O
defined	O
by	O
a	O
clinician	O
consensus	O
diagnosis	O
,	O
using	O
criteria	O
specified	O
in	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
the	O
American	O
Psychiatric	O
Association	O
,	O
Fifth	O
Edition	O
(	O
DSM	O
-	O
5	O
)	O
.	O

TD	O
participants	O
included	O
children	O
with	O
negative	O
ASD	O
screening	O
on	O
the	O
Modified	O
Checklist	O
for	O
Autism	O
in	O
Toddlers—Revised	O
,	O
and	O
children	O
who	O
met	O
typical	O
developmental	O
milestones	O
on	O
standardized	O
physician	O
assessment	O
(	O
e	O
.	O
g	O
.	O
,	O
survey	O
of	O
well	O
-	O
being	O
in	O
young	O
children	O
;	O
parents’	O
evaluation	O
of	O
developmental	O
status	O
)	O
.	O

The	O
DD	O
group	O
included	O
children	O
with	O
an	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
of	O
DD	B-phenotype
(	I-phenotype
e	I-phenotype
.	I-phenotype
g	I-phenotype
.	I-phenotype
,	I-phenotype
expressive	I-phenotype
speech	I-phenotype
delay	I-phenotype
,	I-phenotype
intellectual	I-phenotype
disability	I-phenotype
,	I-phenotype
behavioral	I-phenotype
concern	I-phenotype
)	I-phenotype
who	O
did	O
not	O
meet	O
DSM	B-coding_system
-	I-coding_system
5	I-coding_system
criteria	O
for	O
ASD	B-phenotype
on	O
clinician	O
assessment	O
.	O

Children	O
with	O
feeding	O
tube	O
dependence	O
,	O
active	O
tooth	O
decay	O
,	O
fever	O
,	O
upper	O
respiratory	O
infection	O
,	O
or	O
current	O
use	O
of	O
oral	O
antibiotics	O
were	O
excluded	O
from	O
all	O
groups	O
.	O

Children	O
with	O
a	O
family	O
history	O
of	O
ASD	O
in	O
a	O
first	O
degree	O
relative	O
or	O
a	O
chronic	O
medical	O
condition	O
requiring	O
routine	O
care	O
by	O
a	O
pediatric	O
specialist	O
were	O
excluded	O
from	O
the	O
TD	O
group	O
.	O

Phenotypic	O
subgroup	O
analysis	O
examined	O
ASD	O
children	O
with	O
:	O
(	O
a	O
)	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
;	O
n	O
=	O
43	O
)	O
or	O
(	O
b	O
)	O
GI	O
disturbance	O
(	O
n	O
=	O
39	O
)	O
relative	O
to	O
ASD	O
children	O
without	O
the	O
given	O
comorbidity	O
.	O

ADHD	O
was	O
identified	O
through	O
parental	O
survey	O
,	O
which	O
asked	O
“Does	O
your	O
child	O
have	O
a	O
diagnosis	O
of	O
ADHD	O
/	O
ADD	O
?	O
”	O
Positive	O
answers	O
were	O
confirmed	O
by	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
(	O
F90	B-code
.	I-code
0	I-code
)	O
,	O
or	O
stimulant	O
medication	O
(	O
e	O
.	O
g	O
.	O
,	O
methylphenidate	O
-	O
based	O
prescription	O
)	O
on	O
chart	O
review	O
when	O
possible	O
.	O

GI	O
disturbance	O
was	O
defined	O
as	O
constipation	B-phenotype
(	O
K59	B-code
.	I-code
0	I-code
)	O
,	O
gastroesophageal	B-phenotype
reflux	I-phenotype
(	O
K21	B-code
)	O
,	O
chronic	B-phenotype
abdominal	I-phenotype
pain	I-phenotype
(	O
R10	B-code
)	O
,	O
food	B-phenotype
sensitivities	I-phenotype
(	O
T78	B-code
.	I-code
1	I-code
)	O
,	O
or	O
recurrent	B-phenotype
diarrhea	I-phenotype
(	O
K59	B-code
.	I-code
1	I-code
,	O
R19	B-code
.	I-code
7	I-code
)	O
reported	O
by	O
parental	O
survey	O
and	O
confirmed	O
through	O
chart	O
review	O
of	O
associated	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
codes	O
.	O

Parents	O
of	O
all	O
participants	O
were	O
administered	O
a	O
child	O
medical	O
/	O
demographic	O
survey	O
and	O
the	O
Vineland	O
Adaptive	O
Behavior	O
Scale—Second	O
Edition	O
(	O
VABS	O
-	O
II	O
)	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Most	O
of	O
the	O
ASD	O
(	O
n	O
=	O
138	O
)	O
and	O
DD	O
participants	O
(	O
n	O
=	O
21	O
)	O
were	O
administered	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule—Second	O
Edition	O
(	O
ADOS	O
-	O
2	O
)	O
,	O
or	O
previous	O
assessment	O
scores	O
were	O
documented	O
through	O
chart	O
review	O
when	O
available	O
.	O

ADOS	O
-	O
2	O
administration	O
was	O
performed	O
by	O
a	O
trained	O
certified	O
health	O
professional	O
.	O

The	O
participant	O
characteristics	O
that	O
were	O
collected	O
included	O
:	O
(	O
a	O
)	O
demographic	O
information	O
(	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
body	O
mass	O
index	O
)	O
;	O
(	O
b	O
)	O
oral	O
/	O
GI	O
factors	O
(	O
time	O
of	O
collection	O
,	O
time	O
of	O
last	O
meal	O
,	O
time	O
of	O
last	O
tooth	O
brushing	O
,	O
probiotic	O
use	O
,	O
history	O
of	O
GI	O
disturbance	O
,	O
medical	O
/	O
food	O
allergies	O
,	O
dietary	O
restrictions	O
)	O
;	O
and	O
(	O
c	O
)	O
medical	O
history	O
(	O
birth	O
age	O
,	O
birth	O
delivery	O
route	O
,	O
birth	O
weight	O
,	O
asthma	O
status	O
,	O
vaccination	O
status	O
)	O
.	O

These	O
factors	O
were	O
selected	O
based	O
on	O
potential	O
relevance	O
to	O
the	O
profile	O
of	O
the	O
oral	O
microbiome	O
.	O

Saliva	O
was	O
collected	O
from	O
each	O
participant	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Following	O
an	O
oral	O
water	O
rinse	O
,	O
an	O
ORAcollect	O
swab	O
(	O
DNA	O
Genotek	O
,	O
Ottawa	O
,	O
Canada	O
)	O
was	O
used	O
to	O
obtain	O
saliva	O
from	O
the	O
sublingual	O
and	O
parotid	O
regions	O
of	O
the	O
mouth	O
in	O
a	O
nonfasting	O
state	O
,	O
at	O
least	O
15	O
min	O
after	O
the	O
most	O
recent	O
consumption	O
of	O
food	O
or	O
drink	O
.	O

Swabs	O
were	O
stored	O
at	O
−20°C	O
prior	O
to	O
processing	O
at	O
the	O
State	O
University	O
of	O
New	O
York	O
Upstate	O
Molecular	O
Analysis	O
Core	O
Facility	O
.	O

Salivary	O
RNA	O
was	O
extracted	O
using	O
a	O
standard	O
Trizol	O
technique	O
and	O
the	O
RNeasy	O
mini	O
column	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Yield	O
and	O
quality	O
of	O
RNA	O
was	O
checked	O
with	O
an	O
Agilent	O
Bioanalyzer	O
prior	O
to	O
library	O
construction	O
and	O
quantification	O
with	O
next	O
generation	O
sequencing	O
.	O

Multiplexed	O
samples	O
were	O
processed	O
on	O
a	O
NextSeq	O
500	O
Instrument	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
at	O
a	O
targeted	O
depth	O
of	O
10	O
million	O
single	O
end	O
50	O
base	O
reads	O
per	O
sample	O
.	O

After	O
adapter	O
trimming	O
and	O
quality	O
control	O
analysis	O
,	O
RNA	O
reads	O
were	O
aligned	O
to	O
the	O
Human	O
Microbiome	O
Database	O
using	O
k	O
-	O
SLAM	O
software	O
.	O

Sequence	O
alignment	O
with	O
the	O
k	O
-	O
mer	O
method	O
was	O
used	O
for	O
comprehensive	O
taxonomic	O
classification	O
and	O
identification	O
of	O
microbial	O
genes	O
,	O
as	O
previously	O
described	O
[	O
Ainsworth	O
,	O
Sternberg	O
,	O
Raczy	O
,	O
&	O
Butcher	O
,	O
2017	O
]	O
.	O

Only	O
taxa	O
with	O
raw	O
read	O
counts	O
of	O
10	O
or	O
more	O
in	O
at	O
least	O
20	O
%	O
of	O
samples	O
were	O
interrogated	O
for	O
differential	O
abundance	O
.	O

Individual	O
RNA	O
transcripts	O
were	O
not	O
subjected	O
to	O
analysis	O
.	O

Instead	O
,	O
we	O
interrogated	O
the	O
pathways	O
and	O
ontologies	O
represented	O
by	O
the	O
community	O
of	O
microbial	O
transcripts	O
through	O
cross	O
-	O
referencing	O
the	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
microbial	O
database	O
using	O
MicrobiomAnalyst	O
software	O
.	O

This	O
database	O
consists	O
of	O
82	O
KEGG	O
Ontology	O
(	O
KO	O
)	O
Pathway	O
sets	O
,	O
11	O
KEGG	O
Metabolism	O
sets	O
,	O
and	O
20	O
Clusters	O
of	O
Orthologous	O
Groups	O
Function	O
sets	O
.	O

Mapping	O
was	O
limited	O
to	O
those	O
transcripts	O
present	O
at	O
raw	O
read	O
counts	O
of	O
five	O
or	O
more	O
in	O
at	O
least	O
10	O
%	O
of	O
samples	O
.	O

Both	O
taxonomic	O
and	O
pathway	O
level	O
data	O
were	O
analyzed	O
for	O
differences	O
between	O
groups	O
following	O
quantile	O
normalization	O
,	O
using	O
MetaboAnalyst	O
software	O
[	O
Dhariwal	O
et	O
al	O
.	O
,	O
2017	O
]	O
to	O
perform	O
nonparametric	O
comparisons	O
of	O
the	O
observed	O
abundance	O
counts	O
between	O
groups	O
.	O

These	O
data	O
sets	O
will	O
be	O
made	O
publicly	O
available	O
on	O
the	O
NCBI	O
Sequence	O
Read	O
Archive	O
following	O
acceptance	O
for	O
publication	O
.	O

Differences	O
in	O
medical	O
,	O
demographic	O
,	O
and	O
neuropsychological	O
characteristics	O
between	O
ASD	O
and	O
TD	O
or	O
DD	O
groups	O
were	O
assessed	O
with	O
a	O
two	O
-	O
tailed	O
Student’s	O
t	O
test	O
,	O
with	O
significant	O
differences	O
defined	O
by	O
an	O
uncorrected	O
P	O
<	O
0	O
.	O
05	O
.	O

Taxa	O
with	O
the	O
greatest	O
abundance	O
(	O
present	O
in	O
the	O
largest	O
concentrations	O
)	O
and	O
prevalence	O
(	O
present	O
in	O
the	O
largest	O
number	O
of	O
samples	O
)	O
were	O
reported	O
at	O
the	O
species	O
and	O
phylum	O
levels	O
.	O

The	O
Shannon	O
alpha	O
diversity	O
index	O
and	O
Bray–Curtiss	O
index	O
of	O
beta	O
diversity	O
(	O
homogeneity	O
of	O
group	O
dispersions	O
method	O
)	O
were	O
calculated	O
from	O
the	O
taxonomic	O
profiles	O
and	O
compared	O
across	O
the	O
three	O
groups	O
.	O

Differential	O
taxon	O
expression	O
across	O
all	O
participants	O
was	O
visualized	O
with	O
a	O
multivariate	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(	O
PLS	O
-	O
DA	O
)	O
and	O
variable	O
importance	O
in	O
projection	O
was	O
determined	O
for	O
each	O
taxon	O
.	O

Individual	O
taxa	O
differences	O
among	O
the	O
three	O
groups	O
were	O
investigated	O
with	O
nonparametric	O
Kruskal–Wallis	O
testing	O
,	O
followed	O
by	O
posthoc	O
between	O
group	O
comparisons	O
(	O
ASD	O
:	O
TD	O
or	O
ASD	O
:	O
DD	O
)	O
with	O
a	O
Mann–Whitney	O
U	O
test	O
.	O

Differences	O
in	O
KEGG	O
pathway	O
transcripts	O
between	O
diagnostic	O
groups	O
were	O
evaluated	O
using	O
a	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
with	O
a	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
correction	O
for	O
multiple	O
testing	O
set	O
at	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Post	O
hoc	O
testing	O
was	O
performed	O
between	O
all	O
three	O
groups	O
using	O
a	O
Tukey’s	O
Honestly	O
Significantly	O
Difference	O
test	O
.	O

Taxon	O
associations	O
with	O
a	O
predefined	O
set	O
of	O
ASD	O
endophenotypes	O
were	O
assessed	O
as	O
follows	O
:	O
(	O
a	O
)	O
taxon	O
differences	O
between	O
ASD	O
participants	O
with	O
/	O
without	O
GI	O
disturbance	O
;	O
or	O
with	O
/	O
without	O
ADHD	O
were	O
examined	O
with	O
a	O
nonparametric	O
Mann–Whitney	O
U	O
test	O
.	O

(	O
b	O
)	O
ASD	O
participants	O
were	O
divided	O
into	O
three	O
adaptive	O
behavior	O
groups	O
(	O
0	O
-	O
,	O
1	O
-	O
,	O
or	O
2	O
-	O
SD	O
below	O
the	O
mean	O
value	O
of	O
100	O
)	O
for	O
Communication	O
,	O
Socialization	O
,	O
and	O
Activities	O
of	O
Daily	O
Living	O
subscales	O
of	O
the	O
VABS	O
-	O
II	O
.	O

A	O
three	O
group	O
comparison	O
was	O
chosen	O
to	O
differentiate	O
ASD	O
participants	O
with	O
“minimal	O
,	O
”	O
“moderate	O
,	O
”	O
and	O
“severe”	O
impairment	O
within	O
each	O
subdomain	O
,	O
in	O
light	O
of	O
previous	O
reports	O
that	O
the	O
GI	O
microbiome	O
differed	O
among	O
children	O
with	O
varying	O
autism	O
severity	O
[	O
Finegold	O
et	O
al	O
.	O
,	O
2010	O
]	O
.	O

Between	O
-	O
groups	O
taxonomic	O
differences	O
were	O
assessed	O
with	O
nonparametric	O
Kruskal–Wallis	O
testing	O
for	O
the	O
three	O
VABS	O
-	O
II	O
categories	O
.	O

(	O
c	O
)	O
Relationships	O
between	O
autistic	O
behavior	O
measures	O
on	O
the	O
ADOS	O
-	O
2	O
(	O
Social	O
Affect	O
,	O
Restrictive	O
/	O
Repetitive	O
Behavior	O
,	O
and	O
Comparison	O
Score	O
)	O
and	O
oral	O
taxon	O
activity	O
were	O
assessed	O
with	O
Pearson’s	O
correlations	O
.	O

Factors	O
with	O
Benjamini–Hochberg	O
FDR	O
correction	O
<	O
0	O
.	O
05	O
were	O
reported	O
for	O
each	O
phenotype	O
-	O
taxonomic	O
comparison	O
.	O

Relationships	O
between	O
oral	O
microbe	O
activity	O
,	O
metabolomic	O
pathways	O
(	O
KEGG	O
IDs	O
)	O
,	O
and	O
clinical	O
characteristics	O
were	O
assessed	O
with	O
Pearson’s	O
correlation	O
(	O
for	O
continuous	O
variables	O
)	O
or	O
Spearman’s	O
rank	O
test	O
(	O
for	O
dichotomous	O
variables	O
)	O
.	O

Diagnostic	O
accuracies	O
of	O
taxon	O
levels	O
in	O
the	O
oral	O
microbiome	O
were	O
assessed	O
with	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
comparing	O
:	O
(	O
a	O
)	O
ASD	O
:	O
TD	O
;	O
(	O
b	O
)	O
ASD	O
:	O
DD	O
;	O
and	O
(	O
c	O
)	O
GI	O
disturbance	O
phenotypes	O
across	O
diagnoses	O
.	O

Classification	O
accuracy	O
was	O
visualized	O
with	O
a	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
,	O
using	O
the	O
first	O
50	O
%	O
of	O
samples	O
from	O
each	O
group	O
(	O
chosen	O
at	O
random	O
)	O
and	O
a	O
10	O
-	O
fold	O
cross	O
-	O
validation	O
procedure	O
.	O

The	O
remaining	O
50	O
%	O
of	O
samples	O
were	O
used	O
to	O
validate	O
the	O
predictive	O
model	O
for	O
each	O
comparison	O
.	O

Area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
calculated	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
reported	O
.	O

PsyCourse	O
is	O
an	O
ongoing	O
multicenter	O
study	O
,	O
conducted	O
by	O
a	O
network	O
of	O
clinical	O
sites	O
in	O
Germany	O
and	O
Austria	O
.	O

At	O
the	O
time	O
of	O
writing	O
,	O
18	O
different	O
clinical	O
centers	O
participated	O
in	O
data	O
collection	O
of	O
clinical	O
participants	O
,	O
two	O
of	O
which	O
additionally	O
collect	O
data	O
from	O
nonclinical	O
(	O
control	O
)	O
individuals	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
respective	O
ethics	O
committee	O
for	O
each	O
study	O
center	O
and	O
was	O
carried	O
out	O
following	O
the	O
rules	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
of	O
1975	O
,	O
revised	O
in	O
2008	O
.	O

Initially	O
,	O
the	O
project	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
Medical	O
Center	O
Goettingen	O
.	O

Some	O
clinical	O
centers	O
were	O
teaching	O
hospitals	O
of	O
the	O
University	O
Medical	O
Center	O
Goettingen	O
,	O
and	O
were	O
thus	O
covered	O
by	O
this	O
initial	O
approval	O
.	O

For	O
those	O
clinical	O
sites	O
that	O
were	O
not	O
covered	O
,	O
we	O
obtained	O
additional	O
approval	O
from	O
the	O
respective	O
Ethics	O
Committees	O
.	O

For	O
all	O
centers	O
,	O
these	O
were	O
(	O
clinical	O
centers	O
in	O
parentheses	O
)	O
:	O
Ethics	O
Committees	O
of	O
the	O
University	O
Medical	O
Center	O
Goettingen	O
(	O
UMG	O
Goettingen	O
,	O
Bad	O
Zwischenahn	O
,	O
Eschwege	O
,	O
Asklepios	O
Specialized	O
Hospital	O
Goettingen	O
,	O
Hildesheim	O
,	O
Lüneburg	O
,	O
Liebenburg	O
,	O
Osnabrück	O
,	O
Rotenburg	O
,	O
Tiefenbrunn	O
,	O
Wilhemshaven	O
)	O
,	O
Medical	O
Faculty	O
of	O
the	O
LMU	O
Munich	O
(	O
Munich	O
and	O
Augsburg	O
)	O
,	O
Medical	O
Faculty	O
of	O
the	O
RU	O
Bochum	O
(	O
Bochum	O
)	O
,	O
Medical	O
Association	O
Bremen	O
(	O
Bremen	O
Ost	O
)	O
,	O
Medical	O
University	O
of	O
Graz	O
(	O
Graz	O
)	O
,	O
Ulm	O
University	O
(	O
Günzburg	O
)	O
and	O

Medical	O
Association	O
Westfalen‐Lippe	O
and	O
Medical	O
Faculty	O
University	O
of	O
Münster	O
(	O
Münster	O
)	O
.	O

Study	O
participants	O
are	O
assessed	O
at	O
four	O
points	O
in	O
time	O
,	O
in	O
intervals	O
of	O
6	O
months	O
,	O
hereafter	O
referred	O
to	O
as	O
study	O
visits	O
1	O
(	O
T1	O
;	O
baseline	O
)	O
,	O
2	O
(	O
T2	O
;	O
+	O
6	O
months	O
)	O
,	O
3	O
(	O
T3	O
;	O
+	O
12	O
months	O
)	O
,	O
and	O
4	O
(	O
T4	O
;	O
+	O
18	O
months	O
)	O
.	O

Additional	O
visits	O
should	O
be	O
conducted	O
for	O
clinical	O
participants	O
if	O
they	O
are	O
readmitted	O
for	O
inpatient	O
treatment	O
during	O
the	O
study	O
period	O
.	O

Importantly	O
,	O
participating	O
individuals	O
are	O
allowed	O
to	O
miss	O
one	O
or	O
more	O
follow‐up	O
study	O
visits	O
without	O
being	O
excluded	O
from	O
the	O
study	O
.	O

At	O
each	O
study	O
visit	O
,	O
venous	O
blood	O
samples	O
are	O
collected	O
,	O
permitting	O
extraction	O
of	O
biomaterials	O
such	O
as	O
DNA	O
,	O
RNA	O
,	O
plasma	O
,	O
and	O
serum	O
.	O

In	O
addition	O
,	O
a	O
comprehensive	O
set	O
of	O
phenotype	O
data	O
is	O
collected	O
,	O
assessing	O
symptom	O
dimensions	O
,	O
cognitive	O
function	O
,	O
and	O
self‐report	O
measures	O
(	O
Supporting	O
Information	O
Table	O
1	O
;	O
Altman	O
,	O
Hedeker	O
,	O
Peterson	O
,	O
&	O
Davis	O
,	O
1997	O
;	O
American	O
Psychiatric	O
Association	O
,	O
2002	O
;	O
Angermeyer	O
,	O
Kilian	O
,	O
&	O
Matschinger	O
,	O
2000	O
;	O
Army	O
Individual	O
Test	O
Battery	O
,	O
1944	O
;	O
Aster	O
,	O
Neubauer	O
&	O
Horn	O
,	O
2006	O
;	O
McGuffin	O
,	O
Farmer	O
,	O
&	O
Harvey	O
,	O
1991	O
;	O
Grabe	O
et	O
al	O
.	O
,	O
2012	O
;	O
Grof	O
et	O
al	O
.	O
,	O
2002	O
;	O
Hautzinger	O
,	O
Keller	O
,	O
&	O
Kühner	O
,	O
2006	O
;	O
Helmstaedter	O
,	O
Lendt	O
,	O

&	O
Lux	O
,	O
2001	O
;	O
Kay	O
,	O
Fiszbein	O
,	O
&	O
Opler	O
,	O
1987	O
;	O
Konings	O
,	O
Bak	O
,	O
Hanssen	O
,	O
van	O
Os	O
,	O
&	O
Krabbendam	O
,	O
2006	O
;	O
Krüger	O
,	O
Bräunig	O
,	O
&	O
Shugar	O
,	O
1997	O
;	O
Lehrl	O
,	O
2005	O
;	O
Margraf	O
,	O
1994	O
;	O
McGuffin	O
,	O
Farmer	O
,	O
&	O
Harvey	O
,	O
1991	O
;	O
National	O
Institute	O
of	O
Mental	O
Health	O
,	O
1976	O
;	O
Norbeck	O
,	O
1984	O
;	O
Rammstedt	O
&	O
John	O
,	O
2007	O
;	O
Rush	O
,	O
Carmody	O
,	O
&	O
Reimitz	O
,	O
2000	O
;	O
Stefanis	O
et	O
al	O
.	O
,	O
2002	O
;	O
Ware	O
,	O
Kosinski	O
,	O
&	O
Keller	O
,	O
1996	O
;	O
Wittchen	O
&	O
Fydrich	O
,	O
1997	O
;	O
Young	O
,	O
Biggs	O
,	O
Ziegler	O
,	O
&	O
Meyer	O
,	O
1978	O
)	O
.	O

Adult	O
patients	O
(	O
≥18	O
years	O
)	O
,	O
with	O
an	O
ICD‐10	B-coding_system
life‐time	O
diagnosis	O
of	O
SZ	B-phenotype
(	O
F20	B-code
.	I-code
x	I-code
)	O
,	O
brief	B-phenotype
psychotic	I-phenotype
disorder	I-phenotype
(	O
F23	B-code
.	I-code
x	I-code
)	O
,	O
schizo‐affective	B-phenotype
disorder	I-phenotype
(	I-phenotype
SZA	I-phenotype
;	O
F25	B-code
.	I-code
x	I-code
)	O
,	O
BD	B-phenotype
(	O
F31	B-code
.	I-code
x	I-code
)	O
,	O
manic	B-phenotype
episode	I-phenotype
(	O
F30	B-code
.	I-code
x	I-code
)	O
,	O
or	O
recurrent	B-phenotype
major	I-phenotype
depression	I-phenotype
(	I-phenotype
reMDD	I-phenotype
;	O
F33	B-code
.	I-code
x	I-code
)	O
are	O
identified	O
based	O
on	O
recommendations	O
of	O
the	O
clinical	O
staff	O
or	O
by	O
querying	O
patient	O
registries	O
of	O
the	O
participating	O
clinical	O
centers	O
.	O

Eligible	O
individuals	O
are	O
invited	O
to	O
participate	O
in	O
the	O
first	O
study	O
visit	O
(	O
T1	O
)	O
,	O
where	O
,	O
after	O
giving	O
informed	O
consent	O
(	O
see	O
below	O
)	O
,	O
their	O
diagnosis	O
is	O
reassessed	O
within	O
the	O
DSM‐IV	B-coding_system
framework	O
using	O
an	O
adapted	O
version	O
of	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM‐IV	B-coding_system
;	O
Axis	O
I	O
Disorders	O
(	O
SCID‐I	O
;	O
Wittchen	O
&	O
Fydrich	O
,	O
1997	O
)	O
.	O

Participants	O
with	O
a	O
life‐time	O
DSM‐IV	B-coding_system
diagnosis	O
of	O
SZ	B-phenotype
(	O
295	B-code
.	I-code
10	I-code
/	I-code
295	I-code
.	I-code
20	I-code
/	I-code
295	I-code
.	I-code
30	I-code
/	I-code
295	I-code
.	I-code
60	I-code
/	I-code
295	I-code
.	I-code

90	I-code
)	O
or	O
schizophreniform	B-phenotype
disorder	I-phenotype
(	O
295	B-code
.	I-code
40	I-code
)	O
,	O
brief	B-phenotype
psychotic	I-phenotype
disorder	I-phenotype
(	O
298	B-code
.	I-code
8	I-code
)	O
,	O
or	O
SZA	B-phenotype
(	O
295	B-code
.	I-code
70	I-code
)	O
constitute	O
the	O
group	O
with	O
predominantly	O
psychotic	O
symptoms	O
,	O
whereas	O
those	O
with	O
a	O
life‐time	O
DSM‐IV	B-coding_system
diagnosis	O
of	O
BD	B-phenotype
(	O
296	B-code
.	I-code
0x	I-code
/	I-code
296	I-code
.	I-code
4x	I-code
/	I-code
296	I-code
.	I-code
5x	I-code
/	I-code
296	I-code
.	I-code
6x	I-code
/	I-code
296	I-code
.	I-code
8x	I-code
)	O
or	O
reMDD	B-phenotype
(	O
296	B-code
.	I-code
3x	I-code
)	O
constitute	O
the	O
predominantly	O
affective	O
group	O
.	O

If	O
none	O
of	O
the	O
above	O
DSM‐IV	B-coding_system
diagnoses	O
can	O
be	O
ascertained	O
,	O
clinical	O
participants	O
are	O
excluded	O
from	O
the	O
study	O
.	O

Participants	O
must	O
be	O
proficient	O
in	O
German	O
language	O
to	O
enroll	O
in	O
the	O
study	O
.	O

Inhabitants	O
of	O
the	O
catchment	O
areas	O
of	O
Göttingen	O
and	O
Munich	O
are	O
contacted	O
either	O
by	O
mail	O
,	O
based	O
on	O
address	O
lists	O
acquired	O
from	O
the	O
local	O
Residents’	O
Registration	O
Office	O
,	O
or	O
by	O
advertisements	O
in	O
public	O
areas	O
and	O
are	O
invited	O
to	O
participate	O
in	O
the	O
study	O
.	O

Individuals	O
must	O
be	O
proficient	O
in	O
German	O
language	O
to	O
enroll	O
in	O
the	O
study	O
.	O

Those	O
included	O
in	O
the	O
study	O
follow	O
a	O
similar	O
protocol	O
as	O
the	O
clinical	O
participants	O
(	O
see	O
Supporting	O
Information	O
Table	O
1	O
)	O
.	O

History	O
of	O
affective	O
or	O
psychotic	O
illness	O
is	O
assessed	O
using	O
a	O
short	O
diagnostic	O
interview	O
for	O
mental	O
disorders	O
(	O
Margraf	O
,	O
1994	O
)	O
.	O

Before	O
study	O
participation	O
,	O
written	O
informed	O
consent	O
is	O
obtained	O
from	O
study	O
participants	O
.	O

A	O
special	O
broad	O
informed	O
consent	O
is	O
required	O
from	O
participants	O
,	O
as	O
the	O
exact	O
research	O
objectives	O
are	O
not	O
specified	O
and	O
both	O
phenotypic	O
data	O
and	O
biomaterial	O
are	O
to	O
be	O
stored	O
until	O
they	O
are	O
no	O
longer	O
useful	O
for	O
research	O
(	O
German	O
National	O
Ethics	O
Council	O
,	O
2004	O
)	O
.	O

According	O
to	O
European	O
and	O
German	O
law	O
,	O
such	O
broad	O
informed	O
consent	O
is	O
only	O
possible	O
if	O
special	O
data	O
protection	O
measures	O
are	O
taken	O
to	O
shield	O
personal	O
data	O
from	O
unauthorized	O
access	O
(	O
see	O
Section	O
2	O
.	O
1	O
.	O

5	O
on	O
data	O
protection	O
)	O
.	O

Participating	O
individuals	O
must	O
explicitly	O
agree	O
to	O
these	O
measures	O
,	O
if	O
they	O
want	O
to	O
participate	O
in	O
the	O
study	O
.	O

In	O
addition	O
,	O
potential	O
participants	O
must	O
decide	O
whether	O
they	O
want	O
to	O
be	O
informed	O
about	O
possible	O
incidental	O
findings	O
that	O
the	O
study	O
may	O
uncover	O
.	O

Collaboration	O
with	O
nonpsychiatric	O
research	O
disciplines	O
and	O
the	O
possibility	O
to	O
jointly	O
analyze	O
data	O
together	O
with	O
other	O
researchers	O
or	O
research	O
consortia	O
is	O
explicitly	O
allowed	O
,	O
albeit	O
only	O
using	O
pseudonymized	O
data	O
.	O

Furthermore	O
,	O
participants	O
are	O
asked	O
to	O
release	O
medical	O
facilities	O
involved	O
in	O
their	O
prior	O
treatment	O
from	O
doctor–patient	O
confidentiality	O
,	O
so	O
that	O
information	O
on	O
their	O
past	O
medical	O
records	O
can	O
be	O
obtained	O
.	O

This	O
serves	O
as	O
an	O
additional	O
source	O
of	O
information	O
on	O
their	O
medical	O
history	O
.	O

If	O
a	O
participant	O
decides	O
to	O
opt‐out	O
after	O
enrolling	O
in	O
the	O
study	O
,	O
two	O
options	O
exist	O
:	O
Disposal	O
of	O
the	O
participant	O
'	O
s	O
biomaterial	O
and	O
permanent	O
deletion	O
of	O
all	O
phenotypic	O
data	O
,	O
or	O
All	O
information	O
collected	O
until	O
that	O
point	O
in	O
time	O
will	O
be	O
retained	O
but	O
irreversibly	O
anonymized	O
.	O

Disposal	O
of	O
the	O
participant	O
'	O
s	O
biomaterial	O
and	O
permanent	O
deletion	O
of	O
all	O
phenotypic	O
data	O
,	O
or	O

All	O
information	O
collected	O
until	O
that	O
point	O
in	O
time	O
will	O
be	O
retained	O
but	O
irreversibly	O
anonymized	O
.	O

Data	O
that	O
are	O
already	O
part	O
of	O
scientific	O
analyses	O
at	O
the	O
time	O
of	O
the	O
opt‐out	O
may	O
be	O
used	O
further	O
,	O
regardless	O
of	O
the	O
opt‐out	O
,	O
albeit	O
only	O
in	O
anonymized	O
form	O
.	O

As	O
we	O
collect	O
sensitive	O
phenotypic	O
data	O
and	O
biomaterials	O
,	O
a	O
data	O
protection	O
concept	O
was	O
developed	O
(	O
Demiroglu	O
et	O
al	O
.	O
,	O
2012	O
)	O
.	O

Briefly	O
,	O
it	O
includes	O
an	O
array	O
of	O
organizational	O
measures	O
such	O
as	O
pseudonymization	O
to	O
minimize	O
the	O
risk	O
of	O
participant	O
identification	O
and	O
unauthorized	O
transmission	O
of	O
personal	O
data	O
to	O
third	O
parties	O
.	O

Four	O
different	O
IT	O
components	O
have	O
been	O
established	O
by	O
the	O
Department	O
of	O
Medical	O
Informatics	O
at	O
the	O
University	O
Medical	O
Center	O
,	O
Göttingen	O
,	O
Germany	O
(	O
see	O
Supporting	O
Information	O
Figure	O
1	O
)	O
:	O
The	O
identity	O
tool	O
,	O
responsible	O
for	O
storing	O
the	O
identifying	O
data	O
and	O
for	O
generating	O
two	O
different	O
pseudonyms	O
.	O

The	O
administrative	O
tool	O
,	O
for	O
managing	O
study	O
organization	O
,	O
informed	O
consent	O
,	O
and	O
communication	O
with	O
the	O
study	O
participants	O
(	O
linked	O
to	O
the	O
identity	O
tool	O
)	O
.	O

The	O
phenotype	O
database	O
,	O
containing	O
information	O
collected	O
using	O
rating	O
scales	O
,	O
questionnaires	O
,	O
and	O
cognitive	O
tests	O
.	O

The	O
biomaterial	O
database	O
for	O
administering	O
the	O
collected	O
biological	O
samples	O
.	O

The	O
identity	O
tool	O
,	O
responsible	O
for	O
storing	O
the	O
identifying	O
data	O
and	O
for	O
generating	O
two	O
different	O
pseudonyms	O
.	O

The	O
administrative	O
tool	O
,	O
for	O
managing	O
study	O
organization	O
,	O
informed	O
consent	O
,	O
and	O
communication	O
with	O
the	O
study	O
participants	O
(	O
linked	O
to	O
the	O
identity	O
tool	O
)	O
.	O

The	O
phenotype	O
database	O
,	O
containing	O
information	O
collected	O
using	O
rating	O
scales	O
,	O
questionnaires	O
,	O
and	O
cognitive	O
tests	O
.	O

The	O
biomaterial	O
database	O
for	O
administering	O
the	O
collected	O
biological	O
samples	O
.	O

Interviewers	O
are	O
provided	O
with	O
instructions	O
in	O
written	O
form	O
for	O
all	O
instruments	O
and	O
each	O
new	O
interviewer	O
is	O
extensively	O
trained	O
in	O
administering	O
the	O
phenotyping	O
battery	O
by	O
an	O
experienced	O
interviewer	O
.	O

Depending	O
on	O
interviewer	O
experience	O
,	O
training	O
includes	O
discussing	O
the	O
instructions	O
in	O
detail	O
,	O
watching	O
an	O
experienced	O
investigator	O
conducting	O
a	O
visit	O
and	O
performing	O
a	O
visit	O
under	O
supervision	O
of	O
the	O
latter	O
.	O

In	O
addition	O
,	O
trainings	O
for	O
all	O
investigators	O
are	O
held	O
on	O
a	O
regular	O
basis	O
.	O

Clinical	O
data	O
presented	O
herein	O
are	O
from	O
a	O
snapshot	O
of	O
the	O
phenotype	O
database	O
taken	O
on	O
September	O
19th	O
,	O
2016	O
and	O
include	O
a	O
total	O
of	O
891	O
clinical	O
participants	O
.	O

Regarding	O
biomaterial	O
,	O
venous	O
blood	O
samples	O
were	O
collected	O
at	O
each	O
study	O
visit	O
.	O

Briefly	O
,	O
DNA	O
,	O
RNA	O
,	O
and	O
plasma	O
and	O
serum	O
samples	O
were	O
prepared	O
using	O
standard	O
methods	O
.	O

Data	O
were	O
analyzed	O
using	O
R	O
(	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
,	O
version	O
3	O
.	O
3	O
.	O

2	O
)	O
,	O
and	O
SPSS	O
(	O
IBM	O
,	O
version	O
24	O
)	O
.	O

Cross‐sectional	O
phenotype	O
data	O
were	O
analyzed	O
with	O
Pearson	O
'	O
s	O
chi‐squared	O
and	O
t	O
tests	O
,	O
depending	O
on	O
the	O
type	O
of	O
data	O
(	O
see	O
Table	O
1	O
)	O
.	O

Longitudinal	O
data	O
were	O
analyzed	O
using	O
linear	O
mixed‐effect	O
regression	O
(	O
R	O
package	O
lme4	O
;	O
Bates	O
,	O
Maechler	O
,	O
Bolker	O
,	O
&	O
Walker	O
,	O
2014	O
)	O
.	O

The	O
variables	O
age	O
at	O
first	O
study	O
visit	O
,	O
psychiatric	O
treatment	O
at	O
first	O
study	O
visit	O
(	O
ordinal	O
variable	O
with	O
levels	O
“outpatient	O
/	O
no	O
psychiatric	O
treatment”	O
and	O
“in‐	O
or	O
day	O
patient”	O
)	O
,	O
sex	O
,	O
group	O
,	O
and	O
time	O
as	O
well	O
as	O
interactions	O
between	O
sex	O
,	O
group	O
,	O
and	O
time	O
entered	O
the	O
model	O
as	O
fixed	O
effects	O
.	O

Subject	O
and	O
clinical	O
center	O
of	O
the	O
first	O
study	O
visit	O
were	O
modeled	O
as	O
random	O
intercept	O
effects	O
.	O

To	O
fulfill	O
the	O
requirement	O
of	O
normally	O
distributed	O
residuals	O
,	O
we	O
transformed	O
data	O
of	O
the	O
inventory	O
of	O
depressive	O
symptomatology	O
(	O
IDS‐C	O
30	O
)	O
,	O
the	O
young	O
mania	O
rating	O
scale	O
(	O
YMRS	O
)	O
and	O
the	O
positive	O
and	O
negative	O
syndrome	O
scale	O
(	O
PANSS	O
)	O
positive	O
score	O
using	O
the	O
natural	O
logarithm	O
.	O

Subsequent	O
visual	O
inspection	O
of	O
the	O
residuals	O
of	O
each	O
model	O
did	O
not	O
show	O
any	O
obvious	O
deviation	O
from	O
normality	O
.	O

The	O
ANOVA	O
function	O
in	O
the	O
R	O
lmerTest	O
package	O
(	O
Kuznetsova	O
,	O
Brockhoff	O
,	O
&	O
Christensen	O
,	O
2016	O
)	O
was	O
used	O
to	O
obtain	O
p	O
‐values	O
for	O
fixed	O
effects	O
using	O
Satterthwaite	O
'	O
s	O
approximation	O
of	O
degrees	O
of	O
freedom	O
.	O

p	O
‐Values	O
of	O
the	O
four	O
linear	O
mixed‐effect	O
models	O
were	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
corrected	O
to	O
account	O
for	O
Type‐I	O
error	O
cumulation	O
resulting	O
from	O
multiple	O
comparisons	O
.	O

A	O
coefficient	O
of	O
determination	O
(	O
R	O
2	O
)	O
was	O
calculated	O
for	O
each	O
model	O
with	O
the	O
R	O
r2glmm	O
package	O
(	O
https	O
:	O
/	O
/	O
github	O
.	O
com	O
/	O
bcjaeger	O
/	O
r2glmm	O
)	O
using	O
the	O
Nakagawa	O
and	O
Schielzeth	O
(	O
2013	O
)	O
method	O
.	O

Comparisons	O
between	O
patient	O
groups	O
with	O
predominantly	O
affective	O
versus	O
predominantly	O
psychotic	O
disorders	O
on	O
demographic	O
variables	O
at	O
the	O
first	O
study	O
visit	O
(	O
T1	O
)	O

DF	O
=	O
degrees	O
of	O
freedom	O
.	O

DNA	O
samples	O
of	O
825	O
clinical	O
participants	O
were	O
genotyped	O
using	O
the	O
Illumina	O
Infinium	O
PsychArray	O
(	O
Illumina	O
)	O
,	O
yielding	O
information	O
for	O
approximately	O
590	O
,	O
000	O
genetic	O
markers	O
.	O

More	O
than	O
10	O
%	O
of	O
these	O
markers	O
are	O
in	O
genetic	O
loci	O
previously	O
associated	O
with	O
neuropsychiatric	O
disorders	O
.	O

After	O
standard	O
quality	O
control	O
procedures	O
,	O
genotype	O
imputation	O
was	O
performed	O
using	O
SHAPEIT2	O
(	O
https	O
:	O
/	O
/	O
mathgen	O
.	O
stats	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/	O
genetics	O
_	O
software	O
/	O
shapeit	O
/	O
shapeit	O
.	O
html	O
)	O
and	O
IMPUTE2	O
(	O
http	O
:	O
/	O
/	O
mathgen	O
.	O
stats	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/	O
impute	O
/	O
impute	O
_	O
v2	O
.	O
html	O
;	O
Andlauer	O
et	O
al	O
.	O
,	O
2016	O
;	O
Delaneau	O
,	O
Zagury	O
,	O
&	O
Marchini	O
,	O
2012	O
;	O
Howie	O
,	O
Donnelly	O
,	O
&	O
Marchini	O
,	O
2009	O
)	O
.	O

The	O
1000	O
Genomes	O
project	O
dataset	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
internationalgenome	O
.	O
org	O
/	O
;	O
Phase	O
3	O
integrated	O
variant	O
set	O
)	O
was	O
used	O
as	O
reference	O
panel	O
.	O

Genetic	O
variants	O
with	O
a	O
poor	O
imputation	O
quality	O
(	O
INFO	O
<	O
0	O
.	O
8	O
)	O
were	O
not	O
included	O
in	O
downstream	O
analyses	O
.	O

The	O
EIGENSOFT	O
package	O
(	O
smartPCA	O
;	O
Patterson	O
,	O
Price	O
,	O
&	O
Reich	O
,	O
2006	O
)	O
was	O
used	O
to	O
model	O
ancestry	O
differences	O
between	O
the	O
study	O
participants	O
.	O

It	O
uses	O
a	O
principal	O
component	O
analysis	O
based	O
on	O
a	O
pruned	O
subset	O
of	O
approximately	O
50	O
,	O
000	O
autosomal	O
SNPs	O
,	O
after	O
excluding	O
regions	O
with	O
high	O
linkage	O
disequilibrium	O
.	O

SZ‐PRS	O
were	O
calculated	O
with	O
PLINK	O
1	O
.	O
90	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
cog	O
-	O
genomics	O
.	O
org	O
/	O
plink	O
/	O
1	O
.	O
9	O
)	O
using	O
the	O
imputed	O
genotypes	O
.	O

Briefly	O
,	O
summary	O
statistics	O
from	O
the	O
SZ	O
GWAS	O
of	O
the	O
Psychiatric	O
Genomics	O
Consortium	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
med	O
.	O
unc	O
.	O
edu	O
/	O
pgc	O
;	O
Discovery	O
Sample	O
)	O
were	O
used	O
to	O
ascertain	O
risk	O
variants	O
,	O
their	O
p	O
‐values	O
,	O
and	O
associated	O
odds	O
ratios	O
(	O
ORs	O
;	O
Ripke	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

For	O
this	O
purpose	O
a	O
clumped	O
training	O
dataset	O
of	O
102	O
,	O
636	O
independent	O
SNPs	O
available	O
in	O
the	O
aforementioned	O
website	O
(	O
Psychiatric	O
Genomics	O
Consortium	O
)	O
was	O
used	O
for	O
SZ‐PRS	O
calculations	O
.	O

Our	O
imputed	O
genotyped	O
set	O
had	O
a	O
substantial	O
overlap	O
with	O
the	O
training	O
set	O
(	O
93	O
,	O
700	O
SNPs	O
;	O
91	O
.	O
3	O
%	O
overlap	O
)	O
.	O

In	O
the	O
sample	O
of	O
the	O
present	O
study	O
(	O
Target	O
Sample	O
)	O
,	O
the	O
number	O
of	O
risk	O
alleles	O
carried	O
by	O
an	O
individual	O
(	O
0	O
,	O
1	O
,	O
or	O
2	O
)	O
for	O
each	O
SNP	O
contributing	O
to	O
the	O
PRS	O
,	O
was	O
multiplied	O
by	O
the	O
logarithm	O
of	O
the	O
OR	O
for	O
that	O
particular	O
variant	O
according	O
to	O
the	O
results	O
from	O
the	O
Discovery	O
Sample	O
.	O

The	O
resulting	O
values	O
were	O
summed	O
up	O
in	O
an	O
additive	O
fashion	O
to	O
obtain	O
an	O
estimate	O
of	O
the	O
SZ	O
genetic	O
burden	O
for	O
each	O
individual	O
at	O
11	O
different	O
p	O
‐value	O
thresholds	O
(	O
p	O
≤	O
5	O
*	O
10‐8	O
;	O
p	O
≤	O
.	O
0001	O
;	O
p	O
≤	O
.	O
001	O
;	O
p	O
≤	O
.	O
01	O
;	O
p	O
≤	O
.	O
05	O
;	O
p	O
≤	O
.	O
1	O
;	O
p	O
≤	O
.	O
2	O
;	O
p	O
≤	O
.	O
3	O
;	O
p	O
≤	O
.	O
4	O
;	O
p	O
≤	O
.	O
5	O
;	O
p	O
≤	O
1	O
)	O
.	O

SZ‐PRS	O
do	O
not	O
significantly	O
deviate	O
from	O
normality	O
and	O
were	O
standardized	O
using	O
z‐score	O
transformation	O
.	O

Since	O
two	O
phenotypes	O
(	O
diagnostic	O
group	O
,	O
see	O
Section	O
2	O
.	O
2	O
.	O

5	O
,	O
and	O
follow‐up	O
study	O
participation	O
,	O
see	O
Section	O
2	O
.	O
2	O
.	O

6	O
)	O
were	O
tested	O
for	O
association	O
with	O
SZ‐PRS	O
,	O
all	O
p	O
‐values	O
from	O
these	O
logistic	O
regression	O
models	O
were	O
FDR	O
corrected	O
to	O
account	O
for	O
Type‐I	O
error	O
cumulation	O
resulting	O
from	O
multiple	O
comparisons	O
.	O

Ancestry	O
principal	O
components	O
were	O
calculated	O
specifically	O
for	O
the	O
subsample	O
entering	O
these	O
analyses	O
(	O
for	O
methods	O
see	O
Section	O
2	O
.	O
2	O
.	O

3	O
)	O
to	O
be	O
able	O
to	O
correct	O
for	O
potential	O
effects	O
of	O
population	O
substructure	O
.	O

Blockwise	O
logistic	O
regression	O
analyses	O
were	O
used	O
to	O
estimate	O
the	O
amount	O
of	O
variation	O
of	O
diagnostic	O
group	O
(	O
predominantly	O
affective	O
versus	O
psychotic	O
symptoms	O
)	O
explained	O
by	O
z‐standardized	O
SZ‐PRS	O
at	O
11	O
different	O
p	O
‐value	O
thresholds	O
.	O

Potential	O
confounding	O
variables	O
,	O
namely	O
sex	O
,	O
age	O
at	O
baseline	O
,	O
age	O
2	O
,	O
sex	O
×	O
age	O
interaction	O
as	O
well	O
as	O
the	O
first	O
five	O
ancestry	O
principal	O
components	O
,	O
were	O
entered	O
in	O
the	O
first	O
block	O
.	O

In	O
the	O
second	O
block	O
,	O
the	O
predictor	O
of	O
interest	O
,	O
the	O
respective	O
z‐standardized	O
SZ‐PRS	O
,	O
was	O
added	O
.	O

The	O
reported	O
estimates	O
of	O
change	O
in	O
R	O
2	O
represent	O
the	O
gain	O
in	O
Nagelkerke	O
'	O
s	O
R	O
2	O
by	O
adding	O
SZ‐PRS	O
to	O
the	O
model	O
.	O

As	O
described	O
in	O
Section	O
2	O
.	O
1	O
,	O
study	O
participants	O
are	O
allowed	O
to	O
miss	O
one	O
or	O
more	O
follow‐up	O
study	O
visits	O
without	O
being	O
excluded	O
from	O
the	O
study	O
.	O

To	O
address	O
the	O
question	O
of	O
selective	O
dropouts	O
in	O
the	O
PsyCourse	O
study	O
,	O
subjects	O
with	O
baseline	O
data	O
only	O
,	O
hereafter	O
referred	O
to	O
as	O
the	O
dropout	O
group	O
,	O
were	O
compared	O
to	O
subjects	O
with	O
follow‐up	O
data	O
for	O
at	O
least	O
one	O
timepoint	O
within	O
the	O
18‐month	O
study	O
period	O
,	O
hereafter	O
referred	O
to	O
as	O
the	O
follow‐up	O
group	O
.	O

To	O
assure	O
a	O
valid	O
assignment	O
to	O
these	O
groups	O
in	O
the	O
ongoing	O
project	O
,	O
the	O
study	O
period	O
of	O
18	O
months	O
plus	O
an	O
additional	O
time	O
of	O
5	O
months	O
for	O
data	O
entry	O
were	O
considered	O
.	O

Since	O
the	O
export	O
from	O
the	O
database	O
was	O
carried	O
out	O
on	O
September	O
19th	O
,	O
2016	O
,	O
only	O
subjects	O
with	O
a	O
T1	O
before	O
October	O
19th	O
,	O
2014	O
were	O
selected	O
for	O
these	O
analyses	O
(	O
N	O
=	O
678	O
)	O
.	O

Logistic	O
regression	O
(	O
forced	O
entry	O
method	O
)	O
was	O
used	O
to	O
test	O
the	O
effects	O
of	O
the	O
following	O
phenotypic	O
predictors	O
on	O
group‐membership	O
(	O
dropout	O
group	O
vs	O
.	O
follow‐up	O
group	O
)	O
:	O
sex	O
,	O
age	O
at	O
baseline	O
,	O
age2	O
,	O
age	O
×	O
sex	O
interaction	O
,	O
center	O
,	O
diagnosis	O
,	O
educational	O
status	O
,	O
psychiatric	O
treatment	O
at	O
baseline	O
,	O
duration	O
of	O
illness	O
,	O
PANSS	O
positive	O
score	O
,	O
PANSS	O
negative	O
score	O
,	O
PANSS	O
general	O
score	O
,	O
IDS‐C	O
30	O
sum	O
score	O
,	O
YMRS	O
sum	O
score	O
and	O
global	O
assessment	O
of	O
functioning	O
(	O
GAF	O
)	O
.	O

In	O
a	O
second	O
step	O
,	O
blockwise	O
logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
estimate	O
the	O
effects	O
of	O
SZ‐PRS	O
for	O
11	O
different	O
p	O
‐value	O
thresholds	O
,	O
as	O
explained	O
above	O
.	O

Ancestry	O
principal	O
components	O
were	O
calculated	O
specifically	O
for	O
the	O
subsample	O
entering	O
these	O
analyses	O
(	O
for	O
methods	O
see	O
Section	O
2	O
.	O
2	O
.	O

3	O
)	O
in	O
order	O
to	O
be	O
able	O
to	O
correct	O
for	O
potential	O
effects	O
of	O
population	O
substructure	O
.	O

The	O
significant	O
phenotypic	O
predictors	O
from	O
the	O
previous	O
analyses	O
,	O
namely	O
sex	O
,	O
sex	O
×	O
age	O
interaction	O
and	O
psychiatric	O
treatment	O
at	O
baseline	O
,	O
as	O
well	O
as	O
the	O
first	O
five	O
ancestry	O
principal	O
components	O
were	O
entered	O
as	O
covariates	O
in	O
the	O
first	O
block	O
.	O

In	O
the	O
second	O
block	O
,	O
the	O
respective	O
z‐standardized	O
SZ‐PRS	O
was	O
added	O
as	O
a	O
predictor	O
.	O

Estimates	O
of	O
change	O
in	O
Nagelkerke	O
'	O
s	O
R	O
2	O
relative	O
to	O
the	O
SZ‐PRS	O
are	O
reported	O
.	O

This	O
case	O
-	O
control	O
study	O
is	O
based	O
on	O
a	O
retrospective	O
analysis	O
of	O
administrative	O
claims	O
data	O
taken	O
from	O
the	O
Longitudinal	O
Health	O
Insurance	O
Database	O
2000	O
(	O
LHID2000	O
)	O
.	O

Taiwan	O
began	O
its	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
program	O
in	O
1995	O
to	O
provide	O
affordable	O
and	O
easily	O
accessible	O
medical	O
care	O
for	O
all	O
its	O
citizens	O
(	O
with	O
a	O
copayment	O
of	O
only	O
around	O
US$3	O
~	O
5	O
per	O
outpatient	O
visit	O
)	O
.	O

The	O
LHID2000	O
consists	O
of	O
claims	O
data	O
and	O
registration	O
files	O
of	O
1	O
,	O
000	O
,	O
000	O
individuals	O
randomly	O
sampled	O
from	O
the	O
2000	O
Registry	O
for	O
Beneficiaries	O
(	O
n	O
=	O
23	O
.	O
72	O
million	O
)	O
of	O
the	O
Taiwan	O
NHI	O
program	O
.	O

Many	O
researchers	O
as	O
well	O
as	O
the	O
Taiwan	O
National	O
Health	O
Research	O
Institute	O
have	O
demonstrated	O
the	O
high	O
validity	O
of	O
data	O
derived	O
from	O
the	O
Taiwanese	O
NHI	O
program	O
[	O
18	O
,	O
19	O
]	O
.	O

The	O
LHID2000	O
,	O
which	O
was	O
open	O
to	O
the	O
researchers	O
in	O
Taiwan	O
,	O
was	O
available	O
from	O
the	O
Taiwan	O
National	O
Health	O
Research	O
Institute	O
(	O
http	O
:	O
/	O
/	O
nhird	O
.	O
nhri	O
.	O
org	O
.	O
tw	O
/	O
date	O
_	O
01	O
.	O
html	O
)	O
.	O

This	O
study	O
was	O
approved	O
by	O
institutional	O
review	O
board	O
(	O
IRB	O
)	O
of	O
Taipei	O
Medical	O
University	O
'	O
s	O
IRB	O
(	O
TMU	O
-	O
JIRB	O
201403011	O
)	O
.	O

To	O
select	O
cases	O
for	O
this	O
study	O
,	O
we	O
first	O
identified	O
14	O
,	O
642	O
subjects	O
from	O
the	O
LHID2000	O
who	O
had	O
received	O
a	O
diagnosis	O
of	O
dementia	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
290	B-code
.	I-code
0	I-code
~	I-code
290	I-code
.	I-code

4	I-code
,	O
294	B-code
.	I-code
1	I-code
,	O
331	B-code
.	I-code
0	I-code
~	I-code
331	I-code
.	I-code

2	I-code
,	O
or	O
331	B-code
.	I-code
82	I-code
)	O
during	O
ambulatory	O
care	O
visits	O
between	O
January	O
2002	O
and	O
December	O
2011	O
.	O

Since	O
administrative	O
datasets	O
are	O
always	O
criticized	O
for	O
their	O
diagnostic	O
validity	O
,	O
this	O
study	O
only	O
included	O
those	O
subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
dementia	O
at	O
least	O
twice	O
during	O
the	O
period	O
between	O
2002	O
and	O
2011	O
,	O
with	O
at	O
least	O
one	O
diagnosis	O
being	O
made	O
by	O
a	O
certified	O
neurologist	O
.	O

We	O
indicated	O
their	O
first	O
dementia	O
diagnosis	O
as	O
the	O
index	O
date	O
in	O
this	O
study	O
.	O

We	O
excluded	O
patients	O
under	O
40	O
years	O
of	O
age	O
because	O
of	O
the	O
very	O
low	O
prevalence	O
of	O
dementia	O
in	O
that	O
age	O
group	O
(	O
n	O
=	O
154	O
)	O
.	O

We	O
further	O
excluded	O
those	O
who	O
had	O
a	O
history	O
of	O
major	B-phenotype
psychosis	I-phenotype
or	I-phenotype
a	I-phenotype
substance	I-phenotype
-	I-phenotype
related	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
291	B-code
~	I-code
299	I-code
or	O
303	B-code
~	I-code
305	I-code
)	O
prior	O
to	O
the	O
index	O
date	O
(	O
n	O
=	O
1086	O
)	O
.	O

Ultimately	O
,	O
13	O
,	O
402	O
subjects	O
with	O
dementia	O
were	O
selected	O
as	O
cases	O
in	O
this	O
study	O
.	O

We	O
retrieved	O
three	O
matched	O
controls	O
(	O
n	O
=	O
40	O
,	O
206	O
)	O
per	O
case	O
from	O
the	O
remaining	O
beneficiaries	O
of	O
the	O
LHID2000	O
.	O

Controls	O
were	O
matched	O
by	O
gender	O
,	O
age	O
group	O
(	O
40	O
~	O
49	O
,	O
50	O
~	O
59	O
,	O
60	O
~	O
69	O
,	O
70	O
~	O
79	O
,	O
and	O
>	O
79	O
years	O
)	O
,	O
and	O
index	O
year	O
.	O

While	O
for	O
cases	O
,	O
the	O
year	O
of	O
the	O
index	O
date	O
was	O
the	O
year	O
in	O
which	O
the	O
cases	O
received	O
their	O
first	O
dementia	O
diagnosis	O
,	O
for	O
controls	O
,	O
the	O
year	O
of	O
the	O
index	O
date	O
was	O
simply	O
a	O
matched	O
year	O
in	O
which	O
the	O
controls	O
had	O
a	O
medical	O
utilization	O
.	O

We	O
further	O
assigned	O
the	O
date	O
of	O
their	O
first	O
use	O
of	O
ambulatory	O
care	O
occurring	O
during	O
that	O
matched	O
year	O
as	O
the	O
index	O
date	O
for	O
the	O
controls	O
.	O

In	O
addition	O
,	O
we	O
assured	O
that	O
none	O
of	O
the	O
selected	O
controls	O
had	O
received	O
a	O
dementia	O
diagnosis	O
since	O
initiation	O
of	O
the	O
Taiwan	O
NHI	O
program	O
in	O
1995	O
.	O

We	O
also	O
assured	O
that	O
none	O
of	O
the	O
selected	O
controls	O
had	O
received	O
a	O
diagnosis	O
of	O
major	O
psychosis	O
or	O
a	O
substance	O
-	O
related	O
disorder	O
prior	O
to	O
the	O
index	O
date	O
.	O

In	O
this	O
study	O
,	O
we	O
calculated	O
the	O
odds	O
of	O
having	O
previously	O
been	O
diagnosed	O
with	O
neovascular	O
AMD	O
between	O
cases	O
and	O
controls	O
.	O

We	O
identified	O
cases	O
with	O
neovascular	B-phenotype
AMD	I-phenotype
based	O
on	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
362	B-code
.	I-code
42	I-code
,	O
362	B-code
.	I-code
43	I-code
,	O
362	B-code
.	I-code
52	I-code
,	O
or	O
362	B-code
.	I-code
53	I-code
.	O

In	O
order	O
to	O
increase	O
the	O
diagnostic	O
validity	O
,	O
this	O
study	O
only	O
included	O
subjects	O
who	O
had	O
received	O
two	O
or	O
more	O
diagnoses	O
of	O
neovascular	O
AMD	O
prior	O
to	O
the	O
index	O
date	O
.	O

All	O
analyses	O
were	O
conducted	O
using	O
the	O
SAS	O
system	O
(	O
SAS	O
System	O
for	O
Windows	O
,	O
vers	O
.	O
8	O
.	O
2	O
,	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
.	O

We	O
used	O
a	O
Chi	O
-	O
square	O
test	O
to	O
compare	O
differences	O
in	O
monthly	O
income	O
(	O
NT$0	O
~	O
15	O
,	O
840	O
,	O
15	O
,	O
841	O
~	O
25	O
,	O
000	O
,	O
≥25	O
,	O
001	O
)	O
(	O
In	O
2011	O
,	O
the	O
average	O
exchange	O
rate	O
was	O
US$1	O
≈	O
NT$29	O
)	O
,	O
geographic	O
location	O
(	O
northern	O
,	O
central	O
,	O
eastern	O
,	O
and	O
southern	O
Taiwan	O
)	O
,	O
and	O
urbanization	O
level	O
of	O
the	O
patient’s	O
residence	O
(	O
5	O
levels	O
,	O
with	O
1	O
being	O
the	O
most	O
urbanized	O
and	O
5	O
being	O
the	O
least	O
)	O
between	O
cases	O
and	O
controls	O
.	O

We	O
also	O
took	O
medical	O
comorbidities	O
including	O
hyperlipidemia	O
,	O
diabetes	O
,	O
hypertension	O
,	O
stroke	O
,	O
and	O
ischemic	O
heart	O
disease	O
into	O
consideration	O
in	O
this	O
study	O
.	O

These	O
selected	O
medical	O
comorbidities	O
are	O
all	O
potential	O
risk	O
factors	O
for	O
dementia	O
,	O
and	O
they	O
were	O
only	O
included	O
if	O
they	O
were	O
diagnosed	O
before	O
the	O
index	O
date	O
.	O

In	O
addition	O
,	O
we	O
took	O
whether	O
or	O
not	O
a	O
subject	O
underwent	O
cataract	O
surgery	O
prior	O
to	O
index	O
date	O
into	O
consideration	O
in	O
the	O
regression	O
model	O
.	O

A	O
conditional	O
logistic	O
regression	O
(	O
conditioned	O
on	O
gender	O
and	O
index	O
year	O
)	O
was	O
used	O
to	O
examine	O
the	O
association	O
of	O
dementia	O
with	O
previously	O
diagnosed	O
neovascular	O
AMD	O
.	O

The	O
conventional	O
p	O
≤0	O
.	O
05	O
was	O
used	O
to	O
assess	O
statistical	O
significance	O
.	O

This	O
study	O
is	O
a	O
subgroup	O
analysis	O
of	O
an	O
observational	O
,	O
prospective	O
cohort	O
study	O
evaluating	O
the	O
evolution	O
of	O
cognitive	O
,	O
functional	O
,	O
and	O
psychiatric	O
sequelae	O
one	O
-	O
year	O
post	O
-	O
CA	O
.	O

Inclusion	O
criteria	O
were	O
≥18	O
years	O
of	O
age	O
,	O
resuscitated	O
following	O
in	O
-	O
or	O
out	O
-	O
of	O
-	O
hospital	O
CA	O
,	O
admitted	O
to	O
Columbia	O
University	O
Medical	O
Center	O
,	O
and	O
survived	O
to	O
hospital	O
discharge	O
between	O
September	O
2015	O
and	O
September	O
2017	O
(	O
Supplemental	O
Figure	O
1	O
)	O
.	O

CA	O
was	O
defined	O
as	O
a	O
loss	O
of	O
pulse	O
requiring	O
chest	O
compressions	O
,	O
rescue	O
shock	O
,	O
or	O
both	O
.	O

The	O
study	O
was	O
approved	O
by	O
Columbia	O
University’s	O
institutional	O
review	O
board	O
and	O
written	O
consent	O
was	O
obtained	O
.	O

Details	O
regarding	O
the	O
screening	O
procedure	O
and	O
data	O
collection	O
process	O
have	O
been	O
described	O
previously	O
6	O
(	O
see	O
also	O
Supplemental	O
Methods	O
)	O
.	O

A	O
detailed	O
description	O
of	O
our	O
institutional	O
CA	O
management	O
protocol	O
based	O
on	O
the	O
American	O
Heart	O
Association	O
guidelines	O
is	O
also	O
available	O
.	O

7	O

PTSD	O
symptoms	O
were	O
queried	O
with	O
reference	O
to	O
the	O
acute	O
CA	O
event	O
and	O
subsequent	O
hospitalization	O
within	O
24	O
hours	O
of	O
hospital	O
discharge	O
via	O
the	O
PTSD	O
Checklist	O
-	O
Specific	O
(	O
PCL	O
-	O
S	O
)	O
scale	O
.	O

PCL	O
-	O
S	O
scores	O
range	O
from	O
17–85	O
;	O
a	O
cutoff	O
of	O
36	O
,	O
suggested	O
for	O
specialized	O
medical	O
settings	O
was	O
adopted	O
.	O

8	O
The	O
median	O
assessment	O
time	O
was	O
21	O
days	O
post	O
-	O
CA	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
11–36	O
)	O
.	O

Internal	O
consistency	O
was	O
high	O
(	O
Cronbach’s	O
α	O
=	O
.	O
92	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
either	O
(	O
1	O
)	O
recurrence	O
of	O
a	O
major	O
adverse	O
cardiovascular	O
event	O
(	O
MACE	O
)	O
,	O
including	O
hospitalization	O
for	O
nonfatal	O
myocardial	O
infarction	O
(	O
MI	O
)	O
,	O
unstable	O
angina	O
(	O
UA	O
)	O
,	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
exacerbation	O
,	O
urgent	O
/	O
emergency	O
coronary	O
revascularization	O
procedures	O
(	O
percutaneous	O
coronary	O
intervention	O
,	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
or	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
)	O
,	O
or	O
urgent	O
implantable	O
cardio	O
-	O
defibrillator	O
(	O
ICD	O
)	O
/	O
pacemaker	O
(	O
PPM	O
)	O
placements	O
,	O
or	O
(	O
2	O
)	O
all	O
-	O
cause	O
mortality	O

(	O
ACM	O
)	O
within	O
12	O
-	O
months	O
of	O
the	O
hospital	O
discharge	O
interview	O
(	O
reported	O
via	O
telephone	O
or	O
in	O
-	O
person	O
interview	O
)	O
.	O

For	O
patient	O
-	O
reported	O
hospitalization	O
with	O
MACE	O
,	O
supporting	O
documentation	O
of	O
the	O
event	O
was	O
confirmed	O
in	O
25	O
(	O
86	O
%	O
)	O
patients	O
from	O
hospital	O
electronic	O
medical	O
records	O
.	O

All	O
deaths	O
were	O
verified	O
using	O
the	O
Social	O
Security	O
National	O
Death	O
Index	O
.	O

The	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
for	O
continuous	O
variables	O
and	O
Fisher’s	O
exact	O
test	O
for	O
categorical	O
variables	O
were	O
used	O
to	O
compare	O
those	O
with	O
vs	O
.	O
without	O
CA	O
-	O
induced	O
PTSS	O
on	O
demographic	O
,	O
psychiatric	O
,	O
and	O
medical	O
variables	O
.	O

Cox	O
-	O
hazard	O
regression	O
modeling	O
and	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
was	O
used	O
to	O
compare	O
MACE	O
/	O
ACM	O
outcomes	O
between	O
those	O
with	O
and	O
without	O
CA	O
-	O
induced	O
PTSS	O
.	O

Based	O
on	O
research	O
identifying	O
factors	O
that	O
might	O
confound	O
the	O
association	O
between	O
cardiac	O
-	O
event	O
-	O
induced	O
PTSS	O
and	O
MACE	O
/	O
ACM	O
,	O
4	O
demographic	O
variables	O
(	O
age	O
,	O
sex	O
)	O
,	O
1	O
medical	O
covariates	O
(	O
Charlson	O
Comorbidity	O
Index	O
)	O
,	O
1	O
pre	O
-	O
existing	O
psychiatric	O
disorder	O
,	O
2	O
and	O
non	O
-	O
shockable	O
rhythm	O
1	O
were	O
treated	O
as	O
covariates	O
(	O
Supplemental	O
Methods	O
)	O
.	O

Analyses	O
with	O
continuous	O
PTSS	O
score	O
are	O
described	O
in	O
the	O
Supplemental	O
Results	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
STATA	O
software	O
(	O
StataCorp	O
,	O
College	O
Station	O
,	O
TX	O
)	O
.	O

We	O
invited	O
experts	O
from	O
19	O
European	O
countries	O
:	O
Belgium	O
,	O
Croatia	O
,	O
Czech	O
Republic	O
,	O
Finland	O
,	O
France	O
,	O
Germany	O
,	O
Ireland	O
,	O
Italy	O
,	O
the	O
Netherlands	O
,	O
Norway	O
,	O
Poland	O
,	O
Portugal	O
,	O
Romania	O
,	O
Serbia	O
,	O
Slovakia	O
,	O
Slovenia	O
,	O
Sweden	O
,	O
Switzerland	O
and	O
the	O
United	O
Kingdom	O
(	O
UK	O
)	O
.	O

We	O
identified	O
experts	O
through	O
the	O
secretariat	O
of	O
the	O
European	O
Union	O
of	O
Medicine	O
in	O
Assurance	O
and	O
Social	O
Security	O
(	O
EUMASS	O
)	O
,	O
a	O
network	O
of	O
national	O
associations	O
of	O
insurance	O
medicine	O
in	O
19	O
European	O
countries	O
[	O
27	O
]	O
.	O

EUMASS	O
aims	O
to	O
offer	O
a	O
platform	O
to	O
exchange	O
experiences	O
within	O
the	O
field	O
of	O
insurance	O
medicine	O
between	O
various	O
insurance	O
-	O
related	O
organizations	O
in	O
Europe	O
,	O
mainly	O
focusing	O
on	O
public	O
social	O
security	O
.	O

Each	O
national	O
association	O
is	O
represented	O
in	O
the	O
EUMASS	O
council	O
by	O
up	O
to	O
two	O
staff	O
medical	O
advisor	O
(	O
s	O
)	O
,	O
i	O
.	O
e	O
.	O
experts	O
in	O
disability	O
assessment	O
,	O
and	O
may	O
nominate	O
one	O
deputy	O
for	O
each	O
representative	O
.	O

We	O
invited	O
all	O
council	O
members	O
,	O
35	O
experts	O
,	O
representing	O
the	O
19	O
countries	O
.	O

In	O
the	O
total	O
group	O
of	O
EUMASS	O
expert	O
representatives	O
,	O
the	O
number	O
of	O
eligible	O
respondents	O
per	O
country	O
ranged	O
from	O
one	O
to	O
three	O
.	O

As	O
we	O
invited	O
the	O
total	O
group	O
of	O
35	O
eligible	O
EUMASS	O
representatives	O
we	O
were	O
not	O
able	O
to	O
expand	O
the	O
sample	O
by	O
additional	O
members	O
.	O

We	O
invited	O
the	O
participants	O
to	O
fill	O
in	O
two	O
self	O
-	O
constructed	O
surveys	O
consecutively	O
from	O
June	O
2014	O
through	O
April	O
2015	O
.	O

The	O
language	O
of	O
the	O
survey	O
administration	O
was	O
English	O
for	O
all	O
countries	O
.	O

The	O
questionnaire	O
used	O
in	O
the	O
first	O
survey	O
was	O
independently	O
pilot	O
-	O
tested	O
for	O
readability	O
and	O
usability	O
by	O
four	O
practicing	O
insurance	O
physicians	O
and	O
the	O
questionnaire	O
in	O
the	O
second	O
survey	O
by	O
three	O
researchers	O
with	O
expertise	O
in	O
disability	O
assessment	O
.	O

In	O
the	O
first	O
survey	O
experts	O
received	O
a	O
link	O
to	O
a	O
web	O
-	O
based	O
questionnaire	O
with	O
items	O
on	O
the	O
assessment	O
of	O
work	O
endurance	O
.	O

A	O
second	O
questionnaire	O
was	O
sent	O
by	O
email	O
directly	O
to	O
17	O
participants	O
in	O
the	O
first	O
survey	O
from	O
13	O
countries	O
who	O
had	O
volunteered	O
for	O
the	O
second	O
survey	O
.	O

In	O
both	O
surveys	O
a	O
first	O
and	O
second	O
reminder	O
was	O
sent	O
after	O
four	O
and	O
eight	O
weeks	O
,	O
respectively	O
.	O

Participants	O
from	O
the	O
same	O
country	O
whose	O
answers	O
were	O
not	O
unanimous	O
,	O
were	O
approached	O
separately	O
by	O
email	O
with	O
a	O
request	O
to	O
clarify	O
.	O

Under	O
Dutch	O
law	O
approval	O
of	O
this	O
study	O
by	O
the	O
Medical	O
Ethical	O
Board	O
of	O
the	O
University	O
Medical	O
Centre	O
Groningen	O
was	O
not	O
necessary	O
.	O

In	O
the	O
first	O
survey	O
questionnaire	O
data	O
were	O
gathered	O
on	O
country	O
,	O
profession	O
and	O
expertise	O
of	O
participants	O
.	O

This	O
questionnaire	O
focused	O
on	O
various	O
general	O
aspects	O
of	O
work	O
endurance	O
and	O
its	O
assessment	O
with	O
eight	O
items	O
:	O
the	O
number	O
of	O
working	O
hours	O
per	O
day	O
and	O
per	O
week	O
that	O
is	O
considered	O
normal	O
,	O
the	O
assessment	O
of	O
work	O
endurance	O
as	O
part	O
of	O
the	O
overall	O
disability	O
assessment	O
,	O
the	O
professional	O
assessing	O
work	O
endurance	O
,	O
rules	O
or	O
guidelines	O
that	O
are	O
used	O
,	O
accepted	O
cause	O
(	O
s	O
)	O
for	O
limited	O
work	O
endurance	O
,	O
methods	O
by	O
which	O
work	O
endurance	O
is	O
assessed	O
and	O
any	O
controversies	O
on	O
the	O
assessment	O
of	O
work	O
endurance	O
.	O

The	O
second	O
survey	O
questionnaire	O
with	O
12	O
additional	O
items	O
aimed	O
to	O
provide	O
more	O
detail	O
on	O
work	O
endurance	O
and	O
how	O
it	O
is	O
assessed	O
.	O

It	O
gathered	O
information	O
on	O
the	O
evaluation	O
of	O
the	O
maximum	O
duration	O
to	O
sustain	O
specific	O
activities	O
,	O
the	O
general	O
evaluation	O
of	O
the	O
maximum	O
duration	O
to	O
work	O
in	O
suitable	O
work	O
,	O
specific	O
diseases	O
associated	O
with	O
limited	O
work	O
endurance	O
,	O
causes	O
for	O
limited	O
work	O
endurance	O
and	O
methods	O
suitable	O
to	O
assess	O
work	O
endurance	O
.	O

Suitability	O
was	O
rated	O
on	O
a	O
scale	O
0–10	O
(	O
0	O
=	O
totally	O
unsuitable	O
;	O
10	O
=	O
very	O
suitable	O
)	O
.	O

Health	B-phenotype
conditions	I-phenotype
listed	O
in	O
the	O
second	O
survey	O
questionnaire	O
were	O
grouped	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Disease	I-coding_system
,	I-coding_system
10th	I-coding_system
edition	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
[	O
28	O
]	O
.	O

For	O
the	O
first	O
and	O
second	O
questionnaire	O
,	O
see	O
the	O
supplementary	O
S1	O
Table	O
.	O

Data	O
from	O
the	O
first	O
survey	O
round	O
were	O
collected	O
using	O
Unipark	O
software	O
and	O
automatically	O
transferred	O
in	O
SPPS	O
.	O

Data	O
from	O
the	O
second	O
survey	O
round	O
were	O
collected	O
by	O
e	O
-	O
mail	O
and	O
manually	O
added	O
to	O
the	O
SPSS	O
file	O
by	O
the	O
first	O
author	O
(	O
HJB	O
)	O
.	O

Data	O
were	O
analysed	O
with	O
IBM	O
SPSS	O
version	O
22	O
.	O
0	O
for	O
Windows	O
.	O

Simple	O
frequency	O
statistics	O
and	O
cross	O
tabulations	O
were	O
used	O
.	O

We	O
checked	O
for	O
inconsistencies	O
in	O
respondents	O
in	O
those	O
countries	O
with	O
two	O
or	O
three	O
representatives	O
.	O

If	O
inconsistencies	O
were	O
found	O
,	O
we	O
contacted	O
the	O
representatives	O
and	O
tried	O
to	O
reach	O
consensus	O
.	O

If	O
no	O
consensus	O
could	O
be	O
reached	O
we	O
included	O
the	O
positive	O
answer	O
in	O
the	O
analysis	O
.	O

In	O
those	O
countries	O
with	O
only	O
one	O
representative	O
or	O
respondent	O
it	O
was	O
impossible	O
to	O
check	O
for	O
inconsistencies	O
.	O

If	O
participants	O
filled	O
in	O
a	O
range	O
instead	O
of	O
an	O
absolute	O
number	O
,	O
the	O
mean	O
was	O
taken	O
as	O
value	O
.	O

Clinical	O
test	O
,	O
functional	O
capacity	O
evaluation	O
and	O
psychological	O
test	O
are	O
the	O
most	O
used	O
methods	O
to	O
assess	O
work	O
endurance	O
,	O
see	O
Table	O
3	O
.	O

Participants	O
from	O
four	O
countries	O
provided	O
inconsistent	O
answers	O
to	O
this	O
item	O
.	O

In	O
all	O
countries	O
different	O
combinations	O
of	O
the	O
listed	O
methods	O
are	O
mentioned	O
as	O
most	O
suitable	O
to	O
assess	O
work	O
endurance	O
.	O

+	O
=	O
yes	O
;	O
-	O
=	O
no	O
;	O
+	O
/	O
-	O
=	O
inconsistent	O
;	O
BE	O
=	O
Belgium	O
;	O
HR	O
=	O
Croatia	O
;	O
CZ	O
=	O
Czech	O
Republic	O
;	O
FI	O
=	O
Finland	O
;	O
FR	O
=	O
France	O
;	O
DE	O
=	O
Germany	O
;	O
IT	O
=	O
Italy	O
;	O
NO	O
=	O
Norway	O
;	O
PL	O
=	O
Poland	O
;	O
RO	O
=	O
Romania	O
;	O
SK	O
=	O
Slovakia	O
;	O
SL	O
=	O
Slovenia	O
;	O
SE	O
=	O
Sweden	O
;	O
CH	O
=	O
Switzerland	O
;	O
NL	O
=	O
Netherlands	O
;	O
UK	O
=	O
United	O
Kingdom	O

Clinical	O
tests	O
include	O
flexibility	O
tests	O
of	O
joints	O
,	O
cardiovascular	O
and	O
respiratory	O
functional	O
diagnostics	O
,	O
functional	O
capacity	O
evaluation	O
,	O
ergometry	O
,	O
clinical	O
examination	O
,	O
visual	O
field	O
test	O
,	O
imaging	O
like	O
X	O
-	O
ray	O
,	O
MRI	O
and	O
ultrasound	O
,	O
electromyography	O
,	O
endoscopy	O
,	O
laboratory	O
test	O
,	O
audiometry	O
and	O
electro	O
-	O
encephalography	O
.	O

Other	O
tests	O
include	O
tests	O
on	O
cognitive	O
function	O
,	O
psychological	O
tests	O
,	O
semi	O
-	O
structured	O
interviews	O
,	O
self	O
-	O
report	O
questionnaire	O
and	O
psychiatric	O
evaluation	O
.	O

Ergometry	O
and	O
functional	O
capacity	O
evaluation	O
rate	O
highest	O
with	O
both	O
8	O
.	O
3	O
points	O
(	O
on	O
a	O
scale	O
0–10	O
)	O
as	O
being	O
the	O
most	O
suitable	O
method	O
to	O
assess	O
work	O
endurance	O
,	O
see	O
Table	O
3	O
.	O

Semi	O
-	O
structured	O
interview	O
and	O
self	O
-	O
report	O
questionnaire	O
rate	O
lowest	O
with	O
6	O
.	O
4	O
and	O
4	O
.	O
4	O
points	O
respectively	O
.	O

Controversies	O
are	O
reported	O
on	O
the	O
assessment	O
of	O
work	O
endurance	O
in	O
10	O
countries	O
.	O

Nine	O
of	O
these	O
countries	O
provided	O
short	O
descriptions	O
of	O
controversies	O
,	O
see	O
Table	O
4	O
.	O

a	O
Descriptions	O
are	O
verbatim	O
;	O
only	O
obvious	O
spelling	O
mistakes	O
are	O
corrected	O
.	O

This	O
large	O
-	O
scale	O
study	O
utilized	O
data	O
from	O
the	O
National	O
Health	O
Insurance	O
Research	O
Database	O
(	O
NHIRD	O
)	O
of	O
Taiwan	O
,	O
which	O
was	O
a	O
unique	O
public	O
health	O
and	O
medical	O
insurance	O
system	O
.	O

The	O
National	O
Health	O
Insurance	O
program	O
was	O
launched	O
in	O
1995	O
and	O
covered	O
99	O
.	O
9	O
%	O
of	O
the	O
23	O
million	O
residents	O
of	O
Taiwan	O
by	O
the	O
end	O
of	O
2013	O
.	O

[	O
17	O
]	O
The	O
NHIRD	O
includes	O
all	O
data	O
for	O
persons	O
seeking	O
medical	O
aid	O
,	O
including	O
demographic	O
data	O
,	O
medical	O
records	O
,	O
and	O
medical	O
procedures	O
.	O

We	O
used	O
the	O
Longitudinal	O
Health	O
Insurance	O
Database	O
2000	O
(	O
LHID2000	O
)	O
,	O
which	O
consists	O
of	O
a	O
sub	O
-	O
dataset	O
of	O
the	O
NHIRD	O
-	O
comprised	O
data	O
from	O
1	O
million	O
people	O
randomly	O
selected	O
from	O
the	O
larger	O
NHIRD	O
in	O
2000	O
and	O
representative	O
of	O
the	O
nationwide	O
population	O
.	O

[	O
18	O
]	O

The	O
study	O
subjects	O
were	O
chosen	O
from	O
LHID2000	O
and	O
the	O
study	O
period	O
was	O
between	O
January	O
2000	O
and	O
December	O
2013	O
.	O

This	O
study	O
was	O
divided	O
into	O
2	O
stages	O
:	O
first	O
,	O
recruiting	O
patients	O
with	O
newly	O
diagnosed	O
scabies	O
and	O
matched	O
controls	O
,	O
and	O
second	O
,	O
the	O
follow	O
-	O
up	O
of	O
newly	O
developed	O
PDC	O
.	O

The	O
diagnoses	O
of	O
the	O
patients	O
were	O
sorted	O
according	O
to	O
The	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
Ninth	I-coding_system
Revision	I-coding_system
,	I-coding_system
Clinical	I-coding_system
Modification	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
)	I-coding_system
system	O
.	O

[	O
19	O
]	O
The	O
patients	O
newly	O
diagnosed	O
with	O
scabies	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
133	B-code
.	I-code
0	I-code
)	O
by	O
licensed	O
doctors	O
between	O
2001	O
and	O
2006	O
were	O
enrolled	O
in	O
this	O
study	O
(	O
Fig	O
.	O

1	O
)	O
.	O

The	O
exclusion	O
criteria	O
consisted	O
of	O
patients	O
who	O
were	O
diagnosed	O
with	O
scabies	O
before	O
January	O
1	O
,	O
2001	O
(	O
n	O
=	O
1087	O
)	O
;	O
patients	O
with	O
missing	O
medical	O
records	O
(	O
n	O
=	O
125	O
)	O
;	O
patients	O
older	O
than	O
18	O
years	O
(	O
n	O
=	O
8478	O
)	O
;	O
and	O
patients	O
with	O
history	O
of	O
scabies	O
or	O
any	O
PDC	O
(	O
n	O
=	O
141	O
)	O
.	O

Finally	O
,	O
a	O
total	O
of	O
2137	O
patients	O
with	O
a	O
scabies	O
infection	O
were	O
enrolled	O
as	O
the	O
scabies	O
groups	O
.	O

Patients	O
without	O
scabies	O
were	O
enrolled	O
by	O
randomly	O
matching	O
patients	O
by	O
gender	O
,	O
age	O
,	O
insured	O
region	O
,	O
and	O
urbanization	O
to	O
the	O
scabies	O
group	O
at	O
a	O
ratio	O
of	O
1	O
:	O
4	O
as	O
the	O
control	O
group	O
.	O

Specifically	O
,	O
the	O
nonscabies	O
control	O
group	O
patients	O
were	O
matched	O
by	O
age	O
(	O
0–2	O
,	O
3–5	O
,	O
6–12	O
,	O
and	O
13–18	O
years	O
)	O
,	O
gender	O
,	O
and	O
index	O
year	O
of	O
the	O
scabies	O
diagnoses	O
of	O
the	O
patients	O
in	O
the	O
scabies	O
group	O
.	O

A	O
total	O
of	O
8548	O
subjects	O
were	O
enrolled	O
in	O
the	O
nonscabies	O
control	O
group	O
.	O

Subjects	O
who	O
had	O
a	O
previous	B-phenotype
psychiatric	I-phenotype
history	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
290–319	B-code
)	O
were	O
excluded	O
from	O
both	O
the	O
study	O
and	O
control	O
groups	O
.	O

Flowchart	O
of	O
recruitment	O
of	O
subjects	O
from	O
the	O
1	O
million	O
random	O
sample	O
of	O
the	O
National	O
Health	O
Insurance	O
Research	O
Database	O
from	O
2000	O
to	O
2006	O
in	O
Taiwan	O
.	O

A	O
total	O
of	O
10	O
,	O
685	O
subjects	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
including	O
2137	O
study	O
subjects	O
in	O
the	O
scabies	O
group	O
and	O
8548	O
study	O
subjects	O
in	O
the	O
nonscabies	O
control	O
group	O
.	O

We	O
tracked	O
each	O
subject	O
over	O
a	O
7	O
-	O
year	O
period	O
starting	O
with	O
their	O
index	O
date	O
to	O
determine	O
which	O
subjects	O
were	O
diagnosed	O
with	O
PDC	B-phenotype
,	O
based	O
on	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
,	I-coding_system
Fifth	I-coding_system
Edition	I-coding_system
,	O
[	O
20	O
]	O
which	O
included	O
attention	B-phenotype
deficit	I-phenotype
hyperactivity	I-phenotype
disorder	I-phenotype
(	I-phenotype
ADHD	I-phenotype
)	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
314	B-code
)	O
,	O
autism	B-phenotype
spectrum	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
299	B-code
)	O
,	O
anxiety	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
300	B-code
except	I-code
300	I-code
.	I-code
3	I-code
,	I-code
300	I-code
.	I-code
4	I-code
)	O
,	O
schizophrenia	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
295	B-code
)	O
,	O
intellectual	B-phenotype
disability	I-phenotype
(	I-phenotype
ID	I-phenotype
)	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
317–319	B-code
)	O
,	O
tic	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
2	I-code
)	O
,	O
delayed	B-phenotype

development	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
315	B-code
)	O
,	O
obsessive–compulsive	B-phenotype
disorder	I-phenotype
(	I-phenotype
OCD	I-phenotype
)	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
300	B-code
.	I-code
3	I-code
)	O
,	O
conductive	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
312	B-code
)	O
,	O
disturbance	B-phenotype
of	I-phenotype
emotions	I-phenotype
specific	I-phenotype
to	I-phenotype
childhood	I-phenotype
and	I-phenotype
adolescence	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
313	B-code
)	O
,	O
psychic	B-phenotype
factors	I-phenotype
associated	I-phenotype
with	I-phenotype
diseases	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
316	B-code
)	O
,	O
eating	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
5	I-code
)	O
,	O
stuttering	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
0	I-code
)	O
,	O
communication	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
9	I-code
)	O
,	O
enuresis	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
6	I-code
)	O
,	O
encopresis	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
7	I-code
,	O
787	B-code
.	I-code
6	I-code
)	O
,	O
and	O
separation	B-phenotype
anxiety	I-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
309	B-code
.	I-code
21	I-code
)	O
during	O
the	O
follow	O
-	O
up	O

period	O
.	O

Disturbance	B-phenotype
of	I-phenotype
emotions	I-phenotype
specific	I-phenotype
to	I-phenotype
childhood	I-phenotype
and	I-phenotype
adolescence	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
313	B-code
)	O
comprised	O
the	O
different	O
types	O
of	O
emotional	O
disturbances	O
in	O
childhood	O
and	O
adolescence	O
:	O
overanxious	O
,	O
misery	O
and	O
unhappiness	O
,	O
shyness	O
,	O
introverted	O
disorders	O
,	O
and	O
so	O
on	O
.	O

Mental	O
disturbances	O
or	O
psychic	O
factors	O
which	O
were	O
thought	O
to	O
have	O
played	O
a	O
major	O
part	O
in	O
the	O
etiology	O
of	O
physical	O
conditions	O
were	O
classified	O
in	O
psychic	B-phenotype
factors	I-phenotype
associated	I-phenotype
with	I-phenotype
diseases	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
316	B-code
)	O
,	O
such	O
as	O
psychogenic	O
asthma	O
,	O
dermatitis	O
,	O
and	O
gastric	O
ulcer	O
.	O

Enuresis	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
6	I-code
)	O
was	O
considered	O
as	O
physiological	O
disorder	O
before	O
the	O
age	O
of	O
3	O
years	O
and	O
encopresis	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
307	B-code
.	I-code
7	I-code
,	O
787	B-code
.	I-code
6	I-code
)	O
was	O
regarded	O
as	O
physiological	O
disorder	O
before	O
the	O
age	O
of	O
4	O
years	O
.	O

[	O
20	O
]	O

The	O
outcomes	O
of	O
this	O
study	O
included	O
the	O
number	O
of	O
patients	O
newly	O
diagnosed	O
with	O
any	O
PDC	O
in	O
each	O
group	O
.	O

We	O
also	O
identified	O
and	O
analyzed	O
all	O
the	O
other	O
medical	O
diagnoses	O
and	O
procedures	O
of	O
the	O
patients	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

The	O
diagnoses	O
of	O
PDC	O
were	O
made	O
by	O
psychiatrists	O
on	O
the	O
basis	O
of	O
at	O
least	O
1	O
admission	O
or	O
at	O
least	O
2	O
consistent	O
diagnoses	O
in	O
outpatient	O
departments	O
due	O
to	O
the	O
diseases	O
mentioned	O
above	O
.	O

In	O
addition	O
,	O
PDC	O
was	O
diagnosed	O
by	O
the	O
psychiatrists	O
according	O
to	O
a	O
detailed	O
clinical	O
interviews	O
and	O
based	O
on	O
their	O
experimental	O
judgment	O
with	O
the	O
aim	O
of	O
achieving	O
diagnostic	O
validity	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
Tri	O
-	O
Service	O
General	O
Hospital	O
(	O
approval	O
number	O
:	O
TSGHIRB	O
NO	O
.	O

B	O
-	O
105	O
-	O
06	O
.	O
)	O
.	O

As	O
this	O
was	O
a	O
retrospective	O
study	O
and	O
all	O
data	O
was	O
anonymous	O
,	O
the	O
Institutional	O
Review	O
Board	O
committee	O
agreed	O
with	O
the	O
authors	O
that	O
it	O
was	O
not	O
necessary	O
to	O
obtain	O
patient	O
consent	O
.	O

The	O
covariates	O
of	O
the	O
comorbidities	O
selected	O
in	O
this	O
study	O
consisted	O
of	O
asthma	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
493	B-code
)	O
,	O
atopic	B-phenotype
dermatitis	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
691	B-code
)	O
,	O
allergic	B-phenotype
rhinitis	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
477	B-code
)	O
,	O
and	O
preterm	B-phenotype
labor	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
:	O
765	B-code
.	I-code
0	I-code
,	O
765	B-code
.	I-code
1	I-code
)	O
.	O

Age	O
was	O
categorized	O
into	O
4	O
age	O
groups	O
:	O
0	O
to	O
2	O
,	O
3	O
to	O
5	O
,	O
6	O
to	O
12	O
,	O
and	O
13	O
to	O
18	O
years	O
.	O

Urbanization	O
was	O
classified	O
into	O
4	O
groups	O
.	O

The	O
geographic	O
areas	O
of	O
residency	O
in	O
Taiwan	O
were	O
divided	O
into	O
4	O
regions	O
:	O
the	O
northern	O
,	O
central	O
,	O
southern	O
,	O
and	O
other	O
regions	O
(	O
i	O
.	O
e	O
.	O
,	O
eastern	O
and	O
outlying	O
islands	O
)	O
.	O

We	O
used	O
SPSS	O
software	O
version	O
19	O
.	O
0	O
(	O
SPSS	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
for	O
our	O
statistical	O
analysis	O
and	O
SQL	O
Server	O
2008	O
(	O
Microsoft	O
Cooperation	O
,	O
New	O
Mexico	O
)	O
for	O
data	O
management	O
.	O

A	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
analyze	O
the	O
descriptive	O
data	O
including	O
the	O
demographic	O
characteristics	O
,	O
age	O
,	O
geography	O
,	O
level	O
of	O
urbanization	O
,	O
and	O
comorbidities	O
between	O
the	O
scabies	O
and	O
nonscabies	O
control	O
group	O
.	O

The	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
were	O
performed	O
to	O
estimate	O
the	O
effects	O
of	O
risk	O
factors	O
on	O
the	O
hazard	O
ratio	O
with	O
an	O
accompanying	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
.	O

All	O
models	O
were	O
adjusted	O
for	O
the	O
covariates	O
(	O
i	O
.	O
e	O
.	O
,	O
gender	O
,	O
age	O
,	O
income	O
,	O
geography	O
,	O
urbanization	O
,	O
and	O
comorbidities	O
)	O
to	O
calculate	O
the	O
independent	O
risks	O
of	O
individual	O
diseases	O
.	O

A	O
2	O
-	O
sided	O
P	O
<	O
.	O
05	O
was	O
set	O
as	O
the	O
determinant	O
of	O
statistical	O
significance	O
.	O

The	O
study	O
is	O
a	O
secondary	O
analysis	O
of	O
a	O
blinded	O
,	O
parallel	O
-	O
arm	O
randomised	O
controlled	O
trial	O
.	O

A	O
full	O
description	O
of	O
the	O
design	O
is	O
outlined	O
in	O
the	O
protocol	O
(	O
Priebe	O
et	O
al	O
.	O
,	O
2013	O
)	O
,	O
and	O
details	O
of	O
the	O
procedures	O
and	O
study	O
implementation	O
are	O
available	O
in	O
the	O
published	O
full	O
report	O
(	O
Priebe	O
et	O
al	O
.	O
,	O
2016	O
)	O
.	O

All	O
participants	O
were	O
randomised	O
,	O
with	O
equal	O
probability	O
,	O
to	O
a	O
20	O
-	O
session	O
body	O
psychotherapy	O
or	O
Pilates	O
group	O
.	O

All	O
participants	O
were	O
outpatients	O
recruited	O
from	O
five	O
different	O
NHS	O
Trusts	O
across	O
the	O
UK	O
.	O

The	O
inclusion	O
criteria	O
included	O
an	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
of	O
schizophrenia	B-phenotype
;	O
a	O
score	O
of	O
≥18	O
on	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
negative	O
subscale	O
(	O
Kay	O
et	O
al	O
.	O
,	O
1987	O
)	O
;	O
no	O
change	O
in	O
the	O
type	O
of	O
antipsychotic	O
medication	O
prescribed	O
for	O
at	O
least	O
6	O
weeks	O
;	O
aged	O
18–65	O
;	O
an	O
ability	O
to	O
provide	O
informed	O
consent	O
;	O
and	O
a	O
willingness	O
and	O
ability	O
to	O
participate	O
in	O
physically	O
active	O
groups	O
.	O

Prior	O
to	O
recruitment	O
all	O
participants	O
provided	O
informed	O
consent	O
.	O

In	O
accordance	O
with	O
the	O
original	O
trial	O
,	O
the	O
main	O
outcome	O
of	O
interest	O
for	O
this	O
investigation	O
was	O
the	O
PANSS	O
negative	O
subscale	O
at	O
end	O
of	O
treatment	O
(	O
Kay	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

Expressive	O
and	O
experiential	O
symptoms	O
were	O
examined	O
separately	O
using	O
the	O
Clinical	O
Assessment	O
Interview	O
for	O
Negative	O
Symptoms	O
(	O
CAINS	O
;	O
Kring	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

The	O
CAINS	O
is	O
a	O
13	O
-	O
item	O
semi	O
-	O
structured	O
interview	O
designed	O
to	O
address	O
the	O
methodological	O
and	O
conceptual	O
limitations	O
of	O
earlier	O
negative	O
symptom	O
assessment	O
tools	O
(	O
Blanchard	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

The	O
experiential	O
subscale	O
consists	O
of	O
nine	O
items	O
,	O
measuring	O
how	O
frequently	O
they	O
take	O
part	O
in	O
social	O
and	O
occupational	O
activities	O
,	O
their	O
anticipation	O
of	O
pleasure	O
,	O
and	O
their	O
motivation	O
to	O
complete	O
activities	O
and	O
develop	O
or	O
maintain	O
relationships	O
.	O

The	O
expressive	O
subscale	O
consists	O
of	O
four	O
items	O
,	O
measuring	O
deficits	O
in	O
vocal	O
and	O
gestural	O
aspects	O
of	O
expression	O
.	O

In	O
order	O
to	O
examine	O
the	O
specificity	O
of	O
the	O
findings	O
,	O
the	O
PANSS	O
positive	O
and	O
general	O
subscales	O
were	O
evaluated	O
.	O

The	O
Calgary	O
scale	O
was	O
adopted	O
as	O
a	O
measure	O
of	O
depression	O
(	O
Addington	O
et	O
al	O
.	O
,	O
1993	O
)	O
,	O
EPS	O
were	O
measured	O
using	O
the	O
Simpson	O
Angus	O
Scale	O
(	O
SAS	O
;	O
Simpson	O
and	O
Angus	O
,	O
1970	O
)	O
,	O
and	O
the	O
number	O
of	O
social	O
contacts	O
participants	O
reported	O
over	O
the	O
previous	O
week	O
was	O
recorded	O
using	O
an	O
adapted	O
version	O
of	O
the	O
Social	O
Network	O
Scale	O
(	O
SNS	O
;	O
Dunn	O
et	O
al	O
.	O
,	O
1990	O
)	O
.	O

The	O
Client	O
Service	O
Questionnaire	O
was	O
included	O
as	O
a	O
measure	O
of	O
treatment	O
acceptability	O
at	O
end	O
of	O
treatment	O
(	O
CSQ	O
;	O
Attkisson	O
and	O
Zwick	O
,	O
1982	O
)	O
.	O

Finally	O
,	O
the	O
number	O
of	O
sessions	O
each	O
participant	O
attended	O
were	O
assessed	O
,	O
recorded	O
by	O
the	O
group	O
co	O
-	O
facilitators	O
after	O
every	O
session	O
.	O

The	O
body	O
psychotherapy	O
treatment	O
was	O
a	O
90	O
-	O
minute	O
,	O
20	O
-	O
session	O
group	O
intervention	O
held	O
twice	O
a	O
week	O
on	O
non	O
-	O
consecutive	O
days	O
.	O

The	O
group	O
was	O
facilitated	O
by	O
an	O
accredited	O
dance	O
movement	O
psychotherapist	O
,	O
and	O
assisted	O
by	O
a	O
volunteer	O
co	O
-	O
facilitator	O
.	O

The	O
structure	O
of	O
the	O
therapy	O
is	O
outlined	O
in	O
the	O
published	O
manual	O
(	O
Röhricht	O
,	O
2000	O
)	O
and	O
comprises	O
of	O
five	O
sections	O
.	O

The	O
first	O
section	O
is	O
an	O
opening	O
circle	O
to	O
initiate	O
communication	O
between	O
participants	O
and	O
draw	O
focus	O
towards	O
the	O
body	O
.	O

The	O
second	O
is	O
a	O
warm	O
-	O
up	O
section	O
to	O
stimulate	O
,	O
promote	O
self	O
-	O
awareness	O
,	O
and	O
conduct	O
reality	O
testing	O
exercises	O
.	O

The	O
third	O
includes	O
structured	O
exercises	O
to	O
address	O
bodily	O
disturbances	O
.	O

The	O
fourth	O
includes	O
creative	O
exercises	O
to	O
encourage	O
the	O
use	O
of	O
body	O
as	O
a	O
source	O
of	O
expression	O
and	O
enjoyment	O
.	O

The	O
fifth	O
section	O
is	O
a	O
closing	O
circle	O
,	O
used	O
to	O
review	O
session	O
and	O
disengage	O
from	O
the	O
therapeutic	O
process	O
.	O

In	O
all	O
sections	O
,	O
a	O
key	O
component	O
of	O
the	O
therapy	O
is	O
the	O
facilitation	O
and	O
development	O
of	O
verbal	O
and	O
pre	O
-	O
verbal	O
communication	O
between	O
participants	O
.	O

In	O
order	O
to	O
mirror	O
the	O
structure	O
of	O
the	O
body	O
psychotherapy	O
intervention	O
,	O
the	O
physical	O
activities	O
group	O
was	O
also	O
a	O
90	O
-	O
minute	O
,	O
20	O
-	O
session	O
group	O
held	O
twice	O
a	O
week	O
on	O
non	O
-	O
consecutive	O
days	O
,	O
held	O
in	O
the	O
same	O
venue	O
as	O
each	O
corresponding	O
body	O
psychotherapy	O
group	O
.	O

The	O
groups	O
were	O
facilitated	O
by	O
an	O
accredited	O
Pilates	O
instructor	O
,	O
and	O
assisted	O
by	O
a	O
volunteer	O
co	O
-	O
facilitator	O
.	O

The	O
group	O
was	O
structured	O
as	O
a	O
beginners	O
-	O
level	O
Pilates	O
group	O
,	O
with	O
a	O
guide	O
developed	O
based	O
upon	O
the	O
Pilates	O
Union	O
Matwork	O
Manual	O
(	O
Newham	O
,	O
2010	O
)	O
.	O

In	O
the	O
first	O
part	O
of	O
the	O
analysis	O
,	O
the	O
impact	O
of	O
gender	O
on	O
treatment	O
effectiveness	O
for	O
negative	O
symptoms	O
as	O
a	O
single	O
construct	O
was	O
examined	O
.	O

A	O
mixed	O
-	O
effects	O
model	O
,	O
fitted	O
by	O
restricted	O
maximum	O
likelihood	O
,	O
was	O
used	O
with	O
the	O
PANSS	O
negative	O
symptom	O
subscale	O
at	O
end	O
of	O
treatment	O
included	O
as	O
the	O
dependent	O
variable	O
,	O
with	O
fixed	O
effects	O
for	O
the	O
baseline	O
PANSS	O
negative	O
subscale	O
score	O
,	O
gender	O
,	O
treatment	O
allocation	O
,	O
and	O
the	O
study	O
centre	O
(	O
which	O
was	O
used	O
in	O
the	O
randomisation	O
stratification	O
)	O
.	O

A	O
random	O
effect	O
for	O
the	O
therapy	O
group	O
was	O
included	O
to	O
model	O
for	O
any	O
clustering	O
by	O
group	O
.	O

To	O
examine	O
the	O
impact	O
of	O
gender	O
on	O
treatment	O
outcome	O
,	O
an	O
interaction	O
term	O
between	O
gender	O
and	O
treatment	O
allocation	O
was	O
included	O
,	O
and	O
assessed	O
for	O
significance	O
using	O
the	O
Wald	O
statistic	O
.	O

As	O
part	O
of	O
the	O
analysis	O
,	O
a	O
number	O
of	O
potential	O
extraneous	O
factors	O
which	O
may	O
explain	O
any	O
effect	O
of	O
gender	O
on	O
treatment	O
outcomes	O
were	O
considered	O
.	O

These	O
include	O
:	O
baseline	O
depression	O
scores	O
,	O
given	O
depression	O
can	O
induce	O
secondary	O
negative	O
symptoms	O
(	O
Carpenter	O
et	O
al	O
.	O
,	O
1985	O
)	O
,	O
can	O
respond	O
to	O
body	O
psychotherapy	O
(	O
Röhricht	O
et	O
al	O
.	O
,	O
2013	O
)	O
,	O
and	O
is	O
typically	O
more	O
severe	O
in	O
women	O
with	O
psychosis	O
(	O
Goldstein	O
and	O
Link	O
1988	O
)	O
.	O

Extrapyramidal	O
symptoms	O
(	O
EPS	O
)	O
,	O
given	O
these	O
can	O
mimic	O
negative	O
symptoms	O
(	O
Carpenter	O
et	O
al	O
.	O
,	O
1985	O
)	O
and	O
are	O
more	O
prevalent	O
in	O
men	O
on	O
antipsychotic	O
medication	O
(	O
Abel	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

Number	O
of	O
social	O
contacts	O
,	O
due	O
to	O
women	O
with	O
psychosis	O
typically	O
having	O
a	O
more	O
developed	O
social	O
network	O
(	O
Thorup	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
which	O
may	O
allow	O
for	O
more	O
opportunities	O
to	O
implement	O
any	O
skills	O
learnt	O
during	O
treatment	O
.	O

Prescribed	O
antipsychotic	O
medication	O
dose	O
was	O
also	O
included	O
,	O
with	O
the	O
equivalence	O
between	O
different	O
medications	O
calculated	O
using	O
the	O
defined	O
daily	O
dose	O
(	O
DDD	O
;	O
WHO	O
,	O
2012	O
)	O
.	O

These	O
variables	O
were	O
included	O
as	O
covariates	O
in	O
the	O
model	O
,	O
along	O
with	O
group	O
attendance	O
rates	O
and	O
treatment	O
satisfaction	O
reported	O
at	O
end	O
of	O
treatment	O
to	O
control	O
for	O
the	O
possibility	O
of	O
any	O
effect	O
of	O
treatment	O
being	O
attributable	O
to	O
differences	O
in	O
treatment	O
acceptability	O
,	O
or	O
a	O
dose	O
-	O
response	O
effect	O
.	O

Due	O
to	O
the	O
very	O
high	O
retention	O
rate	O
of	O
the	O
original	O
trial	O
between	O
baseline	O
and	O
follow	O
-	O
up	O
(	O
96	O
.	O
7	O
%	O
)	O
,	O
multiple	O
imputation	O
was	O
not	O
used	O
,	O
and	O
the	O
analysis	O
was	O
based	O
on	O
an	O
available	O
case	O
basis	O
following	O
intention	O
to	O
treat	O
principles	O
.	O

In	O
the	O
second	O
part	O
of	O
the	O
analysis	O
,	O
expressive	O
and	O
experiential	O
deficits	O
as	O
measured	O
by	O
the	O
CAINS	O
were	O
evaluated	O
in	O
order	O
to	O
determine	O
whether	O
any	O
effect	O
of	O
treatment	O
was	O
specific	O
to	O
one	O
particular	O
domain	O
of	O
negative	O
symptoms	O
.	O

In	O
addition	O
,	O
the	O
PANSS	O
positive	O
and	O
general	O
symptom	O
subscales	O
were	O
evaluated	O
in	O
order	O
to	O
determine	O
the	O
specificity	O
of	O
the	O
findings	O
,	O
using	O
the	O
same	O
model	O
previously	O
outlined	O
.	O

We	O
used	O
data	O
from	O
the	O
Stockholm	O
youth	O
cohort	O
,	O
an	O
intergenerational	O
record	O
linkage	O
study	O
comprising	O
all	O
individuals	O
aged	O
0	O
-	O
17	O
living	O
in	O
Stockholm	O
County	O
in	O
2001	O
-	O
11	O
(	O
n=735	O
096	O
)	O
.	O

It	O
contains	O
prospectively	O
recorded	O
data	O
on	O
the	O
cohort	O
members	O
and	O
their	O
first	O
degree	O
relatives	O
collected	O
by	O
record	O
linkage	O
with	O
a	O
range	O
of	O
national	O
and	O
regional	O
healthcare	O
,	O
social	O
,	O
and	O
administrative	O
registries	O
.	O

20	O
21	O
The	O
key	O
for	O
record	O
linkage	O
is	O
the	O
unique	O
national	O
identity	O
numbers	O
assigned	O
to	O
all	O
Swedish	O
residents	O
.	O

Figure	O
1	O
shows	O
the	O
derivation	O
of	O
the	O
sample	O
for	O
our	O
main	O
analysis	O
.	O

We	O
excluded	O
cohort	O
members	O
born	O
before	O
1996	O
as	O
medication	O
data	O
were	O
reliably	O
collected	O
only	O
after	O
this	O
date	O
.	O

We	O
also	O
excluded	O
individuals	O
not	O
linked	O
to	O
the	O
medical	O
birth	O
register	O
(	O
such	O
as	O
those	O
born	O
abroad	O
)	O
,	O
those	O
who	O
could	O
not	O
be	O
linked	O
to	O
their	O
biological	O
mothers	O
,	O
adopted	O
children	O
,	O
and	O
those	O
living	O
in	O
Stockholm	O
County	O
for	O
less	O
than	O
four	O
years	O
.	O

The	O
residence	O
requirement	O
also	O
allowed	O
us	O
to	O
exclude	O
children	O
aged	O
under	O
4	O
in	O
whom	O
a	O
diagnosis	O
of	O
autism	O
might	O
be	O
less	O
reliable	O
.	O

Fig	O
1	O
Derivation	O
of	O
sample	O
from	O
Stockholm	O
youth	O
cohort	O
used	O
in	O
main	O
analysis	O
of	O
maternal	O
use	O
of	O
antidepressants	O
during	O
pregnancy	O
and	O
autism	O
in	O
offspring	O
.	O

*	O
Maternal	O
indications	O
for	O
antidepressant	O
use	O
were	O
anxiety	B-phenotype
disorders	I-phenotype
(	O
F40	B-code
-	I-code
41	I-code
)	O
,	O
bipolar	B-phenotype
disorder	I-phenotype
(	O
F30	B-code
-	I-code
31	I-code
)	O
,	O
depression	B-phenotype
/	I-phenotype
mood	I-phenotype
disorder	I-phenotype
(	O
F32	B-code
-	I-code
39	I-code
)	O
,	O
non	B-phenotype
-	I-phenotype
affective	I-phenotype
psychoses	I-phenotype
(	O
F20	B-code
-	I-code
29	I-code
)	O
,	O
obsessive	B-phenotype
compulsive	I-phenotype
disorders	I-phenotype
(	O
F42	B-code
)	O
,	O
stress	B-phenotype
related	I-phenotype
disorders	I-phenotype
(	O
F43	B-code
)	O
,	O
and	O
other	B-phenotype
neurotic	I-phenotype
disorders	I-phenotype
(	O
F44	B-code
-	I-code
48	I-code
)	O

As	O
mandated	O
by	O
the	O
ethical	O
permission	O
,	O
no	O
attempts	O
were	O
made	O
to	O
contact	O
any	O
cohort	O
members	O
for	O
any	O
aspect	O
of	O
this	O
record	O
linkage	O
study	O
.	O

As	O
such	O
,	O
cohort	O
members	O
were	O
not	O
involved	O
in	O
setting	O
the	O
research	O
question	O
or	O
the	O
outcome	O
measures	O
,	O
nor	O
were	O
they	O
involved	O
in	O
developing	O
plans	O
for	O
the	O
design	O
or	O
implementation	O
of	O
the	O
study	O
.	O

No	O
patients	O
were	O
asked	O
to	O
advise	O
on	O
interpretation	O
or	O
writing	O
up	O
of	O
results	O
.	O

There	O
are	O
no	O
plans	O
to	O
directly	O
disseminate	O
the	O
results	O
of	O
the	O
research	O
to	O
cohort	O
members	O
,	O
but	O
dissemination	O
to	O
the	O
general	O
public	O
and	O
relevant	O
patient	O
groups	O
will	O
be	O
undertaken	O
by	O
using	O
presentations	O
and	O
social	O
media	O
.	O

We	O
derived	O
information	O
on	O
maternal	O
use	O
of	O
antidepressants	O
in	O
pregnancy	O
from	O
the	O
medical	O
birth	O
register	O
(	O
since	O
1997	O
)	O
and	O
supplemented	O
it	O
with	O
the	O
prescribed	O
drug	O
register	O
(	O
available	O
from	O
July	O
2005	O
)	O
.	O

22	O
23	O
The	O
medical	O
birth	O
register	O
contains	O
information	O
on	O
current	O
medications	O
being	O
taken	O
as	O
reported	O
by	O
pregnant	O
women	O
at	O
their	O
antenatal	O
interview	O
,	O
at	O
a	O
median	O
of	O
10	O
weeks’	O
gestation	O
.	O

The	O
data	O
are	O
semi	O
-	O
automatically	O
coded	O
with	O
World	O
Health	O
Organization	O
anatomical	B-coding_system
therapeutic	I-coding_system
classification	I-coding_system
(	I-coding_system
ATC	I-coding_system
)	I-coding_system
codes	O
.	O

The	O
medical	O
birth	O
register	O
also	O
contains	O
free	O
text	O
data	O
,	O
which	O
we	O
processed	O
using	O
a	O
computerised	O
search	O
for	O
generic	O
drug	O
names	O
and	O
Swedish	O
and	O
international	O
brand	O
names	O
of	O
antidepressants	O
using	O
fuzzy	O
pattern	O
matching	O
to	O
account	O
for	O
unknown	O
abbreviations	O
,	O
non	O
-	O
standard	O
terms	O
,	O
and	O
misspellings	O
.	O

24	O
The	O
prescribed	O
drug	O
register	O
contains	O
data	O
on	O
drugs	O
prescribed	O
and	O
dispensed	O
in	O
ambulatory	O
care	O
to	O
the	O
entire	O
Swedish	O
population	O
,	O
and	O
the	O
medications	O
are	O
coded	O
with	O
ATC	O
codes	O
.	O

In	O
the	O
prescribed	O
drug	O
register	O
,	O
we	O
defined	O
exposure	O
to	O
medication	O
during	O
pregnancy	O
as	O
a	O
prescription	O
up	O
to	O
30	O
days	O
before	O
the	O
start	O
of	O
the	O
pregnancy	O
(	O
as	O
estimated	O
by	O
the	O
last	O
menstrual	O
period	O
or	O
evidence	O
from	O
ultrasonography	O
)	O
until	O
the	O
birth	O
date	O
of	O
the	O
child	O
.	O

We	O
considered	O
exposure	O
to	O
antidepressants	O
if	O
there	O
was	O
a	O
record	O
of	O
these	O
in	O
either	O
the	O
medical	O
birth	O
register	O
or	O
the	O
prescribed	O
drug	O
register	O
.	O

The	O
validity	O
of	O
these	O
two	O
data	O
sources	O
have	O
been	O
reported	O
previously	O
.	O

22	O
23	O
We	O
cross	O
validated	O
these	O
two	O
data	O
sources	O
in	O
our	O
sample	O
as	O
data	O
on	O
antidepressant	O
use	O
were	O
available	O
in	O
both	O
registers	O
for	O
cohorts	O
born	O
in	O
2006	O
and	O
2007	O
.	O

Among	O
these	O
,	O
280	O
women	O
out	O
of	O
318	O
with	O
a	O
report	O
of	O
antidepressant	O
use	O
in	O
the	O
medical	O
birth	O
register	O
were	O
also	O
recorded	O
as	O
having	O
prescriptions	O
for	O
an	O
antidepressant	O
during	O
pregnancy	O
in	O
the	O
prescribed	O
drug	O
register	O
(	O
88	O
.	O
1	O
%	O
)	O
.	O

We	O
coded	O
the	O
medications	O
as	O
any	B-phenotype
antidepressant	I-phenotype
(	O
ATC	B-coding_system
code	O
N06A	B-code
)	O
and	O
also	O
divided	O
them	O
into	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRI	O
,	O
ATC	O
N06AB	O
)	O
and	O
all	O
other	O
antidepressants	O
.	O

We	O
also	O
categorised	O
antidepressants	O
based	O
on	O
their	O
affinities	O
for	O
the	O
serotonin	O
transporter	O
into	O
high	O
versus	O
medium	O
or	O
low	O
affinity	O
.	O

2	O

We	O
have	O
described	O
the	O
multisource	O
ascertainment	O
of	O
autism	O
in	O
previous	O
publications	O
.	O

7	O
20	O
21	O
In	O
short	O
,	O
nearly	O
all	O
diagnoses	O
of	O
autism	O
in	O
Sweden	O
are	O
provided	O
through	O
its	O
free	O
and	O
universally	O
accessible	O
system	O
of	O
health	O
and	O
care	O
.	O

We	O
collected	O
diagnostic	O
information	O
from	O
the	O
relevant	O
registers	O
reflecting	O
the	O
pathways	O
to	O
diagnosis	O
.	O

These	O
sources	O
included	O
diagnoses	O
recorded	O
in	O
the	O
national	O
patient	O
register	O
,	O
the	O
Stockholm	O
child	O
and	O
adolescent	O
mental	O
health	O
register	O
,	O
and	O
the	O
habilitation	O
registers	O
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
(	O
299	B-code
)	O
,	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
(	O
F84	B-code
)	O
,	O
or	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
(	O
299	B-code
)	O
codes	O
)	O
.	O

We	O
identified	O
co	B-phenotype
-	I-phenotype
occurring	I-phenotype
intellectual	I-phenotype
disability	I-phenotype
using	O
ICD	B-coding_system
9	I-coding_system
(	O
317	B-code
-	I-code
319	I-code
)	O
,	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
(	O
F70	B-code
-	I-code
79	I-code
)	O
,	O
and	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
(	O
317	B-code
-	I-code
319	I-code
)	O
in	O
the	O
child	O
or	O
adult	O
mental	O
health	O
registers	O
or	O
the	O
national	O
patient	O
register	O
.	O

We	O
have	O
previously	O
carried	O
out	O
two	O
validation	O
procedures—	O
a	O
case	O
note	O
validation	O
study	O
and	O
a	O
cross	O
validation	O
study	O
of	O
diagnosis	O
of	O
autism	O
spectrum	O
disorder	O
with	O
a	O
national	O
twin	O
study—and	O
found	O
a	O
high	O
validity	O
of	O
the	O
diagnoses	O
recorded	O
in	O
the	O
registers	O
.	O

20	O

We	O
used	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
and	I-coding_system
10	I-coding_system
diagnoses	O
recorded	O
in	O
the	O
national	O
patient	O
register	O
,	O
which	O
covers	O
inpatient	O
(	O
with	O
complete	O
national	O
coverage	O
since	O
1973	O
)	O
and	O
outpatient	O
specialist	O
care	O
(	O
since	O
2001	O
)	O
to	O
ascertain	O
depression	B-phenotype
and	O
other	B-phenotype
maternal	I-phenotype
and	I-phenotype
paternal	I-phenotype
diagnoses	I-phenotype
of	I-phenotype
other	I-phenotype
psychiatric	I-phenotype
indications	I-phenotype
for	I-phenotype
antidepressants	I-phenotype
(	I-phenotype
anxiety	I-phenotype
disorder	I-phenotype
,	I-phenotype
bipolar	I-phenotype
disorder	I-phenotype
,	I-phenotype
non	I-phenotype
-	I-phenotype
affective	I-phenotype
psychoses	I-phenotype
,	I-phenotype
obsessive	I-phenotype
-	I-phenotype
compulsive	I-phenotype
disorder	I-phenotype
,	I-phenotype
other	I-phenotype
stress	I-phenotype
related	I-phenotype
and	I-phenotype
neurotic	I-phenotype
disorders	I-phenotype
)	I-phenotype
any	O
time	O
before	O
the	O
birth	O
of	O
the	O
child	O
as	O
described	O
elsewhere	O
.	O

25	O
We	O
supplemented	O
these	O
with	O
diagnoses	O
recorded	O
from	O
the	O
Stockholm	O
adult	O
psychiatric	O
care	O
register	O
,	O
which	O
comprises	O
all	O
publicly	O
financed	O
psychiatric	O
care	O
in	O
Stockholm	O
County	O
(	O
constituting	O
85	O
%	O
of	O
all	O
such	O
care	O
)	O
since	O
1997	O
.	O

26	O

We	O
used	O
prospectively	O
collected	O
data	O
on	O
maternal	O
and	O
paternal	O
age	O
at	O
birth	O
of	O
child	O
(	O
continuous	O
variables	O
used	O
as	O
restricted	O
cubic	O
splines	O
)	O
,	O
fifths	O
of	O
family	O
income	O
adjusted	O
for	O
year	O
of	O
ascertainment	O
and	O
family	O
size	O
,	O
highest	O
education	O
of	O
either	O
parent	O
(	O
≤9	O
years	O
,	O
10	O
-	O
12	O
years	O
,	O
≥13	O
years	O
)	O
,	O
maternal	O
country	O
of	O
birth	O
(	O
Sweden	O
,	O
Europe	O
,	O
other	O
)	O
,	O
parity	O
(	O
0	O
,	O
1	O
,	O
2	O
,	O
or	O
more	O
previous	O
births	O
)	O
as	O
potential	O
confounders	O
.	O

We	O
also	O
used	O
several	O
other	O
variables	O
to	O
construct	O
the	O
propensity	O
score	O
as	O
described	O
below	O
.	O

These	O
included	O
maternal	O
smoking	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
recorded	O
at	O
first	O
antenatal	O
visit	O
,	O
number	O
of	O
diagnoses	O
of	O
maternal	O
depression	O
before	O
birth	O
,	O
type	O
of	O
depression	O
care	O
(	O
inpatient	O
or	O
outpatient	O
)	O
,	O
and	O
a	O
large	O
range	O
of	O
maternal	O
neurological	O
and	O
psychiatric	O
conditions	O
diagnosed	O
before	O
birth	O
(	O
see	O
appendix	O
)	O
.	O

We	O
used	O
R	O
-	O
3	O
.	O
1	O
.	O
3	O
(	O
R	O
Foundation	O
for	O
Statistical	O
Computing	O
)	O
for	O
analysis	O
.	O

After	O
descriptive	O
analyses	O
,	O
we	O
used	O
the	O
following	O
analytic	O
strategies	O
to	O
assess	O
the	O
risk	O
of	O
offspring	O
autism	O
in	O
mothers	O
with	O
antidepressant	O
use	O
during	O
pregnancy	O
.	O

In	O
our	O
first	O
analysis	O
,	O
we	O
used	O
logistic	O
regression	O
to	O
derive	O
odds	O
ratios	O
and	O
their	O
95	O
%	O
confidence	O
intervals	O
as	O
estimates	O
of	O
relative	O
risks	O
for	O
autism	O
in	O
children	O
of	O
mothers	O
who	O
used	O
antidepressants	O
during	O
pregnancy	O
compared	O
with	O
those	O
with	O
a	O
psychiatric	O
disorder	O
who	O
did	O
not	O
use	O
antidepressants	O
.	O

We	O
used	O
this	O
stringent	O
comparison	O
group	O
to	O
better	O
account	O
for	O
confounding	O
by	O
indication	O
and	O
because	O
women	O
without	O
any	O
psychiatric	O
disorder	O
would	O
be	O
ineligible	O
in	O
hypothesised	O
randomised	O
controlled	O
trials	O
of	O
this	O
issue	O
.	O

We	O
adjusted	O
the	O
model	O
for	O
birth	O
year	O
to	O
control	O
for	O
period	O
effects	O
in	O
medication	O
use	O
and	O
ascertainment	O
of	O
autism	O
.	O

21	O
We	O
then	O
adjusted	O
for	O
the	O
presence	O
or	O
absence	O
of	O
specific	O
individual	O
maternal	O
psychiatric	O
disorders	O
(	O
depression	O
,	O
anxiety	O
disorder	O
,	O
bipolar	O
disorder	O
,	O
non	O
-	O
affective	O
psychotic	O
disorders	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
adjustment	O
disorders	O
,	O
post	O
-	O
traumatic	O
stress	O
disorders	O
,	O
and	O
other	O
neurotic	O
disorders	O
)	O
that	O
are	O
indications	O
for	O
antidepressant	O
use	O
(	O
model	O
2	O
)	O
and	O
additionally	O
for	O
child	O
sex	O
,	O
parental	O
ages	O
,	O
birth	O
order	O
,	O
maternal	O
education	O
,	O
family	O
income	O
,	O
and	O
maternal	O
country	O
of	O
birth	O
(	O
model	O
3	O
)	O
.	O

We	O
calculated	O
population	O
attributable	O
fractions	O
(	O
PAF	O
)	O
using	O
the	O
fully	O
adjusted	O
model	O
,	O
estimating	O
the	O
proportion	O
of	O
autism	O
cases	O
that	O
would	O
be	O
prevented	O
if	O
no	O
women	O
with	O
psychiatric	O
disorders	O
were	O
prescribed	O
antidepressants	O
,	O
assuming	O
a	O
causal	O
association	O
and	O
no	O
residual	O
confounding	O
.	O

In	O
a	O
supplementary	O
analysis	O
,	O
we	O
restricted	O
the	O
above	O
treatment	O
group	O
to	O
mothers	O
with	O
antidepressant	O
use	O
who	O
had	O
a	O
recorded	O
psychiatric	O
diagnosis	O
.	O

We	O
also	O
described	O
the	O
associations	O
by	O
the	O
most	O
commonly	O
used	O
individual	O
antidepressants	O
and	O
grouped	O
antidepressants	O
as	O
SSRI	O
and	O
non	O
-	O
SSRIs	O
,	O
and	O
by	O
their	O
serotonin	O
transporter	O
receptor	O
(	O
SERT	O
)	O
affinity	O
into	O
high	O
or	O
low	O
/	O
medium	O
affinity	O
.	O

In	O
our	O
second	O
analysis	O
,	O
we	O
calculated	O
propensity	O
score	O
matched	O
estimates	O
for	O
the	O
above	O
associations	O
.	O

Propensity	O
score	O
matching	O
helps	O
to	O
minimise	O
the	O
potential	O
for	O
confounding	O
from	O
observed	O
variables	O
by	O
comparing	O
exposed	O
and	O
unexposed	O
individuals	O
with	O
similar	O
characteristics	O
.	O

27	O
We	O
estimated	O
propensity	O
scores	O
for	O
antidepressant	O
use	O
during	O
pregnancy	O
using	O
a	O
boosted	O
classification	O
and	O
regression	O
tree	O
model	O
,	O
28	O
from	O
the	O
above	O
covariates	O
and	O
additional	O
variables	O
regarding	O
maternal	O
psychiatric	O
disorders	O
including	O
indicators	O
of	O
severity	O
such	O
as	O
the	O
type	O
of	O
psychiatric	O
care	O
and	O
number	O
of	O
previous	O
care	O
episodes	O
for	O
depression	O
,	O
and	O
the	O
use	O
of	O
other	O
medications	O
(	O
see	O
appendix	O
for	O
complete	O
details	O
)	O
.	O

We	O
matched	O
children	O
of	O
women	O
who	O
did	O
and	O
did	O
not	O
use	O
antidepressants	O
using	O
the	O
propensity	O
score	O
using	O
a	O
maximum	O
of	O
4	O
:	O
1	O
unexposed	O
:	O
exposed	O
nearest	O
neighbour	O
matching	O
with	O
a	O
caliper	O
of	O
0	O
.	O
20	O
SD	O
and	O
exact	O
matching	O
on	O
birth	O
year	O
,	O
sex	O
of	O
child	O
,	O
number	O
of	O
depression	O
diagnoses	O
,	O
anxiety	O
disorders	O
,	O
and	O
obsessive	O
compulsive	O
disorder	O
.	O

We	O
estimated	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
interval	O
from	O
cluster	O
robust	O
logistic	O
regression	O
models	O
.	O

In	O
our	O
third	O
analysis	O
,	O
we	O
examined	O
associations	O
between	O
maternal	O
antidepressant	O
use	O
in	O
pregnancy	O
and	O
autism	O
spectrum	O
disorder	O
in	O
matched	O
sets	O
of	O
outcome	O
discordant	O
siblings	O
(	O
that	O
is	O
,	O
sibling	O
sets	O
in	O
which	O
there	O
is	O
at	O
least	O
one	O
affected	O
sibling	O
and	O
one	O
unaffected	O
sibling	O
,	O
see	O
appendix	O
)	O
.	O

Siblings	O
share	O
up	O
to	O
half	O
of	O
their	O
genetic	O
makeup	O
and	O
generally	O
share	O
their	O
early	O
postnatal	O
environment	O
.	O

Sibling	O
analysis	O
can	O
be	O
a	O
powerful	O
method	O
to	O
control	O
for	O
unmeasured	O
confounders	O
,	O
such	O
as	O
maternal	O
genetic	O
liability	O
for	O
neuropsychiatric	O
conditions	O
,	O
when	O
the	O
confounders	O
are	O
shared	O
more	O
than	O
the	O
exposure	O
.	O

29	O
We	O
derived	O
odds	O
ratios	O
and	O
confidence	O
intervals	O
using	O
conditional	O
logistic	O
regression	O
models	O
adjusted	O
for	O
sex	O
,	O
parity	O
,	O
and	O
birth	O
year	O
.	O

In	O
our	O
fourth	O
analysis	O
,	O
we	O
used	O
paternal	O
use	O
of	O
antidepressant	O
as	O
a	O
negative	O
control	O
exposure	O
with	O
the	O
assumption	O
that	O
the	O
fathers	O
would	O
share	O
many	O
of	O
the	O
unmeasured	O
confounders	O
with	O
mothers	O
,	O
and	O
,	O
if	O
a	O
similar	O
heightened	O
risk	O
of	O
autism	O
was	O
observable	O
with	O
paternal	O
and	O
maternal	O
use	O
of	O
antidepressants	O
,	O
the	O
associations	O
would	O
be	O
unlikely	O
to	O
reflect	O
an	O
in	O
utero	O
effect	O
of	O
the	O
medications	O
.	O

30	O
In	O
these	O
analyses	O
,	O
we	O
used	O
data	O
for	O
the	O
individuals	O
born	O
in	O
2006	O
and	O
2007	O
,	O
for	O
whom	O
we	O
had	O
data	O
on	O
antidepressant	O
prescriptions	O
for	O
the	O
mothers	O
and	O
fathers	O
,	O
and	O
estimated	O
the	O
associations	O
of	O
antidepressant	O
prescriptions	O
in	O
fathers	O
during	O
the	O
time	O
of	O
the	O
mother’s	O
pregnancy	O
with	O
the	O
outcomes	O
.	O

In	O
a	O
sensitivity	O
analysis	O
,	O
we	O
estimated	O
how	O
robust	O
the	O
estimates	O
of	O
associations	O
between	O
antidepressant	O
exposure	O
and	O
autism	O
spectrum	O
disorder	O
were	O
to	O
unmeasured	O
confounding	O
in	O
our	O
propensity	O
score	O
matched	O
sample	O
.	O

We	O
assumed	O
a	O
binary	O
confounder	O
U	O
increased	O
the	O
risk	O
of	O
autism	O
and	O
was	O
more	O
prevalent	O
in	O
antidepressant	O
users	O
than	O
in	O
non	O
-	O
antidepressant	O
users	O
.	O

Given	O
specified	O
parameters	O
such	O
as	O
the	O
relation	O
of	O
U	O
with	O
autism	O
spectrum	O
disorder	O
and	O
the	O
prevalence	O
of	O
U	O
in	O
antidepressant	O
users	O
and	O
non	O
-	O
users	O
,	O
we	O
estimated	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
interval	O
corrected	O
for	O
this	O
unmeasured	O
confounder	O
,	O
specified	O
over	O
a	O
range	O
of	O
plausible	O
parameters	O
.	O

31	O

There	O
were	O
few	O
missing	O
data	O
on	O
the	O
key	O
variables	O
in	O
our	O
main	O
analysis	O
(	O
total	O
1	O
.	O
5	O
%	O
missing	O
data	O
)	O
.	O

More	O
data	O
were	O
missing	O
in	O
some	O
variables	O
used	O
in	O
the	O
generation	O
of	O
propensity	O
scores	O
,	O
but	O
the	O
boosted	O
classification	O
and	O
regression	O
tree	O
model	O
is	O
able	O
to	O
incorporate	O
missing	O
values	O
in	O
the	O
prediction	O
(	O
see	O
appendix	O
)	O
.	O

The	O
study	O
is	O
embedded	O
in	O
the	O
intersectoral	O
research	O
network	O
psychenet	O
:	O
Hamburg	O
Network	O
for	O
Mental	O
Health	O
(	O
2011–2014	O
)	O
,	O
a	O
research	O
and	O
development	O
project	O
funded	O
by	O
the	O
German	O
Federal	O
Ministry	O
for	O
Education	O
and	O
Research	O
(	O
BMBF	O
)	O
[	O
24	O
]	O
.	O

It	O
aims	O
at	O
the	O
improvement	O
of	O
the	O
city’s	O
population’s	O
mental	O
health	O
by	O
implementing	O
new	O
integrated	O
health	O
care	O
networks	O
based	O
on	O
evidence	O
for	O
effective	O
treatment	O
methods	O
and	O
by	O
evaluating	O
selected	O
innovations	O
and	O
complex	O
interventions	O
in	O
the	O
region	O
of	O
Hamburg	O
.	O

The	O
overall	O
project	O
is	O
organized	O
in	O
11	O
sub	O
-	O
projects	O
.	O

While	O
the	O
first	O
five	O
sub	O
-	O
projects	O
(	O
1–5	O
)	O
facilitate	O
mental	O
health	O
across	O
different	O
areas	O
of	O
disease	O
by	O
improving	O
information	O
and	O
education	O
,	O
fostering	O
occupational	O
health	O
or	O
strengthening	O
the	O
participation	O
of	O
sufferers	O
and	O
their	O
family	O
members	O
,	O
five	O
illness	O
-	O
specific	O
health	O
networks	O
have	O
been	O
conceived	O
(	O
sub	O
-	O
projects	O
6–10	O
)	O
.	O

A	O
general	O
accompanying	O
sub	O
-	O
project	O
(	O
11	O
)	O
ensures	O
the	O
quality	O
of	O
the	O
interventions	O
in	O
all	O
sub	O
-	O
projects	O
and	O
conducts	O
evaluative	O
and	O
health	O
-	O
economic	O
investigations	O
[	O
24	O
]	O
.	O

This	O
article	O
describes	O
the	O
study	O
protocol	O
of	O
the	O
health	O
network	O
depression	O
(	O
sub	O
-	O
project	O
7	O
)	O
.	O

Primary	O
objective	O
of	O
this	O
randomized	O
controlled	O
trial	O
is	O
to	O
examine	O
the	O
effectiveness	O
of	O
a	O
complex	O
intervention	O
(	O
stepped	O
care	O
model	O
,	O
SCM	O
)	O
assessed	O
through	O
the	O
reduction	O
in	O
depression	O
severity	O
within	O
a	O
network	O
of	O
general	O
practitioners	O
(	O
GP	O
)	O
,	O
psychiatrists	O
and	O
psychotherapists	O
in	O
routine	O
care	O
.	O

Secondary	O
objectives	O
are	O
to	O
examine	O
the	O
effectiveness	O
of	O
SCM	O
in	O
terms	O
of	O
response	O
,	O
remission	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
as	O
well	O
as	O
to	O
examine	O
its	O
cost	O
-	O
effectiveness	O
.	O

Further	O
objectives	O
are	O
the	O
evaluation	O
of	O
the	O
process	O
quality	O
and	O
of	O
patients’	O
and	O
practitioners’	O
satisfaction	O
with	O
SCM	O
.	O

The	O
study	O
is	O
designed	O
as	O
a	O
randomized	O
controlled	O
intervention	O
trial	O
of	O
a	O
consecutive	O
sample	O
of	O
depressive	O
patients	O
from	O
primary	O
care	O
assessed	O
with	O
a	O
prospective	O
multiple	O
time	O
point	O
survey	O
.	O

GPs	O
are	O
divided	O
into	O
two	O
groups	O
by	O
undertaking	O
a	O
cluster	O
randomization	O
on	O
the	O
level	O
of	O
the	O
participating	O
primary	O
care	O
units	O
.	O

Patients	O
recruited	O
by	O
GPs	O
in	O
the	O
intervention	O
group	O
(	O
IG	O
)	O
are	O
treated	O
within	O
the	O
stepped	O
care	O
approach	O
(	O
SCM	O
,	O
see	O
section	O
Intervention	O
)	O
.	O

Patients	O
recruited	O
by	O
GPs	O
in	O
the	O
control	O
group	O
(	O
CG	O
)	O
receive	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
.	O

Both	O
patient	O
groups	O
are	O
compared	O
with	O
respect	O
to	O
their	O
treatment	O
response	O
within	O
a	O
one	O
-	O
year	O
period	O
.	O

The	O
scientific	O
approach	O
is	O
primarily	O
quantitative	O
with	O
additional	O
qualitative	O
analyses	O
regarding	O
feasibility	O
and	O
acceptance	O
of	O
the	O
SCM	O
by	O
patients	O
as	O
well	O
as	O
by	O
out	O
-	O
and	O
inpatient	O
care	O
providers	O
.	O

The	O
trial	O
evaluates	O
the	O
primary	O
hypothesis	O
that	O
the	O
SCM	O
condition	O
(	O
IG	O
)	O
outperforms	O
the	O
TAU	O
condition	O
(	O
CG	O
)	O
regarding	O
the	O
primary	O
outcome	O
parameter	O
(	O
PHQ	O
-	O
9	O
)	O
,	O
i	O
.	O
e	O
.	O
that	O
stepped	O
care	O
is	O
more	O
effective	O
than	O
treatment	O
as	O
usual	O
in	O
depressive	O
symptom	O
reduction	O
after	O
12	O
months	O
.	O

Cluster	O
-	O
randomization	O
is	O
performed	O
in	O
order	O
to	O
allocate	O
confounding	O
variables	O
in	O
equal	O
parts	O
to	O
both	O
study	O
conditions	O
and	O
thus	O
to	O
control	O
for	O
potential	O
bias	O
in	O
order	O
to	O
guarantee	O
internal	O
validity	O
.	O

In	O
this	O
study	O
,	O
cluster	O
-	O
randomization	O
is	O
undertaken	O
at	O
the	O
level	O
of	O
the	O
participating	O
GP	O
practices	O
,	O
which	O
are	O
allocated	O
to	O
either	O
IG	O
or	O
CG	O
in	O
a	O
3	O
:	O
1	O
ratio	O
.	O

The	O
process	O
of	O
randomization	O
is	O
conducted	O
by	O
a	O
computer	O
program	O
by	O
minimization	O
based	O
on	O
the	O
GP’s	O
practice	O
size	O
(	O
single	O
practice	O
vs	O
.	O
group	O
practice	O
)	O
,	O
the	O
location	O
of	O
the	O
practice	O
within	O
Hamburg	O
classified	O
into	O
the	O
two	O
categories	O
(	O
central	O
vs	O
.	O
peripheral	O
)	O
and	O
income	O
level	O
of	O
the	O
practice’s	O
local	O
district	O
classified	O
into	O
three	O
categories	O
(	O
low	O
,	O
middle	O
and	O
high	O
)	O
.	O

Criteria	O
for	O
selection	O
of	O
clustering	O
variables	O
are	O
relevance	O
and	O
availability	O
.	O

We	O
assume	O
that	O
each	O
GP	O
in	O
the	O
49	O
participating	O
practices	O
is	O
able	O
to	O
recruit	O
15–25	O
patients	O
.	O

A	O
total	O
of	O
36	O
practices	O
is	O
randomized	O
into	O
the	O
IG	O
and	O
13	O
practices	O
into	O
the	O
CG	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
responsible	O
local	O
Ethics	O
Committee	O
in	O
Hamburg	O
and	O
will	O
be	O
conducted	O
according	O
to	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
(	O
2013	O
version	O
)	O
.	O

The	O
recruitment	O
of	O
the	O
patients	O
in	O
the	O
IG	O
and	O
CG	O
is	O
carried	O
out	O
by	O
the	O
participating	O
GPs	O
and	O
comprises	O
three	O
guideline	O
-	O
recommended	O
steps	O
of	O
screening	O
and	O
assessment	O
as	O
displayed	O
in	O
Figure	O
1	O
:	O
First	O
,	O
by	O
applying	O
a	O
2	O
-	O
item	O
-	O
checklist	O
(	O
risk	O
-	O
checklist	O
)	O
the	O
GP	O
systematically	O
identifies	O
those	O
patients	O
with	O
diffuse	O
somatic	O
symptoms	O
and	O
/	O
or	O
with	O
chronic	O
somatic	O
conditions	O
[	O
16	O
,	O
25	O
]	O
,	O
i	O
.	O
e	O
.	O
patients	O
at	O
high	O
risk	O
for	O
depression	O
.	O

For	O
this	O
group	O
of	O
patients	O
,	O
the	O
GP	O
continues	O
the	O
screening	O
procedure	O
by	O
using	O
a	O
further	O
guideline	O
-	O
based	O
2	O
-	O
item	O
-	O
checklist	O
(	O
main	O
-	O
symptom	O
-	O
checklist	O
)	O
assessing	O
the	O
main	O
symptoms	O
of	O
depression	O
.	O

A	O
positive	O
answer	O
in	O
at	O
least	O
one	O
of	O
these	O
questions	O
leads	O
to	O
the	O
third	O
screening	O
step	O
,	O
an	O
assessment	O
with	O
the	O
depression	O
module	O
of	O
the	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
-	O
9	O
)	O
:	O
Patients	O
with	O
a	O
score	O
of	O
five	O
or	O
more	O
points	O
meet	O
the	O
study’s	O
basic	O
inclusion	O
criterion	O
and	O
are	O
informed	O
about	O
the	O
study	O
.	O

After	O
giving	O
informed	O
consent	O
,	O
patients	O
receive	O
their	O
baseline	O
questionnaire	O
.	O

Figure	O
1	O
Design	O
of	O
the	O
study	O
comparing	O
a	O
stepped	O
care	O
model	O
(	O
SCM	O
)	O
to	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
for	O
patients	O
with	O
depression	O
.	O

Design	O
of	O
the	O
study	O
comparing	O
a	O
stepped	O
care	O
model	O
(	O
SCM	O
)	O
to	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
for	O
patients	O
with	O
depression	O
.	O

Inclusion	O
criteria	O
are	O
a	O
minimum	O
age	O
of	O
18	O
,	O
five	O
or	O
more	O
points	O
on	O
PHQ	O
-	O
9	O
and	O
informed	O
consent	O
.	O

Patients	O
with	O
insufficient	O
knowledge	O
of	O
the	O
German	O
language	O
or	O
a	O
health	O
situation	O
that	O
does	O
not	O
allow	O
questionnaire	O
completion	O
are	O
excluded	O
.	O

Neither	O
somatic	O
nor	O
mental	O
comorbidities	O
are	O
exclusion	O
criteria	O
.	O

However	O
,	O
if	O
a	O
mental	O
disorder	O
other	O
than	O
depression	O
is	O
the	O
main	O
treatment	O
focus	O
patients	O
are	O
also	O
excluded	O
from	O
the	O
study	O
.	O

We	O
aim	O
to	O
gain	O
a	O
sample	O
size	O
that	O
permits	O
a	O
small	O
to	O
moderate	O
effect	O
size	O
between	O
SCM	O
and	O
TAU	O
to	O
be	O
detected	O
with	O
a	O
statistical	O
power	O
of	O
80	O
%	O
.	O

A	O
small	O
to	O
moderate	O
effect	O
size	O
is	O
defined	O
as	O
eta	O
2	O
=	O
0	O
.	O
0344	O
(	O
or	O
f	O
=	O
0	O
.	O
175	O
according	O
to	O
Cohen	O
[	O
26	O
]	O
)	O
.	O

We	O
expect	O
a	O
reduction	O
of	O
the	O
error	O
variance	O
of	O
approximately	O
20	O
%	O
by	O
including	O
initial	O
symptom	O
severity	O
(	O
PHQ	O
-	O
9	O
at	O
t0	O
)	O
as	O
a	O
covariate	O
(	O
which	O
can	O
be	O
expected	O
to	O
be	O
uncorrelated	O
to	O
the	O
study	O
conditions	O
due	O
to	O
randomization	O
)	O
.	O

This	O
leads	O
to	O
an	O
adjusted	O
effect	O
size	O
of	O
eta	O
2	O
=	O
0	O
.	O
042	O
(	O
f	O
=	O
0	O
.	O
209	O
)	O
.	O

In	O
this	O
respect	O
and	O
based	O
on	O
α	O
=	O
0	O
.	O
05	O
a	O
sample	O
of	O
n	O
=	O
92	O
patients	O
in	O
each	O
study	O
condition	O
is	O
required	O
for	O
our	O
main	O
analysis	O
.	O

As	O
we	O
presume	O
a	O
drop	O
-	O
out	O
rate	O
of	O
20	O
%	O
in	O
the	O
IG	O
an	O
initial	O
sample	O
of	O
n	O
=	O
110	O
patients	O
is	O
needed	O
in	O
this	O
group	O
to	O
answer	O
the	O
main	O
research	O
question	O
.	O

In	O
order	O
to	O
run	O
further	O
separate	O
analyses	O
for	O
each	O
of	O
the	O
six	O
treatment	O
options	O
within	O
the	O
SCM	O
(	O
and	O
assuming	O
an	O
equal	O
distribution	O
of	O
patients	O
onto	O
each	O
option	O
)	O
we	O
include	O
6	O
*	O
110	O
patients	O
in	O
the	O
intervention	O
group	O
.	O

As	O
for	O
the	O
control	O
group	O
,	O
a	O
larger	O
rate	O
of	O
drop	O
-	O
out	O
has	O
to	O
be	O
expected	O
(	O
approximately	O
50	O
%	O
,	O
due	O
to	O
less	O
personal	O
involvement	O
)	O
,	O
a	O
total	O
of	O
N	O
=	O
200	O
patients	O
is	O
to	O
be	O
recruited	O
in	O
this	O
study	O
condition	O
.	O

Therefore	O
,	O
a	O
total	O
of	O
N	O
=	O
860	O
depressive	O
patients	O
are	O
to	O
be	O
included	O
in	O
the	O
study	O
.	O

For	O
the	O
primary	O
endpoint	O
changes	O
in	O
PHQ	O
-	O
9	O
to	O
baseline	O
after	O
12	O
months	O
we	O
assume	O
a	O
small	O
to	O
moderate	O
effect	O
size	O
defined	O
as	O
Cohen	O
'	O
s	O
d	O
=	O
0	O
.	O
4	O
and	O
set	O
the	O
significance	O
level	O
to	O
0	O
.	O
05	O
(	O
two	O
-	O
sided	O
)	O
.	O

With	O
these	O
settings	O
a	O
sample	O
size	O
of	O
100	O
patients	O
in	O
each	O
group	O
is	O
required	O
to	O
achieve	O
a	O
power	O
of	O
80	O
%	O
.	O

2	O
×	O
100	O
patients	O
need	O
to	O
be	O
included	O
if	O
the	O
randomization	O
occurs	O
at	O
the	O
patient	O
level	O
.	O

With	O
an	O
assumed	O
intra	O
-	O
cluster	O
correlation	O
(	O
ICC	O
)	O
of	O
0	O
.	O
05	O
and	O
20	O
included	O
patients	O
per	O
cluster	O
on	O
average	O
a	O
design	O
effect	O
of	O
1	O
.	O
95	O
is	O
calculated	O
,	O
increasing	O
the	O
sample	O
size	O
to	O
200	O
patients	O
and	O
10	O
practices	O
per	O
group	O
.	O

We	O
decide	O
to	O
recruit	O
the	O
threefold	O
number	O
of	O
patients	O
in	O
the	O
intervention	O
group	O
because	O
we	O
would	O
like	O
to	O
obtain	O
detailed	O
knowledge	O
about	O
the	O
six	O
treatment	O
options	O
.	O

And	O
so	O
we	O
assume	O
to	O
have	O
a	O
sufficient	O
number	O
of	O
patients	O
in	O
each	O
of	O
the	O
treatment	O
options	O
.	O

This	O
approach	O
results	O
in	O
860	O
patients	O
and	O
40	O
practices	O
to	O
recruit	O
with	O
a	O
3	O
:	O
1	O
allocation	O
to	O
the	O
intervention	O
and	O
the	O
control	O
group	O
,	O
respectively	O
.	O

The	O
SCM	O
is	O
embedded	O
in	O
a	O
multiprofessional	O
network	O
(	O
see	O
below	O
)	O
and	O
consists	O
of	O
the	O
following	O
components	O
:	O

GPs	O
of	O
the	O
intervention	O
group	O
continue	O
the	O
diagnostic	O
process	O
with	O
a	O
paper	O
-	O
pencil	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
-	O
checklist	O
to	O
determine	O
depression	B-phenotype
type	I-phenotype
and	I-phenotype
severity	I-phenotype
.	O

Patients	O
are	O
given	O
psycho	O
-	O
education	O
about	O
depression	O
including	O
evidence	O
-	O
based	O
patient	O
information	O
.	O

The	O
decision	O
about	O
which	O
evidence	O
-	O
based	O
treatment	O
option	O
to	O
carry	O
out	O
is	O
made	O
in	O
cooperation	O
with	O
the	O
patient	O
(	O
shared	O
decision	O
-	O
making	O
)	O
.	O

Treatment	O
interventions	O
are	O
allocated	O
with	O
consideration	O
to	O
depression	O
severity	O
and	O
patient	O
preference	O
following	O
guideline	O
recommendations	O
.	O

The	O
six	O
treatment	O
options	O
(	O
as	O
well	O
as	O
the	O
step	O
1	O
option	O
of	O
watchful	O
waiting	O
)	O
,	O
the	O
rationale	O
for	O
treatment	O
selection	O
within	O
stratified	O
stepped	O
care	O
and	O
the	O
care	O
provider	O
responsible	O
for	O
each	O
treatment	O
option	O
are	O
displayed	O
in	O
Table	O
1	O
.	O

While	O
these	O
recommendations	O
offer	O
a	O
rationale	O
orientation	O
for	O
treatment	O
decisions	O
,	O
the	O
assessment	O
of	O
the	O
individual’s	O
preferences	O
may	O
lead	O
to	O
different	O
individual	O
treatment	O
decisions	O
.	O

Table	O
1	O
Criteria	O
for	O
systematic	O
treatment	O
indication	O
and	O
description	O
of	O
responsible	O
care	O
providers	O
for	O
each	O
step	O
Severity	O
of	O
the	O
depressive	O
disorder	O
Step	O
in	O
the	O
SCM	O
Intervention	O
Responsible	O
care	O
provider	O
Mild	O
depressive	O
disorder	O
,	O
duration	O
:	O
up	O
to	O
two	O
weeks	O
1	O
Watchful	O
waiting	O
(	O
active	O
monitoring	O
)	O
for	O
2	O
weeks	O
GP	O
Mild	O
depressive	O
disorder	O
,	O
duration	O
:	O
over	O
two	O
weeks	O
2	O
.	O
a	O
or	O
2	O
.	O
b	O
Bibliotherapy	O
or	O
Internet	O
-	O
based	O
self	O
-	O
help	O
program	O
GP	O
Mild	O
to	O
moderate	O
depressive	O
disorder	O
,	O
duration	O
:	O
over	O
two	O
weeks	O
2	O
plus	O

Telephone	O
-	O
based	O
psychotherapy	O
Psychotherapist	O
Moderate	O
depressive	O
disorder	O
3	O
.	O
a	O
or	O
3	O
.	O
b	O
Psychotherapy	O
or	O
pharmacotherapy	O
Psychotherapist	O
or	O
psychiatrist	O
/	O
GP	O
Severe	O
depressive	O
disorder	O
without	O
/	O
with	O
suicidality	O
4	O
Combination	O
therapy	O
:	O
psycho	O
-	O
and	O
pharmacotherapy	O
(	O
inpatient	O
or	O
outpatient	O
setting	O
)	O
Psychotherapist	O
and	O
psychiatrist	O
;	O
clinic	O

Criteria	O
for	O
systematic	O
treatment	O
indication	O
and	O
description	O
of	O
responsible	O
care	O
providers	O
for	O
each	O
step	O

Three	O
forms	O
of	O
low	O
-	O
intensity	O
treatment	O
for	O
patients	O
with	O
mild	O
depressive	O
disorders	O
are	O
offered	O
:	O
1	O
)	O
step	O
2	O
.	O
a	O
:	O
bibliotherapy	O
;	O
2	O
)	O
step	O
2	O
.	O
b	O
:	O
the	O
Internet	O
-	O
based	O
self	O
-	O
management	O
program	O
“deprexis®”	O
and	O
3	O
)	O
step	O
2	O
plus	O
:	O
telephone	O
-	O
based	O
psychotherapy	O
with	O
a	O
previous	O
face	O
-	O
to	O
-	O
face	O
contact	O
conducted	O
by	O
a	O
licensed	O
psychotherapist	O
.	O

In	O
bibliotherapy	O
,	O
patients	O
work	O
independently	O
and	O
at	O
their	O
own	O
pace	O
with	O
a	O
cognitive	O
-	O
behavioral	O
self	O
-	O
help	O
book	O
(	O
“Selbsthilfe	O
bei	O
Depressionen”	O
)	O
[	O
27	O
]	O
,	O
comprising	O
detailed	O
psycho	O
-	O
education	O
and	O
exercises	O
with	O
a	O
focus	O
on	O
behavioral	O
activation	O
and	O
cognitive	O
restructuring	O
.	O

Personal	O
guidance	O
is	O
limited	O
in	O
its	O
scope	O
and	O
is	O
carried	O
out	O
by	O
the	O
GP	O
who	O
gives	O
an	O
initial	O
introduction	O
to	O
the	O
intervention	O
,	O
hands	O
out	O
the	O
book	O
and	O
monitors	O
the	O
progress	O
of	O
patients	O
in	O
this	O
step	O
.	O

In	O
Internet	O
-	O
based	O
self	O
-	O
management	O
,	O
the	O
GP	O
informs	O
the	O
patient	O
about	O
the	O
program	O
and	O
the	O
procedures	O
and	O
provides	O
the	O
patient	O
with	O
a	O
personal	O
license	O
to	O
register	O
to	O
the	O
software	O
.	O

The	O
program	O
deprexis®	O
is	O
a	O
certified	O
medical	O
product	O
based	O
on	O
a	O
cognitive	O
-	O
behavioral	O
approach	O
that	O
allows	O
patients	O
to	O
work	O
independently	O
and	O
at	O
their	O
own	O
pace	O
[	O
28	O
]	O
.	O

The	O
program	O
consists	O
of	O
12	O
interactive	O
simulated	O
conversations	O
including	O
detailed	O
psycho	O
-	O
education	O
and	O
exercises	O
.	O

It	O
focuses	O
on	O
behavioral	O
activation	O
and	O
cognitive	O
restructuring	O
.	O

For	O
each	O
patient	O
,	O
the	O
program	O
is	O
tailored	O
individually	O
in	O
terms	O
of	O
level	O
of	O
detail	O
,	O
language	O
and	O
personal	O
relevance	O
.	O

The	O
GP	O
monitors	O
and	O
accompanies	O
the	O
patient	O
during	O
the	O
three	O
months	O
scheduled	O
to	O
complete	O
the	O
program	O
.	O

The	O
telephone	O
-	O
based	O
psychotherapy	O
is	O
the	O
translated	O
and	O
adapted	O
version	O
of	O
a	O
specific	O
intervention	O
program	O
[	O
29	O
–	O
31	O
]	O
developed	O
by	O
researchers	O
in	O
Seattle	O
.	O

It	O
includes	O
a	O
patient	O
workbook	O
as	O
well	O
as	O
a	O
therapist	O
manual	O
and	O
will	O
be	O
evaluated	O
in	O
two	O
conditions	O
(	O
delivery	O
with	O
vs	O
.	O
without	O
additional	O
motivating	O
letters	O
from	O
the	O
psychotherapist	O
after	O
each	O
session	O
)	O
.	O

It	O
comprises	O
8	O
to	O
12	O
telephone	O
contacts	O
(	O
20	O
to	O
40	O
minutes	O
)	O
which	O
are	O
carried	O
out	O
weekly	O
and	O
-	O
at	O
a	O
later	O
treatment	O
stage	O
-	O
biweekly	O
.	O

This	O
3	O
-	O
month	O
structured	O
program	O
also	O
follows	O
a	O
cognitive	O
behavioral	O
approach	O
with	O
the	O
main	O
focus	O
on	O
behavioral	O
activation	O
and	O
cognitive	O
restructuring	O
.	O

As	O
the	O
level	O
of	O
guidance	O
and	O
intensity	O
in	O
telephone	O
-	O
based	O
psychotherapy	O
is	O
higher	O
than	O
in	O
bibliotherapy	O
and	O
Internet	O
-	O
based	O
self	O
-	O
management	O
,	O
it	O
can	O
also	O
be	O
carried	O
out	O
with	O
patients	O
suffering	O
from	O
moderate	O
depression	O
,	O
especially	O
if	O
they	O
decline	O
step	O
3	O
(	O
psychotherapeutic	O
or	O
pharmacological	O
treatment	O
)	O
.	O

Psychotherapy	O
and	O
/	O
or	O
pharmacotherapy	O
(	O
as	O
stand	O
-	O
alone	O
and	O
as	O
combination	O
treatment	O
)	O
are	O
conducted	O
by	O
health	O
care	O
providers	O
in	O
outpatient	O
care	O
(	O
psychotherapy	O
:	O
psychologists	O
or	O
physicians	O
licensed	O
as	O
psychotherapists	O
;	O
pharmacotherapy	O
:	O
psychiatrists	O
or	O
GPs	O
)	O
from	O
routine	O
care	O
who	O
undergo	O
initial	O
training	O
and	O
take	O
part	O
in	O
four	O
quality	O
circles	O
per	O
year	O
(	O
see	O
next	O
section	O
)	O
.	O

Depression	O
severity	O
is	O
systematically	O
monitored	O
by	O
the	O
responsible	O
care	O
provider	O
within	O
defined	O
time	O
intervals	O
in	O
order	O
to	O
ensure	O
that	O
a	O
potential	O
under	O
-	O
or	O
oversupply	O
is	O
detected	O
as	O
quickly	O
as	O
possible	O
.	O

During	O
monitoring	O
patients	O
fill	O
out	O
the	O
PHQ	O
-	O
9	O
which	O
is	O
checked	O
by	O
the	O
provider	O
.	O

Additionally	O
,	O
the	O
care	O
provider	O
(	O
GP	O
,	O
psychiatrist	O
or	O
psychotherapist	O
)	O
completes	O
a	O
monitoring	O
sheet	O
.	O

This	O
checklist	O
assesses	O
treatment	O
-	O
related	O
information	O
and	O
is	O
designed	O
to	O
facilitate	O
decisions	O
regarding	O
further	O
treatment	O
(	O
continuing	O
current	O
treatment	O
,	O
stepping	O
up	O
or	O
down	O
,	O
treatment	O
termination	O
)	O
.	O

A	O
necessary	O
framework	O
for	O
the	O
SCM	O
is	O
its	O
integration	O
in	O
a	O
network	O
consisting	O
of	O
the	O
relevant	O
care	O
providers	O
involved	O
in	O
the	O
treatment	O
of	O
depressive	O
patients	O
,	O
i	O
.	O
e	O
.	O

GPs	O
,	O
psychotherapist	O
,	O
psychiatrists	O
and	O
inpatient	O
care	O
facilities	O
.	O

To	O
build	O
such	O
a	O
network	O
these	O
professional	O
groups	O
were	O
sent	O
information	O
and	O
personal	O
invitations	O
to	O
join	O
the	O
project	O
.	O

Additionally	O
,	O
articles	O
in	O
professional	O
journals	O
advertising	O
the	O
study	O
were	O
published	O
and	O
professionals	O
were	O
contacted	O
via	O
telephone	O
.	O

The	O
main	O
focus	O
of	O
the	O
network	O
is	O
facilitation	O
and	O
enhancement	O
of	O
information	O
exchange	O
and	O
communication	O
between	O
all	O
network	O
care	O
providers	O
of	O
the	O
network	O
in	O
order	O
to	O
increase	O
the	O
quality	O
of	O
patients’	O
health	O
care	O
.	O

Another	O
important	O
aspect	O
is	O
the	O
prompt	O
referral	O
to	O
a	O
secondary	O
care	O
provider	O
like	O
psychotherapist	O
or	O
psychiatrist	O
.	O

Information	O
exchange	O
about	O
available	O
treatment	O
capacities	O
in	O
secondary	O
care	O
is	O
enhanced	O
using	O
an	O
online	O
tool	O
specifically	O
developed	O
for	O
this	O
project	O
.	O

Psychotherapists	O
and	O
psychiatrists	O
indicate	O
whether	O
they	O
currently	O
have	O
an	O
available	O
treatment	O
capacity	O
which	O
implies	O
that	O
the	O
psychiatrist	O
or	O
psychotherapist	O
is	O
able	O
to	O
offer	O
the	O
patient	O
a	O
first	O
contact	O
within	O
the	O
next	O
three	O
weeks	O
.	O

This	O
way	O
,	O
GPs	O
are	O
able	O
to	O
make	O
a	O
reservation	O
for	O
their	O
patients	O
online	O
and	O
refer	O
them	O
into	O
secondary	O
treatment	O
without	O
delay	O
.	O

Previous	O
to	O
the	O
implementation	O
of	O
the	O
SCM	O
,	O
participating	O
care	O
providers	O
obtain	O
training	O
regarding	O
the	O
recommendations	O
of	O
the	O
German	O
National	O
Clinical	O
Practice	O
Guideline	O
for	O
unipolar	O
depression	O
[	O
18	O
]	O
,	O
the	O
rationale	O
and	O
the	O
treatment	O
concept	O
of	O
the	O
SCM	O
and	O
the	O
specific	O
interventions	O
.	O

Each	O
GP	O
is	O
additionally	O
visited	O
by	O
the	O
study	O
team	O
at	O
least	O
once	O
in	O
his	O
or	O
her	O
practice	O
to	O
review	O
the	O
diagnostic	O
routines	O
in	O
the	O
everyday	O
routine	O
care	O
.	O

The	O
psychotherapist	O
for	O
the	O
telephone	O
-	O
based	O
treatment	O
receives	O
special	O
training	O
and	O
weekly	O
supervision	O
.	O

Within	O
the	O
network	O
,	O
guideline	O
-	O
based	O
quality	O
standards	O
are	O
defined	O
(	O
e	O
.	O
g	O
.	O
type	O
and	O
frequency	O
of	O
monitoring	O
)	O
.	O

To	O
ensure	O
that	O
these	O
standards	O
are	O
met	O
and	O
to	O
promote	O
the	O
cooperation	O
and	O
information	O
exchange	O
between	O
the	O
participating	O
care	O
providers	O
,	O
quarter	O
-	O
yearly	O
quality	O
circles	O
take	O
place	O
.	O

For	O
the	O
conception	O
of	O
the	O
initial	O
training	O
and	O
quality	O
circles	O
we	O
could	O
integrate	O
experiences	O
from	O
former	O
projects	O
[	O
32	O
–	O
35	O
]	O
.	O

Patients	O
in	O
the	O
control	O
condition	O
receive	O
treatment	O
as	O
usual	O
by	O
their	O
GP	O
and	O
within	O
the	O
regular	O
German	O
health	O
care	O
system	O
.	O

However	O
,	O
systematic	O
screening	O
with	O
the	O
risk	O
-	O
checklist	O
,	O
main	O
-	O
symptom	O
-	O
checklist	O
and	O
PHQ	O
-	O
9	O
are	O
carried	O
out	O
in	O
both	O
intervention	O
and	O
control	O
group	O
to	O
ensure	O
a	O
comparable	O
recruitment	O
and	O
inclusion	O
process	O
.	O

The	O
main	O
data	O
collection	O
comprises	O
paper	O
-	O
pencil	O
questionnaires	O
which	O
are	O
filled	O
out	O
by	O
the	O
patients	O
at	O
four	O
time	O
points	O
:	O
The	O
baseline	O
questionnaire	O
(	O
t0	O
)	O
is	O
handed	O
out	O
by	O
the	O
GP	O
at	O
intake	O
and	O
filled	O
out	O
before	O
any	O
treatment	O
begins	O
.	O

The	O
questionnaires	O
3	O
months	O
(	O
t1	O
)	O
,	O
6	O
months	O
(	O
t2	O
)	O
and	O
12	O
months	O
(	O
t3	O
)	O
after	O
baseline	O
are	O
sent	O
to	O
the	O
patient’s	O
by	O
mail	O
.	O

For	O
each	O
completed	O
questionnaire	O
,	O
patients	O
receive	O
an	O
incentive	O
of	O
5	O
€	O
.	O

Patients	O
who	O
fail	O
to	O
send	O
back	O
their	O
questionnaires	O
are	O
reminded	O
to	O
do	O
so	O
twice	O
by	O
mail	O
.	O

The	O
primary	O
outcome	O
parameter	O
for	O
effectiveness	O
is	O
the	O
change	O
in	O
depressive	O
symptoms	O
from	O
baseline	O
to	O
t3	O
assessed	O
by	O
the	O
PHQ	O
-	O
9	O
.	O

Secondary	O
outcome	O
parameters	O
are	O
response	O
(	O
defined	O
as	O
a	O
50	O
%	O
reduction	O
in	O
the	O
PHQ	O
-	O
9	O
from	O
t0	O
to	O
t3	O
)	O
and	O
remission	O
(	O
defined	O
as	O
<	O
5	O
points	O
in	O
the	O
PHQ	O
-	O
9	O
at	O
t3	O
)	O
,	O
change	O
in	O
health	O
related	O
quality	O
of	O
life	O
(	O
SF	O
-	O
12	O
and	O
EQ	O
-	O
5D	O
-	O
3	O
L	O
)	O
and	O
further	O
clinical	O
and	O
psycho	O
-	O
social	O
variables	O
.	O

To	O
evaluate	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	O
SCM	O
,	O
direct	O
and	O
indirect	O
costs	O
as	O
well	O
as	O
quality	O
-	O
adjusted	O
life	O
years	O
(	O
QALYs	O
)	O
based	O
on	O
the	O
EQ	O
-	O
5D	O
index	O
are	O
measured	O
and	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
is	O
computed	O
as	O
further	O
secondary	O
outcomes	O
.	O

Process	O
analyses	O
refer	O
to	O
treatment	O
paths	O
,	O
decision	O
processes	O
and	O
interface	O
management	O
.	O

Additionally	O
,	O
feasibility	O
and	O
acceptance	O
of	O
the	O
overall	O
model	O
of	O
stepped	O
care	O
and	O
of	O
its	O
components	O
are	O
analyzed	O
taking	O
patient	O
and	O
care	O
provider	O
perspectives	O
into	O
account	O
.	O

Table	O
2	O
summarizes	O
the	O
instruments	O
for	O
the	O
patient	O
self	O
-	O
ratings	O
.	O

Table	O
2	O
Instruments	O
and	O
measurement	O
points	O
(	O
patient	O
self	O
-	O
ratings	O
)	O
Measurements	O
Outcome	O
variables	O
T0	O
T1	O
T2	O
T3	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
-	O
D	O
)	O
X	O
X	O
X	O
X	O
Short	O
Form	O
Health	O
Survey	O
(	O
SF	O
-	O
12	O
)	O
X	O
X	O
X	O
X	O
EuroQol	O
(	O
EQ	O
-	O
5D	O
-	O
3	O
L	O
)	O
X	O
X	O
X	O
X	O
General	O
self	O
-	O
esteem	O
scale	O
(	O
Rosenberg	O
Self	O
-	O
Esteem	O
-	O
Scale	O
RSES	O
)	O
X	O
X	O
X	O
X	O
General	O
self	O
-	O
efficacy	O
scale	O
(	O
GSE	O
)	O
X	O
X	O
X	O
X	O
Self	O
-	O
efficacy	O
for	O
management	O
and	O
relapse	O
prevention	O
in	O
depression	O
X	O
X	O
X	O
X	O
Depression	O
self	O
-	O
management	O
behavior	O
X	O
X	O
X	O
X	O
Medical	O
treatments	O
and	O
services	O
received	O

during	O
the	O
last	O
6	O
months	O
X	O
-	O
X	O
X	O
Medication	O
during	O
the	O
last	O
6	O
months	O
X	O
-	O
X	O
X	O
Health	O
care	O
utilization	O
during	O
the	O
last	O
3	O
resp	O
.	O
6	O
months	O
-	O
X	O
X	O
X	O
Satisfaction	O
with	O
specific	O
treatments	O
during	O
the	O
last	O
3	O
resp	O
.	O
6	O
months	O
-	O
X	O
X	O
X	O
Client	O
Satisfaction	O
Questionnaire	O
(	O
CSQ	O
-	O
8	O
)	O
-	O
-	O
-	O
X	O
Helping	O
Alliance	O
Questionnaire	O
(	O
HAQ	O
)	O
-	O
X	O
X	O
X	O
Further	O
(	O
controlling	O
)	O
variables	O
T0	O
T1	O
T2	O
T3	O
Sociodemographics	O
X	O
-	O
-	O
-	O
Social	O
Support	O
(	O
F	O
-	O
Sozu	O
-	O
14	O
)	O
X	O
-	O
-	O
-	O
Shared	O
decision	O
-	O
making	O
(	O
SDM	O
-	O
Q	O
-	O
9	O
)	O
X	O
-	O
-	O
-	O
Treatment	O
motivation	O
(	O
FPTM	O
-	O
23	O
,	O

subscales	O
“psychological	O
burden”	O
and	O
“expectations”	O
)	O
X	O
-	O
-	O
-	O
Former	O
depression	O
-	O
specific	O
treatments	O
X	O
-	O
-	O
-	O
Symptom	O
course	O
of	O
depression	O
X	O
-	O
-	O
-	O
Referral	O
procedures	O
and	O
interface	O
management	O
-	O
X	O
X	O
X	O
Self	O
-	O
help	O
experiences	O
and	O
habits	O
X	O
-	O
-	O
-	O

Instruments	O
and	O
measurement	O
points	O
(	O
patient	O
self	O
-	O
ratings	O
)	O

The	O
German	O
version	O
[	O
36	O
,	O
37	O
]	O
of	O
the	O
Patient	O
Health	O
Questionnaire	O
[	O
38	O
]	O
is	O
used	O
.	O

Specific	O
subscales	O
assessing	O
following	O
syndromes	O
were	O
selected	O
:	O
major	O
depressive	O
syndrome	O
(	O
9	O
items	O
)	O
,	O
generalized	O
anxiety	O
syndrome	O
(	O
7	O
items	O
)	O
,	O
somatoform	O
syndrome	O
(	O
13	O
items	O
)	O
and	O
panic	O
syndrome	O
(	O
11	O
items	O
)	O
.	O

Additionally	O
,	O
psychosocial	O
functioning	O
resp	O
.	O
psychosocial	O
stressors	O
are	O
measured	O
.	O

The	O
SF	O
-	O
12	O
assesses	O
overall	O
health	O
-	O
related	O
quality	O
of	O
life	O
and	O
is	O
based	O
on	O
the	O
Short	O
Form	O
36	O
Health	O
Survey	O
[	O
39	O
]	O
.	O

It	O
is	O
composed	O
of	O
the	O
two	O
subscales	O
physical	O
health	O
and	O
mental	O
health	O
.	O

Scores	O
are	O
computed	O
by	O
calculating	O
the	O
sum	O
of	O
the	O
12	O
weighted	O
items	O
and	O
then	O
transforming	O
it	O
to	O
a	O
scale	O
from	O
0	O
to	O
100	O
,	O
on	O
which	O
high	O
scores	O
indicate	O
a	O
high	O
level	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

This	O
generic	O
self	O
-	O
rating	O
instrument	O
measures	O
health	O
-	O
related	O
quality	O
of	O
life	O
on	O
five	O
dimensions	O
:	O
mobility	O
,	O
self	O
-	O
care	O
,	O
usual	O
activities	O
,	O
pain	O
/	O
discomfort	O
and	O
anxiety	O
/	O
depression	O
[	O
40	O
,	O
41	O
]	O
.	O

Each	O
dimension	O
has	O
three	O
response	O
categories	O
that	O
represent	O
three	O
levels	O
of	O
severity	O
(	O
“no	O
problems”	O
/	O
“some	O
or	O
moderate	O
problems”	O
/	O
“extreme	O
problems”	O
)	O
.	O

Additionally	O
,	O
a	O
visual	O
analogue	O
scale	O
allows	O
the	O
general	O
assessment	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

From	O
the	O
EQ	O
-	O
5D	O
-	O
3	O
L	O
a	O
preference	O
-	O
based	O
index	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
EQ	O
-	O
5D	O
index	O
)	O
can	O
be	O
derived	O
[	O
42	O
]	O
.	O

The	O
scale	O
was	O
originally	O
designed	O
by	O
Rosenberg	O
in	O
1965	O
to	O
assess	O
global	O
self	O
-	O
esteem	O
and	O
translated	O
to	O
German	O
[	O
43	O
]	O
.	O

It	O
contains	O
5	O
positively	O
and	O
5	O
negatively	O
formulated	O
items	O
with	O
statements	O
referring	O
to	O
the	O
subject’s	O
global	O
attitude	O
towards	O
him	O
-	O
or	O
herself	O
.	O

The	O
answers	O
are	O
given	O
on	O
a	O
four	O
-	O
point	O
scale	O
.	O

After	O
recoding	O
negative	O
items	O
a	O
total	O
score	O
can	O
be	O
computed	O
.	O

This	O
self	O
-	O
rating	O
instrument	O
measures	O
global	O
optimistic	O
beliefs	O
about	O
one’s	O
self	O
on	O
a	O
one	O
-	O
dimensional	O
scale	O
[	O
44	O
]	O
.	O

The	O
underlying	O
concept	O
of	O
self	O
-	O
efficacy	O
includes	O
the	O
self	O
-	O
related	O
expectation	O
to	O
be	O
able	O
to	O
successfully	O
cope	O
with	O
difficult	O
situations	O
.	O

On	O
ten	O
items	O
formulated	O
as	O
statements	O
,	O
subjects	O
indicate	O
their	O
level	O
of	O
agreement	O
on	O
a	O
four	O
-	O
point	O
scale	O
.	O

The	O
depression	O
-	O
related	O
self	O
-	O
efficacy	O
is	O
assessed	O
on	O
a	O
ten	O
-	O
point	O
scale	O
,	O
where	O
subjects	O
indicate	O
the	O
extent	O
of	O
trust	O
in	O
their	O
own	O
ability	O
to	O
cope	O
with	O
their	O
depressive	O
symptoms	O
and	O
complaints	O
[	O
45	O
]	O
.	O

Psychometric	O
analyses	O
have	O
confirmed	O
the	O
scale’s	O
internal	O
consistency	O
.	O

These	O
five	O
items	O
cover	O
depression	O
-	O
related	O
self	O
-	O
management	O
behavior	O
to	O
assess	O
patients’	O
behavioral	O
strategies	O
for	O
handling	O
depression	O
[	O
46	O
]	O
.	O

Patients	O
are	O
questioned	O
about	O
the	O
frequency	O
with	O
which	O
they	O
integrate	O
pleasant	O
and	O
social	O
activities	O
into	O
everyday	O
life	O
as	O
well	O
as	O
about	O
their	O
attention	O
regarding	O
depressive	O
symptoms	O
,	O
early	O
warning	O
signs	O
and	O
situations	O
which	O
put	O
them	O
at	O
risk	O
of	O
depressive	O
episodes	O
.	O

These	O
two	O
parts	O
of	O
the	O
questionnaire	O
aim	O
to	O
explore	O
which	O
offers	O
patients	O
made	O
use	O
of	O
during	O
the	O
last	O
3	O
respectively	O
6	O
months	O
and	O
how	O
they	O
are	O
perceived	O
and	O
evaluated	O
.	O

On	O
eight	O
items	O
,	O
this	O
questionnaire	O
measures	O
the	O
extent	O
of	O
the	O
patient’s	O
satisfaction	O
with	O
received	O
medical	O
and	O
psychotherapeutic	O
treatment	O
[	O
47	O
,	O
48	O
]	O
.	O

Important	O
aspects	O
are	O
the	O
interaction	O
between	O
care	O
provider	O
and	O
patient	O
,	O
information	O
about	O
received	O
treatment	O
elements	O
and	O
the	O
communication	O
between	O
the	O
care	O
providers	O
.	O

The	O
German	O
short	O
version	O
of	O
this	O
questionnaire	O
consists	O
of	O
11	O
items	O
rated	O
on	O
a	O
six	O
-	O
point	O
scale	O
[	O
49	O
]	O
.	O

The	O
HAQ	O
assesses	O
the	O
two	O
factors	O
“perceived	O
helpfulness”	O
and	O
“collaboration	O
or	O
bonding”	O
.	O

It	O
aims	O
to	O
capture	O
the	O
patient’s	O
view	O
of	O
the	O
relationship	O
with	O
the	O
psychotherapist	O
and	O
of	O
process	O
variables	O
.	O

High	O
scores	O
indicate	O
a	O
high	O
level	O
of	O
relationship	O
quality	O
.	O

Following	O
socio	O
-	O
demographic	O
data	O
is	O
collected	O
within	O
a	O
structured	O
questionnaire	O
:	O
age	O
,	O
gender	O
,	O
nationality	O
,	O
family	O
status	O
,	O
partnership	O
,	O
children	O
,	O
educational	O
background	O
,	O
vocational	O
training	O
,	O
housing	O
and	O
professional	O
situation	O
.	O

The	O
14	O
-	O
item	O
Social	O
Support	O
questionnaire	O
assesses	O
perceived	O
social	O
support	O
(	O
practical	O
and	O
emotional	O
support	O
)	O
.	O

By	O
computing	O
means	O
,	O
a	O
total	O
score	O
from	O
1	O
to	O
5	O
points	O
can	O
be	O
calculated	O
[	O
50	O
]	O
.	O

This	O
instrument	O
measures	O
the	O
extent	O
to	O
which	O
the	O
patient	O
is	O
involved	O
in	O
the	O
decision	O
-	O
making	O
process	O
for	O
the	O
treatment	O
[	O
51	O
]	O
.	O

It	O
consists	O
of	O
nine	O
items	O
rated	O
on	O
a	O
6	O
-	O
point	O
scale	O
.	O

To	O
explore	O
the	O
different	O
aspects	O
of	O
patients’	O
self	O
-	O
rated	O
motivation	O
for	O
psychotherapeutic	O
treatment	O
the	O
short	O
version	O
of	O
this	O
instrument	O
with	O
23	O
items	O
rated	O
on	O
a	O
4	O
-	O
point	O
scale	O
is	O
employed	O
[	O
52	O
]	O
.	O

Depression	O
-	O
specific	O
treatments	O
received	O
prior	O
to	O
the	O
study	O
,	O
medical	O
treatments	O
and	O
services	O
received	O
during	O
the	O
last	O
6	O
months	O
and	O
medication	O
during	O
the	O
last	O
6	O
months	O
,	O
symptom	O
course	O
of	O
depression	O
,	O
referral	O
procedures	O
and	O
interface	O
management	O
,	O
self	O
-	O
help	O
experience	O
and	O
habits	O
.	O

These	O
forms	O
help	O
to	O
facilitate	O
and	O
support	O
the	O
diagnostic	O
and	O
treatment	O
process	O
(	O
and	O
are	O
therefore	O
elements	O
of	O
the	O
intervention	O
itself	O
)	O
,	O
as	O
well	O
as	O
to	O
document	O
clinical	O
processes	O
for	O
research	O
purpose	O
:	O
They	O
are	O
used	O
to	O
analyze	O
clinical	O
treatment	O
pathways	O
and	O
their	O
quality	O
as	O
well	O
as	O
to	O
draw	O
conclusions	O
about	O
care	O
providers’	O
adherence	O
to	O
the	O
guidelines	O
.	O

Each	O
health	O
care	O
provider	O
in	O
the	O
SCM	O
fills	O
out	O
a	O
questionnaire	O
assessing	O
the	O
feasibility	O
of	O
and	O
satisfaction	O
and	O
experiences	O
with	O
the	O
SCM	O
as	O
a	O
whole	O
,	O
the	O
single	O
components	O
of	O
the	O
SCM	O
(	O
especially	O
the	O
innovative	O
elements	O
)	O
and	O
the	O
quality	O
of	O
the	O
multi	O
-	O
professional	O
network	O
.	O

Information	O
regarding	O
structural	O
and	O
organizational	O
aspects	O
of	O
the	O
primary	O
care	O
practices	O
and	O
the	O
GPs	O
are	O
gathered	O
in	O
an	O
interview	O
at	O
the	O
beginning	O
of	O
the	O
study	O
.	O

Issues	O
covered	O
are	O
the	O
size	O
of	O
the	O
practices	O
as	O
well	O
as	O
their	O
equipment	O
,	O
catchment	O
area	O
,	O
workload	O
and	O
proportions	O
of	O
different	O
work	O
aspects	O
(	O
patient	O
contacts	O
,	O
administrative	O
tasks	O
,	O
etc	O
.	O
)	O
.	O

The	O
primary	O
analysis	O
of	O
the	O
change	O
in	O
depressive	O
symptoms	O
from	O
baseline	O
to	O
t3	O
assessed	O
by	O
the	O
PHQ	O
-	O
9	O
will	O
be	O
based	O
on	O
the	O
ITT	O
-	O
population	O
.	O

In	O
case	O
of	O
missing	O
follow	O
-	O
up	O
values	O
,	O
a	O
last	O
-	O
observation	O
carried	O
forward	O
(	O
LOCF	O
)	O
imputation	O
will	O
be	O
performed	O
,	O
that	O
is	O
,	O
the	O
baseline	O
determination	O
will	O
be	O
imputed	O
as	O
follow	O
-	O
up	O
determination	O
.	O

A	O
linear	O
mixed	O
model	O
will	O
be	O
calculated	O
with	O
group	O
(	O
SCM	O
/	O
TAU	O
)	O
as	O
a	O
fixed	O
effect	O
and	O
practice	O
as	O
a	O
random	O
effect	O
under	O
control	O
of	O
the	O
baseline	O
value	O
of	O
the	O
PHQ	O
-	O
9	O
as	O
covariate	O
.	O

Only	O
the	O
result	O
of	O
this	O
primary	O
efficacy	O
analysis	O
will	O
be	O
interpreted	O
in	O
a	O
confirmatory	O
manner	O
.	O

The	O
secondary	O
endpoints	O
will	O
be	O
examined	O
in	O
an	O
exploratory	O
manner	O
with	O
appropriate	O
procedures	O
,	O
including	O
subgroup	O
analysis	O
of	O
sex	O
,	O
socio	O
-	O
economic	O
status	O
and	O
symptom	O
severity	O
of	O
patients	O
.	O

Analyses	O
of	O
secondary	O
endpoints	O
should	O
provide	O
an	O
indication	O
on	O
the	O
consistency	O
of	O
the	O
results	O
from	O
the	O
evaluation	O
of	O
primary	O
endpoints	O
.	O

The	O
effects	O
of	O
the	O
selected	O
strata	O
in	O
the	O
minimization	O
algorithm	O
on	O
the	O
primary	O
and	O
secondary	O
endpoints	O
will	O
be	O
evaluated	O
additionally	O
.	O

Regression	O
coefficients	O
,	O
95	O
%	O
confidence	O
intervals	O
and	O
p	O
values	O
will	O
be	O
reported	O
.	O

The	O
analyses	O
will	O
be	O
conducted	O
with	O
the	O
newest	O
SPSS	O
version	O
.	O

With	O
regard	O
to	O
the	O
assessment	O
of	O
cost	O
-	O
effectiveness	O
direct	O
and	O
indirect	O
costs	O
will	O
be	O
calculated	O
.	O

Administrative	O
and	O
market	O
prices	O
will	O
be	O
used	O
to	O
value	O
resource	O
utilization	O
.	O

The	O
human	O
capital	O
approach	O
will	O
be	O
employed	O
to	O
value	O
productivity	O
losses	O
.	O

As	O
effect	O
measure	O
QALYs	O
will	O
be	O
calculated	O
from	O
the	O
EQ	O
-	O
5D	O
-	O
3	O
L	O
.	O

The	O
cost	O
-	O
effectiveness	O
analysis	O
will	O
be	O
performed	O
from	O
a	O
societal	O
perspective	O
.	O

As	O
point	O
estimate	O
of	O
cost	O
-	O
effectiveness	O
the	O
ICER	O
(	O
incremental	O
costs	O
per	O
QALY	O
)	O
will	O
be	O
calculated	O
.	O

To	O
assess	O
the	O
uncertainty	O
of	O
the	O
results	O
a	O
cost	O
-	O
effectiveness	O
-	O
acceptability	O
-	O
curve	O
(	O
CEAC	O
)	O
based	O
on	O
non	O
-	O
parametric	O
bootstrapping	O
will	O
be	O
computed	O
.	O

A	O
net	O
-	O
monetary	O
benefit	O
regression	O
analysis	O
will	O
be	O
performed	O
.	O

This	O
study	O
was	O
a	O
population	O
-	O
based	O
retrospective	O
observational	O
study	O
and	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
Korea	O
National	O
Institute	O
for	O
Bioethics	O
Policy	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
irb	O
.	O
or	O
.	O
kr	O
/	O
,	O
P01	O
-	O
201811-21-008	O
)	O
,	O
which	O
waived	O
the	O
requirement	O
for	O
informed	O
consent	O
because	O
all	O
patient	O
data	O
were	O
de	O
-	O
identified	O
.	O

We	O
used	O
the	O
Korean	O
National	O
Health	O
Insurance	O
Service	O
Senior	O
cohort	O
version	O
3	O
.	O
0	O
(	O
January	O
1	O
,	O
2002	O
to	O
December	O
31	O
,	O
2015	O
)	O
,	O
which	O
contains	O
around	O
550	O
,	O
000	O
patients	O
(	O
>	O
10	O
%	O
of	O
the	O
entire	O
South	O
Korea	O
senior	O
population	O
in	O
2002	O
)	O
.	O

This	O
dataset	O
was	O
extracted	O
from	O
the	O
Korean	O
National	O
Health	O
Insurance	O
Service	O
,	O
which	O
covers	O
over	O
99	O
%	O
of	O
the	O
South	O
Korean	O
population	O
,	O
using	O
a	O
stratified	O
random	O
sampling	O
method	O
with	O
1	O
,	O
476	O
strata	O
;	O
thus	O
,	O
it	O
is	O
representative	O
of	O
the	O
entire	O
Korean	O
senior	O
population	O
.	O

This	O
data	O
set	O
included	O
information	O
on	O
the	O
socioeconomic	O
status	O
of	O
Korean	O
National	O
Health	O
Insurance	O
Service	O
recipients	O
;	O
status	O
was	O
based	O
on	O
income	O
and	O
assets	O
,	O
such	O
as	O
property	O
and	O
automobile	O
ownership	O
.	O

Patients	O
diagnosed	O
with	O
T2DM	O
and	O
prescribed	O
oral	O
hypoglycemic	O
agents	O
or	O
insulin	O
were	O
enrolled	O
(	O
Fig	O
.	O

1	O
)	O
.	O

The	O
index	O
date	O
was	O
January	O
1	O
,	O
2011	O
,	O
and	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
the	O
presence	O
of	O
hypoglycemia	B-phenotype
(	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
10th	I-coding_system
revision	I-coding_system
[	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
]	I-coding_system
codes	O
E11	B-code
.	I-code
63	I-code
,	O
E15	B-code
,	O
E16	B-code
.	I-code
0	I-code
,	O
E16	B-code
.	I-code
1	I-code
,	O
and	O
E16	B-code
.	I-code
2	I-code
)	O
before	O
the	O
index	O
date	O
.	O

Patients	O
who	O
experienced	O
at	O
least	O
one	O
hypoglycemic	O
episode	O
were	O
placed	O
in	O
the	O
hypoglycemia	O
group	O
,	O
which	O
was	O
then	O
divided	O
into	O
three	O
groups	O
according	O
to	O
the	O
number	O
of	O
hypoglycemic	O
episodes	O
(	O
one	O
episode	O
,	O
two	O
or	O
three	O
episodes	O
,	O
or	O
more	O
than	O
three	O
episodes	O
)	O
.	O

Patients	O
with	O
type	B-phenotype
1	I-phenotype
diabetes	I-phenotype
mellitus	I-phenotype
(	O
T1DM	B-phenotype
;	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
code	O
E10	B-code
)	O
or	O
dementia	B-phenotype
diagnoses	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
F00	B-code
,	O
F01	B-code
,	O
F02	B-code
,	O
F03	B-code
,	O
F04	B-code
,	O
F05	B-code
,	O
G30	B-code
,	O
or	O
G31	B-code
)	O
or	O
a	O
medication	O
prescribed	O
to	O
treat	O
dementia	O
(	O
donepezil	O
,	O
memantin	O
,	O
rivastigmine	O
,	O
or	O
galantamine	O
)	O
before	O
the	O
index	O
date	O
(	O
January	O
1	O
,	O
2002	O
to	O
December	O
31	O
,	O
2010	O
)	O
were	O
excluded	O
.	O

The	O
loss	O
of	O
samples	O
is	O
described	O
in	O
Fig	O
.	O

1	O
.	O

Because	O
the	O
Korean	O
National	O
Health	O
Insurance	O
Service	O
Senior	O
cohort	O
consists	O
of	O
patients	O
≥60	O
years	O
old	O
in	O
2002	O
,	O
all	O
patients	O
were	O
>	O
68	O
years	O
of	O
age	O
on	O
the	O
index	O
date	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
first	O
diagnosis	O
of	O
all	B-phenotype
-	I-phenotype
cause	I-phenotype
dementia	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
F00	B-code
,	O
F01	B-code
,	O
F02	B-code
,	O
F03	B-code
,	O
F04	B-code
,	O
F05	B-code
,	O
G30	B-code
,	O
or	O
G31	B-code
)	O
.	O

The	O
secondary	O
outcome	O
was	O
the	O
first	O
diagnosis	O
of	O
AD	B-phenotype
(	O
F00	B-code
,	O
G30	B-code
)	O
or	O
VaD	B-phenotype
(	O
F01	B-code
)	O
.	O

Additionally	O
,	O
we	O
assessed	O
differences	O
in	O
the	O
risk	O
of	O
dementia	O
according	O
to	O
the	O
number	O
of	O
hypoglycemic	O
episodes	O
by	O
dividing	O
the	O
sample	O
into	O
three	O
groups	O
.	O

Subgroup	O
analyses	O
were	O
performed	O
according	O
to	O
sex	O
,	O
age	O
(	O
<	O
75	O
and	O
≥75	O
years	O
)	O
,	O
and	O
the	O
presence	O
of	O
T2DM	O
microvascular	O
(	O
any	O
diagnosis	O
of	O
diabetic	O
nephropathy	O
,	O
neuropathy	O
,	O
or	O
retinopathy	O
)	O
or	O
macrovascular	O
complications	O
(	O
any	O
diagnosis	O
of	O
stroke	O
,	O
transient	O
ischemic	O
attack	O
,	O
acute	O
myocardial	O
infarction	O
,	O
other	O
ischemic	O
heart	O
disease	O
,	O
and	O
peripheral	O
artery	O
occlusive	O
disease	O
)	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
R	O
software	O
version	O
3	O
.	O
3	O
.	O

3	O
(	O
R	O
Development	O
Core	O
Team	O
,	O
Vienna	O
,	O
Austria	O
)	O
and	O
SAS	O
version	O
9	O
.	O
4	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

All	O
values	O
are	O
presented	O
as	O
mean±standard	O
deviation	O
.	O

The	O
differences	O
between	O
patients	O
with	O
and	O
without	O
an	O
underlying	O
hypoglycemic	O
event	O
were	O
adjusted	O
with	O
propensity	O
score	O
matching	O
using	O
the	O
nearest	O
-	O
neighbor	O
technique	O
with	O
a	O
caliper	O
of	O
0	O
.	O
1	O
on	O
the	O
probability	O
scale	O
.	O

We	O
set	O
age	O
,	O
sex	O
,	O
socioeconomic	O
status	O
(	O
index	O
date	O
)	O
,	O
diagnoses	O
(	O
1	O
year	O
before	O
the	O
index	O
date	O
)	O
,	O
and	O
prescribed	O
drugs	O
(	O
180	O
days	O
before	O
the	O
index	O
date	O
)	O
as	O
confounding	O
variables	O
(	O
all	O
variables	O
presented	O
in	O
Table	O
1	O
)	O
and	O
those	O
were	O
used	O
to	O
calculate	O
propensity	O
scores	O
.	O

The	O
balance	O
achieved	O
by	O
matching	O
propensity	O
scores	O
was	O
assessed	O
using	O
standardized	O
differences	O
,	O
t	O
-	O
tests	O
(	O
age	O
)	O
,	O
chi	O
-	O
square	O
tests	O
(	O
all	O
other	O
variables	O
except	O
age	O
and	O
socioeconomic	O
status	O
)	O
,	O
and	O
Mantel	O
-	O
Haenszel	O
chi	O
-	O
square	O
tests	O
(	O
socioeconomic	O
status	O
)	O
;	O
an	O
absolute	O
standardized	O
difference	O
between	O
groups	O
<	O
0	O
.	O
1	O
was	O
considered	O
negligible	O
.	O

After	O
the	O
propensity	O
score	O
matching	O
,	O
a	O
Kaplan	O
-	O
Meier	O
curve	O
and	O
Cox	O
proportional	O
hazards	O
model	O
were	O
used	O
to	O
evaluate	O
the	O
dementia	O
risk	O
of	O
hypoglycemia	O
.	O

Because	O
all	O
confounding	O
variables	O
were	O
adjusted	O
in	O
propensity	O
score	O
matching	O
,	O
1	O
minus	O
Kaplan	O
-	O
Meier	O
estimate	O
,	O
and	O
a	O
univariate	O
Cox	O
regression	O
analysis	O
were	O
performed	O
.	O

To	O
ensure	O
protection	O
of	O
human	O
subjects	O
,	O
this	O
observational	O
study	O
was	O
conducted	O
with	O
approval	O
from	O
Brandeis	O
University’s	O
Committee	O
for	O
Protection	O
of	O
Human	O
Subjects	O
,	O
Boston	O
University’s	O
Institutional	O
Review	O
Board	O
,	O
and	O
the	O
DoD	O
Human	O
Research	O
Protection	O
Program	O
(	O
DoD	O
Directive	O
3216	O
.	O
02	O
)	O
at	O
the	O
Office	O
of	O
the	O
Assistant	O
Secretary	O
of	O
Defense	O
for	O
Health	O
Affairs	O
/	O
TRICARE	O
Management	O
Activity	O
(	O
OASD	O
/	O
TMA	O
)	O
.	O

The	O
TMA	O
Privacy	O
and	O
Civil	O
Liberties	O
Office	O
executed	O
a	O
Data	O
Sharing	O
Agreement	O
for	O
our	O
use	O
of	O
protected	O
health	O
information	O
to	O
ensure	O
compliance	O
with	O
DoD	O
privacy	O
and	O
security	O
regulations	O
and	O
the	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
.	O

All	O
active	O
duty	O
Army	O
service	O
members	O
who	O
returned	O
from	O
deployments	O
in	O
FY2010	O
were	O
included	O
in	O
the	O
study	O
cohort	O
.	O

Army	O
service	O
members	O
were	O
identified	O
by	O
branch	O
of	O
military	O
service	O
and	O
active	O
duty	O
status	O
from	O
the	O
Defense	O
Eligibility	O
and	O
Enrollment	O
Service	O
(	O
DEERS	O
)	O
file	O
.	O

From	O
the	O
Contingency	O
Tracking	O
System	O
(	O
CTS	O
)	O
,	O
deployment	O
records	O
which	O
had	O
end	O
dates	O
during	O
FY2010	O
were	O
selected	O
.	O

Deployment	O
records	O
were	O
cleaned	O
by	O
collapsing	O
records	O
which	O
had	O
overlapping	O
time	O
periods	O
into	O
one	O
deployment	O
.	O

If	O
there	O
was	O
more	O
than	O
one	O
CTS	O
record	O
for	O
a	O
service	O
member	O
with	O
a	O
return	O
date	O
in	O
FY2010	O
,	O
then	O
the	O
deployment	O
with	O
the	O
first	O
return	O
date	O
in	O
FY2010	O
was	O
identified	O
as	O
the	O
“index	O
deployment”	O
.	O

The	O
resulting	O
cohort	O
was	O
comprised	O
of	O
137	O
,	O
814	O
men	O
and	O
14	O
,	O
633	O
women	O
for	O
a	O
total	O
of	O
152	O
,	O
477	O
cohort	O
members	O
with	O
deployments	O
ending	O
in	O
FY2010	O
.	O

In	O
addition	O
to	O
DEERS	O
and	O
CTS	O
records	O
,	O
the	O
study	O
obtained	O
for	O
each	O
cohort	O
member	O
selected	O
encounters	O
and	O
claims	O
from	O
the	O
DoD	O
Military	O
Health	O
System	O
Data	O
Repository	O
(	O
MDR	O
)	O
.	O

The	O
DoD	O
MDR	O
is	O
a	O
worldwide	O
health	O
care	O
management	O
system	O
comprised	O
of	O
direct	O
care	O
in	O
MTFs	O
,	O
purchased	O
care	O
from	O
civilian	O
or	O
other	O
non	O
-	O
DoD	O
facilities	O
,	O
and	O
the	O
DoD	O
prescription	O
drug	O
transaction	O
system	O
.	O

The	O
behavioral	O
health	O
encounters	O
and	O
claims	O
selected	O
for	O
these	O
analyses	O
came	O
from	O
the	O
“mental	O
health	O
cube”	O
data	O
system	O
,	O
which	O
summarizes	O
all	O
institutional	O
,	O
ambulatory	O
,	O
and	O
prescription	O
drug	O
utilization	O
for	O
service	O
members	O
since	O
FY2002	O
.	O

We	O
analyzed	O
person	O
-	O
level	O
summary	O
records	O
from	O
this	O
longitudinal	O
data	O
set	O
.	O

The	O
observation	O
period	O
for	O
the	O
dependent	O
variables	O
,	O
“prior	O
year”	O
,	O
was	O
a	O
unique	O
window	O
constructed	O
for	O
each	O
Army	O
cohort	O
member	O
based	O
on	O
the	O
start	O
date	O
of	O
the	O
index	O
deployment	O
,	O
and	O
was	O
defined	O
as	O
the	O
365	O
days	O
prior	O
to	O
the	O
index	O
deployment	O
start	O
date	O
.	O

The	O
intention	O
was	O
to	O
observe	O
service	O
members	O
when	O
they	O
were	O
not	O
currently	O
on	O
a	O
deployment	O
,	O
but	O
were	O
preparing	O
for	O
an	O
upcoming	O
deployment	O
.	O

For	O
8	O
%	O
of	O
the	O
cohort	O
members	O
(	O
9	O
%	O
of	O
men	O
,	O
6	O
%	O
of	O
women	O
)	O
,	O
the	O
prior	O
year	O
was	O
less	O
than	O
365	O
days	O
because	O
their	O
index	O
deployment	O
occurred	O
less	O
than	O
one	O
year	O
after	O
a	O
previous	O
deployment	O
(	O
dates	O
of	O
occurrence	O
not	O
available	O
)	O
.	O

“Military	O
lifetime”	O
was	O
used	O
for	O
some	O
covariates	O
and	O
was	O
defined	O
as	O
the	O
period	O
starting	O
with	O
the	O
cohort	O
member’s	O
first	O
date	O
of	O
military	O
health	O
system	O
(	O
MHS	O
)	O
entitlement	O
(	O
or	O
the	O
beginning	O
of	O
FY2002	O
for	O
service	O
members	O
whose	O
entitlement	O
began	O
before	O
FY2002	O
)	O
to	O
the	O
one	O
year	O
prior	O
to	O
the	O
start	O
date	O
of	O
the	O
index	O
deployment	O
.	O

For	O
the	O
first	O
research	O
question	O
,	O
the	O
dependent	O
variable	O
was	O
SUDX	B-coding_system
in	O
military	O
lifetime	O
,	O
defined	O
by	O
examining	O
all	O
diagnoses	O
on	O
all	O
claims	O
and	O
encounters	O
independent	O
of	O
position	O
.	O

To	O
qualify	O
as	O
a	O
SUDX	O
,	O
we	O
required	O
either	O
one	O
inpatient	O
record	O
or	O
two	O
outpatient	O
claims	O
/	O
encounters	O
with	O
a	O
SUDX	B-coding_system
.	O

SUDX	B-coding_system
codes	O
covered	O
a	O
broad	O
range	O
of	O
diagnoses	O
inclusive	O
of	O
the	O
Agency	B-coding_system
for	I-coding_system
Healthcare	I-coding_system
Research	I-coding_system
and	I-coding_system
Quality	I-coding_system
Clinical	I-coding_system
Classification	I-coding_system
codes	O
for	O
alcohol	B-phenotype
abuse	I-phenotype
,	I-phenotype
substance	I-phenotype
abuse	I-phenotype
,	I-phenotype
personal	I-phenotype
history	I-phenotype
of	I-phenotype
alcohol	I-phenotype
abuse	I-phenotype
or	I-phenotype
substance	I-phenotype
abuse	I-phenotype
codes	I-phenotype
,	O
and	O
additional	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
for	O
acute	B-phenotype
drug	I-phenotype
abuse	I-phenotype
,	I-phenotype
acute	I-phenotype
alcohol	I-phenotype
disease	I-phenotype
,	I-phenotype
chronic	I-phenotype
alcohol	I-phenotype
disease	I-phenotype
,	I-phenotype
opioid	I-phenotype
dependence	I-phenotype
,	I-phenotype
and	I-phenotype
sedative	I-phenotype
,	I-phenotype
hypnotic	I-phenotype
,	I-phenotype
and	I-phenotype
anxiolytic	I-phenotype
dependence	I-phenotype
.	O

For	O
the	O
second	O
and	O
third	O
research	O
questions	O
,	O
the	O
dependent	O
variable	O
was	O
any	O
SUT	O
utilization	O
measured	O
as	O
one	O
or	O
more	O
inpatient	O
(	O
IP	O
)	O
admissions	O
or	O
outpatient	O
(	O
OP	O
)	O
encounters	O
assigned	O
a	O
major	O
diagnostic	O
code	O
(	O
MDC	O
)	O
of	O
20	O
(	O
alcohol	O
/	O
other	O
drug	O
use	O
or	O
alcohol	O
/	O
drug	O
induced	O
mental	O
disorders	O
)	O
.	O

MDCs	B-phenotype
are	O
based	O
on	O
principal	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
diagnoses	O
,	O
grouping	O
all	O
codes	O
into	O
25	O
mutually	O
exclusive	O
categories	O
.	O

While	O
MDC	O
20	O
does	O
not	O
indicate	O
type	O
of	O
care	O
,	O
the	O
stay	O
or	O
encounter	O
was	O
characterized	O
as	O
services	O
for	O
alcohol	O
and	O
other	O
drug	O
disorder	O
because	O
of	O
the	O
diagnosis	O
codes’	O
principal	O
position	O
.	O

We	O
note	O
that	O
,	O
based	O
on	O
diagnosis	O
,	O
the	O
MDC	O
20	O
group	O
captures	O
detoxification	O
and	O
non	O
-	O
rehabilitation	O
procedures	O
as	O
well	O
as	O
rehabilitation	O
and	O
therapeutic	O
counseling	O
.	O

A	O
secondary	O
dependent	O
variable	O
for	O
the	O
third	O
research	O
question	O
was	O
the	O
number	O
of	O
outpatient	O
SUT	O
ambulatory	O
encounters	O
among	O
those	O
who	O
had	O
at	O
least	O
one	O
such	O
encounter	O
,	O
again	O
defined	O
by	O
encounters	O
assigned	O
MDC	O
20	O
.	O

Gender	O
was	O
the	O
primary	O
independent	O
variable	O
in	O
our	O
analyses	O
.	O

A	O
primary	O
covariate	O
was	O
the	O
propensity	O
to	O
receive	O
a	O
SUDX	O
in	O
military	O
lifetime	O
(	O
used	O
for	O
research	O
questions	O
two	O
and	O
three	O
only	O
and	O
described	O
in	O
statistical	O
methods	O
below	O
)	O
.	O

All	O
demographic	O
covariates	O
were	O
measured	O
at	O
the	O
start	O
date	O
of	O
the	O
index	O
deployment	O
.	O

The	O
demographic	O
measures	O
included	O
:	O
Age	O
in	O
years	O
,	O
marital	O
status	O
(	O
married	O
,	O
divorced	O
/	O
widowed	O
,	O
single	O
)	O
,	O
military	O
rank	O
(	O
enlisted	O
,	O
commissioned	O
officer	O
,	O
warrant	O
officer	O
)	O
,	O
race	O
/	O
ethnicity	O
(	O
white	O
,	O
black	O
,	O
Asian	O
,	O
other	O
)	O
,	O
number	O
of	O
military	O
dependents	O
sponsored	O
by	O
the	O
service	O
member	O
,	O
and	O
single	O
parent	O
status	O
(	O
yes	O
/	O
no	O
)	O
defined	O
as	O
single	O
or	O
divorced	O
/	O
widowed	O
marital	O
status	O
and	O
one	O
or	O
more	O
military	O
dependents	O
.	O

We	O
included	O
deployment	O
history	O
measures	O
that	O
may	O
influence	O
SUT	O
,	O
including	O
any	O
deployment	O
prior	O
to	O
the	O
index	O
deployment	O
(	O
yes	O
/	O
no	O
)	O
,	O
and	O
short	O
dwell	O
time	O
(	O
yes	O
/	O
no	O
)	O
defined	O
as	O
less	O
than	O
365	O
days	O
between	O
the	O
index	O
deployment	O
start	O
date	O
and	O
the	O
end	O
of	O
a	O
prior	O
deployment	O
.	O

We	O
also	O
adjusted	O
for	O
the	O
variation	O
in	O
service	O
members’	O
length	O
of	O
military	O
service	O
by	O
constructing	O
a	O
covariate	O
for	O
months	O
of	O
TRICARE	O
eligibility	O
,	O
defined	O
as	O
the	O
total	O
months	O
between	O
first	O
eligibility	O
date	O
and	O
start	O
date	O
of	O
the	O
index	O
deployment	O
.	O

Finally	O
,	O
we	O
constructed	O
a	O
measure	O
of	O
physical	O
injury	O
comorbidity	O
for	O
the	O
prior	O
year	O
and	O
mental	O
health	O
treatment	O
utilization	O
.	O

Physical	O
injury	O
comorbidity	O
was	O
based	O
on	O
the	O
Wounded	O
,	O
Ill	O
,	O
and	O
Injured	O
definitions	O
in	O
the	O
MHS	O
and	O
was	O
defined	O
as	O
amputations	O
,	O
burns	O
,	O
fractures	O
,	O
spinal	O
injury	O
,	O
shrapnel	O
,	O
or	O
blindness	O
in	O
the	O
military	O
lifetime	O
.	O

Mental	O
health	O
treatment	O
utilization	O
was	O
defined	O
as	O
any	O
admission	O
or	O
encounter	O
for	O
MDC	O
19	O
(	O
mental	O
diseases	O
and	O
disorders	O
)	O
in	O
the	O
military	O
lifetime	O
.	O

Bivariate	O
associations	O
were	O
tested	O
using	O
the	O
chi	O
-	O
square	O
test	O
for	O
independence	O
(	O
categorical	O
variables	O
)	O
or	O
the	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
(	O
continuous	O
variables	O
)	O
.	O

Due	O
to	O
the	O
extreme	O
right	O
skew	O
of	O
the	O
distribution	O
of	O
the	O
number	O
of	O
outpatient	O
SUT	O
encounters	O
,	O
we	O
recoded	O
all	O
values	O
at	O
or	O
above	O
26	O
(	O
95th	O
percentile	O
)	O
to	O
26	O
before	O
performing	O
regression	O
analyses	O
.	O

We	O
wanted	O
to	O
adjust	O
for	O
gender	O
differences	O
in	O
SUDX	O
so	O
that	O
observed	O
gender	O
differences	O
in	O
SUT	O
would	O
not	O
be	O
confounded	O
with	O
gender	O
differences	O
in	O
SUDX	O
.	O

Therefore	O
,	O
propensity	O
score	O
modeling	O
was	O
used	O
to	O
address	O
this	O
confounding	O
(	O
Schmidt	O
,	O
Tam	O
,	O
&	O
Larson	O
,	O
2012	O
;	O
Suarez	O
&	O
Faries	O
,	O
2010	O
)	O
.	O

The	O
propensity	O
model	O
was	O
a	O
logistic	O
regression	O
that	O
regressed	O
military	O
lifetime	O
SUDX	O
on	O
eight	O
covariates	O
(	O
gender	O
,	O
age	O
in	O
years	O
,	O
race	O
/	O
ethnicity	O
,	O
marital	O
status	O
,	O
military	O
rank	O
,	O
TRICARE	O
eligibility	O
,	O
prior	O
deployment	O
,	O
short	O
dwell	O
time	O
)	O
,	O
each	O
hypothesized	O
to	O
be	O
associated	O
with	O
the	O
severity	O
of	O
need	O
for	O
SUT	O
and	O
selected	O
a	O
priori	O
based	O
on	O
prior	O
research	O
.	O

To	O
assess	O
the	O
association	O
of	O
gender	O
with	O
military	O
lifetime	O
SUDX	O
(	O
i	O
.	O
e	O
.	O
,	O
risk	O
of	O
need	O
for	O
SUT	O
)	O
,	O
we	O
compared	O
histograms	O
of	O
propensity	O
scores	O
for	O
each	O
gender	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Fig	O
.	O

1	O
indicates	O
that	O
the	O
distribution	O
of	O
risk	O
of	O
military	O
lifetime	O
SUDX	O
is	O
on	O
average	O
higher	O
for	O
Army	O
men	O
than	O
women	O
,	O
although	O
the	O
overlap	O
in	O
risk	O
is	O
also	O
apparent	O
.	O

Army	O
men	O
and	O
women	O
with	O
the	O
same	O
military	O
lifetime	O
SUDX	O
propensity	O
scores	O
are	O
interpreted	O
as	O
having	O
similar	O
average	O
risk	O
of	O
need	O
for	O
SUT	O
.	O

Hence	O
,	O
we	O
included	O
the	O
service	O
members’	O
calculated	O
propensity	O
scores	O
in	O
the	O
multivariate	O
models	O
of	O
SUT	O
in	O
order	O
to	O
yield	O
an	O
unbiased	O
estimate	O
of	O
the	O
association	O
between	O
gender	O
and	O
SUT	O
utilization	O
the	O
year	O
prior	O
to	O
deployment	O
.	O

We	O
examined	O
two	O
SUT	O
utilization	O
dependent	O
variables	O
,	O
any	O
SUT	O
and	O
number	O
of	O
SUT	O
ambulatory	O
encounters	O
the	O
year	O
prior	O
to	O
deployment	O
.	O

Logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
association	O
of	O
gender	O
with	O
SUT	O
,	O
and	O
the	O
adjusted	O
odds	O
ratios	O
(	O
AORs	O
)	O
and	O
95th	O
percentile	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
reported	O
.	O

Negative	O
binomial	O
regression	O
was	O
used	O
to	O
model	O
the	O
association	O
of	O
gender	O
with	O
the	O
number	O
of	O
SUT	O
encounters	O
among	O
service	O
members	O
with	O
SUT	O
encounters	O
,	O
and	O
results	O
were	O
reported	O
as	O
risk	O
ratios	O
(	O
RR	O
)	O
and	O
95	O
%	O
CIs	O
or	O
percent	O
change	O
in	O
risk	O
(	O
calculated	O
as	O
RR	O
–	O
1	O
,	O
expressed	O
as	O
a	O
percent	O
)	O
.	O

All	O
independent	O
variables	O
discussed	O
above	O
were	O
included	O
in	O
both	O
models	O
and	O
to	O
incorporate	O
the	O
individual’s	O
propensity	O
score	O
,	O
we	O
included	O
the	O
propensity	O
scores	O
in	O
quintiles	O
.	O

Due	O
to	O
the	O
large	O
sample	O
size	O
of	O
this	O
study	O
,	O
we	O
relied	O
on	O
both	O
the	O
magnitude	O
of	O
the	O
statistic	O
(	O
e	O
.	O
g	O
.	O
,	O
odds	O
ratio	O
or	O
relative	O
risk	O
)	O
and	O
95	O
%	O
CI	O
instead	O
of	O
p	O
-	O
values	O
to	O
judge	O
the	O
importance	O
of	O
differences	O
between	O
gender	O
groups	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SAS	O
/	O
STAT	O
software®	O
9	O
.	O
2	O
(	O
SAS	O
Institute	O
Incorporated	O
,	O
2008	O
)	O
.	O

This	O
study	O
is	O
a	O
randomized	O
,	O
multicenter	O
,	O
double	O
blind	O
clinical	O
trial	O
with	O
two	O
treatment	O
groups	O
(	O
tVNS	O
and	O
sham	O
tVNS	O
)	O
.	O

Please	O
see	O
flow	O
chart	O
(	O
Figure	O
1	O
)	O
for	O
more	O
details	O
regarding	O
the	O
clinical	O
procedures	O
.	O

The	O
clinical	O
endpoints	O
are	O
assessed	O
by	O
blinded	O
independent	O
observers	O
.	O

The	O
central	O
randomization	O
system	O
is	O
used	O
to	O
assign	O
patients	O
to	O
the	O
tVNS	O
or	O
sham	O
tVNS	O
treatment	O
groups	O
.	O

All	O
procedures	O
are	O
performed	O
by	O
the	O
Clinical	O
Evaluation	O
Center	O
at	O
the	O
China	O
Academy	O
of	O
Chinese	O
Medical	O
Sciences	O
(	O
CACMS	O
)	O
in	O
Beijing	O
.	O

The	O
Ethics	O
committee	O
of	O
Institute	O
of	O
Acupuncture	O
and	O
Moxibustion	O
,	O
CACMS	O
approved	O
the	O
experiment	O
procedure	O
.	O

Flow	O
chart	O
of	O
the	O
clinical	O
trial	O
.	O

Investigators	O
are	O
conducting	O
the	O
trial	O
in	O
four	O
hospitals	O
in	O
Beijing	O
,	O
China	O
.	O

These	O
four	O
hospitals	O
are	O
:	O
Guang	O
An	O
Men	O
Hospital	O
,	O
China	O
Academy	O
of	O
Chinese	O
Medical	O
Sciences	O
;	O
Huguosi	O
TCM	O
Hospital	O
,	O
Beijing	O
University	O
of	O
TCM	O
;	O
Acupuncture	O
Hospital	O
,	O
China	O
Academy	O
of	O
Chinese	O
Medical	O
Sciences	O
.	O

As	O
a	O
double	O
-	O
blinded	O
trial	O
,	O
both	O
study	O
physicians	O
/	O
investigators	O
and	O
patients	O
are	O
blinded	O
to	O
treatment	O
group	O
(	O
tVNS	O
versus	O
sham	O
tVNS	O
)	O
.	O

To	O
ensure	O
that	O
both	O
investigators	O
and	O
patients	O
remain	O
blinded	O
,	O
two	O
carbon	O
-	O
impregnated	O
silicone	O
electrodes	O
are	O
fixed	O
to	O
one	O
ear	O
clamp	O
(	O
Figure	O
2	O
)	O
.	O

Only	O
one	O
of	O
the	O
electrodes	O
;	O
however	O
,	O
is	O
connected	O
to	O
the	O
electrical	O
lead	O
(	O
wire	O
)	O
imbedded	O
in	O
the	O
clamp	O
in	O
order	O
to	O
keep	O
the	O
operation	O
of	O
the	O
study	O
double	O
blind	O
.	O

In	O
the	O
tVNS	O
group	O
,	O
the	O
upper	O
electrode	O
was	O
wired	O
to	O
the	O
transcutaneous	O
electrical	O
nerve	O
stimulator	O
(	O
TENS	O
)	O
while	O
in	O
the	O
sham	O
tVNS	O
group	O
the	O
lower	O
electrode	O
is	O
inactively	O
wired	O
to	O
the	O
TENS	O
.	O

Locations	O
and	O
the	O
stimulation	O
electrodes	O
on	O
the	O
auricular	O
surface	O
.	O

Red	O
spots	O
indicate	O
the	O
locations	O
for	O
transcutaneous	O
auricular	O
vagus	O
nerve	O
stimulation	O
(	O
tVNS	O
)	O
and	O
blue	O
spots	O
indicate	O
the	O
locations	O
for	O
sham	O
tVNS	O
.	O

The	O
left	O
figure	O
shows	O
the	O
two	O
tVNS	O
points	O
being	O
in	O
the	O
innervation	O
area	O
of	O
the	O
auricular	O
branch	O
of	O
vagus	O
nerve	O
(	O
green	O
)	O
.	O

The	O
right	O
figure	O
indicates	O
the	O
clip	O
/	O
electrode	O
used	O
in	O
the	O
study	O
.	O

To	O
achieve	O
the	O
design	O
of	O
double	O
-	O
blind	O
,	O
two	O
paired	O
electrodes	O
were	O
fixed	O
to	O
one	O
ear	O
clamp	O
.	O

But	O
only	O
one	O
of	O
them	O
was	O
connected	O
with	O
the	O
wire	O
that	O
was	O
imbedded	O
in	O
the	O
clamp	O
in	O
order	O
to	O
keep	O
the	O
operation	O
of	O
double	O
-	O
blind	O
.	O

In	O
the	O
tVNS	O
group	O
,	O
the	O
upper	O
electrodes	O
are	O
wired	O
to	O
the	O
machine	O
while	O
in	O
the	O
sham	O
tVNS	O
group	O
the	O
lower	O
electrodes	O
are	O
wired	O
.	O

Both	O
the	O
physician’s	O
and	O
the	O
patient’s	O
blindness	O
to	O
the	O
mode	O
of	O
treatment	O
are	O
assessed	O
after	O
completion	O
of	O
all	O
post	O
-	O
treatment	O
measurements	O
by	O
asking	O
each	O
individual	O
to	O
guess	O
the	O
treatment	O
modality	O
they	O
received	O
given	O
three	O
options	O
,	O
“real	O
tVNS”	O
,	O
“sham	O
tVNS”	O
or	O
“uncertain”	O
.	O

Patients	O
with	O
mild	O
or	O
moderate	O
MDD	O
are	O
recruited	O
for	O
the	O
trial	O
.	O

ICD	B-coding_system
-	I-coding_system
10	I-coding_system
Classification	I-coding_system
of	I-coding_system
Mental	I-coding_system
and	I-coding_system
Behavioral	I-coding_system
Disorders	I-coding_system
are	O
used	O
for	O
diagnosis	O
of	O
MDD	B-phenotype
.	O

Patients	O
who	O
voluntarily	O
provide	O
informed	O
consent	O
and	O
meet	O
inclusion	O
/	O
exclusion	O
criteria	O
are	O
enrolled	O
in	O
this	O
study	O
.	O

Inclusion	O
and	O
exclusion	O
criteria	O
include	O
:	O

1	O
.	O

Patient	O
meets	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
diagnosis	O
standard	O
:	O
mild	O
(	O
2	O
typical	O
+	O
2	O
other	O
core	O
symptoms	O
)	O
,	O
moderate	O
(	O
2	O
typical	O
+	O
3	O
other	O
core	O
symptoms	O
)	O
.	O

2	O
.	O

Patient	O
is	O
16–70	O
years	O
of	O
age	O

3	O
.	O

Patient	O
stopped	O
taking	O
anti	O
-	O
depressive	O
medication	O
or	O
other	O
psychiatric	O
medications	O
2	O
weeks	O
before	O
the	O
intervention	O
started	O
.	O

4	O
.	O

Patient	O
is	O
educated	O
beyond	O
junior	O
high	O
school	O
,	O
in	O
order	O
to	O
understand	O
the	O
scales	O
.	O

5	O
.	O

Patient	O
has	O
exhibited	O
symptoms	O
for	O
at	O
least	O
2	O
months	O
,	O
and	O
no	O
longer	O
than	O
2	O
years	O
.	O

1	O
.	O

Patients	O
with	O
current	O
addiction	O
to	O
drugs	O

2	O
.	O

Patients	O
with	O
severe	O
depression	O
or	O
suicidal	O
thoughts	O

3	O
.	O

Patients	O
with	O
severe	O
medical	O
disorders	O

4	O
.	O

Patients	O
with	O
poor	O
compliance	O

The	O
investigators	O
recruit	O
patients	O
with	O
mild	O
or	O
moderate	O
depressive	O
symptoms	O
using	O
advertising	O
and	O
by	O
sending	O
flyers	O
to	O
the	O
four	O
hospitals	O
involved	O
in	O
the	O
study	O
.	O

After	O
passing	O
a	O
pre	O
-	O
screening	O
,	O
potentially	O
eligible	O
patients	O
provide	O
informed	O
consent	O
in	O
the	O
presence	O
of	O
a	O
study	O
physician	O
.	O

The	O
points	O
for	O
tVNS	O
are	O
located	O
in	O
the	O
auricular	O
concha	O
area	O
where	O
there	O
is	O
rich	O
vagus	O
nerve	O
branch	O
distribution	O
(	O
Figure	O
2	O
)	O
.	O

Patients	O
take	O
a	O
seated	O
position	O
or	O
they	O
lay	O
on	O
their	O
side	O
.	O

After	O
the	O
stimulation	O
points	O
are	O
disinfected	O
according	O
to	O
standard	O
practice	O
,	O
ear	O
clips	O
are	O
attached	O
to	O
the	O
ear	O
area	O
(	O
auricular	O
concha	O
)	O
that	O
will	O
be	O
stimulated	O
.	O

Stimulation	O
parameters	O
include	O
:	O
1	O
)	O
density	O
wave	O
adjusted	O
to	O
20Hz	O
,	O
with	O
less	O
than	O
1ms	O
wave	O
width	O
;	O
and	O
2	O
)	O
1mA	O
current	O
turned	O
on	O
.	O

The	O
intensity	O
is	O
adjusted	O
based	O
on	O
the	O
tolerance	O
of	O
the	O
patient	O
.	O

Each	O
treatment	O
lasts	O
for	O
30	O
minutes	O
and	O
is	O
carried	O
on	O
twice	O
a	O
day	O
,	O
5	O
days	O
per	O
week	O
for	O
the	O
duration	O
of	O
the	O
treatment	O
period	O
(	O
12	O
weeks	O
)	O
.	O

The	O
stimulation	O
points	O
for	O
sham	O
tVNS	O
are	O
located	O
at	O
the	O
superior	O
scapha	O
(	O
outer	O
ear	O
margin	O
midpoint	O
)	O
,	O
where	O
there	O
is	O
no	O
vagus	O
nerve	O
distribution	O
(	O
Figure	O
2	O
)	O
.	O

All	O
procedures	O
performed	O
in	O
the	O
sham	O
tVNS	O
treatment	O
group	O
are	O
identical	O
to	O
the	O
procedures	O
for	O
the	O
verum	O
tVNS	O
group	O
.	O

All	O
endpoints	O
are	O
measured	O
at	O
week	O
0	O
and	O
week	O
10	O
.	O

The	O
endpoints	O
include	O
the	O
24	O
-	O
item	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAM	O
-	O
D	O
-	O
24	O
)	O
,	O
the	O
17	O
-	O
item	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAM	O
-	O
D	O
-	O
17	O
)	O
,	O
Self	O
-	O
rating	O
Anxiety	O
Scale	O
(	O
SAS	O
)	O
,	O
Self	O
-	O
rating	O
Depression	O
Scale	O
(	O
SDS	O
)	O
,	O
electrocardiogram	O
rate	O
,	O
breathing	O
rate	O
,	O
and	O
skin	O
conduction	O
response	O
.	O

Similar	O
to	O
previous	O
studies	O
[	O
12	O
,	O
13	O
]	O
,	O
the	O
primary	O
outcome	O
is	O
the	O
categorical	O
classification	O
of	O
treatment	O
response	O
.	O

We	O
are	O
interested	O
in	O
comparing	O
the	O
difference	O
in	O
treatment	O
response	O
rate	O
between	O
the	O
two	O
groups	O
as	O
measured	O
by	O
HAM	O
-	O
D	O
-	O
24	O
,	O
where	O
treatment	O
response	O
is	O
defined	O
as	O
a	O
50	O
%	O
or	O
greater	O
reduction	O
in	O
HAM	O
-	O
D	O
-	O
24	O
scores	O
following	O
a	O
10	O
-	O
week	O
treatment	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
[	O
14	O
-	O
17	O
]	O
suggest	O
that	O
expectations	O
for	O
symptom	O
relief	O
can	O
significantly	O
influence	O
the	O
response	O
to	O
medications	O
,	O
acupuncture	O
,	O
and	O
placebo	O
.	O

Thus	O
,	O
before	O
the	O
first	O
treatment	O
,	O
patients	O
are	O
asked	O
to	O
rate	O
on	O
a	O
scale	O
how	O
much	O
they	O
expect	O
the	O
treatment	O
will	O
relieve	O
their	O
symptoms	O
,	O
from	O
“complete	O
relief”	O
to	O
“do	O
not	O
work	O
at	O
all”	O
.	O

We	O
present	O
here	O
our	O
power	O
analysis	O
for	O
the	O
primary	O
outcome	O
only	O
.	O

Since	O
this	O
is	O
a	O
novel	O
therapy	O
,	O
we	O
used	O
the	O
data	O
from	O
a	O
previous	O
non	O
-	O
controlled	O
pilot	O
study	O
on	O
treatment	O
-	O
resistant	O
MDD	O
in	O
senior	O
patients	O
[	O
18	O
]	O
to	O
calculate	O
the	O
power	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
the	O
categorical	O
classification	O
of	O
response	O
;	O
we	O
define	O
the	O
treatment	O
response	O
as	O
a	O
50	O
%	O
or	O
greater	O
reduction	O
in	O
HAM	O
-	O
D	O
-	O
24	O
scores	O
following	O
treatments	O
.	O

From	O
a	O
previous	O
proof	O
of	O
concept	O
study	O
[	O
18	O
]	O
,	O
the	O
response	O
rate	O
in	O
the	O
tVNS	O
group	O
is	O
39	O
%	O
;	O
assuming	O
a	O
20	O
%	O
dropout	O
rate	O
,	O
with	O
60	O
patient	O
in	O
each	O
group	O
,	O
we	O
will	O
have	O
80	O
%	O
power	O
to	O
detect	O
a	O
difference	O
of	O
25	O
%	O
or	O
greater	O
in	O
response	O
rate	O
between	O
the	O
tVNS	O
and	O
the	O
sham	O
tVNS	O
group	O
based	O
on	O
a	O
chi	O
square	O
test	O
at	O
a	O
0	O
.	O
05	O
significance	O
level	O
.	O

In	O
this	O
study	O
,	O
the	O
primary	O
outcome	O
measure	O
is	O
the	O
categorical	O
classification	O
of	O
treatment	O
response	O
.	O

We	O
define	O
the	O
treatment	O
response	O
as	O
a	O
50	O
%	O
or	O
greater	O
reduction	O
in	O
HAM	O
-	O
D	O
-	O
24	O
scores	O
following	O
treatments	O
.	O

Response	O
rates	O
across	O
the	O
two	O
groups	O
will	O
be	O
compared	O
with	O
the	O
chi	O
square	O
(	O
x	O
2	O
)	O
test	O
.	O

Additionally	O
,	O
we	O
will	O
also	O
use	O
the	O
HAM	O
-	O
D	O
-	O
24	O
score	O
as	O
continuous	O
variable	O
and	O
apply	O
a	O
regression	O
model	O
to	O
compare	O
the	O
different	O
between	O
two	O
treatment	O
groups	O
.	O

More	O
specifically	O
,	O
in	O
the	O
model	O
,	O
the	O
dependent	O
variable	O
is	O
post	O
-	O
treatment	O
HAM	O
-	O
D	O
-	O
24	O
score	O
,	O
the	O
independent	O
variable	O
is	O
treatment	O
mode	O
(	O
tVNS	O
versus	O
sham	O
tVNS	O
)	O
,	O
and	O
covariances	O
will	O
include	O
pre	O
-	O
treatment	O
HAM	O
score	O
,	O
age	O
and	O
gender	O
.	O

Similar	O
analyses	O
will	O
also	O
be	O
performed	O
in	O
other	O
clinical	O
and	O
physiological	O
outcome	O
measurements	O
.	O

Independent	O
data	O
safety	O
monitoring	O
board	O
members	O
will	O
meet	O
every	O
6	O
months	O
or	O
as	O
needed	O
.	O

Participants	O
who	O
show	O
persistent	O
worsening	O
symptoms	O
during	O
the	O
course	O
of	O
a	O
clinical	O
trial	O
or	O
develop	O
unstable	O
psychiatric	O
symptoms	O
(	O
e	O
.	O
g	O
.	O
,	O
suicidality	O
,	O
homicidality	O
,	O
psychosis	O
)	O
will	O
be	O
withdrawn	O
from	O
the	O
study	O
and	O
will	O
be	O
referred	O
for	O
appropriate	O
treatment	O
immediately	O
.	O

According	O
to	O
the	O
following	O
classifications	O
,	O
a	O
safety	O
monitoring	O
board	O
will	O
review	O
and	O
rate	O
adverse	O
events	O
to	O
determine	O
whether	O
to	O
suspend	O
the	O
test	O
condition	O
.	O

Level	O
1	O
:	O
Security	O
,	O
without	O
any	O
adverse	O
reactions	O
.	O

Level	O
2	O
:	O
Safe	O
,	O
and	O
have	O
mild	O
adverse	O
reaction	O
,	O
do	O
not	O
need	O
any	O
treatment	O
can	O
continue	O
to	O
treatment	O
.	O

Level	O
3	O
:	O
There	O
are	O
security	O
issues	O
;	O
there	O
is	O
a	O
moderate	O
adverse	O
reaction	O
,	O
after	O
treatment	O
may	O
continue	O
to	O
treatment	O
.	O

Level	O
4	O
:	O
Because	O
of	O
adverse	O
reactions	O
,	O
terminate	O
this	O
research	O
.	O

All	O
adverse	O
events	O
will	O
be	O
reported	O
to	O
the	O
Human	O
Research	O
Committee	O
promptly	O
in	O
accordance	O
with	O
guidelines	O
.	O

Patients	O
were	O
included	O
in	O
the	O
study	O
if	O
they	O
had	O
been	O
diagnosed	O
with	O
hyperlipidemia	O
and	O
were	O
statin	O
users	O
without	O
dementia	O
at	O
baseline	O
(	O
January	O
1	O
,	O
2002	O
)	O
.	O

We	O
summarized	O
the	O
claim	O
records	O
of	O
each	O
patient	O
into	O
1	O
record	O
,	O
and	O
we	O
used	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
Ninth	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
9	I-coding_system
)	I-coding_system
Clinical	O
Modification	O
code	O
to	O
define	O
dementia	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
290	B-code
)	O
.	O

Statin	O
users	O
were	O
those	O
patients	O
who	O
received	O
at	O
least	O
a	O
28	O
-	O
day	O
statin	O
prescription	O
during	O
the	O
period	O
between	O
January	O
1	O
and	O
December	O
31	O
,	O
2002	O
.	O

In	O
contrast	O
,	O
nonusers	O
were	O
those	O
patients	O
who	O
did	O
not	O
receive	O
a	O
statin	O
prescription	O
throughout	O
the	O
whole	O
study	O
period	O
.	O

Participants	O
were	O
included	O
in	O
the	O
study	O
if	O
they	O
had	O
been	O
newly	O
diagnosed	O
with	O
hyperlipidemia	O
between	O
January	O
1	O
and	O
June	O
30	O
,	O
2002	O
.	O

At	O
least	O
1	O
of	O
the	O
following	O
enrollment	O
criteria	O
had	O
to	O
be	O
met	O
for	O
inclusion	O
in	O
the	O
study	O
:	O
2	O
or	O
more	O
outpatient	O
visits	O
within	O
a	O
6	O
-	O
month	O
period	O
,	O
continuous	O
administration	O
of	O
all	O
statin	O
prescriptions	O
for	O
more	O
than	O
6	O
months	O
within	O
a	O
12	O
-	O
year	O
follow	O
-	O
up	O
period	O
,	O
or	O
1	O
or	O
more	O
inpatient	O
admissions	O
with	O
a	O
diagnosis	O
of	O
hyperlipidemia	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
development	O
of	O
NODs	O
,	O
which	O
was	O
defined	O
by	O
the	O
time	B-phenotype
dementia	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
codes	O
290	B-code
)	O
first	O
appeared	O
in	O
the	O
inpatient	O
or	O
outpatient	O
claim	O
records	O
.	O

Comorbidities	O
related	O
to	O
dementia	O
were	O
defined	O
according	O
to	O
the	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
and	O
included	O
coronary	B-phenotype
heart	I-phenotype
disease	I-phenotype
(	I-phenotype
CHD	I-phenotype
;	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
410–415	B-code
)	O
,	O
hypertension	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
401–405	B-code
)	O
,	O
diabetes	B-phenotype
mellitus	I-phenotype
(	I-phenotype
DM	I-phenotype
)	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
250	B-code
)	O
,	O
and	O
cerebrovascular	B-phenotype
attack	I-phenotype
(	I-phenotype
CVA	I-phenotype
;	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
-	I-coding_system
CM	I-coding_system
code	O
430–438	B-code
)	O
.	O

In	O
a	O
previous	O
study	O
,	O
Zissimopoulos	O
et	O
al	O
[	O
18	O
]	O
defined	O
high	O
statin	O
exposure	O
as	O
“at	O
least	O
the	O
50th	O
percentile	O
of	O
days	O
of	O
filled	O
prescriptions	O
in	O
a	O
given	O
year	O
for	O
at	O
least	O
2	O
years	O
during	O
2006	O
,	O
2007	O
,	O
and	O
2008	O
.	O
”	O
Therefore	O
,	O
defined	O
daily	O
doses	O
(	O
DDDs	O
)	O
>	O
730	O
was	O
considered	O
as	O
high	O
exposure	O
and	O
≤730	O
as	O
low	O
exposure	O
.	O

Patients	O
who	O
fulfilled	O
any	O
of	O
the	O
following	O
criteria	O
were	O
excluded	O
from	O
the	O
study	O
:	O
a	O
prior	O
history	O
of	O
dementia	O
before	O
January	O
1	O
,	O
2002	O
,	O
and	O
patients	O
aged	O
more	O
than	O
85	O
years	O
.	O

Initially	O
,	O
104	O
,	O
858	O
outpatients	O
fulfilled	O
the	O
inclusion	O
criteria	O
;	O
however	O
,	O
1128	O
patients	O
were	O
excluded	O
based	O
on	O
the	O
diagnosis	O
of	O
dementia	O
before	O
January	O
1	O
,	O
2002	O
.	O

A	O
total	O
of	O
103	O
,	O
730	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
at	O
baseline	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Furthermore	O
,	O
1851	O
patients	O
who	O
were	O
lost	O
to	O
follow	O
-	O
up	O
and	O
1269	O
patients	O
who	O
died	O
without	O
the	O
diagnosis	O
of	O
NODs	O
or	O
NOD	O
-	O
related	O
deaths	O
were	O
excluded	O
.	O

Finally	O
,	O
a	O
total	O
of	O
100	O
,	O
610	O
outpatients	O
were	O
involved	O
in	O
this	O
study	O
,	O
and	O
it	O
included	O
38	O
,	O
012	O
patients	O
with	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Flowchart	O
of	O
all	O
patients	O
for	O
the	O
inclusion	O
in	O
this	O
study	O
.	O

NOD	O
=	O
new	O
-	O
onset	O
dementia	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
ethics	O
committee	O
of	O
the	O
Chung	O
Shan	O
Medical	O
University	O
Hospital	O
(	O
CS2	O
-	O
17084	O
)	O
.	O

Written	O
consent	O
was	O
not	O
obtained	O
from	O
the	O
study	O
participants	O
as	O
only	O
deidentified	O
data	O
were	O
obtained	O
from	O
the	O
longitudinal	O
health	O
insurance	O
database	O
2010	O
,	O
and	O
a	O
waiver	O
of	O
patient	O
consent	O
was	O
provided	O
by	O
the	O
ethics	O
committee	O
for	O
this	O
study	O
.	O

Continuous	O
variables	O
were	O
presented	O
as	O
mean	O
±	O
standard	O
deviation	O
.	O

Differences	O
in	O
continuous	O
variables	O
were	O
analyzed	O
using	O
an	O
unpaired	O
Student	O
t	O
test	O
.	O

Categorical	O
and	O
discrete	O
variables	O
were	O
presented	O
as	O
frequencies	O
and	O
percentages	O
.	O

The	O
NOD	O
-	O
free	O
survival	O
rates	O
in	O
the	O
3	O
groups	O
were	O
calculated	O
using	O
the	O
Kaplan–Meier	O
method	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

The	O
Cox	O
proportional	O
hazard	O
regression	O
model	O
was	O
used	O
to	O
compare	O
the	O
risk	O
of	O
NOD	O
development	O
between	O
statin	O
users	O
and	O
nonusers	O
.	O

Adjusted	O
hazard	O
ratios	O
(	O
HRs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
,	O
adjusting	O
for	O
important	O
risk	O
factors	O
for	O
the	O
development	O
of	O
dementia	O
that	O
includes	O
age	O
,	O
sex	O
,	O
medication	O
use	O
,	O
and	O
comorbidities	O
.	O

P	O
<	O
.	O
05	O
were	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

All	O
statistical	O
calculations	O
were	O
performed	O
using	O
statistical	O
analysis	O
software	O
,	O
version	O
9	O
.	O
3	O
(	O
SAS	O
Institute	O
,	O
Inc	O
,	O
Cary	O
,	O
NC	O
)	O
.	O

An	O
18	O
-	O
month	O
prospective	O
cohort	O
study	O
was	O
undertaken	O
.	O

Data	O
collection	O
took	O
place	O
between	O
1	O
June	O
2012	O
and	O
the	O
31	O
December	O
2013	O
.	O

The	O
study	O
took	O
place	O
in	O
a	O
20	O
-	O
bed	O
mixed	O
medical	O
/	O
surgical	O
critical	O
care	O
unit	O
in	O
Glasgow	O
Royal	O
Infirmary	O
(	O
GRI	O
)	O
.	O

It	O
is	O
a	O
tertiary	O
referral	O
centre	O
for	O
burn	O
and	O
pancreatic	O
care	O
and	O
is	O
situated	O
in	O
an	O
area	O
of	O
high	O
socioeconomic	O
deprivation	O
,	O
with	O
42	O
%	O
of	O
the	O
most	O
deprived	O
geographical	O
areas	O
in	O
Scotland	O
residing	O
in	O
the	O
GRI	O
catchment	O
area	O
[	O
19	O
]	O
.	O

The	O
primary	O
inclusion	O
criterion	O
for	O
the	O
cohort	O
study	O
was	O
all	O
patients	O
admitted	O
to	O
the	O
ICU	O
during	O
the	O
18	O
-	O
month	O
study	O
period	O
as	O
level	O
-	O
three	O
patients	O
.	O

The	O
term	O
level	O
-	O
three	O
patients	O
,	O
refers	O
to	O
the	O
UK	O
Intensive	O
Care	O
Society	O
definition	O
of	O
ICU	O
patients	O
.	O

Level	O
-	O
three	O
patients	O
require	O
multiple	O
organ	O
support	O
or	O
invasive	O
respiratory	O
support	O
only	O
[	O
20	O
]	O
.	O

Within	O
the	O
UK	O
context	O
,	O
level	O
-	O
three	O
patients	O
require	O
support	O
within	O
a	O
critical	O
care	O
environment	O
.	O

The	O
only	O
exclusion	O
was	O
patients	O
younger	O
than	O
18	O
years	O
.	O

The	O
majority	O
of	O
patients	O
in	O
Scottish	O
ICUs	O
are	O
admitted	O
under	O
the	O
Adults	O
with	O
Incapacity	O
Act	O
.	O

Therefore	O
,	O
decisions	O
about	O
discharge	O
would	O
have	O
been	O
made	O
by	O
medical	O
staff	O
only	O
,	O
with	O
patients	O
unable	O
to	O
self	O
-	O
discharge	O
.	O

Information	O
on	O
alcohol	O
history	O
was	O
recorded	O
by	O
an	O
admitting	O
member	O
of	O
ICU	O
medical	O
staff	O
.	O

If	O
an	O
alcohol	O
screen	O
had	O
been	O
obtained	O
in	O
the	O
ward	O
setting	O
or	O
accident	O
and	O
emergency	O
unit	O
before	O
admission	O
to	O
the	O
ICU	O
using	O
the	O
fast	O
alcohol	O
screening	O
tool	O
(	O
FAST	O
)	O
score	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
,	O
this	O
was	O
used	O
to	O
assign	O
the	O
patient	O
to	O
the	O
appropriate	O
study	O
group	O
.	O

If	O
the	O
FAST	O
score	O
had	O
not	O
been	O
completed	O
prior	O
to	O
ICU	O
referral	O
patients	O
were	O
classified	O
using	O
the	O
World	O
Health	O
Organisation	O
(	O
WHO	O
)	O
classification	O
.	O

The	O
admitting	O
medical	O
staff	O
used	O
a	O
standardised	O
flow	O
sheet	O
(	O
Additional	O
file	O
2	O
:	O
Table	O
S2	O
)	O
to	O
allocate	O
patients	O
to	O
each	O
category	O
from	O
the	O
information	O
available	O
from	O
relatives	O
or	O
the	O
medical	O
records	O
.	O

This	O
sheet	O
was	O
available	O
on	O
the	O
patient	O
management	O
system	O
and	O
additional	O
hard	O
copies	O
were	O
available	O
.	O

The	O
study	O
groups	O
utilised	O
were	O
based	O
on	O
the	O
WHO	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
definition	O
for	O
AUDs	B-phenotype
[	O
21	O
]	O
as	O
low	O
risk	O
,	O
harmful	O
/	O
hazardous	O
or	O
alcohol	O
dependency	O
(	O
Additional	O
file	O
2	O
:	O
Table	O
S2	O
)	O
.	O

The	O
alcohol	O
groups	O
used	O
within	O
the	O
FAST	O
screening	O
tool	O
are	O
the	O
same	O
as	O
the	O
WHO	O
groups	O
.	O

Blood	O
alcohol	O
concentrations	O
were	O
not	O
obtained	O
as	O
they	O
have	O
been	O
shown	O
to	O
be	O
less	O
reliable	O
than	O
screening	O
tools	O
such	O
as	O
FAST	O
and	O
alcohol	O
use	O
disorder	O
identification	O
test	O
(	O
AUDIT	O
)	O
[	O
22	O
]	O
.	O

Patients	O
were	O
allocated	O
to	O
the	O
smoking	O
group	O
if	O
they	O
were	O
a	O
current	O
smoker	O
.	O

Furthermore	O
,	O
patients	O
were	O
allocated	O
to	O
the	O
drug	O
-	O
use	O
group	O
in	O
this	O
study	O
if	O
they	O
were	O
admitted	O
due	O
to	O
recreational	O
drug	O
use	O
or	O
were	O
known	O
intravenous	O
drug	O
users	O
.	O

Data	O
collected	O
during	O
the	O
ICU	O
stay	O
was	O
collected	O
prospectively	O
from	O
various	O
clinical	O
information	O
systems	O
.	O

The	O
ICU	O
utilises	O
the	O
Philips	O
IntelliVue	O
Clinical	O
Information	O
Portfolio	O
(	O
ICIP	O
)	O
,	O
locally	O
known	O
as	O
CareVue	O
(	O
Revision	O
D	O
.	O
03	O
)	O
.	O

CareVue	O
is	O
a	O
repository	O
of	O
electronic	O
patients’	O
notes	O
,	O
utilised	O
for	O
the	O
duration	O
of	O
the	O
patients’	O
ICU	O
stay	O
.	O

Analysts	O
from	O
Information	O
Services	O
Division	O
Scotland	O
linked	O
the	O
ICU	O
patient	O
population	O
being	O
studied	O
with	O
the	O
death	O
registry	O
for	O
Scotland	O
and	O
extracted	O
outcomes	O
for	O
patients	O
at	O
six	O
months	O
post	O
ICU	O
discharge	O
.	O

Data	O
obtained	O
included	O
:	O
gender	O
;	O
age	O
;	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
)	O
II	O
;	O
ICU	O
admission	O
diagnosis	O
;	O
previous	O
medical	O
history	O
including	O
co	O
-	O
morbidities	O
;	O
baseline	O
blood	O
results	O
;	O
admitting	O
speciality	O
;	O
days	O
on	O
ventilator	O
;	O
days	O
on	O
renal	O
replacement	O
therapy	O
;	O
diagnosis	O
of	O
septic	O
shock	O
;	O
duration	O
of	O
vasopressor	O
use	O
;	O
ICU	O
outcome	O
;	O
total	O
hospital	O
stay	O
;	O
hospital	O
outcome	O
;	O
six	O
-	O
month	O
outcome	O
and	O
Scottish	O
index	O
of	O
multiple	O
deprivation	O
(	O
SIMD	O
)	O
decile	O
.	O

The	O
SIMD	O
is	O
the	O
Scottish	O
Government’s	O
official	O
tool	O
for	O
identifying	O
those	O
geographical	O
areas	O
suffering	O
from	O
deprivation	O
[	O
19	O
]	O
.	O

It	O
incorporates	O
different	O
aspects	O
of	O
deprivation	O
and	O
summarises	O
them	O
into	O
one	O
score	O
.	O

Deprivation	O
was	O
defined	O
as	O
the	O
two	O
lowest	O
deciles	O
of	O
the	O
SIMD	O
.	O

A	O
patient	O
was	O
diagnosed	O
with	O
cirrhosis	O
by	O
an	O
independent	O
clinician	O
outwith	O
the	O
research	O
team	O
.	O

A	O
diagnosis	O
was	O
made	O
if	O
they	O
had	O
features	O
of	O
chronic	O
liver	O
disease	O
with	O
evidence	O
of	O
portal	O
hypertension	O
,	O
ascites	O
,	O
encephalopathy	O
or	O
liver	O
and	O
spleen	O
imaging	O
consistent	O
with	O
cirrhosis	O
.	O

Blood	O
results	O
did	O
not	O
guide	O
this	O
diagnosis	O
.	O

A	O
diagnosis	O
of	O
septic	O
shock	O
was	O
based	O
on	O
the	O
Surviving	O
Sepsis	O
Campaign	O
guidelines	O
[	O
23	O
]	O
.	O

A	O
definition	O
of	O
septic	O
shock	O
or	O
cirrhosis	O
could	O
be	O
made	O
at	O
any	O
point	O
during	O
the	O
ICU	O
stay	O
.	O

The	O
West	O
of	O
Scotland	O
Research	O
Ethics	O
approved	O
this	O
study	O
(	O
Reference	O
Number	O
12	O
/	O
WS	O
/	O
0039	O
)	O
.	O

Individual	O
patient	O
consent	O
was	O
not	O
required	O
,	O
as	O
all	O
data	O
were	O
collected	O
as	O
part	O
of	O
routine	O
care	O
.	O

The	O
data	O
were	O
transferred	O
to	O
the	O
statistical	O
package	O
RStudio	O
(	O
version	O
0	O
.	O
98	O
.	O

493	O
)	O
for	O
statistical	O
analysis	O
[	O
24	O
]	O
.	O

All	O
missing	O
data	O
fields	O
were	O
kept	O
blank	O
.	O

The	O
Kruskall	O
-	O
Wallis	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
initially	O
utilised	O
to	O
compare	O
the	O
three	O
study	O
groups	O
.	O

If	O
there	O
was	O
a	O
significant	O
difference	O
between	O
the	O
three	O
study	O
groups	O
,	O
a	O
set	O
of	O
post	O
hoc	O
tests	O
were	O
carried	O
out	O
.	O

Continuous	O
variables	O
were	O
expressed	O
as	O
median	O
and	O
inter	O
quartile	O
range	O
or	O
mean	O
and	O
range	O
and	O
analysed	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
or	O
the	O
two	O
sample	O
t	O
-	O
test	O
.	O

Categorical	O
variables	O
were	O
compared	O
using	O
the	O
chi	O
-	O
squared	O
test	O
.	O

At	O
this	O
point	O
the	O
Bonferroni	O
correction	O
was	O
also	O
used	O
to	O
adjust	O
the	O
error	O
rate	O
.	O

All	O
tests	O
were	O
two	O
-	O
sided	O
and	O
a	O
P	O
-	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

Kaplan	O
-	O
Meier	O
curves	O
with	O
the	O
log	O
rank	O
test	O
were	O
used	O
to	O
compare	O
six	O
-	O
month	O
outcomes	O
between	O
the	O
three	O
study	O
groups	O
.	O

Logistic	O
regression	O
models	O
were	O
used	O
to	O
determine	O
independent	O
associations	O
between	O
variables	O
and	O
a	O
Cox	O
proportion	O
model	O
was	O
used	O
to	O
determine	O
the	O
difference	O
between	O
the	O
three	O
study	O
groups	O
with	O
survival	O
analysis	O
.	O

These	O
results	O
were	O
expressed	O
in	O
terms	O
of	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
with	O
the	O
corresponding	O
95	O
%	O
CI	O
.	O

There	O
are	O
many	O
approaches	O
to	O
building	O
and	O
creating	O
statistical	O
models	O
in	O
medical	O
research	O
[	O
25	O
]	O
.	O

Within	O
this	O
study	O
,	O
models	O
were	O
ranked	O
using	O
the	O
Akaike	O
information	O
criterion	O
(	O
AIC	O
)	O
.	O

Although	O
this	O
approach	O
was	O
taken	O
to	O
determine	O
the	O
best	O
available	O
model	O
for	O
the	O
data	O
,	O
clinical	O
relevance	O
and	O
applicability	O
was	O
also	O
used	O
to	O
ensure	O
that	O
the	O
statistical	O
models	O
being	O
created	O
would	O
be	O
clinically	O
meaningful	O
.	O

The	O
association	O
between	O
negative	O
symptoms	O
and	O
subsequent	O
psychiatric	O
hospitalization	O
was	O
examined	O
by	O
merging	O
data	O
from	O
an	O
epidemiological	O
study	O
conducted	O
in	O
Israel	O
in	O
the	O
1980	O
'	O
s	O
with	O
data	O
from	O
the	O
National	O
Psychiatric	O
Hospitalization	O
Case	O
Registry	O
.	O

After	O
receiving	O
approval	O
from	O
the	O
IRB	O
at	O
the	O
Sheba	O
Medical	O
Center	O
,	O
these	O
databases	O
were	O
linked	O
in	O
2007	O
using	O
the	O
national	O
identification	O
number	O
(	O
analogous	O
to	O
the	O
US	O
Social	O
Security	O
number	O
)	O
as	O
the	O
linking	O
variable	O
.	O

For	O
subjects	O
who	O
participated	O
in	O
the	O
epidemiological	O
study	O
and	O
appeared	O
in	O
the	O
hospitalization	O
registry	O
,	O
dates	O
of	O
hospitalizations	O
and	O
discharge	O
diagnoses	O
were	O
added	O
to	O
the	O
file	O
.	O

Individuals	O
who	O
had	O
a	O
discharge	O
diagnosis	O
of	O
schizophrenia	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
F20	B-code
.	I-code
0	I-code
-	I-code
F20	I-code
.	I-code
9	I-code
)	O
at	O
any	O
hospitalization	O
were	O
considered	O
as	O
clinically	O
diagnosed	O
with	O
schizophrenia	O
.	O

To	O
preserve	O
subjects	O
'	O
confidentiality	O
,	O
the	O
national	O
identification	O
number	O
was	O
removed	O
before	O
the	O
linked	O
file	O
was	O
transferred	O
to	O
the	O
investigators	O
.	O

Hence	O
,	O
patient	O
records	O
were	O
anonymized	O
and	O
de	O
-	O
identified	O
prior	O
to	O
analysis	O
.	O

This	O
study	O
utilized	O
data	O
from	O
a	O
two	O
-	O
stage	O
epidemiological	O
study	O
of	O
mental	O
disorders	O
among	O
young	O
adults	O
in	O
a	O
10	O
-	O
year	O
birth	O
cohort	O
(	O
1949–1958	O
)	O
conducted	O
in	O
Israel	O
in	O
the	O
1980	O
'	O
s	O
[	O
9	O
,	O
10	O
]	O
.	O

As	O
part	O
of	O
the	O
original	O
study’s	O
goal	O
to	O
compare	O
the	O
risk	O
of	O
selected	O
disorders	O
in	O
socio	O
-	O
economically	O
contrasting	O
ethnic	O
groups	O
,	O
a	O
sample	O
of	O
19	O
,	O
000	O
Israel	O
-	O
born	O
individuals	O
was	O
drawn	O
from	O
the	O
population	O
registry	O
and	O
screened	O
for	O
father’s	O
continent	O
of	O
origin	O
(	O
North	O
Africa	O
or	O
Europe	O
)	O
and	O
level	O
of	O
education	O
.	O

This	O
was	O
done	O
to	O
balance	O
socioeconomic	O
status	O
within	O
advantaged	O
and	O
disadvantaged	O
ethnic	O
groups	O
by	O
over	O
-	O
sampling	O
disadvantaged	O
subjects	O
from	O
North	O
African	O
origin	O
with	O
high	O
educational	O
level	O
and	O
advantaged	O
subjects	O
of	O
European	O
origin	O
with	O
low	O
educational	O
level	O
.	O

Based	O
on	O
gender	O
,	O
education	O
,	O
ethnicity	O
,	O
and	O
year	O
of	O
birth	O
,	O
5	O
,	O
200	O
subjects	O
were	O
selected	O
.	O

This	O
cohort	O
-	O
based	O
sample	O
was	O
screened	O
and	O
diagnosed	O
for	O
psychotic	O
and	O
other	O
psychiatric	O
disorders	O
in	O
two	O
stages	O
.	O

During	O
the	O
screening	O
stage	O
,	O
94	O
.	O
5	O
%	O
(	O
n	O
=	O
4	O
,	O
914	O
)	O
were	O
interviewed	O
using	O
a	O
Hebrew	O
version	O
of	O
the	O
Psychiatric	O
Epidemiology	O
Research	O
Interview	O
(	O
PERI	O
)	O
,	O
a	O
well	O
validated	O
screening	O
tool	O
[	O
11	O
–	O
13	O
]	O
.	O

Data	O
were	O
not	O
obtained	O
for	O
5	O
.	O
5	O
%	O
subjects	O
(	O
n	O
=	O
286	O
)	O
.	O

Mean	O
age	O
at	O
the	O
time	O
of	O
the	O
interview	O
was	O
29	O
.	O
4	O
years	O
(	O
SD	O
=	O
3	O
.	O
1	O
years	O
)	O
;	O
49	O
.	O
6	O
%	O
were	O
men	O
.	O

The	O
PERI	O
interview	O
also	O
included	O
self	O
-	O
report	O
of	O
lifetime	O
use	O
of	O
cannabis	O
(	O
including	O
single	O
or	O
rare	O
usage	O
)	O
,	O
coded	O
0	O
=	O
no	O
,	O
1	O
=	O
yes	O
.	O

Subjects	O
reaching	O
predetermined	O
cut	O
-	O
off	O
values	O
on	O
the	O
PERI	O
screening	O
stage	O
[	O
13	O
]	O
,	O
unable	O
to	O
complete	O
the	O
screening	O
interview	O
,	O
or	O
suspected	O
of	O
having	O
a	O
history	O
of	O
psychiatric	O
illness	O
,	O
were	O
referred	O
for	O
a	O
clinical	O
diagnostic	O
(	O
second	O
)	O
stage	O
(	O
n	O
=	O
2	O
,	O
643	O
)	O
.	O

In	O
addition	O
,	O
to	O
determine	O
the	O
rates	O
of	O
false	O
negatives	O
,	O
18	O
.	O
3	O
%	O
of	O
the	O
2271	O
screened	O
negatives—who	O
did	O
not	O
reach	O
the	O
predetermined	O
cut	O
-	O
off	O
values	O
on	O
the	O
PERI—were	O
randomly	O
selected	O
and	O
also	O
referred	O
for	O
a	O
diagnostic	O
interview	O
[	O
10	O
]	O
.	O

From	O
this	O
sub	O
-	O
sample	O
,	O
2	O
,	O
741	O
(	O
90	O
.	O
8	O
%	O
)	O
persons	O
were	O
interviewed	O
by	O
psychiatrists	O
using	O
a	O
modified	O
lifetime	O
version	O
of	O
the	O
Schedule	O
for	O
Affective	O
Disorders	O
and	O
Schizophrenia	O
(	O
SADS	O
-	O
I	O
;	O
I	O
for	O
Israel	O
)	O
to	O
arrive	O
at	O
a	O
Research	O
Diagnostic	O
Criteria	O
(	O
RDC	O
)	O
[	O
14	O
]	O
diagnosis	O
.	O

The	O
SADS	O
-	O
I	O
also	O
included	O
an	O
assessment	O
of	O
the	O
best	O
level	O
of	O
social	O
functioning	O
during	O
the	O
five	O
years	O
preceding	O
the	O
interview	O
,	O
rated	O
on	O
a	O
scale	O
of	O
1	O
(	O
superior	O
)	O
to	O
7	O
(	O
grossly	O
inadequate	O
)	O
.	O

Mean	O
time	O
from	O
the	O
screening	O
stage	O
(	O
PERI	O
)	O
to	O
the	O
second	O
stage	O
(	O
SADS	O
-	O
I	O
)	O
was	O
1	O
.	O
1	O
years	O
±11	O
.	O
5	O
months	O
(	O
range	O
0–4	O
.	O
5	O
years	O
)	O
.	O

Two	O
of	O
the	O
study	O
researchers	O
(	O
MW	O
and	O
NW	O
)	O
reviewed	O
the	O
symptoms	O
covered	O
in	O
the	O
PERI	O
and	O
identified	O
items	O
assessing	O
negative	O
symptoms	O
similar	O
to	O
those	O
assessed	O
in	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
[	O
15	O
]	O
and	O
the	O
Scale	O
for	O
the	O
Assessment	O
of	O
Negative	O
Symptoms	O
(	O
SANS	O
)	O
[	O
16	O
]	O
,	O
scales	O
commonly	O
used	O
for	O
the	O
assessment	O
of	O
negative	O
symptoms	O
.	O

Fourteen	O
symptoms	O
(	O
9	O
self	O
-	O
reported	O
and	O
5	O
interviewer	O
-	O
rated	O
;	O
see	O
S1	O
Table	O
)	O
were	O
identified	O
.	O

The	O
self	O
-	O
report	O
items	O
were	O
scored	O
on	O
a	O
5	O
-	O
point	O
Likert	O
scale	O
,	O
ranging	O
from	O
(	O
0	O
)	O
“never”	O
to	O
(	O
4	O
)	O
“very	O
often”	O
or	O
“not	O
at	O
all	O
like	O
you”	O
(	O
0	O
)	O
to	O
“very	O
much	O
like	O
you”	O
(	O
4	O
)	O
,	O
whereas	O
the	O
interviewer	O
-	O
rated	O
items	O
were	O
scored	O
“present”	O
or	O
absent”	O
.	O

The	O
fourteen	O
negative	O
symptoms	O
were	O
included	O
in	O
a	O
principal	O
component	O
analysis	O
with	O
varimax	O
rotation	O
.	O

Four	O
symptom	O
clusters	O
were	O
extracted	O
in	O
this	O
analysis	O
:	O
avolition	O
(	O
4	O
items	O
)	O
,	O
social	O
withdrawal	O
(	O
5	O
items	O
)	O
,	O
speech	O
deficits	O
(	O
2	O
items	O
)	O
,	O
flat	O
affect	O
and	O
poor	O
hygiene	O
(	O
3	O
items	O
)	O
(	O
Table	O
1	O
)	O
.	O

As	O
flat	O
affect	O
and	O
poor	O
hygiene	O
are	O
two	O
distinct	O
concepts	O
,	O
this	O
cluster	O
was	O
split	O
into	O
two	O
:	O
flat	O
affect	O
(	O
2	O
items	O
)	O
and	O
poor	O
hygiene	O
(	O
1	O
item	O
)	O
.	O

Self	O
-	O
reports	O
of	O
psychotic	O
experiences	O
were	O
assessed	O
using	O
the	O
13	O
-	O
item	O
False	O
Beliefs	O
and	O
Perceptions	O
sub	O
-	O
scale	O
of	O
the	O
PERI	O
.	O

Subjects	O
were	O
asked	O
whether	O
they	O
had	O
experienced	O
psychotic	O
experiences	O
and	O
the	O
frequency	O
of	O
each	O
symptom	O
during	O
the	O
past	O
year	O
was	O
recorded	O
on	O
a	O
5	O
-	O
item	O
Likert	O
scale	O
rated	O
(	O
0	O
)	O
“never”	O
,	O
(	O
1	O
)	O
“rarely”	O
,	O
(	O
2	O
)	O
“sometimes”	O
,	O
(	O
3	O
)	O
“often”	O
,	O
and	O
(	O
4	O
)	O
“very	O
often”	O
.	O

As	O
in	O
previous	O
studies	O
,	O
including	O
one	O
using	O
this	O
sample	O
[	O
5	O
,	O
6	O
,	O
17	O
,	O
18	O
]	O
,	O
separate	O
scores	O
were	O
defined	O
for	O
“weak”	O
(	O
occurring	O
rarely	O
or	O
sometimes	O
)	O
and	O
“strong”	O
(	O
occurring	O
often	O
or	O
very	O
often	O
)	O
psychotic	O
experiences	O
.	O

The	O
scale	O
includes	O
questions	O
assessing	O
core	O
positive	O
symptoms	O
such	O
as	O
delusions	O
,	O
hallucinations	O
,	O
bizarre	O
thinking	O
;	O
feeling	O
possessed	O
;	O
feeling	O
dissolved	O
;	O
feeling	O
that	O
thoughts	O
were	O
not	O
one	O
'	O
s	O
own	O
;	O
and	O
beliefs	O
of	O
mind	O
control	O
.	O

An	O
example	O
of	O
a	O
typical	O
question	O
is	O
:	O
“have	O
you	O
felt	O
that	O
your	O
mind	O
was	O
dominated	O
by	O
external	O
forces	O
that	O
you	O
had	O
no	O
control	O
over	O
?	O
”	O
The	O
PERI	O
-	O
False	O
Beliefs	O
and	O
Perceptions	O
sub	O
-	O
scale	O
is	O
based	O
on	O
similar	O
criteria	O
to	O
that	O
of	O
the	O
CIDI	O
psychosis	O
section	O
(	O
version	O
1	O
.	O
1	O
)	O
,	O
the	O
favored	O
instrument	O
in	O
similar	O
studies	O
[	O
3	O
,	O
17	O
,	O
19	O
,	O
20	O
]	O
.	O

The	O
PERI	O
screening	O
scales	O
,	O
including	O
the	O
False	O
Beliefs	O
and	O
Perceptions	O
sub	O
-	O
scale	O
,	O
were	O
tested	O
for	O
reliability	O
and	O
criterion	O
validity	O
,	O
and	O
calibrated	O
against	O
known	O
cases	O
of	O
psychiatric	O
disorders	O
in	O
a	O
pilot	O
research	O
project	O
conducted	O
in	O
Israel	O
[	O
13	O
]	O
.	O

In	O
addition	O
to	O
the	O
ability	O
to	O
discern	O
between	O
psychiatric	O
cases	O
and	O
non	O
-	O
cases	O
[	O
13	O
]	O
,	O
the	O
False	O
Beliefs	O
and	O
Perceptions	O
sub	O
-	O
scale	O
has	O
high	O
internal	O
reliability	O
(	O
α	O
=	O
0	O
.	O
80	O
in	O
the	O
current	O
study	O
and	O
0	O
.	O
85	O
in	O
previous	O
studies	O
[	O
21	O
]	O
)	O
.	O

The	O
National	O
Psychiatric	O
Hospitalization	O
Case	O
Registry	O
[	O
22	O
,	O
23	O
]	O
is	O
a	O
complete	O
listing	O
of	O
all	O
psychiatric	O
hospitalizations	O
in	O
the	O
country	O
,	O
including	O
psychiatric	O
hospitals	O
,	O
day	O
hospitals	O
,	O
and	O
psychiatric	O
units	O
in	O
general	O
hospitals	O
,	O
using	O
ICD	O
discharge	O
diagnoses	O
assigned	O
by	O
a	O
board	O
-	O
certified	O
psychiatrist	O
.	O

Reporting	O
is	O
regularly	O
monitored	O
to	O
ensure	O
accuracy	O
.	O

A	O
study	O
comparing	O
RDC	O
diagnoses	O
with	O
registry	O
diagnoses	O
found	O
that	O
the	O
sensitivity	O
of	O
the	O
registry	O
diagnosis	O
of	O
non	O
-	O
affective	O
psychotic	O
disorders	O
was	O
0	O
.	O
89	O
,	O
and	O
of	O
schizophrenia	O
was	O
0	O
.	O
87	O
[	O
22	O
,	O
23	O
]	O
.	O

A	O
recent	O
study	O
on	O
this	O
data	O
set	O
showed	O
that	O
93	O
%	O
of	O
patients	O
with	O
schizophrenia	O
were	O
hospitalized	O
at	O
some	O
point	O
during	O
their	O
lifetime	O
[	O
24	O
]	O
.	O

Of	O
the	O
4	O
,	O
914	O
subjects	O
who	O
participated	O
in	O
the	O
screening	O
interview	O
,	O
172	O
had	O
a	O
psychiatric	O
hospitalization	O
,	O
73	O
(	O
1	O
.	O
6	O
%	O
)	O
of	O
whom	O
were	O
hospitalized	O
at	O
least	O
once	O
with	O
a	O
diagnosis	O
of	O
schizophrenia	O
either	O
before	O
or	O
after	O
screening	O
.	O

During	O
the	O
follow	O
up	O
,	O
169	O
cohort	O
members	O
had	O
died	O
and	O
were	O
thus	O
excluded	O
from	O
the	O
analysis	O
.	O

In	O
addition	O
,	O
we	O
removed	O
from	O
the	O
analyses	O
subjects	O
1	O
)	O
diagnosed	O
with	O
a	O
psychotic	O
disorder	O
during	O
the	O
SADS	O
-	O
I	O
interview	O
;	O
2	O
)	O
hospitalized	O
in	O
psychiatric	O
facilities	O
prior	O
to	O
the	O
PERI	O
assessment	O
;	O
and	O
3	O
)	O
with	O
missing	O
data	O
on	O
the	O
PERI	O
assessment	O
of	O
psychiatric	O
symptoms	O
.	O

The	O
final	O
analytic	O
sample	O
included	O
4	O
,	O
638	O
subjects	O
(	O
94	O
.	O
4	O
%	O
of	O
the	O
original	O
sample	O
;	O
see	O
Fig	O
.	O

1	O
)	O
.	O

During	O
the	O
follow	O
-	O
up	O
period	O
(	O
mean	O
time	O
from	O
PERI	O
interview	O
to	O
first	O
hospitalization	O
or	O
to	O
date	O
of	O
merger	O
in	O
2007	O
was	O
23	O
.	O
5	O
years	O
,	O
SD	O
=	O
3	O
.	O
7	O
)	O
,	O
19	O
individuals	O
(	O
0	O
.	O
4	O
%	O
)	O
were	O
identified	O
in	O
the	O
Psychiatric	O
Hospitalization	O
Case	O
Registry	O
as	O
having	O
been	O
later	O
hospitalized	O
at	O
least	O
once	O
for	O
schizophrenia	O
.	O

The	O
reason	O
for	O
this	O
relatively	O
low	O
rate	O
of	O
schizophrenia	O
(	O
0	O
.	O
4	O
%	O
)	O
in	O
the	O
analytic	O
sample	O
is	O
because	O
the	O
peak	O
incidence	O
of	O
schizophrenia	O
is	O
in	O
the	O
decade	O
15–24	O
[	O
25	O
]	O
;	O
thus	O
,	O
the	O
majority	O
of	O
the	O
subjects	O
with	O
this	O
disorder	O
had	O
already	O
manifested	O
their	O
illness	O
at	O
the	O
time	O
of	O
the	O
epidemiological	O
study	O
,	O
and	O
hence	O
they	O
were	O
excluded	O
from	O
this	O
analysis	O
.	O

Twelve	O
subjects	O
(	O
0	O
.	O
3	O
%	O
)	O
were	O
identified	O
as	O
having	O
psychotic	O
disorders	O
other	O
than	O
schizophrenia	O
.	O

An	O
additional	O
81	O
subjects	O
(	O
1	O
.	O
7	O
%	O
)	O
were	O
identified	O
as	O
having	O
been	O
hospitalized	O
for	O
non	O
-	O
psychotic	O
disorders	O
,	O
including	O
drug	O
use	O
,	O
personality	O
disorders	O
,	O
affective	O
disorders	O
,	O
anxiety	O
disorders	O
and	O
organic	O
mental	O
disorders	O
.	O

All	O
analyses	O
were	O
performed	O
using	O
the	O
software	O
package	O
Stata	O
,	O
version	O
10	O
[	O
26	O
]	O
.	O

The	O
data	O
were	O
weighted	O
to	O
estimate	O
the	O
rates	O
of	O
negative	O
symptoms	O
in	O
the	O
original	O
population	O
from	O
which	O
the	O
cohort	O
sample	O
was	O
drawn	O
.	O

This	O
was	O
done	O
using	O
Stata’s	O
tools	O
for	O
complex	O
survey	O
data	O
analysis	O
which	O
incorporates	O
the	O
survey	O
design	O
characteristics	O
(	O
weighting	O
,	O
clustering	O
,	O
and	O
stratification	O
)	O
into	O
the	O
data	O
analysis	O
to	O
provide	O
accurate	O
point	O
estimates	O
and	O
standard	O
errors	O
[	O
27	O
]	O
.	O

All	O
numbers	O
shown	O
represent	O
the	O
actual	O
number	O
of	O
subjects	O
,	O
whereas	O
the	O
percentages	O
are	O
weighted	O
.	O

As	O
the	O
PERI	O
was	O
not	O
designed	O
to	O
assess	O
negative	O
symptoms	O
,	O
we	O
tested	O
the	O
construct	O
validity	O
of	O
the	O
negative	O
symptoms	O
identified	O
by	O
comparing	O
the	O
prevalence	O
of	O
these	O
symptoms	O
between	O
people	O
who	O
were	O
diagnosed	O
with	O
schizophrenia	O
at	O
the	O
initial	O
assessment	O
in	O
the	O
epidemiological	O
study	O
in	O
the	O
1980	O
'	O
s	O
(	O
n	O
=	O
24	O
)	O
,	O
those	O
diagnosed	O
with	O
other	O
definite	O
RDC	O
mental	O
disorders	O
(	O
n	O
=	O
1	O
,	O
624	O
)	O
and	O
the	O
rest	O
of	O
the	O
sample	O
.	O

First	O
,	O
in	O
order	O
to	O
assess	O
the	O
effect	O
of	O
baseline	O
reports	O
of	O
negative	O
symptom	O
on	O
later	O
hospitalization	O
for	O
schizophrenia	O
,	O
with	O
no	O
assumptions	O
regarding	O
the	O
relative	O
importance	O
of	O
the	O
frequency	O
at	O
which	O
the	O
symptom	O
was	O
endorsed	O
,	O
we	O
created	O
for	O
each	O
subject	O
a	O
mean	O
negative	O
symptom	O
score	O
of	O
the	O
9	O
self	O
-	O
report	O
items	O
(	O
rated	O
0–4	O
)	O
.	O

This	O
mean	O
score	O
was	O
then	O
used	O
in	O
a	O
logistic	O
regression	O
model	O
to	O
predict	O
later	O
hospitalization	O
for	O
schizophrenia	O
.	O

Next	O
,	O
for	O
purposes	O
of	O
analysis	O
,	O
each	O
self	O
-	O
report	O
item	O
was	O
dichotomized	O
as	O
present	O
(	O
indicating	O
a	O
score	O
of	O
4	O
)	O
or	O
absent	O
(	O
indicating	O
a	O
score	O
of	O
0–3	O
)	O
,	O
similar	O
to	O
the	O
coding	O
of	O
the	O
interviewer	O
-	O
rated	O
items	O
.	O

We	O
then	O
examined	O
the	O
prevalence	O
of	O
negative	O
symptoms	O
in	O
the	O
population	O
,	O
as	O
well	O
as	O
the	O
prevalence	O
of	O
negative	O
symptom	O
clusters	O
(	O
avolition	O
,	O
social	O
withdrawal	O
,	O
speech	O
deficit	O
,	O
flat	O
affect	O
and	O
poor	O
hygiene	O
)	O
.	O

Next	O
,	O
a	O
logistic	O
regression	O
analysis	O
examining	O
the	O
presence	O
of	O
any	O
negative	O
symptom	O
and	O
risk	O
of	O
later	O
hospitalization	O
for	O
schizophrenia	O
was	O
performed	O
.	O

To	O
examine	O
the	O
specificity	O
of	O
negative	O
symptoms	O
as	O
predictors	O
of	O
schizophrenia	O
,	O
risk	O
of	O
hospitalization	O
for	O
non	O
-	O
psychotic	O
disorders	O
was	O
also	O
tested	O
.	O

For	O
all	O
logistic	O
regression	O
models	O
,	O
the	O
reference	O
group	O
was	O
people	O
who	O
did	O
not	O
report	O
any	O
negative	O
symptoms	O
.	O

Associations	O
were	O
expressed	O
as	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

Finally	O
,	O
we	O
divided	O
those	O
with	O
negative	O
symptoms	O
into	O
sub	O
-	O
groups	O
based	O
on	O
the	O
co	O
-	O
occurrence	O
of	O
psychotic	O
experiences	O
(	O
i	O
.	O
e	O
,	O
negative	O
symptoms	O
alone	O
or	O
negative	O
symptoms	O
and	O
psychotic	O
experiences	O
together	O
)	O
.	O

We	O
then	O
estimated	O
the	O
interaction	O
between	O
psychotic	O
experiences	O
(	O
coded	O
as	O
absent	O
/	O
weak	O
/	O
strong	O
)	O
and	O
negative	O
symptoms	O
(	O
coded	O
as	O
absent	O
/	O
present	O
)	O
in	O
the	O
model	O
predicting	O
hospitalization	O
for	O
schizophrenia	O
,	O
comparing	O
multiplicative	O
effect	O
sizes	O
(	O
odds	O
ratios	O
)	O
using	O
the	O
Stata	O
test	O
command	O
.	O

The	O
Centre	O
for	O
Anxiety	O
Disorders	O
and	O
Trauma	O
,	O
Maudsley	O
Hospital	O
,	O
UK	O
,	O
is	O
an	O
outpatient	O
clinic	O
specializing	O
in	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
in	O
adults	O
.	O

It	O
was	O
opened	O
in	O
April	O
2001	O
and	O
is	O
part	O
of	O
the	O
British	O
National	O
Health	O
Service	O
,	O
receiving	O
referrals	O
from	O
General	O
Practitioners	O
and	O
Community	O
Mental	O
Health	O
Teams	O
.	O

The	O
clinic	O
offers	O
assessment	O
and	O
treatment	O
for	O
survivors	O
of	O
trauma	O
in	O
adulthood	O
who	O
suffer	O
from	O
PTSD	O
.	O

It	O
serves	O
a	O
population	O
of	O
about	O
867	O
,	O
000	O
people	O
living	O
in	O
the	O
South	O
London	O
Boroughs	O
of	O
Southwark	O
,	O
Lewisham	O
and	O
Lambeth	O
.	O

These	O
areas	O
have	O
substantially	O
higher	O
rates	O
of	O
social	O
deprivation	O
,	O
crime	O
,	O
and	O
a	O
greater	O
proportion	O
of	O
ethnic	O
minorities	O
than	O
the	O
UK	O
average	O
.	O

The	O
present	O
study	O
included	O
all	O
consecutive	O
patients	O
who	O
were	O
referred	O
for	O
assessment	O
for	O
possible	O
PTSD	O
between	O
April	O
2001	O
and	O
August	O
2008	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
research	O
ethics	O
committee	O
.	O

Fig	O
.	O

1	O
shows	O
that	O
577	O
patients	O
completed	O
the	O
assessment	O
,	O
and	O
408	O
were	O
suitable	O
for	O
trauma	O
-	O
focused	O
treatment	O
.	O

The	O
main	O
reasons	O
for	O
not	O
being	O
suitable	O
at	O
the	O
time	O
of	O
assessment	O
were	O
that	O
the	O
patient	O
did	O
not	O
have	O
PTSD	O
(	O
n	O
=	O
42	O
)	O
,	O
or	O
first	O
needed	O
treatment	O
for	O
another	O
primary	O
problem	O
such	O
as	O
alcohol	O
dependence	O
or	O
immediate	O
suicide	O
risk	O
(	O
n	O
=	O
73	O
)	O
.	O

The	O
main	O
reasons	O
for	O
not	O
being	O
offered	O
CT	O
-	O
PTSD	O
despite	O
suitability	O
for	O
treatment	O
(	O
n	O
=	O
78	O
)	O
were	O
that	O
the	O
patient	O
did	O
not	O
want	O
treatment	O
(	O
n	O
=	O
27	O
)	O
or	O
participated	O
in	O
a	O
trial	O
where	O
they	O
received	O
another	O
psychological	O
treatment	O
(	O
n	O
=	O
21	O
)	O
.	O

A	O
total	O
of	O
330	O
patients	O
were	O
offered	O
a	O
course	O
of	O
CT	O
-	O
PTSD	O
.	O

Data	O
for	O
initial	O
assessment	O
and	O
the	O
last	O
treatment	O
session	O
were	O
available	O
for	O
all	O
patients	O
,	O
including	O
dropouts	O
.	O

Two	O
thirds	O
(	O
n	O
=	O
220	O
)	O
of	O
the	O
patients	O
provided	O
follow	O
-	O
up	O
data	O
.	O

Fifty	O
-	O
six	O
percent	O
(	O
n	O
=	O
185	O
)	O
of	O
the	O
330	O
patients	O
in	O
the	O
intent	O
-	O
to	O
-	O
treat	O
sample	O
were	O
female	O
.	O

Their	O
ages	O
ranged	O
from	O
18	O
to	O
83	O
years	O
,	O
M	O
=	O
38	O
.	O
8	O
,	O
SD	O
=	O
11	O
.	O
5	O
.	O

A	O
large	O
proportion	O
(	O
43	O
.	O
7	O
%	O
)	O
of	O
the	O
patients	O
were	O
from	O
ethnic	O
minorities	O
,	O
and	O
either	O
unemployed	O
(	O
33	O
.	O
7	O
%	O
)	O
,	O
or	O
on	O
disability	O
/	O
retired	O
(	O
8	O
.	O
7	O
%	O
)	O
or	O
sick	O
leave	O
(	O
16	O
.	O
0	O
%	O
)	O
because	O
of	O
their	O
symptoms	O
.	O

The	O
majority	O
(	O
42	O
.	O
8	O
%	O
)	O
was	O
single	O
,	O
37	O
.	O
7	O
%	O
were	O
married	O
/	O
cohabitating	O
with	O
a	O
partner	O
,	O
and	O
19	O
.	O
5	O
%	O
were	O
divorced	O
/	O
widowed	O
.	O

The	O
majority	O
(	O
43	O
.	O
8	O
%	O
)	O
had	O
completed	O
mandatory	O
school	O
education	O
up	O
to	O
age	O
16	O
(	O
GCSE	O
or	O
equivalent	O
)	O
,	O
18	O
%	O
had	O
not	O
completed	O
school	O
exams	O
,	O
15	O
%	O
had	O
taken	O
higher	O
school	O
exams	O
at	O
age	O
18	O
(	O
A	O
level	O
)	O
,	O
and	O
23	O
.	O
2	O
%	O
had	O
attended	O
university	O
.	O

The	O
most	O
common	O
type	O
of	O
trauma	O
addressed	O
in	O
treatment	O
was	O
interpersonal	O
violence	O
(	O
including	O
physical	O
assault	O
,	O
sexual	O
assault	O
,	O
terrorist	O
attack	O
and	O
torture	O
,	O
56	O
.	O
7	O
%	O
)	O
;	O
followed	O
by	O
accidents	O
or	O
disaster	O
(	O
22	O
.	O
4	O
%	O
)	O
,	O
traumatic	O
death	O
/	O
harm	O
to	O
others	O
(	O
9	O
.	O
5	O
%	O
)	O
,	O
and	O
other	O
traumas	O
(	O
11	O
.	O
2	O
%	O
)	O
.	O

In	O
22	O
.	O
5	O
%	O
of	O
patients	O
,	O
the	O
trauma	O
had	O
involved	O
the	O
death	O
of	O
another	O
person	O
.	O

The	O
main	O
traumas	O
that	O
were	O
addressed	O
in	O
treatment	O
had	O
happened	O
between	O
3	O
and	O
360	O
months	O
ago	O
,	O
M	O
=	O
36	O
.	O
5	O
,	O
SD	O
=	O
56	O
.	O
9	O
.	O

Most	O
patients	O
(	O
82	O
.	O
0	O
%	O
)	O
had	O
been	O
injured	O
during	O
their	O
traumas	O
,	O
and	O
21	O
.	O
5	O
%	O
had	O
suffered	O
permanent	O
physical	O
disabilities	O
or	O
loss	O
of	O
function	O
due	O
to	O
the	O
trauma	O
.	O

A	O
third	O
of	O
the	O
patients	O
(	O
33	O
.	O
7	O
%	O
)	O
had	O
received	O
previous	O
treatment	O
for	O
their	O
PTSD	O
,	O
and	O
9	O
.	O
1	O
%	O
had	O
had	O
a	O
previous	O
course	O
of	O
trauma	O
-	O
focused	O
CBT	O
.	O

The	O
majority	O
(	O
63	O
.	O
0	O
%	O
)	O
reported	O
a	O
history	O
of	O
further	O
traumas	O
,	O
and	O
17	O
.	O
8	O
%	O
reported	O
a	O
history	O
of	O
childhood	O
abuse	O
.	O

Comorbidity	O
with	O
other	O
disorders	O
was	O
common	O
;	O
75	O
.	O
8	O
%	O
met	O
diagnostic	O
criteria	O
for	O
at	O
least	O
one	O
current	O
comorbid	O
Axis	O
1	O
disorders	O
,	O
and	O
29	O
.	O
1	O
%	O
met	O
criteria	O
for	O
Axis	O
II	O
disorders	O
.	O

The	O
most	O
common	O
comorbid	O
Axis	O
1	O
conditions	O
were	O
mood	O
disorders	O
(	O
50	O
.	O
9	O
%	O
)	O
,	O
other	O
anxiety	O
disorders	O
(	O
42	O
.	O
7	O
%	O
)	O
and	O
substance	O
abuse	O
(	O
22	O
.	O
1	O
%	O
)	O
.	O

Nearly	O
half	O
(	O
48	O
.	O
5	O
%	O
)	O
reported	O
current	O
suicidal	O
ideation	O
,	O
and	O
14	O
.	O
2	O
%	O
reported	O
past	O
suicide	O
attempts	O
.	O

A	O
history	O
of	O
major	O
depression	O
was	O
common	O
(	O
69	O
.	O
7	O
%	O
)	O
,	O
and	O
a	O
significant	O
minority	O
(	O
18	O
.	O
8	O
%	O
)	O
reported	O
a	O
history	O
of	O
substance	O
dependence	O
.	O

The	O
mean	O
number	O
of	O
comorbid	O
disorders	O
was	O
2	O
.	O
2	O
,	O
SD	O
=	O
2	O
.	O
1	O
.	O

Patients	O
taking	O
psychotropic	O
medication	O
(	O
n	O
=	O
132	O
,	O
40	O
.	O
0	O
%	O
)	O
were	O
asked	O
to	O
remain	O
on	O
a	O
stable	O
dose	O
for	O
two	O
months	O
before	O
treatment	O
started	O
and	O
to	O
stay	O
on	O
the	O
same	O
dose	O
for	O
the	O
duration	O
of	O
treatment	O
,	O
and	O
the	O
majority	O
of	O
patients	O
reported	O
that	O
they	O
followed	O
this	O
advice	O
.	O

The	O
majority	O
(	O
54	O
.	O
5	O
%	O
)	O
of	O
these	O
patients	O
were	O
taking	O
SSRIs	O
,	O
16	O
.	O
3	O
%	O
tricyclic	O
antidepressants	O
,	O
4	O
.	O
9	O
%	O
benzodiazepines	O
,	O
6	O
.	O
5	O
%	O
hypnotics	O
.	O

and	O
17	O
.	O
9	O
%	O
other	O
medication	O
.	O

Patients	O
who	O
provided	O
follow	O
-	O
up	O
data	O
(	O
n	O
=	O
220	O
)	O
were	O
comparable	O
to	O
those	O
who	O
did	O
not	O
(	O
n	O
=	O
110	O
)	O
on	O
most	O
demographic	O
,	O
diagnostic	O
and	O
trauma	O
history	O
characteristics	O
,	O
but	O
had	O
higher	O
education	O
levels	O
,	O
χ	O
2	O
(	O
3	O
,	O
n	O
=	O
306	O
)	O
=	O
11	O
.	O
91	O
,	O
p	O
=	O
.	O
008	O
;	O
were	O
more	O
likely	O
to	O
be	O
employed	O
,	O
χ	O
2	O
(	O
1	O
,	O
n	O
=	O
312	O
)	O
=	O
4	O
.	O
91	O
,	O
p	O
=	O
.	O
027	O
,	O
and	O
less	O
likely	O
to	O
have	O
comorbid	O
mood	O
disorders	O
,	O
χ	O
2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
14	O
.	O
77	O
,	O
p	O
<	O
.	O
001	O
,	O
current	O
substance	O
abuse	O
,	O
χ	O
2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
5	O
.	O
62	O
,	O
p	O
<	O
.	O
018	O
,	O
or	O
personality	O
disorders	O
,	O
χ	O
2	O
(	O
1	O
,	O
n	O
=	O
330	O
)	O
=	O
4	O
.	O
99	O
,	O
p	O
=	O
.	O
025	O
.	O

Therapists	O
included	O
both	O
qualified	O
clinicians	O
and	O
therapists	O
in	O
training	O
.	O

A	O
total	O
of	O
34	O
different	O
therapists	O
with	O
a	O
wide	O
range	O
of	O
prior	O
experience	O
in	O
CBT	O
treated	O
patients	O
during	O
the	O
study	O
period	O
.	O

This	O
included	O
clinical	O
psychologists	O
(	O
qualified	O
n	O
=	O
15	O
,	O
44	O
.	O
1	O
%	O
;	O
trainees	O
=	O
11	O
,	O
32	O
.	O
3	O
%	O
)	O
,	O
nurse	O
therapists	O
(	O
n	O
=	O
3	O
,	O
8	O
.	O
8	O
%	O
)	O
and	O
psychiatrists	O
(	O
trainees	O
,	O
n	O
=	O
5	O
,	O
14	O
.	O
7	O
%	O
)	O
.	O

Each	O
therapist	O
participated	O
in	O
a	O
two	O
-	O
day	O
workshop	O
in	O
CT	O
-	O
PTSD	O
.	O

They	O
then	O
received	O
close	O
individual	O
supervision	O
in	O
treating	O
their	O
first	O
few	O
cases	O
and	O
had	O
the	O
opportunity	O
to	O
act	O
as	O
co	O
-	O
therapists	O
with	O
a	O
trained	O
therapist	O
for	O
at	O
least	O
one	O
case	O
.	O

Thereafter	O
,	O
cases	O
were	O
discussed	O
in	O
weekly	O
CT	O
-	O
PTSD	O
focused	O
group	O
supervision	O
.	O

Data	O
for	O
all	O
patients	O
including	O
training	O
cases	O
were	O
included	O
in	O
the	O
data	O
analysis	O
.	O

Two	O
aspects	O
of	O
therapist	O
experience	O
were	O
coded	O
:	O
first	O
,	O
whether	O
the	O
therapist	O
was	O
a	O
trainee	O
or	O
a	O
staff	O
therapist	O
,	O
and	O
second	O
,	O
the	O
therapists	O
'	O
experience	O
with	O
CT	O
-	O
PTSD	O
(	O
experienced	O
was	O
defined	O
as	O
having	O
treated	O
more	O
than	O
12	O
patients	O
with	O
CT	O
-	O
PTSD	O
)	O
.	O

CT	O
-	O
PTSD	O
is	O
based	O
on	O
Ehlers	O
and	O
Clark	O
'	O
s	O
(	O
2000	O
)	O
model	O
of	O
PTSD	O
and	O
targets	O
three	O
factors	O
specified	O
in	O
this	O
model	O
.	O

It	O
is	O
suggested	O
that	O
people	O
with	O
PTSD	O
perceive	O
a	O
serious	O
current	O
threat	O
which	O
has	O
two	O
sources	O
,	O
excessively	O
negative	O
appraisals	O
of	O
the	O
trauma	O
and	O
/	O
or	O
its	O
sequelae	O
and	O
characteristics	O
of	O
trauma	O
memories	O
that	O
lead	O
to	O
reexperiencing	O
symptoms	O
.	O

The	O
problem	O
is	O
maintained	O
by	O
cognitive	O
strategies	O
and	O
behaviors	O
(	O
such	O
as	O
thought	O
suppression	O
,	O
rumination	O
,	O
and	O
safety	O
-	O
seeking	O
behaviors	O
)	O
that	O
are	O
intended	O
to	O
reduce	O
the	O
sense	O
of	O
current	O
threat	O
,	O
but	O
maintain	O
the	O
problem	O
by	O
preventing	O
change	O
in	O
the	O
appraisals	O
or	O
trauma	O
memory	O
,	O
and	O
/	O
or	O
by	O
increasing	O
symptoms	O
.	O

Details	O
of	O
the	O
treatment	O
procedures	O
are	O
found	O
in	O
Clark	O
and	O
Ehlers	O
(	O
2004	O
)	O
,	O
Ehlers	O
et	O
al	O
.	O
(	O
2005	O
)	O
and	O
Ehlers	O
et	O
al	O
.	O
(	O
2010	O
,	O
http	O
:	O
/	O
/	O
oxcadat	O
.	O
psy	O
.	O
ox	O
.	O
ac	O
.	O
uk	O
/	O
downloads	O
/	O
CT	O
-	O
PTSD	O
%	O
20Treatment	O
%	O
20Procedures	O
.	O
pdf	O
/	O
view	O
)	O
.	O

Treatment	O
was	O
conducted	O
in	O
English	O
in	O
individual	O
treatment	O
sessions	O
.	O

Patients	O
received	O
a	O
mean	O
of	O
M	O
=	O
10	O
.	O
6	O
weekly	O
treatment	O
sessions	O
,	O
SD	O
=	O
5	O
.	O
0	O
,	O
and	O
M	O
=	O
2	O
.	O
0	O
monthly	O
booster	O
sessions	O
,	O
SD	O
=	O
3	O
.	O
0	O
,	O
similar	O
to	O
previous	O
trials	O
(	O
Ehlers	O
et	O
al	O
.	O
,	O
2003	O
,	O
2005	O
)	O
.	O

Therapists	O
kept	O
detailed	O
notes	O
about	O
each	O
treatment	O
session	O
,	O
and	O
an	O
independent	O
rater	O
rated	O
the	O
extent	O
to	O
which	O
the	O
session	O
focused	O
on	O
the	O
PTSD	O
treatment	O
model	O
,	O
on	O
a	O
scale	O
from	O
1	O
to	O
3	O
(	O
1	O
=	O
mainly	O
followed	O
trauma	O
-	O
focused	O
protocol	O
,	O
2	O
=	O
equal	O
focus	O
on	O
trauma	O
-	O
focused	O
protocol	O
and	O
other	O
problems	O
,	O
3	O
=	O
main	O
focus	O
on	O
other	O
problems	O
)	O
.	O

The	O
mean	O
rating	O
for	O
all	O
sessions	O
was	O
M	O
=	O
1	O
.	O
35	O
,	O
SD	O
=	O
0	O
.	O
39	O
,	O
and	O
for	O
90	O
.	O
1	O
%	O
of	O
the	O
patients	O
treatment	O
mainly	O
focused	O
on	O
the	O
PTSD	O
treatment	O
protocol	O
(	O
mean	O
rating	O
of	O
below	O
2	O
)	O
.	O

The	O
most	O
common	O
other	O
problems	O
addressed	O
in	O
the	O
sessions	O
were	O
comorbid	O
disorders	O
,	O
and	O
other	O
stressors	O
such	O
as	O
social	O
problems	O
(	O
e	O
.	O
g	O
.	O
,	O
financial	O
,	O
housing	O
,	O
legal	O
issues	O
)	O
or	O
physical	O
health	O
problems	O
.	O

Self	O
-	O
reports	O
of	O
symptom	O
severity	O
were	O
taken	O
at	O
initial	O
assessment	O
,	O
at	O
the	O
first	O
and	O
last	O
treatment	O
session	O
,	O
and	O
at	O
follow	O
-	O
up	O
(	O
mean	O
280	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
change	O
in	O
PTSD	O
symptoms	O
.	O

Patients	O
completed	O
the	O
Posttraumatic	O
Diagnostic	O
Scale	O
(	O
PDS	O
,	O
Foa	O
,	O
Cashman	O
,	O
Jaycox	O
,	O
&	O
Perry	O
,	O
1997	O
)	O
.	O

The	O
PDS	O
asks	O
patients	O
to	O
rate	O
how	O
often	O
they	O
were	O
bothered	O
by	O
each	O
of	O
the	O
PTSD	B-phenotype
symptoms	I-phenotype
specified	O
in	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
ranging	O
from	O
0	O
=	O
never	O
to	O
3	O
=	O
5	O
times	O
per	O
week	O
or	O
more	O
/	O
almost	O
always	O
.	O

The	O
PDS	O
yields	O
a	O
sum	O
score	O
measuring	O
the	O
overall	O
severity	O
of	O
PTSD	O
symptoms	O
.	O

Foa	O
et	O
al	O
.	O
(	O
1997	O
)	O
showed	O
that	O
the	O
self	O
-	O
report	O
questionnaire	O
has	O
good	O
reliability	O
and	O
concurrent	O
validity	O
with	O
other	O
PTSD	O
measures	O
.	O

Internal	O
consistency	O
in	O
this	O
sample	O
was	O
α	O
=	O
.	O
85	O
.	O

Symptoms	O
of	O
anxiety	O
and	O
depression	O
were	O
secondary	O
outcome	O
measures	O
.	O

Patients	O
completed	O
the	O
Beck	O
Anxiety	O
Inventory	O
(	O
BAI	O
,	O
Beck	O
&	O
Steer	O
,	O
1993a	O
)	O
and	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
,	O
Beck	O
&	O
Steer	O
,	O
1993b	O
)	O
,	O
standard	O
21	O
-	O
item	O
self	O
-	O
report	O
measures	O
with	O
high	O
reliability	O
and	O
validity	O
.	O

Internal	O
consistencies	O
in	O
this	O
sample	O
were	O
α	O
=	O
.	O
92	O
and	O
α	O
=	O
.	O
90	O
,	O
respectively	O
.	O

At	O
initial	O
assessments	O
,	O
clinicians	O
conducted	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
(	I-coding_system
SCID	I-coding_system
)	I-coding_system
to	O
assess	O
Axis	O
I	O
(	O
First	O
,	O
Spitzer	O
,	O
Gibbon	O
,	O
&	O
Williams	O
,	O
1996	O
)	O
and	O
II	O
diagnoses	O
(	O
First	O
,	O
Gibbon	O
,	O
Spitzer	O
,	O
&	O
Williams	O
,	O
1995	O
)	O
.	O

Interrater	O
-	O
reliability	O
for	O
PTSD	O
(	O
determined	O
from	O
a	O
random	O
selection	O
of	O
37	O
audiotapes	O
of	O
the	O
interviews	O
)	O
was	O
κ	O
=	O
0	O
.	O
95	O
.	O

Clinicians	O
also	O
determined	O
in	O
the	O
interview	O
what	O
the	O
patient	O
'	O
s	O
main	O
problem	O
was	O
and	O
assessed	O
physical	O
consequences	O
of	O
the	O
trauma	O
(	O
disability	O
,	O
chronic	O
pain	O
)	O
and	O
the	O
patients	O
'	O
treatment	O
and	O
trauma	O
history	O
(	O
adapted	O
from	O
the	O
Clinician	O
Administered	O
PTSD	O
Scale	O
,	O
Blake	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Patients	O
provided	O
demographic	O
information	O
.	O

Four	O
groups	O
of	O
potential	O
moderators	O
were	O
extracted	O
on	O
the	O
basis	O
of	O
the	O
literature	O
reviewed	O
above	O
.	O

1	O
.	O

Selection	O
criteria	O
used	O
in	O
some	O
previous	O
RCTs	O
:	O
male	O
sex	O
;	O
age	O
;	O
patient	O
does	O
not	O
meet	O
full	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
criteria	I-coding_system
(	I-coding_system
American	I-coding_system
Psychiatric	I-coding_system
Association	I-coding_system
,	I-coding_system
1994	I-coding_system
)	I-coding_system
and	O
only	O
meets	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
(	I-coding_system
World	I-coding_system
Health	I-coding_system
Organization	I-coding_system
,	I-coding_system
2010	I-coding_system
)	I-coding_system
PTSD	B-phenotype
criteria	O
;	O
PTSD	O
is	O
not	O
the	O
main	O
problem	O
(	O
i	O
.	O
e	O
.	O
,	O
another	O
disorder	O
is	O
so	O
severe	O
that	O
it	O
needs	O
principal	O
concurrent	O
treatment	O
in	O
its	O
own	O
right	O
,	O
e	O
.	O
g	O
.	O
,	O
very	O
severe	O
depression	O
or	O
agoraphobia	O
)	O
;	O
borderline	O
personality	O
disorder	O
;	O
current	O
substance	O
abuse	O
;	O
current	O
PTSD	O
is	O
linked	O
to	O
multiple	O
traumas	O
;	O
history	O

of	O
childhood	O
abuse	O
;	O
no	O
memory	O
for	O
the	O
trauma	O
;	O
patient	O
had	O
a	O
previous	O
course	O
of	O
trauma	O
-	O
focused	O
CBT	O
for	O
PTSD	O
.	O
2	O
.	O

Demographic	O
variables	O
:	O
ethnic	O
group	O
;	O
education	O
;	O
social	O
problems	O
(	O
defined	O
as	O
one	O
or	O
more	O
of	O
unemployment	O
,	O
financial	O
hardship	O
,	O
housing	O
problems	O
)	O
;	O
relationship	O
status	O
(	O
never	O
married	O
/	O
lived	O
with	O
partner	O
vs	O
.	O
married	O
,	O
cohabiting	O
,	O
widowed	O
or	O
divorced	O
)	O
;	O
ongoing	O
legal	O
proceedings	O
,	O
any	O
previous	O
treatment	O
for	O
PTSD	O
.	O
3	O
.	O

Comorbidity	O
:	O
current	O
comorbid	O
anxiety	O
disorder	O
,	O
mood	O
disorders	O
,	O
other	O
axis	O
1	O
disorders	O
,	O
personality	O
disorder	O
,	O
suicidal	O
ideation	O
,	O
taking	O
psychotropic	O
medication	O
;	O
physical	O
disability	O
resulting	O
from	O
trauma	O
,	O
chronic	O
pain	O
;	O
history	O
of	O
major	O
depression	O
,	O
substance	O
dependence	O
,	O
or	O
suicide	O
attempts	O
.	O

4	O
.	O

Aspects	O
of	O
trauma	O
history	O
:	O
Trauma	O
type	O
(	O
interpersonal	O
trauma	O
vs	O
other	O
)	O
;	O
trauma	O
involved	O
death	O
of	O
other	O
person	O
;	O
injured	O
in	O
trauma	O
;	O
months	O
since	O
main	O
trauma	O
;	O
history	O
of	O
other	O
traumas	O
;	O
total	O
number	O
of	O
traumas	O
experienced	O
.	O

Selection	O
criteria	O
used	O
in	O
some	O
previous	O
RCTs	O
:	O
male	O
sex	O
;	O
age	O
;	O
patient	O
does	O
not	O
meet	O
full	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
criteria	I-coding_system
(	I-coding_system
American	I-coding_system
Psychiatric	I-coding_system
Association	I-coding_system
,	I-coding_system
1994	I-coding_system
)	I-coding_system
and	O
only	O
meets	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
(	I-coding_system
World	I-coding_system
Health	I-coding_system
Organization	I-coding_system
,	I-coding_system
2010	I-coding_system
)	I-coding_system
PTSD	B-phenotype
criteria	O
;	O
PTSD	O
is	O
not	O
the	O
main	O
problem	O
(	O
i	O
.	O
e	O
.	O
,	O
another	O
disorder	O
is	O
so	O
severe	O
that	O
it	O
needs	O
principal	O
concurrent	O
treatment	O
in	O
its	O
own	O
right	O
,	O
e	O
.	O
g	O
.	O
,	O
very	O
severe	O
depression	O
or	O
agoraphobia	O
)	O
;	O
borderline	O
personality	O
disorder	O
;	O
current	O
substance	O
abuse	O
;	O
current	O
PTSD	O
is	O
linked	O
to	O
multiple	O
traumas	O
;	O
history	O

of	O
childhood	O
abuse	O
;	O
no	O
memory	O
for	O
the	O
trauma	O
;	O
patient	O
had	O
a	O
previous	O
course	O
of	O
trauma	O
-	O
focused	O
CBT	O
for	O
PTSD	O
.	O

Demographic	O
variables	O
:	O
ethnic	O
group	O
;	O
education	O
;	O
social	O
problems	O
(	O
defined	O
as	O
one	O
or	O
more	O
of	O
unemployment	O
,	O
financial	O
hardship	O
,	O
housing	O
problems	O
)	O
;	O
relationship	O
status	O
(	O
never	O
married	O
/	O
lived	O
with	O
partner	O
vs	O
.	O
married	O
,	O
cohabiting	O
,	O
widowed	O
or	O
divorced	O
)	O
;	O
ongoing	O
legal	O
proceedings	O
,	O
any	O
previous	O
treatment	O
for	O
PTSD	O
.	O

Comorbidity	O
:	O
current	O
comorbid	O
anxiety	O
disorder	O
,	O
mood	O
disorders	O
,	O
other	O
axis	O
1	O
disorders	O
,	O
personality	O
disorder	O
,	O
suicidal	O
ideation	O
,	O
taking	O
psychotropic	O
medication	O
;	O
physical	O
disability	O
resulting	O
from	O
trauma	O
,	O
chronic	O
pain	O
;	O
history	O
of	O
major	O
depression	O
,	O
substance	O
dependence	O
,	O
or	O
suicide	O
attempts	O
.	O

Aspects	O
of	O
trauma	O
history	O
:	O
Trauma	O
type	O
(	O
interpersonal	O
trauma	O
vs	O
other	O
)	O
;	O
trauma	O
involved	O
death	O
of	O
other	O
person	O
;	O
injured	O
in	O
trauma	O
;	O
months	O
since	O
main	O
trauma	O
;	O
history	O
of	O
other	O
traumas	O
;	O
total	O
number	O
of	O
traumas	O
experienced	O
.	O

Three	O
aspects	O
of	O
the	O
course	O
of	O
treatment	O
were	O
coded	O
from	O
the	O
session	O
notes	O
to	O
test	O
possible	O
effects	O
of	O
the	O
moderators	O
on	O
treatment	O
delivery	O
.	O

1	O
.	O

Dropout	O
:	O
This	O
was	O
defined	O
as	O
attending	O
less	O
than	O
8	O
sessions	O
,	O
unless	O
the	O
earlier	O
termination	O
was	O
determined	O
in	O
agreement	O
with	O
the	O
therapist	O
.	O

This	O
criterion	O
was	O
chosen	O
because	O
UK	O
treatment	O
guidelines	O
(	O
National	O
Institute	O
for	O
Health	O
and	O
Clinical	O
Excellence	O
,	O
2005	O
)	O
recommend	O
8	O
sessions	O
as	O
an	O
adequate	O
trial	O
of	O
trauma	O
-	O
focused	O
treatments	O
for	O
PTSD	O
on	O
the	O
basis	O
of	O
prior	O
research	O
.	O

2	O
.	O

Attendance	O
:	O
Therapists	O
indicated	O
in	O
the	O
session	O
notes	O
whether	O
or	O
not	O
the	O
patient	O
was	O
often	O
late	O
or	O
missed	O
appointments	O
without	O
notifying	O
the	O
therapist	O
.	O

3	O
.	O

Trauma	O
focus	O
:	O
the	O
degree	O
to	O
which	O
treatment	O
followed	O
the	O
trauma	O
-	O
focused	O
PTSD	O
treatment	O
protocol	O
,	O
as	O
above	O
.	O

Dropout	O
:	O
This	O
was	O
defined	O
as	O
attending	O
less	O
than	O
8	O
sessions	O
,	O
unless	O
the	O
earlier	O
termination	O
was	O
determined	O
in	O
agreement	O
with	O
the	O
therapist	O
.	O

This	O
criterion	O
was	O
chosen	O
because	O
UK	O
treatment	O
guidelines	O
(	O
National	O
Institute	O
for	O
Health	O
and	O
Clinical	O
Excellence	O
,	O
2005	O
)	O
recommend	O
8	O
sessions	O
as	O
an	O
adequate	O
trial	O
of	O
trauma	O
-	O
focused	O
treatments	O
for	O
PTSD	O
on	O
the	O
basis	O
of	O
prior	O
research	O
.	O

Attendance	O
:	O
Therapists	O
indicated	O
in	O
the	O
session	O
notes	O
whether	O
or	O
not	O
the	O
patient	O
was	O
often	O
late	O
or	O
missed	O
appointments	O
without	O
notifying	O
the	O
therapist	O
.	O

Trauma	O
focus	O
:	O
the	O
degree	O
to	O
which	O
treatment	O
followed	O
the	O
trauma	O
-	O
focused	O
PTSD	O
treatment	O
protocol	O
,	O
as	O
above	O
.	O

The	O
main	O
outcome	O
variable	O
was	O
the	O
change	O
in	O
PDS	O
scores	O
with	O
treatment	O
.	O

Several	O
further	O
measures	O
of	O
treatment	O
response	O
were	O
calculated	O
for	O
comparability	O
with	O
previous	O
studies	O
.	O

Reliable	O
change	O
thresholds	O
for	O
the	O
PDS	O
were	O
calculated	O
by	O
Foa	O
et	O
al	O
.	O
(	O
2002	O
)	O
on	O
the	O
basis	O
of	O
the	O
retest	O
reliability	O
and	O
standard	O
deviation	O
of	O
the	O
scale	O
.	O

Reliable	O
improvement	O
and	O
exacerbation	O
are	O
decreases	O
/	O
increases	O
in	O
PDS	O
scores	O
of	O
greater	O
than	O
6	O
.	O
15	O
,	O
respectively	O
.	O

Clinical	O
significant	O
response	O
was	O
defined	O
as	O
in	O
Jacobson	O
and	O
Truax	O
(	O
1991	O
)	O
.	O

Patients	O
had	O
to	O
show	O
a	O
reliable	O
improvement	O
and	O
their	O
score	O
at	O
the	O
end	O
of	O
treatment	O
had	O
to	O
be	O
lower	O
than	O
the	O
halfway	O
point	O
between	O
2	O
SD	O
below	O
the	O
patients	O
'	O
scores	O
at	O
the	O
beginning	O
of	O
treatment	O
,	O
and	O
2	O
SD	O
above	O
the	O
mean	O
of	O
a	O
sample	O
of	O
466	O
traumatized	O
people	O
without	O
PTSD	O
from	O
the	O
same	O
catchment	O
area	O
(	O
M	O
=	O
7	O
.	O
22	O
,	O
SD	O
=	O
7	O
.	O
75	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
lower	O
than	O
19	O
.	O
775	O
.	O

This	O
criterion	O
is	O
similar	O
to	O
the	O
PDS	O
cut	O
-	O
offs	O
between	O
clinical	O
and	O
nonclinical	O
presentations	O
established	O
by	O
Ehring	O
,	O
Kleim	O
,	O
Clark	O
,	O
Foa	O
,	O
and	O
Ehlers	O
(	O
2007	O
)	O
on	O
the	O
basis	O
of	O
agreement	O
with	O
structured	O
diagnostic	O
interviews	O
.	O

Treatment	O
effect	O
sizes	O
for	O
changes	O
in	O
symptom	O
scores	O
between	O
the	O
pre	O
treatment	O
assessment	O
and	O
final	O
treatment	O
session	O
were	O
calculated	O
using	O
Cohen	O
'	O
s	O
d	O
statistic	O
(	O
Cohen	O
,	O
1988	O
)	O
.	O

As	O
other	O
studies	O
vary	O
in	O
whether	O
effect	O
sizes	O
are	O
reported	O
in	O
relation	O
to	O
pooled	O
pre	O
-	O
post	O
standard	O
deviations	O
,	O
or	O
pre	O
-	O
treatment	O
standard	O
deviations	O
,	O
we	O
report	O
both	O
for	O
comparison	O
.	O

The	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
,	O
version	O
20	O
,	O
was	O
used	O
for	O
data	O
analysis	O
.	O

Hierarchical	O
linear	O
modeling	O
investigated	O
the	O
effect	O
of	O
candidate	O
moderators	O
and	O
therapist	O
effects	O
on	O
the	O
degree	O
of	O
improvement	O
in	O
the	O
PDS	O
with	O
treatment	O
,	O
following	O
guidelines	O
by	O
Heck	O
,	O
Thomas	O
,	O
and	O
Tabata	O
(	O
2010	O
)	O
.	O

This	O
analysis	O
uses	O
data	O
from	O
all	O
patients	O
.	O

All	O
variables	O
were	O
centered	O
for	O
this	O
analysis	O
(	O
Kraemer	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

At	O
Level	O
1	O
,	O
the	O
effects	O
of	O
repeated	O
observations	O
nested	O
within	O
patients	O
were	O
considered	O
.	O

Model	O
1	O
modeled	O
the	O
slope	O
of	O
improvement	O
in	O
PDS	O
scores	O
from	O
pre	O
treatment	O
to	O
post	O
treatment	O
to	O
follow	O
-	O
up	O
and	O
tested	O
random	O
slopes	O
and	O
intercepts	O
for	O
patients	O
.	O

Linear	O
and	O
quadratic	O
changes	O
in	O
PDS	O
scores	O
with	O
time	O
were	O
fitted	O
,	O
using	O
an	O
autoregressive	O
covariance	O
structure	O
at	O
Level	O
1	O
.	O

At	O
Level	O
2	O
,	O
patient	O
characteristics	O
that	O
may	O
influence	O
outcome	O
were	O
first	O
added	O
individually	O
(	O
because	O
of	O
some	O
missing	O
data	O
on	O
some	O
of	O
the	O
variables	O
)	O
to	O
the	O
model	O
to	O
test	O
for	O
main	O
effects	O
on	O
PDS	O
scores	O
(	O
indicating	O
nonspecific	O
prediction	O
of	O
symptom	O
severity	O
,	O
Kraemer	O
et	O
al	O
.	O
,	O
2002	O
)	O
and	O
interactions	O
with	O
the	O
slope	O
of	O
improvement	O
(	O
moderator	O
effects	O
,	O
Kraemer	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Next	O
,	O
variables	O
that	O
showed	O
significant	O
interactions	O
were	O
combined	O
into	O
an	O
overall	O
Model	O
2	O
to	O
determine	O
unique	O
moderators	O
of	O
slope	O
of	O
improvement	O
.	O

At	O
Level	O
3	O
(	O
therapist	O
effects	O
)	O
,	O
random	O
slopes	O
and	O
intercepts	O
for	O
therapists	O
were	O
included	O
in	O
Model	O
3	O
.	O

In	O
Model	O
4	O
,	O
the	O
two	O
measures	O
of	O
therapist	O
experience	O
were	O
added	O
,	O
trainee	O
versus	O
staff	O
therapist	O
and	O
experienced	O
versus	O
inexperienced	O
in	O
delivering	O
CT	O
-	O
PTSD	O
.	O

Recently	O
hospitalized	O
older	O
adults	O
in	O
an	O
urban	O
acute	O
care	O
hospital	O
were	O
screened	O
for	O
depression	O
before	O
discharge	O
.	O

Eligible	O
individuals	O
were	O
approached	O
for	O
the	O
study	O
after	O
discharge	O
.	O

Inclusion	O
criteria	O
were	O
age	O
≥55	O
years	O
,	O
positive	O
depression	O
screen	O
,	O
and	O
participation	O
in	O
the	O
hospital’s	O
insurance	O
contract	O
management	O
program	O
which	O
insured	O
access	O
medical	O
and	O
medication	O
records	O
.	O

Patients	O
were	O
excluded	O
from	O
participation	O
if	O
they	O
were	O
discharged	O
to	O
a	O
skilled	O
nursing	O
facility	O
,	O
had	O
more	O
than	O
mild	O
cognitive	O
impairment	O
,	O
had	O
a	O
chart	O
diagnosis	O
of	O
bipolar	O
disorder	O
or	O
schizophrenia	O
,	O
or	O
were	O
actively	O
taking	O
an	O
antipsychotic	O
or	O
mood	O
stabilizer	O
.	O

Written	O
consent	O
from	O
the	O
primary	O
care	O
providers	O
allowed	O
investigators	O
to	O
obtain	O
oral	O
consent	O
from	O
the	O
patients	O
with	O
the	O
approval	O
of	O
the	O
Montefiore	O
Medical	O
Center	O
Institutional	O
Review	O
Board	O
.	O

Subjects	O
were	O
randomized	O
prior	O
to	O
the	O
initial	O
research	O
interview	O
,	O
which	O
occurred	O
within	O
the	O
first	O
week	O
of	O
discharge	O
.	O

Those	O
in	O
the	O
routine	O
care	O
group	O
were	O
reassessed	O
by	O
telephone	O
at	O
4	O
and	O
12	O
weeks	O
.	O

Those	O
in	O
the	O
facilitated	O
group	O
were	O
also	O
reassessed	O
by	O
telephone	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
and	O
12	O
weeks	O
,	O
receiving	O
techniques	O
for	O
solving	O
problems	O
,	O
behavioral	O
activation	O
,	O
self	O
management	O
,	O
monitoring	O
response	O
to	O
treatment	O
and	O
countering	O
premature	O
discontinuation	O
of	O
medication	O
.	O

The	O
facilitator	O
did	O
not	O
provide	O
psychotherapy	O
or	O
make	O
diagnoses	O
.	O

Respondents	O
with	O
thoughts	O
of	O
death	O
or	O
self	O
harm	O
were	O
referred	O
to	O
a	O
senior	O
clinician	O
(	O
GJK	O
)	O
for	O
assessment	O
of	O
suicide	O
risk	O
.	O

Results	O
of	O
assessments	O
for	O
the	O
facilitated	O
group	O
were	O
sent	O
to	O
physicians	O
with	O
treatment	O
guidelines	O
adapted	O
from	O
the	O
STAR	O
*	O
D	O
study	O
.	O

11	O
After	O
initial	O
reports	O
that	O
subjects	O
demonstrated	O
a	O
low	O
percentage	O
of	O
antidepressant	O
therapy	O
,	O
the	O
hospital	O
medical	O
director	O
sent	O
a	O
letter	O
to	O
participating	O
physicians	O
requesting	O
that	O
they	O
reply	O
and	O
state	O
which	O
treatment	O
for	O
depression	O
,	O
if	O
any	O
,	O
they	O
chose	O
for	O
their	O
patients	O
who	O
were	O
identified	O
with	O
depression	O
in	O
the	O
study	O
.	O

Symptoms	O
of	O
depression	O
were	O
first	O
screened	O
with	O
the	O
Patient	O
Health	O
Questionnaire	O
(	O
PHQ	O
)	O
-	O
2	O
,	O
a	O
two	O
-	O
item	O
depression	O
screen	O
12	O
conducted	O
by	O
either	O
research	O
or	O
hospital	O
personnel	O
.	O

Patients	O
with	O
a	O
score	O
of	O
≥3	O
on	O
the	O
PHQ	O
-	O
2	O
were	O
approached	O
for	O
the	O
study	O
.	O

The	O
PHQ	O
-	O
9	O
was	O
used	O
to	O
further	O
assess	O
symptoms	O
and	O
severity	O
of	O
depression	O
.	O

13	O
A	O
score	O
of	O
≥10	O
was	O
indicative	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

The	O
PHQ	O
-	O
9	O
has	O
been	O
validated	O
against	O
MDD	B-phenotype
in	O
a	O
meta	O
-	O
analysis	O
of	O
14	O
studies	O
with	O
sensitivity	O
0	O
.	O
80	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
71–0	O
.	O

87	O
)	O
and	O
specificity	O
0	O
.	O
92	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
88–0	O
.	O

95	O
)	O
;	O
14	O
and	O
0	O
.	O
63	O
(	O
95	O
%	O
CI	O
;	O
90	O
.	O
33–0	O
.	O

86	O
)	O
and	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
78–0	O
.	O

85	O
)	O
respectively	O
against	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
in	O
older	O
primary	O
care	O
patients	O
.	O

15	O
It	O
has	O
also	O
been	O
shown	O
to	O
have	O
good	O
internal	O
consistency	O
with	O
a	O
Cronbach’s	O
alpha	O
of	O
0	O
.	O
803	O
.	O

16	O
Response	O
to	O
treatment	O
was	O
defined	O
as	O
a	O
5	O
-	O
point	O
decrease	O
from	O
baseline	O
at	O
any	O
time	O
during	O
the	O
12	O
-	O
week	O
trial	O
.	O

Remission	O
was	O
defined	O
as	O
a	O
total	O
score	O
of	O
≤5	O
.	O

17	O

Individuals	O
with	O
a	O
level	O
of	O
memory	O
impairment	O
that	O
might	O
make	O
their	O
responses	O
unreliable	O
were	O
excluded	O
from	O
the	O
study	O
using	O
the	O
Memory	O
Impairment	O
Screen	O
(	O
MIS	O
)	O
18	O
which	O
is	O
reliable	O
for	O
telephone	O
use	O
19	O
and	O
provides	O
an	O
efficient	O
and	O
valid	O
screen	O
for	O
dementia	O
in	O
primary	O
care	O
.	O

20	O

Pharmacy	O
data	O
were	O
captured	O
using	O
Amisys®	O
Client	O
Server	O
(	O
ACS®	O
)	O
,	O
a	O
comprehensive	O
managed	O
care	O
system	O
which	O
maintained	O
a	O
full	O
history	O
of	O
coverage	O
and	O
clinical	O
data	O
from	O
the	O
medical	O
center	O
systems	O
.	O

Information	O
from	O
the	O
telephone	O
interviews	O
were	O
collected	O
using	O
the	O
McKesson	O
CareEnhance™	O
Clinical	O
Management	O
System	O
(	O
CCMS®	O
)	O
which	O
was	O
integrated	O
with	O
ACS®	O
.	O

Descriptive	O
statistics	O
are	O
presented	O
as	O
relative	O
frequencies	O
for	O
categorical	O
variables	O
;	O
and	O
as	O
means	O
and	O
standard	O
deviations	O
,	O
or	O
medians	O
and	O
ranges	O
for	O
continuous	O
variables	O
.	O

Differences	O
between	O
the	O
routine	O
and	O
facilitated	O
care	O
groups	O
in	O
baseline	O
categorical	O
variables	O
were	O
analyzed	O
using	O
chi	O
-	O
square	O
tests	O
,	O
if	O
assumptions	O
were	O
met	O
,	O
or	O
Exact	O
tests	O
otherwise	O
for	O
categorical	O
variables	O
.	O

Differences	O
in	O
ordinal	O
variables	O
were	O
tested	O
using	O
Wilcoxon	O
Rank	O
Sum	O
tests	O
,	O
or	O
t	O
-	O
tests	O
if	O
normally	O
distributed	O
.	O

The	O
primary	O
outcome	O
for	O
comparison	O
between	O
those	O
receiving	O
the	O
intervention	O
and	O
those	O
that	O
were	O
not	O
was	O
the	O
initiation	O
of	O
antidepressant	O
medication	O
;	O
factors	O
including	O
treatment	O
group	O
were	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

Secondary	O
outcomes	O
included	O
depressive	O
symptoms	O
by	O
PHQ	O
-	O
9	O
score	O
post	O
-	O
baseline	O
,	O
any	O
response	O
to	O
treatment	O
during	O
the	O
study	O
period	O
,	O
and	O
remission	O
of	O
depressive	O
symptoms	O
.	O

Mixed	O
effects	O
models	O
assessed	O
the	O
significance	O
of	O
the	O
intervention	O
on	O
PHQ	O
-	O
9	O
outcomes	O
,	O
controlling	O
for	O
such	O
covariates	O
as	O
medical	O
comorbidities	O
(	O
from	O
ICD	B-coding_system
-	I-coding_system
9	I-coding_system
codes	O
)	O
,	O
age	O
,	O
gender	O
,	O
concomitant	O
medications	O
,	O
and	O
history	O
of	O
depression	O
,	O
and	O
logistic	O
regression	O
was	O
used	O
to	O
identify	O
factors	O
predictive	O
of	O
use	O
of	O
an	O
antidepressant	O
at	O
each	O
key	O
timepoint	O
.	O

Covariates	O
were	O
retained	O
in	O
the	O
final	O
model	O
if	O
significant	O
at	O
p	O
<	O
0	O
.	O
20	O
.	O

This	O
study	O
is	O
part	O
of	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
that	O
has	O
been	O
registered	O
(	O
http	O
:	O
/	O
/	O
clinicaltrials	O
.	O
gov	O
;	O
ID	O
NCT01174927	O
)	O
.	O

Each	O
patient	O
was	O
scanned	O
twice	O
,	O
with	O
a	O
short	O
interval	O
between	O
scans	O
(	O
mean	O
9	O
SD	O
3	O
.	O
8	O
days	O
)	O
.	O

On	O
one	O
day	O
,	O
the	O
subjects	O
received	O
an	O
injection	O
of	O
heroin	O
or	O
placebo	O
(	O
saline	O
)	O
before	O
the	O
scan	O
and	O
on	O
the	O
other	O
after	O
the	O
scan	O
.	O

Patients	O
received	O
their	O
regular	O
morning	O
dose	O
of	O
diacetylmorphine	O
,	O
corresponding	O
to	O
half	O
of	O
their	O
daily	O
dose	O
.	O

The	O
order	O
of	O
heroin	O
and	O
placebo	O
administration	O
was	O
randomized	O
and	O
patients	O
were	O
blinded	O
to	O
what	O
they	O
received	O
.	O

A	O
study	O
nurse	O
administered	O
the	O
substance	O
intravenously	O
20	O
minutes	O
before	O
the	O
scanning	O
session	O
started	O
.	O

The	O
ASL	O
perfusion	O
data	O
were	O
acquired	O
one	O
hour	O
after	O
injection	O
(	O
Mean	O
=	O
69	O
min	O
;	O
SD	O
=	O
11	O
min	O
)	O
,	O
corresponding	O
to	O
the	O
euphoria	O
phase	O
during	O
heroin	O
condition	O
.	O

Heroin	O
-	O
induced	O
alterations	O
in	O
physiological	O
parameters	O
were	O
assessed	O
within	O
the	O
scanner	O
by	O
measuring	O
heart	O
rate	O
,	O
blood	O
pressure	O
and	O
blood	O
oxygen	O
saturation	O
every	O
5	O
minutes	O
.	O

The	O
psychological	O
effects	O
of	O
the	O
applied	O
substance	O
were	O
assessed	O
by	O
a	O
45	O
-	O
item	O
Heroin	O
Craving	O
Questionnaire	O
(	O
HCQ	O
)	O
[	O
27	O
]	O
and	O
visual	O
analogue	O
scales	O
(	O
VAS	O
)	O
for	O
intoxication	O
,	O
sedation	O
,	O
withdrawal	O
,	O
and	O
strength	O
of	O
drug	O
effects	O
(	O
range	O
0	O
to	O
10	O
)	O
.	O

Fifteen	B-phenotype
(	I-phenotype
9	I-phenotype
male	I-phenotype
)	I-phenotype
non	I-phenotype
-	I-phenotype
left	I-phenotype
-	I-phenotype
handed	I-phenotype
heroin	I-phenotype
-	I-phenotype
dependent	I-phenotype
patients	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
=	O
F11	B-code
.	I-code
22	I-code
)	O
were	O
included	O
in	O
the	O
study	O
.	O

All	O
subjects	O
participated	O
in	O
a	O
national	O
program	O
of	O
standardized	O
DAM	O
(	O
“heroin”	O
)	O
-	O
assisted	O
treatment	O
(	O
JANUS	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Participants	O
were	O
told	O
to	O
abstain	O
from	O
illicit	O
drug	O
use	O
other	O
than	O
prescribed	O
heroin	O
for	O
the	O
duration	O
of	O
the	O
study	O
,	O
from	O
alcohol	O
intake	O
for	O
72	O
hours	O
and	O
from	O
tobacco	O
consumption	O
for	O
2	O
hours	O
before	O
scanning	O
.	O

Illicit	O
substances	O
and	O
medications	O
were	O
controlled	O
by	O
a	O
urine	O
test	O
at	O
each	O
session	O
.	O

The	O
exclusion	O
criteria	O
were	O
a	O
positive	O
alcohol	O
breathalyzer	O
test	O
,	O
a	O
history	O
of	O
significant	O
medical	O
problems	O
or	O
a	O
major	O
mental	O
disorder	O
(	O
other	O
than	O
substance	O
use	O
disorders	O
)	O
.	O

All	O
patients	O
gave	O
written	O
informed	O
consent	O
and	O
Basel	O
Ethics	O
Committee	O
(	O
EKBB	O
,	O
Switzerland	O
,	O
[	O
http	O
:	O
/	O
/	O
www	O
.	O
ekbb	O
.	O
ch	O
/	O
]	O
)	O
approved	O
the	O
study	O
.	O

Patients	O
were	O
informed	O
that	O
they	O
received	O
their	O
regular	O
heroin	O
dose	O
(	O
half	O
of	O
a	O
daily	O
dose	O
)	O
before	O
or	O
after	O
the	O
scan	O
.	O

Imaging	O
was	O
performed	O
on	O
a	O
3	O
Tesla	O
MRI	O
scanner	O
(	O
Magnetom	O
Verio	O
,	O
Siemens	O
Healthcare	O
,	O
Germany	O
)	O
at	O
Basel	O
University	O
Hospital	O
.	O

For	O
high	O
resolution	O
anatomical	O
data	O
,	O
a	O
3D	O
T1	O
-	O
weighted	O
scan	O
(	O
MPRAGE	O
)	O
was	O
acquired	O
with	O
1×1×1	O
mm	O
3	O
isotropic	O
resolution	O
,	O
repetition	O
time	O
(	O
TR	O
)	O
of	O
2000	O
ms	O
,	O
inversion	O
time	O
(	O
TI	O
)	O
of	O
1000	O
ms	O
and	O
echo	O
time	O
(	O
TE	O
)	O
of	O
3	O
.	O
4	O
ms	O
.	O
For	O
perfusion	O
data	O
,	O
a	O
pulsed	O
ASL	O
sequence	O
[	O
28	O
]	O
based	O
on	O
a	O
flow	O
-	O
sensitive	O
alternating	O
inversion	O
recovery	O
(	O
FAIR	O
)	O
spin	O
labeling	O
scheme	O
[	O
29	O
]	O
was	O
applied	O
,	O
combined	O
with	O
modified	O
Q2TIPS	O
(	O
TI	O
periodic	O
saturation	O
)	O
pulse	O
preparation	O
and	O
a	O
single	O
-	O
shot	O
3D	O
GRASE	O
(	O
gradient	O
-	O
spin	O
echo	O
)	O
readout	O
[	O
30	O
]	O
.	O

For	O
quantification	O
of	O
cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
,	O
a	O
time	O
series	O
with	O
14	O
incremental	O
TI	O
(	O
200	O
to	O
2800	O
ms	O
in	O
200	O
ms	O
steps	O
)	O
was	O
acquired	O
.	O

For	O
each	O
TI	O
,	O
two	O
images	O
were	O
acquired	O
:	O
one	O
after	O
slice	O
-	O
selective	O
inversion	O
(	O
control	O
image	O
)	O
and	O
one	O
after	O
non	O
-	O
selective	O
inversion	O
(	O
labeled	O
image	O
)	O
.	O

The	O
sequence	O
parameters	O
were	O
:	O
repetition	O
time	O
3200	O
ms	O
,	O
echo	O
time	O
12	O
.	O
7	O
ms	O
and	O
spatial	O
resolution	O
4	O
.	O
6×4	O
.	O

6×4	O
mm	O
3	O
(	O
interpolated	O
to	O
2	O
.	O
3×2	O
.	O

3×4	O
mm	O
3	O
)	O
.	O

Maps	O
of	O
quantified	O
CBF	O
(	O
perfusion	O
maps	O
)	O
were	O
calculated	O
from	O
ASL	O
raw	O
data	O
.	O

Difference	O
images	O
of	O
label	O
and	O
control	O
images	O
at	O
different	O
TI	O
were	O
derived	O
and	O
the	O
time	O
course	O
was	O
fitted	O
to	O
a	O
model	O
describing	O
different	O
stages	O
of	O
arterial	O
blood	O
passage	O
,	O
using	O
in	O
-	O
house	O
software	O
,	O
[	O
28	O
]	O
.	O

The	O
resulting	O
MHD	O
files	O
were	O
converted	O
to	O
the	O
NIFTI	O
format	O
with	O
MedINRIA	O
1	O
.	O
9	O
.	O

2	O
(	O
http	O
:	O
/	O
/	O
med	O
.	O
inria	O
.	O
fr	O
)	O
.	O

Further	O
image	O
processing	O
and	O
analyses	O
were	O
performed	O
using	O
Statistical	O
Parametric	O
Mapping	O
(	O
SPM8	O
;	O
Wellcome	O
Department	O
of	O
Cognitive	O
Neurology	O
,	O
London	O
,	O
United	O
Kingdom	O
)	O
.	O

At	O
the	O
subject	O
level	O
,	O
MPRAGE	O
images	O
were	O
segmented	O
to	O
gray	O
matter	O
(	O
GM	O
)	O
and	O
intracranial	O
tissue	O
(	O
ICT	O
;	O
sum	O
of	O
GM	O
,	O
white	O
matter	O
,	O
and	O
cerebrospinal	O
fluid	O
)	O
.	O

Perfusion	O
maps	O
were	O
reoriented	O
to	O
the	O
standard	O
direction	O
.	O

Both	O
conditions	O
were	O
first	O
realigned	O
and	O
then	O
coregistered	O
to	O
segmented	O
GM	O
images	O
,	O
resulting	O
in	O
optimal	O
MPRAGE	O
coregistration	O
.	O

Then	O
perfusion	O
maps	O
were	O
masked	O
with	O
binarized	O
ICT	O
(	O
binarization	O
threshold	O
:	O
voxel	O
intensity	O
>	O
0	O
.	O
1	O
)	O
to	O
remove	O
the	O
extracerebral	O
signal	O
.	O

The	O
resulting	O
perfusion	O
maps	O
were	O
normalized	O
to	O
standard	O
stereotactic	O
MNI	O
(	O
Montreal	O
Neurological	O
Institute	O
)	O
space	O
by	O
applying	O
the	O
transformation	O
parameters	O
of	O
normalized	O
MPRAGE	O
images	O
.	O

Finally	O
normalized	O
perfusion	O
maps	O
were	O
smoothed	O
using	O
a	O
6	O
mm	O
full	O
-	O
width	O
-	O
at	O
half	O
-	O
maximum	O
(	O
FWHM	O
)	O
Gaussian	O
kernel	O
.	O

All	O
processed	O
images	O
were	O
assessed	O
with	O
respect	O
to	O
quality	O
and	O
registration	O
.	O

See	O
preprocessing	O
steps	O
in	O
figure	O
1	O
.	O

BIN	O
:	O
Binarization	O
;	O
CSF	O
:	O
Cerebrospinal	O
fluid	O
;	O
GM	O
:	O
Gray	O
matter	O
;	O
WM	O
:	O
White	O
matter	O
.	O

At	O
the	O
group	O
level	O
,	O
a	O
voxel	O
-	O
wise	O
whole	O
brain	O
comparison	O
between	O
the	O
heroin	O
and	O
placebo	O
conditions	O
was	O
performed	O
with	O
a	O
basic	O
general	O
linear	O
model	O
(	O
GLM	O
)	O
.	O

A	O
proportional	O
scaling	O
method	O
in	O
SPM8	O
was	O
used	O
to	O
normalize	O
each	O
subject	O
'	O
s	O
perfusion	O
maps	O
.	O

MNI	O
coordinates	O
of	O
significant	O
clusters	O
were	O
converted	O
into	O
Talairach	O
space	O
and	O
labeled	O
with	O
the	O
Talairach	O
Client	O
2	O
.	O
4	O
.	O

3	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
talairach	O
.	O
org	O
/	O
client	O
.	O
html	O
)	O
.	O

We	O
performed	O
a	O
repeated	O
measures	O
(	O
within	O
-	O
subject	O
)	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
for	O
whole	O
brain	O
analysis	O
.	O

Pre	O
-	O
processed	O
heroin	O
and	O
placebo	O
perfusion	O
maps	O
were	O
used	O
as	O
input	O
data	O
.	O

The	O
following	O
tests	O
were	O
applied	O
:	O
heroin	O
<	O
placebo	O
(	O
higher	O
perfusion	O
during	O
heroin	O
)	O
and	O
heroin	O
>	O
placebo	O
(	O
lower	O
perfusion	O
during	O
heroin	O
)	O
.	O

Statistical	O
significance	O
was	O
assessed	O
at	O
the	O
cluster	O
-	O
forming	O
threshold	O
of	O
p	O
<	O
0	O
.	O
01	O
(	O
uncorrected	O
)	O
.	O

At	O
the	O
cluster	O
level	O
,	O
only	O
clusters	O
with	O
p	O
<	O
0	O
.	O
05	O
corrected	O
for	O
family	O
-	O
wise	O
error	O
(	O
FWE	O
)	O
were	O
considered	O
significant	O
[	O
31	O
]	O
.	O

We	O
used	O
the	O
eigenvariate	O
function	O
in	O
SPM8	O
to	O
extract	O
mean	O
perfusion	O
values	O
within	O
the	O
significant	O
clusters	O
.	O

Cohen	O
'	O
s	O
d	O
was	O
performed	O
to	O
calculate	O
effect	O
sizes	O
of	O
perfusion	O
reduction	O
.	O

We	O
used	O
paired	O
t	O
-	O
tests	O
in	O
SPSS	O
Statistics	O
(	O
IBM	O
SPSS	O
Statistics	O
;	O
Armonk	O
,	O
NY	O
:	O
IBM	O
Corp	O
)	O
to	O
analyze	O
differences	O
in	O
HCQ	O
scores	O
,	O
VAS	O
values	O
and	O
physiological	O
parameters	O
between	O
the	O
heroin	O
and	O
placebo	O
conditions	O
.	O

To	O
analyze	O
demographic	O
,	O
clinical	O
and	O
perfusion	O
differences	O
(	O
extracted	O
values	O
)	O
between	O
men	O
and	O
women	O
,	O
we	O
used	O
independent	O
-	O
samples	O
t	O
-	O
tests	O
.	O

Pearson	O
'	O
s	O
r	O
correlations	O
were	O
performed	O
to	O
assess	O
the	O
association	O
of	O
heroin	O
dependence	O
duration	O
and	O
extracted	O
perfusion	O
values	O
.	O

The	O
tested	O
group	O
consisted	O
of	O
142	O
alcohol	O
-	O
dependent	O
patients	O
(	O
127	O
men	O
and	O
15	O
women	O
)	O
from	O
detoxification	O
ward	O
(	O
Department	O
of	O
Detoxification	O
,	O
Psychiatric	O
Hospital	O
in	O
Choroszcz	O
)	O
.	O

Patients	O
were	O
initially	O
examined	O
and	O
interviewed	O
regarding	O
history	O
of	O
disease	O
and	O
their	O
use	O
of	O
alcohol	O
.	O

The	O
diagnosis	O
of	O
dependency	B-phenotype
was	O
made	O
on	O
the	O
basis	O
of	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
WHO	O
criteria	O
.	O

The	O
self	O
-	O
reported	O
mean	O
alcohol	O
consumption	O
was	O
1311	O
g	O
of	O
ethanol	O
per	O
week	O
and	O
mean	O
time	O
of	O
dependency	O
was	O
18	O
years	O
.	O

The	O
patients	O
did	O
not	O
undergo	O
the	O
liver	O
biopsy	O
,	O
and	O
fibrosis	O
stage	O
was	O
established	O
in	O
FibroTest	O
which	O
was	O
used	O
as	O
the	O
reference	O
standard	O
.	O

Study	O
was	O
in	O
accordance	O
with	O
Helsinki	O
Declaration	O
and	O
was	O
approved	O
by	O
the	O
Bioethical	O
Committee	O
at	O
the	O
Medical	O
University	O
in	O
Bialystok	O
.	O

Blood	O
samples	O
from	O
a	O
peripheral	O
vein	O
from	O
each	O
patient	O
were	O
collected	O
.	O

After	O
centrifugation	O
,	O
sera	O
were	O
collected	O
into	O
2	O
tubes	O
and	O
stored	O
at	O
-	O
86°C	O
until	O
assayed	O
.	O

Besides	O
serum	O
,	O
a	O
part	O
of	O
each	O
sample	O
was	O
collected	O
into	O
tubes	O
containing	O
3	O
.	O
8	O
%	O
liquid	O
sodium	O
citrate	O
and	O
EDTA	O
-	O
2	O
.	O

AST	O
,	O
ALT	O
,	O
GGT	O
,	O
cholesterol	O
,	O
α	O
2	O
-	O
macroglobulin	O
,	O
hyaluronic	O
acid	O
,	O
and	O
bilirubin	O
were	O
determined	O
on	O
the	O
Architect	O
c8000	O
(	O
Abbott	O
Laboratories	O
,	O
Abbott	O
Park	O
,	O
USA	O
)	O
.	O

PLT	O
count	O
was	O
measured	O
on	O
Sysmex	O
XS	O
-	O
800i	O
(	O
Sysmex	O
Corporation	O
,	O
Singapore	O
)	O
.	O

The	O
serum	O
biochemical	O
markers	O
,	O
α	O
2	O
-	O
macroglobulin	O
,	O
haptoglobin	O
,	O
apolipoprotein	O
A1	O
,	O
γ	O
-	O
glutamyltransferase	O
,	O
alanine	O
aminotransferase	O
,	O
and	O
total	O
bilirubin	O
,	O
were	O
determined	O
according	O
to	O
methods	O
recommended	O
by	O
BioPredictive	O
(	O
Paris	O
,	O
France	O
)	O
.	O

FibroTest	O
scores	O
were	O
computed	O
by	O
BioPredictive	O
company	O
according	O
to	O
the	O
arrangement	O
,	O
and	O
results	O
were	O
provided	O
with	O
security	O
algorithms	O
.	O

CDT	O
immunoassays	O
were	O
carried	O
out	O
using	O
the	O
N	O
Latex	O
CDT	O
test	O
(	O
Siemens	O
Healthcare	O
Diagnostics	O
,	O
Marburg	O
,	O
Germany	O
)	O
on	O
BN	O
II	O
System	O
(	O
Siemens	O
Healthcare	O
Diagnostics	O
,	O
USA	O
)	O
.	O

CDT	O
values	O
were	O
expressed	O
as	O
percentages	O
of	O
total	O
transferrin	O
.	O

(	O
1	O
)	O
A	O
P	O
R	O
I	O
=	O
A	O
S	O
T	O
I	O
U	O
/	O
L	O
/	O
50	O
I	O
U	O
/	O
L	O
P	O
L	O
T	O
10	O
9	O
/	O
L	O
∗	O
100	O
G	O
A	O
P	O
R	O
I	O
=	O
G	O
G	O
T	O
I	O
U	O
/	O
L	O
P	O
L	O
T	O
10	O
9	O
/	O
L	O
∗	O
100	O
F	O
I	O
B	O
-	O
4	O
=	O
a	O
g	O
e	O
∗	O
A	O
S	O
T	O
I	O
U	O
/	O
L	O
P	O
L	O
T	O
10	O
9	O
/	O
L	O
∗	O
√	O
A	O
L	O
T	O
I	O
U	O
/	O
L	O
Forn	O
'	O
s	O
i	O
n	O
d	O
e	O
x	O
=	O
7	O
.	O
811	O
−	O
3	O
.	O
131	O
ln	O
⁡	O
P	O
L	O
T	O
10	O
9	O
/	O
L	O
+	O
0	O
.	O
781	O
ln	O
⁡	O
G	O
G	O
T	O
I	O
U	O
/	O
L	O
+	O
3	O
.	O
467	O
ln	O
⁡	O
a	O
g	O
e	O
−	O
0	O
.	O
014	O
c	O
h	O
o	O
l	O
e	O
s	O
t	O
e	O
r	O
o	O
l	O
m	O
g	O
/	O
d	O
L	O
A	O
P	O
i	O
n	O
d	O
e	O
x	O
=	O
a	O
g	O
e	O
+	O
P	O
L	O
T	O
a	O
g	O
e	O
:	O
<	O
30	O
=	O
0	O
;	O
30	O
-	O
39	O
=	O
1	O
;	O
40	O
-	O
49	O
=	O
2	O
;	O
50	O
-	O
59	O
=	O
3	O
;	O
60	O
-	O
69	O
=	O
4	O
;	O
≥	O
70	O
=	O
50	O
,	O
P	O
L	O
T	O
×	O
10	O
9	O
/	O
L	O
:	O
≥	O
225	O
=	O
0	O
;	O
200	O
-	O
224	O
=	O
1	O
;	O
175	O

-	O
199	O
=	O
2	O
;	O
150	O
-	O
174	O
=	O
3	O
;	O
125	O
-	O
149	O
=	O
4	O
;	O
<	O
125	O
=	O
5	O
H	O
e	O
p	O
a	O
s	O
c	O
o	O
r	O
e	O
=	O
Y	O
1	O
+	O
Y	O
Y	O
=	O
e	O
x	O
p	O
-	O
4	O
.	O
185818	O
−	O
0	O
.	O
0249	O
∗	O
a	O
g	O
e	O
+	O
0	O
.	O
7464	O
∗	O
s	O
e	O
x	O
+	O
1	O
.	O
0039	O
∗	O
α	O
2	O
-	O
m	O
a	O
c	O
r	O
o	O
g	O
l	O
o	O
b	O
u	O
l	O
i	O
n	O
+	O
0	O
.	O
0302	O
∗	O
h	O
y	O
a	O
l	O
u	O
r	O
o	O
n	O
i	O
c	O
a	O
c	O
i	O
d	O
n	O
g	O
/	O
m	O
L	O
+	O
0	O
.	O
0691	O
∗	O
t	O
o	O
t	O
a	O
l	O
b	O
i	O
l	O
i	O
r	O
u	O
b	O
i	O
n	O
–	O
0	O
.	O
0012	O
∗	O
G	O
G	O
T	O
I	O
U	O
/	O
L	O
The	O
values	O
for	O
sex	O
:	O
1	O
for	O
men	O
and	O
0	O
for	O
women	O
.	O

The	O
normality	O
of	O
distribution	O
was	O
checked	O
by	O
means	O
of	O
Kolmogorov	O
-	O
Smirnov	O
test	O
with	O
the	O
Lilliefors	O
correction	O
.	O

The	O
analysis	O
revealed	O
that	O
the	O
distribution	O
of	O
APRI	O
,	O
FIB	O
-	O
4	O
,	O
GAPRI	O
,	O
and	O
Hepascore	O
does	O
not	O
follow	O
a	O
normal	O
distribution	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
Forns	O
index	O
and	O
AP	O
follow	O
a	O
normal	O
distribution	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
(	O
Figure	O
1	O
)	O
.	O

The	O
differences	O
between	O
stages	O
of	O
liver	O
fibrosis	O
were	O
evaluated	O
by	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

To	O
test	O
the	O
effect	O
of	O
liver	O
diseases	O
on	O
the	O
values	O
of	O
markers	O
,	O
ANOVA	O
rank	O
Kruskal	O
-	O
Wallis	O
test	O
was	O
performed	O
.	O

We	O
considered	O
P	O
-	O
values	O
<	O
0	O
.	O
05	O
as	O
statistically	O
significant	O
.	O

The	O
diagnostic	O
performance	O
of	O
each	O
test	O
was	O
calculated	O
as	O
sensitivity	O
,	O
specificity	O
,	O
PPV	O
,	O
NPV	O
,	O
and	O
accuracy	O
.	O

To	O
calculate	O
the	O
diagnostic	O
accuracy	O
of	O
algorithms	O
,	O
the	O
ROC	O
curve	O
was	O
used	O
.	O

The	O
GET	O
UP	O
PIANO	O
trial	O
(	O
Ruggeri	O
et	O
al	O
.	O
,	O
2012	O
)	O
is	O
a	O
large	O
multi	O
-	O
centre	O
randomised	O
controlled	O
cluster	O
trial	O
comparing	O
an	O
add	O
-	O
on	O
multi	O
-	O
element	O
psychosocial	O
early	O
intervention	O
with	O
‘routine	O
care’	O
for	O
patients	O
with	O
FEP	O
and	O
their	O
caregivers	O
provided	O
within	O
Italian	O
public	O
general	O
mental	O
health	O
services	O
.	O

It	O
was	O
designed	O
to	O
assess	O
early	O
multi	O
-	O
element	O
psychosocial	O
interventions	O
in	O
epidemiologically	O
representative	O
samples	O
of	O
patients	O
and	O
families	O
treated	O
in	O
routine	O
generic	O
mental	O
health	O
settings	O
.	O

Of	O
the	O
126	O
community	O
mental	O
health	O
centres	O
(	O
CMHCs	O
)	O
located	O
in	O
two	O
northern	O
Italian	O
regions	O
(	O
Veneto	O
and	O
Emilia	O
-	O
Romagna	O
)	O
and	O
the	O
urban	O
areas	O
of	O
Florence	O
,	O
Milan	O
and	O
Bolzano	O
,	O
117	O
(	O
92	O
.	O
8	O
%	O
)	O
participated	O
,	O
covering	O
an	O
area	O
of	O
9	O
304	O
093	O
inhabitants	O
.	O

The	O
assignment	O
units	O
(	O
clusters	O
)	O
were	O
the	O
CMHCs	O
,	O
and	O
the	O
units	O
of	O
observation	O
and	O
analysis	O
were	O
patients	O
and	O
their	O
families	O
.	O

The	O
trial	O
received	O
approval	O
by	O
the	O
ethics	O
committees	O
of	O
the	O
coordinating	O
centre	O
(	O
Azienda	O
Ospedaliera	O
Universitaria	O
Integrata	O
di	O
Verona	O
)	O
and	O
each	O
participating	O
unit	O
and	O
was	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT01436331	O
)	O
.	O

Full	O
details	O
on	O
the	O
protocol	O
of	O
the	O
GET	O
UP	O
PIANO	O
study	O
and	O
on	O
the	O
main	O
findings	O
of	O
the	O
GET	O
UP	O
PIANO	O
trial	O
are	O
given	O
elsewhere	O
(	O
Ruggeri	O
et	O
al	O
.	O
,	O
2012	O
,	O
2015	O
)	O
.	O

During	O
the	O
index	O
period	O
,	O
all	O
CMHCs	O
participating	O
in	O
the	O
GET	O
UP	O
PIANO	O
trial	O
were	O
asked	O
to	O
refer	O
potential	O
cases	O
of	O
psychosis	O
at	O
first	O
contact	O
to	O
the	O
study	O
team	O
.	O

Inclusion	O
eligibility	O
comprised	O
patients	O
aged	O
18–54	O
years	O
;	O
residence	O
within	O
specified	O
CMHC	O
catchment	O
area	O
;	O
presence	O
of	O
at	O
least	O
one	O
of	O
the	O
following	O
:	O
hallucinations	O
,	O
delusions	O
,	O
qualitative	O
speech	O
disorder	O
,	O
qualitative	O
psychomotor	O
disorder	O
,	O
bizarre	O
or	O
grossly	O
inappropriate	O
behaviour	O
,	O
or	O
two	O
of	O
the	O
following	O
:	O
loss	O
of	O
interest	O
,	O
initiative	O
and	O
drive	O
,	O
social	O
withdrawal	O
,	O
episodic	O
severe	O
excitement	O
,	O
purposeless	O
destructiveness	O
,	O
overwhelming	O
fear	O
or	O
marked	O
self	O
-	O
neglect	O
(	O
as	O
rated	O
by	O
the	O
World	O
Health	O
Organisation	O

(	O
WHO	O
)	O
Screening	O
Schedule	O
for	O
Psychosis	O
(	O
WHO	O
,	O
1992	O
)	O
,	O
and	O
first	O
contact	O
with	O
CMHC	O
)	O
.	O

Exclusion	O
criteria	O
comprised	O
a	O
3	O
-	O
month	O
or	O
greater	O
history	O
of	O
use	O
of	O
anti	O
-	O
psychotic	O
medication	O
for	O
treatment	O
of	O
the	O
same	O
or	O
similar	O
mental	O
health	O
problem	O
;	O
presence	O
of	O
other	O
mental	O
health	O
condition	O
(	O
s	O
)	O
due	O
to	O
general	O
medical	O
condition	O
;	O
other	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
-	I-coding_system
10	I-coding_system
psychiatric	B-phenotype
diagnosis	I-phenotype
(	I-phenotype
apart	I-phenotype
from	I-phenotype
psychosis	I-phenotype
)	I-phenotype
;	O
moderate–severe	O
learning	O
disability	O
confirmed	O
by	O
clinical	O
functional	O
assessment	O
.	O

Across	O
both	O
study	O
arms	O
,	O
patients	O
meeting	O
inclusion	O
criteria	O
were	O
invited	O
to	O
undertake	O
standardised	O
assessments	O
as	O
soon	O
as	O
possible	O
,	O
once	O
they	O
achieved	O
clinical	O
stabilisation	O
and	O
provision	O
of	O
informed	O
written	O
consent	O
.	O

They	O
were	O
provided	O
with	O
information	O
detailing	O
the	O
nature	O
,	O
scope	O
and	O
possible	O
consequences	O
of	O
participation	O
in	O
the	O
trial	O
and	O
informed	O
that	O
they	O
could	O
withdraw	O
consent	O
at	O
any	O
time	O
.	O

Patient	O
participants	O
were	O
also	O
asked	O
to	O
give	O
consent	O
for	O
family	O
member	O
contact	O
;	O
family	O
members	O
who	O
agreed	O
to	O
participate	O
provided	O
written	O
informed	O
consent	O
.	O

There	O
were	O
no	O
inclusion	O
or	O
exclusion	O
criteria	O
for	O
relatives	O
,	O
beyond	O
that	O
all	O
eligible	O
patient	O
participants	O
were	O
required	O
to	O
provide	O
consent	O
to	O
involve	O
a	O
key	O
family	O
member	O
in	O
the	O
assessments	O
.	O

The	O
data	O
are	O
based	O
on	O
one	O
identified	O
carer	O
per	O
household	O
.	O

The	O
experimental	O
treatment	O
consisted	O
of	O
a	O
multi	O
-	O
element	O
psychosocial	O
intervention	O
,	O
adjunctive	O
to	O
routine	O
care	O
.	O

It	O
included	O
the	O
delivery	O
of	O
cognitive	O
behavioural	O
therapy	O
(	O
CBT	O
)	O
for	O
psychosis	O
to	O
patients	O
(	O
Kuipers	O
et	O
al	O
.	O
,	O
1998	O
;	O
Garety	O
et	O
al	O
.	O
,	O
2008	O
)	O
,	O
and	O
of	O
psychosis	O
-	O
focused	O
family	O
intervention	O
(	O
FI	O
)	O
(	O
Kuipers	O
et	O
al	O
.	O
,	O
2002	O
)	O
to	O
families	O
,	O
together	O
with	O
case	O
management	O
(	O
Burns	O
and	O
Firn	O
,	O
2002	O
)	O
,	O
involving	O
both	O
patients	O
and	O
their	O
families	O
.	O

The	O
family	O
-	O
based	O
,	O
psychosis	O
-	O
focused	O
intervention	O
treatments	O
were	O
provided	O
by	O
psychiatrists	O
and	O
psychologists	O
in	O
the	O
participating	O
teams	O
.	O

They	O
had	O
completed	O
specialist	O
therapy	O
training	O
and	O
had	O
their	O
competencies	O
assessed	O
with	O
a	O
specified	O
minimum	O
threshold	O
level	O
required	O
to	O
offer	O
treatment	O
to	O
patients	O
.	O

The	O
interventions	O
typically	O
include	O
psychoeducation	O
,	O
emotional	O
support	O
,	O
coping	O
strategies	O
,	O
problem	O
solving	O
,	O
emotional	O
processing	O
and	O
relapse	O
prevention	O
(	O
crisis	O
planning	O
)	O
components	O
that	O
vary	O
according	O
to	O
the	O
presenting	O
needs	O
and	O
agreed	O
goals	O
.	O

The	O
interventions	O
comprised	O
an	O
optimal	O
10–15	O
sessions	O
(	O
typically	O
six	O
sessions	O
in	O
the	O
initial	O
3	O
months	O
followed	O
by	O
monthly	O
sessions	O
over	O
the	O
remaining	O
6	O
months	O
)	O
delivered	O
over	O
a	O
9	O
-	O
month	O
period	O
.	O

Interventions	O
were	O
for	O
individual	O
families	O
and	O
delivered	O
in	O
accordance	O
with	O
the	O
Kuipers	O
et	O
al	O
.	O
’s	O
(	O
2002	O
)	O
evidence	O
-	O
based	O
treatment	O
manual	O
.	O

To	O
support	O
treatment	O
fidelity	O
and	O
avoid	O
therapy	O
drift	O
,	O
therapists	O
attended	O
regular	O
supervision	O
with	O
external	O
therapy	O
experts	O
that	O
included	O
written	O
session	O
summaries	O
.	O

An	O
independent	O
team	O
of	O
raters	O
assessed	O
random	O
samples	O
of	O
audiotaped	O
therapy	O
recordings	O
against	O
therapy	O
checklist	O
.	O

Control	O
arm	O
CMHCs	O
provided	O
only	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
,	O
which	O
,	O
in	O
Italy	O
,	O
comprises	O
personalised	O
outpatient	O
psychopharmacological	O
treatment	O
and	O
non	O
-	O
specific	O
supportive	O
clinical	O
management	O
by	O
the	O
CMHC	O
(	O
Ferrannini	O
et	O
al	O
.	O
,	O
2014	O
)	O
.	O

FIs	O
in	O
TAU	O
consisted	O
of	O
non	O
-	O
specific	O
informal	O
support	O
sessions	O
.	O

Carer	O
outcomes	O
(	O
i	O
.	O
e	O
.	O
burden	O
and	O
emotional	O
distress	O
)	O
were	O
assessed	O
by	O
the	O
Involvement	O
Evaluation	O
Questionnaire	O
(	O
IEQ	O
-	O
EU	O
,	O
van	O
Wijngaarden	O
et	O
al	O
.	O
,	O
2000	O
)	O
and	O
the	O
GHQ	O
-	O
12	O
(	O
Goldberg	O
and	O
Williams	O
,	O
1988	O
)	O
at	O
baseline	O
(	O
before	O
treatment	O
was	O
initiated	O
)	O
and	O
at	O
9	O
-	O
month	O
follow	O
-	O
up	O
,	O
by	O
independent	O
researchers	O
,	O
blind	O
to	O
treatment	O
allocation	O
.	O

The	O
IEQ	O
-	O
EU	O
(	O
van	O
Wijngaarden	O
et	O
al	O
.	O
,	O
2000	O
)	O
is	O
a	O
widely	O
used	O
measure	O
of	O
carer	O
burden	O
that	O
taps	O
broad	O
domains	O
of	O
caregiving	O
experience	O
and	O
easy	O
to	O
complete	O
.	O

It	O
is	O
a	O
31	O
-	O
item	O
four	O
subscale	O
questionnaire	O
.	O

The	O
subscales	O
relate	O
to	O
the	O
encouragement	O
and	O
care	O
that	O
the	O
caregiver	O
has	O
to	O
give	O
to	O
the	O
patient	O
(	O
urging	O
)	O
;	O
to	O
personal	O
problems	O
between	O
patient	O
and	O
caregiver	O
(	O
tension	O
)	O
;	O
to	O
the	O
caregiver	O
'	O
s	O
worries	O
(	O
worrying	O
)	O
;	O
and	O
burden	O
and	O
monitoring	O
patients	O
about	O
their	O
medication	O
,	O
sleep	O
and	O
any	O
dangerous	O
behaviours	O
(	O
supervision	O
)	O
.	O

All	O
items	O
are	O
scored	O
on	O
a	O
five	O
-	O
point	O
Likert	O
scale	O
.	O

Higher	O
scores	O
indicate	O
greater	O
burden	O
of	O
care	O
as	O
an	O
overall	O
scale	O
and	O
within	O
each	O
domain	O
.	O

The	O
measure	O
has	O
been	O
translated	O
into	O
several	O
different	O
languages	O
and	O
culturally	O
validated	O
,	O
including	O
for	O
use	O
with	O
Italian	O
populations	O
.	O

It	O
is	O
psychometrically	O
sound	O
with	O
proven	O
reliability	O
and	O
validity	O
data	O
(	O
Van	O
Wijngaarden	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Across	O
different	O
studies	O
,	O
internal	O
consistency	O
ratings	O
(	O
Cronbach	O
'	O
s	O
α	O
)	O
across	O
the	O
separate	O
subscales	O
have	O
ranged	O
from	O
0	O
.	O
68	O
to	O
0	O
.	O
86	O
and	O
for	O
the	O
total	O
scores	O
has	O
been	O
0	O
.	O
87–0	O
.	O
90	O
.	O

The	O
test–retest	O
reliability	O
ratings	O
are	O
at	O
least	O
at	O
0	O
.	O
70	O
(	O
Van	O
Wijngaarden	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

The	O
GHQ	O
-	O
12	O
(	O
Goldberg	O
and	O
Williams	O
,	O
1988	O
)	O
is	O
a	O
global	O
,	O
widely	O
used	O
and	O
cross	O
-	O
culturally	O
validated	O
measure	O
to	O
screen	O
and	O
identify	O
minor	O
psychiatric	O
disorders	O
.	O

Each	O
item	O
assesses	O
the	O
severity	O
of	O
a	O
mental	O
health	O
problem	O
over	O
the	O
past	O
few	O
weeks	O
using	O
a	O
four	O
-	O
point	O
Likert	O
scale	O
.	O

Higher	O
scores	O
indicate	O
more	O
psychological	O
(	O
emotional	O
)	O
distress	O
.	O

Its	O
application	O
as	O
a	O
unidimensional	O
measure	O
of	O
distress	O
has	O
been	O
most	O
common	O
through	O
multidimensional	O
approaches	O
and	O
focus	O
on	O
the	O
individual	O
factors	O
(	O
Graetz	O
,	O
1991	O
)	O
.	O

It	O
has	O
extensive	O
,	O
worldwide	O
published	O
data	O
attesting	O
its	O
reliability	O
and	O
validity	O
in	O
different	O
groups	O
(	O
e	O
.	O
g	O
.	O

Werneke	O
et	O
al	O
.	O
,	O
2000	O
;	O
Chandra	O
Kashyap	O
and	O
Kant	O
Singh	O
,	O
2017	O
)	O
including	O
those	O
from	O
Italy	O
(	O
Politi	O
et	O
al	O
.	O
,	O
1994	O
)	O
,	O
which	O
yielded	O
Cronbach	O
'	O
s	O
α	O
ratings	O
of	O
0	O
.	O
81	O
.	O

In	O
its	O
original	O
form	O
,	O
the	O
GHQ	O
-	O
12	O
was	O
60	O
items	O
that	O
were	O
subsequently	O
reduced	O
to	O
30	O
items	O
,	O
24	O
items	O
and	O
then	O
12	O
items	O
.	O

The	O
12	O
-	O
item	O
version	O
yields	O
comparable	O
reliability	O
ratings	O
to	O
longer	O
forms	O
and	O
has	O
good	O
validation	O
against	O
standardised	O
mental	O
health	O
interviews	O
(	O
Goldberg	O
et	O
al	O
.	O
,	O
1997	O
;	O
Politi	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

The	O
25	O
-	O
item	O
Parental	O
Bonding	O
Instrument	O
(	O
Parker	O
et	O
al	O
.	O
,	O
1979	O
)	O
measures	O
an	O
adult	O
'	O
s	O
retrospective	O
account	O
of	O
the	O
parenting	O
they	O
received	O
up	O
to	O
the	O
age	O
of	O
16	O
years	O
.	O

The	O
measure	O
is	O
completed	O
separately	O
for	O
care	O
received	O
from	O
the	O
mother	O
and	O
father	O
.	O

It	O
yields	O
two	O
scales	O
:	O
‘care’	O
and	O
‘overprotection’	O
(	O
or	O
‘control’	O
)	O
.	O

Higher	O
scores	O
reflect	O
a	O
greater	O
recollection	O
of	O
that	O
parenting	O
style	O
.	O

Optimal	O
parenting	O
is	O
typically	O
expressed	O
by	O
participant	O
reports	O
of	O
high	O
care	O
and	O
low	O
control	O
.	O

The	O
Level	O
of	O
Expressed	O
Emotion	O
Scale	O
(	O
LEE	O
,	O
Cole	O
and	O
Kazarian	O
,	O
1988	O
;	O
Cole	O
and	O
Kazarian	O
,	O
1993	O
)	O
is	O
a	O
60	O
-	O
item	O
self	O
-	O
report	O
measure	O
designed	O
to	O
assess	O
patient	O
perceptions	O
of	O
carer	O
EE	O
.	O

It	O
was	O
originally	O
conceived	O
as	O
a	O
reliable	O
and	O
expedient	O
alternative	O
to	O
the	O
Camberwell	O
Family	O
Interview	O
(	O
Vaughn	O
and	O
Leff	O
,	O
1976	O
)	O
,	O
the	O
gold	O
standard	O
measurement	O
of	O
carer	O
EE	O
.	O

It	O
comprises	O
four	O
subscales	O
:	O
emotional	O
response	O
(	O
e	O
.	O
g	O
.	O
high	O
emotional	O
response	O
to	O
illness	O
(	O
e	O
.	O
g	O
.	O
anger	O
)	O
)	O
,	O
negative	O
attitude	O
(	O
e	O
.	O
g	O
.	O
doubt	O
patient	O
is	O
genuinely	O
ill	O
,	O
blame	O
patient	O
for	O
illness	O
)	O
,	O
intrusiveness	O
(	O
e	O
.	O
g	O
.	O
offering	O
unsolicited	O
often	O
critical	O
advice	O
and	O
frequent	O
attempts	O
to	O
have	O
contact	O
)	O
and	O
low	O
tolerance	O
and	O
high	O
expectations	O
(	O
e	O
.	O
g	O
.	O
intolerance	O
of	O
illness	O
behaviour	O
and	O
impairments	O
)	O
.	O

Respondents	O
are	O
required	O
to	O
read	O
through	O
a	O
set	O
of	O
brief	O
statements	O
and	O
indicate	O
to	O
what	O
degree	O
the	O
statement	O
accurately	O
represents	O
their	O
carer	O
'	O
s	O
behaviour	O
towards	O
them	O
during	O
the	O
preceding	O
3	O
months	O
on	O
a	O
Likert	O
scale	O
of	O
1	O
(	O
untrue	O
)	O
to	O
4	O
(	O
true	O
)	O
.	O

An	O
overall	O
EE	O
and	O
subscale	O
scores	O
are	O
generated	O
.	O

As	O
a	O
global	O
measure	O
of	O
patient	O
symptomatology	O
,	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
,	O
Kay	O
et	O
al	O
.	O
,	O
1987	O
)	O
was	O
used	O
.	O

The	O
PANSS	O
is	O
a	O
30	O
-	O
item	O
semi	O
-	O
structured	O
interview	O
used	O
to	O
rate	O
psychotic	O
symptomatology	O
and	O
comprises	O
three	O
subscales	O
related	O
to	O
positive	O
symptoms	O
,	O
negative	O
symptoms	O
and	O
general	O
psychopathology	O
.	O

Interview	O
items	O
are	O
rated	O
on	O
a	O
seven	O
-	O
point	O
Likert	O
scale	O
that	O
reflects	O
increasing	O
levels	O
of	O
psychopathology	O
with	O
higher	O
scores	O
indicating	O
higher	O
levels	O
of	O
symptomatology	O
.	O

The	O
Childhood	O
Experience	O
of	O
Care	O
and	O
Abuse	O
Questionnaire	O
(	O
CECAQ	O
,	O
Bifulco	O
et	O
al	O
.	O
,	O
1994	O
)	O
is	O
a	O
self	O
-	O
report	O
questionnaire	O
that	O
taps	O
adverse	O
childhood	O
experiences	O
including	O
reports	O
of	O
physical	O
and	O
sexual	O
abuse	O
and	O
neglect	O
.	O

A	O
single	O
item	O
that	O
assesses	O
patient	O
perceptions	O
of	O
caregiver	O
criticism	O
was	O
used	O
as	O
an	O
additional	O
method	O
to	O
assess	O
relationship	O
quality	O
.	O

Before	O
starting	O
the	O
assessments	O
,	O
independent	O
evaluators	O
received	O
formal	O
training	O
in	O
the	O
use	O
and	O
administration	O
of	O
instruments	O
,	O
with	O
measurement	O
of	O
their	O
knowledge	O
,	O
skills	O
and	O
assessment	O
of	O
inter	O
-	O
rater	O
reliability	O
to	O
assess	O
competency	O
.	O

Assessments	O
followed	O
once	O
patients	O
had	O
achieved	O
clinical	O
stabilisation	O
(	O
i	O
.	O
e	O
.	O
sufficient	O
mental	O
state	O
stability	O
to	O
engage	O
in	O
a	O
brief	O
clinical	O
assessment	O
)	O
,	O
provided	O
written	O
informed	O
consent	O
and	O
prior	O
to	O
commencement	O
of	O
interventions	O
.	O

Analyses	O
were	O
conducted	O
using	O
an	O
intention	O
-	O
to	O
-	O
treat	O
approach	O
.	O

IEQ	O
-	O
EU	O
and	O
GHQ	O
-	O
12	O
scores	O
were	O
analysed	O
separately	O
in	O
mixed	O
-	O
effects	O
random	O
regression	O
models	O
.	O

In	O
order	O
to	O
take	O
into	O
account	O
the	O
trial	O
design	O
in	O
which	O
caregivers	O
(	O
level	O
1	O
)	O
were	O
nested	O
within	O
CMHCs	O
(	O
level	O
2	O
)	O
(	O
CONSORT	O
guidelines	O
for	O
cluster	O
randomised	O
trials	O
;	O
Campbell	O
et	O
al	O
.	O
,	O
2012	O
)	O
,	O
the	O
individual	O
CMHCs	O
were	O
included	O
in	O
the	O
models	O
as	O
a	O
random	O
effect	O
.	O

In	O
order	O
to	O
identify	O
predictors	O
and	O
moderators	O
of	O
treatment	O
outcome	O
according	O
to	O
MacArthur	O
'	O
s	O
approach	O
(	O
Kraemer	O
et	O
al	O
.	O
,	O
2002	O
)	O
,	O
we	O
selected	O
,	O
a	O
priori	O
,	O
on	O
clinical	O
or	O
empirical	O
grounds	O
and	O
derived	O
from	O
the	O
literature	O
,	O
pre	O
-	O
treatment	O
caregivers’	O
variables	O
.	O

Specifically	O
,	O
we	O
investigated	O
age	O
and	O
gender	O
of	O
caregiver	O
,	O
family	O
relationship	O
shared	O
with	O
patient	O
(	O
parents	O
v	O
.	O

others	O
)	O
,	O
hours	O
per	O
week	O
spent	O
with	O
patient	O
(	O
<	O
32	O
v	O
.	O

⩾32	O
)	O
,	O
mother	O
'	O
s	O
criticism	O
and	O
father	O
'	O
s	O
criticism	O
(	O
assessed	O
by	O
CECA	O
-	O
Q	O
item	O
6	O
;	O
yes	O
v	O
.	O

no	O
)	O
,	O
PBI	O
(	O
care	O
and	O
protection	O
(	O
mother	O
)	O
,	O
care	O
and	O
protection	O
(	O
father	O
)	O
)	O
,	O
LEE	O
(	O
emotional	O
response	O
,	O
negative	O
attitude	O
,	O
intrusiveness	O
,	O
tolerance	O
and	O
expectations	O
)	O
and	O
IEQ	O
-	O
EU	O
tension	O
at	O
baseline	O
(	O
this	O
last	O
variable	O
considered	O
only	O
for	O
GHQ	O
-	O
12	O
)	O
.	O

Each	O
model	O
included	O
treatment	O
allocation	O
(	O
T	O
coded	O
as	O
+	O
1	O
/	O
2	O
for	O
caregivers	O
in	O
the	O
Experimental	O
Treatment	O
Group	O
and	O
−1	O
/	O
2	O
for	O
those	O
in	O
the	O
TAU	O
Group	O
)	O
,	O
one	O
predictor	O
/	O
moderator	O
(	O
M	O
standardised	O
)	O
,	O
their	O
interaction	O
(	O
T	O
×	O
M	O
)	O
and	O
the	O
baseline	O
score	O
of	O
the	O
outcome	O
investigated	O
(	O
B	O
standardised	O
)	O
.	O

When	O
the	O
main	O
effect	O
of	O
a	O
variable	O
was	O
significant	O
,	O
but	O
the	O
interaction	O
was	O
not	O
,	O
the	O
variable	O
was	O
considered	O
a	O
non	O
-	O
specific	O
predictor	O
of	O
outcome	O
.	O

When	O
the	O
interaction	O
was	O
significant	O
(	O
regardless	O
of	O
the	O
significance	O
of	O
main	O
effects	O
)	O
,	O
the	O
variable	O
was	O
considered	O
as	O
a	O
moderator	O
.	O

In	O
a	O
secondary	O
analysis	O
,	O
missing	O
data	O
on	O
outcomes	O
were	O
estimated	O
using	O
a	O
multiple	O
imputation	O
approach	O
by	O
chained	O
equations	O
(	O
MICE	O
)	O
,	O
which	O
generate	O
50	O
different	O
plausible	O
imputed	O
data	O
sets	O
and	O
combines	O
results	O
from	O
each	O
of	O
them	O
.	O

Multiple	O
imputations	O
by	O
chained	O
equations	O
were	O
applied	O
because	O
it	O
enables	O
different	O
variable	O
types	O
to	O
be	O
handled	O
;	O
specifically	O
,	O
we	O
used	O
predictive	O
mean	O
matching	O
to	O
deal	O
with	O
possible	O
non	O
-	O
normality	O
when	O
imputing	O
continuous	O
variables	O
.	O

The	O
α	O
level	O
was	O
set	O
to	O
0	O
.	O
05	O
for	O
all	O
main	O
effects	O
and	O
interactions	O
.	O

No	O
correction	O
for	O
multiple	O
testing	O
was	O
applied	O
due	O
to	O
the	O
exploratory	O
nature	O
of	O
the	O
study	O
.	O

All	O
statistical	O
analyses	O
were	O
carried	O
out	O
using	O
the	O
STATA	O
software	O
package	O
,	O
version	O
13	O
(	O
Stata	O
Corp	O
,	O
2013	O
)	O

The	O
flow	O
of	O
participants	O
in	O
the	O
study	O
is	O
presented	O
in	O
Figure	O
1	O
.	O

The	O
protocol	O
for	O
this	O
trial	O
and	O
supporting	O
Consort	O
checklist	O
are	O
available	O
as	O
supporting	O
information	O
,	O
see	O
Checklist	O
S1	O
and	O
Protocol	O
S1	O
and	O
S2	O
.	O

Candidates	O
for	O
the	O
study	O
were	O
recruited	O
by	O
their	O
therapist	O
.	O

They	O
had	O
to	O
be	O
10–12	O
years	O
of	O
age	O
and	O
previously	O
diagnosed	O
at	O
specialist	O
outpatient	O
clinics	O
with	O
F90	B-code
.	I-code
0	I-code
Hyperkinetic	B-phenotype
disorder	I-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
)	O
(	O
WHO	O
,	O
1992	O
)	O
,	O
equivalent	O
to	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
diagnosis	O
of	O
ADHD	B-phenotype
combined	I-phenotype
type	I-phenotype
,	O
and	O
in	O
treatment	O
for	O
ADHD	O
within	O
the	O
Departments	O
for	O
Child	O
and	O
Adolescent	O
Psychiatry	O
in	O
Vestfold	O
or	O
Telemark	O
Hospital	O
Trusts	O
,	O
Norway	O
.	O

Exclusion	O
criteria	O
were	O
IQ	O
below	O
70	O
(	O
WISC	O
-	O
III	O
or	O
WISC	O
-	O
IV	O
)	O
,	O
or	O
a	O
comorbid	O
diagnosis	O
of	O
Pervasive	O
Developmental	O
Disorder	O
,	O
Tourette	O
'	O
s	O
Syndrome	O
,	O
Conduct	O
Disorder	O
or	O
evidence	O
of	O
psychosis	O
or	O
epilepsy	O
.	O

Only	O
one	O
candidate	O
was	O
excluded	O
based	O
on	O
the	O
exclusion	O
criteria	O
.	O

Seventy	O
two	O
of	O
the	O
original	O
77	O
children	O
recruited	O
to	O
participate	O
in	O
the	O
study	O
completed	O
the	O
study	O
.	O

Of	O
the	O
72	O
children	O
completing	O
the	O
study	O
,	O
five	O
children	O
were	O
omitted	O
from	O
the	O
analyses	O
presented	O
here	O
due	O
to	O
changes	O
in	O
medication	O
during	O
the	O
project	O
period	O
.	O

Of	O
the	O
67	O
children	O
included	O
in	O
the	O
presented	O
analyses	O
,	O
forty	O
-	O
one	O
of	O
the	O
participants	O
were	O
medicated	O
with	O
methylphenidate	O
(	O
MPH	O
)	O
and	O
five	O
with	O
atomoxetine	O
in	O
the	O
same	O
dosage	O
throughout	O
the	O
study	O
.	O

One	O
patient	O
was	O
medicated	O
with	O
risperidone	O
as	O
well	O
.	O

Twenty	O
-	O
one	O
participants	O
did	O
not	O
use	O
medication	O
at	O
the	O
time	O
of	O
inclusion	O
.	O

Importantly	O
,	O
no	O
participants	O
included	O
in	O
the	O
analyses	O
started	O
up	O
on	O
medication	O
or	O
changed	O
dosage	O
after	O
the	O
Pre	O
-	O
test	O
,	O
i	O
.	O
e	O
.	O
no	O
risk	O
of	O
medication	O
effects	O
confounding	O
training	O
effects	O
.	O

All	O
children	O
12	O
years	O
of	O
age	O
and	O
more	O
and	O
their	O
parents	O
signed	O
written	O
consent	O
forms	O
prior	O
to	O
participation	O
.	O

Demographic	O
information	O
is	O
presented	O
in	O
Table	O
1	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
with	O
regard	O
to	O
sex	O
,	O
age	O
,	O
medication	O
status	O
,	O
IQ	O
or	O
education	O
level	O
of	O
parents	O
.	O

Sixty	O
percent	O
of	O
all	O
participants	O
received	O
special	O
education	O
at	O
school	O
in	O
the	O
form	O
of	O
more	O
individualized	O
,	O
structured	O
instruction	O
by	O
a	O
designated	O
resource	O
person	O
.	O

Thirty	O
-	O
five	O
percent	O
came	O
from	O
homes	O
with	O
a	O
single	O
parent	O
/	O
caregiver	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
intervention	O
and	O
control	O
groups	O
on	O
any	O
of	O
the	O
demographic	O
measures	O
.	O

The	O
ratio	O
of	O
boys	O
to	O
girls	O
in	O
the	O
current	O
study	O
is	O
3∶1	O
,	O
which	O
is	O
the	O
same	O
approximate	O
gender	O
ratio	O
found	O
in	O
international	O
epidemiological	O
studies	O
for	O
ADHD	O
(	O
Gershon	O
,	O
2002	O
)	O
.	O

The	O
IQ	O
level	O
of	O
participants	O
is	O
slightly	O
under	O
the	O
average	O
level	O
for	O
non	O
-	O
clinical	O
groups	O
,	O
but	O
at	O
a	O
similar	O
level	O
for	O
ADHD	O
cohorts	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

Verbal	O
Comprehension	O
index	O
score	O
,	O
2	O
Perceptual	O
Organization	O
index	O
score	O
.	O

The	O
invitation	O
to	O
participate	O
in	O
the	O
study	O
and	O
consent	O
form	O
emphasized	O
that	O
the	O
study	O
was	O
a	O
randomized	O
controlled	O
trial	O
,	O
and	O
that	O
half	O
of	O
the	O
participants	O
would	O
be	O
drawn	O
at	O
random	O
to	O
take	O
part	O
in	O
the	O
training	O
.	O

Participants	O
in	O
the	O
control	O
group	O
were	O
offered	O
the	O
chance	O
to	O
participate	O
in	O
the	O
training	O
program	O
immediately	O
after	O
conclusion	O
of	O
the	O
study	O
.	O

During	O
the	O
study	O
period	O
,	O
all	O
of	O
the	O
participants	O
continued	O
with	O
treatment	O
-	O
as	O
-	O
usual	O
,	O
which	O
included	O
regular	O
follow	O
-	O
up	O
by	O
a	O
health	O
professional	O
at	O
the	O
local	O
specialized	O
youth	O
health	O
services	O
facility	O
and	O
the	O
same	O
special	O
education	O
classes	O
at	O
school	O
that	O
they	O
had	O
participated	O
in	O
before	O
the	O
start	O
of	O
the	O
study	O
.	O

No	O
difference	O
was	O
made	O
between	O
the	O
groups	O
in	O
their	O
already	O
existing	O
treatment	O
or	O
educational	O
programs	O
,	O
except	O
for	O
the	O
addition	O
of	O
the	O
WM	O
training	O
program	O
for	O
the	O
children	O
randomly	O
assigned	O
to	O
the	O
training	O
group	O
.	O

The	O
experimental	O
design	O
included	O
a	O
pretest	O
immediately	O
before	O
the	O
start	O
of	O
the	O
training	O
period	O
,	O
a	O
post	O
-	O
test	O
at	O
the	O
conclusion	O
of	O
the	O
training	O
period	O
and	O
follow	O
-	O
up	O
testing	O
.	O

At	O
each	O
stage	O
of	O
testing	O
,	O
the	O
children	O
in	O
training	O
and	O
control	O
groups	O
were	O
tested	O
in	O
the	O
same	O
time	O
period	O
during	O
the	O
day	O
in	O
a	O
randomly	O
assigned	O
sequence	O
.	O

The	O
original	O
plans	O
called	O
for	O
follow	O
-	O
up	O
testing	O
to	O
take	O
place	O
six	O
months	O
after	O
conclusion	O
of	O
the	O
training	O
period	O
,	O
but	O
due	O
to	O
unforeseen	O
delays	O
in	O
completing	O
the	O
training	O
program	O
due	O
to	O
a	O
flu	O
epidemic	O
,	O
the	O
actual	O
follow	O
-	O
up	O
testing	O
took	O
place	O
eight	O
months	O
after	O
conclusion	O
of	O
the	O
training	O
period	O
.	O

Participants	O
meeting	O
the	O
inclusion	O
criteria	O
were	O
matched	O
as	O
to	O
gender	O
and	O
medication	O
status	O
,	O
and	O
randomized	O
by	O
drawing	O
numbers	O
corresponding	O
to	O
ID	O
numbers	O
to	O
either	O
training	O
or	O
control	O
group	O
by	O
a	O
staff	O
member	O
not	O
involved	O
in	O
training	O
or	O
testing	O
.	O

Staff	O
members	O
responsible	O
for	O
testing	O
were	O
not	O
involved	O
in	O
conducting	O
the	O
training	O
sessions	O
for	O
the	O
intervention	O
group	O
,	O
which	O
took	O
place	O
at	O
participants	O
'	O
schools	O
by	O
a	O
teacher	O
or	O
other	O
person	O
designated	O
by	O
a	O
school	O
official	O
.	O

Training	O
sessions	O
took	O
place	O
at	O
the	O
participant	O
'	O
s	O
school	O
during	O
regular	O
school	O
hours	O
and	O
all	O
testing	O
took	O
place	O
at	O
the	O
Departments	O
for	O
Child	O
and	O
Adolescent	O
Psychiatry	O
in	O
Vestfold	O
or	O
Telemark	O
Hospital	O
Trusts	O
,	O
Norway	O
.	O

The	O
study	O
was	O
approved	O
in	O
advance	O
(	O
18	O
.	O
06	O
.	O

2009	O
)	O
by	O
the	O
Regional	O
Committees	O
for	O
Medical	O
and	O
Health	O
Research	O
Ethics	O
(	O
REC	O
South	O
East	O
:	O
available	O
on	O
their	O
webside	O
:	O
https	O
:	O
/	O
/	O
helseforskning	O
.	O
etikkom	O
.	O
no	O
/	O
ikbViewer	O
/	O
page	O
/	O
prosjekterirek	O
/	O
prosjektregister	O
?	O
_	O
ikbLanguageCode=us	O
&	O
p	O
_	O
dim=34977	O
&	O
9F508B87E7D8620DE040F28156A418DC	O
.	O
p	O
_	O
search	O
_	O
id=26503	O
.	O

This	O
study	O
is	O
also	O
registered	O
as	O
ISRCTN19133620	O
(	O
www	O
.	O
controlled	O
-	O
trials	O
.	O
com	O
)	O
.	O

Recruitment	O
and	O
enrollment	O
began	O
in	O
01	O
.	O
08	O
.	O

2009	O
and	O
follow	O
-	O
up	O
testing	O
was	O
completed	O
31	O
.	O
12	O
.	O
2010	O
.	O

The	O
WM	O
training	O
program	O
for	O
the	O
treatment	O
group	O
consisted	O
of	O
13	O
different	O
PC	O
-	O
based	O
exercises	O
(	O
CogMed	O
)	O
.	O

The	O
same	O
training	O
program	O
has	O
been	O
used	O
in	O
all	O
of	O
the	O
computerized	O
WM	O
studies	O
referred	O
to	O
in	O
this	O
study	O
.	O

The	O
training	O
program	O
includes	O
three	O
letter	O
span	O
tasks	O
(	O
all	O
forward	O
condition	O
)	O
,	O
three	O
digit	O
span	O
tasks	O
(	O
one	O
forward	O
condition	O
,	O
two	O
backward	O
conditions	O
)	O
,	O
and	O
seven	O
visuospatial	O
tasks	O
(	O
all	O
forward	O
sequenced	O
)	O
,	O
including	O
static	O
visuospatial	O
tasks	O
(	O
one	O
2D	O
visuospatial	O
task	O
,	O
one	O
3D	O
visuospatial	O
task	O
)	O
,	O
and	O
two	O
dynamic	O
visuospatial	O
tasks	O
,	O
in	O
which	O
students	O
recall	O
the	O
positions	O
of	O
rotated	O
or	O
moving	O
objects	O
.	O

Nine	O
of	O
the	O
tasks	O
are	O
presented	O
purely	O
in	O
visual	O
format	O
,	O
and	O
four	O
are	O
delivered	O
with	O
an	O
auditory	O
input	O
.	O

Eleven	O
of	O
the	O
tasks	O
are	O
forward	O
sequenced	O
,	O
while	O
only	O
two	O
are	O
reverse	O
-	O
order	O
tasks	O
.	O

A	O
critical	O
feature	O
of	O
the	O
program	O
is	O
adaptivity	O
,	O
i	O
.	O
e	O
.	O
the	O
level	O
of	O
difficulty	O
is	O
adjusted	O
continuously	O
to	O
the	O
individual	O
student	O
'	O
s	O
skill	O
level	O
throughout	O
the	O
training	O
program	O
.	O

The	O
training	O
group	O
completed	O
10–15	O
trials	O
of	O
eight	O
exercises	O
each	O
day	O
for	O
a	O
total	O
of	O
115	O
WM	O
trials	O
per	O
day	O
.	O

Training	O
time	O
averaged	O
about	O
30–40	O
minutes	O
per	O
day	O
,	O
depending	O
on	O
the	O
exercise	O
set	O
and	O
the	O
student	O
'	O
s	O
performance	O
level	O
.	O

Training	O
participants	O
agreed	O
in	O
advance	O
with	O
the	O
person	O
administering	O
the	O
training	O
program	O
on	O
a	O
reward	O
schedule	O
for	O
achieving	O
training	O
targets	O
.	O

They	O
received	O
daily	O
verbal	O
and	O
visual	O
feedback	O
about	O
increases	O
in	O
performance	O
and	O
were	O
rewarded	O
after	O
training	O
by	O
being	O
allowed	O
to	O
play	O
the	O
RoboRacing	O
-	O
computer	O
game	O
.	O

Every	O
fifth	O
day	O
participants	O
received	O
an	O
additional	O
individualized	O
reward	O
agreed	O
to	O
by	O
the	O
school	O
administration	O
.	O

Parents	O
were	O
instructed	O
not	O
to	O
provide	O
any	O
rewards	O
.	O

Four	O
subjects	O
completed	O
less	O
than	O
the	O
planned	O
number	O
of	O
25	O
training	O
sessions	O
(	O
3	O
had	O
24	O
sessions	O
and	O
one	O
had	O
21	O
)	O
.	O

The	O
training	O
program	O
has	O
a	O
built	O
-	O
in	O
compliance	O
measure	O
,	O
which	O
is	O
calculated	O
by	O
subtracting	O
the	O
Start	O
Index	O
(	O
results	O
of	O
day	O
2	O
and	O
3	O
)	O
from	O
the	O
Max	O
Index	O
(	O
results	O
from	O
the	O
two	O
best	O
training	O
days	O
)	O
.	O

Average	O
improvement	O
index	O
in	O
the	O
training	O
program	O
for	O
the	O
whole	O
group	O
was	O
24	O
(	O
s	O
.	O
d	O
.	O
8	O
)	O
,	O
slightly	O
less	O
(	O
23	O
)	O
for	O
those	O
completing	O
less	O
than	O
25	O
training	O
days	O
.	O

Four	O
subjects	O
discontinued	O
training	O
for	O
about	O
one	O
week	O
or	O
more	O
during	O
the	O
planned	O
training	O
period	O
due	O
to	O
a	O
flu	O
epidemic	O
.	O

These	O
days	O
were	O
compensated	O
for	O
by	O
training	O
additional	O
days	O
when	O
they	O
returned	O
to	O
school	O
.	O

Due	O
to	O
varying	O
lengths	O
of	O
sick	O
leave	O
,	O
one	O
participant	O
trained	O
for	O
26	O
days	O
and	O
three	O
trained	O
for	O
30	O
days	O
.	O

Digit	O
span	O
is	O
a	O
common	O
neuropsychological	O
test	O
in	O
the	O
WISC	O
-	O
IV	O
battery	O
used	O
to	O
assess	O
auditory	O
working	O
memory	O
[	O
34	O
]	O
.	O

The	O
test	O
features	O
forward	O
and	O
backward	O
tasks	O
that	O
tap	O
distinguishable	O
cognitive	O
processes	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
.	O

Digits	O
Forward	O
involves	O
repeating	O
a	O
sequence	O
of	O
numbers	O
in	O
the	O
same	O
order	O
right	O
after	O
they	O
have	O
been	O
read	O
aloud	O
,	O
and	O
Digits	O
Backward	O
involves	O
repeating	O
the	O
numbers	O
in	O
reverse	O
order	O
.	O

The	O
Leiter	O
International	O
Performance	O
Scale	O
-	O
Revised	O
(	O
Leiter–R	O
)	O
is	O
a	O
proven	O
cognitive	O
assessment	O
tool	O
that	O
has	O
a	O
unique	O
response	O
format	O
which	O
is	O
expressively	O
nonverbal	O
[	O
37	O
]	O
,	O
[	O
38	O
]	O
.	O

Two	O
tests	O
from	O
this	O
battery	O
were	O
chosen	O
to	O
assess	O
Visual	O
WM	O
:	O
The	O
Remembering	O
Game	O
(	O
Visual	O
span	O
,	O
forward	O
)	O
,	O
and	O
The	O
Backwards	O
Game	O
(	O
Visual	O
span	O
,	O
backward	O
)	O
.	O

In	O
both	O
tasks	O
,	O
the	O
stimuli	O
to	O
be	O
remembered	O
are	O
visual	O
images	O
of	O
familiar	O
items	O
(	O
e	O
.	O
g	O
.	O
a	O
frog	O
,	O
a	O
ship	O
,	O
a	O
shoe	O
)	O
.	O

In	O
the	O
Letter	O
-	O
Number	O
Sequencing	O
task	O
,	O
a	O
list	O
of	O
intermingled	O
numbers	O
and	O
letters	O
of	O
increasing	O
lengths	O
are	O
read	O
aloud	O
[	O
34	O
]	O
.	O

Subjects	O
are	O
asked	O
to	O
recall	O
the	O
numbers	O
in	O
ascending	O
order	O
and	O
the	O
letters	O
in	O
alphabetical	O
order	O
,	O
with	O
numbers	O
always	O
coming	O
first	O
.	O

Mental	O
manipulation	O
is	O
one	O
of	O
the	O
cognitive	O
processes	O
taxed	O
by	O
this	O
task	O
involving	O
simultaneous	O
reordering	O
of	O
a	O
series	O
of	O
letters	O
and	O
numbers	O
[	O
39	O
]	O
.	O

In	O
the	O
Sentence	O
Span	O
task	O
,	O
subjects	O
must	O
reproduce	O
the	O
words	O
in	O
a	O
sentence	O
read	O
aloud	O
in	O
the	O
exact	O
same	O
sequence	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
.	O

The	O
sentence	O
length	O
is	O
increased	O
gradually	O
until	O
three	O
incomplete	O
sentences	O
are	O
registered	O
.	O

The	O
manipulation	O
component	O
of	O
WM	O
is	O
taxed	O
in	O
that	O
rehearsal	O
and	O
updating	O
is	O
needed	O
as	O
the	O
child	O
'	O
s	O
phonological	O
memory	O
span	O
is	O
surpassed	O
[	O
9	O
]	O
.	O

Raw	O
scores	O
were	O
converted	O
into	O
scaled	O
scores	O
based	O
on	O
the	O
norms	O
provided	O
in	O
the	O
respective	O
manuals	O
before	O
aggregating	O
the	O
results	O
into	O
composites	O
.	O

The	O
following	O
composites	O
were	O
then	O
calculated	O
based	O
on	O
a	O
component	O
analysis	O
deriving	O
an	O
empirically	O
-	O
based	O
tri	O
-	O
partite	O
division	O
of	O
WM	O
aspects	O
.	O

Auditory	O
WM	O
:	O
(	O
Digit	O
span	O
forward	O
+	O
Digit	O
Span	O
backward	O
)	O
/	O
2	O
,	O
Visual	O
WM	O
:	O
(	O
Leiter	O
R	O
forward	O
+	O
Leiter	O
R	O
backward	O
)	O
/	O
2	O
,	O
and	O
Manipulation	O
WM	O
(	O
Letter	O
-	O
Number	O
+	O
Sentence	O
Span	O
)	O
/	O
2	O
.	O

A	O
reliability	O
analysis	O
was	O
performed	O
for	O
each	O
of	O
the	O
composites	O
indicating	O
satisfactory	O
internal	O
consistency	O
.	O

The	O
Cronbach	O
alpha	O
coefficient	O
was	O
.	O
772	O
for	O
the	O
six	O
items	O
in	O
the	O
Visual	O
WM	O
composite	O
,	O
.	O
747	O
for	O
the	O
six	O
items	O
in	O
the	O
Auditory	O
WM	O
composite	O
and	O
.	O
720	O
for	O
the	O
six	O
items	O
in	O
the	O
Manipulation	O
WM	O
composite	O
.	O

Data	O
analyses	O
were	O
conducted	O
using	O
the	O
statistical	O
package	O
IBM	O
SPSS	O
Statistics	O
for	O
Windows	O
,	O
version	O
18	O
.	O
0	O
(	O
SPSS	O
,	O
Inc	O
.	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

Demographic	O
and	O
clinical	O
background	O
information	O
at	O
baseline	O
was	O
analyzed	O
with	O
Analysis	O
of	O
Variance	O
for	O
continuous	O
variables	O
and	O
Chi	O
-	O
square	O
for	O
categorical	O
variables	O
.	O

Baseline	O
levels	O
for	O
all	O
dependent	O
measures	O
were	O
compared	O
between	O
the	O
un	O
-	O
medicated	O
and	O
the	O
medicated	O
groups	O
.	O

The	O
six	O
tasks	O
in	O
the	O
study	O
taxing	O
working	O
memory	O
components	O
were	O
subjected	O
to	O
a	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
with	O
varimax	O
rotation	O
.	O

The	O
PCA	O
revealed	O
the	O
presence	O
of	O
three	O
pairs	O
of	O
components	O
that	O
grouped	O
together	O
(	O
further	O
description	O
in	O
Results	O
section	O
)	O
.	O

Baseline	O
performance	O
of	O
the	O
two	O
groups	O
and	O
between	O
medicated	O
and	O
unmedicated	O
subjects	O
were	O
analyzed	O
with	O
Analysis	O
of	O
Variance	O
(	O
ANOVA	O
)	O
.	O

Treatment	O
effects	O
were	O
analyzed	O
with	O
Repeated	O
Measures	O
Analysis	O
of	O
Variance	O
(	O
Pre	O
-	O
test	O
compared	O
to	O
Post	O
-	O
test	O
1	O
or	O
Post	O
-	O
test	O
2	O
)	O
as	O
within	O
-	O
subjects	O
factor	O
and	O
group	O
as	O
the	O
between	O
-	O
subjects	O
factor	O
.	O

Only	O
statistical	O
measures	O
of	O
the	O
interaction	O
between	O
time	O
points	O
and	O
group	O
are	O
reported	O
,	O
as	O
that	O
accounts	O
for	O
a	O
differential	O
effect	O
in	O
one	O
of	O
the	O
groups	O
.	O

Effect	O
sizes	O
are	O
reported	O
as	O
Cohens	O
d	O
,	O
computed	O
as	O
the	O
difference	O
between	O
standard	O
scores	O
at	O
Pre	O
-	O
test	O
and	O
Post	O
-	O
test	O
1	O
or	O
Post	O
-	O
test	O
2	O
in	O
the	O
two	O
groups	O
,	O
divided	O
with	O
the	O
pooled	O
standard	O
deviation	O
at	O
baseline	O
.	O

The	O
gain	O
scores	O
for	O
all	O
composites	O
at	O
Post	O
-	O
test	O
1	O
and	O
Post	O
-	O
test	O
2	O
were	O
calculated	O
by	O
subtracting	O
the	O
Pre	O
-	O
test	O
baseline	O
value	O
from	O
the	O
Post	O
-	O
test	O
1	O
and	O
Post	O
-	O
test	O
2	O
scores	O
,	O
which	O
gave	O
a	O
net	O
improvement	O
score	O
at	O
Post	O
-	O
test	O
1	O
and	O
Post	O
-	O
test	O
2	O
.	O

The	O
net	O
change	O
on	O
the	O
Digit	O
Forward	O
task	O
from	O
Pre	O
-	O
test	O
to	O
Post	O
-	O
test	O
2	O
was	O
included	O
as	O
a	O
covariate	O
in	O
subsequent	O
analyses	O
of	O
the	O
Manipulation	O
WM	O
composite	O
in	O
order	O
to	O
control	O
for	O
the	O
effect	O
any	O
increase	O
in	O
simple	O
maintenance	O
capacity	O
might	O
have	O
had	O
on	O
the	O
outcome	O
.	O

Our	O
study	O
was	O
a	O
retrospective	O
analysis	O
of	O
a	O
sample	O
of	O
all	O
available	O
national	O
claims‐level	O
data	O
from	O
2015	O
to	O
2016	O
.	O

We	O
analyzed	O
data	O
from	O
the	O
Centers	O
for	O
Medicare	O
&	O
Medicaid	O
Services	O
(	O
CMS	O
)	O
Research	O
Data	O
Assistance	O
Center	O
'	O
s	O
(	O
ResDAC	O
)	O
5	O
%	O
sample	O
limited	O
data	O
set	O
that	O
includes	O
claims	O
from	O
older	O
adults	O
enrolled	O
in	O
traditional	O
Medicare	O
plans	O
(	O
ie	O
,	O
Plans	O
A	O
and	O
B	O
)	O
.	O

CMS	O
data	O
are	O
one	O
of	O
the	O
richest	O
sources	O
of	O
national	O
utilization	O
information	O
with	O
sizable	O
samples	O
,	O
documented	O
procedures	O
and	O
diagnoses	O
,	O
verified	O
deaths	O
,	O
beneficiary	O
demographic	O
information	O
,	O
and	O
revenue	O
center	O
details	O
.	O

This	O
study	O
adheres	O
to	O
the	O
Reporting	O
of	O
Studies	O
Conducted	O
Using	O
Observational	O
Routinely	O
Collected	O
Health	O
Data	O
(	O
RECORD	O
)	O
statement	O
that	O
provides	O
guidelines	O
for	O
conducting	O
studies	O
using	O
existing	O
health	O
data	O
(	O
Supplementary	O
Table	O
S1	O
shows	O
a	O
RECORD	O
checklist	O
)	O
.	O

We	O
had	O
full	O
access	O
to	O
the	O
database	O
population	O
used	O
to	O
create	O
the	O
study	O
population	O
.	O

We	O
identified	O
independent	O
variables	O
for	O
inclusion	O
in	O
our	O
regression	O
equation	O
through	O
developing	O
a	O
conceptual	O
model	O
that	O
draws	O
on	O
Andersen	O
'	O
s	O
behavioral	O
model	O
of	O
health	O
services	O
use	O
19	O
,	O
20	O
,	O
21	O
and	O
additional	O
frameworks	O
on	O
both	O
dementia	O
and	O
health	O
services	O
use	O
in	O
the	O
Medicare	O
claims	O
data	O
literature	O
.	O

22	O
,	O
23	O
,	O
24	O
,	O
25	O
This	O
hybrid	O
approach	O
incorporates	O
the	O
traditional	O
categories	O
that	O
are	O
hallmarks	O
of	O
Andersen	O
'	O
s	O
model	O
(	O
ie	O
,	O
predisposing	O
characteristics	O
,	O
enabling	O
characteristics	O
,	O
and	O
need	O
characteristics	O
)	O
while	O
leveraging	O
proxy	O
indicators	O
to	O
reconcile	O
with	O
the	O
limitations	O
of	O
Medicare	O
claims	O
data	O
that	O
lack	O
a	O
full	O
range	O
of	O
detailed	O
information	O
on	O
socioeconomic	O
,	O
behavioral	O
,	O
and	O
environmental	O
factors	O
.	O

Based	O
on	O
this	O
approach	O
,	O
predisposing	O
characteristics	O
therefore	O
included	O
race	O
,	O
age	O
,	O
sex	O
,	O
and	O
geographic	O
region	O
.	O

Enabling	O
characteristics	O
included	O
Medicaid	O
dual	O
eligibility	O
and	O
having	O
a	O
claim	O
associated	O
with	O
a	O
visit	O
to	O
a	O
primary	O
care	O
provider	O
in	O
the	O
past	O
12	O
months	O
.	O

Need	O
characteristics	O
included	O
a	O
modified	O
Charlson	O
Comorbidity	O
Score	O
,	O
discharge	O
to	O
an	O
SNF	O
from	O
initial	O
index	O
ED	O
encounter	O
,	O
and	O
dementia	O
diagnosis	O
between	O
January	O
2015	O
and	O
a	O
patient	O
'	O
s	O
first	O
ED	O
encounter	O
in	O
2016	O
.	O

To	O
be	O
considered	O
for	O
inclusion	O
in	O
our	O
study	O
,	O
we	O
looked	O
at	O
all	O
claims	O
for	O
patients	O
65	O
years	O
of	O
age	O
and	O
older	O
with	O
continuous	O
fee‐for‐service	O
Medicare	O
enrollment	O
throughout	O
the	O
entirety	O
of	O
2015	O
and	O
2016	O
.	O

Only	O
outpatient	O
claims	O
associated	O
with	O
an	O
ED	O
visit	O
based	O
on	O
revenue	O
center	O
codes	O
(	O
0450‐0459	O
,	O
0981	O
,	O
0760	O
,	O
0761	O
,	O
0762	O
)	O
26	O
were	O
included	O
as	O
qualifying	O
encounters	O
.	O

Once	O
inclusion	O
criteria	O
were	O
applied	O
,	O
we	O
had	O
a	O
total	O
of	O
294	O
871	O
patients	O
for	O
our	O
analyses	O
.	O

Figure	O
1	O
shows	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

Inclusion	O
criteria	O
.	O

ED	O
,	O
emergency	O
department	O
;	O
FFS	O
,	O
fee	O
for	O
service	O
.	O

For	O
our	O
study	O
,	O
we	O
compared	O
two	O
cohorts	O
:	O
a	O
dementia	O
cohort	O
and	O
a	O
comparison	O
group	O
of	O
beneficiaries	O
without	O
dementia	O
(	O
ie	O
,	O
no‐dementia	O
group	O
)	O
.	O

The	O
groups	O
were	O
constructed	O
as	O
follows	O
:	O

Only	O
outpatient	O
claims	O
associated	O
with	O
an	O
ED	O
visit	O
between	O
January	O
and	O
November	O
2016	O
were	O
included	O
as	O
a	O
qualifying	O
index	O
encounter	O
.	O

Of	O
the	O
294	O
871	O
eligible	O
patients	O
,	O
dementia	O
was	O
identified	O
across	O
the	O
entire	O
claim	O
history	O
based	O
on	O
the	O
presence	O
of	O
any	O
claim	O
during	O
2015	O
up	O
until	O
the	O
index	O
encounter	O
in	O
2016	O
that	O
included	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
)	I-coding_system
‐9	I-coding_system
or	O
ICD‐10	B-coding_system
diagnosis	O
codes	O
as	O
outlined	O
in	O
the	O
chronic	O
conditions	O
warehouse	O
list	O
of	O
dementia	B-phenotype
codes	O
(	O
331	B-code
.	I-code
0	I-code
,	O
331	B-code
.	I-code
11	I-code
,	O
331	B-code
.	I-code
19	I-code
,	O
331	B-code
.	I-code
2	I-code
,	O
331	B-code
.	I-code
7	I-code
,	O
290	B-code
.	I-code
0	I-code
,	O
290	B-code
.	I-code
10	I-code
,	O
290	B-code
.	I-code
11	I-code
,	O
290	B-code
.	I-code
12	I-code
,	O
290	B-code
.	I-code
13	I-code
,	O
290	B-code
.	I-code
20	I-code
,	O
290	B-code
.	I-code
21	I-code
,	O
290	B-code
.	I-code
3	I-code
,	O
290	B-code
.	I-code
40	I-code
,	O
290	B-code
.	I-code
41	I-code
,	O
290	B-code
.	I-code
42	I-code
,	O
290	B-code
.	I-code
43	I-code
,	O
294	B-code
.	I-code
0	I-code
,	O
294	B-code
.	I-code
10	I-code
,	O
294	B-code
.	I-code
11	I-code
,	O
294	B-code
.	I-code
20	I-code
,	O
294	B-code
.	I-code
21	I-code
,	O

294	B-code
.	I-code
8	I-code
,	O
797	B-code
,	O
F01	B-code
.	I-code
50	I-code
,	O
F01	B-code
.	I-code
51	I-code
,	O
F02	B-code
.	I-code
80	I-code
,	O
F02	B-code
.	I-code
81	I-code
,	O
F03	B-code
.	I-code
90	I-code
,	O
F03	B-code
.	I-code
91	I-code
,	O
F04	B-code
,	O
G13	B-code
.	I-code
8	I-code
,	O
F05	B-code
,	O
F06	B-code
.	I-code
1	I-code
,	O
F06	B-code
.	I-code
8	I-code
,	O
G30	B-code
.	I-code
0	I-code
,	O
G30	B-code
.	I-code
1	I-code
,	O
G30	B-code
.	I-code
8	I-code
,	O
G30	B-code
.	I-code
9	I-code
,	O
G31	B-code
.	I-code
1	I-code
,	O
G31	B-code
.	I-code
2	I-code
,	O
G31	B-code
.	I-code
01	I-code
,	O
G31	B-code
.	I-code
09	I-code
,	O
G94	B-code
,	O
R41	B-code
.	I-code
81	I-code
,	O
R54	B-code
)	O
.	O

27	O
We	O
limited	O
dementia	O
diagnoses	O
to	O
claims	O
where	O
at	O
least	O
one	O
of	O
these	O
codes	O
was	O
documented	O
at	O
least	O
once	O
,	O
at	O
which	O
point	O
the	O
patient	O
was	O
flagged	O
for	O
inclusion	O
to	O
the	O
dementia	O
cohort	O
.	O

Index	O
visit	O
was	O
defined	O
as	O
the	O
first	O
outpatient	O
ED	O
claim	O
in	O
2016	O
.	O

Using	O
these	O
methods	O
,	O
we	O
identified	O
a	O
total	O
of	O
54	O
622	O
qualifying	O
patients	O
with	O
a	O
dementia	O
diagnosis	O
and	O
index	O
ED	O
claim	O
.	O

The	O
no‐dementia	O
group	O
consisted	O
of	O
patients	O
with	O
no	B-phenotype
dementia	I-phenotype
diagnosis	I-phenotype
(	O
via	O
the	O
ICD‐9	B-coding_system
or	O
ICD‐10	B-coding_system
diagnoses	O
codes	O
previously	O
outlined	O
)	O
present	O
during	O
all	O
of	O
2015	O
and	O
2016	O
.	O

The	O
index	O
encounter	O
for	O
this	O
group	O
was	O
also	O
determined	O
by	O
including	O
the	O
first	O
eligible	O
outpatient	O
ED	O
visit	O
during	O
2016	O
.	O

Of	O
the	O
eligible	O
294	O
871	O
patients	O
,	O
a	O
total	O
of	O
240	O
249	O
patients	O
without	O
dementia	O
were	O
selected	O
for	O
our	O
no‐dementia	O
group	O
.	O

We	O
classified	O
an	O
ED	O
revisit	O
as	O
a	O
subsequent	O
ED	O
visit	O
for	O
any	O
reason	O
within	O
30	O
days	O
following	O
the	O
index	O
encounter	O
.	O

If	O
an	O
index	O
visit	O
had	O
at	O
least	O
one	O
additional	O
ED	O
visit	O
within	O
30	O
days	O
for	O
any	O
reason	O
,	O
it	O
was	O
classified	O
as	O
a	O
revisit	O
.	O

The	O
unit	O
of	O
analysis	O
for	O
the	O
study	O
was	O
at	O
the	O
patient	O
level	O
.	O

Once	O
ED	O
revisit	O
criteria	O
were	O
applied	O
,	O
the	O
dementia	O
cohort	O
included	O
a	O
total	O
of	O
9877	O
patients	O
who	O
had	O
a	O
30‐day	O
ED	O
revisit	O
following	O
the	O
index	O
encounter	O
,	O
and	O
our	O
no‐dementia	O
group	O
included	O
33	O
290	O
patients	O
with	O
30‐day	O
ED	O
revisits	O
for	O
inclusion	O
in	O
the	O
final	O
analysis	O
.	O

Our	O
primary	O
outcome	O
measure	O
was	O
30‐day	O
all‐cause	O
ED	O
revisits	O
.	O

Using	O
this	O
outcome	O
measure	O
,	O
we	O
then	O
compared	O
the	O
proportion	O
of	O
30‐day	O
all‐cause	O
ED	O
revisits	O
between	O
those	O
that	O
did	O
,	O
and	O
did	O
not	O
,	O
have	O
a	O
dementia	O
diagnosis	O
between	O
2015	O
and	O
first	O
ED	O
visit	O
in	O
2016	O
(	O
ie	O
,	O
the	O
index	O
encounter	O
)	O
.	O

Once	O
the	O
index	O
encounter	O
was	O
determined	O
in	O
both	O
cohorts	O
,	O
we	O
calculated	O
utilization	O
metrics	O
for	O
the	O
12	O
months	O
before	O
the	O
index	O
visit	O
to	O
gain	O
insight	O
into	O
annual	O
utilization	O
patterns	O
.	O

We	O
looked	O
at	O
the	O
average	O
number	O
of	O
ED	O
visits	O
and	O
the	O
average	O
number	O
of	O
primary	O
care	O
physician	O
(	O
PCP	O
)	O
visits	O
.	O

ED	O
visits	O
were	O
identified	O
using	O
the	O
same	O
methodology	O
mentioned	O
earlier	O
,	O
using	O
the	O
same	O
revenue	O
center	O
codes	O
.	O

PCP	B-phenotype
visits	I-phenotype
were	O
determined	O
by	O
using	O
the	O
Provider	B-coding_system
Specialty	I-coding_system
code	O
found	O
on	O
institutional	O
carrier	O
file	O
(	O
Medicare	O
Part	O
B	O
)	O
claims	O
(	O
codes	O
11	B-code
,	O
08	B-code
,	O
01	B-code
,	O
38	B-code
,	O
50	B-code
,	O
35	B-code
,	O
97	B-code
,	O
25	B-code
)	O
,	O
as	O
determined	O
by	O
a	O
practicing	O
physician	O
.	O

All	O
statistical	O
analyses	O
were	O
conducted	O
with	O
SAS	O
Studio	O
,	O
v	O
.	O
3	O
.	O
71	O
.	O

We	O
examined	O
unadjusted	O
and	O
adjusted	O
differences	O
in	O
proportion	O
of	O
patients	O
experiencing	O
an	O
ED	O
revisit	O
within	O
30	O
days	O
of	O
the	O
index	O
visit	O
.	O

For	O
our	O
unadjusted	O
results	O
,	O
we	O
used	O
the	O
Pearson	O
χ	O
2	O
test	O
to	O
compare	O
revisits	O
for	O
both	O
groups	O
.	O

Our	O
adjusted	O
analysis	O
used	O
a	O
logistic	O
regression	O
model	O
to	O
control	O
for	O
potential	O
covariates	O
such	O
as	O
beneficiary	O
age	O
,	O
sex	O
,	O
race	O
,	O
region	O
,	O
Medicaid	O
status	O
(	O
as	O
a	O
proxy	O
for	O
economic	O
status	O
)	O
,	O
transfer	O
to	O
an	O
SNF	O
after	O
ED	O
,	O
PCP	O
use	O
12	O
months	O
before	O
index	O
,	O
and	O
comorbidity	O
.	O

Model	O
fit	O
statistics	O
including	O
R‐squared	O
and	O
Akaike	O
information	O
criterion	O
were	O
used	O
in	O
establishing	O
the	O
model	O
.	O

To	O
address	O
comorbidity	O
,	O
we	O
calculated	O
a	O
Charlson	O
Comorbidity	O
Index	O
score	O
for	O
each	O
beneficiary	O
with	O
a	O
qualifying	O
index	O
claim	O
.	O

The	O
Charlson	O
score	O
is	O
constructed	O
by	O
assessing	O
whether	O
certain	O
high‐acuity	O
conditions	O
appear	O
as	O
a	O
diagnosis	O
within	O
the	O
patient	O
'	O
s	O
record	O
during	O
a	O
given	O
historical	O
period	O
(	O
often	O
1	O
year	O
prior	O
)	O
.	O

Several	O
variations	O
of	O
the	O
score	O
exist	O
based	O
on	O
varying	O
definitions	O
and	O
applications	O
.	O

For	O
this	O
analysis	O
,	O
we	O
calculated	O
a	O
weighted	O
Charlson	O
score	O
based	O
on	O
the	O
Deyo	O
scale	O
.	O

28	O
For	O
each	O
claim	O
,	O
the	O
Charlson	O
score	O
was	O
calculated	O
based	O
on	O
information	O
from	O
any	O
claims	O
that	O
occurred	O
within	O
the	O
12	O
months	O
before	O
the	O
index	O
visit	O
.	O

Because	O
the	O
Charlson	O
score	O
takes	O
dementia	O
diagnosis	O
into	O
consideration	O
,	O
we	O
removed	O
it	O
from	O
our	O
calculation	O
so	O
we	O
would	O
not	O
bias	O
the	O
dementia	O
cohort	O
with	O
higher	O
Charlson	O
scores	O
.	O

Variables	O
were	O
chosen	O
based	O
on	O
the	O
conceptual	O
model	O
as	O
described	O
earlier	O
.	O

A	O
total	O
of	O
eight	O
patients	O
had	O
missing	O
data	O
for	O
the	O
elements	O
specified	O
in	O
the	O
model	O
and	O
thus	O
were	O
excluded	O
from	O
the	O
model	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
rtfMRI	O
NFB	O
and	O
identify	O
the	O
underlying	O
neural	O
mechanisms	O
we	O
will	O
include	O
N	O
=	O
100	O
patients	O
with	O
a	O
diagnosis	O
of	O
alcohol	O
use	O
disorder	O
recruited	O
from	O
the	O
outpatient	O
and	O
inpatient	O
clinics	O
of	O
the	O
Department	O
of	O
Addiction	O
Behavior	O
and	O
Addiction	O
Medicine	O
at	O
the	O
Central	O
Institute	O
of	O
Mental	O
Health	O
(	O
CIMH	O
)	O
,	O
Mannheim	O
,	O
Germany	O
.	O

Participants	O
will	O
be	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
parallel	O
groups	O
.	O

All	O
groups	O
will	O
receive	O
true	O
rtfMRI	O
NFB	O
from	O
different	O
brain	O
processes	O
and	O
will	O
be	O
followed	O
up	O
monthly	O
for	O
three	O
months	O
(	O
Fig	O
.	O

1	O
)	O
.	O

Fig	O
.	O

1	O
Study	O
flow	O
chart	O
.	O

N	O
=	O
100	O
patients	O
with	O
a	O
diagnosis	O
of	O
alcohol	O
addiction	O
from	O
the	O
local	O
inpatient	O
and	O
outpatient	O
addiction	O
clinics	O
are	O
randomized	O
to	O
5	O
single	O
-	O
blind	O
groups	O
,	O
receive	O
rtfMRI	O
NFB	O
treatment	O
on	O
3	O
days	O
within	O
two	O
weeks	O
,	O
and	O
are	O
followed	O
up	O
monthly	O
for	O
3	O
months	O

Study	O
flow	O
chart	O
.	O

N	O
=	O
100	O
patients	O
with	O
a	O
diagnosis	O
of	O
alcohol	O
addiction	O
from	O
the	O
local	O
inpatient	O
and	O
outpatient	O
addiction	O
clinics	O
are	O
randomized	O
to	O
5	O
single	O
-	O
blind	O
groups	O
,	O
receive	O
rtfMRI	O
NFB	O
treatment	O
on	O
3	O
days	O
within	O
two	O
weeks	O
,	O
and	O
are	O
followed	O
up	O
monthly	O
for	O
3	O
months	O

Eligible	O
participants	O
are	O
between	O
18	O
and	O
65	O
years	O
with	O
normal	O
or	O
corrected	O
-	O
to	O
-	O
normal	O
vision	O
.	O

They	O
are	O
diagnosed	O
with	O
alcohol	B-phenotype
dependence	I-phenotype
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
tenth	I-coding_system
edition	I-coding_system
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
:	O
F10	B-code
.	I-code
2	I-code
)	O
with	O
controlled	O
abstinence	O
for	O
at	O
least	O
5	O
and	O
a	O
maximum	O
of	O
21	O
days	O
prior	O
to	O
study	O
inclusion	O
.	O

Additionally	O
,	O
a	O
medically	O
supervised	O
detoxification	O
program	O
(	O
treatment	O
of	O
withdrawal	O
symptoms	O
with	O
short	O
-	O
acting	O
benzodiazepines	O
or	O
clomethiazole	O
)	O
has	O
to	O
have	O
been	O
completed	O
for	O
at	O
least	O
3	O
days	O
.	O

Exclusion	O
criteria	O
are	O
:	O
meeting	O
the	O
criteria	O
of	O
any	O
axis	B-phenotype
I	I-phenotype
psychiatric	I-phenotype
disorder	I-phenotype
according	O
to	O
the	O
Diagnostic	B-coding_system
and	I-coding_system
Statistical	I-coding_system
Manual	I-coding_system
of	I-coding_system
Mental	I-coding_system
Disorders	I-coding_system
,	I-coding_system
fourth	I-coding_system
edition	I-coding_system
(	I-coding_system
DSM	I-coding_system
-	I-coding_system
IV	I-coding_system
)	I-coding_system
and	O
the	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
within	O
the	O
past	O
12	O
months	O
,	O
with	O
the	O
exception	O
of	O
alcohol	O
and	O
nicotine	O
abuse	O
/	O
dependence	O
and	O
a	O
mild	O
depression	O
related	O
to	O
alcohol	O
consumption	O
or	O
detoxification	O
.	O

Further	O
exclusion	O
criteria	O
are	O
a	O
positive	O
urine	O
drug	O
screening	O
,	O
current	O
use	O
of	O
psychotropic	O
or	O
anticonvulsive	O
medications	O
,	O
epilepsy	O
or	O
neurological	O
or	O
severe	O
medical	O
illness	O
,	O
suicidal	O
tendencies	O
,	O
pregnancy	O
,	O
and	O
breastfeeding	O
.	O

For	O
recruitment	O
,	O
participants	O
are	O
informed	O
by	O
a	O
psychologist	O
of	O
the	O
study	O
team	O
about	O
the	O
study	O
purpose	O
and	O
are	O
able	O
to	O
ask	O
all	O
questions	O
concerning	O
the	O
study	O
content	O
.	O

Participants	O
are	O
then	O
asked	O
to	O
provide	O
written	O
informed	O
consent	O
before	O
being	O
screened	O
for	O
in	O
-	O
and	O
exclusion	O
criteria	O
.	O

Participants	O
are	O
able	O
to	O
withdraw	O
their	O
consent	O
at	O
any	O
time	O
.	O

Screening	O
for	O
in	O
-	O
and	O
exclusion	O
criteria	O
includes	O
the	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
(	I-coding_system
SKID	I-coding_system
-	I-coding_system
I	I-coding_system
)	I-coding_system
[	O
51	O
]	O
conducted	O
by	O
a	O
clinical	O
psychologist	O
.	O

Either	O
during	O
the	O
detoxification	O
program	O
or	O
the	O
screening	O
assessment	O
a	O
drug	O
and	O
pregnancy	O
test	O
is	O
conducted	O
.	O

Please	O
see	O
Table	O
1	O
for	O
further	O
information	O
on	O
the	O
schedule	O
of	O
measurements	O
.	O

Table	O
1	O
Schedule	O
of	O
measurements	O
conducted	O
in	O
the	O
study	O
Measurement	O
S	O
a	O
T0	O
a	O
MRI1	O
a	O
MRI2	O
a	O
MRI3	O
a	O
FU1	O
/	O
2	O
b	O
FU3	O
a	O
Sociodemographic	O
information	O
X	O
Structured	O
Clinical	O
Interview	O
(	O
SKID	O
–	O
I	O
)	O
X	O
Drinking	O
Assessment	O
Interview	O
(	O
Form	O
90	O
)	O
X	O
Blood	O
sample	O
(	O
AUD	O
-	O
related	O
markers	O
)	O
X	O
X	O
Urine	O
sample	O
(	O
pregnancy	O
,	O
drugs	O
)	O
X	O
Current	O
medication	O
X	O
X	O
c	O
X	O
c	O
Current	O
smoking	O
behavior	O
X	O
c	O
X	O
c	O
X	O
c	O
X	O
c	O
X	O
c	O
X	O
c	O
Breath	O
alcohol	O
test	O
X	O
Current	O
drug	O
use	O
X	O
c	O
X	O
c	O
Incentive	O
Conflict	O
Task	O
X	O
Clinical	O
&	O
Personality	O
Questionnaires	O
Edinburgh	O
Inventory	O

of	O
Handedness	O
X	O
Beck	O
Depression	O
Inventory	O
X	O
State	O
Trait	O
Anxiety	O
Inventory	O
X	O
Behavioral	O
Inhibition	O
/	O
Approach	O
System	O
X	O
Barratt	O
Impulsiveness	O
Scale	O
X	O
Fagerstrøm	O
Test	O
of	O
Nicotine	O
Dependence	O
X	O
Alcohol	O
-	O
Related	O
Questionnaires	O
Quick	O
Drinking	O
Assessment	O
Interview	O
(	O
Form	O
90	O
-	O
AQ	O
)	O
X	O
X	O
Alcohol	O
Dependence	O
Scale	O
X	O
Alcohol	O
Abstinence	O
Self	O
-	O
Efficacy	O
Scale	O
X	O
X	O
X	O
German	O
Inventory	O
of	O
Drinking	O
Situations	O
X	O
Obsessive	O
Compulsive	O
Drinking	O
Scale	O
X	O
X	O
X	O
Alcohol	O
Urge	O
Questionnaire	O
X	O
X	O
X	O
Craving	O
-	O
Automatized	O
-	O
Scale	O
-	O
Alcohol	O
X	O
X	O
X	O
MRI	O

Anatomical	O
image	O
(	O
MPRAGE	O
)	O
X	O
X	O
X	O
Resting	O
state	O
X	O
X	O
X	O
Neurofeedback	O
X	O
X	O
X	O
Transfer	O
run	O
X	O
X	O
Craving	O
(	O
visual	O
analog	O
scale	O
)	O
pre	O
&	O
post	O
scanning	O
X	O
X	O
X	O
Perceived	O
control	O
over	O
NFB	O
(	O
visual	O
analog	O
scale	O
)	O
X	O
X	O
X	O
S	O
screening	O
assessment	O
,	O
T0	O
baseline	O
assessment	O
,	O
MRI	O
rtfMRI	O
scanning	O
days	O
,	O
FU	O
monthly	O
follow	O
-	O
up	O
.	O

a	O
face	O
-	O
to	O
-	O
face	O
;	O
b	O
via	O
telephone	O
;	O
c	O
self	O
-	O
reported	O
(	O
if	O
unclear	O
)	O

Schedule	O
of	O
measurements	O
conducted	O
in	O
the	O
study	O

S	O
screening	O
assessment	O
,	O
T0	O
baseline	O
assessment	O
,	O
MRI	O
rtfMRI	O
scanning	O
days	O
,	O
FU	O
monthly	O
follow	O
-	O
up	O
.	O

a	O
face	O
-	O
to	O
-	O
face	O
;	O
b	O
via	O
telephone	O
;	O
c	O
self	O
-	O
reported	O
(	O
if	O
unclear	O
)	O

Participants	O
who	O
meet	O
inclusion	O
criteria	O
are	O
randomly	O
assigned	O
to	O
one	O
of	O
five	O
groups	O
:	O
three	O
experimental	O
and	O
two	O
control	O
groups	O
,	O
respectively	O
.	O

Each	O
group	O
has	O
to	O
fulfil	O
different	O
tasks	O
with	O
either	O
downregulating	O
the	O
ventral	O
striatum	O
,	O
upregulating	O
the	O
right	O
inferior	O
frontal	O
gyrus	O
(	O
rIFG	O
)	O
,	O
increasing	O
the	O
connectivity	O
(	O
negative	O
correlation	O
)	O
between	O
rIFG	O
and	O
VS	O
,	O
downregulating	O
the	O
auditory	O
cortex	O
(	O
downregulation	O
control	O
)	O
or	O
upregulating	O
the	O
auditory	O
cortex	O
(	O
upregulation	O
control	O
)	O
.	O

The	O
auditory	O
cortex	O
was	O
chosen	O
as	O
control	O
region	O
because	O
it	O
is	O
not	O
involved	O
in	O
cue	O
-	O
reactivity	O
[	O
22	O
]	O
.	O

Group	O
allocation	O
of	O
included	O
participants	O
is	O
conducted	O
by	O
the	O
study	O
team	O
with	O
a	O
computer	O
-	O
generated	O
random	O
list	O
based	O
on	O
the	O
sequence	O
of	O
inclusion	O
.	O

No	O
stratification	O
factors	O
are	O
used	O
in	O
the	O
allocation	O
process	O
.	O

After	O
group	O
allocation	O
,	O
all	O
participants	O
take	O
part	O
in	O
a	O
baseline	O
assessment	O
about	O
demographic	O
questions	O
,	O
alcohol	O
use	O
,	O
actual	O
medication	O
,	O
personality	O
,	O
and	O
clinical	O
symptoms	O
(	O
see	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
participants	O
conduct	O
the	O
computer	O
-	O
based	O
Incentive	O
Conflict	O
Task	O
(	O
ICT	O
,	O
[	O
52	O
]	O
)	O
during	O
the	O
baseline	O
assessment	O
.	O

rtfMRI	O
NFB	O
is	O
conducted	O
at	O
Siemens	O
3	O
T	O
Tim	O
Trio	O
scanners	O
(	O
Siemens	O
Healthineers	O
,	O
Erlangen	O
,	O
Germany	O
)	O
at	O
the	O
Central	O
Institute	O
of	O
Mental	O
Health	O
in	O
Mannheim	O
,	O
Germany	O
.	O

Each	O
participant	O
receives	O
neurofeedback	O
training	O
on	O
three	O
scanning	O
days	O
within	O
a	O
period	O
of	O
two	O
weeks	O
.	O

On	O
each	O
day	O
a	O
5	O
:	O
21	O
min	O
T1	O
-	O
weighted	O
anatomical	O
MPRAGE	O
scan	O
,	O
a	O
12	O
:	O
00	O
min	O
functional	O
resting	O
state	O
scan	O
with	O
eyes	O
closed	O
,	O
and	O
three	O
neurofeedback	O
runs	O
of	O
9	O
:	O
29	O
min	O
are	O
conducted	O
.	O

At	O
the	O
beginning	O
of	O
each	O
session	O
an	O
MPRAGE	O
image	O
is	O
acquired	O
with	O
a	O
time	O
of	O
repetition	O
(	O
TR	O
)	O
of	O
2	O
.	O
3	O
s	O
,	O
an	O
echo	O
time	O
(	O
TE	O
)	O
of	O
3	O
.	O
03	O
ms	O
,	O
9°	O
flip	O
angle	O
,	O
a	O
field	O
of	O
view	O
of	O
256	O
mm	O
with	O
192	O
sagittal	O
slice	O
,	O
a	O
matrix	O
size	O
of	O
256	O
×	O
256	O
mm	O
,	O
1x1x1	O
mm	O
voxel	O
size	O
,	O
and	O
GRAPPA	O
with	O
iPAT	O
=	O
2	O
.	O

Resting	O
state	O
and	O
NFB	O
sessions	O
are	O
scanned	O
with	O
echo	O
-	O
planar	O
imaging	O
(	O
EPI	O
)	O
sequences	O
with	O
a	O
TR	O
of	O
1	O
.	O
64	O
s	O
,	O
a	O
TE	O
of	O
30	O
ms	O
,	O
73°	O
flip	O
angle	O
,	O
a	O
field	O
of	O
view	O
of	O
192	O
mm	O
,	O
3x3x3	O
mm	O
voxel	O
size	O
,	O
33	O
slices	O
of	O
3	O
mm	O
thickness	O
with	O
a	O
distance	O
factor	O
of	O
33	O
%	O
,	O
and	O
GRAPPA	O
with	O
iPAT	O
=	O
2	O
.	O

During	O
NFB	O
scans	O
,	O
reconstructed	O
DICOM	O
images	O
are	O
transferred	O
from	O
the	O
imaging	O
computer	O
to	O
a	O
laptop	O
that	O
preprocesses	O
the	O
images	O
and	O
extracts	O
the	O
neurofeedback	O
signal	O
by	O
means	O
of	O
an	O
in	O
-	O
house	O
software	O
.	O

The	O
feedback	O
value	O
is	O
then	O
send	O
to	O
a	O
presentation	O
computer	O
and	O
shown	O
to	O
the	O
participant	O
in	O
the	O
scanner	O
as	O
a	O
thermometer	O
value	O
besides	O
the	O
picture	O
of	O
an	O
alcoholic	O
beverage	O
preferred	O
by	O
the	O
participant	O
(	O
beer	O
,	O
wine	O
,	O
or	O
both	O
)	O
.	O

See	O
Fig	O
.	O

2	O
for	O
an	O
illustration	O
.	O

The	O
thermometer	O
is	O
updated	O
with	O
every	O
new	O
volume	O
.	O

The	O
order	O
of	O
pictures	O
is	O
randomized	O
between	O
participants	O
.	O

Fig	O
.	O

2	O
Real	O
-	O
time	O
fMRI	O
neurofeedback	O
setup	O
.	O

Acquired	O
images	O
are	O
reconstructed	O
and	O
send	O
to	O
a	O
laptop	O
running	O
in	O
-	O
house	O
MATLAB	O
(	O
MathWorks	O
Inc	O
.	O
,	O
Sherborn	O
,	O
MA	O
,	O
USA	O
)	O
scripts	O
based	O
on	O
SPM8	O
(	O
Wellcome	O
Department	O
of	O
Cognitive	O
Neurology	O
,	O
London	O
,	O
UK	O
)	O
functions	O
to	O
preprocess	O
the	O
images	O
and	O
extract	O
the	O
neurofeedback	O
signal	O
.	O

The	O
feedback	O
value	O
is	O
send	O
to	O
a	O
computer	O
running	O
Presentation	O
software	O
(	O
Neurobehavioral	O
Systems	O
,	O
Inc	O
.	O
,	O
Albany	O
,	O
CA	O
,	O
USA	O
)	O
and	O
presented	O
to	O
the	O
participant	O
in	O
the	O
scanner	O
as	O
a	O
thermometer	O
value	O
besides	O
a	O
picture	O
of	O
an	O
alcoholic	O
beverage	O

Real	O
-	O
time	O
fMRI	O
neurofeedback	O
setup	O
.	O

Acquired	O
images	O
are	O
reconstructed	O
and	O
send	O
to	O
a	O
laptop	O
running	O
in	O
-	O
house	O
MATLAB	O
(	O
MathWorks	O
Inc	O
.	O
,	O
Sherborn	O
,	O
MA	O
,	O
USA	O
)	O
scripts	O
based	O
on	O
SPM8	O
(	O
Wellcome	O
Department	O
of	O
Cognitive	O
Neurology	O
,	O
London	O
,	O
UK	O
)	O
functions	O
to	O
preprocess	O
the	O
images	O
and	O
extract	O
the	O
neurofeedback	O
signal	O
.	O

The	O
feedback	O
value	O
is	O
send	O
to	O
a	O
computer	O
running	O
Presentation	O
software	O
(	O
Neurobehavioral	O
Systems	O
,	O
Inc	O
.	O
,	O
Albany	O
,	O
CA	O
,	O
USA	O
)	O
and	O
presented	O
to	O
the	O
participant	O
in	O
the	O
scanner	O
as	O
a	O
thermometer	O
value	O
besides	O
a	O
picture	O
of	O
an	O
alcoholic	O
beverage	O

rtfMRI	O
NFB	O
is	O
conducted	O
with	O
in	O
-	O
house	O
MATLAB	O
(	O
MathWorks	O
Inc	O
.	O
,	O
Sherborn	O
,	O
MA	O
,	O
USA	O
)	O
scripts	O
based	O
on	O
SPM8	O
functions	O
(	O
Wellcome	O
Department	O
of	O
Cognitive	O
Neurology	O
,	O
London	O
,	O
UK	O
)	O
,	O
and	O
Presentation	O
software	O
(	O
Neurobehavioral	O
Systems	O
,	O
Inc	O
.	O
,	O
Albany	O
,	O
CA	O
,	O
USA	O
)	O
to	O
present	O
pictures	O
and	O
the	O
feedback	O
signal	O
.	O

On	O
each	O
scanning	O
day	O
,	O
the	O
acquired	O
anatomical	O
image	O
is	O
first	O
segmented	O
and	O
normalized	O
to	O
MNI	O
standard	O
space	O
.	O

The	O
inverse	O
deformations	O
of	O
the	O
normalization	O
are	O
then	O
applied	O
to	O
warp	O
the	O
masks	O
of	O
the	O
target	O
regions	O
into	O
subject	O
space	O
.	O

During	O
rtfMRI	O
NFB	O
scanning	O
,	O
functional	O
images	O
are	O
realigned	O
to	O
the	O
mean	O
of	O
the	O
first	O
10	O
functional	O
images	O
and	O
resliced	O
.	O

Then	O
,	O
the	O
mask	O
images	O
are	O
resampled	O
to	O
the	O
space	O
of	O
the	O
current	O
image	O
and	O
mean	O
intensity	O
values	O
from	O
the	O
voxels	O
in	O
the	O
target	O
regions	O
are	O
extracted	O
.	O

For	O
activation	O
NFB	O
,	O
intensity	O
values	O
during	O
presentation	O
of	O
alcohol	O
images	O
are	O
averaged	O
over	O
the	O
last	O
three	O
volumes	O
(	O
moving	O
average	O
)	O
to	O
stabilize	O
the	O
feedback	O
signal	O
and	O
percent	O
signal	O
change	O
with	O
regard	O
to	O
the	O
preceding	O
fixation	O
cross	O
block	O
is	O
calculated	O
.	O

The	O
scale	O
of	O
the	O
feedback	O
thermometer	O
is	O
adaptively	O
adjusted	O
to	O
the	O
maximum	O
absolute	O
signal	O
change	O
and	O
the	O
feedback	O
signal	O
is	O
presented	O
to	O
the	O
participant	O
.	O

For	O
connectivity	O
NFB	O
,	O
partial	O
correlations	O
between	O
the	O
intensity	O
values	O
of	O
the	O
VS	O
and	O
right	O
IFG	O
adjusted	O
for	O
the	O
cerebro	O
-	O
spinal	O
fluid	O
signal	O
over	O
the	O
last	O
15	O
volumes	O
are	O
used	O
to	O
calculate	O
the	O
feedback	O
signal	O
.	O

Again	O
,	O
the	O
scale	O
of	O
the	O
feedback	O
thermometer	O
is	O
adaptively	O
adjusted	O
to	O
the	O
maximum	O
absolute	O
value	O
reached	O
.	O

In	O
this	O
exploratory	O
group	O
,	O
the	O
goal	O
of	O
the	O
intervention	O
is	O
to	O
increase	O
the	O
inhibiting	O
influence	O
of	O
the	O
rIFG	O
to	O
the	O
VS	O
and	O
the	O
participants	O
are	O
instructed	O
to	O
downregulate	O
the	O
depicted	O
process	O
.	O

However	O
,	O
a	O
negative	O
correlation	O
between	O
VS	O
and	O
rIFG	O
could	O
arise	O
from	O
the	O
desired	O
state	O
,	O
but	O
also	O
from	O
an	O
inverse	O
behavior	O
of	O
the	O
system	O
with	O
increased	O
VS	O
and	O
diminished	O
frontal	O
activity	O
.	O

To	O
enforce	O
the	O
top	O
-	O
down	O
inhibitory	O
state	O
of	O
the	O
system	O
we	O
included	O
the	O
additional	O
constraints	O
in	O
the	O
connectivity	O
feedback	O
that	O
the	O
VS	O
should	O
be	O
downregulated	O
and	O
the	O
rIFG	O
should	O
be	O
upregulated	O
and	O
switch	O
negative	O
feedback	O
values	O
to	O
positive	O
if	O
these	O
constraints	O
are	O
not	O
met	O
.	O

NFB	O
sessions	O
have	O
a	O
block	O
design	O
with	O
alternating	O
presentation	O
of	O
a	O
fixation	O
cross	O
(	O
baseline	O
;	O
41	O
s	O
)	O
and	O
a	O
picture	O
of	O
a	O
preferred	O
alcoholic	O
beverage	O
(	O
beer	O
,	O
wine	O
,	O
or	O
both	O
;	O
approx	O
.	O

51	O
s	O
)	O
,	O
each	O
for	O
6	O
times	O
.	O

Approximately	O
10	O
s	O
after	O
onset	O
of	O
the	O
alcoholic	O
pictures	O
a	O
feedback	O
thermometer	O
is	O
shown	O
on	O
both	O
sides	O
of	O
the	O
picture	O
and	O
updated	O
every	O
TR	O
(	O
feedback	O
;	O
41	O
s	O
)	O
.	O

On	O
the	O
first	O
and	O
third	O
day	O
,	O
the	O
last	O
(	O
third	O
)	O
run	O
is	O
conducted	O
as	O
a	O
transfer	O
run	O
without	O
presentation	O
of	O
the	O
feedback	O
signal	O
(	O
Fig	O
.	O

3	O
)	O
.	O

Fig	O
.	O

3	O
Experimental	O
design	O
.	O

Design	O
of	O
neurofeedback	O
(	O
left	O
)	O
and	O
transfer	O
(	O
right	O
)	O
tasks	O
.	O

Each	O
run	O
consists	O
of	O
6	O
repetitions	O
of	O
the	O
displayed	O
sequences	O
.	O

The	O
last	O
(	O
third	O
)	O
runs	O
on	O
the	O
first	O
and	O
third	O
scanning	O
day	O
are	O
conducted	O
as	O
transfer	O
sessions	O
without	O
the	O
neurofeedback	O
signal	O
.	O

TR	O
:	O
Time	O
of	O
Repetition	O
(	O
1	O
TR	O
=	O
1	O
.	O
64	O
s	O
)	O

Experimental	O
design	O
.	O

Design	O
of	O
neurofeedback	O
(	O
left	O
)	O
and	O
transfer	O
(	O
right	O
)	O
tasks	O
.	O

Each	O
run	O
consists	O
of	O
6	O
repetitions	O
of	O
the	O
displayed	O
sequences	O
.	O

The	O
last	O
(	O
third	O
)	O
runs	O
on	O
the	O
first	O
and	O
third	O
scanning	O
day	O
are	O
conducted	O
as	O
transfer	O
sessions	O
without	O
the	O
neurofeedback	O
signal	O
.	O

TR	O
:	O
Time	O
of	O
Repetition	O
(	O
1	O
TR	O
=	O
1	O
.	O
64	O
s	O
)	O

On	O
each	O
scanning	O
day	O
participants	O
rate	O
their	O
craving	O
on	O
a	O
visual	O
analog	O
scale	O
directly	O
before	O
and	O
after	O
scanning	O
.	O

After	O
completing	O
the	O
third	O
MRI	O
scanning	O
session	O
,	O
participants	O
are	O
asked	O
to	O
answer	O
alcohol	O
-	O
related	O
questionnaires	O
(	O
see	O
Table	O
1	O
)	O
.	O

Follow	O
-	O
up	O
assessments	O
take	O
place	O
monthly	O
after	O
the	O
last	O
MRI	O
session	O
over	O
a	O
period	O
of	O
three	O
months	O
.	O

At	O
the	O
first	O
two	O
time	O
points	O
participants	O
are	O
contacted	O
by	O
phone	O
and	O
asked	O
about	O
their	O
current	O
medication	O
,	O
their	O
abuse	O
of	O
tobacco	O
,	O
nicotine	O
and	O
drugs	O
and	O
a	O
potential	O
alcohol	O
relapse	O
(	O
see	O
Table	O
1	O
)	O
.	O

Three	O
months	O
after	O
the	O
last	O
MRI	O
session	O
,	O
patients	O
are	O
invited	O
to	O
a	O
final	O
appointment	O
at	O
the	O
CIMH	O
.	O

During	O
this	O
session	O
,	O
blood	O
samples	O
are	O
collected	O
and	O
participants	O
are	O
asked	O
about	O
substance	O
use	O
and	O
answer	O
alcohol	O
-	O
related	O
questionnaires	O
(	O
see	O
Table	O
1	O
)	O
.	O

For	O
the	O
final	O
appointment	O
,	O
patients	O
receive	O
a	O
monetary	O
compensation	O
of	O
50	O
€	O
.	O

As	O
primary	O
outcome	O
analysis	O
we	O
will	O
conduct	O
group	O
comparisons	O
of	O
relapse	O
rates	O
with	O
survival	O
analysis	O
and	O
assess	O
reduction	O
of	O
alcohol	O
intake	O
during	O
the	O
follow	O
-	O
up	O
phase	O
.	O

As	O
secondary	O
and	O
exploratory	O
outcome	O
measures	O
we	O
will	O
assess	O
whether	O
rtfMRI	O
NFB	O
reduces	O
alcohol	O
craving	O
during	O
the	O
NFB	O
sessions	O
,	O
how	O
brain	O
activation	O
and	O
brain	O
connectivity	O
changes	O
within	O
and	O
between	O
the	O
sessions	O
,	O
whether	O
functional	O
or	O
structural	O
MRI	O
markers	O
can	O
be	O
identified	O
that	O
predict	O
neurofeedback	O
learning	O
and	O
the	O
success	O
of	O
the	O
intervention	O
,	O
and	O
whether	O
differences	O
in	O
efficacy	O
of	O
the	O
group	O
-	O
specific	O
interventions	O
do	O
exist	O
.	O

To	O
analyze	O
the	O
effects	O
of	O
rtfMRI	O
NFB	O
,	O
offline	O
data	O
analysis	O
will	O
be	O
conducted	O
with	O
MATLAB	O
and	O
SPM	O
.	O

Data	O
preprocessing	O
will	O
consist	O
of	O
slice	O
-	O
time	O
correction	O
,	O
realignment	O
,	O
segmentation	O
of	O
the	O
anatomical	O
image	O
,	O
normalization	O
to	O
the	O
MNI	O
space	O
,	O
smoothing	O
,	O
and	O
identification	O
of	O
outlier	O
volumes	O
with	O
excessive	O
head	O
motion	O
.	O

The	O
preprocessed	O
data	O
will	O
be	O
used	O
in	O
first	O
level	O
single	O
subject	O
analyses	O
in	O
which	O
the	O
time	O
courses	O
of	O
the	O
experimental	O
conditions	O
will	O
be	O
convolved	O
with	O
the	O
canonical	O
hemodynamic	O
response	O
function	O
and	O
used	O
in	O
a	O
general	O
linear	O
model	O
to	O
estimate	O
brain	O
responses	O
during	O
rtfMRI	O
NFB	O
.	O

Then	O
,	O
first	O
level	O
results	O
will	O
be	O
used	O
in	O
second	O
level	O
group	O
comparisons	O
to	O
estimate	O
differential	O
activation	O
between	O
groups	O
,	O
test	O
for	O
associations	O
with	O
clinical	O
variables	O
,	O
and	O
assess	O
the	O
predictive	O
value	O
of	O
imaging	O
markers	O
for	O
the	O
future	O
course	O
of	O
the	O
disease	O
.	O

Additionally	O
,	O
large	O
-	O
scale	O
adaptations	O
in	O
functional	O
networks	O
during	O
rtfMRI	O
NFB	O
will	O
be	O
assessed	O
by	O
whole	O
-	O
brain	O
psychophysiological	O
interaction	O
analysis	O
[	O
53	O
]	O
.	O

Depending	O
on	O
the	O
type	O
of	O
the	O
data	O
,	O
missing	O
data	O
will	O
either	O
be	O
left	O
out	O
from	O
the	O
analyses	O
(	O
e	O
.	O
g	O
.	O
fMRI	O
data	O
)	O
,	O
or	O
imputed	O
(	O
e	O
.	O
g	O
.	O
missing	O
questionnaire	O
items	O
)	O
.	O

Power	O
calculations	O
were	O
conducted	O
with	O
the	O
G	O
*	O
Power	O
software	O
package	O
[	O
54	O
]	O
.	O

In	O
the	O
clinical	O
analysis	O
(	O
follow	O
-	O
up	O
measures	O
)	O
the	O
power	O
for	O
detecting	O
group	O
differences	O
at	O
p	O
<	O
.	O
05	O
under	O
the	O
assumption	O
of	O
a	O
medium	O
effect	O
size	O
(	O
Cohen’s	O
d	O
=	O
.	O
5	O
)	O
is	O
78	O
%	O
with	O
two	O
sample	O
t	O
-	O
tests	O
when	O
treatment	O
(	O
n	O
=	O
60	O
)	O
and	O
control	O
groups	O
(	O
n	O
=	O
40	O
)	O
are	O
pooled	O
.	O

Assuming	O
an	O
effect	O
size	O
of	O
f	O
=	O
.	O
61	O
as	O
observed	O
for	O
the	O
neurofeedback	O
effect	O
on	O
VS	O
reduction	O
in	O
our	O
pilot	O
study	O
[	O
18	O
]	O
,	O
the	O
neurofeedback	O
analyses	O
based	O
on	O
an	O
ANOVA	O
repeated	O
measures	O
model	O
with	O
a	O
group	O
x	O
time	O
contrast	O
has	O
a	O
power	O
of	O
89	O
%	O
in	O
the	O
VS	O
and	O
of	O
88	O
%	O
in	O
the	O
rIFG	O
to	O
detect	O
FWE	O
(	O
Bonferroni	O
)	O
corrected	O
significant	O
results	O
in	O
the	O
respective	O
ROI	O
analyses	O
.	O

To	O
ensure	O
data	O
quality	O
,	O
questionnaires	O
are	O
automatically	O
scanned	O
and	O
entered	O
into	O
the	O
study	O
data	O
base	O
.	O

Data	O
management	O
and	O
monitoring	O
is	O
conducted	O
by	O
the	O
study	O
team	O
.	O

Study	O
data	O
will	O
be	O
stored	O
on	O
servers	O
of	O
the	O
Central	O
Institute	O
of	O
Mental	O
Health	O
separated	O
from	O
personal	O
information	O
of	O
the	O
participants	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
personal	O
information	O
will	O
be	O
deleted	O
.	O

The	O
procedures	O
comply	O
with	O
German	O
data	O
privacy	O
laws	O
.	O

We	O
will	O
conduct	O
interim	O
analyses	O
on	O
the	O
acquired	O
data	O
to	O
present	O
the	O
study	O
to	O
scientific	O
audiences	O
(	O
e	O
.	O
g	O
.	O
at	O
conferences	O
,	O
meetings	O
,	O
etc	O
.	O
)	O
during	O
the	O
data	O
acquisition	O
phase	O
.	O

Results	O
of	O
the	O
final	O
analyses	O
will	O
be	O
published	O
in	O
scientific	O
journals	O
and	O
presented	O
on	O
scientific	O
conferences	O
.	O

Authorship	O
will	O
be	O
defined	O
in	O
accordance	O
to	O
the	O
German	O
Research	O
Foundation’s	O
recommendations	O
for	O
safeguarding	O
good	O
scientific	O
practice	O
[	O
55	O
]	O
.	O

Study	O
conduct	O
is	O
reported	O
and	O
audited	O
in	O
interim	O
and	O
final	O
reports	O
of	O
the	O
SyBil	O
-	O
AA	O
consortium	O
to	O
the	O
funding	O
agency	O
.	O

Data	O
from	O
death	O
certificates	O
,	O
obtained	O
from	O
vital	O
statistics	O
in	O
Japan	O
,	O
were	O
analysed	O
.	O

A	O
detailed	O
description	O
of	O
these	O
data	O
has	O
been	O
reported	O
elsewhere	O
.	O

17	O
Data	O
regarding	O
deaths	O
of	O
Japanese	O
residents	O
aged	O
65	O
years	O
or	O
older	O
were	O
extracted	O
from	O
those	O
regarding	O
deaths	O
that	O
occurred	O
in	O
Japan	O
between	O
October	O
1996	O
and	O
September	O
2016	O
.	O

As	O
dementia	O
care	O
services	O
usually	O
involve	O
universal	O
health	O
and	O
social	O
care	O
systems	O
and	O
dementia	O
-	O
specific	O
services	O
,	O
we	O
examined	O
the	O
associations	O
between	O
places	O
of	O
death	O
and	O
changes	O
in	O
health	O
and	O
social	O
care	O
systems	O
and	O
the	O
national	O
dementia	O
plan	O
.	O

Four	O
major	O
changes	O
in	O
health	O
and	O
social	O
care	O
systems	O
were	O
identified	O
(	O
table	O
1	O
)	O
:	O
(	O
1	O
)	O
the	O
public	O
long	O
-	O
term	O
care	O
insurance	O
(	O
LTCI	O
)	O
programme	O
was	O
introduced	O
in	O
April	O
2000	O
;	O
(	O
2	O
)	O
general	O
community	O
support	O
centres	O
and	O
community	O
-	O
based	O
care	O
services	O
,	O
including	O
group	O
homes	O
,	O
as	O
well	O
as	O
home	O
-	O
care	O
support	O
clinics	O
were	O
introduced	O
in	O
April	O
2006	O
;	O
(	O
3	O
)	O
a	O
medical	O
care	O
system	O
for	O
older	O
people	O
was	O
introduced	O
in	O
April	O
2008	O
and	O
(	O
4	O
)	O
the	O
national	O
dementia	O
plan	O
was	O
launched	O
in	O
April	O
2013	O
.	O

Four	O
changes	O
in	O
health	O
and	O
social	O
care	O
systems	O
in	O
Japan	O

Each	O
local	O
(	O
city	O
)	O
government	O
serves	O
as	O
an	O
insurer	O
providing	O
long	O
-	O
term	O
care	O
insurance	O
for	O
older	O
inhabitants	O
.	O

Care	O
managers	O
handle	O
monthly	O
care	O
plans	O
for	O
home	O
-	O
care	O
clients	O
,	O
who	O
usually	O
purchase	O
home	O
-	O
care	O
services	O
from	O
providers	O
other	O
than	O
the	O
care	O
managers	O
.	O

Residential	O
care	O
services	O
consist	O
of	O
special	O
nursing	O
homes	O
,	O
intermediate	O
geriatric	O
care	O
facilities	O
and	O
long	O
-	O
term	O
sanatorium	O
care	O
beds	O
.	O

Special	O
nursing	O
homes	O
are	O
the	O
only	O
facilities	O
that	O
provide	O
permanent	O
residence	O
under	O
long	O
-	O
term	O
care	O
insurance	O
residential	O
services	O
.	O

Intermediate	O
geriatric	O
care	O
facilities	O
provide	O
rehabilitation	O
with	O
the	O
aim	O
of	O
home	O
discharge	O
.	O

General	O
community	O
support	O
centres	O
serve	O
as	O
a	O
first	O
access	O
point	O
for	O
older	O
inhabitants	O
,	O
including	O
those	O
with	O
dementia	O
,	O
in	O
each	O
local	O
area	O
.	O

Community	O
-	O
based	O
care	O
service	O
providers	O
handle	O
monthly	O
care	O
plans	O
and	O
offer	O
a	O
package	O
of	O
home	O
-	O
based	O
care	O
services	O
to	O
clients	O
.	O

Community	O
-	O
based	O
care	O
services	O
include	O
group	O
homes	O
that	O
accommodate	O
residents	O
with	O
mild	O
to	O
moderate	O
dementia	O
.	O

Home	O
-	O
care	O
support	O
clinics	O
provide	O
home	O
-	O
based	O
end	O
-	O
of	O
-	O
life	O
care	O
for	O
all	O
diseases	O
,	O
including	O
dementia	O
,	O
in	O
collaboration	O
with	O
home	O
-	O
visit	O
nursing	O
care	O
services	O
.	O

The	O
medical	O
care	O
system	O
for	O
older	O
people	O
established	O
prefectural	O
(	O
state	O
)	O
health	O
insurers	O
to	O
cover	O
inhabitants	O
aged	O
75	O
years	O
or	O
older	O
in	O
the	O
prefecture	O
.	O

Initial	O
-	O
phase	O
intensive	O
support	O
teams	O
were	O
established	O
in	O
general	O
community	O
support	O
centres	O
to	O
provide	O
referrals	O
to	O
‘medical	O
centres	O
for	O
dementia’	O
to	O
provide	O
definitive	O
dementia	O
diagnoses	O
and	O
support	O
for	O
people	O
in	O
the	O
early	O
stage	O
of	O
dementia	O
and	O
their	O
families	O
.	O

Psychiatric	O
inpatient	O
care	O
involves	O
behaviour	O
management	O
and	O
assistance	O
in	O
the	O
process	O
of	O
home	O
discharge	O
for	O
people	O
with	O
dementia	O
.	O

General	O
community	O
support	O
centres	O
serve	O
as	O
a	O
first	O
access	O
point	O
for	O
older	O
residents	O
,	O
including	O
those	O
with	O
dementia	O
,	O
in	O
each	O
local	O
area	O
.	O

9	O
Group	O
homes	O
offer	O
small	O
-	O
scale	O
,	O
homelike	O
accommodation	O
for	O
residents	O
with	O
mild	O
to	O
moderate	O
dementia	O
,	O
and	O
residents	O
with	O
dementia	O
in	O
these	O
homes	O
have	O
shown	O
higher	O
quality	O
of	O
life	O
relative	O
to	O
that	O
of	O
those	O
living	O
at	O
home	O
.	O

18	O
The	O
medical	O
care	O
system	O
for	O
older	O
people	O
includes	O
prefectural	O
(	O
state	O
)	O
health	O
insurers	O
that	O
cover	O
inhabitants	O
aged	O
75	O
years	O
or	O
older	O
in	O
the	O
prefecture	O
.	O

Home	O
-	O
care	O
support	O
clinics	O
offer	O
palliative	O
and	O
end	O
-	O
of	O
-	O
life	O
care	O
services	O
to	O
older	O
patients	O
with	O
cancer	O
and	O
other	O
diseases	O
.	O

19	O
The	O
national	O
dementia	O
plan	O
includes	O
initial	O
-	O
phase	O
intensive	O
support	O
teams	O
in	O
general	O
community	O
support	O
centres	O
9	O
and	O
provides	O
psychiatric	O
inpatient	O
care	O
,	O
which	O
involves	O
behaviour	O
management	O
and	O
assistance	O
in	O
the	O
process	O
of	O
home	O
discharge	O
for	O
people	O
with	O
dementia	O
.	O

Patients	O
and	O
public	O
were	O
not	O
involved	O
in	O
this	O
study	O
.	O

Data	O
regarding	O
the	B-phenotype
primary	I-phenotype
cause	I-phenotype
of	I-phenotype
death	I-phenotype
were	O
obtained	O
from	O
death	O
certificates	O
using	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
,	I-coding_system
Tenth	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
codes	O
.	O

In	O
Japan	O
,	O
death	O
certificates	O
are	O
completed	O
by	O
a	O
medical	O
doctor	O
within	O
7	O
days	O
of	O
death	O
,	O
and	O
the	O
leading	O
cause	O
of	O
death	O
is	O
identified	O
.	O

Deaths	O
resulting	O
from	O
dementia	O
were	O
identified	O
using	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
codes	O
F00	B-code
(	O
dementia	B-phenotype
in	I-phenotype
Alzheimer’s	I-phenotype
disease	I-phenotype
)	O
,	O
F01	B-code
(	O
vascular	B-phenotype
dementia	I-phenotype
)	O
,	O
F02	B-code
(	O
dementia	B-phenotype
in	I-phenotype
other	I-phenotype
disease	I-phenotype
)	O
,	O
F03	B-code
(	O
unspecified	B-phenotype
dementia	I-phenotype
)	O
and	O
G30	B-code
(	O
Alzheimer’s	B-phenotype
disease	I-phenotype
)	O
.	O

As	O
clinical	O
diagnoses	O
of	O
dementia	O
are	O
under	O
-	O
reported	O
as	O
the	O
main	O
cause	O
of	O
death	O
on	O
death	O
certificates	O
,	O
20	O
21	O
deaths	O
resulting	O
from	O
senility	B-phenotype
(	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
,	O
R54	B-code
)	O
were	O
also	O
extracted	O
from	O
the	O
mortality	O
data	O
.	O

Senility	O
is	O
included	O
in	O
the	O
following	O
category	O
that	O
requires	O
palliative	O
care	O
:	O
‘Alzheimer’s	O
disease	O
,	O
dementia	O
and	O
senility’	O
.	O

13	O

In	O
total	O
,	O
22	O
308	O
402	O
deaths	O
were	O
registered	O
in	O
Japan	O
between	O
October	O
1996	O
and	O
September	O
2016	O
,	O
of	O
which	O
22	O
262	O
049	O
involved	O
Japanese	O
residents	O
.	O

In	O
addition	O
,	O
18	O
546	O
639	O
(	O
83	O
.	O
2	O
%	O
of	O
22	O
262	O
049	O
)	O
occurred	O
in	O
people	O
aged	O
65	O
years	O
or	O
older	O
.	O

Of	O
the	O
18	O
546	O
639	O
decedents	O
who	O
had	O
been	O
resident	O
in	O
Japan	O
and	O
aged	O
65	O
years	O
or	O
older	O
,	O
982	O
809	O
(	O
5	O
.	O
3	O
%	O
)	O
died	O
of	O
Alzheimer’s	O
disease	O
(	O
n=73	O
531	O
;	O
0	O
.	O
4	O
%	O
)	O
,	O
vascular	O
or	O
other	O
dementias	O
(	O
n=108	O
427	O
;	O
0	O
.	O
6	O
%	O
)	O
or	O
senility	O
(	O
n=800	O
851	O
;	O
4	O
.	O
3	O
%	O
)	O
.	O

The	O
dementia	O
-	O
related	O
death	O
rate	O
per	O
100	O
000	O
inhabitants	O
aged	O
65	O
years	O
or	O
older	O
was	O
9	O
.	O
9	O
in	O
October	O
1996	O
and	O
26	O
.	O
8	O
in	O
September	O
2016	O
.	O

The	O
dependent	O
variable	O
was	O
place	O
of	O
death	O
,	O
which	O
was	O
classified	O
into	O
the	O
following	O
categories	O
on	O
the	O
death	O
certificates	O
:	O
‘hospital’	O
(	O
medical	O
institution	O
with	O
20	O
or	O
more	O
beds	O
)	O
,	O
‘clinic’	O
(	O
outpatient	O
clinic	O
or	O
medical	O
institution	O
with	O
1–19	O
beds	O
)	O
,	O
‘intermediate	O
geriatric	O
care	O
facility’	O
(	O
rehabilitation	O
facility	O
aimed	O
at	O
home	O
discharge	O
)	O
,	O
‘nursing	O
home’	O
,	O
‘own	O
home’	O
or	O
‘other	O
place	O
,	O
unspecified’	O
.	O

Nursing	O
homes	O
included	O
special	O
nursing	O
homes	O
and	O
fee	O
-	O
based	O
homes	O
for	O
older	O
people	O
.	O

Special	O
nursing	O
homes	O
are	O
the	O
only	O
facilities	O
that	O
provide	O
permanent	O
residence	O
under	O
LTCI	O
residential	O
services	O
.	O

Fee	O
-	O
based	O
homes	O
for	O
older	O
people	O
include	O
housing	O
facilities	O
that	O
are	O
provided	O
in	O
accordance	O
with	O
the	O
Public	O
Aid	O
for	O
the	O
Aged	O
Act	O
,	O
offer	O
additional	O
care	O
and	O
are	O
comparable	O
to	O
assisted	O
living	O
in	O
the	O
USA	O
and	O
extra	O
-	O
care	O
housing	O
in	O
England	O
.	O

Own	O
homes	O
included	O
group	O
homes	O
.	O

Places	O
of	O
death	O
classified	O
as	O
‘other	O
place	O
,	O
unspecified’	O
were	O
excluded	O
from	O
the	O
analysis	O
.	O

The	O
independent	O
variables	O
were	O
related	O
to	O
the	O
decedents’	O
personal	O
characteristics	O
,	O
regional	O
numbers	O
of	O
hospital	O
and	O
nursing	O
home	O
beds	O
per	O
inhabitant	O
and	O
changes	O
in	O
health	O
and	O
social	O
care	O
systems	O
.	O

Information	O
regarding	O
sex	O
,	O
age	O
at	O
death	O
,	O
marital	O
status	O
and	O
municipality	O
of	O
residence	O
was	O
obtained	O
from	O
death	O
certificate	O
data	O
.	O

Municipality	O
of	O
residence	O
was	O
associated	O
with	O
the	O
number	O
of	O
available	O
hospital	O
and	O
nursing	O
home	O
beds	O
in	O
the	O
decedent’s	O
health	O
region	O
,	O
as	O
follows	O
:	O
available	O
hospital	O
beds	O
per	O
1000	O
inhabitants	O
,	O
available	O
special	O
nursing	O
home	O
beds	O
per	O
1000	O
inhabitants	O
aged	O
65	O
years	O
or	O
older	O
and	O
available	O
fee	O
-	O
based	O
home	O
beds	O
per	O
1000	O
inhabitants	O
aged	O
65	O
years	O
or	O
older	O
.	O

Regional	O
data	O
were	O
obtained	O
by	O
summing	O
the	O
municipal	O
data	O
for	O
each	O
of	O
the	O
variables	O
(	O
online	O
supplementary	O
table	O
1	O
)	O
.	O

Hospital	O
beds	O
were	O
categorised	O
into	O
general	O
acute	O
care	O
,	O
long	O
-	O
term	O
sanatorium	O
care	O
and	O
psychiatric	O
care	O
.	O

The	O
prefectural	O
government	O
allocates	O
healthcare	O
resources	O
based	O
on	O
health	O
regions	O
(	O
called	O
‘the	O
secondary	O
tier	O
of	O
medical	O
care’	O
)	O
,	O
which	O
usually	O
include	O
multiple	O
municipalities	O
.	O

During	O
the	O
study	O
period	O
,	O
the	O
number	O
of	O
municipalities	O
decreased	O
from	O
3252	O
to	O
1741	O
because	O
of	O
a	O
municipal	O
merger	O
.	O

There	O
were	O
347	O
health	O
regions	O
as	O
of	O
1	O
October	O
1996	O
,	O
and	O
the	O
boundaries	O
were	O
revised	O
according	O
to	O
the	O
municipal	O
merger	O
.	O

Therefore	O
,	O
each	O
variable	O
was	O
calculated	O
based	O
on	O
the	O
boundaries	O
of	O
the	O
municipalities	O
and	O
health	O
regions	O
as	O
of	O
the	O
latest	O
survey	O
date	O
following	O
death	O
.	O

The	O
distribution	O
of	O
places	O
of	O
death	O
was	O
calculated	O
per	O
month	O
from	O
October	O
1996	O
to	O
September	O
2016	O
.	O

Yearly	O
age	O
-	O
adjusted	O
ORs	O
of	O
places	O
of	O
death	O
were	O
calculated	O
using	O
multinomial	O
logistic	O
analysis	O
with	O
reference	O
to	O
the	O
first	O
year	O
(	O
October	O
1996	O
to	O
September	O
1997	O
)	O
.	O

Multivariate	O
multinomial	O
logistic	O
analysis	O
was	O
also	O
performed	O
using	O
the	O
place	O
of	O
dementia	O
-	O
related	O
death	O
as	O
the	O
dependent	O
variable	O
and	O
the	O
implementation	O
of	O
the	O
national	O
dementia	O
plan	O
as	O
the	O
independent	O
variable	O
.	O

Other	O
decedent	O
and	O
regional	O
characteristics	O
and	O
three	O
changes	O
in	O
health	O
and	O
social	O
care	O
systems	O
were	O
included	O
as	O
covariates	O
.	O

Because	O
data	O
were	O
collected	O
from	O
decedents	O
nested	O
within	O
health	O
regions	O
,	O
a	O
multilevel	O
model	O
was	O
developed	O
using	O
generalised	O
linear	O
and	O
latent	O
mixed	O
models	O
in	O
Stata	O
(	O
Stata	O
,	O
College	O
Station	O
,	O
Texas	O
,	O
USA	O
)	O
.	O

22	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Stata	O
SE	O
for	O
Windows	O
,	O
V	O
.	O
15	O
.	O
1	O
(	O
Stata	O
)	O
.	O

The	O
two	O
-	O
tailed	O
significance	O
level	O
was	O
set	O
at	O
.	O

05	O
.	O

Eligible	O
participants	O
were	O
first	O
year	O
undergraduate	O
nursing	O
students	O
completing	O
a	O
practical	O
unit	O
(	O
approximately	O
n	O
=	O
250	O
)	O
;	O
enrolled	O
in	O
the	O
internal	O
study	O
mode	O
;	O
studying	O
at	O
the	O
main	O
campus	O
;	O
and	O
aged	O
18	O
years	O
or	O
older	O
.	O

The	O
university	O
student	O
intranet	O
,	O
an	O
in	O
-	O
class	O
presentation	O
delivered	O
by	O
one	O
of	O
the	O
research	O
team	O
members	O
,	O
and	O
fliers	O
were	O
used	O
to	O
advertise	O
the	O
study	O
.	O

Participants	O
were	O
provided	O
the	O
MHFA	O
course	O
at	O
no	O
charge	O
(	O
control	O
group	O
participants	O
were	O
able	O
to	O
complete	O
the	O
online	O
course	O
after	O
the	O
T	O
3	O
data	O
collection	O
period	O
)	O
and	O
were	O
able	O
to	O
use	O
course	O
participant	O
for	O
a	O
portion	O
of	O
volunteer	O
hours	O
required	O
for	O
the	O
practical	O
unit	O
.	O

No	O
other	O
incentives	O
were	O
provided	O
.	O

As	O
the	O
literature	O
[	O
29	O
,	O
31	O
]	O
suggested	O
a	O
high	O
correlation	O
of	O
0	O
.	O
8	O
for	O
the	O
baseline	O
-	O
post	O
measurements	O
,	O
it	O
was	O
necessary	O
to	O
have	O
50	O
students	O
in	O
each	O
the	O
intervention	O
and	O
the	O
control	O
group	O
to	O
detect	O
5	O
%	O
level	O
of	O
significance	O
with	O
90	O
%	O
power	O
in	O
order	O
to	O
detect	O
medium	O
effect	O
sizes	O
in	O
the	O
outcome	O
variables	O
[	O
28	O
]	O
.	O

For	O
the	O
purpose	O
of	O
the	O
power	O
analysis	O
mental	O
health	O
knowledge	O
was	O
selected	O
as	O
the	O
key	O
outcome	O
variable	O
.	O

Based	O
on	O
the	O
findings	O
of	O
Jorm	O
et	O
al	O
.	O
[	O
29	O
]	O
a	O
conservative	O
1	O
.	O
5	O
difference	O
between	O
baseline	O
and	O
post	O
intervention	O
knowledge	O
scores	O
was	O
estimated	O
.	O

Participation	O
in	O
university	O
studies	O
has	O
been	O
found	O
to	O
be	O
low	O
[	O
32	O
,	O
33	O
]	O
.	O

In	O
order	O
to	O
ensure	O
an	O
adequate	O
sample	O
size	O
for	O
both	O
the	O
intervention	O
and	O
control	O
groups	O
at	O
the	O
completion	O
of	O
the	O
study	O
all	O
undergraduate	O
students	O
enrolled	O
in	O
the	O
designated	O
unit	O
(	O
approximately	O
n	O
=	O
250	O
)	O
were	O
invited	O
to	O
register	O
interest	O
.	O

Students	O
were	O
advised	O
of	O
potential	O
dates	O
for	O
the	O
MHFA	O
course	O
and	O
of	O
the	O
eligibility	O
criteria	O
hence	O
reducing	O
the	O
likelihood	O
of	O
recruiting	O
ineligible	O
participants	O
.	O

A	O
total	O
of	O
200	O
students	O
initially	O
expressed	O
interest	O
in	O
taking	O
part	O
in	O
the	O
study	O
.	O

The	O
recruitment	O
was	O
influenced	O
by	O
the	O
practicalities	O
of	O
working	O
within	O
a	O
large	O
university	O
which	O
required	O
delivering	O
the	O
intervention	O
during	O
semester	O
at	O
a	O
time	O
convenient	O
to	O
university	O
scheduling	O
and	O
clinical	O
rotations	O
for	O
students	O
(	O
see	O
Fig	O
.	O

1	O
)	O
.	O

Fig	O
.	O

1	O
Trial	O
schema	O

Trial	O
schema	O

After	O
online	O
registration	O
of	O
interest	O
(	O
n	O
=	O
200	O
)	O
students	O
who	O
successfully	O
completed	O
registration	O
and	O
who	O
were	O
eligible	O
(	O
n	O
=	O
181	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
intervention	O
or	O
control	O
group	O
using	O
computer	O
generated	O
automated	O
randomisation	O
and	O
were	O
notified	O
of	O
their	O
intervention	O
condition	O
(	O
intervention	O
n	O
=	O
92	O
;	O
control	O
n	O
=	O
89	O
)	O
.	O

The	O
computer	O
generated	O
randomisation	O
and	O
notification	O
was	O
implemented	O
by	O
a	O
Research	O
Assistant	O
Consent	O
was	O
obtained	O
from	O
all	O
participants	O
at	O
the	O
beginning	O
of	O
the	O
baseline	O
questionnaire	O
(	O
intervention	O
n	O
=	O
59	O
;	O
control	O
n	O
=	O
81	O
)	O
.	O

Due	O
to	O
logistics	O
involved	O
in	O
attending	O
the	O
face	O
-	O
to	O
-	O
face	O
course	O
and	O
the	O
need	O
to	O
provide	O
volunteer	O
hours	O
for	O
participation	O
in	O
the	O
intervention	O
in	O
a	O
specific	O
unit	O
during	O
the	O
university	O
semester	O
,	O
participants	O
were	O
aware	O
of	O
allocation	O
to	O
intervention	O
or	O
control	O
group	O
at	O
the	O
time	O
of	O
completion	O
of	O
the	O
baseline	O
questionnaire	O
.	O

Consent	O
was	O
obtained	O
from	O
all	O
participants	O
at	O
the	O
beginning	O
of	O
the	O
baseline	O
questionnaire	O
.	O

More	O
detail	O
regarding	O
the	O
research	O
methods	O
can	O
be	O
found	O
in	O
the	O
study	O
protocol	O
[	O
28	O
]	O
.	O

This	O
study	O
follows	O
the	O
CONSORT	O
Guidelines	O
[	O
34	O
]	O
for	O
the	O
design	O
and	O
implementation	O
of	O
randomised	O
controlled	O
trials	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Curtin	O
University	O
Human	O
Research	O
Ethics	O
Committee	O
(	O
SPH	O
-	O
74	O
-	O
2013	O
)	O
.	O

Intervention	O
group	O
participants	O
received	O
the	O
tailored	O
MHFA	O
course	O
for	O
nursing	O
students	O
[	O
28	O
]	O
.	O

The	O
training	O
included	O
:	O
signs	O
,	O
symptoms	O
and	O
risk	O
factors	O
for	O
common	O
mental	O
health	O
problems	O
,	O
including	O
depression	O
,	O
anxiety	O
,	O
substance	O
use	O
disorders	O
,	O
psychosis	O
and	O
eating	O
disorders	O
and	O
strategies	O
to	O
assist	O
someone	O
experiencing	O
a	O
number	O
of	O
mental	O
health	O
crises	O
[	O
28	O
]	O
.	O

Two	O
face	O
to	O
face	O
courses	O
were	O
delivered	O
during	O
semester	O
by	O
accredited	O
MHFA	O
facilitators	O
.	O

Each	O
course	O
comprised	O
two	O
-	O
6	O
.	O
5	O
h	O
sessions	O
run	O
over	O
two	O
days	O
.	O

All	O
participants	O
were	O
provided	O
the	O
MHFA	O
manual	O
[	O
35	O
]	O
,	O
standardised	O
MHFA	O
materials	O
including	O
specific	O
materials	O
designed	O
for	O
nurses	O
.	O

MHFA	O
is	O
a	O
standardised	O
course	O
[	O
36	O
,	O
37	O
]	O
,	O
facilitated	O
by	O
accredited	O
professionals	O
therefore	O
enhancing	O
the	O
fidelity	O
of	O
the	O
course	O
and	O
reducing	O
risk	O
of	O
Type	O
111	O
error	O
[	O
38	O
]	O
.	O

The	O
control	O
group	O
received	O
no	O
intervention	O
during	O
the	O
data	O
collection	O
period	O
(	O
baseline	O
:	O
T	O
1	O
to	O
two	O
months	O
post	O
intervention	O
:	O
T	O
3	O
)	O
.	O

Once	O
control	O
group	O
participants	O
completed	O
the	O
T	O
3	O
questionnaire	O
they	O
were	O
offered	O
the	O
online	O
version	O
of	O
the	O
MHFA	O
course	O
.	O

The	O
online	O
course	O
was	O
completed	O
by	O
64	O
study	O
participants	O
within	O
one	O
month	O
of	O
T	O
3	O
data	O
collection	O
.	O

Participants	O
completed	O
an	O
online	O
self	O
-	O
report	O
questionnaire	O
at	O
three	O
time	O
intervals	O
:	O
baseline	O
(	O
one	O
week	O
prior	O
to	O
the	O
intervention	O
)	O
:	O
(	O
T	O
1	O
)	O
,	O
post	O
intervention	O
(	O
T	O
2	O
)	O
,	O
and	O
two	O
months	O
post	O
intervention	O
follow	O
up	O
(	O
T	O
3	O
)	O
.	O

Demographics	O
questions	O
were	O
excluded	O
in	O
the	O
post	O
intervention	O
and	O
follow	O
up	O
questionnaires	O
.	O

Two	O
months	O
post	O
intervention	O
was	O
selected	O
for	O
follow	O
up	O
data	O
collection	O
to	O
work	O
within	O
the	O
constraints	O
of	O
university	O
semesters	O
and	O
clinical	O
rotations	O
.	O

Four	O
reminder	O
emails	O
were	O
sent	O
to	O
non	O
-	O
completers	O
over	O
a	O
two	O
week	O
period	O
(	O
see	O
Fig	O
.	O

1	O
)	O
.	O

Data	O
were	O
collected	O
to	O
measure	O
demographics	O
,	O
mental	O
health	O
knowledge	O
,	O
recognition	O
of	O
depression	O
,	O
confidence	O
in	O
helping	O
,	O
mental	O
health	O
first	O
aid	O
intentions	O
and	O
stigmatising	O
attitudes	O
including	O
social	O
distance	O
.	O

Mental	O
health	O
knowledge	O
was	O
assessed	O
using	O
20	O
statements	O
for	O
which	O
students	O
were	O
asked	O
to	O
respond	O
‘true’	O
or	O
‘false’	O
.	O

These	O
questions	O
were	O
adapted	O
from	O
previously	O
validated	O
MHFA	O
knowledge	O
statements	O
[	O
29	O
]	O
.	O

A	O
score	O
(	O
0–20	O
)	O
was	O
computed	O
with	O
a	O
higher	O
score	O
indicating	O
better	O
knowledge	O
.	O

The	O
questionnaire	O
used	O
the	O
vignette	O
described	O
below	O
to	O
guide	O
questions	O
associated	O
with	O
recognition	O
of	O
mental	O
health	O
problems	O
,	O
confidence	O
assisting	O
with	O
mental	O
health	O
,	O
social	O
distance	O
,	O
and	O
personal	O
and	O
perceived	O
stigma	O
.	O

The	O
vignette	O
was	O
adapted	O
from	O
previous	O
questionnaires	O
[	O
26	O
,	O
29	O
]	O
and	O
meets	O
the	O
diagnostic	O
criteria	O
set	O
by	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
[	O
39	O
]	O
and	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
for	O
major	B-phenotype
depression	I-phenotype
[	O
40	O
]	O
and	O
is	O
described	O
below	O
:	O

John	O
is	O
a	O
21	O
-	O
year	O
-	O
old	O
student	O
who	O
has	O
been	O
feeling	O
unusually	O
sad	O
and	O
miserable	O
for	O
the	O
last	O
few	O
weeks	O
.	O

He	O
is	O
tired	O
all	O
the	O
time	O
and	O
has	O
trouble	O
sleeping	O
at	O
night	O
.	O

John	O
doesn’t	O
feel	O
like	O
eating	O
and	O
has	O
lost	O
weight	O
.	O

He	O
can’t	O
keep	O
his	O
mind	O
on	O
his	O
studies	O
and	O
his	O
marks	O
have	O
dropped	O
.	O

He	O
puts	O
off	O
making	O
any	O
decisions	O
and	O
even	O
day	O
-	O
to	O
-	O
day	O
tasks	O
seem	O
too	O
much	O
for	O
him	O
.	O

His	O
parents	O
and	O
friends	O
are	O
very	O
concerned	O
about	O
him	O
.	O

John	O
feels	O
he	O
will	O
never	O
be	O
happy	O
again	O
and	O
believes	O
his	O
family	O
would	O
be	O
better	O
off	O
without	O
him	O
.	O

John	O
has	O
been	O
so	O
desperate	O
,	O
he	O
has	O
been	O
thinking	O
of	O
ways	O
to	O
end	O
his	O
life	O
.	O

John	O
is	O
a	O
21	O
-	O
year	O
-	O
old	O
student	O
who	O
has	O
been	O
feeling	O
unusually	O
sad	O
and	O
miserable	O
for	O
the	O
last	O
few	O
weeks	O
.	O

He	O
is	O
tired	O
all	O
the	O
time	O
and	O
has	O
trouble	O
sleeping	O
at	O
night	O
.	O

John	O
doesn’t	O
feel	O
like	O
eating	O
and	O
has	O
lost	O
weight	O
.	O

He	O
can’t	O
keep	O
his	O
mind	O
on	O
his	O
studies	O
and	O
his	O
marks	O
have	O
dropped	O
.	O

He	O
puts	O
off	O
making	O
any	O
decisions	O
and	O
even	O
day	O
-	O
to	O
-	O
day	O
tasks	O
seem	O
too	O
much	O
for	O
him	O
.	O

His	O
parents	O
and	O
friends	O
are	O
very	O
concerned	O
about	O
him	O
.	O

John	O
feels	O
he	O
will	O
never	O
be	O
happy	O
again	O
and	O
believes	O
his	O
family	O
would	O
be	O
better	O
off	O
without	O
him	O
.	O

John	O
has	O
been	O
so	O
desperate	O
,	O
he	O
has	O
been	O
thinking	O
of	O
ways	O
to	O
end	O
his	O
life	O
.	O

Similar	O
to	O
other	O
studies	O
[	O
27	O
]	O
to	O
measure	O
recognition	O
of	O
depression	O
participants	O
were	O
provided	O
the	O
vignette	O
then	O
asked	O
an	O
open	O
-	O
ended	O
question	O
“	O
what	O
,	O
if	O
anything	O
is	O
wrong	O
with	O
John	O
?	O
”	O
Responses	O
of	O
‘depressed’	O
,	O
‘depression’	O
,	O
‘affective	O
disorder’	O
or	O
‘mood	O
disorder’	O
signified	O
a	O
correct	O
identification	O
of	O
John’s	O
problem	O
.	O

Mental	O
health	O
first	O
aid	O
intentions	O
was	O
measured	O
by	O
an	O
open	O
-	O
ended	O
question	O
which	O
asked	O
participants	O
to	O
:	O
Imagine	O
John	O
is	O
someone	O
you	O
have	O
known	O
for	O
a	O
long	O
time	O
and	O
care	O
about	O
.	O

You	O
want	O
to	O
help	O
him	O
.	O

What	O
would	O
you	O
do	O
?	O
This	O
was	O
scored	O
by	O
a	O
research	O
assistant	O
then	O
ratified	O
by	O
three	O
researchers	O
using	O
the	O
scoring	O
system	O
described	O
by	O
Yap	O
and	O
Jorm	O
[	O
41	O
]	O
.	O

This	O
system	O
is	O
based	O
on	O
the	O
ALGEE	O
action	O
plan	O
which	O
is	O
a	O
key	O
focus	O
of	O
the	O
MHFA	O
course	O
[	O
35	O
]	O
.	O

Responses	O
may	O
receive	O
0–2	O
points	O
per	O
component	O
of	O
the	O
ALGEE	O
(	O
Approach	O
the	O
person	O
;	O
Assess	O
and	O
Assist	O
with	O
any	O
crisis	O
;	O
Listen	O
non	O
-	O
judgementally	O
;	O
Give	O
support	O
and	O
information	O
;	O
Encourage	O
appropriate	O
professional	O
help	O
;	O
and	O
encourage	O
other	O
supports	O
)	O
(	O
Total	O
score	O
0–12	O
)	O
[	O
42	O
]	O
.	O

To	O
assess	O
confidence	O
to	O
assist	O
someone	O
with	O
a	O
mental	O
health	O
problem	O
,	O
participants	O
were	O
asked	O
about	O
their	O
confidence	O
in	O
their	O
ability	O
to	O
help	O
John	O
.	O

Responses	O
included	O
a	O
five	O
point	O
Likert	O
scale	O
ranging	O
from	O
:	O
1	O
(	O
don’t	O
know	O
)	O
to	O
5	O
(	O
very	O
confident	O
)	O
(	O
Score	O
0–5	O
)	O
.	O

MHFA	O
and	O
other	O
community	O
-	O
based	O
studies	O
have	O
consistently	O
used	O
the	O
Depression	O
Stigma	O
Scale	O
(	O
DSS	O
)	O
[	O
43	O
]	O
and	O
the	O
Social	O
Distance	O
Scale	O
(	O
SDS	O
)	O
[	O
44	O
]	O
to	O
measure	O
the	O
constructs	O
of	O
stigmatising	O
attitudes	O
.	O

While	O
the	O
DSS	O
measures	O
beliefs	O
about	O
people	O
with	O
mental	O
health	O
illnesses	O
,	O
the	O
SDS	O
measures	O
intended	O
avoidance	O
behaviour	O
[	O
45	O
]	O
.	O

As	O
for	O
other	O
studies	O
[	O
27	O
,	O
45	O
,	O
46	O
]	O
,	O
due	O
to	O
the	O
complexity	O
of	O
measuring	O
these	O
constructs	O
this	O
study	O
measured	O
personal	O
and	O
perceived	O
stigma	O
and	O
social	O
distance	O
.	O

Personal	O
and	O
perceived	O
stigma	O
were	O
measured	O
using	O
a	O
seven	O
item	O
scale	O
which	O
was	O
adapted	O
from	O
the	O
validated	O
Depression	O
Stigma	O
Scale	O
(	O
DSS	O
)	O
[	O
43	O
]	O
.	O

Respondents	O
were	O
asked	O
two	O
sets	O
of	O
questions	O
,	O
the	O
first	O
about	O
their	O
personal	O
feelings	O
towards	O
John	O
and	O
the	O
second	O
about	O
their	O
perception	O
of	O
others’	O
feelings	O
towards	O
John	O
.	O

Consistent	O
with	O
other	O
MHFA	O
studies	O
[	O
46	O
]	O
some	O
questions	O
were	O
excluded	O
,	O
for	O
example	O
,	O
voting	O
for	O
John	O
as	O
a	O
politician	O
,	O
and	O
the	O
wording	O
was	O
modified	O
.	O

Personal	O
stigma	O
statements	O
included	O
:	O
‘	O
John	O
could	O
make	O
himself	O
better	O
if	O
he	O
wanted	O
,	O
’	O
‘	O
John’s	O
problem	O
is	O
a	O
sign	O
of	O
personal	O
weakness	O
,	O
’	O
‘	O
John’s	O
problem	O
is	O
not	O
a	O
real	O
medical	O
illness	O
,	O
’	O
‘	O
John	O
is	O
dangerous	O
,	O
’	O
‘	O
It	O
is	O
best	O
to	O
avoid	O
John	O
so	O
that	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself	O
,	O
’	O
‘	O
John’s	O
problem	O
makes	O
him	O
unpredictable	O
,	O
’	O
and	O
‘	O
You	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
John’s’	O
.	O

Responses	O
were	O
scored	O
on	O
a	O
five	O
point	O
Likert	O
scale	O
from	O
“strongly	O
agree”	O
to	O
“strongly	O
disagree”	O
.	O

The	O
perceived	O
stigma	O
questions	O
used	O
the	O
same	O
questions	O
,	O
response	O
items	O
and	O
scoring	O
method	O
however	O
participants	O
were	O
asked	O
to	O
consider	O
‘what	O
you	O
think	O
most	O
other	O
people	O
believe’	O
.	O

Personal	O
and	O
perceived	O
stigma	O
scores	O
were	O
computed	O
and	O
divided	O
by	O
seven	O
with	O
higher	O
scores	O
representing	O
lower	O
stigmatising	O
attitudes	O
.	O

Social	O
distance	O
was	O
measured	O
by	O
a	O
scale	O
adapted	O
from	O
the	O
previously	O
validated	O
Social	O
Distance	O
Scale	O
(	O
SDS	O
)	O
[	O
44	O
]	O
and	O
used	O
in	O
other	O
MHFA	O
studies	O
[	O
27	O
,	O
46	O
]	O
.	O

Participants	O
were	O
asked	O
to	O
respond	O
to	O
five	O
statements	O
asking	O
how	O
they	O
would	O
feel	O
spending	O
time	O
with	O
John	O
.	O

A	O
five	O
point	O
Likert	O
scale	O
was	O
used	O
with	O
responses	O
ranging	O
from	O
“definitely	O
not”	O
through	O
to	O
“definitely”	O
.	O

Students	O
were	O
asked	O
if	O
they	O
would	O
be	O
happy	O
to	O
‘	O
go	O
out	O
with	O
John	O
on	O
the	O
weekend	O
’	O
,	O
‘	O
to	O
work	O
on	O
a	O
project	O
with	O
John	O
,	O
’	O
‘	O
to	O
invite	O
John	O
around	O
to	O
your	O
house	O
,	O
’	O
‘	O
to	O
go	O
to	O
John’s	O
house	O
,	O
’	O
and	O
to	O
‘	O
develop	O
a	O
close	O
friendship	O
with	O
John’	O
.	O

Scores	O
were	O
computed	O
then	O
divided	O
by	O
5	O
to	O
derive	O
a	O
mean	O
[	O
44	O
]	O
with	O
higher	O
scores	O
representing	O
less	O
social	O
distance	O
and	O
lower	O
stigmatising	O
attitudes	O
[	O
47	O
]	O
.	O

A	O
Principal	O
Component	O
Analysis	O
with	O
varimax	O
rotation	O
was	O
employed	O
to	O
reduce	O
stigma	O
and	O
social	O
distance	O
items	O
.	O

Previous	O
studies	O
have	O
employed	O
Principal	O
Component	O
Analysis	O
[	O
29	O
]	O
and	O
Exploratory	O
Structural	O
Equational	O
Modelling	O
[	O
45	O
]	O
to	O
reduce	O
stigma	O
and	O
social	O
distance	O
items	O
.	O

While	O
components	O
are	O
similar	O
across	O
studies	O
there	O
is	O
some	O
variation	O
.	O

For	O
example	O
,	O
the	O
study	O
by	O
Jorm	O
and	O
Wright	O
[	O
46	O
]	O
included	O
a	O
‘social	O
distance’	O
,	O
‘stigma	O
perceived	O
in	O
others’	O
,	O
‘dangerous	O
and	O
unpredictable’	O
and	O
a	O
‘weak	O
-	O
not	O
sick’	O
component	O
.	O

A	O
fifth	O
component	O
‘reluctance	O
to	O
disclose’	O
which	O
included	O
the	O
single	O
item	O
‘you	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
John’s’	O
was	O
also	O
included	O
.	O

A	O
study	O
by	O
Yap	O
et	O
al	O
.	O
[	O
45	O
]	O
also	O
include	O
a	O
social	O
distance	O
component	O
,	O
in	O
addition	O
to	O
‘personal	O
weak	O
not	O
sick’	O
‘personal	O
dangerous	O
/	O
unpredictable’	O
,	O
perceived	O
weak	O
not	O
sick’	O
and	O
perceived	O
weak	O
not	O
sick’	O
.	O

Measuring	O
personal	O
and	O
perceived	O
stigma	O
separately	O
was	O
seen	O
to	O
be	O
important	O
for	O
community	O
interventions	O
[	O
45	O
]	O
.	O

Yap	O
et	O
al	O
.	O
[	O
45	O
]	O
found	O
the	O
‘reluctance	O
to	O
disclose’	O
item	O
to	O
load	O
moderately	O
on	O
to	O
the	O
personal	O
and	O
the	O
perceived	O
‘dangerous	O
/	O
unpredictable’	O
factors	O
for	O
the	O
general	O
community	O
,	O
but	O
not	O
for	O
the	O
youth	O
survey	O
.	O

The	O
personal	O
and	O
perceived	O
items	O
about	O
‘it	O
is	O
best	O
to	O
avoid	O
people	O
like	O
John	O
so	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself’	O
to	O
load	O
only	O
moderately	O
onto	O
both	O
the	O
‘weak	O
not	O
sick’	O
and	O
the	O
‘dangerous	O
/	O
unpredictable’	O
factors	O
[	O
45	O
]	O
.	O

Others	O
have	O
also	O
found	O
weak	O
but	O
moderate	O
loadings	O
for	O
this	O
variable	O
onto	O
both	O
of	O
these	O
factors	O
[	O
48	O
]	O
.	O

This	O
study	O
found	O
a	O
weak	O
moderate	O
loading	O
for	O
the	O
perceived	O
but	O
not	O
for	O
the	O
personal	O
stigma	O
factors	O
.	O

In	O
the	O
initial	O
analysis	O
the	O
addition	O
of	O
‘it	O
is	O
best	O
to	O
avoid	O
people	O
like	O
John	O
so	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself’	O
to	O
the	O
‘perceived	O
dangerous	O
-	O
not	O
-	O
weak’	O
factor	O
did	O
not	O
alter	O
the	O
current	O
findings	O
for	O
this	O
factor	O
.	O

Reavley	O
et	O
al	O
.	O
[	O
48	O
]	O
found	O
‘	O
you	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
John’s’	O
to	O
load	O
moderate	O
onto	O
dangerous	O
/	O
unpredictable	O
.	O

In	O
contrast	O
our	O
study	O
found	O
a	O
moderately	O
significant	O
loading	O
onto	O
‘perceived	O
weak	O
not	O
sick’	O
but	O
no	O
loading	O
onto	O
the	O
personal	O
factor	O
.	O

While	O
there	O
is	O
some	O
differentiation	O
between	O
some	O
of	O
the	O
variables	O
associated	O
with	O
the	O
personal	O
and	O
perceived	O
stigma	O
items	O
,	O
the	O
social	O
distance	O
items	O
appear	O
to	O
consistently	O
load	O
relatively	O
uniformly	O
onto	O
a	O
single	O
factor	O
across	O
studies	O
[	O
45	O
,	O
46	O
]	O
.	O

Based	O
on	O
the	O
findings	O
of	O
others	O
[	O
45	O
]	O
,	O
and	O
of	O
the	O
principal	O
component	O
analysis	O
this	O
study	O
measured	O
a	O
social	O
distance	O
score	O
,	O
a	O
total	O
personal	O
stigma	O
and	O
total	O
perceived	O
stigma	O
score	O
in	O
addition	O
to	O
‘personal	O
weak	O
-	O
not	O
-	O
sick’	O
,	O
‘personal	O
dangerous	O
/	O
unpredictable’	O
,	O
‘perceived	O
weak	O
-	O
not	O
-	O
sick’	O
and	O
‘perceived	O
dangerous	O
/	O
unpredictable’	O
scores	O
.	O

‘Personal	O
weak	O
-	O
not	O
-	O
sick’	O
included	O
“	O
John	O
could	O
make	O
himself	O
better	O
if	O
he	O
wanted	O
‘	O
,	O
‘	O
John’s	O
problem	O
is	O
a	O
sign	O
of	O
personal	O
weakness	O
’	O
,	O
‘	O
John’s	O
problem	O
is	O
not	O
a	O
real	O
medical	O
illn	O
ess’	O
.	O

‘Personal	O
dangerous	O
/	O
unpredictable’	O
included	O
‘	O
John	O
is	O
dangerous	O
’	O
and	O
‘	O
John’s	O
problem	O
makes	O
him	O
unpredictabl	O
e’	O
.	O

‘Perceived	O
weak	O
-	O
not	O
-	O
sick’	O
and	O
‘dangerous	O
/	O
unpredictable’	O
used	O
the	O
same	O
items	O
presented	O
in	O
relation	O
to	O
what	O
the	O
participant	O
felt	O
most	O
other	O
people	O
believe	O
.	O

Social	O
distance	O
items	O
loaded	O
consistently	O
as	O
described	O
above	O
.	O

The	O
perceived	O
stigma	O
items	O
‘	O
you	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
John’s’	O
loaded	O
moderately	O
onto	O
‘perceived	O
weak	O
not	O
sick’	O
and	O
‘	O
it	O
is	O
best	O
to	O
avoid	O
John	O
so	O
that	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself	O
’	O
loaded	O
‘moderately	O
onto	O
perceived	O
dangerous	O
/	O
unpredictable’	O
.	O

However	O
given	O
the	O
very	O
moderate	O
loading	O
,	O
and	O
to	O
ensure	O
consistency	O
with	O
other	O
studies	O
[	O
27	O
]	O
these	O
items	O
were	O
not	O
included	O
in	O
the	O
final	O
analysis	O
of	O
factors	O
.	O

Table	O
1	O
describes	O
the	O
Principal	O
Component	O
Analysis	O
.	O

Table	O
1	O
Principal	O
component	O
factor	O
analysis	O
Social	O
distance	O
Perceived	O
stigma	O
(	O
weak	O
not	O
sick	O
)	O
Perceived	O
dangerous	O
/	O
unpredictable	O
Personal	O
weak	O
not	O
sick	O
Personal	O
dangerous	O
not	O
sick	O
No	O
factor	O
Would	O
you	O
be	O
happy	O
to	O
:	O
Go	O
to	O
Johns	O
house	O
.	O
852	O
Go	O
out	O
with	O
John	O
on	O
the	O
weekend	O
.	O
828	O
Develop	O
a	O
close	O
friendship	O
with	O
John	O
.	O
819	O
Invite	O
John	O
around	O
to	O
your	O
house	O
.	O
805	O
Work	O
on	O
a	O
project	O
with	O
John	O
.	O
642	O
.	O
.	O
tell	O
us	O
about	O
what	O
you	O
think	O
MOST	O
OTHER	O
PEOPLE	O
believe	O
Johns	O
problem	O
is	O
Not	O
a	O
real	O
medical	O
illness	O
.	O
784	O
Johns	O
problem	O

is	O
A	O
sign	O
of	O
personal	O
weakness	O
.	O
774	O
John	O
could	O
make	O
himself	O
better	O
if	O
he	O
wanted	O
.	O
797	O
You	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
Johns	O
.	O
522	O
.	O
241	O
John	O
is	O
dangerous	O
.	O
746	O
John’s	O
problem	O
makes	O
him	O
unpredictable	O
.	O
748	O
It	O
is	O
best	O
to	O
avoid	O
John	O
so	O
that	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself	O
.	O
464	O
.	O
553	O
Indicate	O
how	O
Strongly	O
YOU	O
PERSONALLY	O
agree	O
/	O
disagree	O
with	O
the	O
statement	O
Johns	O
problem	O
is	O
Not	O
a	O
real	O
medical	O
illness	O
.	O
830	O
Johns	O
problem	O
is	O
A	O
sign	O
of	O
personal	O
weakness	O
.	O
838	O
John	O
could	O
make	O
himself	O
better	O

if	O
he	O
wanted	O
.	O
609	O
You	O
would	O
not	O
tell	O
anyone	O
if	O
you	O
had	O
a	O
problem	O
like	O
Johns	O
.	O
302	O
.	O
642	O
John’s	O
problem	O
makes	O
him	O
unpredictable	O
.	O
802	O
John	O
is	O
dangerous	O
.	O
754	O
It	O
is	O
best	O
to	O
avoid	O
John	O
so	O
that	O
you	O
don’t	O
develop	O
this	O
problem	O
yourself	O
.	O
807	O

Principal	O
component	O
factor	O
analysis	O

Chi	O
square	O
analysis	O
was	O
conducted	O
to	O
test	O
associations	O
of	O
categorical	O
variables	O
between	O
the	O
intervention	O
and	O
control	O
group	O
.	O

Intention	O
to	O
treat	O
analyses	O
were	O
performed	O
.	O

Multiple	O
imputation	O
was	O
used	O
to	O
impute	O
variables	O
for	O
participants	O
who	O
completed	O
baseline	O
questionnaires	O
but	O
did	O
not	O
complete	O
T	O
2	O
and	O
/	O
or	O
T	O
3	O
questionnaire	O
.	O

Missing	O
values	O
were	O
computed	O
using	O
baseline	O
values	O
.	O

Repeated	O
measures	O
ANOVA	O
was	O
employed	O
to	O
determine	O
if	O
time	O
(	O
T	O
1	O
,	O
T	O
2	O
and	O
T	O
3	O
)	O
and	O
group	O
(	O
intervention	O
and	O
control	O
)	O
had	O
a	O
significant	O
effect	O
on	O
the	O
outcome	O
variables	O
[	O
38	O
]	O
.	O

Between	O
and	O
within	O
subject	O
analyses	O
were	O
conducted	O
.	O

Results	O
are	O
reported	O
considering	O
the	O
interaction	O
between	O
time	O
and	O
group	O
.	O

Partial	O
eta	O
squared	O
was	O
used	O
to	O
determine	O
effect	O
size	O
.	O

Data	O
were	O
analysed	O
using	O
SPSS	O
Version	O
22	O
.	O

Significance	O
level	O
was	O
set	O
at	O
5	O
%	O
.	O

The	O
objectives	O
were	O
addressed	O
by	O
performing	O
quantitative	O
laboratory	O
analysis	O
(	O
immunoassays	O
)	O
and	O
qualitative	O
data	O
analysis	O
(	O
questionnaires	O
,	O
face	O
-	O
to	O
-	O
face	O
interviews	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
opioid	O
dependent	O
persons	O
at	O
a	O
withdrawal	O
centre	O
at	O
Amstetten	O
/	O
Mauer	O
(	O
Austria	O
)	O
who	O
had	O
been	O
undergoing	O
an	O
OST	O
program	O
for	O
2	O
weeks	O
.	O

Samples	O
from	O
IDU	O
were	O
taken	O
prior	O
(	O
baseline	O
)	O
and	O
1	O
hour	O
after	O
substitution	O
treatment	O
.	O

The	O
first	O
blood	O
sampling	O
was	O
conducted	O
10	O
minutes	O
before	O
morning	O
administration	O
.	O

Subsequent	O
sampling	O
proceeded	O
1	O
hour	O
after	O
oral	O
intake	O
of	O
substitution	O
substance	O
.	O

Blood	O
analysis	O
served	O
in	O
the	O
determination	O
of	O
baseline	O
allergic	O
biomarkers	O
,	O
such	O
as	O
histamine	O
,	O
diamine	O
oxidase	O
(	O
DAO	O
)	O
,	O
tryptase	O
and	O
lipoprotein	O
associated	O
phospholipase	O
A	O
2	O
(	O
LpPLA	O
2	O
)	O
.	O

Serum	O
and	O
plasma	O
samples	O
were	O
collected	O
into	O
plain	O
and	O
EDTA	O
vacutainers	O
,	O
using	O
VACUETTE®	O
products	O
manufactured	O
by	O
Greiner	O
Bio	O
-	O
One	O
.	O

The	O
tubes	O
were	O
transported	O
in	O
dry	O
ice	O
and	O
centrifuged	O
within	O
30	O
minutes	O
after	O
sampling	O
.	O

After	O
centrifugation	O
at	O
3000U	O
/	O
min	O
for	O
10	O
minutes	O
,	O
samples	O
were	O
immediately	O
stored	O
at	O
-	O
20°C	O
until	O
analysis	O
.	O

Laboratory	O
analyses	O
were	O
performed	O
at	O
the	O
Floridsdorfer	O
Allergy	O
Centre	O
(	O
FAZ	O
)	O
,	O
Vienna	O
(	O
Austria	O
)	O
.	O

Supplementary	O
,	O
the	O
clinical	O
picture	O
of	O
long	O
-	O
term	O
IDU	O
before	O
and	O
after	O
substitution	O
was	O
documented	O
.	O

Therefore	O
face	O
-	O
to	O
-	O
face	O
interviews	O
and	O
questionnaire	O
procedures	O
were	O
used	O
.	O

A	O
structured	O
datasheet	O
was	O
used	O
to	O
record	O
the	O
following	O
factors	O
:	O
demographics	O
,	O
characteristics	O
of	O
allergen	O
/	O
trigger	O
exposure	O
(	O
kind	O
of	O
opioid	O
,	O
daily	O
dosage	O
,	O
mean	O
duration	O
of	O
regular	O
abuse	O
,	O
etc	O
.	O
)	O
,	O
pre	O
-	O
existent	O
allergic	O
conditions	O
and	O
/	O
or	O
mastocytosis	O
as	O
well	O
as	O
self	O
-	O
reported	O
allergic	O
reactions	O
and	O
side	O
-	O
effects	O
shown	O
during	O
former	O
IV	O
drug	O
consumption	O
.	O

After	O
substitution	O
,	O
a	O
structured	O
datasheet	O
was	O
filled	O
in	O
to	O
record	O
treatments	O
,	O
side	O
effects	O
and	O
individual	O
reaction	O
features	O
after	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
180	O
minutes	O
.	O

All	O
participants	O
gave	O
their	O
written	O
informed	O
consent	O
.	O

Approval	O
was	O
also	O
obtained	O
from	O
relevant	O
federal	O
authorities	O
and	O
the	O
ethics	O
committee	O
.	O

At	O
the	O
withdrawal	O
centre	O
in	O
Amstetten	O
/	O
Mauer	O
,	O
78	O
drug	O
addicts	O
(	O
58	O
male	O
/	O
20	O
female	O
)	O
were	O
tested	O
from	O
a	O
patient	O
population	O
.	O

The	O
key	O
inclusion	O
criteria	O
for	O
OST	O
were	O
a	O
main	O
diagnosis	O
of	O
opiate	B-phenotype
dependence	I-phenotype
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system

[	O
25	O
]	O
as	O
well	O
as	O
suitable	O
venous	O
conditions	O
for	O
blood	O
sampling	O
.	O

Patients’	O
age	O
,	O
sex	O
,	O
or	O
ethnic	O
background	O
were	O
not	O
considered	O
as	O
recruitment	O
criteria	O
for	O
this	O
study	O
.	O

The	O
presence	O
of	O
underlying	O
allergic	O
disease	O
was	O
reported	O
in	O
22	O
of	O
78	O
cases	O
,	O
such	O
as	O
medication	O
(	O
n	O
=	O
11	O
)	O
,	O
grass	O
pollen	O
(	O
n	O
=	O
8	O
)	O
,	O
food	O
(	O
n	O
=	O
3	O
)	O
and	O
insect	O
sting	O
(	O
n	O
=	O
2	O
)	O
allergies	O
.	O

Further	O
clinical	O
risk	O
factors	O
for	O
anaphylaxis	O
,	O
comprising	O
comorbidities	O
such	O
as	O
asthma	O
,	O
cardiovascular	O
disease	O
or	O
mastocytosis	O
,	O
were	O
not	O
recognized	O
.	O

In	O
the	O
final	O
analysis	O
,	O
56	O
IDU	O
without	O
underlying	O
allergic	O
disease	O
,	O
were	O
included	O
in	O
the	O
study	O
population	O
.	O

Most	O
subjects	O
had	O
a	O
significant	O
history	O
of	O
regular	O
opioids	O
abuse	O
,	O
ranging	O
from	O
2	O
to	O
25	O
years	O
.	O

The	O
mean	O
duration	O
of	O
regular	O
heroin	O
abuse	O
was	O
7	O
±	O
5	O
.	O
3	O
years	O
.	O

All	O
participants	O
at	O
the	O
withdrawal	O
centre	O
in	O
Amstetten	O
/	O
Mauer	O
were	O
treated	O
with	O
Substitol®retard	O
.	O

In	O
Austria	O
,	O
Substitol	O
found	O
its	O
role	O
in	O
OST	O
programs	O
to	O
treat	O
heroin	O
addiction	O
as	O
a	O
controlled	O
,	O
slow	O
releasing	O
oral	O
medicine	O
.	O

It	O
is	O
a	O
semi	O
-	O
synthetic	O
,	O
highly	O
potent	O
and	O
long	O
acting	O
opioid	O
analgesic	O

[	O
26	O
]	O
.	O

Single	O
substance	O
doses	O
varied	O
from	O
120	O
to	O
1000	O
mg	O
(	O
482	O
±	O
220	O
mg	O
)	O
,	O
depending	O
on	O
type	O
of	O
substance	O
,	O
duration	O
of	O
intake	O
and	O
daily	O
dosage	O
.	O

For	O
the	O
comparison	O
group	O
volunteers	O
(	O
n	O
=	O
103	O
)	O
were	O
recruited	O
during	O
the	O
same	O
period	O
as	O
the	O
drug	O
addicts	O
between	O
October	O
2011	O
and	O
December	O
2012	O
.	O

38	O
male	O
and	O
65	O
female	O
persons	O
were	O
included	O
,	O
ages	O
varied	O
from	O
18	O
to	O
61	O
years	O
(	O
age	O
31	O
.	O
4	O
±	O
11	O
.	O
8	O
)	O
.	O

Subjects	O
with	O
known	O
allergic	O
diseases	O
were	O
excluded	O
.	O

Histamine	O
,	O
a	O
biogenic	O
amine	O
,	O
is	O
the	O
most	O
important	O
inflammatory	O
mediator	O
released	O
by	O
degranulation	O
of	O
mast	O
cells	O
and	O
basophils	O
during	O
an	O
allergic	O
reaction	O

[	O
27	O
,	O
28	O
]	O
.	O

Many	O
opioids	O
are	O
known	O
to	O
be	O
potent	O
histamine	O
releasers	O

[	O
29	O
,	O
30	O
]	O
.	O

Therefore	O
it	O
is	O
of	O
high	O
interest	O
to	O
evaluate	O
baseline	O
histamine	O
concentrations	O
in	O
chronic	O
IDUs	O
.	O

Histamine	O
levels	O
were	O
determined	O
by	O
radioimmunoassay	O
(	O
Immunotec	O
,	O
France	O
)	O

[	O
31	O
]	O
.	O

In	O
brief	O
,	O
blood	O
was	O
collected	O
in	O
a	O
chilled	O
tube	O
containing	O
EDTA	O
and	O
immediately	O
cooled	O
on	O
ice	O
.	O

Samples	O
were	O
centrifuged	O
for	O
10	O
minutes	O
at	O
900	O
g	O
/	O
4°C	O
.	O

Acylation	O
buffer	O
and	O
calibrator	O
were	O
then	O
added	O
and	O
immediately	O
vortexed	O
.	O

Results	O
were	O
obtained	O
from	O
the	O
standard	O
curve	O
by	O
interpolation	O
.	O

Normal	O
histamine	O
levels	O
in	O
living	O
subjects	O
are	O
<	O
0	O
.	O
3	O
ng	O
/	O
ml	O

[	O
32	O
]	O
.	O

DAO	O
is	O
a	O
major	O
histamine	O
-	O
degrading	O
enzyme	O
which	O
is	O
found	O
in	O
various	O
tissues	O
,	O
but	O
is	O
primarily	O
active	O
in	O
the	O
intestinal	O
mucosa	O

[	O
33	O
]	O
.	O

DAO	O
activity	O
in	O
serum	O
samples	O
of	O
healthy	O
individuals	O
normally	O
ranged	O
from	O
10	O
to	O
30U	O
/	O
ml	O
.	O

Lower	O
DAO	O
activity	O
was	O
described	O
as	O
a	O
potential	O
indicator	O
for	O
intestinal	O
mucosa	O
damage	O
in	O
inflammatory	O
and	O
neoplastic	O
disease	O

[	O
34	O
]	O
as	O
well	O
as	O
in	O
cases	O
of	O
fatal	O
anaphylaxis	O

[	O
35	O
]	O
.	O

The	O
activity	O
of	O
DAO	O
was	O
determined	O
by	O
quantitating	O
the	O
reaction	O
product	O
(	O
Sciotec	O
Diagnostics	O
Tulln	O
,	O
Austria	O
)	O

[	O
36	O
]	O
.	O

Radiolabelled	O
putrescine	O
-	O
dihydrochloride	O
was	O
used	O
as	O
a	O
substrate	O
.	O

The	O
result	O
Δ	O
1	O
pyrroline	O
,	O
containing	O
the	O
radiolabel	O
,	O
was	O
extracted	O
selectively	O
from	O
the	O
matrix	O
by	O
a	O
liquid	O
extraction	O
step	O
.	O

A	O
non	O
-	O
toxic	O
,	O
chlorine	O
-	O
free	O
solvent	O
with	O
high	O
capacity	O
was	O
used	O
for	O
extraction	O
.	O

Finally	O
scintillation	O
fluid	O
was	O
added	O
to	O
the	O
organic	O
phase	O
containing	O
the	O
radiolabelled	O
Δ	O
1	O
-	O
pyrroline	O
and	O
radioactivity	O
was	O
determined	O
in	O
a	O
beta	O
-	O
counter	O
.	O

The	O
signal	O
was	O
directly	O
proportional	O
to	O
the	O
activity	O
of	O
DAO	O
in	O
the	O
sample	O
.	O

Results	O
<	O
11U	O
/	O
ml	O
are	O
judged	O
to	O
be	O
reduced	O
.	O

Mast	O
cell	O
tryptase	O
(	O
MCT	O
)	O
is	O
a	O
tetrameric	O
neutral	O
serine	O
protease	O
which	O
is	O
nearly	O
exclusive	O
to	O
mast	O
cells	O

[	O
16	O
,	O
37	O
]	O
.	O

It	O
is	O
more	O
stable	O
,	O
has	O
a	O
longer	O
half	O
-	O
life	O
than	O
histamine	O
and	O
can	O
be	O
detected	O
from	O
a	O
few	O
minutes	O
up	O
to	O
several	O
hours	O
after	O
mast	O
cell	O
degranulation	O

[	O
20	O
,	O
38	O
]	O
.	O

Anti	O
-	O
Tryptase	O
,	O
covalently	O
bound	O
to	O
a	O
solid	O
phase	O
reacted	O
with	O
the	O
tryptase	O
in	O
the	O
serum	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Austria	O
)	O

[	O
39	O
]	O
.	O

After	O
a	O
washing	O
procedure	O
,	O
enzyme	O
labelled	O
antibodies	O
against	O
tryptase	O
was	O
added	O
to	O
form	O
a	O
complex	O
.	O

After	O
incubation	O
,	O
unbound	O
enzyme	O
anti	O
-	O
tryptase	O
was	O
washed	O
away	O
and	O
the	O
bound	O
complex	O
incubated	O
with	O
a	O
developer	O
.	O

After	O
stopping	O
the	O
reaction	O
,	O
the	O
fluorescense	O
of	O
the	O
eluate	O
was	O
measured	O
.	O

The	O
fluorescence	O
was	O
directly	O
proportional	O
to	O
the	O
tryptase	O
concentration	O
of	O
the	O
serum	O
.	O

Normal	O
levels	O
were	O
<	O
11	O
.	O
4	O
μg	O
/	O
l	O
.	O

Lipoprotein	O
-	O
associated	O
phospholipase	O
A	O
2	O
(	O
LpPLA	O
2	O
)	O
,	O
a	O
Ca	O
2	O
+	O
independent	O
phospholipase	O
A	O
2	O
,	O
was	O
identified	O
in	O
human	O
plasma	O
and	O
found	O
to	O
be	O
responsible	O
for	O
hydrolysis	O
and	O
inactivation	O
of	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
and	O
certain	O
oxidized	O
phospholipids	O

[	O
40	O
]	O
.	O

Although	O
the	O
role	O
of	O
LpPLA	O
2	O
as	O
a	O
pro	O
-	O
or	O
anti	O
-	O
atherosclerotic	O
enzyme	O
is	O
frequently	O
debated	O
,	O
several	O
studies	O
have	O
shown	O
it	O
to	O
be	O
an	O
independent	O
marker	O
of	O
cardiovascular	O
disease	O

[	O
41	O
,	O
42	O
]	O
.	O

This	O
method	O
(	O
diaDexus	O
,	O
South	O
San	O
Francisco	O
)	O

[	O
43	O
]	O
utilizes	O
monoclonal	O
anti	O
-	O
LpPLA	O
2	O
antibodies	O
directed	O
against	O
LpPLA	O
2	O
for	O
solid	O
phase	O
immobilization	O
on	O
the	O
micro	O
well	O
plate	O
.	O

Serum	O
samples	O
were	O
added	O
to	O
the	O
plate	O
and	O
after	O
incubation	O
,	O
second	O
monoclonal	O
anti	O
-	O
LpPLA	O
2	O
antibody	O
labelled	O
with	O
the	O
enzyme	O
horseradish	O
peroxidase	O
,	O
were	O
added	O
and	O
then	O
incubated	O
with	O
the	O
immobilized	O
antigen	O
.	O

The	O
added	O
substrate	O
,	O
tetramethylbenzidine	O
,	O
followed	O
the	O
immunological	O
reaction	O
.	O

The	O
absorbance	O
of	O
the	O
enzymatic	O
turnover	O
of	O
the	O
substrate	O
was	O
determined	O
by	O
spectrophotometry	O
at	O
450	O
nm	O
.	O

It	O
was	O
directly	O
proportional	O
to	O
the	O
present	O
concentration	O
of	O
LpPLA	O
2	O
.	O

Descriptive	O
statistical	O
analyses	O
of	O
quantitative	O
data	O
were	O
performed	O
by	O
using	O
SPSS	O
,	O
version	O
20	O
.	O

Comparisons	O
between	O
groups	O
were	O
made	O
by	O
using	O
the	O
Mann	O
-	O
Withney	O
Test	O
.	O

Data	O
was	O
expressed	O
as	O
mean	O
±	O
SD	O
.	O

The	O
level	O
of	O
significance	O
was	O
set	O
at	O
5	O
%	O
.	O

We	O
obtained	O
data	O
from	O
a	O
large	O
national	O
multicenter	O
cross	O
-	O
sectional	O
study	O
conducted	O
in	O
2006	O
.	O

The	O
main	O
objective	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
infection	O
with	O
HIV	O
,	O
syphilis	O
,	O
and	O
hepatitis	O
B	O
and	O
C	O
in	O
a	O
sample	O
of	O
adult	O
psychiatric	O
patients	O
(	O
18	O
years	O
of	O
age	O
or	O
older	O
)	O
in	O
treatment	O
in	O
Brazil	O
20	O
.	O

A	O
two	O
-	O
stage	O
sampling	O
procedure	O
was	O
carried	O
out	O
with	O
a	O
random	O
selection	O
of	O
centers	O
in	O
each	O
region	O
followed	O
by	O
random	O
selection	O
of	O
participants	O
within	O
each	O
center	O
20	O
.	O

Sample	O
size	O
calculation	O
considered	O
50	O
%	O
average	O
estimate	O
of	O
the	O
conditions	O
,	O
0	O
.	O
2	O
%	O
precision	O
,	O
5	O
%	O
confidence	O
level	O
,	O
and	O
a	O
potential	O
40	O
%	O
loss	O
.	O

It	O
was	O
proportional	O
to	O
the	O
type	O
of	O
care	O
(	O
hospital	O
or	O
Psychosocial	O
Care	O
Centers	O
[	O
CAPS	O
]	O
)	O
and	O
to	O
the	O
distribution	O
of	O
AIDS	O
cases	O
in	O
the	O
regions	O
.	O

Among	O
the	O
3	O
,	O
255	O
patients	O
recruited	O
,	O
2	O
,	O
763	O
(	O
84	O
.	O
9	O
%	O
)	O
were	O
considered	O
eligible	O
as	O
previously	O
described	O
8	O
.	O

From	O
these	O
patients	O
,	O
288	O
(	O
10	O
.	O
4	O
%	O
)	O
did	O
not	O
participate	O
for	O
various	O
reasons	O
(	O
such	O
as	O
refusal	O
,	O
non	O
-	O
attendance	O
,	O
death	O
)	O
,	O
amounting	O
to	O
a	O
26	O
%	O
loss	O
for	O
the	O
interview	O
,	O
below	O
the	O
initial	O
estimate	O
of	O
40	O
%	O
.	O

Public	O
outpatient	O
mental	O
health	O
clinics	O
that	O
exclusively	O
treated	O
substance	O
use	O
disorders	O
(	O
CAPS	O
AD	O
)	O
were	O
excluded	O
from	O
the	O
sampling	O
process	O
to	O
prevent	O
the	O
overestimation	O
of	O
the	O
selected	O
risk	O
behaviors	O
or	O
prevalence	O
rates	O
.	O

The	O
study	O
was	O
carried	O
out	O
with	O
2	O
,	O
475	O
patients	O
recruited	O
from	O
11	O
psychiatric	O
hospitals	O
and	O
15	O
public	O
mental	O
health	O
outpatient	O
clinics	O
(	O
CAPS	O
)	O
distributed	O
in	O
the	O
five	O
Brazilian	O
macroregions	O
.	O

Patients	O
who	O
agreed	O
to	O
participate	O
and	O
were	O
considered	O
eligible	O
underwent	O
a	O
face	O
-	O
to	O
-	O
face	O
interview	O
with	O
a	O
semi	O
-	O
structured	O
questionnaire	O
,	O
tested	O
in	O
a	O
preliminary	O
pilot	O
study	O
8	O
,	O
to	O
collect	O
information	O
about	O
health	O
care	O
,	O
behavioral	O
characteristics	O
,	O
and	O
sociodemographic	O
profile	O
.	O

Healthcare	O
professionals	O
who	O
worked	O
at	O
the	O
treatment	O
services	O
administered	O
the	O
interviews	O
.	O

Additional	O
clinical	O
data	O
such	O
as	O
psychiatric	O
diagnosis	O
and	O
treatment	O
characteristics	O
were	O
collected	O
from	O
the	O
medical	O
records	O
.	O

The	O
study	O
included	O
only	O
patients	O
able	O
to	O
provide	O
written	O
informed	O
consent	O
and	O
who	O
were	O
able	O
to	O
answer	O
the	O
questionnaire	O
after	O
the	O
administration	O
of	O
a	O
preliminary	O
assessment	O
adapted	O
from	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
.	O

Further	O
details	O
have	O
been	O
previously	O
published	O
8	O
.	O

The	O
outcome	O
of	O
interest	O
for	O
this	O
analysis	O
was	O
recent	O
illicit	O
drug	O
use	O
(	O
i	O
.	O
e	O
.	O
,	O
patients	O
that	O
reported	O
using	O
any	O
illicit	O
drug	O
at	O
least	O
once	O
during	O
the	O
12	O
months	O
prior	O
to	O
the	O
interview	O
)	O
.	O

The	O
illicit	O
drugs	O
considered	O
were	O
marijuana	O
,	O
cocaine	O
,	O
crack	O
,	O
hallucinogens	O
,	O
amphetamines	O
,	O
opiates	O
,	O
solvents	O
,	O
or	O
other	O
non	O
-	O
prescribed	O
or	O
illicit	O
drugs	O
.	O

Potential	O
explanatory	O
variables	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sociodemographic	O
,	O
clinical	O
characteristics	O
,	O
and	O
risk	O
behavior	O
.	O

Sociodemographic	O
characteristics	O
included	O
age	O
,	O
skin	O
color	O
,	O
marital	O
status	O
,	O
schooling	O
,	O
having	O
an	O
income	O
in	O
the	O
last	O
six	O
months	O
,	O
place	O
of	O
residence	O
,	O
and	O
professing	O
a	O
religion	O
.	O

Median	O
age	O
(	O
40	O
years	O
old	O
)	O
was	O
used	O
as	O
a	O
cutoff	O
point	O
.	O

Skin	O
color	O
was	O
dichotomized	O
as	O
non	O
-	O
white	O
and	O
white	O
.	O

For	O
marital	O
status	O
,	O
those	O
who	O
were	O
single	O
,	O
separated	O
/	O
divorced	O
,	O
or	O
widowed	O
were	O
grouped	O
into	O
one	O
category	O
.	O

The	O
cutoff	O
point	O
for	O
schooling	O
was	O
five	O
years	O
(	O
first	O
cycle	O
of	O
elementary	O
school	O
)	O
.	O

For	O
housing	O
,	O
those	O
living	O
in	O
houses	O
or	O
apartments	O
were	O
considered	O
stable	O
,	O
while	O
those	O
living	O
in	O
shelters	O
,	O
pensions	O
,	O
hostels	O
,	O
and	O
on	O
streets	O
were	O
grouped	O
as	O
unstable	O
.	O

Clinical	O
characteristics	O
included	O
main	O
psychiatric	O
diagnosis	O
,	O
history	O
of	O
hospitalization	O
,	O
medical	O
comorbidities	O
,	O
and	O
history	O
of	O
sexually	O
transmitted	O
infections	O
(	O
STI	O
)	O
.	O

The	O
main	B-phenotype
psychiatric	I-phenotype
diagnosis	I-phenotype
was	O
classified	O
according	O
to	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
,	O
defined	O
by	O
a	O
psychiatrist	O
as	O
registered	O
in	O
the	O
medical	O
chart	O
.	O

This	O
variable	O
was	O
dichotomized	O
into	O
severe	O
mental	O
illness	O
(	O
SMI	O
)	O
and	O
compared	O
to	O
the	O
other	O
diagnoses	O
.	O

Severe	O
mental	O
illnesses	O
included	O
diagnoses	O
of	O
schizophrenia	O
,	O
bipolar	O
disorders	O
,	O
and	O
depression	O
with	O
psychotic	O
symptoms	O
25	O
.	O

History	O
of	O
hospitalization	O
was	O
analyzed	O
by	O
dividing	O
the	O
sample	O
into	O
three	O
categories	O
:	O
those	O
who	O
were	O
hospitalized	O
in	O
one	O
of	O
the	O
participating	O
psychiatric	O
hospitals	O
during	O
the	O
study	O
;	O
those	O
who	O
were	O
under	O
care	O
in	O
CAPS	O
but	O
had	O
a	O
history	O
of	O
any	O
previous	O
hospitalization	O
;	O
and	O
those	O
who	O
were	O
under	O
care	O
in	O
CAPS	O
and	O
had	O
never	O
been	O
hospitalized	O
.	O

Risk	O
behavior	O
characteristics	O
included	O
the	O
following	O
variables	O
:	O
lifetime	O
tobacco	O
use	O
,	O
lifetime	O
alcohol	O
use	O
,	O
history	O
of	O
homelessness	O
,	O
history	O
of	O
physical	O
and	O
sexual	O
violence	O
,	O
history	O
of	O
incarceration	O
,	O
age	O
of	O
first	O
sexual	O
intercourse	O
,	O
number	O
of	O
partners	O
,	O
and	O
practice	O
of	O
unprotected	O
sex	O
.	O

Lifetime	O
risk	O
behavior	O
self	O
-	O
reports	O
have	O
demonstrated	O
reliability	O
8	O
.	O

The	O
cutoff	O
point	O
for	O
age	O
at	O
first	O
sexual	O
intercourse	O
was	O
18	O
years	O
.	O

Finally	O
,	O
those	O
with	O
two	O
or	O
more	O
lifetime	O
sexual	O
partners	O
were	O
compared	O
to	O
those	O
with	O
only	O
one	O
or	O
no	O
partners	O
,	O
and	O
unprotected	O
sex	O
was	O
defined	O
as	O
not	O
always	O
using	O
condoms	O
in	O
all	O
sexual	O
practices	O
(	O
ever	O
)	O
.	O

Analyses	O
were	O
conducted	O
separately	O
for	O
men	O
and	O
women	O
.	O

Descriptive	O
analyses	O
were	O
carried	O
out	O
and	O
the	O
prevalence	O
of	O
recent	O
illicit	O
drug	O
use	O
was	O
calculated	O
by	O
dividing	O
the	O
number	O
of	O
participants	O
who	O
reported	O
using	O
any	O
illicit	O
drug	O
in	O
the	O
12	O
months	O
prior	O
to	O
the	O
interview	O
by	O
the	O
total	O
number	O
of	O
participants	O
,	O
with	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
)	O
.	O

For	O
the	O
univariate	O
analysis	O
,	O
differences	O
in	O
proportion	O
were	O
assessed	O
by	O
Pearson’s	O
Chi	O
-	O
square	O
test	O
,	O
and	O
the	O
magnitude	O
of	O
the	O
associations	O
was	O
estimated	O
by	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
with	O
95	O
%	O
CI	O
.	O

A	O
multivariate	O
logistic	O
model	O
was	O
used	O
to	O
estimate	O
the	O
independent	O
effect	O
of	O
potential	O
explanatory	O
variables	O
,	O
using	O
a	O
sequential	O
backward	O
elimination	O
method	O
.	O

Variables	O
that	O
presented	O
p	O
<	O
0	O
.	O
20	O
in	O
the	O
univariate	O
analysis	O
were	O
initially	O
included	O
.	O

Wald	O
test	O
was	O
used	O
to	O
assess	O
the	O
statistical	O
significance	O
of	O
each	O
variable	O
.	O

Only	O
those	O
with	O
p	O
<	O
0	O
.	O
05	O
remained	O
in	O
the	O
final	O
model	O
.	O

Goodness	O
of	O
fit	O
was	O
assessed	O
by	O
the	O
Hosmer	O
-	O
Lemeshow	O
test	O
.	O

For	O
statistical	O
analysis	O
,	O
EpiInfo	O
7	O
and	O
Stata	O
12	O
were	O
used	O
.	O

In	O
2008	O
,	O
orthogeriatric	O
care	O
at	O
Oslo	O
University	O
Hospital	O
was	O
reorganized	O
and	O
became	O
a	O
part	O
of	O
the	O
acute	O
geriatric	O
ward	O
.	O

The	O
new	O
service	O
had	O
the	O
capacity	O
to	O
serve	O
approximately	O
half	O
of	O
the	O
patients	O
admitted	O
with	O
hip	O
fracture	O
.	O

The	O
remaining	O
patients	O
were	O
treated	O
in	O
the	O
orthopedic	O
ward	O
.	O

To	O
evaluate	O
the	O
new	O
model	O
,	O
we	O
randomly	O
allocated	O
patients	O
between	O
the	O
acute	O
geriatric	O
and	O
the	O
orthopedic	O
wards	O
.	O

The	O
first	O
hip	O
fracture	O
patient	O
was	O
admitted	O
to	O
the	O
acute	O
geriatric	O
ward	O
in	O
June	O
2008	O
and	O
after	O
a	O
pilot	O
period	O
inclusion	O
in	O
the	O
study	O
started	O
in	O
September	O
2009	O
.	O

The	O
recruitment	O
ended	O
in	O
January	O
2012	O
.	O

The	O
study	O
protocol	O
containing	O
further	O
information	O
is	O
published	O
elsewhere	O

[	O
17	O
]	O
.	O

We	O
carried	O
out	O
a	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blind	O
trial	O
comparing	O
pre	O
-	O
and	O
postoperative	O
orthogeriatric	O
care	O
integrated	O
in	O
the	O
acute	O
geriatric	O
ward	O
to	O
usual	O
care	O
in	O
the	O
orthopedic	O
ward	O
.	O

Inclusion	O
and	O
randomization	O
took	O
place	O
in	O
the	O
emergency	O
department	O
,	O
overseen	O
by	O
the	O
duty	O
orthopedic	O
surgeon	O
.	O

Allocation	O
was	O
by	O
sealed	O
,	O
opaque	O
,	O
numbered	O
envelopes	O
.	O

Randomization	O
was	O
based	O
on	O
computer	O
-	O
generated	O
random	O
numbers	O
(	O
blocks	O
of	O
variable	O
and	O
unknown	O
size	O
)	O
and	O
was	O
carried	O
out	O
by	O
a	O
statistician	O
(	O
ES	O
)	O
not	O
involved	O
in	O
the	O
clinical	O
service	O
.	O

Randomization	O
was	O
stratified	O
according	O
to	O
whether	O
or	O
not	O
the	O
patients	O
were	O
admitted	O
from	O
nursing	O
homes	O
.	O

Included	O
patients	O
were	O
transferred	O
directly	O
from	O
the	O
emergency	O
department	O
to	O
the	O
allocated	O
ward	O
,	O
and	O
had	O
their	O
entire	O
hospital	O
stay	O
in	O
the	O
same	O
ward	O
except	O
for	O
time	O
in	O
the	O
operating	O
theater	O
and	O
a	O
few	O
hours	O
in	O
the	O
postoperative	O
care	O
unit	O
.	O

Operative	O
and	O
anesthetic	O
procedures	O
were	O
the	O
same	O
in	O
the	O
two	O
groups	O
.	O

All	O
patients	O
admitted	O
acutely	O
to	O
Oslo	O
University	O
Hospital	O
with	O
a	O
hip	O
fracture	O
(	O
a	O
femoral	O
neck	O
fracture	O
,	O
a	O
trochanteric	O
or	O
a	O
sub	O
-	O
trochanteric	O
fracture	O
)	O
were	O
eligible	O
for	O
inclusion	O
.	O

Patients	O
were	O
excluded	O
if	O
the	O
hip	O
fracture	O
was	O
a	O
part	O
of	O
a	O
high	O
energy	O
trauma	O
(	O
defined	O
as	O
a	O
fall	O
from	O
higher	O
than	O
one	O
meter	O
)	O
or	O
if	O
they	O
were	O
moribund	O
on	O
admission	O
.	O

Patients	O
randomized	O
to	O
intervention	O
were	O
treated	O
in	O
the	O
acute	O
geriatric	O
ward	O
(	O
Table	O
1	O
)	O
.	O

This	O
was	O
a	O
20	O
bed	O
ward	O
,	O
mainly	O
admitting	O
patients	O
suffering	O
from	O
acute	O
medical	O
disorders	O
superimposed	O
upon	O
frailty	O
,	O
co	O
-	O
morbidities	O
and	O
polypharmacy	O
.	O

The	O
only	O
surgical	O
patients	O
treated	O
in	O
the	O
ward	O
were	O
the	O
hip	O
fracture	O
patients	O
included	O
in	O
the	O
trial	O
.	O

On	O
average	O
during	O
the	O
inclusion	O
period	O
,	O
two	O
to	O
four	O
beds	O
were	O
used	O
for	O
hip	O
fracture	O
patients	O
.	O

The	O
acute	O
geriatric	O
ward	O
was	O
regularly	O
full	O
or	O
over	O
-	O
crowded	O
.	O

To	O
avoid	O
randomization	O
violation	O
,	O
the	O
ward	O
was	O
instructed	O
to	O
admit	O
included	O
hip	O
fracture	O
patients	O
even	O
if	O
the	O
ward	O
was	O
full	O
.	O

Thus	O
,	O
some	O
hip	O
fracture	O
patients	O
had	O
to	O
be	O
treated	O
in	O
the	O
corridor	O
until	O
a	O
room	O
was	O
available	O
,	O
usually	O
within	O
the	O
first	O
24	O
hours	O
.	O

Organization	O
of	O
treatment	O
in	O
the	O
acute	O
geriatric	O
ward	O
and	O
the	O
orthopedic	O
ward	O

a	O
For	O
the	O
orthopedic	O
ward	O
,	O
only	O
figures	O
from	O
2011	O
were	O
available	O
.	O

A	O
key	O
element	O
of	O
the	O
intervention	O
was	O
a	O
Comprehensive	O
Geriatric	O
Assessment	O
(	O
CGA	O
)	O
as	O
a	O
basis	O
for	O
treatment	O
planning	O
.	O

All	O
team	O
members	O
(	O
geriatrician	O
,	O
nurse	O
,	O
physiotherapist	O
and	O
occupational	O
therapist	O
)	O
were	O
expected	O
to	O
assess	O
patients	O
during	O
their	O
first	O
day	O
on	O
the	O
ward	O
,	O
and	O
the	O
team	O
had	O
daily	O
meetings	O
to	O
co	O
-	O
ordinate	O
treatment	O
and	O
to	O
plan	O
discharge	O
.	O

Clinical	O
routines	O
were	O
developed	O
based	O
on	O
a	O
literature	O
search	O
,	O
experience	O
from	O
earlier	O
orthogeriatric	O
models	O
and	O
the	O
pilot	O
phase	O
prior	O
to	O
the	O
start	O
of	O
randomization	O
.	O

Checklists	O
were	O
printed	O
out	O
and	O
made	O
immediately	O
available	O
for	O
the	O
treatment	O
team	O
for	O
each	O
patient	O
.	O

Details	O
about	O
the	O
clinical	O
routines	O
have	O
been	O
published	O

[	O
17	O
]	O
and	O
included	O
medication	O
reviews	O
,	O
early	O
and	O
intensive	O
mobilization	O
,	O
optimizing	O
pre	O
-	O
and	O
postoperative	O
nutrition	O
and	O
early	O
discharge	O
planning	O
.	O

The	O
control	O
group	O
was	O
treated	O
in	O
the	O
orthopedic	O
ward	O
,	O
a	O
52	O
bed	O
ward	O
admitting	O
a	O
range	O
of	O
elective	O
and	O
non	O
-	O
elective	O
orthopedic	O
patients	O
.	O

The	O
staff	O
-	O
patient	O
ratio	O
was	O
similar	O
to	O
that	O
of	O
the	O
acute	O
geriatric	O
ward	O
(	O
Table	O
1	O
)	O
.	O

There	O
were	O
,	O
however	O
,	O
no	O
multidisciplinary	O
meetings	O
and	O
no	O
geriatric	O
assessments	O
.	O

Early	O
mobilization	O
was	O
emphasized	O
,	O
and	O
hip	O
fracture	O
patients	O
were	O
seen	O
by	O
a	O
physiotherapist	O
soon	O
after	O
surgery	O
.	O

The	O
postoperative	O
care	O
unit	O
was	O
within	O
the	O
orthopedic	O
ward	O
,	O
where	O
all	O
patients	O
(	O
including	O
those	O
allocated	O
to	O
intervention	O
)	O
were	O
observed	O
after	O
surgery	O
.	O

All	O
patients	O
included	O
in	O
the	O
trial	O
were	O
offered	O
a	O
control	O
in	O
the	O
orthopedic	O
outpatient	O
clinic	O
four	O
months	O
after	O
surgery	O
.	O

There	O
was	O
no	O
additional	O
intervention	O
after	O
discharge	O
from	O
hospital	O
.	O

Social	O
and	O
demographic	O
information	O
was	O
collected	O
during	O
the	O
acute	O
stay	O
.	O

Information	O
regarding	O
surgical	O
and	O
anesthetic	O
procedures	O
,	O
medical	O
diagnoses	O
(	O
Charlson	O
comorbidity	O
index	O

[	O
18	O
]	O
)	O
,	O
drug	O
use	O
and	O
complications	O
was	O
also	O
collected	O
.	O

Proxies	O
were	O
interviewed	O
regarding	O
pre	O
-	O
fracture	O
Activities	O
of	O
Daily	O
Living	O
(	O
Barthel	O
ADL	O
Index	O
(	O
BADL	O

[	O
19	O
]	O
)	O
and	O
Nottingham	O
Extended	O
ADL	O
Index	O
(	O
NEADL	O

[	O
20	O
]	O
)	O
)	O
and	O
cognitive	O
function	O
(	O
Informant	O
Questionnaire	O
on	O
Cognitive	O
Decline	O
in	O
the	O
Elderly	O
(	O
IQCODE	O

[	O
21	O
]	O
)	O
)	O
.	O

Estimated	O
height	O
was	O
derived	O
using	O
knee	O
-	O
heel	O
length	O

[	O
22	O
]	O
and	O
the	O
patients	O
were	O
weighed	O
using	O
a	O
chair	O
scale	O
.	O

Mobilization	O
after	O
surgery	O
was	O
used	O
as	O
a	O
process	O
measure	O
,	O
recorded	O
on	O
day	O
two	O
post	O
-	O
surgery	O
from	O
case	O
notes	O
and	O
observations	O
.	O

From	O
September	O
2011	O
,	O
mobility	O
was	O
recorded	O
with	O
the	O
activPAL™	O
body	O
-	O
worn	O
sensor	O
system	O

[	O
23	O
]	O
.	O

The	O
sensor	O
was	O
attached	O
on	O
the	O
anterior	O
aspect	O
of	O
the	O
non	O
-	O
affected	O
thigh	O
as	O
soon	O
as	O
possible	O
after	O
surgery	O
and	O
worn	O
until	O
discharge	O
.	O

All	O
patients	O
were	O
screened	O
once	O
daily	O
for	O
delirium	O
using	O
the	O
Confusion	O
Assessment	O
Method	O
(	O
CAM	O
)	O

[	O
24	O
]	O
preoperatively	O
and	O
until	O
the	O
fifth	O
postoperative	O
day	O
(	O
all	O
)	O
or	O
until	O
discharge	O
(	O
delirious	O
patients	O
)	O
.	O

The	O
study	O
geriatrician	O
or	O
a	O
study	O
nurse	O
completed	O
all	O
the	O
assessments	O
.	O

If	O
the	O
nurse	O
was	O
unsure	O
about	O
the	O
diagnosis	O
,	O
the	O
study	O
geriatrician	O
was	O
consulted	O
.	O

The	O
CAM	O
score	O
was	O
based	O
on	O
information	O
from	O
nurses	O
,	O
close	O
relatives	O
and	O
hospital	O
records	O
related	O
to	O
the	O
preceding	O
24	O
hours	O
,	O
in	O
combination	O
with	O
a	O
10	O
to	O
30	O
minute	O
interview	O
with	O
the	O
patient	O
.	O

Tests	O
of	O
cognition	O
,	O
attention	O
and	O
alertness	O
included	O
the	O
digit	O
span	O
test	O
(	O
forward	O
and	O
backward	O
)	O
,	O
orientation	O
and	O
delayed	O
recall	O
(	O
from	O
the	O
Memorial	O
Delirium	O
Assessment	O
Scale	O
(	O
MDAS	O
)	O

[	O
25	O
]	O
)	O
.	O

Delirium	O
severity	O
was	O
measured	O
with	O
MDAS	O
.	O

Patients	O
were	O
assessed	O
regularly	O
on	O
weekdays	O
,	O
but	O
staff	O
members	O
who	O
had	O
been	O
working	O
during	O
weekends	O
were	O
interviewed	O
every	O
Monday	O
,	O
and	O
the	O
case	O
notes	O
scrutinized	O
in	O
order	O
to	O
ascertain	O
potential	O
episodes	O
of	O
delirium	O
.	O

The	O
mean	O
number	O
of	O
delirium	O
assessments	O
during	O
the	O
stay	O
was	O
5	O
.	O
7	O
(	O
SD	O
2	O
.	O
7	O
)	O
.	O

Follow	O
up	O
visits	O
were	O
carried	O
out	O
four	O
and	O
twelve	O
months	O
after	O
surgery	O
(	O
with	O
a	O
time	O
window	O
of	O
±	O
three	O
weeks	O
)	O
by	O
study	O
nurses	O
blind	O
to	O
allocation	O
and	O
to	O
all	O
clinical	O
data	O
during	O
the	O
original	O
hospital	O
stay	O
.	O

The	O
patients	O
were	O
assessed	O
in	O
their	O
current	O
place	O
of	O
residence	O
.	O

Each	O
visit	O
typically	O
lasted	O
for	O
two	O
to	O
three	O
hours	O
,	O
and	O
the	O
evaluators	O
started	O
the	O
assessment	O
with	O
the	O
cognitive	O
tests	O
of	O
the	O
primary	O
outcome	O
.	O

At	O
each	O
follow	O
-	O
up	O
visit	O
,	O
proxies	O
were	O
interviewed	O
regarding	O
physical	O
(	O
ADL	O
)	O
and	O
cognitive	O
function	O
,	O
using	O
the	O
same	O
scoring	O
systems	O
as	O
during	O
the	O
index	O
stay	O
.	O

Mobility	O
at	O
the	O
follow	O
-	O
up	O
visits	O
was	O
assessed	O
with	O
the	O
short	O
physical	O
performance	O
battery	O
(	O
SPPB	O
)	O

[	O
26	O
]	O
.	O

Weight	O
at	O
follow	O
-	O
up	O
was	O
assessed	O
using	O
a	O
standing	O
scale	O
that	O
was	O
calibrated	O
to	O
the	O
chair	O
scale	O
used	O
during	O
hospital	O
stay	O
.	O

Patients	O
and	O
proxies	O
were	O
asked	O
about	O
any	O
hospital	O
readmissions	O
since	O
surgery	O
.	O

One	O
specialist	O
in	O
geriatric	O
medicine	O
(	O
TBW	O
)	O
and	O
one	O
specialist	O
in	O
old	O
age	O
psychiatry	O
(	O
KE	O
)	O
independently	O
assessed	O
whether	O
the	O
patients	O
fulfilled	O
the	O
International	B-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
,	I-coding_system
version	I-coding_system
10	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
)	I-coding_system
criteria	O
for	O
dementia	B-phenotype
at	O
baseline	O
and	O
12	O
months	O
after	O
surgery	O
.	O

The	O
assessors	O
had	O
access	O
to	O
all	O
clinical	O
data	O
,	O
but	O
were	O
blinded	O
to	O
allocation	O
and	O
delirium	O
status	O
during	O
hospital	O
stay	O
.	O

The	O
inter	O
-	O
rater	O
agreement	O
upon	O
the	O
dementia	O
diagnosis	O
was	O
satisfactory	O
(	O
kappa	O
0	O
.	O
87	O
at	O
baseline	O
and	O
0	O
.	O
83	O
at	O
12	O
months	O
)	O
;	O
disagreements	O
were	O
resolved	O
through	O
discussion	O
.	O

The	O
primary	O
outcome	O
was	O
cognitive	O
function	O
four	O
months	O
after	O
surgery	O
,	O
which	O
was	O
expected	O
to	O
show	O
a	O
wide	O
range	O
of	O
severity	O
from	O
severe	O
dementia	O
to	O
no	O
cognitive	O
impairment	O
.	O

To	O
be	O
able	O
to	O
measure	O
differences	O
in	O
both	O
the	O
higher	O
and	O
the	O
lower	O
spectrum	O
of	O
cognitive	O
function	O
,	O
we	O
combined	O
two	O
scales	O
:	O

–	O
The	O
10	O
words	O
test	O
from	O
the	O
Consortium	O
to	O
Establish	O
a	O
Registry	O
for	O
Alzheimer’s	O
disease	O
battery	O
(	O
CERAD	O
)	O

[	O
27	O
]	O
.	O

In	O
this	O
memory	O
test	O
patients	O
are	O
asked	O
to	O
recall	O
10	O
words	O
after	O
having	O
them	O
presented	O
orally	O
or	O
visually	O
.	O

We	O
used	O
the	O
immediate	O
and	O
delayed	O
recall	O
tasks	O
of	O
the	O
test	O
.	O

This	O
test	O
is	O
shown	O
to	O
be	O
sensitive	O
for	O
memory	O
changes	O
in	O
persons	O
with	O
good	O
cognitive	O
functioning	O

[	O
28	O
]	O
.	O

–	O
The	O
Clinical	O
Dementia	O
Rating	O
scale	O
(	O
CDR	O

[	O
29	O
]	O
)	O
.	O

CDR	O
is	O
based	O
on	O
information	O
from	O
the	O
best	O
available	O
sources	O
as	O
a	O
combination	O
of	O
patient	O
and	O
proxy	O
information	O
and	O
is	O
sensitive	O
for	O
cognitive	O
changes	O
in	O
patients	O
with	O
dementia	O
.	O

We	O
used	O
the	O
‘sum	O
of	O
boxes’	O
scoring	O
adding	O
up	O
to	O
a	O
sum	O
score	O
ranging	O
from	O
zero	O
(	O
no	O
dementia	O
symptoms	O
)	O
to	O
18	O
(	O
severe	O
dementia	O
)	O
.	O

In	O
most	O
studies	O
the	O
sum	O
score	O
is	O
shown	O
to	O
correlate	O
highly	O
with	O
the	O
original	O
categorical	O
score	O
of	O
zero	O
to	O
three	O

[	O
30	O
]	O
.	O

To	O
construct	O
the	O
combined	O
outcome	O
measure	O
,	O
we	O
normalized	O
these	O
scales	O
into	O
a	O
0	O
to	O
100	O
scoring	O
(	O
CDR	O
had	O
to	O
be	O
reversed	O
since	O
it	O
is	O
scaled	O
in	O
the	O
opposite	O
direction	O
)	O
.	O

The	O
CDR	O
carried	O
a	O
50	O
%	O
weighting	O
,	O
and	O
the	O
immediate	O
and	O
delayed	O
recall	O
parts	O
of	O
the	O
10	O
word	O
test	O
each	O
contributed	O
25	O
%	O
in	O
the	O
combined	O
measure	O
.	O

Thus	O
,	O
a	O
higher	O
score	O
on	O
the	O
primary	O
outcome	O
indicated	O
better	O
cognitive	O
performance	O
.	O

Secondary	O
outcomes	O
included	O
preoperative	O
delirium	O
,	O
delirium	O
severity	O
,	O
length	O
of	O
stay	O
,	O
mortality	O
,	O
mobility	O
,	O
place	O
of	O
residence	O
,	O
ADL	O
function	O
and	O
weight	O
changes	O
at	O
the	O
follow	O
up	O
controls	O
.	O

CDR	O
and	O
the	O
10	O
words	O
test	O
were	O
analyzed	O
separately	O
,	O
in	O
addition	O
to	O
other	O
measures	O
of	O
cognition	O
(	O
Mini	O
-	O
mental	O
state	O
examination	O
(	O
MMSE	O
)	O

[	O
31	O
]	O
,	O
clock	O
drawing	O
test	O

[	O
32	O
]	O
,	O
IQCODE	O
)	O
.	O

No	O
pre	O
-	O
trial	O
data	O
were	O
available	O
to	O
carry	O
out	O
precise	O
power	O
estimates	O
.	O

Based	O
upon	O
previous	O
experience	O
with	O
the	O
CDR	O
,	O
we	O
judged	O
300	O
patients	O
to	O
be	O
sufficient	O
to	O
detect	O
clinically	O
meaningful	O
differences	O

[	O
30	O
]	O
.	O

As	O
20	O
%	O
of	O
hip	O
fracture	O
patients	O
can	O
be	O
expected	O
to	O
die	O
within	O
four	O
months	O
of	O
surgery	O
,	O
we	O
aimed	O
to	O
randomize	O
370	O
patients	O
.	O

Recruitment	O
ended	O
after	O
randomization	O
of	O
332	O
patients	O
due	O
to	O
resource	O
constraints	O
.	O

A	O
statistical	O
analysis	O
plan	O
(	O
SAP	O
)	O
was	O
developed	O
(	O
and	O
published	O
online	O
)	O
prior	O
to	O
un	O
-	O
blinding	O
of	O
the	O
data	O

[	O
33	O
]	O
.	O

The	O
primary	O
analysis	O
was	O
carried	O
out	O
blind	O
to	O
allocation	O
by	O
the	O
study	O
statistician	O
(	O
ES	O
)	O
.	O

The	O
primary	O
analysis	O
was	O
carried	O
out	O
as	O
a	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
including	O
patients	O
with	O
CDR	O
and	O
a	O
complete	O
10	O
-	O
word	O
test	O
at	O
the	O
four	O
-	O
month	O
control	O
.	O

Two	O
patients	O
were	O
sent	O
to	O
the	O
ward	O
opposite	O
to	O
randomization	O
allocation	O
,	O
and	O
these	O
patients	O
were	O
analyzed	O
according	O
to	O
the	O
group	O
in	O
which	O
they	O
were	O
treated	O
(	O
Figure	O
1	O
)	O
.	O

Three	O
moribund	O
patients	O
(	O
two	O
randomized	O
to	O
the	O
acute	O
geriatric	O
ward	O
and	O
one	O
to	O
the	O
orthopedic	O
ward	O
)	O
were	O
recruited	O
in	O
error	O
,	O
and	O
were	O
excluded	O
from	O
the	O
primary	O
analysis	O
.	O

CONSORT	O
flow	O
diagram	O
.	O

CDR	O
,	O
Clinical	O
Dementia	O
Rating	O
;	O
10	O
WT	O
,	O
10	O
word	O
test	O
(	O
from	O
CERAD	O
,	O
Consortium	O
to	O
Establish	O
a	O
Registry	O
for	O
Alzheimer’s	O
Disease	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
not	O
normally	O
distributed	O
but	O
the	O
sample	O
size	O
was	O
large	O
and	O
parametric	O
methods	O
could	O
therefore	O
be	O
applied	O
.	O

To	O
adjust	O
for	O
any	O
inequality	O
in	O
the	O
distribution	O
of	O
important	O
prognostic	O
variables	O
between	O
the	O
intervention	O
and	O
control	O
group	O
,	O
we	O
performed	O
a	O
linear	O
regression	O
with	O
the	O
primary	O
outcome	O
as	O
the	O
dependent	O
variable	O
,	O
and	O
variables	O
with	O
known	O
or	O
believed	O
influence	O
on	O
the	O
outcome	O
were	O
included	O
in	O
the	O
model	O
in	O
a	O
stepwise	O
manner	O
,	O
in	O
addition	O
to	O
the	O
randomization	O
group	O
.	O

If	O
their	O
introduction	O
to	O
the	O
model	O
changed	O
the	O
effect	O
estimate	O
for	O
the	O
randomization	O
variable	O
by	O
10	O
%	O
or	O
more	O
,	O
they	O
were	O
included	O
in	O
the	O
final	O
model	O
.	O

Variables	O
were	O
removed	O
by	O
stepwise	O
backwards	O
elimination	O
until	O
the	O
final	O
model	O
was	O
reached	O
.	O

Age	O
(	O
negatively	O
skewed	O
)	O
and	O
waiting	O
time	O
to	O
surgery	O
(	O
positively	O
skewed	O
)	O
had	O
non	O
-	O
normal	O
distributions	O
,	O
and	O
were	O
squared	O
and	O
log	O
transformed	O
,	O
respectively	O
,	O
to	O
achieve	O
better	O
fit	O
of	O
the	O
model	O
.	O

Secondary	O
outcomes	O
were	O
analyzed	O
by	O
the	O
Mann–Whitney	O
test	O
,	O
t	O
-	O
tests	O
and	O
Chi	O
-	O
square	O
tests	O
depending	O
on	O
data	O
distribution	O
.	O

Pre	O
-	O
planned	O
subgroup	O
analyses	O
were	O
carried	O
out	O
in	O
patients	O
admitted	O
from	O
nursing	O
homes	O
,	O
and	O
in	O
patients	O
with	O
and	O
without	O
pre	O
-	O
fracture	O
dementia	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
IBM	O
SPSS	O
Statistics	O
version	O
20	O
,	O
except	O
for	O
median	O
differences	O
and	O
corresponding	O
95	O
%	O
confidence	O
intervals	O
that	O
were	O
estimated	O
by	O
the	O
Hodges	O
Lehmann	O
estimator	O
using	O
StatXact	O
8	O
.	O
0	O
.	O

As	O
a	O
sensitivity	O
analysis	O
we	O
analyzed	O
the	O
primary	O
outcome	O
with	O
the	O
non	O
-	O
parametric	O
Mann–Whitney	O
test	O
.	O

We	O
also	O
carried	O
out	O
sensitivity	O
analyses	O
including	O
the	O
three	O
moribund	O
patients	O
who	O
were	O
erroneously	O
recruited	O
,	O
and	O
a	O
strict	O
intention	O
to	O
treat	O
analysis	O
with	O
all	O
patients	O
analyzed	O
according	O
to	O
allocation	O
.	O

Missing	O
values	O
for	O
the	O
primary	O
outcome	O
were	O
imputed	O
in	O
different	O
ways	O
in	O
order	O
to	O
explore	O
their	O
potential	O
influence	O
on	O
the	O
results	O
:	O

–	O
if	O
a	O
patient	O
had	O
the	O
combined	O
outcome	O
available	O
after	O
twelve	O
but	O
not	O
four	O
months	O
,	O
those	O
values	O
were	O
imputed	O
in	O
the	O
four	O
-	O
month	O
dataset	O
(	O
ten	O
patients	O
)	O
.	O

–	O
imputation	O
of	O
the	O
worst	O
possible	O
score	O
for	O
all	O
patients	O
who	O
had	O
died	O
.	O

–	O
imputation	O
of	O
the	O
worst	O
possible	O
score	O
for	O
all	O
missing	O
patients	O
.	O

–	O
imputation	O
of	O
the	O
mean	O
score	O
for	O
the	O
randomization	O
group	O
the	O
patient	O
belonged	O
to	O
for	O
all	O
missing	O
patients	O
.	O

The	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
the	O
patients	O
or	O
substitute	O
decision	O
-	O
makers	O
if	O
patients	O
did	O
not	O
have	O
capacity	O
to	O
consent	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Regional	O
Committee	O
for	O
Ethics	O
in	O
Medical	O
Research	O
in	O
Norway	O
(	O
REK	O
S	O
-	O
09169a	O
)	O
and	O
the	O
Data	O
Protection	O
Officer	O
at	O
Oslo	O
University	O
Hospital	O
(	O
Ref	O
.	O

1361	O
)	O
.	O

This	O
is	O
a	O
single	O
-	O
center	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
registered	O
at	O
clinicaltrial	O
.	O
gov	O
(	O
NCT03133052	O
)	O
.	O

The	O
study	O
report	O
will	O
comply	O
with	O
the	O
CONSORT	O
statement	O
and	O
CONSORT	O
-	O
NPT	O
(	O
non	O
-	O
pharmacologic	O
treatments	O
)	O
statement	O
[	O
34	O
,	O
35	O
]	O
.	O

The	O
primary	O
goal	O
of	O
this	O
trial	O
is	O
to	O
investigate	O
whether	O
cognitive	O
control	O
training	O
can	O
enhance	O
episodic	O
memory	O
retrieval	O
in	O
aMCI	O
patients	O
.	O

The	O
secondary	O
goal	O
of	O
this	O
trial	O
is	O
to	O
evaluate	O
the	O
efficacy	O
of	O
cognitive	O
control	O
training	O
on	O
neural	O
plasticity	O
in	O
aMCI	O
patients	O
.	O

The	O
expected	O
flow	O
of	O
patients	O
through	O
the	O
trial	O
can	O
be	O
seen	O
in	O
Fig	O
.	O

1	O
.	O

The	O
SPIRIT	O
checklist	O
with	O
the	O
recommended	O
items	O
to	O
address	O
in	O
a	O
clinical	O
trial	O
protocol	O
is	O
available	O
(	O
Additional	O
file	O
1	O
)	O
.	O

Fig	O
.	O

1	O
Flow	O
chart	O
of	O
the	O
experimental	O
design	O

Flow	O
chart	O
of	O
the	O
experimental	O
design	O

Seventy	O
qualified	O
individuals	O
are	O
currently	O
being	O
recruited	O
from	O
the	O
memory	O
clinic	O
of	O
the	O
First	O
Affiliated	O
Hospital	O
of	O
Zhejiang	O
University	O
and	O
randomly	O
assigned	O
to	O
the	O
cognitive	O
training	O
or	O
control	O
group	O
.	O

Age	O
>	O
55	O
years	O
;	O
Elementary	O
school	O
education	O
or	O
higher	O
;	O
Chief	O
complaint	O
of	O
memory	O
impairment	O
confirmed	O
by	O
relatives	O
;	O
Ability	O
to	O
read	O
a	O
computer	O
screen	O
;	O
Normal	O
overall	O
cognitive	O
function	O
as	O
evidenced	O
by	O
Clinical	O
Dementia	O
Rating	O
-	O
global	O
(	O
CDR	O
-	O
global	O
)	O
=	O
0	O
.	O
5	O
,	O
Mini	O
-	O
mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
score	O
≥	O
22	O
with	O
a	O
concurrent	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
score	O
≤	O
20	O
for	O
those	O
with	O
elementary	O
educational	O
level	O
and	O
MMSE	O
score	O
≥	O
26	O
with	O
a	O
MoCA	O
score	O
≤	O
25	O
for	O
those	O
with	O
junior	O
educational	O
level	O
or	O
above	O
;	O

Auditory	O
Verbal	O
Learning	O
Test	O
-	O
Huashan	O
version	O
(	O
AVLT	O
-	O
H	O
)	O
scores	O
1	O
.	O
5	O
standard	O
deviations	O
lower	O
than	O
age	O
-	O
matched	O
controls	O
;	O
Activities	O
of	O
Daily	O
Living	O
assessment	O
-	O
20	O
(	O
ADL	O
-	O
20	O
)	O
≤	O
23	O
;	O
Do	O
not	O
comply	O
with	O
AD	B-phenotype
diagnostic	I-phenotype
criteria	I-phenotype
proposed	O
by	O
the	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
,	I-coding_system
10th	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
for	I-coding_system
research	I-coding_system
use	I-coding_system
)	I-coding_system
and	O
the	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
Alzheimer’s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
(	O
NINCDS	O
-	O
ADRDA	O
)	O
.	O

Age	O
>	O
55	O
years	O
;	O

Elementary	O
school	O
education	O
or	O
higher	O
;	O

Chief	O
complaint	O
of	O
memory	O
impairment	O
confirmed	O
by	O
relatives	O
;	O

Ability	O
to	O
read	O
a	O
computer	O
screen	O
;	O

Normal	O
overall	O
cognitive	O
function	O
as	O
evidenced	O
by	O
Clinical	O
Dementia	O
Rating	O
-	O
global	O
(	O
CDR	O
-	O
global	O
)	O
=	O
0	O
.	O
5	O
,	O
Mini	O
-	O
mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
score	O
≥	O
22	O
with	O
a	O
concurrent	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
score	O
≤	O
20	O
for	O
those	O
with	O
elementary	O
educational	O
level	O
and	O
MMSE	O
score	O
≥	O
26	O
with	O
a	O
MoCA	O
score	O
≤	O
25	O
for	O
those	O
with	O
junior	O
educational	O
level	O
or	O
above	O
;	O

Auditory	O
Verbal	O
Learning	O
Test	O
-	O
Huashan	O
version	O
(	O
AVLT	O
-	O
H	O
)	O
scores	O
1	O
.	O
5	O
standard	O
deviations	O
lower	O
than	O
age	O
-	O
matched	O
controls	O
;	O

Activities	O
of	O
Daily	O
Living	O
assessment	O
-	O
20	O
(	O
ADL	O
-	O
20	O
)	O
≤	O
23	O
;	O

Do	O
not	O
comply	O
with	O
AD	B-phenotype
diagnostic	I-phenotype
criteria	I-phenotype
proposed	O
by	O
the	O
International	B-coding_system
Statistical	I-coding_system
Classification	I-coding_system
of	I-coding_system
Diseases	I-coding_system
and	I-coding_system
Related	I-coding_system
Health	I-coding_system
Problems	I-coding_system
,	I-coding_system
10th	I-coding_system
Revision	I-coding_system
(	I-coding_system
ICD	I-coding_system
-	I-coding_system
10	I-coding_system
for	I-coding_system
research	I-coding_system
use	I-coding_system
)	I-coding_system
and	O
the	O
National	O
Institute	O
of	O
Neurological	O
and	O
Communicative	O
Disorders	O
and	O
Stroke	O
and	O
Alzheimer’s	O
Disease	O
and	O
Related	O
Disorders	O
Association	O
(	O
NINCDS	O
-	O
ADRDA	O
)	O
.	O

Lack	O
of	O
a	O
home	O
computer	O
or	O
computer	O
literacy	O
;	O
A	O
medical	O
history	O
of	O
stroke	O
and	O
nervous	O
system	O
lesions	O
,	O
cerebral	O
infarction	O
,	O
encephalomalacia	O
lesions	O
,	O
or	O
other	O
space	O
occupying	O
lesions	O
detected	O
by	O
head	O
MRI	O
plain	O
scan	O
;	O
Other	O
nervous	O
system	O
diseases	O
likely	O
to	O
cause	O
brain	O
dysfunction	O
,	O
such	O
as	O
schizophrenia	O
,	O
severe	O
depression	O
,	O
frontotemporal	O
lobe	O
dementia	O
,	O
Huntington’s	O
disease	O
,	O
brain	O
tumors	O
,	O
Parkinson’s	O
disease	O
,	O
metabolic	O
encephalopathy	O
,	O
encephalitis	O
,	O
multiple	O
sclerosis	O
,	O
epilepsy	O
,	O
brain	O
trauma	O
,	O
or	O
normal	O

hydrocephalus	O
;	O
Other	O
systematic	O
diseases	O
likely	O
to	O
impair	O
cognition	O
,	O
such	O
as	O
hypothyroidism	O
,	O
deficiency	O
of	O
folic	O
acid	O
or	O
vitamin	O
B12	O
,	O
or	O
viral	O
infection	O
(	O
syphilis	O
or	O
HIV	O
)	O
;	O
Ethanol	O
or	O
drug	O
misuse	O
;	O
Severe	O
liver	O
and	O
renal	O
insufficiency	O
,	O
pulmonary	O
incompetence	O
,	O
anemia	O
,	O
malnutrition	O
,	O
gastrointestinal	O
tract	O
disease	O
,	O
arrhythmia	O
,	O
or	O
heart	O
infarction	O
in	O
the	O
previous	O
six	O
months	O
;	O
Metal	O
implantation	O
or	O
other	O
MRI	O
contraindications	O
;	O
Aphasia	O
,	O
consciousness	O
disorder	O
,	O
or	O
other	O
diseases	O
precluding	O
cognitive	O
examination	O
;	O

Use	O
of	O
drugs	O
that	O
affect	O
cognitive	O
function	O
,	O
such	O
as	O
sedatives	O
,	O
anti	O
-	O
anxiety	O
drugs	O
,	O
nootropic	O
drugs	O
,	O
sleeping	O
pills	O
,	O
and	O
cholinomimetic	O
drugs	O
.	O

Lack	O
of	O
a	O
home	O
computer	O
or	O
computer	O
literacy	O
;	O

A	O
medical	O
history	O
of	O
stroke	O
and	O
nervous	O
system	O
lesions	O
,	O
cerebral	O
infarction	O
,	O
encephalomalacia	O
lesions	O
,	O
or	O
other	O
space	O
occupying	O
lesions	O
detected	O
by	O
head	O
MRI	O
plain	O
scan	O
;	O

Other	O
nervous	O
system	O
diseases	O
likely	O
to	O
cause	O
brain	O
dysfunction	O
,	O
such	O
as	O
schizophrenia	O
,	O
severe	O
depression	O
,	O
frontotemporal	O
lobe	O
dementia	O
,	O
Huntington’s	O
disease	O
,	O
brain	O
tumors	O
,	O
Parkinson’s	O
disease	O
,	O
metabolic	O
encephalopathy	O
,	O
encephalitis	O
,	O
multiple	O
sclerosis	O
,	O
epilepsy	O
,	O
brain	O
trauma	O
,	O
or	O
normal	O
hydrocephalus	O
;	O

Other	O
systematic	O
diseases	O
likely	O
to	O
impair	O
cognition	O
,	O
such	O
as	O
hypothyroidism	O
,	O
deficiency	O
of	O
folic	O
acid	O
or	O
vitamin	O
B12	O
,	O
or	O
viral	O
infection	O
(	O
syphilis	O
or	O
HIV	O
)	O
;	O

Ethanol	O
or	O
drug	O
misuse	O
;	O

Severe	O
liver	O
and	O
renal	O
insufficiency	O
,	O
pulmonary	O
incompetence	O
,	O
anemia	O
,	O
malnutrition	O
,	O
gastrointestinal	O
tract	O
disease	O
,	O
arrhythmia	O
,	O
or	O
heart	O
infarction	O
in	O
the	O
previous	O
six	O
months	O
;	O

Metal	O
implantation	O
or	O
other	O
MRI	O
contraindications	O
;	O

Aphasia	O
,	O
consciousness	O
disorder	O
,	O
or	O
other	O
diseases	O
precluding	O
cognitive	O
examination	O
;	O

Use	O
of	O
drugs	O
that	O
affect	O
cognitive	O
function	O
,	O
such	O
as	O
sedatives	O
,	O
anti	O
-	O
anxiety	O
drugs	O
,	O
nootropic	O
drugs	O
,	O
sleeping	O
pills	O
,	O
and	O
cholinomimetic	O
drugs	O
.	O

All	O
individuals	O
are	O
randomly	O
and	O
evenly	O
assigned	O
to	O
the	O
cognitive	O
training	O
or	O
control	O
group	O
using	O
the	O
random	O
number	O
table	O
method	O
by	O
an	O
independent	O
statistician	O
using	O
SAS	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Written	O
informed	O
consent	O
is	O
obtained	O
from	O
all	O
participants	O
.	O

After	O
enrolment	O
,	O
the	O
random	O
and	O
intervention	O
number	O
labels	O
are	O
sent	O
to	O
the	O
memory	O
clinic	O
.	O

If	O
a	O
participant	O
needs	O
emergency	O
treatment	O
,	O
blinding	O
will	O
be	O
broken	O
,	O
and	O
the	O
participant	O
will	O
then	O
be	O
managed	O
as	O
off	O
-	O
trial	O
.	O

The	O
participants	O
,	O
nurses	O
,	O
neuroimaging	O
specialists	O
,	O
statisticians	O
,	O
and	O
psychologists	O
are	O
all	O
blind	O
to	O
group	O
allocation	O
.	O

Data	O
management	O
,	O
evaluation	O
,	O
and	O
analysis	O
will	O
also	O
be	O
conducted	O
blind	O
to	O
group	O
membership	O
.	O

Cognitive	O
control	O
training	O
will	O
be	O
conducted	O
using	O
a	O
computerized	O
self	O
-	O
adaption	O
training	O
pattern	O
(	O
i	O
.	O
e	O
.	O
individually	O
adjusted	O
task	O
difficulty	O
to	O
bring	O
individuals	O
to	O
their	O
performance	O
maximum	O
)	O
.	O

Training	O
tasks	O
which	O
were	O
effectively	O
used	O
in	O
previous	O
studies	O
will	O
be	O
adopted	O
[	O
36	O
]	O
,	O
including	O
Flanker	O
task	O
[	O
37	O
]	O
,	O
n	O
-	O
back	O
working	O
memory	O
task	O
[	O
38	O
]	O
,	O
task	O
switching	O
[	O
39	O
]	O
,	O
and	O
Stroop	O
task	O
[	O
40	O
]	O
.	O

To	O
guarantee	O
adaptability	O
to	O
training	O
difficulty	O
,	O
different	O
levels	O
of	O
difficulty	O
will	O
be	O
established	O
as	O
in	O
previous	O
studies	O
with	O
larger	O
sample	O
sizes	O
.	O

Briefly	O
,	O
at	O
the	O
beginning	O
,	O
each	O
individual	O
is	O
assigned	O
a	O
task	O
of	O
similar	O
difficulty	O
.	O

On	O
each	O
training	O
day	O
,	O
the	O
participants	O
are	O
required	O
to	O
complete	O
five	O
tasks	O
three	O
times	O
,	O
with	O
2	O
min	O
for	O
each	O
training	O
session	O
(	O
for	O
a	O
total	O
daily	O
test	O
time	O
of	O
30	O
min	O
)	O
.	O

For	O
each	O
task	O
,	O
the	O
task	O
difficulty	O
will	O
be	O
advanced	O
when	O
the	O
accuracy	O
rate	O
exceeds	O
80	O
%	O
.	O

To	O
adjust	O
for	O
individual	O
variation	O
in	O
adaptability	O
,	O
the	O
number	O
of	O
types	O
of	O
stimuli	O
,	O
the	O
presentation	O
probability	O
of	O
each	O
type	O
of	O
stimuli	O
,	O
and	O
the	O
size	O
and	O
duration	O
of	O
a	O
stimulus	O
were	O
systematically	O
set	O
.	O

To	O
keep	O
a	O
systematical	O
setting	O
,	O
only	O
one	O
parameter	O
will	O
be	O
adjusted	O
;	O
the	O
remaining	O
parameters	O
will	O
remain	O
unchanged	O
when	O
the	O
task	O
difficulty	O
is	O
elevated	O
.	O

If	O
the	O
accuracy	O
rate	O
of	O
a	O
certain	O
task	O
exceeds	O
80	O
%	O
of	O
normal	O
counterparts	O
,	O
the	O
task	O
will	O
be	O
substituted	O
for	O
another	O
of	O
higher	O
difficulty	O
.	O

The	O
training	O
program	O
will	O
be	O
implemented	O
five	O
times	O
weekly	O
for	O
12	O
consecutive	O
weeks	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
training	O
tasks	O
include	O
just	O
the	O
Flanker	O
task	O
and	O
1	O
-	O
back	O
task	O
.	O

Importantly	O
,	O
a	O
fixed	O
,	O
primary	O
difficulty	O
level	O
will	O
be	O
set	O
.	O

The	O
training	O
tasks	O
will	O
be	O
performed	O
five	O
times	O
weekly	O
,	O
30	O
min	O
per	O
session	O
,	O
for	O
12	O
consecutive	O
weeks	O
.	O

With	O
the	O
guidance	O
of	O
doctors	O
,	O
the	O
initial	O
training	O
will	O
be	O
done	O
in	O
clinic	O
and	O
the	O
rest	O
of	O
the	O
training	O
will	O
be	O
completed	O
at	O
home	O
.	O

The	O
training	O
will	O
be	O
supervised	O
by	O
an	O
independent	O
neurologist	O
by	O
telephone	O
and	O
the	O
Internet	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
memory	O
retrieval	O
function	O
assessed	O
by	O
delayed	O
recall	O
of	O
Auditory	O
Verbal	O
Learning	O
Test	O
-	O
Huashan	O
version	O
(	O
AVLT	O
-	O
H	O
)	O
.	O

To	O
be	O
specific	O
,	O
participants	O
were	O
asked	O
to	O
study	O
a	O
list	O
of	O
12	O
frequent	O
and	O
concrete	O
words	O
three	O
times	O
.	O

Words	O
were	O
presented	O
acoustically	O
and	O
free	O
recall	O
was	O
measured	O
in	O
an	O
immediate	O
recall	O
condition	O
,	O
a	O
5	O
-	O
min	O
short	O
delayed	O
recall	O
condition	O
,	O
and	O
a	O
20	O
-	O
min	O
long	O
delayed	O
recall	O
condition	O
.	O

Secondary	O
outcome	O
measures	O
include	O
neuronal	O
plasticity	O
metrics	O
obtained	O
by	O
MRI	O
.	O

Structural	O
MRI	O
using	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
-	O
T1	O
and	O
diffusion	O
tensor	O
imaging	O
(	O
DTI	O
)	O
techniques	O
will	O
be	O
adopted	O
to	O
investigate	O
gray	O
matter	O
volume	O
,	O
white	O
matter	O
fiber	O
integrity	O
,	O
and	O
nerve	O
fiber	O
connectivity	O
among	O
cognition	O
-	O
related	O
brain	O
regions	O
(	O
prefrontal	O
lobe	O
and	O
parietal	O
lobe	O
)	O
and	O
memory	O
-	O
related	O
brain	O
regions	O
(	O
hippocampus	O
,	O
medial	O
temporal	O
lobe	O
,	O
and	O
prefrontal	O
lobe	O
)	O
in	O
participants	O
before	O
and	O
after	O
cognitive	O
control	O
training	O
.	O

Functional	O
MRI	O
(	O
fMRI	O
)	O
will	O
be	O
used	O
to	O
reveal	O
changes	O
in	O
the	O
cerebral	O
activation	O
.	O

Resting	O
-	O
fMRI	O
and	O
task	O
-	O
fMRI	O
will	O
be	O
performed	O
to	O
statistically	O
compare	O
changes	O
in	O
regional	O
function	O
signals	O
within	O
episodic	O
memory	O
-	O
and	O
cognitive	O
control	O
-	O
related	O
brain	O
regions	O
(	O
frontal	O
,	O
prefrontal	O
,	O
and	O
parietal	O
lobes	O
)	O
,	O
and	O
changes	O
in	O
connectivity	O
among	O
implementation	O
,	O
memory	O
and	O
default	O
networks	O
,	O
especially	O
the	O
prefrontal	O
lobe	O
-	O
hippocampus	O
function	O
connection	O
.	O

For	O
task	O
-	O
fMRI	O
,	O
a	O
scan	O
with	O
an	O
episodic	O
memory	O
task	O
will	O
be	O
included	O
.	O

Demographic	O
data	O
(	O
gender	O
,	O
age	O
,	O
educational	O
level	O
,	O
and	O
occupation	O
)	O
,	O
medical	O
and	O
disease	O
histories	O
,	O
and	O
results	O
of	O
physical	O
examinations	O
,	O
nervous	O
system	O
examinations	O
,	O
neuropsychological	O
evaluations	O
,	O
and	O
blood	O
analyses	O
are	O
collected	O
from	O
consecutive	O
patients	O
according	O
to	O
exclusion	O
criteria	O
.	O

Qualified	O
individuals	O
will	O
receive	O
structural	O
and	O
functional	O
head	O
MRI	O
scans	O
.	O

Routine	O
blood	O
tests	O
will	O
be	O
performed	O
for	O
detection	O
of	O
blood	O
cell	O
counts	O
,	O
liver	O
and	O
kidney	O
function	O
,	O
blood	O
glucose	O
levels	O
,	O
thyroid	O
function	O
,	O
folic	O
acid	O
and	O
vitamin	O
b12	O
levels	O
,	O
and	O
syphilis	O
and	O
HIV	O
antibodies	O
.	O

After	O
12	O
weeks	O
of	O
cognitive	O
training	O
,	O
repeat	O
physical	O
examinations	O
,	O
nervous	O
system	O
examinations	O
,	O
neuropsychological	O
evaluations	O
,	O
and	O
structural	O
and	O
functional	O
MRI	O
will	O
be	O
performed	O
(	O
Fig	O
.	O

1	O
)	O
.	O

The	O
neuropsychological	O
assessment	O
employs	O
several	O
commonly	O
used	O
measures	O
of	O
cognitive	O
and	O
daily	O
functions	O
.	O

Measures	O
include	O
MMSE	O
,	O
MoCA	O
,	O
CDR	O
,	O
AVLT	O
-	O
H	O
,	O
Boston	O
Naming	O
Test	O
(	O
BNT	O
)	O
,	O
DIGIT	O
span	O
test	O
(	O
DST	O
)	O
,	O
TRAIL	O
Making	O
Test	O
(	O
TMT	O
)	O
,	O
Hachinski	O
Ischemia	O
Scale	O
(	O
HIS	O
)	O
,	O
Geriatric	O
Depression	O
Scale	O
(	O
GDS	O
)	O
,	O
and	O
ADL	O
assessment	O
.	O

Of	O
these	O
,	O
CDR	O
,	O
HIS	O
,	O
GDS	O
,	O
and	O
ADL	O
will	O
only	O
be	O
performed	O
in	O
the	O
recruitment	O
phase	O
(	O
Fig	O
.	O

2	O
)	O
.	O

Furthermore	O
,	O
in	O
the	O
memory	O
domain	O
,	O
episodic	O
memory	O
tasks	O
that	O
include	O
a	O
learning	O
session	O
and	O
a	O
test	O
session	O
will	O
be	O
conducted	O
both	O
outside	O
and	O
inside	O
the	O
scanner	O
.	O

Fig	O
.	O

2	O
Standard	O
Protocol	O
Items	O
:	O
Recommendations	O
for	O
Interventional	O
Trials	O
(	O
SPIRIT	O
)	O
figure	O
with	O
the	O
schedule	O
of	O
enrollment	O
,	O
interventions	O
and	O
assessments	O
.	O

MRI	O
magnetic	O
resonance	O
imaging	O
,	O
MMSE	O
Mini	O
-	O
mental	O
State	O
Examination	O
,	O
MoCA	O
Montreal	O
Cognitive	O
Assessment	O
,	O
BNT	O
Boston	O
Naming	O
Test	O
,	O
AVLT	O
-	O
H	O
Auditory	O
Verbal	O
Learning	O
Test	O
-	O
Huashan	O
version	O
,	O
DST	O
DIGIT	O
span	O
test	O
,	O
TMT	O
TRAIL	O
Making	O
Test	O
,	O
CDR	O
Clinical	O
Dementia	O
Rating	O
,	O
HIS	O
Hachinski	O
Ischemia	O
Scale	O
,	O
GDS	O
Geriatric	O
Depression	O
Scale	O
,	O
ADL	O
Activities	O
of	O
Daily	O
Living	O

Standard	O
Protocol	O
Items	O
:	O
Recommendations	O
for	O
Interventional	O
Trials	O
(	O
SPIRIT	O
)	O
figure	O
with	O
the	O
schedule	O
of	O
enrollment	O
,	O
interventions	O
and	O
assessments	O
.	O

MRI	O
magnetic	O
resonance	O
imaging	O
,	O
MMSE	O
Mini	O
-	O
mental	O
State	O
Examination	O
,	O
MoCA	O
Montreal	O
Cognitive	O
Assessment	O
,	O
BNT	O
Boston	O
Naming	O
Test	O
,	O
AVLT	O
-	O
H	O
Auditory	O
Verbal	O
Learning	O
Test	O
-	O
Huashan	O
version	O
,	O
DST	O
DIGIT	O
span	O
test	O
,	O
TMT	O
TRAIL	O
Making	O
Test	O
,	O
CDR	O
Clinical	O
Dementia	O
Rating	O
,	O
HIS	O
Hachinski	O
Ischemia	O
Scale	O
,	O
GDS	O
Geriatric	O
Depression	O
Scale	O
,	O
ADL	O
Activities	O
of	O
Daily	O
Living	O

All	O
participants	O
will	O
receive	O
MRI	O
scans	O
at	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
cognitive	O
training	O
using	O
an	O
identical	O
3	O
-	O
T	O
device	O
(	O
GE	O
DISCOVERY	O
MR750	O
)	O
in	O
the	O
same	O
scan	O
modes	O
.	O

The	O
3D	O
-	O
T1	O
structural	O
images	O
of	O
the	O
brain	O
will	O
be	O
obtained	O
by	O
3D	O
magnetization	O
-	O
prepared	O
rapid	O
acquisition	O
with	O
gradient	O
echo	O
(	O
3D	O
-	O
MPRAGE	O
)	O
using	O
the	O
following	O
acquisition	O
parameters	O
:	O
176	O
sagittal	O
slices	O
;	O
thickness	O
=	O
1	O
mm	O
;	O
TR	O
=	O
8	O
.	O
2	O
ms	O
;	O
TE	O
=	O
3	O
.	O
2	O
ms	O
;	O
flip	O
angle	O
=	O
8°	O
;	O
FOV	O
=	O
250	O
×	O
250	O
mm	O
;	O
and	O
matrix	O
=	O
256	O
×	O
256	O
.	O

fMRI	O
scan	O
will	O
be	O
performed	O
using	O
a	O
T2	O
-	O
weighted	O
echo	O
-	O
planar	O
imaging	O
(	O
EPI	O
)	O
sequence	O
with	O
the	O
following	O
acquisition	O
parameters	O
:	O
slices	O
=	O
43	O
;	O
TR	O
=	O
2000	O
ms	O
;	O
TE	O
=	O
30	O
ms	O
;	O
flip	O
angle	O
=	O
90°	O
;	O
FOV	O
=	O
220	O
×	O
200	O
mm	O
;	O
and	O
matrix	O
=	O
64	O
×	O
64	O
.	O

DTI	O
will	O
be	O
conducted	O
using	O
a	O
single	O
excitation	O
EPI	O
sequence	O
and	O
the	O
following	O
scan	O
parameters	O
:	O
FOV	O
=	O
192	O
×	O
192	O
mm	O
;	O
TR	O
=	O
8600	O
ms	O
;	O
TE	O
=	O
84	O
ms	O
;	O
b	O
=	O
1000	O
s	O
/	O
mm	O
2	O
;	O
diffusion	O
sensitive	O
gradient	O
magnetic	O
fields	O
=	O
30	O
;	O
slices	O
=	O
67	O
;	O
thickness	O
=	O
1	O
.	O
5	O
mm	O
;	O
layer	O
interval	O
=	O
0	O
mm	O
;	O
NEX	O
=	O
2	O
;	O
and	O
4	O
b0	O
images	O
.	O

Image	O
quality	O
will	O
be	O
validated	O
by	O
an	O
experienced	O
imaging	O
specialist	O
.	O

Individuals	O
with	O
potential	O
cerebral	O
impairments	O
or	O
structural	O
abnormalities	O
revealed	O
by	O
neuroimaging	O
will	O
be	O
excluded	O
from	O
subsequent	O
experiments	O
.	O

All	O
neuropsychological	O
evaluations	O
will	O
be	O
conducted	O
by	O
the	O
same	O
neuropsychologist	O
,	O
all	O
MRI	O
scans	O
completed	O
using	O
an	O
identical	O
machine	O
,	O
and	O
image	O
quality	O
examined	O
after	O
each	O
scan	O
cycle	O
.	O

According	O
to	O
a	O
previous	O
study	O
[	O
41	O
]	O
,	O
in	O
which	O
computerized	O
cognitive	O
training	O
was	O
administered	O
for	O
six	O
weeks	O
,	O
the	O
mean	O
difference	O
in	O
AVLT	O
-	O
H	O
score	O
between	O
the	O
cognitive	O
training	O
and	O
control	O
groups	O
was	O
0	O
.	O
26	O
±	O
0	O
.	O
3	O
.	O

Based	O
upon	O
this	O
difference	O
,	O
22	O
samples	O
are	O
required	O
to	O
yield	O
a	O
statistical	O
power	O
of	O
80	O
%	O
at	O
a	O
statistical	O
significance	O
level	O
of	O
0	O
.	O
05	O
.	O

The	O
sample	O
size	O
was	O
estimated	O
using	O
the	O
following	O
equation	O
:	O
\	O
documentclass	O
[	O
12pt	O
]	O
{	O
minimal	O
}	O

\	O
usepackage	O
{	O
amsmath	O
}	O

\	O
usepackage	O
{	O
wasysym	O
}	O

\	O
usepackage	O
{	O
amsfonts	O
}	O

\	O
usepackage	O
{	O
amssymb	O
}	O

\	O
usepackage	O
{	O
amsbsy	O
}	O

\	O
usepackage	O
{	O
mathrsfs	O
}	O

\	O
usepackage	O
{	O
upgreek	O
}	O

\	O
setlength	O
{	O
\	O
oddsidemargin	O
}	O
{	O
-	O
69pt	O
}	O

\	O
begin	O
{	O
document	O
}	O
$$	O
n=	O
\	O
frac	O
{	O
\	O
left	O
(	O
{	O
q	O
_	O
1	O
}	O
^	O
{	O
-	O
1	O
}	O
+	O
{	O
q	O
_	O
2	O
}	O
^	O
{	O
-	O
1	O
}	O
\	O
right	O
)	O
{	O
\	O
left	O
(	O
{	O
t	O
}	O
_	O
{	O
\	O
alpha	O
/	O
2	O
}	O
+	O
{	O
t	O
}	O
_	O
{	O
\	O
beta	O
}	O
\	O
right	O
)	O
}	O
^	O
2	O
{	O
S	O
}	O
^	O
2	O
}	O
{	O
\	O
delta	O
^	O
2	O
}	O
$$	O
\	O
end	O
{	O
document	O
}	O
n	O
=	O
q	O
1	O
−	O
1	O
+	O
q	O
2	O
−	O
1	O
t	O
α	O
/	O
2	O
+	O
t	O
β	O
2	O
S	O
2	O
δ	O
2	O

where	O
q	O
1	O
and	O
q	O
2	O
are	O
the	O
sample	O
size	O
ratio	O
of	O
two	O
groups	O
(	O
q	O
1	O
=	O
q	O
2	O
=	O
0	O
.	O
5	O
)	O
,	O
α	O
is	O
the	O
statistical	O
significance	O
level	O
(	O
α	O
=	O
0	O
.	O
05	O
)	O
,	O
β	O
is	O
calculated	O
from	O
1	O
-	O
β	O
which	O
stands	O
for	O
statistical	O
power	O
(	O
1	O
-	O
β	O
=	O
0	O
.	O
8	O
)	O
,	O
δ	O
is	O
the	O
mean	O
difference	O
(	O
δ	O
=	O
0	O
.	O
26	O
)	O
,	O
and	O
S	O
is	O
the	O
standard	O
deviation	O
(	O
S	O
=	O
0	O
.	O
3	O
)	O
used	O
in	O
the	O
analyses	O
.	O

Considering	O
the	O
instability	O
of	O
standard	O
deviation	O
and	O
dropout	O
rate	O
,	O
the	O
sample	O
size	O
for	O
each	O
group	O
is	O
set	O
as	O
35	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
no	O
adverse	O
events	O
caused	O
by	O
cognitive	O
training	O
have	O
been	O
reported	O
yet	O
.	O

To	O
make	O
sure	O
that	O
baseline	O
levels	O
between	O
groups	O
(	O
cognitive	O
training	O
,	O
control	O
)	O
are	O
comparable	O
,	O
questionnaire	O
measures	O
will	O
be	O
analyzed	O
using	O
independent	O
sample	O
t	O
-	O
tests	O
.	O

To	O
determine	O
the	O
training	O
efficacy	O
from	O
baseline	O
to	O
outcome	O
,	O
paired	O
sample	O
t	O
-	O
tests	O
will	O
be	O
used	O
in	O
each	O
group	O
,	O
respectively	O
,	O
for	O
the	O
changes	O
in	O
scores	O
of	O
trained	O
tasks	O
.	O

The	O
neuropsychological	O
changes	O
will	O
be	O
correlated	O
with	O
the	O
score	O
changes	O
of	O
the	O
trained	O
tasks	O
to	O
test	O
the	O
training	O
effect	O
on	O
neuropsychological	O
performance	O
.	O

To	O
determine	O
the	O
training	O
transfer	O
effect	O
,	O
ANOVAs	O
will	O
then	O
be	O
performed	O
on	O
each	O
dependent	O
variable	O
,	O
with	O
time	O
(	O
baseline	O
,	O
outcome	O
)	O
as	O
the	O
within	O
-	O
subjects	O
factor	O
and	O
group	O
(	O
cognitive	O
training	O
,	O
control	O
)	O
as	O
the	O
between	O
-	O
subjects	O
factor	O
.	O

The	O
methodology	O
of	O
data	O
collection	O
is	O
described	O
in	O
our	O
earlier	O
work	O
[	O
20	O
]	O
,	O
but	O
in	O
brief	O
,	O
clinical	O
notes	O
of	O
patients	O
admitted	O
to	O
the	O
NPS	O
between	O
2001	O
and	O
2007	O
were	O
collated	O
and	O
retrospective	O
analysed	O
using	O
the	O
OPCRIT	O
system	O
.	O

Ethical	O
approval	O
for	O
such	O
retrospective	O
analysis	O
of	O
patient	O
case	O
notes	O
was	O
approved	O
by	O
the	O
Research	O
and	O
Development	O
office	O
of	O
South	O
London	O
and	O
Maudsley	O
NHS	O
Foundation	O
Trust	O
,	O
UK	O
.	O

Of	O
the	O
182	O
patients	O
admitted	O
during	O
this	O
time	O
,	O
153	O
case	O
notes	O
(	O
86	O
male	O
,	O
67	O
female	O
)	O
were	O
deemed	O
to	O
contain	O
sufficient	O
information	O
to	O
allow	O
reliable	O
assessment	O
of	O
clinical	O
information	O
:	O
all	O
patients	O
with	O
such	O
information	O
were	O
included	O
in	O
the	O
study	O
,	O
and	O
no	O
other	O
inclusion	O
or	O
exclusion	O
criteria	O
were	O
utilised	O
.	O

Mean	O
participant	O
age	O
at	O
the	O
point	O
of	O
admission	O
was	O
33	O
(	O
s	O
.	O
d	O
.	O
=	O
10	O
.	O
9	O
)	O
;	O
mean	O
duration	O
of	O
admission	O
was	O
254	O
days	O
(	O
s	O
.	O
d	O
.	O
=	O
169	O
)	O
.	O

All	O
participants	O
met	O
ICD	B-Coding_system
-	I-Coding_system
10	I-Coding_system
criteria	O
for	O
a	O
primary	O
diagnosis	O
of	O
schizophrenia	B-Phenotype
,	O
which	O
was	O
by	O
definition	O
of	O
admission	O
to	O
this	O
tertiary	O
unit	O
,	O
considered	O
considerably	O
treatment	O
refractory	O
;	O
36	O
had	O
a	O
comorbid	O
personality	O
disorder	O
;	O
36	O
had	O
a	O
lifetime	O
history	O
(	O
and	O
24	O
at	O
the	O
point	O
of	O
admission	O
)	O
of	O
alcohol	O
dependency	O
or	O
harmful	O
use	O
;	O
49	O
had	O
a	O
lifetime	O
history	O
(	O
and	O
37	O
at	O
the	O
point	O
of	O
admission	O
)	O
of	O
cannabis	O
dependency	O
or	O
harmful	O
use	O
;	O
and	O
31	O
a	O
lifetime	O
history	O
(	O
23	O
at	O
the	O
point	O
of	O
admission	O
)	O
of	O
dependency	O
or	O
harmful	O

use	O
of	O
other	O
substances	O
.	O

These	O
categories	O
are	O
not	O
exclusive	O
,	O
with	O
some	O
individuals	O
having	O
more	O
than	O
one	O
co	O
-	O
morbidity	O
.	O

The	O
only	O
exclusion	O
criterion	O
for	O
patient	O
admission	O
to	O
the	O
National	O
Psychosis	O
Unit	O
is	O
if	O
they	O
cannot	O
be	O
physically	O
managed	O
by	O
staff	O
due	O
to	O
risk	O
of	O
significant	O
agitation	O
or	O
violence	O
.	O

The	O
OPCRIT	O
is	O
a	O
reliable	O
and	O
validated	O
tool	O
[	O
21	O
]	O
utilising	O
an	O
inventory	O
of	O
psychopathological	O
symptoms	O
,	O
demographics	O
,	O
and	O
disease	O
course	O
variables	O
that	O
are	O
scored	O
,	O
with	O
algorithms	O
for	O
clinical	O
diagnosis	O
[	O
22	O
]	O
.	O

The	O
notes	O
on	O
admission	O
to	O
,	O
and	O
discharge	O
from	O
,	O
the	O
NPS	O
were	O
assessed	O
to	O
yield	O
OPCRIT	O
mental	O
state	O
examination	O
(	O
MSE	O
)	O
severity	O
scores	O
for	O
each	O
time	O
point	O
across	O
5	O
domains	O
:	O
affective	O
symptoms	O
,	O
abnormal	O
perceptions	O
,	O
abnormal	O
beliefs	O
,	O
speech	O
and	O
thought	O
disorders	O
,	O
and	O
appearance	O
and	O
behaviour	O
.	O

Demographic	O
information	O
was	O
collated	O
for	O
all	O
participants	O
;	O
and	O
medications	O
,	O
including	O
dose	O
,	O
on	O
admission	O
and	O
discharge	O
,	O
were	O
recorded	O
.	O

The	O
primary	O
measures	O
of	O
outcome	O
were	O
change	O
in	O
mental	O
state	O
examination	O
(	O
MSE	O
)	O
symptom	O
severity	O
measured	O
as	O
the	O
sum	O
of	O
the	O
5	O
OPCRIT	O
mental	O
state	O
variables	O
.	O

Each	O
symptom	O
domain	O
score	O
is	O
ordinal	O
(	O
with	O
zero	O
indicating	O
an	O
absence	O
of	O
those	O
symptoms	O
and	O
higher	O
values	O
indicating	O
increasing	O
symptom	O
severity	O
)	O
with	O
maximum	O
values	O
as	O
follows	O
:	O
affective	O
symptoms	O
(	O
maximum	O
score	O
=	O
58	O
)	O
,	O
abnormal	O
perception	O
(	O
12	O
)	O
,	O
abnormal	O
belief	O
(	O
41	O
)	O
,	O
speech	O
and	O
thought	O
disorder	O
(	O
13	O
)	O
,	O
and	O
appearance	O
and	O
behaviour	O
(	O
24	O
)	O
;	O
resulting	O
in	O
a	O
maximum	O
summed	O
symptom	O
severity	O
of	O
148	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
percentage	O
change	O
in	O
total	O
5	O
-	O
domain	O
MSE	O
symptom	O
score	O
at	O
admission	O
and	O
discharge	O
(	O
for	O
example	O
,	O
if	O
the	O
total	O
score	O
at	O
admission	O
is	O
95	O
,	O
and	O
at	O
discharge	O
55	O
,	O
this	O
represents	O
a	O
percentage	O
improvement	O
of	O
42	O
%	O
)	O
.	O

We	O
also	O
performed	O
analyses	O
on	O
this	O
primary	O
outcome	O
for	O
clozapine	O
monotherapy	O
,	O
and	O
clozapine	O
augmented	O
with	O
the	O
two	O
most	O
frequently	O
prescribed	O
(	O
in	O
our	O
sample	O
)	O
antipsychotics	O
(	O
quetiapine	O
,	O
amisulpride	O
)	O
and	O
mood	O
stabilisers	O
(	O
lithium	O
,	O
valproate	O
)	O
.	O

For	O
these	O
analyses	O
,	O
a	O
simple	O
linear	O
regression	O
was	O
used	O
to	O
study	O
the	O
effect	O
of	O
each	O
drug	O
,	O
dose	O
and	O
interactions	O
between	O
drugs	O
/	O
dose	O
on	O
the	O
primary	O
outcome	O
.	O

Pre	O
-	O
processing	O
and	O
data	O
quality	O
checking	O
were	O
performed	O
using	O
MATLAB	O
2013a	O
.	O

Tabulated	O
data	O
for	O
each	O
analysis	O
was	O
then	O
exported	O
for	O
graphing	O
using	O
the	O
R	O
statistical	O
package	O
with	O
ggplot2	O
libraries	O
.	O

For	O
the	O
exploratory	O
analysis	O
of	O
potential	O
drug	O
effects	O
on	O
specific	O
symptom	O
domains	O
we	O
evaluated	O
if	O
the	O
six	O
most	O
commonly	O
prescribed	O
drugs	O
-	O
on	O
which	O
we	O
had	O
enough	O
data	O
to	O
model	O
–	O
produced	O
changes	O
in	O
OPCRIT	O
outcomes	O
,	O
which	O
we	O
defined	O
categorically	O
as	O
:	O
1	O
,	O
worse	O
that	O
average	O
improvement	O
from	O
admission	O
to	O
discharge	O
,	O
where	O
average	O
was	O
defined	O
as	O
the	O
median	O
change	O
for	O
all	O
patients	O
during	O
this	O
time	O
;	O
2	O
,	O
average	O
improvement	O
during	O
this	O
time	O
;	O
3	O
,	O
better	O
than	O
average	O
improvement	O
.	O

Patients	O
who	O
scored	O
worse	O
than	O
the	O
median	O
-	O
IQR	O
(	O
interquartile	O
range	O
)	O
get	O
assigned	O
outcome	O
1	O
for	O
that	O
mental	O
state	O
outcome	O
(	O
e	O
.	O
g	O
.	O
speech	O
and	O
thought	O
)	O
;	O
those	O
who	O
scored	O
median	O
+	O
/	O
−	O
IQR	O
got	O
assigned	O
2	O
;	O
and	O
those	O
who	O
outperformed	O
and	O
scored	O
over	O
the	O
median	O
+	O
IQR	O
got	O
outcome	O
3	O
.	O

In	O
this	O
subanalysis	O
each	O
patient	O
therefore	O
had	O
an	O
ordinal	O
,	O
categorical	O
score	O
(	O
valued	O
at	O
either	O
1	O
,	O
2	O
or	O
3	O
)	O
in	O
the	O
five	O
outcome	O
domains	O
(	O
the	O
OPCRIT	O
domains	O
relating	O
to	O
mental	O
state	O
)	O
.	O

Conventional	O
multiple	O
regression	O
analysis	O
can	O
only	O
model	O
univariate	O
or	O
continuous	O
outcomes	O
,	O
whereas	O
we	O
aimed	O
to	O
explore	O
the	O
relationship	O
between	O
multiple	O
outcomes	O
and	O
multiple	O
drug	O
/	O
drug	O
combinations	O
.	O

To	O
proceed	O
,	O
we	O
constructed	O
five	O
separate	O
ordinal	O
probit	O
regression	O
models	O
,	O
one	O
for	O
each	O
of	O
the	O
mental	O
state	O
categorical	O
outcomes	O
with	O
the	O
same	O
drug	O
combinations	O
as	O
predictors	O
.	O

This	O
effectively	O
represents	O
five	O
sub	O
-	O
analyses	O
on	O
the	O
same	O
predictors	O
but	O
with	O
different	O
outcomes	O
,	O
there	O
is	O
a	O
risk	O
of	O
Type	O
II	O
error	O
,	O
where	O
a	O
significant	O
association	O
between	O
drug	O
combinations	O
(	O
i	O
.	O
e	O
.	O
regression	O
coefficients	O
with	O
p	O
values	O
less	O
than	O
0	O
.	O
05	O
)	O
is	O
found	O
purely	O
by	O
chance	O
because	O
of	O
the	O
number	O
of	O
sub	O
-	O
analyses	O
conducted	O
.	O

To	O
counter	O
this	O
,	O
the	O
fitted	O
regression	O
coefficients	O
for	O
each	O
of	O
the	O
five	O
ordinal	O
probit	O
regressions	O
were	O
tabulated	O
together	O
in	O
descending	O
rank	O
order	O
of	O
their	O
p	O
-	O
values	O
.	O

These	O
augmented	O
regression	O
coefficients	O
were	O
then	O
subjected	O
to	O
false	O
-	O
discovery	O
rate	O
(	O
FDR	O
)	O
corrections	O
using	O
the	O
Benjamini	O
and	O
Hochberg	O
method	O
to	O
control	O
the	O
Type	O
II	O
error	O
rate	O
.	O

We	O
then	O
report	O
only	O
associations	O
where	O
regression	O
coefficients	O
survived	O
FDR	O
correction	O
at	O
the	O
q	O
<	O
0	O
.	O
2	O
level	O
appropriate	O
for	O
exploratory	O
analyses	O
.	O

From	O
the	O
small	O
subset	O
of	O
significant	O
results	O
,	O
we	O
then	O
transformed	O
the	O
regression	O
coefficients	O
to	O
probabilities	O
of	O
being	O
in	O
the	O
worse	O
,	O
average	O
or	O
better	O
than	O
average	O
categories	O
for	O
each	O
drug	O
combination	O
in	O
each	O
of	O
the	O
five	O
mental	O
state	O
domains	O
.	O

The	O
advantage	O
of	O
this	O
method	O
is	O
that	O
it	O
captures	O
associations	O
between	O
drug	O
combinations	O
and	O
changes	O
over	O
the	O
mental	O
state	O
domains	O
similarly	O
to	O
multivariate	O
pattern	O
classification	O
methods	O
,	O
while	O
retaining	O
the	O
ability	O
to	O
draw	O
inferences	O
about	O
effect	O
sizes	O
in	O
an	O
interpretable	O
fashion	O
(	O
e	O
.	O
g	O
.	O
by	O
extracting	O
regression	O
coefficients	O
that	O
quantify	O
the	O
strength	O
and	O
direction	O
of	O
the	O
association	O
with	O
mental	O
state	O
domains	O
)	O
.	O

Of	O
153	O
records	O
,	O
11	O
patients	O
had	O
one	O
missing	O
drug	O
dose	O
value	O
for	O
medications	O
on	O
discharge	O
and	O
one	O
patient	O
was	O
missing	O
2	O
dose	O
values	O
.	O

In	O
total	O
,	O
3	O
.	O
5	O
%	O
(	O
145	O
individual	O
values	O
from	O
a	O
total	O
of	O
4131	O
)	O
of	O
the	O
demographics	O
data	O
had	O
missing	O
values	O
.	O

There	O
was	O
no	O
systematic	O
relationship	O
between	O
these	O
missing	O
values	O
;	O
they	O
were	O
treated	O
as	O
missing	O
-	O
at	O
-	O
random	O
and	O
non	O
-	O
parametric	O
imputation	O
by	O
k	O
-	O
nearest	O
neighbours	O
was	O
used	O
to	O
impute	O
missing	O
values	O
.	O

The	O
Measuring	O
the	O
Impact	O
on	O
Nicotine	O
Dependence	O
after	O
Stroke	O
(	O
MINDS	O
)	O
study	O
population	O
consisted	O
of	O
adults	O
aged	O
18	O
years	O
and	O
older	O
who	O
were	O
admitted	O
to	O
one	O
of	O
three	O
acute	O
care	O
hospitals	O
in	O
Rochester	O
,	O
NY	O
with	O
a	O
diagnosis	O
of	O
acute	B-Phenotype
ischemic	I-Phenotype
stroke	I-Phenotype
(	O
ICD	B-Coding_system
-	I-Coding_system
9	I-Coding_system
code	O
434	B-Code
.	I-Code
91	I-Code
)	O
and	O
were	O
active	O
cigarette	O
smokers	O
at	O
the	O
time	O
of	O
stroke	O
onset	O
.	O

Patients	O
were	O
eligible	O
to	O
participate	O
if	O
they	O
met	O
all	O
of	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
smoked	O
at	O
least	O
one	O
cigarette	O
per	O
day	O
during	O
the	O
month	O
prior	O
to	O
their	O
stroke	O
and	O
at	O
least	O
100	O
in	O
their	O
lifetime	O
;	O
(	O
2	O
)	O
understand	O
and	O
speak	O
the	O
English	O
language	O
;	O
(	O
3	O
)	O
stable	O
enough	O
,	O
as	O
determined	O
by	O
a	O
nurse	O
practitioner	O
,	O
to	O
give	O
autonomous	O
informed	O
consent	O
and	O
respond	O
to	O
the	O
survey	O
questions	O
verbally	O
or	O
on	O
paper	O
;	O
and	O
(	O
4	O
)	O
willing	O
to	O
respond	O
to	O
the	O
follow	O
-	O
up	O
survey	O
three	O
months	O
after	O
hospital	O
admission	O
.	O

Exclusion	O
criteria	O
were	O
only	O
applicable	O
for	O
follow	O
-	O
up	O
evaluations	O
and	O
are	O
not	O
relevant	O
for	O
the	O
current	O
study	O
using	O
only	O
admission	O
data	O
.	O

We	O
needed	O
125	O
participants	O
to	O
detect	O
a	O
2	O
.	O
35	O
-	O
point	O
difference	O
in	O
withdrawal	O
scale	O
scores	O
between	O
groups	O
(	O
23	O
)	O
with	O
80	O
%	O
power	O
and	O
0	O
.	O
05	O
probability	O
of	O
Type	O
I	O
error	O
.	O

A	O
total	O
of	O
470	O
ever	O
smokers	O
with	O
acute	O
ischemic	O
stroke	O
were	O
identified	O
between	O
June	O
2013	O
and	O
February	O
2014	O
;	O
data	O
collection	O
ended	O
May	O
2014	O
.	O

Among	O
the	O
204	O
(	O
43	O
.	O
4	O
%	O
)	O
who	O
met	O
the	O
definition	O
of	O
a	O
current	O
smoker	O
,	O
48	O
(	O
23	O
.	O
5	O
%	O
)	O
were	O
excluded	O
for	O
not	O
meeting	O
the	O
eligibility	O
criteria	O
(	O
16	O
declined	O
to	O
participate	O
,	O
10	O
were	O
aphasic	O
during	O
admission	O
,	O
9	O
were	O
discharged	O
before	O
consent	O
,	O
6	O
smoked	O
less	O
than	O
one	O
cigarette	O
per	O
day	O
,	O
4	O
had	O
language	O
barriers	O
,	O
and	O
3	O
died	O
in	O
the	O
hospital	O
)	O
.	O

After	O
these	O
exclusions	O
,	O
156	O
patients	O
were	O
enrolled	O
into	O
the	O
study	O
(	O
oversampled	O
by	O
20	O
%	O
)	O
.	O

All	O
participants	O
signed	O
informed	O
consent	O
forms	O
.	O

The	O
institutional	O
review	O
boards	O
at	O
all	O
participating	O
institutions	O
approved	O
the	O
study	O
protocols	O
and	O
procedures	O
.	O

Acute	O
infarctions	O
to	O
the	O
insular	O
cortex	O
,	O
the	O
primary	O
region	O
of	O
interest	O
,	O
and	O
the	O
aforementioned	O
mesocorticolimbic	O
structures	O
were	O
characterized	O
by	O
neuroradiologists	O
(	O
H	O
.	O
Z	O
.	O
W	O
.	O

,	O
E	O
.	O
M	O
.	O
S	O
.	O

,	O
B	O
.	O
E	O
.	O
S	O
.	O
)	O
using	O
standard	O
of	O
care	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
techniques	O
in	O
all	O
participants	O
(	O
Figure	O
1	O
)	O
.	O

Unexposed	O
participants	O
were	O
those	O
with	O
cerebral	O
infarctions	O
not	O
in	O
the	O
insular	O
cortex	O
.	O

The	O
findings	O
from	O
MRI	O
were	O
weighed	O
more	O
than	O
CT	O
;	O
however	O
CT	O
imaging	O
was	O
used	O
when	O
MRI	O
was	O
contraindicated	O
.	O

On	O
MRI	O
,	O
diffusion	O
weighted	O
imaging	O
was	O
used	O
to	O
evaluate	O
lesion	O
location	O
if	O
done	O
within	O
a	O
few	O
days	O
from	O
the	O
stroke	O
.	O

If	O
follow	O
-	O
up	O
MRI	O
scans	O
were	O
available	O
,	O
the	O
fluid	O
attenuated	O
inversion	O
recovery	O
sequence	O
was	O
used	O
to	O
verify	O
the	O
initial	O
MRI	O
findings	O
.	O

The	O
NAc	O
and	O
VTA	O
were	O
the	O
two	O
most	O
difficult	O
regions	O
to	O
evaluate	O
as	O
they	O
are	O
not	O
routinely	O
evaluated	O
in	O
practice	O
and	O
the	O
standard	O
MRI	O
uses	O
5mm	O
slices	O
which	O
may	O
be	O
too	O
thick	O
to	O
detect	O
lesions	O
in	O
these	O
areas	O
.	O
(	O
24	O
)	O
Of	O
the	O
156	O
participants	O
,	O
acute	O
to	O
subacute	O
infarctions	O
in	O
the	O
insula	O
were	O
detected	O
in	O
38	O
(	O
24	O
.	O
4	O
%	O
)	O
participants	O
.	O

Further	O
lesion	O
characterizations	O
of	O
regions	O
of	O
interest	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Severity	O
of	O
stroke	O
was	O
measured	O
using	O
the	O
National	O
Institutes	O
of	O
Health	O
Stroke	O
Scale	O
(	O
NIHSS	O
)	O
(	O
25	O
)	O
,	O
a	O
15	O
-	O
item	O
neurologic	O
assessment	O
tool	O
administered	O
by	O
clinicians	O
at	O
bedside	O
to	O
evaluate	O
acuity	O
of	O
patients	O
,	O
guide	O
treatment	O
,	O
and	O
predict	O
outcomes	O
.	O

The	O
scale	O
measures	O
levels	O
of	O
consciousness	O
,	O
speech	O
impairment	O
,	O
neglect	O
,	O
visual	O
perception	O
,	O
extraocular	O
movement	O
,	O
motor	O
function	O
,	O
ataxia	O
,	O
dysarthria	O
,	O
and	O
sensory	O
loss	O
.	O

Lesion	O
volumes	O
from	O
diffusion	O
and	O
perfusion	O
-	O
weighted	O
MRI	O
are	O
highly	O
correlated	O
with	O
NIHSS	O
score	O
in	O
acute	O
ischemic	O
stroke	O
patients	O
(	O
r	O
=	O
0	O
.	O
96	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
thus	O
serves	O
as	O
a	O
surrogate	O
measure	O
for	O
infarction	O
size	O
.	O
(	O
26	O
)	O

Exposure	O
data	O
were	O
collected	O
and	O
managed	O
using	O
Research	O
Electronic	O
Data	O
Capture	O
(	O
REDCap	O
)	O
(	O
27	O
)	O
tools	O
hosted	O
at	O
the	O
University	O
of	O
Rochester	O
.	O

Lesions	O
in	O
80	O
(	O
51	O
.	O
3	O
%	O
)	O
participants	O
were	O
identified	O
using	O
only	O
MRI	O
,	O
22	O
(	O
14	O
.	O
1	O
%	O
)	O
using	O
only	O
CT	O
,	O
and	O
54	O
(	O
34	O
.	O
6	O
%	O
)	O
using	O
both	O
MRI	O
and	O
CT	O
.	O

All	O
participants	O
were	O
confirmed	O
to	O
have	O
acute	O
to	O
subacute	O
infarctions	O
.	O

During	O
hospitalization	O
,	O
patients	O
were	O
not	O
permitted	O
to	O
leave	O
the	O
unit	O
to	O
smoke	O
,	O
signifying	O
a	O
period	O
of	O
smoking	O
abstinence	O
from	O
the	O
time	O
of	O
stroke	O
.	O

Since	O
withdrawal	O
symptoms	O
typically	O
emerge	O
within	O
a	O
few	O
hours	O
following	O
the	O
last	O
smoked	O
cigarette	O
and	O
peak	O
within	O
a	O
few	O
days	O
to	O
one	O
week	O
(	O
28	O
,	O
29	O
)	O
,	O
this	O
period	O
represents	O
an	O
ideal	O
window	O
to	O
assess	O
the	O
presence	O
and	O
intensity	O
of	O
these	O
symptoms	O
.	O

The	O
Wisconsin	O
Smoking	O
Withdrawal	O
Scale	O
(	O
WSWS	O
)	O
(	O
30	O
)	O
and	O
Minnesota	O
Nicotine	O
Withdrawal	O
Scale	O
(	O
MNWS	O
)	O
(	O
31	O
)	O
were	O
administered	O
at	O
bedside	O
after	O
consent	O
(	O
mean	O
=	O
4	O
.	O
4	O
days	O
post	O
-	O
admission	O
)	O
to	O
quantify	O
severity	O
of	O
nicotine	O
withdrawal	O
symptoms	O
in	O
both	O
exposure	O
groups	O
.	O

The	O
primary	O
outcome	O
,	O
the	O
WSWS	O
,	O
is	O
a	O
28	O
-	O
item	O
scale	O
that	O
uses	O
three	O
to	O
five	O
items	O
to	O
measure	O
seven	O
constructs	O
,	O
including	O
irritability	O
,	O
depression	O
,	O
increased	O
appetite	O
,	O
difficulty	O
concentrating	O
,	O
insomnia	O
,	O
anxiety	O
,	O
and	O
urge	O
.	O

The	O
WSWS	O
has	O
been	O
effectively	O
used	O
in	O
both	O
clinical	O
and	O
research	O
settings	O
and	O
shown	O
to	O
be	O
highly	O
reliable	O
and	O
valid	O
.	O
(	O
30	O
)	O
The	O
total	O
WSWS	O
score	O
was	O
calculated	O
by	O
averaging	O
the	O
items	O
for	O
each	O
withdrawal	O
symptom	O
(	O
excluding	O
urge	O
since	O
this	O
is	O
not	O
a	O
DMS	O
-	O
IV	O
criteria	O
for	O
withdrawal	O
;	O
we	O
also	O
wanted	O
to	O
differentiate	O
withdrawal	O
from	O
cravings	O
)	O
(	O
32	O
)	O
and	O
summing	O
the	O
means	O
.	O

The	O
MNWS	O
,	O
a	O
secondary	O
measure	O
of	O
withdrawal	O
with	O
less	O
robust	O
psychometrics	O
but	O
more	O
historical	O
value	O
,	O
is	O
an	O
eight	O
-	O
item	O
scale	O
measuring	O
eight	O
constructs	O
,	O
including	O
the	O
seven	O
previously	O
listed	O
plus	O
restlessness	O
.	O
(	O
31	O
)	O
Total	O
MNWS	O
score	O
was	O
calculated	O
by	O
taking	O
the	O
mean	O
of	O
the	O
eight	O
items	O
.	O

Only	O
one	O
rater	O
(	O
A	O
.	O
A	O
.	O
)	O
conducted	O
all	O
the	O
assessments	O
and	O
was	O
blinded	O
to	O
exposure	O
status	O
.	O

NRT	O
use	O
(	O
yes	O
/	O
no	O
)	O
during	O
hospitalization	O
,	O
including	O
the	O
use	O
of	O
nicotine	O
inhaler	O
,	O
lozenge	O
,	O
patch	O
,	O
gum	O
,	O
and	O
nasal	O
spray	O
,	O
was	O
self	O
-	O
reported	O
by	O
the	O
patient	O
and	O
confirmed	O
in	O
the	O
electronic	O
medical	O
record	O
.	O

Patients	O
were	O
not	O
allowed	O
to	O
use	O
any	O
other	O
forms	O
of	O
tobacco	O
or	O
electronic	O
cigarettes	O
during	O
their	O
hospitalization	O
.	O

Baseline	O
characteristics	O
of	O
participants	O
were	O
described	O
using	O
relative	O
frequencies	O
for	O
categorical	O
measures	O
and	O
means	O
and	O
standard	O
deviations	O
(	O
SD	O
)	O
for	O
continuous	O
measures	O
.	O

To	O
test	O
for	O
a	O
difference	O
in	O
mean	O
WSWS	O
and	O
MNWS	O
scores	O
during	O
hospitalization	O
between	O
insular	O
and	O
non	O
-	O
insular	O
damaged	O
participants	O
,	O
an	O
independent	O
samples	O
Student	O
t	O
-	O
test	O
was	O
used	O
assuming	O
normally	O
distributed	O
scores	O
while	O
median	O
values	O
and	O
Wilcoxon	O
-	O
Mann	O
-	O
Whitney	O
test	O
were	O
used	O
for	O
non	O
-	O
parametric	O
statistics	O
.	O

To	O
examine	O
effects	O
of	O
individual	O
symptoms	O
,	O
identical	O
analyses	O
were	O
done	O
stratifying	O
the	O
WSWS	O
into	O
its	O
subscale	O
components	O
.	O

A	O
two	O
-	O
sided	O
p	O
-	O
value	O
of	O
less	O
than	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

In	O
addition	O
to	O
unadjusted	O
comparisons	O
,	O
multivariable	O
linear	O
regression	O
models	O
were	O
used	O
to	O
control	O
for	O
covariates	O
that	O
were	O
predictive	O
of	O
outcomes	O
in	O
this	O
particular	O
study	O
as	O
well	O
as	O
all	O
a	O
priori	O
theoretical	O
risk	O
factors	O
for	O
the	O
outcomes	O
,	O
including	O
age	O
,	O
baseline	O
FTND	O
(	O
asked	O
retrospectively	O
)	O
,	O
NRT	O
use	O
during	O
admission	O
(	O
yes	O
/	O
no	O
)	O
,	O
NIHSS	O
score	O
,	O
acute	O
mesocorticolimbic	O
infarction	O
(	O
yes	O
/	O
no	O
)	O
,	O
and	O
intent	O
to	O
quit	O
(	O
prior	O
to	O
stroke	O
)	O
in	O
the	O
next	O
month	O
with	O
an	O
attempt	O
in	O
the	O
past	O
year	O
(	O
asked	O
retrospectively	O
;	O
yes	O
/	O
no	O
)	O
.	O

To	O
evaluate	O
whether	O
NRT	O
use	O
differed	O
between	O
exposure	O
groups	O
during	O
hospitalization	O
,	O
a	O
logistic	O
regression	O
analysis	O
was	O
performed	O
in	O
which	O
the	O
binary	O
dependent	O
variable	O
was	O
whether	O
or	O
not	O
patients	O
received	O
NRT	O
to	O
cope	O
with	O
their	O
withdrawal	O
symptoms	O
.	O

Crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
calculated	O
,	O
controlling	O
for	O
age	O
,	O
baseline	O
FTND	O
,	O
NIHSS	O
score	O
,	O
acute	O
mesocorticolimbic	O
infarction	O
,	O
and	O
prior	O
intent	O
to	O
quit	O
.	O

All	O
statistical	O
procedures	O
were	O
performed	O
using	O
SAS	O
version	O
9	O
.	O
3	O
(	O
SAS	O
Institute	O
,	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
)	O
.	O

We	O
used	O
NH	O
consultation	O
data	O
from	O
two	O
palliative	O
care	O
organizations	O
in	O
two	O
U	O
.	O
S	O
.	O
states	O
(	O
North	O
Carolina	O
(	O
NC	O
)	O
and	O
Rhode	O
Island	O
(	O
RI	O
)	O
)	O
.	O

The	O
NHs	O
in	O
which	O
these	O
consultations	O
were	O
provided	O
were	O
located	O
in	O
eight	O
counties	O
(	O
two	O
in	O
NC	O
and	O
six	O
in	O
RI	O
)	O
where	O
the	O
organizations	O
in	O
the	O
study	O
years	O
were	O
the	O
exclusive	O
providers	O
of	O
specialty	O
palliative	O
care	O
consultations	O
.	O

Collaboration	O
with	O
the	O
providers	O
was	O
necessary	O
since	O
there	O
is	O
no	O
Medicare	O
payment	O
stream	O
for	O
specialty	O
palliative	O
care	O
consultations	O
and	O
thus	O
no	O
Medicare	O
payment	O
code	O
(	O
s	O
)	O
to	O
validly	O
identify	O
consultation	O
recipients	O
.	O

Prior	O
to	O
study	O
commencement	O
,	O
we	O
obtained	O
a	O
data	O
use	O
agreement	O
(	O
DUA	O
)	O
from	O
the	O
Centers	O
for	O
Medicare	O
&	O
Medicaid	O
Services	O
(	O
CMS	O
)	O
and	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
(	O
HIPAA	O
)	O
waiver	O
approvals	O
from	O
the	O
two	O
organizations	O
sharing	O
2005–2010	O
NH	O
consultation	O
data	O
.	O

This	O
study	O
was	O
approved	O
by	O
Brown	O
University’s	O
Institutional	O
Review	O
Board	O
.	O

Palliative	O
care	O
provider	O
data	O
were	O
linked	O
to	O
Medicare	O
enrollment	O
and	O
Part	O
A	O
claims	O
data	O
,	O
as	O
well	O
as	O
NH	O
resident	O
assessment	O
Minimum	O
Data	O
Set	O
(	O
MDS	O
)	O
data	O
.	O
(	O
24	O
)	O
The	O
enrollment	O
file	O
contains	O
data	O
on	O
vital	O
status	O
,	O
Medicare	O
eligibility	O
,	O
and	O
Medicare	O
Advantage	O
enrollment	O
.	O

Part	O
A	O
claims	O
data	O
provides	O
information	O
including	O
dates	O
of	O
service	O
and	O
diagnoses	O
on	O
hospital	O
,	O
skilled	O
nursing	O
facility	O
(	O
SNF	O
)	O
,	O
emergency	O
room	O
(	O
ER	O
)	O
,	O
home	O
health	O
care	O
and	O
hospice	O
use	O
.	O

Nursing	O
home	O
level	O
aggregated	O
resident	O
characteristics	O
from	O
the	O
MDS	O
and	O
data	O
from	O
the	O
Online	O
Survey	O
,	O
Certification	O
and	O
Reporting	O
(	O
OSCAR	O
)	O
provided	O
information	O
on	O
NH	O
characteristics	O
.	O

As	O
described	O
in	O
further	O
detail	O
elsewhere	O
,	O
(	O
19	O
)	O
we	O
began	O
with	O
a	O
sample	O
of	O
508	O
NH	O
decedents	O
with	O
initial	O
palliative	O
care	O
consultations	O
in	O
the	O
last	O
six	O
months	O
of	O
life	O
who	O
were	O
Medicare	O
-	O
eligible	O
and	O
not	O
enrolled	O
in	O
Medicare	O
Advantage	O
in	O
the	O
last	O
year	O
of	O
life	O
,	O
and	O
who	O
had	O
a	O
MDS	O
assessment	O
within	O
180	O
days	O
prior	O
to	O
their	O
initial	O
consultation	O
(	O
index	O
MDS	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
include	O
only	O
those	O
of	O
the	O
508	O
residents	O
who	O
had	O
moderate	O
to	O
very	O
severe	O
dementia	O
at	O
baseline	O
.	O

Residents	O
identified	O
as	O
having	O
a	O
dementia	B-Phenotype
diagnoses	O
had	O
a	O
baseline	O
MDS	O
with	O
a	O
coded	O
or	O
identified	B-Phenotype
(	I-Phenotype
“checked”	I-Phenotype
)	I-Phenotype
dementia	I-Phenotype
diagnosis	O
or	O
any	B-Phenotype
dementia	I-Phenotype
diagnosis	O
on	O
a	O
Part	O
A	O
claim	O
in	O
the	O
last	O
year	O
of	O
life	O
(	O
identified	O
from	O
ICD	B-Coding_system
-	I-Coding_system
9	I-Coding_system
diagnosis	O
codes	O
290	B-Code
.	I-Code
XX	I-Code
,	O
291	B-Code
.	I-Code
2	I-Code
,	O
292	B-Code
.	I-Code
82	I-Code
,	O
294	B-Code
.	I-Code
1	I-Code
,	O
294	B-Code
.	I-Code
8	I-Code
,	O
294	B-Code
.	I-Code
10	I-Code
,	O
294	B-Code
.	I-Code
11	I-Code
,	O
331	B-Code
,	O
331	B-Code
.	I-Code
0	I-Code
,	O
331	B-Code
.	I-Code
00	I-Code
,	O
331	B-Code
.	I-Code
1	I-Code
,	O
331	B-Code
.	I-Code
11	I-Code
,	O
331	B-Code
.	I-Code
19	I-Code
,	O
331	B-Code
.	I-Code
2	I-Code
,	O
and	O
331	B-Code
.	I-Code
82	I-Code
)	O
.	O

We	O
determined	O
the	O
level	O
of	O
cognitive	O
impairment	O
by	O
using	O
the	O
Cognitive	O
Performance	O
Scale	O
(	O
CPS	O
)	O
score	O
(	O
25	O
)	O
derived	O
from	O
the	O
baseline	O
MDS	O
.	O

We	O
included	O
residents	O
with	O
dementia	O
diagnoses	O
and	O
with	O
a	O
CPS	O
score	O
of	O
3	O
or	O
greater	O
,	O
indicating	O
moderate	O
to	O
very	O
severe	O
(	O
advanced	O
)	O
cognitive	O
impairment	O
(	O
217	O
decedents	O
in	O
31	O
NHs	O
)	O
.	O

To	O
control	O
for	O
potential	O
differences	O
in	O
preferences	O
for	O
life	O
-	O
sustaining	O
treatments	O
and	O
sociodemographic	O
and	O
clinical	O
characteristics	O
,	O
we	O
chose	O
pscore	O
matched	O
controls	O
.	O

Decedents	O
,	O
eligible	O
to	O
serve	O
as	O
controls	O
came	O
from	O
the	O
same	O
NHs	O
and	O
timeframes	O
,	O
met	O
the	O
same	O
inclusion	O
criteria	O
as	O
residents	O
with	O
consults	O
,	O
and	O
also	O
had	O
MDS	O
assessments	O
in	O
time	O
periods	O
comparable	O
to	O
consultation	O
recipients’	O
baseline	O
assessments	O
.	O

We	O
first	O
stratified	O
the	O
treatment	O
sample	O
into	O
two	O
treatment	O
groups	O
by	O
days	O
between	O
the	O
initial	O
consultation	O
and	O
death	O
to	O
enable	O
examination	O
of	O
the	O
timing	O
of	O
palliative	O
care	O
:	O
earlier	O
initial	O
consultations	O
(	O
31–180	O
days	O
prior	O
to	O
death	O
)	O
and	O
later	O
initial	O
consultations	O
(	O
1–30	O
days	O
prior	O
to	O
death	O
)	O
.	O

Variables	O
for	O
pscore	O
model	O
inclusion	O
were	O
largely	O
based	O
on	O
an	O
earlier	O
related	O
research	O
.	O
(	O
12	O
,	O
13	O
,	O
26	O
–	O
28	O
)	O
Thirteen	O
consultation	O
recipients	O
were	O
dropped	O
from	O
the	O
sample	O
due	O
to	O
either	O
missing	O
information	O
on	O
the	O
covariates	O
used	O
for	O
matching	O
(	O
n=9	O
)	O
or	O
a	O
lack	O
of	O
potential	O
matches	O
within	O
their	O
particular	O
NH	O
(	O
n=4	O
)	O
.	O

Using	O
propensity	O
score	O
matching	O
with	O
replacement	O
,	O
we	O
identified	O
three	O
matched	O
controls	O
for	O
203	O
of	O
the	O
remaining	O
204	O
(	O
99	O
.	O
5	O
%	O
)	O
consultation	O
decedents	O
for	O
a	O
total	O
of	O
429	O
propensity	O
-	O
matched	O
controls	O
.	O

(	O
See	O
also	O
Supplemental	O
file	O
.	O
)	O

The	O
treatment	O
of	O
interest	O
was	O
initial	O
exposure	O
to	O
any	O
specialty	O
palliative	O
care	O
consultation	O
in	O
the	O
last	O
six	O
months	O
of	O
life	O
.	O

Like	O
other	O
consultations	O
,	O
these	O
consults	O
are	O
ordered	O
by	O
physicians	O
often	O
at	O
the	O
request	O
of	O
NH	O
staff	O
or	O
families	O
;	O
unlike	O
hospice	O
,	O
no	O
enrollment	O
is	O
required	O
.	O
(	O
29	O
)	O
Palliative	O
care	O
consultation	O
visits	O
at	O
both	O
study	O
organizations	O
are	O
made	O
by	O
nurse	O
practitioner	O
palliative	O
care	O
specialists	O
,	O
under	O
the	O
supervision	O
of	O
certified	O
palliative	O
care	O
physicians	O
.	O

While	O
interdisciplinary	O
palliative	O
care	O
team	O
members	O
visit	O
residents	O
when	O
needs	O
exist	O
,	O
such	O
visits	O
are	O
not	O
routinely	O
provided	O
or	O
integral	O
to	O
this	O
model	O
.	O

At	O
both	O
study	O
sites	O
,	O
initial	O
consultations	O
typically	O
include	O
a	O
review	O
of	O
diagnoses	O
and	O
prognoses	O
and	O
address	O
symptom	O
control	O
needs	O
.	O

To	O
ensure	O
treatment	O
consistent	O
with	O
preferences	O
,	O
specialists	O
also	O
review	O
advance	O
directives	O
,	O
if	O
available	O
,	O
and	O
discuss	O
goals	O
of	O
care	O
.	O

Family	O
meetings	O
are	O
a	O
key	O
component	O
of	O
many	O
consultations	O
.	O

Similar	O
to	O
other	O
studies	O
,	O
(	O
11	O
,	O
13	O
,	O
14	O
,	O
26	O
,	O
30	O
,	O
31	O
)	O
we	O
considered	O
hospice	O
enrollment	O
(	O
after	O
initial	O
consultation	O
)	O
to	O
be	O
within	O
the	O
treatment	O
pathway	O
.	O

Outcomes	O
were	O
measured	O
using	O
Medicare	O
claims	O
.	O

For	O
both	O
residents	O
with	O
earlier	O
or	O
later	O
initial	O
consultations	O
the	O
outcomes	O
were	O
any	O
hospitalization	O
in	O
the	O
last	O
7	O
days	O
of	O
life	O
and	O
any	O
(	O
potentially	O
)	O
burdensome	O
end	O
-	O
of	O
-	O
life	O
transition	O
.	O

A	O
resident	O
was	O
considered	O
to	O
have	O
had	O
a	O
burdensome	O
transition	O
if	O
s	O
/	O
he	O
had	O
a	O
hospitalization	O
or	O
hospice	O
admission	O
within	O
three	O
days	O
of	O
death	O
or	O
more	O
than	O
one	O
hospitalization	O
or	O
ER	O
visit	O
in	O
the	O
last	O
30	O
days	O
of	O
life	O
.	O

For	O
those	O
with	O
earlier	O
initial	O
consultations	O
,	O
outcomes	O
also	O
included	O
any	O
hospitalization	O
or	O
any	O
ER	O
visit	O
(	O
without	O
subsequent	O
hospitalization	O
)	O
in	O
the	O
last	O
30	O
days	O
of	O
life	O
.	O

We	O
also	O
compared	O
total	O
Medicare	O
Part	O
A	O
expenditures	O
(	O
inpatient	O
,	O
outpatient	O
,	O
hospice	O
,	O
and	O
SNF	O
)	O
standardized	O
to	O
2007	O
dollars	O
.	O

As	O
with	O
our	O
other	O
outcomes	O
,	O
because	O
we	O
were	O
interested	O
in	O
post	O
-	O
consultation	O
time	O
periods	O
only	O
,	O
we	O
compared	O
expenditures	O
in	O
the	O
last	O
7	O
days	O
of	O
life	O
for	O
both	O
groups	O
and	O
expenditures	O
in	O
the	O
last	O
30	O
days	O
for	O
residents	O
with	O
earlier	O
initial	O
consultations	O
.	O

Resident	O
-	O
level	O
covariates	O
were	O
derived	O
from	O
the	O
baseline	O
MDS	O
unless	O
otherwise	O
noted	O
.	O

Sociodemographic	O
variables	O
included	O
age	O
,	O
gender	O
,	O
marital	O
status	O
(	O
married	O
vs	O
.	O
other	O
)	O
,	O
and	O
race	O
(	O
non	O
-	O
white	O
vs	O
.	O
white	O
)	O
.	O

Whether	O
a	O
NH	O
stay	O
was	O
short	O
or	O
long	O
(	O
≥	O
90	O
days	O
)	O
and	O
preference	O
variables	O
indicating	O
the	O
presence	O
or	O
absence	O
of	O
do	O
-	O
not	O
-	O
resuscitate	O
(	O
DNR	O
)	O
and	O
do	O
-	O
not	O
-	O
hospitalize	O
(	O
DNH	O
)	O
orders	O
were	O
also	O
included	O
.	O

Functional	O
impairment	O
was	O
represented	O
by	O
the	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
scale	O
,	O
ranging	O
from	O
0	O
to	O
28	O
(	O
higher	O
values	O
indicating	O
greater	O
impairment	O
)	O
.	O

The	O
CPS	O
reflected	O
cognitive	O
impairment	O
,	O
with	O
scores	O
for	O
this	O
study	O
ranging	O
from	O
3	O
to	O
6	O
indicating	O
moderate	O
(	O
3	O
)	O
,	O
moderate	O
severe	O
(	O
4	O
)	O
,	O
severe	O
(	O
5	O
)	O
and	O
very	O
severe	O
(	O
6	O
)	O
impairment	O
.	O

In	O
addition	O
,	O
a	O
variable	O
denoting	O
unstable	O
,	O
deteriorating	O
,	O
or	O
declining	O
cognitive	O
or	O
functional	O
status	O
was	O
included	O
as	O
were	O
variables	O
to	O
reflect	O
the	O
days	O
between	O
the	O
baseline	O
MDS	O
and	O
death	O
.	O

Cancer	O
was	O
defined	O
using	O
both	O
the	O
baseline	O
MDS	O
and	O
Part	O
A	O
Medicare	O
claims	O
in	O
the	O
last	O
year	O
of	O
life	O
,	O
as	O
were	O
congestive	O
heart	O
failure	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
which	O
we	O
included	O
only	O
when	O
evaluating	O
outcomes	O
for	O
residents	O
receiving	O
consultations	O
later	O
.	O

Finally	O
,	O
we	O
controlled	O
for	O
previous	O
acute	O
care	O
use	O
as	O
defined	O
by	O
whether	O
a	O
resident	O
had	O
any	O
hospitalizations	O
90	O
days	O
prior	O
to	O
the	O
baseline	O
MDS	O
.	O

Using	O
aggregated	O
MDS	O
data	O
,	O
we	O
created	O
continuous	O
variables	O
reflecting	O
a	O
NH’s	O
percentage	O
of	O
non	O
-	O
white	O
residents	O
and	O
its	O
case	O
mix	O
severity	O
,	O
based	O
on	O
Medicare’s	O
Resource	O
Utilization	O
Groups	O
(	O
RUGS	O
)	O
.	O

Dichotomous	O
(	O
yes	O
/	O
no	O
)	O
NH	O
-	O
level	O
variables	O
from	O
the	O
OSCAR	O
database	O
included	O
chain	O
affiliation	O
,	O
for	O
-	O
profit	O
status	O
,	O
the	O
presence	O
of	O
an	O
Alzheimer’s	O
unit	O
,	O
whether	O
a	O
NH’s	O
proportion	O
of	O
residents	O
with	O
dementia	O
was	O
above	O
the	O
median	O
of	O
all	O
study	O
NHs	O
(	O
in	O
a	O
given	O
year	O
)	O
,	O
and	O
whether	O
it	O
employed	O
any	O
nurse	O
practitioner	O
/	O
physician	O
assistant	O
.	O

Continuous	O
OSCAR	O
measures	O
included	O
the	O
proportion	O
of	O
residents	O
with	O
Medicaid	O
or	O
Medicare	O
as	O
primary	O
payer	O
.	O

Finally	O
,	O
a	O
continuous	O
variable	O
represented	O
the	O
distance	O
from	O
the	O
NH	O
to	O
the	O
nearest	O
hospital	O
and	O
state	O
(	O
RI	O
or	O
NC	O
)	O
and	O
resident’s	O
year	O
of	O
death	O
were	O
represented	O
by	O
indicator	O
variables	O
.	O

Propensity	O
scores	O
were	O
derived	O
from	O
logistic	O
regression	O
models	O
.	O

Using	O
Stata	O
14	O
.	O
2	O
,	O
pscore	O
matching	O
with	O
replacement	O
resulted	O
in	O
112	O
consultation	O
decedents	O
and	O
259	O
(	O
unduplicated	O
)	O
controls	O
in	O
the	O
later	O
consultation	O
group	O
and	O
91	O
decedents	O
and	O
170	O
(	O
unduplicated	O
)	O
controls	O
in	O
the	O
earlier	O
consultation	O
group	O
.	O

Covariate	O
balance	O
was	O
achieved	O
by	O
examining	O
standardized	O
differences	O
and	O
Kernal	O
Density	O
plots	O
before	O
and	O
after	O
matching	O
(	O
see	O
Supplemental	O
file	O
)	O
.	O
(	O
32	O
,	O
33	O
)	O

To	O
evaluate	O
outcomes	O
,	O
we	O
controlled	O
for	O
any	O
remaining	O
confounding	O
(	O
34	O
)	O
by	O
using	O
weighted	O
multivariate	O
logistic	O
regressions	O
with	O
most	O
of	O
the	O
same	O
variables	O
used	O
for	O
matching	O
,	O
as	O
appropriate	O
to	O
the	O
modeled	O
outcome	O
.	O

The	O
weights	O
were	O
normalized	O
weights	O
generated	O
by	O
the	O
pscore	O
matching	O
process	O
,	O
and	O
the	O
Wald	O
X	O
2	O
test	O
was	O
used	O
to	O
assess	O
fit	O
of	O
the	O
weighted	O
models	O
.	O

Using	O
Stata’s	O
margins	O
command	O
we	O
determined	O
average	O
individual	O
risk	O
differences	O
(	O
average	O
marginal	O
effects	O
)	O
.	O

To	O
evaluate	O
Medicare	O
expenditures	O
given	O
the	O
skewed	O
nature	O
of	O
such	O
data	O
,	O
we	O
used	O
generalized	O
linear	O
modeling	O
with	O
gamma	O
distribution	O
and	O
a	O
log	O
link	O
function	O
in	O
Stata	O
.	O

The	O
study	O
was	O
done	O
at	O
the	O
Addiction	O
Research	O
Centre	O
,	O
Alternative	O
Georgia	O
,	O
a	O
independent	O
non	O
-	O
profit	O
research	O
institution	O
located	O
in	O
a	O
residential	O
area	O
in	O
one	O
of	O
the	O
central	O
districts	O
of	O
Tbilisi	O
.	O

It	O
is	O
closely	O
affiliated	O
with	O
the	O
nearby	O
Centre	O
for	O
Medical	O
,	O
Socio	O
-	O
economic	O
and	O
Cultural	O
Issues	O
,	O
the	O
second	O
largest	O
addiction	O
program	O
in	O
the	O
country	O
and	O
one	O
that	O
provides	O
in	O
-	O
patient	O
detoxification	O
,	O
psychosocial	O
-	O
based	O
outpatient	O
treatment	O
,	O
and	O
methadone	O
maintenance	O
.	O

Patients	O
were	O
recruited	O
through	O
word	O
of	O
mouth	O
,	O
fliers	O
and	O
advertisements	O
in	O
addiction	O
clinics	O
,	O
harm	O
reduction	O
programs	O
,	O
and	O
other	O
facilities	O
frequented	O
by	O
injection	O
drug	O
users	O
.	O

All	O
screening	O
,	O
assessment	O
and	O
follow	O
-	O
up	O
evaluations	O
were	O
done	O
at	O
Uranti	O
.	O

The	O
clinical	O
director	O
(	O
ZS	O
)	O
was	O
responsible	O
for	O
enrolling	O
participants	O
,	O
as	O
well	O
as	O
for	O
assigning	O
them	O
to	O
interventions	O
following	O
randomization	O
.	O

The	O
consent	O
form	O
included	O
information	O
about	O
the	O
purpose	O
of	O
the	O
study	O
,	O
pharmacology	O
of	O
methadone	O
and	O
Buprenorphine	O
-	O
naloxone	O
,	O
the	O
importance	O
of	O
taking	O
medication	O
as	O
prescribed	O
and	O
keeping	O
appointments	O
,	O
the	O
conditions	O
under	O
which	O
medication	O
can	O
be	O
stopped	O
,	O
and	O
the	O
times	O
when	O
assessments	O
are	O
needed	O
.	O

Eligibility	O
criteria	O
included	O
:	O
opioid	B-phenotype
dependent	I-phenotype
with	I-phenotype
physiological	I-phenotype
features	I-phenotype
for	O
the	O
past	O
three	O
or	O
more	O
years	O
according	O
to	O
ICD	B-coding_system
-	I-coding_system
10	I-coding_system
;	O
age	O
25	O
or	O
above	O
as	O
per	O
Georgian	O
regulations	O
;	O
injecting	O
buprenorphine	O
10	O
or	O
more	O
times	O
in	O
the	O
past	O
30	O
days	O
;	O
buprenorphine	O
and	O
/	O
or	O
opioid	O
positive	O
urine	O
test	O
;	O
not	O
on	O
methadone	O
maintenance	O
in	O
last	O
4	O
weeks	O
;	O
stable	O
address	O
within	O
Tbilisi	O
area	O
and	O
not	O
planning	O
to	O
move	O
;	O
home	O
or	O
cellular	O
telephone	O
number	O
at	O
which	O
the	O
participant	O
can	O
be	O
reached	O
;	O
and	O
willingness	O
and	O
ability	O
to	O
give	O

informed	O
consent	O
and	O
otherwise	O
participate	O
,	O
including	O
daily	O
clinic	O
attendance	O
since	O
take	O
-	O
home	O
dosing	O
is	O
not	O
permitted	O
by	O
Georgian	O
law	O
.	O

Institutional	O
Review	O
Boards	O
at	O
the	O
University	O
of	O
Pennsylvania	O
and	O
the	O
Georgian	O
National	O
Council	O
on	O
Bioethics	O
approved	O
the	O
study	O
.	O

Patients	O
were	O
randomized	O
1	O
:	O
1	O
to	O
methadone	O
or	O
Buprenorphine	O
-	O
naloxone	O
in	O
blocks	O
of	O
four	O
and	O
stratified	O
according	O
to	O
gender	O
and	O
age	O
(	O
over	O
30	O
/	O
30	O
or	O
below	O
)	O
.	O

The	O
study	O
statistician	O
generated	O
the	O
random	O
allocation	O
sequence	O
using	O
Statistical	O
Computer	O
Program	O
R	O
version	O
2	O
.	O
6	O
.	O

2	O
(	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
)	O
.	O

Methadone	O
and	O
Buprenorphine	O
-	O
naloxone	O
were	O
administered	O
7	O
days	O
/	O
week	O
at	O
Uranti	O
under	O
direct	O
observation	O
and	O
patients	O
were	O
offered	O
weekly	O
individual	O
drug	O
counseling	O
and	O
group	O
therapy	O
.	O

Counseling	O
sessions	O
lasted	O
approximately	O
45	O
minutes	O
and	O
were	O
delivered	O
by	O
trained	O
and	O
experienced	O
staff	O
using	O
procedures	O
described	O
in	O
a	O
drug	O
counseling	O
that	O
has	O
been	O
modified	O
for	O
opioid	O
use	O
and	O
translated	O
into	O
Russian	O
(	O
which	O
is	O
well	O
understood	O
by	O
Georgians	O
)	O
,	O
and	O
whose	O
original	O
version	O
is	O
available	O
on	O
the	O
NIDA	O
web	O
site	O
:	O
(	O
http	O
:	O
/	O
/	O
archives	O
.	O
drugabuse	O
.	O
gov	O
/	O
TXManuals	O
/	O
IDCA	O
/	O
IDCA1	O
.	O
html	O
)	O
.	O

Detailed	O
assessments	O
were	O
done	O
at	O
baseline	O
and	O
at	O
weeks	O
4	O
,	O
8	O
,	O
12	O
and	O
20	O
;	O
brief	O
assessments	O
were	O
done	O
in	O
weeks	O
1–12	O
and	O
at	O
week	O
20	O
.	O

Patients	O
who	O
requested	O
methadone	O
treatment	O
at	O
the	O
end	O
of	O
12	O
weeks	O
were	O
switched	O
to	O
methadone	O
after	O
completing	O
the	O
medication	O
phase	O
.	O

There	O
was	O
only	O
one	O
Buprenorphine	O
-	O
naloxone	O
program	O
in	O
Tbilisi	O
at	O
the	O
time	O
and	O
it	O
had	O
limited	O
capacity	O
thus	O
most	O
patients	O
that	O
did	O
not	O
want	O
to	O
be	O
treated	O
with	O
methadone	O
were	O
placed	O
on	O
a	O
3	O
-	O
week	O
dose	O
taper	O
with	O
followup	O
at	O
Uranti	O
.	O

At	O
intake	O
each	O
patient	O
had	O
a	O
physical	O
examination	O
that	O
included	O
a	O
CBC	O
,	O
glucose	O
,	O
bilirubin	O
,	O
liver	O
enzymes	O
,	O
ECG	O
,	O
testing	O
for	O
HIV	O
and	O
hepatitis	O
B	O
and	O
C	O
;	O
a	O
urine	O
drug	O
screen	O
using	O
an	O
on	O
-	O
site	O
kit	O
that	O
tested	O
for	O
opioids	O
,	O
benzodiazepines	O
,	O
amphetamine	O
,	O
buprenorphine	O
,	O
methadone	O
and	O
THC	O
;	O
the	O
Addiction	O
Severity	O
Index	O
(	O
ASI	O
)	O
5	O
th	O
edition	O
(	O
McLellan	O
et	O
al	O
.	O
,	O
1992	O
)	O
;	O
a	O
timeline	O
follow	O
-	O
back	O
(	O
TLFB	O
)	O
for	O
self	O
-	O
reported	O
drug	O
use	O
with	O
a	O
timeframe	O
of	O
past	O
30	O
days	O
(	O
Sobell	O
and	O
Sobell	O
,	O
1992	O
)	O
;	O
a	O
visual	O
analogue	O
scale	O
for	O

current	O
opioid	O
craving	O
(	O
0–100	O
;	O
0=not	O
at	O
all	O
,	O
100=very	O
much	O
)	O
;	O
and	O
the	O
Risk	O
Assessment	O
Battery	O
(	O
RAB	O
)	O
,	O
a	O
self	O
-	O
reported	O
measure	O
of	O
drug	O
and	O
sexual	O
HIV	O
risk	O
behaviors	O
using	O
the	O
timeframe	O
of	O
past	O
six	O
months	O
.	O

Urine	O
drug	O
screens	O
,	O
opioid	O
craving	O
and	O
the	O
TLFB	O
with	O
a	O
timeframe	O
of	O
past	O
7	O
days	O
were	O
repeated	O
in	O
weeks	O
1–12	O
and	O
at	O
week	O
20	O
.	O

Attendance	O
at	O
counseling	O
sessions	O
was	O
recorded	O
weekly	O
and	O
doses	O
of	O
study	O
medication	O
were	O
available	O
from	O
pharmacy	O
dispensing	O
records	O
.	O

Adverse	O
Events	O
(	O
AEs	O
)	O
and	O
use	O
of	O
concomitant	O
medications	O
were	O
assessed	O
at	O
all	O
visits	O
,	O
and	O
the	O
severity	O
of	O
AEs	O
and	O
their	O
potential	O
relationship	O
to	O
study	O
procedures	O
were	O
assessed	O
and	O
monitored	O
until	O
the	O
event	O
resolved	O
.	O

The	O
ASI	O
and	O
RAB	O
were	O
repeated	O
at	O
weeks	O
4	O
,	O
8	O
,	O
12	O
and	O
20	O
using	O
the	O
timeframe	O
of	O
past	O
30	O
days	O
.	O

Interviews	O
and	O
assessments	O
were	O
conducted	O
in	O
Georgian	O
.	O

Study	O
instruments	O
were	O
translated	O
into	O
Georgian	O
and	O
back	O
translated	O
into	O
English	O
to	O
ensure	O
correct	O
interpretation	O
in	O
the	O
Georgian	O
language	O
and	O
that	O
the	O
Georgian	O
and	O
English	O
case	O
-	O
report	O
forms	O
matched	O
each	O
other	O
.	O

Data	O
were	O
entered	O
into	O
a	O
web	O
-	O
based	O
system	O
developed	O
by	O
the	O
data	O
management	O
unit	O
at	O
the	O
Penn	O
/	O
VA	O
Center	O
for	O
Studies	O
on	O
Addiction	O
and	O
analyzed	O
by	O
GK	O
in	O
Tbilisi	O
.	O

Buprenorphine	O
and	O
other	O
opioid	O
use	O
,	O
study	O
retention	O
,	O
and	O
HIV	O
drug	O
risk	O
behavior	O
were	O
the	O
focus	O
of	O
the	O
analyses	O
presented	O
here	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
statistical	O
package	O
SPSS	O
20	O
.	O
0	O
.	O

The	O
study	O
was	O
designed	O
to	O
have	O
80	O
%	O
power	O
to	O
detect	O
an	O
effect	O
size	O
of	O
Cohen’s	O
d=0	O
.	O
7	O
at	O
a	O
two	O
-	O
sided	O
significance	O
level	O
of	O
0	O
.	O
05	O
.	O

For	O
a	O
comparison	O
of	O
binary	O
outcomes	O
,	O
80	O
%	O
power	O
was	O
set	O
to	O
detect	O
a	O
difference	O
of	O
about	O
30	O
%	O
in	O
rates	O
of	O
use	O
.	O

For	O
the	O
quantitative	O
endpoints	O
the	O
Student’s	O
t	O
test	O
(	O
for	O
the	O
comparison	O
of	O
two	O
groups	O
)	O
or	O
ANOVA	O
or	O
Univariate	O
General	O
Linear	O
Model	O
approach	O
(	O
for	O
more	O
than	O
two	O
groups	O
)	O
were	O
used	O
.	O

The	O
categorical	O
endpoints	O
were	O
compared	O
using	O
χ	O
2	O
test	O
or	O
Fisher’s	O
exact	O
test	O
(	O
where	O
appropriate	O
according	O
to	O
the	O
size	O
of	O
the	O
outcome	O
)	O
.	O

Sixty	O
-	O
two	O
right	O
-	O
handed	O
boys	O
(	O
Edinburgh	O
Handedness	O
Inventory	O
)	O
(	O
Oldfield	O
1971	O
)	O
(	O
25	O
controls	O
,	O
18	O
with	O
ADHD	O
and	O
19	O
with	O
ASD	O
)	O
aged	O
10–17	O
,	O
IQ	O
>	O
70	O
(	O
Wechsler	O
Abbreviated	O
Scale	O
of	O
Intelligence	O
-	O
Revised	O
(	O
WASI	O
-	O
R	O
)	O
(	O
Wechsler	O
1999	O
)	O
participated	O
in	O
this	O
study	O
.	O

ADHD	O
boys	O
had	O
a	O
clinical	O
diagnosis	O
of	O
non	O
-	O
comorbid	O
ADHD	O
,	O
inattentive	O
/	O
hyperactive	O
-	O
impulsive	O
combined	O
subtype	O
,	O
as	O
assessed	O
by	O
an	O
experienced	O
child	O
psychiatrist	O
using	O
the	O
standardised	O
Maudsley	O
diagnostic	O
interview	O
that	O
assesses	O
ADHD	B-phenotype
according	O
to	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
criteria	O
(	O
Goldberg	O
and	O
Murray	O
2006	O
)	O
.	O

They	O
scored	O
above	O
clinical	O
threshold	O
for	O
ADHD	O
symptoms	O
on	O
the	O
Strengths	O
and	O
Difficulties	O
Questionnaire	O
(	O
SDQ	O
)	O
(	O
Goodman	O
and	O
Scott	O
1999	O
)	O
and	O
the	O
Conners’	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
(	O
CPRS	O
-	O
R	O
)	O
(	O
Conners	O
et	O
al	O
.	O
1998	O
)	O
.	O

Four	O
of	O
the	O
ADHD	O
boys	O
were	O
medication	O
-	O
naïve	O
,	O
three	O
had	O
ceased	O
taking	O
methylphenidate	O
for	O
a	O
year	O
(	O
1	O
)	O
,	O
or	O
3	O
months	O
(	O
2	O
)	O
and	O
11	O
received	O
chronic	O
stimulants	O
,	O
but	O
had	O
a	O
48	O
-	O
h	O
medication	O
washout	O
prior	O
to	O
scanning	O
.	O

ADHD	O
boys	O
were	O
excluded	O
if	O
they	O
scored	O
above	O
15	O
on	O
the	O
Social	O
Communication	O
Questionnaire	O
(	O
SCQ	O
)	O
(	O
Rutter	O
et	O
al	O
.	O
2003	O
)	O
.	O

ASD	O
diagnosis	O
was	O
made	O
using	O
ICD	O
-	O
10	O
(	O
World	O
Health	O
Organisation	O
(	O
WHO	O
)	O
1994	O
)	O
diagnostic	O
criteria	O
and	O
confirmed	O
by	O
the	O
Autism	O
Diagnostic	O
Interview	O
-	O
Revised	O
(	O
ADI–R	O
)	O
(	O
Lord	O
et	O
al	O
.	O
1994	O
)	O
and	O
the	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
(	O
ADOS	O
)	O
(	O
Lord	O
et	O
al	O
.	O
2000	O
)	O
.	O

All	O
ASD	O
subjects	O
were	O
medication	O
-	O
naïve	O
apart	O
from	O
one	O
patient	O
,	O
who	O
took	O
melatonin	O
(	O
but	O
underwent	O
a	O
2	O
-	O
week	O
medication	O
washout	O
)	O
.	O

ASD	O
exclusion	O
criteria	O
included	O
a	O
score	O
above	O
7	O
on	O
the	O
hyperactivity	O
/	O
inattention	O
subscale	O
of	O
the	O
SDQ	O
or	O
a	O
t	O
score	O
above	O
70	O
on	O
the	O
DSM	B-coding_system
-	I-coding_system
IV	I-coding_system
subscale	O
of	O
the	O
CPRS	O
-	O
R	O
.	O

Exclusion	O
criteria	O
for	O
all	O
were	O
comorbidity	O
with	O
other	O
psychiatric	O
or	O
neurological	O
disorders	O
and	O
drug	O
/	O
alcohol	O
dependency	O
.	O

Patients	O
were	O
recruited	O
from	O
local	O
clinics	O
and	O
support	O
groups	O
.	O

Patients	O
were	O
scanned	O
twice	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
design	O
,	O
using	O
a	O
Latin	O
square	O
randomization	O
design	O
for	O
counter	O
-	O
balanced	O
effects	O
.	O

Due	O
to	O
the	O
half	O
-	O
life	O
of	O
fluoxetine	O
(	O
1–3	O
days	O
)	O
and	O
its	O
metabolite	O
norfluoxetine	O
(	O
5–16	O
days	O
)	O
(	O
Wong	O
et	O
al	O
.	O
1995	O
)	O
,	O
each	O
scan	O
was	O
3–4	O
weeks	O
apart	O
.	O

To	O
ensure	O
that	O
fluoxetine	O
had	O
reached	O
its	O
peak	O
plasma	O
levels	O
,	O
after	O
5–8	O
h	O
(	O
Wong	O
et	O
al	O
.	O
1995	O
)	O
,	O
patients	O
were	O
scanned	O
5	O
h	O
after	O
administration	O
.	O

Liquid	O
fluoxetine	O
was	O
titrated	O
to	O
age	O
and	O
weight	O
(	O
see	O
supplement	O
)	O
.	O

Placebo	O
was	O
equivalent	O
amounts	O
of	O
peppermint	O
water	O
with	O
similar	O
taste	O
to	O
fluoxetine	O
.	O

Twenty	O
-	O
five	O
healthy	O
,	O
handedness	O
and	O
age	O
-	O
matched	O
boys	O
were	O
recruited	O
by	O
advertisement	O
and	O
scored	O
below	O
clinical	O
thresholds	O
on	O
the	O
SDQ	O
,	O
SCQ	O
and	O
CPRS	O
.	O

Participants	O
gave	O
written	O
informed	O
consent	O
/	O
assent	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
Ethics	O
Committee	O
.	O

Participants	O
were	O
paid	O
£50	O
for	O
each	O
scan	O
.	O

For	O
recruitment	O
,	O
demographic	O
and	O
clinical	O
details	O
of	O
participants	O
,	O
see	O
Table	O
1	O
.	O

Table	O
1	O
Sample	O
characteristics	O
for	O
healthy	O
control	O
boys	O
and	O
patients	O
with	O
ADHD	O
and	O
ASD	O
Variables	O
Controls	O
(	O
25	O
)	O
mean	O
(	O
SD	O
)	O
ADHD	O
(	O
18	O
)	O
mean	O
(	O
SD	O
)	O
ASD	O
(	O
19	O
)	O
mean	O
(	O
SD	O
)	O
Age	O
(	O
years	O
)	O
13	O
.	O
4	O
(	O
2	O
.	O
4	O
)	O
14	O
.	O
3	O
(	O
1	O
.	O
8	O
)	O
14	O
.	O
7	O
(	O
2	O
.	O
0	O
)	O
IQ	O
109	O
(	O
13	O
)	O
95	O
(	O
11	O
)	O
112	O
(	O
15	O
)	O
SDQ	O
hyperactive	O
-	O
impulsive	O
/	O
inattentive	O
subscale	O
1	O
.	O
8	O
(	O
1	O
.	O
6	O
)	O
9	O
.	O
2	O
(	O
0	O
.	O
9	O
)	O
4	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
SDQ—emotional	O
distress	O
subscale	O
0	O
.	O
5	O
(	O
0	O
.	O
8	O
)	O
3	O
.	O
6	O
(	O
3	O
.	O
0	O
)	O
4	O
.	O
2	O
(	O
3	O
.	O
0	O
)	O
SDQ—conduct	O
subscale	O
0	O
.	O
3	O
(	O
0	O
.	O
7	O
)	O
5	O
.	O
0	O
(	O
2	O
.	O
4	O
)	O
2	O
.	O
1	O
(	O
2	O
.	O
0	O
)	O
SDQ—peer	O
relations	O
subscale	O
.	O
6	O
(	O
1	O
.	O
1	O
)	O
3	O
.	O
4	O
(	O
2	O
.	O
5	O
)	O
6	O
.	O
1	O
(	O
2	O
.	O
4	O
)	O
SDQ—prosocial	O
behaviour	O

subscale	O
9	O
.	O
1	O
(	O
1	O
.	O
3	O
)	O
6	O
.	O
7	O
(	O
2	O
.	O
3	O
)	O
5	O
.	O
1	O
(	O
2	O
.	O
3	O
)	O
SDQ—total	O
scores	O
3	O
.	O
3	O
(	O
2	O
.	O
9	O
)	O
21	O
.	O
2	O
(	O
4	O
.	O
9	O
)	O
16	O
.	O
8	O
(	O
5	O
.	O
7	O
)	O
SCQ	O
total	O
1	O
.	O
6	O
(	O
2	O
.	O
7	O
)	O
7	O
.	O
0	O
(	O
3	O
.	O
4	O
)	O
23	O
.	O
5	O
(	O
5	O
.	O
5	O
)	O
CPRS	O
-	O
R	O
total	O
T	O
score	O
44	O
(	O
3	O
)	O
83	O
(	O
7	O
)	O
57	O
(	O
8	O
)	O
ADOS	O
communication	O
scores	O
–	O
–	O
2	O
(	O
1	O
)	O
ADOS	O
social	O
interaction	O
scores	O
–	O
–	O
7	O
(	O
4	O
)	O
ADOS	O
communication	O
and	O
social	O
scores	O
–	O
–	O
9	O
(	O
5	O
)	O
ADOS	O
stereotyped	O
behaviour	O
scores	O
–	O
–	O
1	O
(	O
1	O
)	O
ADI	O
communication	O
scores	O
–	O
–	O
14	O
(	O
4	O
)	O
ADI	O
social	O
Interaction	O
scores	O
–	O
–	O
17	O
(	O
5	O
)	O
ADI	O
stereotyped	O
scores	O
–	O
–	O
6	O
(	O
3	O
)	O
SDQ	O
Strengths	O
and	O
Difficulties	O
Questionnaire	O
,	O
SCQ	O
Social	O

Communication	O
Questionnaire	O
,	O
CPRS	O
-	O
R	O
Conners’	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
,	O
ADOS	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
,	O
ADI	O
Autism	O
Diagnostic	O
Interview	O

Sample	O
characteristics	O
for	O
healthy	O
control	O
boys	O
and	O
patients	O
with	O
ADHD	O
and	O
ASD	O

SDQ	O
Strengths	O
and	O
Difficulties	O
Questionnaire	O
,	O
SCQ	O
Social	O
Communication	O
Questionnaire	O
,	O
CPRS	O
-	O
R	O
Conners’	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
,	O
ADOS	O
Autism	O
Diagnostic	O
Observation	O
Schedule	O
,	O
ADI	O
Autism	O
Diagnostic	O
Interview	O

Subjects	O
practised	O
the	O
task	O
once	O
prior	O
to	O
each	O
scan	O
under	O
supervision	O
of	O
the	O
researcher	O
who	O
made	O
sure	O
the	O
participants	O
understood	O
the	O
task	O
and	O
performed	O
accordingly	O
(	O
by	O
inhibiting	O
more	O
or	O
less	O
50	O
%	O
of	O
trials	O
)	O
.	O

The	O
8	O
min	O
49	O
s	O
minute	O
visual	O
tracking	O
stop	O
task	O
requires	O
withholding	O
of	O
an	O
already	O
triggered	O
motor	O
response	O
to	O
a	O
go	O
stimulus	O
when	O
it	O
is	O
followed	O
unpredictably	O
by	O
a	O
stop	O
signal	O
(	O
Cubillo	O
et	O
al	O
.	O
2014	O
;	O
Rubia	O
et	O
al	O
.	O
2011	O
;	O
Rubia	O
et	O
al	O
.	O
2003	O
;	O
Rubia	O
et	O
al	O
.	O
2005b	O
;	O
Rubia	O
et	O
al	O
.	O
2007	O
)	O
.	O

Subjects	O
have	O
to	O
respond	O
as	O
quickly	O
as	O
possible	O
to	O
left	O
or	O
right	O
pointing	O
“go”	O
arrows	O
(	O
500	O
ms	O
duration	O
,	O
80	O
%	O
of	O
294	O
trials	O
)	O
with	O
a	O
left	O
or	O
right	O
(	O
thumb	O
)	O
button	O
press	O
,	O
followed	O
by	O
a	O
gap	O
of	O
1100	O
to	O
1500	O
ms	O
(	O
which	O
makes	O
up	O
a	O
mean	O
trial	O
length	O
of	O
1	O
.	O
8	O
s	O
;	O
jittered	O
between	O
1	O
.	O
6	O
and	O
2	O
s	O
to	O
optimise	O
statistical	O
efficiency	O
)	O
.	O

In	O
20	O
%	O
of	O
trials	O
(	O
60	O
)	O
,	O
pseudo	O
-	O
randomly	O
interspersed	O
,	O
and	O
at	O
least	O
3	O
repetition	O
times	O
apart	O
for	O
adequate	O
separation	O
of	O
the	O
hemodynamic	O
response	O
,	O
go	O
signals	O
are	O
followed	O
(	O
about	O
250	O
ms	O
later	O
)	O
by	O
arrows	O
pointing	O
upwards	O
(	O
300	O
ms	O
duration	O
)	O
(	O
stop	O
signals	O
)	O
,	O
and	O
subjects	O
have	O
to	O
inhibit	O
their	O
motor	O
response	O
.	O

A	O
tracking	O
algorithm	O
changes	O
the	O
time	O
interval	O
between	O
go	O
and	O
stop	O
-	O
signal	O
onsets	O
according	O
to	O
each	O
subject’s	O
inhibitory	O
performance	O
,	O
which	O
is	O
recalculated	O
after	O
each	O
stop	O
signal	O
based	O
on	O
the	O
average	O
percentage	O
of	O
inhibition	O
over	O
previous	O
stop	O
trials	O
to	O
provide	O
50	O
%	O
successful	O
and	O
50	O
%	O
unsuccessful	O
inhibition	O
trials	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O

Given	O
that	O
the	O
contrast	O
of	O
stop	O
-	O
go	O
trials	O
is	O
confounded	O
by	O
the	O
attentional	O
oddball	O
effect	O
of	O
the	O
low	O
frequency	O
of	O
stop	O
trials	O
(	O
20	O
%	O
)	O
relative	O
to	O
go	O
trials	O
(	O
80	O
%	O
)	O
,	O
which	O
also	O
activates	O
IFC	O
(	O
Hampshire	O
et	O
al	O
.	O
2010	O
;	O
Pauls	O
et	O
al	O
.	O
2012b	O
)	O
,	O
for	O
the	O
fMRI	O
analysis	O
,	O
brain	O
activation	O
to	O
the	O
50	O
%	O
unsuccessful	O
stop	O
trials	O
was	O
subtracted	O
from	O
the	O
50	O
%	O
successful	O
stop	O
trials	O
,	O
controlling	O
for	O
the	O
attentional	O
oddball	O
effect	O
of	O
the	O
infrequent	O
stop	O
signal	O
appearance	O
.	O

The	O
dependent	O
inhibition	O
variable	O
is	O
the	O
stop	O
signal	O
reaction	O
time	O
(	O
SSRT	O
)	O
,	O
calculated	O
by	O
subtracting	O
the	O
mean	O
stop	O
signal	O
delay	O
(	O
SSD	O
:	O
the	O
average	O
time	O
between	O
go	O
and	O
stop	O
signal	O
at	O
which	O
the	O
subject	O
managed	O
to	O
inhibit	O
to	O
50	O
%	O
of	O
trials	O
)	O
from	O
the	O
mean	O
reaction	O
time	O
(	O
MRT	O
)	O
to	O
go	O
trials	O
,	O
i	O
.	O
e	O
.	O

MRT	O
-	O
SSD	O
(	O
Logan	O
et	O
al	O
.	O
1997	O
)	O
.	O

MRT	O
,	O
intrasubject	O
standard	O
deviation	O
of	O
MRT	O
,	O
and	O
omission	O
error	O
percentage	O
are	O
variables	O
of	O
the	O
executive	O
process	O
of	O
the	O
task	O
.	O

MANOVAs	O
compared	O
performance	O
variables	O
between	O
controls	O
and	O
the	O
two	O
patient	O
groups	O
under	O
placebo	O
and	O
between	O
controls	O
and	O
the	O
two	O
patient	O
groups	O
under	O
fluoxetine	O
.	O

Multiple	O
repeated	O
-	O
measures	O
ANOVAs	O
within	O
the	O
two	O
patient	O
groups	O
with	O
group	O
(	O
ADHD	O
,	O
ASD	O
)	O
as	O
independent	O
factor	O
and	O
drug	O
condition	O
(	O
placebo	O
/	O
fluoxetine	O
)	O
as	O
repeated	O
measures	O
were	O
conducted	O
to	O
test	O
for	O
group	O
by	O
medication	O
interaction	O
effects	O
on	O
performance	O
.	O

Gradient	O
-	O
echo	O
echoplanar	O
MR	O
imaging	O
(	O
EPI	O
)	O
data	O
were	O
acquired	O
on	O
a	O
General	O
Electric	O
Signa	O
3T	O
Horizon	O
HDx	O
system	O
at	O
the	O
Centre	O
for	O
Neuroimaging	O
Sciences	O
,	O
Institute	O
of	O
Psychiatry	O
,	O
King’s	O
College	O
London	O
,	O
UK	O
.	O

A	O
semiautomated	O
quality	O
control	O
procedure	O
ensured	O
consistent	O
image	O
quality	O
.	O

A	O
quadrature	O
birdcage	O
headcoil	O
was	O
used	O
for	O
RF	O
transmission	O
and	O
reception	O
.	O

In	O
each	O
of	O
28	O
non	O
-	O
contiguous	O
planes	O
parallel	O
to	O
the	O
anterior	O
-	O
posterior	O
commissure	O
,	O
296	O
T2	O
*	O
-	O
weighted	O
MR	O
images	O
depicting	O
BOLD	O
contrast	O
covering	O
the	O
whole	O
brain	O
were	O
acquired	O
with	O
TE	O
=	O
30	O
ms	O
,	O
TR	O
=	O
1	O
.	O
8	O
s	O
,	O
flip	O
angle	O
=	O
75°	O
,	O
in	O
-	O
plane	O
voxel	O
-	O
size	O
=	O
3	O
mm	O
,	O
slice	O
thickness	O
=	O
5	O
.	O
5	O
mm	O
and	O
slice	O
-	O
skip	O
=	O
0	O
.	O
5	O
mm	O
.	O

A	O
whole	O
-	O
brain	O
high	O
-	O
resolution	O
structural	O
scan	O
(	O
inversion	O
recovery	O
gradient	O
echo	O
planar	O
image	O
)	O
on	O
which	O
to	O
superimpose	O
the	O
individual	O
activation	O
maps	O
,	O
was	O
also	O
acquired	O
in	O
the	O
inter	O
-	O
commissural	O
plane	O
with	O
TE	O
=	O
30	O
ms	O
,	O
TR	O
=	O
3	O
s	O
,	O
flip	O
angle	O
=	O
90°	O
,	O
43	O
slices	O
,	O
slice	O
thickness	O
=	O
3	O
.	O
0	O
mm	O
,	O
slice	O
skip	O
=	O
0	O
.	O
3	O
mm	O
and	O
in	O
-	O
plane	O
voxel	O
-	O
size	O
=	O
1	O
.	O
875	O
mm	O
.	O

All	O
subjects	O
performed	O
three	O
other	O
fMRI	O
tasks	O
which	O
are	O
not	O
reported	O
here	O
.	O

The	O
XBAM	O
software	O
package	O
was	O
used	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
brainmap	O
.	O
co	O
.	O
uk	O
/	O
)	O
(	O
Brammer	O
et	O
al	O
.	O
1997	O
)	O
which	O
makes	O
no	O
normality	O
assumptions	O
(	O
often	O
violated	O
in	O
fMRI	O
data	O
)	O
,	O
but	O
instead	O
uses	O
median	O
statistics	O
to	O
control	O
outlier	O
effects	O
and	O
permutation	O
rather	O
than	O
normal	O
theory	O
-	O
based	O
inference	O
(	O
Thirion	O
et	O
al	O
.	O
2007	O
)	O
.	O

Individual	O
-	O
and	O
group	O
-	O
level	O
analyses	O
are	O
described	O
in	O
further	O
detail	O
elsewhere	O
(	O
Brammer	O
et	O
al	O
.	O
1997	O
;	O
Cubillo	O
et	O
al	O
.	O
2014	O
;	O
Rubia	O
et	O
al	O
.	O
2003	O
;	O
Rubia	O
et	O
al	O
.	O
2005b	O
;	O
Rubia	O
et	O
al	O
.	O
2007	O
)	O
and	O
in	O
the	O
supplementary	O
material	O
.	O

Briefly	O
,	O
the	O
fMRI	O
data	O
were	O
realigned	O
to	O
minimise	O
motion	O
-	O
related	O
artefacts	O
and	O
smoothed	O
using	O
a	O
Gaussian	O
filter	O
(	O
FWHM	O
8	O
.	O
82	O
mm	O
)	O
(	O
Bullmore	O
et	O
al	O
.	O
1999a	O
)	O
.	O

Further	O
data	O
analysis	O
included	O
slice	O
timing	O
correction	O
and	O
the	O
residual	O
effects	O
of	O
motion	O
were	O
regressed	O
out	O
from	O
the	O
time	O
series	O
(	O
using	O
the	O
estimated	O
motion	O
parameters	O
)	O
before	O
fitting	O
a	O
general	O
linear	O
model	O
.	O

Time	O
-	O
series	O
analysis	O
of	O
individual	O
subject	O
activation	O
was	O
performed	O
with	O
a	O
wavelet	O
-	O
based	O
resampling	O
method	O
previously	O
described	O
(	O
Bullmore	O
et	O
al	O
.	O
2001	O
)	O
.	O

We	O
convolved	O
the	O
task	O
epoch	O
of	O
the	O
contrasts	O
of	O
interest	O
(	O
i	O
.	O
e	O
.	O
successful	O
stop—implicit	O
go	O
trials	O
;	O
failed	O
stop	O
trials—implicit	O
go	O
trials	O
)	O
and	O
the	O
higher	O
level	O
contrast	O
(	O
successful	O
stop	O
-	O
go	O
trials	O
minus	O
unsuccessful	O
stop	O
-	O
go	O
trials	O
)	O
with	O
two	O
Poisson	O
model	O
functions	O
(	O
delays	O
of	O
4	O
and	O
8	O
s	O
)	O
.	O

Individual	O
activation	O
maps	O
were	O
recalculated	O
by	O
testing	O
the	O
goodness	O
-	O
of	O
-	O
fit	O
of	O
this	O
convolution	O
with	O
the	O
BOLD	O
time	O
series	O
;	O
the	O
goodness	O
-	O
of	O
-	O
fit	O
calculation	O
used	O
the	O
ratio	O
of	O
the	O
sum	O
of	O
squares	O
of	O
deviations	O
from	O
the	O
mean	O
intensity	O
value	O
due	O
to	O
the	O
model	O
(	O
fitted	O
time	O
series	O
)	O
divided	O
by	O
the	O
sum	O
of	O
squares	O
due	O
to	O
the	O
residuals	O
(	O
original	O
time	O
series	O
minus	O
model	O
time	O
series	O
)	O
.	O

This	O
statistic	O
,	O
the	O
sum	O
of	O
squares	O
(	O
SSQ	O
)	O
ratio	O
,	O
was	O
used	O
in	O
further	O
analyses	O
.	O

Using	O
rigid	O
body	O
and	O
affine	O
transformation	O
,	O
the	O
individual	O
maps	O
were	O
registered	O
into	O
Talairach	O
standard	O
space	O
.	O

A	O
group	O
brain	O
activation	O
map	O
was	O
then	O
produced	O
for	O
each	O
medication	O
condition	O
and	O
each	O
experimental	O
condition	O
(	O
see	O
supplementary	O
material	O
)	O
.	O

For	O
between	O
-	O
group	O
comparisons	O
between	O
controls	O
and	O
patients	O
under	O
either	O
placebo	O
or	O
fluoxetine	O
,	O
one	O
-	O
way	O
ANCOVA	O
analyses	O
with	O
group	O
as	O
factor	O
and	O
rotational	O
and	O
translation	O
movement	O
in	O
Euclidian	O
3	O
-	O
D	O
space	O
as	O
covariate	O
,	O
were	O
conducted	O
using	O
randomization	O
-	O
based	O
tests	O
for	O
voxel	O
or	O
cluster	O
-	O
wise	O
differences	O
as	O
described	O
in	O
detail	O
elsewhere	O
(	O
Bullmore	O
et	O
al	O
.	O
2001	O
;	O
Bullmore	O
et	O
al	O
.	O
1999b	O
)	O
.	O

For	O
these	O
between	O
-	O
group	O
comparisons	O
,	O
less	O
than	O
one	O
false	O
activated	O
cluster	O
was	O
expected	O
at	O
p	O
<	O
0	O
.	O
05	O
for	O
voxel	O
and	O
p	O
<	O
0	O
.	O
01	O
for	O
cluster	O
comparisons	O
.	O

Given	O
that	O
right	O
IFC	O
was	O
an	O
a	O
priori	O
hypothesised	O
region	O
,	O
we	O
used	O
a	O
more	O
lenient	O
cluster	O
level	O
threshold	O
of	O
p	O
<	O
0	O
.	O
05	O
and	O
also	O
conducted	O
a	O
region	O
of	O
interest	O
analysis	O
using	O
the	O
IFC	O
as	O
a	O
mask	O
.	O

Then	O
the	O
standardised	O
BOLD	O
response	O
values	O
for	O
each	O
participant	O
were	O
extracted	O
for	O
the	O
significant	O
clusters	O
of	O
the	O
ANCOVA	O
analyses	O
and	O
post	O
hoc	O
t	O
-	O
tests	O
(	O
correcting	O
for	O
multiple	O
comparisons	O
using	O
least	O
significant	O
difference	O
(	O
LSD	O
)	O
)	O
were	O
conducted	O
to	O
identify	O
the	O
direction	O
of	O
the	O
group	O
differences	O
.	O

A	O
2	O
×	O
2	O
ANCOVA	O
(	O
2	O
medication	O
conditions	O
,	O
2	O
groups	O
)	O
with	O
rotational	O
and	O
translation	O
movement	O
as	O
covariate	O
was	O
conducted	O
using	O
randomised	O
-	O
based	O
testing	O
for	O
voxel	O
or	O
cluster	O
-	O
wise	O
differences	O
as	O
described	O
elsewhere	O
(	O
Bullmore	O
et	O
al	O
.	O
2001	O
)	O
.	O

Less	O
than	O
one	O
false	O
positive	O
activation	O
cluster	O
was	O
expected	O
at	O
p	O
<	O
0	O
.	O
05	O
at	O
voxel	O
and	O
p	O
<	O
0	O
.	O
01	O
at	O
cluster	O
level	O
.	O

For	O
our	O
a	O
priori	O
hypothesised	O
region	O
in	O
right	O
IFC	O
,	O
a	O
more	O
lenient	O
p	O
<	O
0	O
.	O
05	O
was	O
used	O
as	O
well	O
as	O
a	O
region	O
of	O
interest	O
analysis	O
using	O
the	O
IFC	O
as	O
a	O
mask	O
.	O

Statistical	O
measures	O
of	O
BOLD	O
response	O
for	O
each	O
participant	O
were	O
then	O
extracted	O
in	O
each	O
of	O
the	O
significant	O
clusters	O
and	O
post	O
hoc	O
t	O
tests	O
(	O
corrected	O
for	O
multiple	O
comparisons	O
with	O
LSD	O
)	O
were	O
conducted	O
to	O
identify	O
the	O
direction	O
of	O
the	O
interaction	O
effects	O
.	O

